
<html lang="en"     class="pb-page"  data-request-id="dcb2da5f-1da9-44c1-a778-e1cbd59e5a92"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-5;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01746;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Inhibitors of Eukaryotic Translational Machinery as Therapeutic Agents" /></meta><meta name="dc.Creator" content="Angela  Fan" /></meta><meta name="dc.Creator" content="Phillip P.  Sharp" /></meta><meta name="dc.Description" content="Inhibiting eukaryotic protein translation with small molecules is emerging as a powerful therapeutic strategy. The advantage of targeting cellular translational machinery is that it is required for..." /></meta><meta name="Description" content="Inhibiting eukaryotic protein translation with small molecules is emerging as a powerful therapeutic strategy. The advantage of targeting cellular translational machinery is that it is required for..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 16, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01746" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01746" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01746" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01746" /></link>
        
    
    

<title>Inhibitors of Eukaryotic Translational Machinery as Therapeutic Agents | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01746" /></meta><meta property="og:title" content="Inhibitors of Eukaryotic Translational Machinery as Therapeutic Agents" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0028.jpeg" /></meta><meta property="og:description" content="Inhibiting eukaryotic protein translation with small molecules is emerging as a powerful therapeutic strategy. The advantage of targeting cellular translational machinery is that it is required for the highly proliferative state of many neoplastic cells, replication of certain viruses, and ultimately the expression of a wide variety of protein targets. Although, this approach has been exploited to develop clinical agents, such as homoharringtonine (HHT, 1), used to treat chronic myeloid leukemia (CML), inhibiting components of the translational machinery is often associated with cytotoxic phenotypes. However, recent studies have demonstrated that certain small molecules can inhibit the translation of specific subsets of proteins, leading to lower cytotoxicity, and opening-up therapeutic opportunities for translation inhibitors to be deployed in indications beyond oncology and infectious disease. This review summarizes efforts to develop inhibitors of the eukaryotic translational machinery as therapeutic agents and highlights emerging opportunities for translation inhibitors in the future." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01746"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01746">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01746&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01746&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01746&amp;href=/doi/10.1021/acs.jmedchem.0c01746" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2436-2465</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01487" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c02176" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Inhibitors of Eukaryotic Translational Machinery as Therapeutic Agents</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Angela Fan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Angela Fan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Angela++Fan">Angela Fan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor">Phillip P. Sharp</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Phillip P. Sharp</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#87d7efeeebebeef7a9f4efe6f5f7c7eae2f5e4eca9e4e8ea"><span class="__cf_email__" data-cfemail="34645c5d58585d441a475c55464474595146575f1a575b59">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Phillip+P.++Sharp">Phillip P. Sharp</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4416-2303" title="Orcid link">http://orcid.org/0000-0003-4416-2303</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01746&amp;href=/doi/10.1021%2Facs.jmedchem.0c01746" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2436–2465</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 16, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 October 2020</li><li><span class="item_label"><b>Published</b> online</span>16 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 March 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01746" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01746</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2436%26pageCount%3D30%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAngela%2BFan%252C%2BPhillip%2BP.%2BSharp%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D5%26contentID%3Dacs.jmedchem.0c01746%26title%3DInhibitors%2Bof%2BEukaryotic%2BTranslational%2BMachinery%2Bas%2BTherapeutic%2BAgents%26numPages%3D30%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2465%26publicationDate%3DMarch%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01746"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1190</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01746" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Inhibitors of Eukaryotic Translational Machinery as Therapeutic Agents&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;Fan&quot;},{&quot;first_name&quot;:&quot;Phillip&quot;,&quot;last_name&quot;:&quot;P. Sharp&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2436-2465&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01746&quot;},&quot;abstract&quot;:&quot;Inhibiting eukaryotic protein translation with small molecules is emerging as a powerful therapeutic strategy. The advantage of targeting cellular translational machinery is that it is required for the highly proliferative state of many neoplastic cells, replication of certain viruses, and ultimately the expression of a wide variety of protein targets. Although, this approach has been exploited to develop clinical agents, such as homoharringtonine (HHT, 1), used to treat chronic myeloid leukemia (CML), inhibiting components of the translational machinery is often associated with cytotoxic phenotypes. However, recent studies have demonstrated that certain small molecules can inhibit the translation of specific subsets of proteins, leading to lower cytotoxicity, and opening-up therapeutic opportunities for translation inhibitors to be deployed in indications beyond oncology and infectious disease. This review summarizes efforts to develop inhibitors of the eukaryotic translational machinery as therapeutic agent&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01746&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01746" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01746&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01746" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01746&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01746" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01746&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01746&amp;href=/doi/10.1021/acs.jmedchem.0c01746" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01746" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01746" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (14 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01746%26sid%3Dliteratum%253Aachs%26pmid%3D33592144%26genre%3Darticle%26aulast%3DFan%26date%3D2021%26atitle%3DInhibitors%2Bof%2BEukaryotic%2BTranslational%2BMachinery%2Bas%2BTherapeutic%2BAgents%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D5%26spage%3D2436%26epage%3D2465%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292519" title="Cancer therapy">Cancer therapy</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/jmcmar.2021.64.issue-5/20210311/jmcmar.2021.64.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Inhibiting eukaryotic protein translation with small molecules is emerging as a powerful therapeutic strategy. The advantage of targeting cellular translational machinery is that it is required for the highly proliferative state of many neoplastic cells, replication of certain viruses, and ultimately the expression of a wide variety of protein targets. Although, this approach has been exploited to develop clinical agents, such as homoharringtonine (HHT, <b>1</b>), used to treat chronic myeloid leukemia (CML), inhibiting components of the translational machinery is often associated with cytotoxic phenotypes. However, recent studies have demonstrated that certain small molecules can inhibit the translation of specific subsets of proteins, leading to lower cytotoxicity, and opening-up therapeutic opportunities for translation inhibitors to be deployed in indications beyond oncology and infectious disease. This review summarizes efforts to develop inhibitors of the eukaryotic translational machinery as therapeutic agents and highlights emerging opportunities for translation inhibitors in the future.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84250" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84250" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The translation of genetic information from mRNA into protein is a fundamental process of life. Indeed, every protein requires ribosome-mediated translation for biogenesis. Given its central importance in biology, it is not surprising that pharmacological perturbation of translation with small molecules can have significant physiological consequences. Chief among them is the ability to halt protein synthesis, which has been successfully applied in the clinic. One example is the eukaryotic elongation factor 1A (eEF1A) inhibitor plitidepsin (<b>2</b>), which was recently approved to treat multiple myeloma in combination with dexamethasone by the Therapeutic Goods Agency (TGA) in Australia (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected translation inhibitors with various mechanisms of action and species selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several other components of the translational machinery have been demonstrated to be amenable to small molecule inhibition, including eukaryotic initiation factors (eIFs), eukaryotic elongation factors (eEFs), and various binding sites on the 80S ribosome complex. Since translation initiation and elongation factors regulate the expression of numerous proteins in eukaryotes, including important oncogenes, such as MYC and MDM2, and immune checkpoints such as PD-L1, they are attractive drug targets, particularly in oncology.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a></div><div class="NLM_p">Historically, nature has provided the most abundant source of small molecule translation inhibitors. These highly evolved, structurally complex peptide, polyketide, and alkaloid secondary metabolites usually progress through preclinical and into clinical development with little to no synthetic modifications. More recently, target-based and phenotypic screens have uncovered novel synthetic small molecule translation inhibitors with more drug-like physical properties, facilitating their preclinical development (<i>vide infra</i>).</div><div class="NLM_p last">This perspective article will focus on discovery, medicinal chemistry, and clinical development of small molecules that bind directly to proteinaceous elements of the eukaryotic translational machinery. For example, the eIF4A inhibitor zotatifin (<b>3</b>) and ribosome-binding molecules such as homoharringtonine (<b>1</b>, HHT) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which are highly potent and eukaryote-selective translation inhibitors, are discussed. Small molecules, such as the antibiotics linezolid (<b>3</b>) and erythromycin (<b>4</b>), which selectively bind to the prokaryotic ribosome, are out of scope for this review, and readers are referred to reviews by Fernandez and co-workers, and Jelić et. al.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> Similarly, very broad spectrum translation inhibitors, such as the universal protein synthesis inhibitor cycloheximide (<b>5</b>), which binds to a conserved site C3993 on the 28S rRNA (mouse ribosome sequence numbering) across both eukaryotic and prokaryotic organisms, are considered out of scope.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Also considered out of scope for this perspective are molecules that modulate protein synthesis indirectly, i.e., by phosphorylation or other post-translational modification of an element of the translational machinery, or modulation of the mTORC signaling pathway. In addition, excellent reviews on small molecules that bind mRNA are available and so will not be covered in this perspective.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Finally, to clarify terminology, the term “selective eukaryotic protein translation inhibitor” will be used to describe molecules that not only selectively exert an effect on the eukaryotic translational machinery over that expressed in prokaryotic organisms but also demonstrate an additional level of selectivity, such as selective inhibition of rapidly proliferating cancer cells, or selective inhibition of certain translating mRNAs.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Inhibition of Eukaryotic Protein Translation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17210" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17210" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The ultimate goal for the discovery and development of therapeutic translation inhibitors is achieving cell-type or mRNA transcript-level selectivity in order to block production of unwanted cells or proteins, while maintaining healthy cellular proteostasis. In practice, this usually involves targeting the specific translational machinery components that differentially regulate protein expression in healthy and disease states, or targeting specific mRNA–protein interactions.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Therefore, identifying components of the translational machinery that regulate specific disease states and determining the extent to which those components are druggable with small molecules are essential for developing translation inhibitors with drug candidate profiles suitable for clinical applications.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Protein Translation in Eukaryotes</h3><div class="NLM_p">Eukaryotic protein translation occurs in a cycle, whereby multiple 80S ribosome complexes assemble on a single mRNA strand to form a polysome (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The polysome complex converts the mRNA sequence into multiple copies of an elongated protein by sequential transfer of amino acids from aminoacyl-tRNAs. Following the termination of polypeptide synthesis, the ribosome disassembles and is recycled. Therefore, the translation cycle is generally divided into four phases: (1) initiation, (2) elongation, (3) termination, and (4) recycling.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Eukaryotic translation initiation and subsequent translation elongation cycle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i5" class="anchor-spacer"></div><h4 class="article-section__title" id="_i5">2.1.1.  Initiation</h4><div class="NLM_p last">Translation initiation differs in eukaryotes from prokaryotes in several important ways. For example, in prokaryotes translation is initiated the instant RNA emerges from the bacterial RNA polymerase through recognition of the Shine–Dalgarno sequence (5′-AGGAGGU-3′) on the RNA by the 30S ribosomal subunit.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Conversely, in eukaryotes mRNA must first exit the nucleus in order to encounter initiation factors for translation to proceed. Additionally, eukaryotic translation occurs in a cap-dependent manner (or for a few mRNAs it is mediated though an internal ribosome entry site, IRES).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> In cap-dependent translation initiation, as the mRNA enters the cytosol, it is recognized by the eukaryotic initiation factor (eIF) eIF4F complex, containing eIF4E, eIF4G, and eIF4A (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The eIF4F complex binds the 7-methylguanylate (m7G)-modified cap on the 5′ end of the mRNA, which activates mRNA for translation. The 43S complex, which contains the small (40S) ribosomal subunit, eIFs (eIF3, eIF1, eIF1A, and eIF5) and the eIF2·Met-tRNAiMet·GTP ternary complex, recruits the activated mRNA. This initiator complex binds to the 3′-poly(A) tail of the mRNA transcript via poly(A) tail binding protein 1 (PABP1). Subsequently, the mRNA sequence is scanned in a 5′ to 3′ direction by the ribosomal subunit and associated factors, and this scanning locates the proper start codon, usually an AUG. When a start codon is selected, the codon–anticodon interaction that is formed with Met-tRNAiMet in the P-site produces the 48S preinitiation complex, priming the mRNA for elongation. At this stage, the initiation complex dissembles followed by binding of the large (60S) ribosome subunit, creating an elongation-competent 80S ribosome.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6">2.1.2.  Elongation</h4><div class="NLM_p">Peptide synthesis proceeds as the eukaryotic elongation factor 1A (eEF1A)—in its GTP-bound state—binds and delivers aminoacyl-tRNAs (aa-tRNAs) to the A-site of the ribosome (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). When the aa-tRNA is delivered to the A-site, it forms a strong codon-anticodon pairing interaction with the mRNA sequence in the ribosome, GTP hydrolysis , and the eEF1A·GTP complex dissociates form the ribosome. The A-site and P-site tRNAs are then appropriately positioned to undergo peptidyl transfer in the peptidyl transferase center, and this reaction is facilitated by catalytic bases in the 60S ribosomal subunit. A second elongation factor eEF2, a translocase, is required to move the ribosome along the mRNA to present the next codon so that peptide elongation can continue.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Peptidyl transfer in the ribosome during eukaryotic translation elongation. eEF1A delivers amino acyl-tRNA to the A-site of the 80S ribosome complex. GTP is hydrolyzed, and eEF1A is released. Peptidyl transfer takes place, during which the nucleophilic tRNA in the A-site attacks the electrophilic peptidyl-tRNA in the P-site. eEF2 mediates transposition of the tRNAs during which GTP is hydrolyzed. Once the stop codon has been reached, ERFs bind in the A-site and assist with release of the completed peptide chain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7">2.1.3.  Termination</h4><div class="NLM_p last">When a stop codon (UAA, UGA, or UAG) enters the A-site, eukaryotic release factors (eRFs) bind into the A-site and, along with other factors, including ATP-binding cassette subfamily E member 1 (ABCE1), promote release of the peptide.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> eRF1 recognizes the stop codon and binds onto the ribosomal A-site. eRF3 and GTP from a ternary complex with eRF1, which interacts with the PABP1 to hydrolyze GTP, cleave the peptidyl-tRNA bind and release the newly synthesized polypeptide.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div></div><div id="sec2_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">2.1.4.  Recycling</h4><div class="NLM_p last">Once the ribosome has terminated protein synthesis, the P-site tRNA remains associated with the ribosome in post-termination complexes (post-TCs). Unlike prokaryotic organisms, eukaryotes do not code specific ribosome release factors (RRFs), but recycling is assisted by initiation factors eIF3, eIF1, and eIF1A. These proteins promote release of P-site deacylated tRNA from the ribosome and prime it for a second round of initiation.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.2.  Translation Initiation Inhibitors</h3><div class="NLM_p">Initiation is a key rate limiting node in eukaryotic translation and therefore has been a high priority target pathway for the development of therapeutics. Several small molecule inhibitors of eukaryotic translation initiation factors eIF4A and eIF4E have been described, and they are the focus of multiple ongoing preclinical and clinical development programs.</div><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">2.2.1.  eIF4A</h4><div class="NLM_p">Eukaryotic initiation factor 4A (eIF4A) is a 46 kDa ATP-dependent DEAD (D-E-A-D comes from the Asp-Glu-Ala-Asp sequence of the Walker B motif common to the DEAD box family of proteins) box RNA helicase and a core member of the eIF4F complex.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> Three isoforms of eIF4A exist, but only two (eIF4AI and eIF4AII) are involved in protein synthesis.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> eIF4AI (DDX2A) and eIF4AII (DDX2B) are highly related homologues with 91% structural similarity, and both play key roles in unwinding the secondary structures in the 5′-UTR, which allows for the 43S preinitiation complex to bind and scan the mRNA for the initiator codon.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a><i>In vitro</i>, eIF4A has bidirectional and nonprocessive helicase activity; however, engagement with other initiation factors provide specific 5′ to 3′ directionality.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This helicase activity requires iterative cycling between an open and closed conformation.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Binding of ATP and RNA induces the closed conformation, and the subsequent ATP hydrolysis and RNA disengagement causes the shift to the open conformation. About three eIF4A proteins are present per ribosome, making it the most abundant initiation factor necessary for the eIF4F complex, but only about 10% of eIF4A is actively engaged in the complex.<a onclick="showRef(event, 'ref9 ref20'); return false;" href="javascript:void(0);" class="ref ref9 ref20">(9,20)</a></div><div class="NLM_p last">eIF4A has been shown to have roles in tumor cell replication and viral replication, indicating that eIF4A inhibitors may have multiple therapeutic applications. For instance, eIF4A overexpression has been shown to promote cellular transformations and malignancy.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Additionally, many oncogenic mRNAs have long, highly structured 5′ UTR regions stabilized by intramolecular hydrogen bonding, which need to be “unwound” in order for the initiation complex to scan the mRNA to find the start codon. This makes transcripts with highly structured regions upstream of the start codon more sensitive to changes in eIF4A helicase activity.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Examples of transcripts that have been found to depend highly on eIF4A include MYC, cyclin D1, cyclin D3, and BCL2, which contribute to tumor survival, cell proliferation, and cell cycle progression.<a onclick="showRef(event, 'ref20 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref22">(20,22)</a> Similarly, eIF4A is of recent interest as an antiviral because some viruses employ native translation factors for their own survival.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> For example, the influenza virus requires host eIF4A proteins in order to translate its own mRNA.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Coronaviruses, picornaviruses, and other positive strand RNA viruses may also rely on eIF4A helicase activity to unwind their long, highly structured 5′-UTRs.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">2.2.2.  eIF4A Inhibitors</h4><div class="NLM_p">The tetrahydrocyclopenta[b]benzofuran, rocaglamide A (or rocaglamide, or RocA (<b>7</b>)) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), was first isolated from <i>Aglaia elliptifolia</i> in 1982, and it showed significant antiproliferative activity against P388 leukemic cells.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Despite the early evidence of their biological activity, the mechanism of action and molecular targets of rocaglates were not determined until almost two decades after their discovery.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In 2008, it was reported that the cytotoxic mechanism of rocaglates derives from stabilizing the interaction between eIF4A and RNA, which inhibits translation initiation, leading to cell death.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In 2016, RocA (<b>7</b>) was reported to clamp eIF4A specifically to polypurine sequences within mRNA in an ATP-dependent manner, effectively inhibiting scanning by the 43S ribosome subunit.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> A CRISPR-based study investigated the capability of a drug-resistant eIF4A1 allele to rescue function, which further verified the rocaglate-eIF4A inhibitory relationship.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Ultimately, the crystal structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZC9">5ZC9</a>) showing RocA interaction with eIF4A, polypurine RNA, and AMPPNP was solved, showing direct binding to both RNA and protein (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Structure of rocaglamide A (<b>7</b>). (B) Co-crystal structure of the eIF4A·AMPPNP·RocA·polypurine complex (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZC9">5ZC9</a>). (C) Co-crystal structure of the eIF4A·AMPPNP·RocA·polypurine complex highlighting key binding interactions. Gray = rRNA base; green = eIF4A protein; teal = RocA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Silvestrol (<b>8</b>), a particularly potent natural rocaglate, has been of significant interest since it isolated from the <i>Aglaia foveolata</i> plant in 2004.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Structurally, silvestrol contains an unprecedented dioxanyl group, which is a methyl group in the majority of RocA derivatives, making it a uniquely bulky congener.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Silvestrol inhibits [<sup>35</sup>S]methionine incorporation in HeLa cells with an IC<sub>50</sub> = 0.02 μM, ∼5 times more potent than RocA ([<sup>35</sup>S]methionine incorporation in HeLa cells IC<sub>50</sub> = 0.1 μM).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Silvestrol induces dimerization of eIF4A and RNA to inhibit protein translation, depleting available eIF4A from associating with the eIF4F complex as confirmed by poly(rG)-agarose pull down assays.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In order to understand the transcript selectivity of silvestrol, Wolfe et al. used ribosome footprinting to profile mRNA transcripts contained in actively translating ribosome complexes arrested by silvestrol.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> This analysis revealed that silvestrol preferentially stalled transcripts containing sequence features such as 12-nucleotide guanine quartet (CGG)<sub>4</sub>, which can form G-quadruplex structures in their 5′-UTR. Importantly, specific oncogenes such as MYC, MDM2, and RUNX1, which contain several (CGG)<sub>4</sub> motifs, were found to be enriched in silvestrol stalled ribosome complex preparations, whereas housekeeping genes, which typically have shorter 5′-UTRs, were not.</div><div class="NLM_p"><i>In vitro</i>, silvestrol has potent antiproliferative effects ranging from IC<sub>50</sub> = 4–10 nM in various acute myeloid leukemia (AML) cell lines and in chronic lymphocytic leukemia (CLL) patient tumor cells.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> On the basis of its <i>in vitro</i> efficacy, silvestrol has been investigated as a therapeutic agent against B-cell malignancies <i>in vivo</i>.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> These studies showed that silvestrol effectively and selectively acts on B-cells in a mouse CLL model when administered at a 1.5 mg/kg dose per day for 5 days over 2 weeks.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> This treatment resulted in a significant decrease in B cell count and no notable change in T cell count, similar to the results from the <i>in vitro</i> CLL assay (B cell selectivity over T cell).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> On the basis of the compelling biological activity, silvestrol underwent preclinical development by the NCI Developmental Therapeutics Program’s Drug Development Group with intentions of future clinical testing. However, significant pharmacokinetic challenges face the clinical application of silvestrol. For example, silvestrol is an effective efflux pump substrate and has a short half-life in plasma across species.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> As a result of these limitations, no clinical studies with silvestrol have been reported.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p">The discovery of cytotoxic activity of rocaglates, and their complex tricyclic framework, spurred significant interest in their synthesis, which has greatly enabled their therapeutic development.<a onclick="showRef(event, 'ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42">(39−42)</a> Recently, Chu et al. undertook a medicinal chemistry campaign that led to the identification of potent synthetic RocA derivative CR-1–31-B (<b>9</b>) (IC<sub>50</sub> = 9 nM in NIH/3T3 cells) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref31 ref43'); return false;" href="javascript:void(0);" class="ref ref31 ref43">(31,43)</a> Key SAR findings were the addition of an electron-rich hydroxamate, which forms a hydrogen bonding interaction with Glu195 in eIF4A. Further improvements in potency were gained by incorporation of an imidazolidine ring to the cyclopenta[b]benzofuran core, which is believed to provide additional binding energy by interacting with the N7 guanine ring.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The combined modifications led to CMLD012612 (<b>10</b>), which also showed higher polypurine sequence selectivity and cytotoxicity levels when compared to CR-1-31-B (<b>9</b>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a><i>In vivo</i>, CMLD012612 sensitized myr-Akt/Eμ-Myc lymphomas to doxorubicin in mice, leading to total tumor loss in 16 days, making amidino rocaglates a promising subclass of rocaglates to consider as anticancer therapeutics.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of synthetic rocaglamide analogues CR-1-31-B (<b>10</b>), CMLD012612 (<b>11</b>), Zotatifin (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Zotatifin (<b>3</b>), also known as eFT226, is a synthetic rocaglate being developed by eFFECTOR Therapeutics.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Similar to other rocaglates, zotatifin effectively stabilizes eIF4A binding to RNA polypurine sequences in an ATP-independent manner.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> From SAR studies, the unprecedented replacement of the trialkoxyphenyl ring in RocA to a 7-pyridyl heterocycle lowered lipophilicity and encouraged additional π stacking with the adenine A7, increasing sequence specific binding of the compound at polypurine tracts of the mRNA. Replacement of the amide found in most rocaglates with the tertiary amine also led to significant improvement in potency and reduced lipophilicity, which greatly aided solubility of the series.<a onclick="showRef(event, 'ref31 ref44'); return false;" href="javascript:void(0);" class="ref ref31 ref44">(31,44)</a> Analysis of the mRNA-sequence selectivity of zotatifin showed preference for binding to polypurine (AGAGAG) motifs, as expected. <i>In vitro</i> potency studies showed IC<sub>50</sub> values of 11 nM in MDA-MB-231 breast cancer cell lines.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Resistance mutation screening identified the eEIF4A F163L mutant, which was about 60 times less sensitive to zotatifin. In murine orthotopic MDA-MB-231 triple negative breast cancer (TNBC) models, Zotatifin treatment at 1 mg/kg once weekly for 2 weeks led to tumor regression (122% tumor growth inhibition) relative to vehicle-treated animals. In 2019, eFFECTOR Therapeutics initiated clinical trials to evaluate zotatifin (eFT226) in advanced solid tumor malignancies, and it is currently in phase I/II (NCT04092673).</div><div class="NLM_p">More recently, rocaglates have been considered as antiviral therapeutics. Silvestrol was first shown to be effective against the Ebola virus (EBOV) and has come under renewed interest due to the urgency surrounding the 2020 SARS-CoV-2 pandemic.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Silvestrol showed promising results as an antiviral drug against Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) and human coronavirus 226E (HCoV-226E) in studies in 2018.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Interestingly, silvestrol is able to inhibit viral transcripts that do not contain polypurine sequences in their 5′-UTR, such as hepatitis E virus (HEV).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In this case, the high degree of secondary structure in the HEV 5′-UTR is potentially highly dependent on eIF4A. Consistent with this, the synthetic rocaglate CB-1-31-B, which shows higher polypurine sequence binding specificity, is less effective at inhibiting HEV replication in MRC-5 cells.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Additionally, after identifying the host translational machinery as strong interactors with the SARS-CoV-2 virus, a screen of compounds for activity against SARS-CoV-2 in human cells identified Zotatifin as a promising lead, demonstrating a decrease in viral nucleoprotein load at concentrations that did not cause significant cytotoxicity.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> A phase I study of zotatifin in adults with mild to moderate COVID-19 has now been initiated (NCT04632381).</div><div class="NLM_p">Pateamine A (PatA, <b>11</b>), a thiazole-containing macrolide, was first isolated from the New Zealand marine sponge <i>Mycale sp</i>. in 1991 and was determined to have cytotoxic effects on P388 murine leukemia cell lines (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Early mechanistic studies showed that PatA inhibits translation initiation.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> Washout experiments indicated that PatA binds irreversibly to eIF4A and was likely the cause of its high cytotoxic in HeLa cells.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The irreversible binding may derive from 1,4-addition of a ribosomal protein residue with the unsaturated ester within PatA, although to date direct evidence for a covalent bond formation between pateamine A and eIF4A has not been observed. Further studies into its mechanism of action showed that PatA induces eIF4A into its closed conformation, and in this state it cannot bind ATP and RNA.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> As part of the efforts to find simplified derivatives of pateamine A with improved biological activity, Romo et al. probed the SAR by deconstructing the molecule into two basic fragments. The C1–C5 beta amino acid fragment was tolerant of several major modifications, suggesting it is quite flexible and that it largely plays a scaffolding role. The rigid C6–C24 fragment was significantly less tolerant to modifications, suggesting that it acts as part of the binding surface. One C1–C5 simplified derivative DMDAPatA (des-methyl des-amino pateamine A, <b>12</b>) demonstrated more potent suppression of T-cell receptor-mediated IL-2 expression (IC<sub>50</sub> = 0.8 nM, DMDAPatA; IC<sub>50</sub> = 4 nM, PatA) in Jurkat cells.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> While utilizing DMDAPatA to gain insight into the mechanism for PatA has been encouraging, further research is still needed to provide a full and accurate mechanism of action for pateamine A.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The irreversible mechanism of action suggests that pateamine A analogues have low therapeutic potential.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of eIF1A inhibitors pateamine A (PatA, <b>11</b>), synthetic analogue of PatA DMDAPatA (<b>12</b>), and hippuristanol (<b>13</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Hippuristanol (<b>13</b>) is a polyoxygenated sterol first isolated from the <i>Isis hippuris</i> coral in 1981 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). It was found to inhibit the growth of DBA/MC fibrosarcoma cells and to have activity <i>in vivo</i> against lymphocytic leukemia P388 mice tumors.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> In 2006, studies showed that hippuristanol reversibly inhibits cap-dependent protein synthesis in a dose-dependent manner with an IC<sub>50</sub> of 0.07 μM in HeLa cells.<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a> Disrupted polysomes in the presence of hippuristanol indicated that it targets protein initiation, as opposed to elongation or other steps.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Further mechanistic studies into hippuristanol in 2008 showed that it interacts with the C-terminal domain (CTD) of eIF4AI to effectively block eIF4A RNA binding, helicase activity, and RNA-dependent ATPase activity.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Without a crystal structure, NMR-based structure elucidation revealed that hippuristanol binds directly to the <i>N</i>-terminal E5 and E6 beta strands, as well as to the C-terminal end of helix H4. The binding site does not align with the RNA-interacting face of eIF4A, indicating that hippuristanol likely works allosterically by disrupting interactions between the N-terminal domain (NTD) and CTD. Recently, studies into conformational dynamics revealed that eIF4A uses ATP hydrolysis to transition between an open and closed conformation in order to unwind the RNA.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Hippuristanol utilizes this transition to inhibit eIF4A by locking it into its closed conformation so it is unable to function as a helicase.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><div class="NLM_p last">Antineoplastic studies involving hippuristanol have been ongoing since its discovery in 1981. Hippuristanol has been studied as a chemosensitizer in Eμ-Myc lymphomas, where it was able to work synergistically with DNA-damaging agents doxorubicin as well as cyclophosphamide.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Data have also shown that hippuristanol is active against primary effusion lymphoma (PEL) and adult T-cell leukemia (ATL) in xenograft mice.<a onclick="showRef(event, 'ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62">(60−62)</a> Previously, challenges in synthesizing hippuristanol have impeded pharmacological studies, due to limited supply of the compound.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The unusual stereosensitive bicyclic spiroketal of the steroid core makes hippuristanol a unique structure with a challenging and low-yielding synthesis. However, various synthetic routes have been reported and may potentially allow for further preclinical investigation.<a onclick="showRef(event, 'ref56 ref63 ref64 ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref56 ref63 ref64 ref65 ref66">(56,63−66)</a></div></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">2.2.3.  eIF4E</h4><div class="NLM_p">Eukaryotic initiation factor 4E (eIF4E) is a conserved cap-binding protein, essential for protein translation initiation.<a onclick="showRef(event, 'ref23 ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref23 ref67 ref68">(23,67,68)</a> The structure of eIF4E contains eight antiparallel β-sheets and three α-helices in a cupped formation (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69,70)</a> Specific mRNA cap recognition occurs at the concave surface of eIF4E where the m7G cap has a cation-π interaction with W56 and W102.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Interactions with eIF4G and 4E-binding protein (4E-BP), however, occur at the convex surface. Additionally, eIF4E has been shown to have mRNA nuclear export protein functions.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Regulation of eIF4E is important in the cell to ensure proper levels of protein translation. Phosphorylation at eIF4E S209 by MAP-kinase signal-integrating kinases (Mnk1 and Mnk2) increases its affinity for the mRNA cap structure, whereas dephosphorylation causes decreased translation rates. Indeed, Mnk inhibitors are being investigated as anticancer therapeutics but lie outside the scope of this review.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Hypophosphorylated 4E-BP proteins regulate eIF4E by sequestering it, so it is no longer able to interact with eIF4G to form eIF4F. Once 4E-BP is hyperphosphorylated, eIF4E is released to participate in translation initiation.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Chemical structure of mRNA 5′-7-methylguanylate (m7G) cap. (B) <i>In vivo</i> transformation of ribavirin (<b>15</b>) to predicted active metabolite RTP (<b>16</b>). (C) Cocrystal structure of m7G bound to eIF4E (PDB: IL8B). (C) eIF4E inhibitors ribavirin (<b>15</b>) and ribavirin triphosphate (RTP, <b>16</b>) and (D) Rib4C (<b>17</b>) and tiazafurin (<b>18</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">eIF4E is the rate limiting initiation factor in the eIF4F complex, making it a desirable target for reducing levels of protein translation.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The concentration of eIF4E present is most influential in mRNAs that are long and highly structured.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Many structured mRNAs encode for proteins that are implicated in cell cycle progression, tumor growth, and angiogenesis, such as MYC, VEGF, and FGF2, making eIF4E inhibitors a promising anticancer therapeutic.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Thirty years ago, eIF4E was discovered to be a proto-oncoprotein that causes tumorigenesis when overexpressed in cells.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Experiments using mice models verified that eIF4E overexpression <i>in vivo</i> also caused and accelerated tumorigenesis in various tissues.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In humans, eIF4E overexpression has also been linked to head and neck squamous cell carcinoma (HNSCC), various leukemias and lymphomas, tumors in the breast, lung, and colon, and chemoresistance to common and targeted therapeutics.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p last">The importance of eIF4E as an antiviral target has been studied extensively. Caliciviruses, positive-sense single-stranded RNA viruses, utilize a unique eIF4E recruiting mechanism in order to successfully undergo translation.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> For example, the potyvirus-derived viral genome-linked protein (VPg) binds directly to eIF4E and directly competes with the eukaryotic mRNA m7G cap for translation initiation.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div></div><div id="sec2_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">2.2.4.  eIF4E Inhibitors</h4><div class="NLM_p">1-β-<span class="smallcaps smallerCapital">d</span>-Ribofuranosyl-1,2,4-triazole-3-carboxamide, also known as ribavirin (<b>15</b>), is a synthetic nucleoside with strong, broad spectrum antiviral activity, first reported in 1972 by the ICN Nucleic Acid Research Institute (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77,78)</a> Since then, Ribavirin received FDA approval for treatment in respiratory syncytial virus (RSV), Lassa fever, and hepatitis C virus (HCV), but the mechanism of action was not clearly understood at the time of approval.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Ribavirin becomes mono-, di-, and tri-phosphorylated at its 5′-end, and it is the triphosphate form (RTP, <b>16</b>) that was attributed to the antiviral activity through an unknown mechanism potentially involving RNA polymerase and mRNA capping.<a onclick="showRef(event, 'ref80 ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref80 ref81 ref82">(80−82)</a></div><div class="NLM_p">Ribavirin has since been rediscovered as an anti-neoplastic agent, prompting renewed interest in its mechanism.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> In 2004, data indicated that ribavirin was acting as a m7G-cap mimetic, competing for direct binding to eIF4E to disrupt the eIF4E·m7G mRNA cap complex at low micromolar concentrations.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The positive quaternary amine in m7G due to methylation results in strong π stacking ability with eIF4E residues Trp56 and Trp102 in the binding pocket. Mutation studies (W56A) in eIF4E showed similar decreases in binding with ribavirin and m7G mRNA cap despite ribavirin predicted to be neutral under physiological conditions.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Comparing ribavirin and an isomer Rib4C (1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl-1,2,3-triazole-4-carboxamide, <b>17</b>), Rib4C was unable to bind eIF4E, demonstrating the importance of the heterocycle for activity.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Similarly, tiazofurin (<b>18</b>), another ribavirin analogue with electronics similar to guanosine, did not bind to eIF4E.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> A few reports showed data that ribavirin failed to bind eIF4E or bound at very low levels, and did not inhibit translation of exogenous mRNAs.<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85,86)</a> However, these concerns were explained by differences in experimental conditions.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> An important note is that an m7G cap mimetic mechanism would not explain ribavirin’s potent effects on viruses that do not utilize cellular mRNA processing, like HCV and poliovirus, which rather is attributed to incorporation of ribavirin into the viral mRNA by RNA polymerases, leading to mutagenesis in those viruses.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Nevertheless, the mode of action for Ribavirin in cancer is attributed to the disruption of eIF4E·m7G mRNA cap binding.<a onclick="showRef(event, 'ref83 ref88'); return false;" href="javascript:void(0);" class="ref ref83 ref88">(83,88)</a> Consistent with its selective antiproliferative effect, in <i>KMT2A</i>-rearranged acute lymphoblastic leukemia (ALL) cells, ribavirin selectively inhibits translation of eIF4E-dependent transcripts MYC, MCL1, NBN, and BCL2, but not translation of eIF4E-independent transcripts such as actin.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div><div class="NLM_p">Currently, ribavirin has been a part of about 20 clinical trials as an anticancer drug.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> eIF4E elevation in M4/M5 AML cancers made it a strong therapeutic candidate.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> A phase I/II study showed no toxicities due to the therapy (NCT00559091) and prompted combination studies with common anticancer drugs used to treat AML cancers including Cytarabine arabinoside, Vismodegib, and Decitabine (NCT01056523, NCT02073838).<a onclick="showRef(event, 'ref90 ref91'); return false;" href="javascript:void(0);" class="ref ref90 ref91">(90,91)</a> On the basis of the promising data, phase I/II studies have begun for metastatic breast cancer and other solid tumors (NCT01056757). Ribavirin, alongside interferon treatment, has also been used to reduce risk of hepatocellular carcinoma after chronic HCV infection (NCT01051414, NCT01497834).<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Additionally, there are promising results using ribavirin <i>in vivo</i> in combination with doxorubicin to sensitize the cancer cells and increase the inhibitory effect of doxorubicin.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Ribavirin has also been studied as a therapeutic or combination therapeutic for glioblastoma, atypical teratoid/rhabdoid tumors (pediatric brain tumor), retinoblastoma, renal cell carcinoma, prostate cancer, and others.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> It should be noted that ribavirin was initially considered as an antiviral therapeutic for the SARS-CoV-2 pandemic in 2020; however, a comparative assay showed EC<sub>50</sub> values of 109.5 μM, rendering it ineffective for curing infected cells.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div><div class="NLM_p">Although eIF4E is an attractive therapeutic target, the discovery that the active metabolite of ribavirin is the highly polar triphosphate, RTP, provides significant limitations to the physical properties of such compounds with the cap-mimetic mechanism of action. Several medicinal chemistry groups have attempted to address these challenges by trying to replace the phosphate moiety or using a prodrug strategy.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div><div class="NLM_p">In 1989, studies into 7-mGMP analogues for protein translation inhibitors showed that 7-BnGMP (<b>19</b>) had a higher inhibitory effect than 7-mGMP on eIF4E cap binding activity.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> The crystal structure of 7Bn-GMP with eIF4E (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V8X">2V8X</a>) indicated that there was a conformational change in the cap-binding site that increased the affinity for the benzyl moiety (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref97 ref98">(97,98)</a> When 7Bn-GMP is bound, the eIF4E Trp102 indole flips 180° to allow the benzyl to reside in a cavity behind Trp102 and Trp166, and incorporation of the benzyl ring in the cavity removes two water molecules, increasing entropy.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Despite the change in conformation, the key interactions are maintained: purine ring stacking with Trp102 and Trp56, three hydrogen bond interactions with Glu103 and Trp102, and ring overlap of the six-membered ring section of purine, Trp102, and Trp56.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Additionally, the orientation of the α-phosphate and Arg157 maintains the ability to form a salt bridge and interact with two conserved water molecules.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Although it is an effective binder, 7-BnGMP has poor solubility and permeability due to the highly charged phosphate and flat, rigid shape of the molecule.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> To circumvent this issue, Ghosh et al. synthesized 4Ei-1, a stable pronucleotide pro-drug that is metabolized into 7-BnGMP once inside the cell.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> 4Ei-1 is a nucleoside phosphoramidate that binds to histidine triad nucleotide binding proteins (HINT) and is metabolized into the active 5′ monophosphate nucleotide. Cancer cells tend to overexpress human HINT proteins (hHINT-1), making 4Ei-1 a promising anticancer therapy.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Structures of synthetic 5′-7-methylguanosine cap mimetics <b>19</b> and <b>20</b>. (B) Cocrystal structure of eIF4A with 7Bn-GMP (<b>19</b>) (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V8X">2V8X</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">4Ei-1 was found to inhibit epithelial-to-mesenchymal transition (EMT), a crucial step in cancer and tissue fibrosis, in a zebrafish explant model.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Importantly, 4Ei-1 showed no developmental abnormalities in zebrafish embryos and no other signs of toxicity <i>in vivo</i> or <i>in vitro</i>. This positioned 4Ei-1 as a promising lead as a potential drug for slowing progressive fibrosis and as an anti-neoplastic therapeutic.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Further work investigating 4Ei-1 in EMT showed that it inhibited the eIF4E-dependent TGF-β1-mediated EMT in lung epithelial cells.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> More specifically, once converted into 7-BnGMP, it was able to fully inhibit ribosome recruitment to the overactivated Snail1 mRNA transcript. Given the role of tissue fibrosis in multiple metabolic and inflammatory diseases, nontoxic translation inhibitors may offer a promising alternative therapeutic approach.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> 4Ei-1 has also been shown to be an effective chemosensitizing agent for gemcitabine in breast and lung cancers, for pemetrexed in mesothelioma, as well as a tumor reducing drug in mesothelioma cancer cell lines.<a onclick="showRef(event, 'ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref103 ref104">(103,104)</a></div><div class="NLM_p">Another strategy to overcome the limited cell permeability associated with eIF4E inhibitors was taken by Wan et al., who used a covalent docking strategy to identify small molecules that bind covalently to the noncatalytic lysine (Lys162) in eIF4E.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> One of the advantages of this strategy is that the sulfonyl fluoride electrophilic warhead mimics the phosphate group yet is uncharged and therefore imparts improved cell permeability and solubility on the compounds. Initial virtual screening identified several scaffolds, and following synthesis of prioritized hits, lactam <b>20</b> was identified as a bona fide eIF4E binder by observation of the eIF4E-adduct by liquid chromatography mass spectrometry (LCMS) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Structure-based optimization of eIF4E inhibition (as determined by % eIF4E modification by LCMS) involved introduction of a pyridine, which extended into a hydrophobic pocket allowing the pyridine nitrogen to form a hydrogen bond with serine Ser92, leading to compound <b>21</b>. Additional hydrogen bonding interactions were obtained by incorporation of the aminopyrimidinone motif, better mimicking the adenine pharmacophore and ultimately leading to optimized analogue <b>22</b>. Importantly, <b>22</b> showed dose-dependent labeling of eIF4E in cells and represents the first demonstration of a cell active covalent eIF4E inhibitor. While further studies of covalent eIF4E inhibitors will be required before their therapeutic potential can be assessed, they provide valuable tools for dissecting the role of eIF4E in translational control in health and disease.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Structures of covalent eIF4E inhibitors. (B) Cocrystal structure of <b>21</b> bound to eIF4E via covalent bond to Lys162 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UO9">6UO9</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The small molecule thiazole 4EGI-1 (<b>23</b>) was discovered in 2007 through a fluorescence polarization assay screen, measuring disruption of the eIF4E interaction with eIF4G. On the basis of these experiments, the binding affinity of 4EGI-1 for eIF4E was estimated at <i>K</i><sub>D</sub> ≈ 25 μM.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> NMR analysis of 4EGI-1 indicated that the E- and Z-isomers easily interconverted, but only the E-isomer can effectively bind eIF4E. The crystal structure of 4EGI-1 and eIF4E complex was solved in 2014 and shows 4EGI-1 binding at a basic, hydrophobic pocket (between the Leu60-Thr68 β2-strand and the Glu69-Asn77 α1-helix) distant to the eIF4G binding pocket, indicating allosteric inhibition (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4TPW">4TPW</a>) (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Additionally, the crystal structure captures two different interconverting eIF4E states, one version that is unable to bind 4EGI-1. On the basis of mutational studies on the α1-helix, this is the source of flexibility that affords the multiple conformation states for either eIF4G or 4EGI-1 binding. The mechanism was further elucidated in 2015, when it was determined via NMR and fluorescence quenching that 4EGI-1 and 4E-BP can bind eIF4E simultaneously despite partial overlap in the binding site.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> 4EGI-1 has a unique dual action mechanism that prohibits eIF4G binding and stabilizes 4E-BP binding, meaning it provides an additional amount of functional inhibition and tumor suppression especially in the case that 4E-BP dissociates due to hyperphosphorylation.</div><div class="NLM_p">Early studies of 4EGI-1 showed promising anti-neoplastic properties without toxicity at therapeutic doses in xenograft models for human breast cancer and melanoma cancer.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Pull-down studies in glioma U87 cells saw 4EGI-1-based inhibition of eIF4E·eIF4G complex, leading to downregulation of survivin, c-MYC, and cyclin D expression.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Since 4EGI-1 failed to impact the expression or phosphorylation of eIF4E and 4E-BP, the data support that 4EGI-1 acts independently of 4E-BP and enhances 4E-BP binding to eIF4E.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> 4EGI-1 was also used to suppress cap-dependent translation initiation in malignant pleural mesothelioma (MPM) through apoptosis induction and oncoprotein reduction.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> In nonsmall cell lung cancer (NSCLC) cells, 4EGI-1 was able to diminish the presence of oncoproteins cyclin D1, survivin, BCL-2, and MYC.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Additional <i>in vitro</i> studies showed that 4EGI-1 has chemosensitizing properties and has potential as a combined therapy with Gemcitabine.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><div class="NLM_p">In an effort to discover a small molecule that inhibits eIF4E binding to both eIF4G and 4E-BP, 4E1RCat (<b>24</b>) was identified through a library screen, subsequent <i>in vitro</i> assays, and SAR studies (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> In silico modeling studies indicated potential for 4E1RCat binding at four shallow pockets on eIF4E that would disrupt eIF4G and 4E-BP binding.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Modeling of similar molecule, 4E2RCat (<b>25</b>), indicated that it interacts similarly with eIF4E at four of its eIF4G and 4E-BP binding sites. Additionally, 4E1RCat was able to reduce formation of the 80S complex, but not fully prohibit recruitment. Pulldown assays verified that 4E2RCat inhibits eIF4E·eIF4G and eIF4E·4E-BP complexes.<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112,113)</a><i>In vivo</i>, 4E1RCat successfully synergized with doxorubicin to sensitize tumors in Pten ± Eμ-Myc and Tsc2 ± Eμ-Myc lymphoma models, tumor models that were previously resistant to doxorubicin alone.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Further work indicated that when a single therapeutic dose was not effective, 4E1RCat is capable of synergizing with Salubrinal to impair the development of xenograft melanoma development in mice as well as inhibiting cell cycle progression and reducing cyclin expression.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> 4E2RCat was also showed dose- and time-dependent activity as an antiviral against human coronavirus 229E (hCoV-229E) in infected cells.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> The <i>in vitro</i> antiviral studies would indicate that 4E2RCat was more potent than hippuristanol and silvestrol (eIF4A inhibitors).<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a><named-content content-type="anchor" rid="fig11" type="simple"></named-content></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of synthetic eIF4E inhibitors 4EGI-1 (<b>23</b>), 4E1RCat (<b>24</b>), and 4E2RCat (<b>25</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Cocrystal structure of 4EGI-1 bound to eIF4E (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4TPW">4TPW</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">2.3.  Translation Elongation Inhibitors</h3><div class="NLM_p">Multiple inhibitors of eukaryotic translation elongation have been discovered. The eukaryotic elongation factor 1A (eEF1A) and the ribosome are the most common targets of elongation inhibitors, and in many cases translation termination is also affected (<i>vide infra</i>). The high cellular abundance of these proteins makes achieving high levels of target engagement challenging. However, in the context of essential cellular machinery, a high level of target engagement is not necessarily the goal of translation elongation inhibitor optimization; rather, it is to achieve selective translation inhibition. Differences in target, binding site, binding mode, and pharmacodynamics can all lead to differences in translation inhibitor selectivity and, ultimately, phenotypical outcome.</div><div id="sec2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">2.3.1.  eEF1A</h4><div class="NLM_p">The eukaryotic elongation factor 1 A (eEF1A) is an evolutionarily conserved 40 kDa GTPase required for protein synthesis. eEF1A exists in two isoforms (eEF1A2 and eEF1A2). The isoforms differ in their tissue expression—eEF1A1 is ubiquitously expressed, while eEF1A2 expression is highly localized to muscle, although the two isoforms are thought to have degenerate functions.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> eEF1A is one of the most abundant proteins in the cell and plays a key role in protein synthesis by shuttling aminoacyl-tRNA complexes to the ribosomal A-site in preparation for integration into the elongating polypeptide. In its GTP-bound form, eEF1A binds to aa-tRNA forming the eEF1A·GTP·aa-tRNA ternary complex.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> This ternary complex binds to the ribosome at the interface of the 60S and 40S ribosomal subunits, and upon interaction with the mRNA codon sequence, hydrolyses GTP, dissociates from the ribosome, and is then recycled for a second round of amide bond formation. In addition to its role in translation, eEF1A has also been shown to interact with components of the cellular cytoskeleton, such as actin and tubulin, and has several other roles such as nuclear transport.<a onclick="showRef(event, 'ref15 ref117'); return false;" href="javascript:void(0);" class="ref ref15 ref117">(15,117)</a> There is also emerging evidence that phosphorylation of eEF1A is an additional mechanism of translational regulation. Such phosphorylation events have been shown to produce a 2-fold increase in the rate of GDP to GTP exchange.<a onclick="showRef(event, 'ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref118 ref119">(118,119)</a></div><div class="NLM_p">Both eEF1A1 and eEF1A2 are known to sustain the progression and severity of cancer and have therefore attracted attention as possible drug targets for oncology indications.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Overexpression of eEF1A is observed in hepatocellular carcinoma (HCC) cell lines and clinical samples. It is an indicator of poor prognosis and is thought to play a causative role in HCC as a result of the aberrant rate of protein synthesis in these neoplastic tissue subtypes.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Rictor and co-workers also describe a case of undifferentiated small round cell sarcoma with excessive eEF1A expression.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></div><div class="NLM_p last">Viruses can hijack the host for replication machinery to translate their viral genome. For example, coronaviruses have been shown to directly interact with eEF1A, and knockdown of eEF1A has been shown to impair replication in transmissible gastroenteritis coronavirus (TGEV) in mammalian cells.<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122,123)</a></div></div><div id="sec2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">2.3.2.  eEF1A Inhibitors</h4><div class="NLM_p">Plitidepsin (<b>2</b>), also known as dehydrodidemnin B, belongs to a class of cyclic depsipeptide natural products including didemnin A (<b>26</b>) and didemnin B (<b>27</b>), first identified in 1977 by Rinehart and co-workers following their antiproliferative bioassay-guided isolation from the Carribean marine tunicate (sea squirt) <i>Aplidium albicans</i> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).<a onclick="showRef(event, 'ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref124 ref125">(124,125)</a> Early studies of the didemnin class of compounds revealed that they had potent antiproliferative activity across a range of cancer cell lines, and they had antiviral activity against both DNA and RNA viruses.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Mechanism of action studies on these compounds revealed potent inhibition of protein synthesis and that this was likely responsible for its antiproliferative effect in cancer cell lines.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> The <i>in vitro</i> anticancer effects of plitidepsin are particularly strong (EC<sub>50</sub> < 1 nM) against blood cancers multiple myeloma, lymphoma, and leukemia, and solid tumors such as nonsmall cell lung, pancreas, breast, melanoma, sarcoma, gastric, ovarian, bladder, and colon cancer cell lines. Crews et al. ultimately identified the binding partner of didemnin B to be eEF1A.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> These mechanistic studies also revealed interesting pharmacological characteristics of the compound. First, the binding of didemnin B is GTP dependent. Second, the action of didemnin B appears to be irreversible. These observations can be explained at the molecular level by the cryo-EM structure of didemnin·EF1A·GDP·tRNA·ribosome ternary complexes trapped during elongation and purified from rabbit reticulocytes.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Didemnin B binds at the interface between the ribosome and domain III of eEF1A and traps elongating polypeptide complexes at multiple codon positions. The cyclic peptide backbone of didemnin B forms a rigid framework enforced by intramolecular hydrogen bonds between the carbonyl oxygen of the lactyl side chain with the amide N–H of the leucine (Leu) fragment (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). A second interaction occurs between the α-C-H of the threonine fragment and the Leu carbonyl. Didemnin B largely interacts with eEF1A through hydrophobic interactions. For example, the Leu residue is buried deep into eEF1A into a pocket formed by a hydrophobic stretch of residues (Val435-Gly436-Val437). The ligand is held in place by several hydrogen bonds that are formed via Ser383 and Arg382 along the β-hairpin (β15-β16, residues 375–391) of eEF1A to the amido group of the side chain, and macrocyclic backbone of didemnin B, respectively. This binding mode is thought to prevent a conformational twist within eEF1A that is required to release aa-tRNA and may be how didemnin B irreversibly traps eEF1A on the ribosome in a posthydrolysis GDP-bound state.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Molecular structures of members of the didemnin class of natural products didemnin A (<b>26</b>), didemnin B (<b>27</b>), <b>28</b>, and dehydrodidemnin B (plitidepsin) (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structures of didemnin B bound to eEF1A (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LZS">5LZS</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Sakai et. al undertook a structure–activity relationship study of the antiproliferative effects of 42 natural and synthetic didemnin congeners across a panel of cancer cell lines, protein synthesis, and against RNA and DNA viruses.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> It was clear from these studies that modifications to the depsipeptide backbone significantly abrogated the activity, as is often the case with cyclic peptide natural products, given that the peptide backbone usually plays a scaffolding role, reinforced through intramolecular hydrogen bonds. Under the cell-based conditions of this SAR analysis, it is difficult to determine whether the lack activity was due to cell permeability or target engagement. Nevertheless, modifications of the side chain lactylproline (LacPro) side chain led to some improvements in activity. For example, didemnin A (<b>26</b>), B (<b>27</b>), and <b>28</b> that differ in the identity of the side chain, show differing cytotoxicity, which does not closely correlate with global inhibition of protein synthesis (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).<a onclick="showRef(event, 'ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref130 ref131">(130,131)</a> The oxidized congener, dehydrodidemnin B (also known as plitidepsin), was found to be more active than the parent peptide. Plitidepsin has been shown to have significant antitumor activity in multiple myeloma xenograft models either alone or in combination with dexamethasone, diffuse large B-cell and Burkitt’s lymphoma, either alone or combined with rituximab.<a onclick="showRef(event, 'ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref132 ref133">(132,133)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Growth Inhibition as Measured by Counting Live Cells<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (nM) 72 h</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center" char=".">didemnin A (<b>26</b>)</th><th class="colsep0 rowsep0" align="center" char=".">didemnin B (<b>27</b>)</th><th class="colsep0 rowsep0" align="center" char=".">dehydrodidemnin B (<b>2</b>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P388</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HT-29</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MEL-28</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibition of Protein and DNA and RNA Synthesis in P388 Cells As Measured by [<sup>14</sup>C]Leucine, [<sup>3</sup>H]dThD 5-[<sup>3</sup>H]Uridine Incorporation, Respectively<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (μM) 72 h</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">didemnin A (<b>26</b>)</th><th class="colsep0 rowsep0" align="center">didemnin B (<b>27</b>)</th><th class="colsep0 rowsep0" align="center">dehydrodidemnin B (<b>2</b>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein synthesis</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DNA</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RNA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="left">>1</td></tr></tbody></table></div></div><div class="NLM_p">On the basis of its potent anticancer activity, multiple clinical trials on the didemnin class of molecules have been undertaken. The parent compound didemnin B (<b>27</b>) entered clinical trials for non-Hodgkins lymphoma over three decades ago. Despite its promising anticancer activity, cardiac toxicities prevented administration at efficacious doses and halted further development.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Plitidepsin (<b>2</b>) has also been evaluated in several clinical trials.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> In phase I trials, no cardiac toxicity was observed, but dose limiting toxicities (DLT) were associated with muscle weakness, increases of creatine kinase levels, and some mild hematological toxicity.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Similar DLTs were found in other phase I trials of plitidepsin.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Investigation of the mechanism leading to muscle toxicity identified type II fiber atrophy without inflammation. Inhibition of carnitine palmitoyltransferase 2 (CPT2), an enzyme responsible for carnitine trafficking across the mitochondrial membrane, is believed to underlie the mechanism of plitidepsin-induced muscle toxicity. This is likely due to direct binding of plitidepsin to CPT2, since the related congener didemnin B is known to directly bind and inhibit the related palmitoyltransferase PPT1.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> In support of this hypothesis, coadministration of <span class="smallcaps smallerCapital">l</span>-carnitine allowed higher doses of plitidepsin to be tolerated in clinical sudies.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> In an open label, single arm, phase II clinical study of plitidepsin in relapsed and refractory multiple myeloma either as a single agent or in combination with dexamethasone, an overall response rate for the plitidepsin as a single agent cohort was 13%, and in combination with dexamethasone was 22%. Notably, a longer plitidepsin plasma half-life was observed in patients with better clinical responses.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> However, it should be noted that the relationships between plitidepsin pharmacokinetics and efficacy have been difficult to establish due to high patient variability in exposure and poor correlation of exposure to dose.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> In the ADMYRE randomized, phase III clinical study of plitidepsin in combination with dexamethasone versus dexamethasone alone in relapsed and refractory multiple myeloma, the plitidepsin combination arm showed a superior progression free survival (PFS) of 3.8 months compared to dexamethasone alone 1.9 months.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> In 2018, plitidepsin was approved in Australia to treat patients with multiple myeloma in combination with dexamethasone who have failed front-line treatments such as immunomodulatory imide drugs (IMiDs) and proteasome inhibitors. Plitidepsin is currently marketed by PharmaMa under the trade name Aplidin.</div><div class="NLM_p">In addition to its anticancer activity, recent <i>in vitro</i> studies have also demonstrated that plitidepsin may have antiviral activity, including against the novel coronavirus, SARS-Cov-2.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> On the basis of the demonstrated <i>in vitro</i> activity of plitidepsin against corona viruses, the urgency of the current COVID-19 pandemic, and previous clinical safety profile of plitidepsin, phase II clinical trials have now been initiated to evaluate Aplidin in patients with COVID-19 (NCT04382066).</div><div class="NLM_p">Other classes of natural translation inhibitors have also shown promising antiproliferative activity. Nannocystins are a class of 21-membered mixed polyketide-tripeptides first isolated by Sanofi labs from the myxobacterial metabolite from the genus <i>Nannocyctis sp</i>. (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Soon after, an independent discovery of the same molecule was made by Novartis.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Nannocystin A (<b>29</b>) was found to potently inhibit fungal growth and display broad antiproliferative activity against various cancer cell lines at nanomolar concentrations (EC<sub>50</sub> 1 nM and 12 nM for PC3 and HL60 cells, respectively). As part the investigation of nannocyctin A by Kratstel and co-workers, a screen for resistance in colorectal cancer cell line HCT-116 identified resistant clones harboring mutations in eEF1A. Robust tumor cell resistance to nannocystin A mapped to A399V and V437L mutations in domain III of eEF1A. These mutations were found to be cross-resistant toward didemnin B, indicating both natural products bind to overlapping binding sites, a hypothesis that was supported by molecular docking models.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Following the development of synthetic routes to nannocystins by Hu, Furstner and others, medicinal chemistry efforts on this class of molecules have uncovered important SAR.<a onclick="showRef(event, 'ref145 ref146 ref147'); return false;" href="javascript:void(0);" class="ref ref145 ref146 ref147">(145−147)</a> For example, LQ18 (<b>30</b>) and simplified analogues of nannocystin A lacking the potentially unstable epoxide were shown to retain antiproliferative activity. Additional manipulations of the substitution pattern, for example, the tyrosine residue, were also seemed to be well tolerated.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> To date, no <i>in vivo</i> studies involving nannocystins have been reported.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structure of nannocyctin A (<b>29</b>) and synthetic derivative LQ18 (<b>30</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ternatins are a class of cyclic peptide isolated by Simokawa and co-workers from the ethyl ether extract of the mushroom <i>Cloriolis versicolor</i>. The protypical member of this class ternatin (<b>31</b>) inhibited fat accumulation in mouse 3T3-L1 adipocyte with an EC<sub>50</sub> of 20 nM.<a onclick="showRef(event, 'ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref149 ref150">(149,150)</a> At higher concentrations, ternatins show antiproliferative profile across cancer cell lines similar to that of didemnins. Mutations in eEF1A that induce resistance to didemnins and nannocystins (A399V) also confer resistance to ternatins.<a onclick="showRef(event, 'ref144 ref149'); return false;" href="javascript:void(0);" class="ref ref144 ref149">(144,149)</a> Mechanism of action and structural studies proved that ternatins bind to the EF1A·GTP·aa-tRNA complex and, like didemnin, trap EF1A on the ribosome. However, unlike didemnin B, ternatins display reversible binding and can be “washed out” in cell-based proliferation experiments.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Early SAR studies on the ternatin side chain residues identified critical functional groups and led to significant improvements in antiproliferative potency. For example, truncation of Leu4 to an alanine residue almost completely abrogates activity (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> On the other hand, the synthetic congener <b>32</b>, in which the Leu4 has been replaced with dehydrohomoleucine, coupled with replacement of the methylalanine (MeAla) residue with a pipecolic acid, affords a ∼10-fold boost in its potency in HCT-116 cells (IC<sub>50</sub> = 5 nM). Given the subtle pharmacological differences and presumably differentiated pharmacokinetics, it will be interesting to compare the efficacy and therapeutic window between ternatin and didemnin classes of translation inhibitors.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Ternatin (<b>31</b>) and synthetic derivative (<b>32</b>) with improved antiproliferative activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Other classes of cytotoxic natural products, for example, the ansatrienins (e.g., Ansatrienin A (<b>33</b>)), have also been shown to be sensitive to the nannocystin-induced resistance mutations.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Members of the amaryllidaceae isocarbostyril alkaloids, such as narsiclasine (<b>34</b>), have also been shown to bind to eEF1A and display potent antiproliferative effects in melanoma cell lines (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Given the potent anticancer activities of plitidepsin and its similar mechanism, these related natural products may serve as an alternative starting point for new anticancer EF1A inhibitors.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Other potential eEF1A binding molecules ansatrienin A (<b>33</b>) and nasiclasine (<b>34</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">2.3.3.  80S Ribosome</h4><div class="NLM_p">In eukaryotes, the ribosome is a ∼3.2 MDa macromolecular complex composed of proteins and RNA that catalyze peptide bond formation during protein translation (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>).<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> It is composed of two subunits, the larger ∼2.0 MDa 60S subunit, which consists of 47 r-proteins and 3 rRNA molecules, and the smaller ∼1.2 MDa 40S subunit, which consists of 32 r-proteins and 1 rRNA (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>).<a onclick="showRef(event, 'ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref155 ref156">(155,156)</a> While the ribosome is smaller in other organisms (∼2.0 MDa in bacteria), the catalytic transamidase site, which consists of rRNA bases, is highly conserved. The transamination reaction is catalyzed by rRNA, which forms an A-loop within the peptidyl transferase center of the 60S subunit. Adenosine 2451 acts as the catalytic base, whereby the adenine N3 deprotonates the incoming nucleophilic aa-tRNA in the first step in peptide bond formation and stabilizes the corresponding tetrahedral intermediate (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). As the peptidyl transfer proceeds, the large 60S and smaller 40S subunits undergo a twist, like opening an Oreo, that allows translocation of the A-site tRNA to move across into the P-site, poised to accept an incoming nucleophilic amino group from the next amino acyl tRNA.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> During this process, the small 40S subunit enables correct tRNA codon pairing and governs mRNA decoding.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Eukaryotic 80S ribosome complex during elongation (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4UJE">4UJE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Base-catalyzed mechanism of peptidyl transfer in the peptidyl transfer center of the ribosome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The ribosome is the key node in translational control, and the translational efficiency of the cell is linked to ribosome abundance.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> The upregulation of ribosome concentration and transcript-specific changes in translation are known to be driven by oncogenes such as mTOR, MYC, and KRAS.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Since mRNA transcript levels often do not reflect the activity of many signaling pathways, measuring <i>translationally active</i> mRNA transcripts can identify proteins that are under control at the translational level and better reflect the cellular state. In general, cancer cells display higher ribosome occupancy reflecting overall greater translational activity. Advances in ribosome profiling technologies such as Ribo-Seq can now offer a single-codon resolution picture of transcript-specific translational activity.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> For example, <i>in vivo</i> ribosome profiling in mouse models of glioma reveal tumor specific altered ribosome positioning (differential ribosome activity) associated with DNA replication and cell division ontologies.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> In a comparison of translational efficiencies in clinical hepatocellular carcinoma (HCC) tumor samples, differential translational efficiency of proteins involved in metabolism, such as lactate dehydrogenase B (LDHB), were observed.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Ribosome profiling in human CD4+ Th1 cells revealed that many metabolic processes in these cells are regulated at the translational level, which is not reflected by mRNA levels alone in those cell types.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> The identification of metabolic protein expression levels in immune cells under translational control raises the possibility that modulating translation with small molecules could have applications in metabolic and immune disease therapy, in addition to established applications cancer and infectious disease.</div><div class="NLM_p">At least 10% of inherited human genetic diseases are caused by nonsense mutations.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> These mutations introduce premature termination codon (PTC) into the coding region of the affected mRNA and can cause translation of the protein to halt and/or for truncated and nonfunctional protein variants to be produced leading to a variety of pathologies.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> For example, cystic fibrosis, beta thalassemia, Duchenes muscular dystrophy (DMD), and dystrophic epidermolysis bullosa all result from PTCs in the coding region of the corresponding mRNAs. Many cancers also harbor PTCs in the coding region of tumor suppressor genes.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Some small molecules with the ability to induce “readthrough” of PTCs, such as aminoglycoside antibiotics, have been shown to restore protein levels in human diseases such as cystic fibrosis.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> These translational readthrough inducing drugs (TRIDs) are discussed in <a class="ref internalNav" href="#sec2_3_4" aria-label="section 2.3.4">section 2.3.4</a>.</div><div class="NLM_p last">Diseases caused by congenital defects in either rRNA or r-protein components are referred to as ribosomopathies. These genetic mutations often leading to bone marrow failure, developmental abnormalities and increased risk of cancer. Such diseases are the focus of various gene therapy discovery efforts and are beyond the scope of this review.<a onclick="showRef(event, 'ref166 ref167'); return false;" href="javascript:void(0);" class="ref ref166 ref167">(166,167)</a></div></div><div id="sec2_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">2.3.4.  Ribosome Modulators</h4><div class="NLM_p">Multiple small molecules that bind to the ribosome have been identified over the last few decades. Of those, many bind selectively to the eukaryotic ribosome.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> The binding partner and mechanism of action of these compounds is often discovered after their biological activity has been identified; i.e., eukaryotic ribosome binding molecules are not usually identified through rational approaches. However, the growing number of ribosome-binding small molecules now being discovered, both natural and synthetic in origin, with different mechanisms of action are beginning to teach us how to design molecules to perturb this macromolecular machine in novel ways to achieve desirable pharmacological outcomes.</div><div class="NLM_p">The harringtonines are a family of pentacyclic alkaloid natural products first isolated from the Japanese plum-yew <i>Cephalotaxus harrintonia</i>. The prototypical members of this class are cephaloxtaxine (<b>35</b>), harringtonine (HT, <b>36</b>), isoharringtonine (<b>37</b>), deoxyharringtonine (<b>38</b>), and homoharringtonine (HHT, <b>1</b>), which all contain a fused pentacyclic core but differ in the nature of the C-3 ester (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>). Early <i>in vivo</i> studies on HT showed antilymphoma activity at doses as low as 1 mg/kg.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Mechanistic studies by Fresno et al. uncovered that HT blocks the elongation step in translation by preventing binding of aa-tRNA to the A-site of the ribosome, and also that harringtonines do not interact with polysomes and therefore probably bind during the early stages of peptide elongation, an observation supported by ribosome profiling experiments.<a onclick="showRef(event, 'ref170 ref171'); return false;" href="javascript:void(0);" class="ref ref170 ref171">(170,171)</a> Profiling of HT across a panel of cancer cell lines showed more potent antiproliferative effects against HL-60 (acute promyelocytic) and RPMI-8402 (T-cell acute lymphocytic) and significantly weaker (>50-fold) antiproliferative effects on BALM-2 (B-cell acute lymphoblastic leukemia) and DND-41 (T-cell acute lymphoblastic leukemia). The differential activity was not related to cellular uptake or efflux based on radiolabeling studies using [<sup>3</sup>H]HT. There was also a correlation found between sensitivity toward HT and proliferation rate of the cell line, supporting the selective effect on highly proliferative cancer cells.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Despite the promising <i>in vivo</i> and <i>in vitro</i> anticancer activity of the harringtonine class of alkaloids, the complex tetracyclic frameworks and stereochemically complex esters have limited exploration of SAR. The cocrystal structure of HHT bound to the ribosome shows that it binds to the 60S subunit, in the peptidyl transferase center in a pocket made up mostly of rRNA. Key polar interactions occur between basic C4398 and the protonated tertiary amine of HHT, and A4449 forms hydrogen bonding interactions between the methoxy and C-3 ester carbonyl, which extends deep into the peptidyl transferase center. The observed multiple interactions between the C-3 ester of HHT and the ribosome is consistent with extensive SAR of the C-3 ester moiety. One such study of more than 40 esters of cephalotaxine assessed for antilymphoma activity by Mikolajczak and co-workers found the ester to be crucial for antitumor activity <i>in vivo</i> and that the natural congener HHT displayed the strongest antiproliferative activity.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Ultimately, based on its remarkable antiproliferative activity and despite significant challenges obtaining the material, which relied on harvesting from bulk cephalotoxus trees, the natural congener homoharringtonine (HHT) progressed into clinical development.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. (A) Structure of naturally occurring cephalotaxine natural products and clinical used analogue HHT (<b>1</b>). (B) Cryo-EM structure indicating the binding site and key interactions with rRNA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The initial human trials of HHT in cancers date back several decades.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Those studies demonstrated that HHT administration, as a single agent, produced good responses in blood cancers such as acute myeloid leukemia (AML) myelodysplastic syndrome, acute promyelocytic leukemia, and chronic myeloid leukemia (CML), but poor responses were observed in solid tumors. Early trials in acute myeloid leukemia (AML) patients showed complete response rates (CR) of up to 90% in combination with cytarabine, and 25% as a single agent treatment. Several recent clinical studies have also shown positive response rates with HHT as a single agent in CML, and acute promyelocytic leukemia (APL), supporting the clinical use of HHT in CML (NCT00462943).<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> At efficacious doses, the main dose-limiting toxicities are myeloid suppression, and at higher doses cardiovascular complications are observed. The hematological toxicities are usually observed in the form of neutropenia and lymphopenia. Indeed neutrophils have been shown to be particularly sensitive to HHT compared to transformed myeloid cells.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> In 2012 the Food and Drug Administration (FDA) approved HHT for treating CML in patients with resistance to two or more tyrosine kinase inhibitors. HHT is currently marketed as SYNRIBO, Omacetaxine Mepesuccinate.</div><div class="NLM_p">In addition to its anticancer activity, recent <i>in vitro</i> studies demonstrated that HHT exhibits broad antiviral activity. Work by Dong et al. showed that HHT inhibited VSV replication at concentration 1000 times lower than ribavirin, underscoring its potential as a novel antiviral.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a><i>In vivo</i> HHT has significant activity against Newcastle disease virus (NDV) and porcine epidemic diarrhea virus (PEDV).<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> HHT has been shown to decrease levels of p-eIF4E, which is thought to be a contributor to its antiviral mechanism. However, although increased levels of phosphorylation of eIF4E are associated with certain viral infections, dephosphorylation of p-eIF4E occurs in the case of VSV infection, and so this is likely not the mechanism by which HHT exerts its broad antiviral activity.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> More recently, HHT has also been shown to inhibit SARS-CoV-2 replication with an EC<sub>50</sub> of 0.06 μM.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> Given the renewed need for new effective pan-antiviral therapeutics, compounds that have achieved regulatory approval for clinical use, such as HHT, are promising candidates as new antiviral drugs.</div><div class="NLM_p">Several other classes of natural products that selectively bind to the eukaryotic ribosome have been discovered. For example, the agelestatins are a class of halogenated alkaloids first isolated by Pietra and co-workers in 1993 from the Coral Sea sponge <i>Agelas dendromorpha</i> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Agelestain A (<b>39</b>) has been the most intensively studied of the natural congeners and demonstrates low nanomolar activity against a wide panel of cancer cell lines, as well as primary human umbilical vein endothelial cells (HUVECS), and inhibits osteopontin-mediated adhesion, invasion, and colony formation in human breast cancer cell lines.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Pietra and co-workers also established that AglA confers a significant survival benefit (average 63% longer lifespan) in murine L1210 xenograft models.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Mechanism of action studies showed that AglA blocks protein translation, and structural studies pinpointed that AglA binds specifically to the ribosomal A-site preventing peptidyl transfer during translation elongation (PDB: 4V88).<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> A significant amount of work has been applied to the synthesis of agelestatins, and these efforts have been covered in detail elsewhere.<a onclick="showRef(event, 'ref181 ref183'); return false;" href="javascript:void(0);" class="ref ref181 ref183">(181,183)</a> In the most recent iterations, a biomimetic strategy employed by the Movassaghi group allowed the synthesis of all known natural Agelastatin analogues.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Synthetic analogue (<b>40</b>) reported by Stout et. al replaces the bromine with a trifluoromethyl group, retains potent sub-micromolar IC<sub>50</sub> against chronic lymphocytic leukemia (CLL) cell lines, but also displays increases in <i>C</i><sub>max</sub> and AUC.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> Agelamide class of molecules have not progressed further in preclinical development.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. (A) Structure of naturally occurring alegestatin A (<b>39</b>) and synthetic analogue <b>40</b>. (B) Cryo-EM structure indicating the binding site and key interactions with rRNA (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MEI">5MEI</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Mycalamides, another class of marine natural product, are polyketides first isolated from the marine ascidian <i>Polysincraton sp</i>. (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). Early biological studies on mycalamides demonstrated that mycalamide A (Myc A, <b>41</b>) has potent antiproliferative activity in a number of human cancer cell lines. Particularly noteworthy was the observation that MycA inhibited EGF-stimulated transformation of JB6 C141 P+ cells (a model of anchorage-independent colony growth) at concentrations as low as 35 pM. Since this concentration is approximately 50 times lower that the IC<sub>50</sub> for viability in the same cell line (1 nM), albeit at a much shorter time point, it implies that these molecules can block cell colony growth without causing significant cytoxicity.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Interestingly, a much smaller window (∼8 times) was observed for HeLa cells (viability IC<sub>50</sub> = 5 nM) indicating that the therapeutic window is highly cell type dependent. [<sup>35</sup>S]Methionine incorporation experiments indicated that the related molecule, mycalamide B (MycB, <b>42</b>) inhibited protein synthesis. Specifically, MycB was shown to inhibit translation elongation by direct blockade of eEF2-mediated translocation to the ribosome. On the basis of homology to cocrystal structures of mycalamide A bound to the archeal ribosome, MycA binds the E-site of the ribosome. The C3993 28S rRNA residue on the 60S subunit of plays an important role in binding.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Interestingly, ribosome profiling revealed that MycB arrests the ribosome on the mRNA one codon ahead of the broad-spectrum ribosome inhibitor cycloheximide (CHX), which binds in the E-site, distal to mycalamide B binding site. This subtle difference suggests that the mechanisms of ribosome stalling can be mRNA sequence dependent and therefore may be display selectivity toward inhibition of certain mRNAs over others.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structure of naturally occurring translation inhibitors mycalamide A (<b>41</b>) and mycalamide B (<b>42</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, a novel class of small molecule that selectively inhibits the translation of a specific subset of proteins have been described by Petersen and co-workers.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> Using a phenotypic screen for small molecule inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) accumulation in CHO-K1 cells, they identified the isoquinoline R-IMPP (<b>43</b>) (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>), which inhibited PCSK9 production with an IC<sub>50</sub> of 4.8 μM but showed no cytotoxicity in the same cell line. [<sup>35</sup>S]Methionine incorporation studies showed that R-IMPP inhibited production of both the mature PCSK9 and the pro-PCSK9 form of the protein, indicating that R-IMPP acts on protein synthesis rather than degradation. Affinity-selection mass spectrometry (ASMS) experiments demonstrated that R-IMPP binds selectively to the eukaryotic 80S ribosome, but not the <i>E. coli</i> ribosome.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Structures of transcript-selective ribosome binding small molecules.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Medicinal chemistry optimization of this series of molecules led to PF-06446846 (PF846, <b>44</b>), which inhibits PCSK9 secretion with an IC<sub>50</sub> = 300 nM.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> Proteome wide profiling of the effect of PF846 on Huh-7 cells using stable isotope-labeling of amino acids in cell culture (SILAC) LCMS/MS revealed that the compound had essentially no impact on global protein production and only led to downregulation of a small set of proteins including PCSK9, HSD17β11, USO1, and CDH1. Ribosome profiling of PCSK9 transcripts in PF846 treated cells provided ribosomal footprints centered around codon 34, indicating ribosome stalling at this position. Ribosome profiling also identified HSD17β11, MDK, CDH1 USO1, PLAG15, and CD99 as PF846 sensitive transcripts. Although the stall site for each of these transcripts generally lies within the first 50 codons, there does not appear to be a simple consensus sequence that explains the selectivity.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> This observation is consistent with previous studies of chimeric PCSK9 variants which mapped the R-IMPP sensitivity of PCSK9 to the N-terminal signal peptide and the first 20 amino acids of the pro-domain.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> Comparison of ribosome footprints between PF846 and closely related congener PF503 (<b>45</b>) in Huh-7 cells also confirmed both molecules stalled PCSK9 translation and found that both compounds additionally inhibited translation of CCR1, MDK PLA2G15, and PCYX1L transcripts. Interestingly, despite a modest structural change between the two compounds, PF503 was found to affect the translation of 46 mRNAs transcripts, whereas PF846 inhibited only 24 transcripts and showed a greater selectivity for PCSK9.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> Structural studies have shed light on how PF846 selectively inhibits translation of certain transcripts. A cryo-EM structure derived from PF846-stalled ribosomes in the process of translating CDH1 show that PF846 binds in the ribosomal exit tunnel, interacting with 28S ribosomal rRNA base C1576 through the piperidine nitrogen and G1577 through the pyridyl nitrogen, which overall form a binding site unique to eukaryotic ribosome (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> The triazolopyridine ring interacts with the LLIL sequence of the peptide nascent chain (the density in this region of the structure indicated a superposition of a cluster of stalled states). This interaction between the RNC and the triazolopyridine ring enforces a “kink” in the RNC, which in turn disrupts interactions between the P-loop and the nascent chain-tRNA 3′CAA, which is important for efficient eEF2-mediated translocation. Similarly, in the cryo-EM structure of PCSK9-RNC ribosome complexes, the triazolopyridine interacts with a LGPA sequence and adopts an alternative kinked conformation enforced by a proline residue in the RNC. Notably, profiling of random mutation libraries centered around the CDH1 stall site identified sequences enriched in charged residues such as histidine. Two new CDH1 stall inducing sequences HYHS and RSCK motifs were identified.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> However, these sequences did not induce stalling when introduced into PCSK9, which requires additional mutations in the N-terminus. These structural observations are consistent with the sensitivity of PCSK9 transcripts mapping to the first 20 amino acids, which would be positioned upstream the small molecule interaction site. Further investigation into the mechanism of translational stalling found that PF846 also affects translation termination.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> Specifically, when the termination factor eRF1 binds into the ribosomal A-site, PF846 interacts with specific NCs and prevents conformational changes in the ribosome required for hydrolysis of the NC from the P-site tRNA, ultimately inhibiting translation termination.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> The number of other proteins that produce nascent chains with unique structural features amenable to selective inhibition during translation remains an open question, but the growing empirical evidence described here suggests it is at least possible for at least more targets than just PCSK9.<named-content content-type="anchor" rid="tbl3" type="simple"></named-content></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Codon Stall Sites for Top 10 Treatment-Induced Stalled Transcripts Identified from Huh-7 Cells Treated with PF846 (<b>44</b>) or PF503 (<b>45</b>)<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">PF846 (<b>44</b>)</th><th class="rowsep1 colsep0" colspan="2" align="center">PF503 (<b>45</b>)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">gene</th><th class="colsep0 rowsep0" align="center">main stall codon</th><th class="colsep0 rowsep0" align="center" char=".">log 2 fold change 1.5 μM</th><th class="colsep0 rowsep0" align="center">main stall codon</th><th class="colsep0 rowsep0" align="center" char=".">log 2 fold change 1.5 μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PCSK9</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="char" char=".">–2.0</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="char" char=".">–1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HSD17B11</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="char" char=".">–1.6</td><td class="colsep0 rowsep0" align="left">300</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PLA2G15</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="char" char=".">–1.5</td><td class="colsep0 rowsep0" align="left">25,30</td><td class="colsep0 rowsep0" align="char" char=".">–1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDK</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="char" char=".">–1.4</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="char" char=".">–2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RPL27</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="char" char=".">–1.4</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="char" char=".">–1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TM2D3</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="char" char=".">–1.3</td><td class="colsep0 rowsep0" align="left">undef</td><td class="colsep0 rowsep0" align="char" char=".">–0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MST1</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="char" char=".">–1.3</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="char" char=".">–0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LTBP3</td><td class="colsep0 rowsep0" align="left">undef</td><td class="colsep0 rowsep0" align="char" char=".">–1.2</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="char" char=".">–0.9</td></tr></tbody></table></div></div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structures of PF846 bound to ribosome-RNC complexes. (A) PCSK9 nascent chain residues Pro25-Ala26 interacting with PF846 at the dipeptide (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OM0">6OM0</a>). (B) CDH1 nascent chain residues Leu721-ILeu723 interacting with PF846 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OLE">6OLE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><i>In vivo</i>, in healthy rats, orally administered PF846 was shown to reduce circulating PCSK9 and concomitant LDL levels in a dose-dependent manner from 5 mg/kg up to 50 mg/kg daily, for 14 days. Importantly, under all dosing regimens, PF846 was well tolerated leading to only subtle changes in eating habits, no observed effect on body weight, some mild reductions in hematological counts, and no liver pathologies.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> This underscores the potential of transcript-selective protein translation to have low <i>in vivo</i> toxicity, which is a valuable proof of concept for therapeutic translation inhibitors. While the current suite of LDL lowering therapies may mean PF846 or similar molecules may not be the best approach for targeting hypercholesterolemia, the promising <i>in vivo</i> safety profile of such transcript-selective ribosome inhibitors provides a compelling first glimpse at a potentially new therapeutic strategy for metabolic diseases.</div><div class="NLM_p">Aminoglycosides comprise a large class of broad spectrum, clinically used antibiotics that contain a dibasic aminocyclitol ring, most commonly a 2-deoxystrepatmine (2-DOS). Although their antibiotic action derives from interactions with the bacterial ribosome, certain aminoglycosides also bind to distinct sites on the eukaryotic ribosome, endowing them with unique biological activity and lower cytotoxicity in eukaryotic organisms.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> Specifically, studies in yeast by Singh et al. demonstrated that certain aminoglycosides such as paromomycin (<b>47</b>) (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>) are able to promote translational readthrough of premature termination codons (PTCs) in eukaryotic cells, while not causing cell death.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> Generally, the efficiency of PTC readthrough by aminoglycosides can be ordered UGA > UAG > UAA, but normal termination codons (NTCs) are often suppressed less efficiently than PTCs due to differences in their local sequence environment.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> Paromomycin and other aminoglycosides have been shown to effectively suppress PTCs in mRNA transcripts associated with cystic fibrosis (CF), Duchenne’s muscular dystrophy (DMD), and dystrophic epidermolysis bullosa, which has spurred significant interest in the development of aminoglycosides and other TRIDs for disease indications beyond infectious disease and rationalizes their inclusion in this perspective.<a onclick="showRef(event, 'ref196 ref197'); return false;" href="javascript:void(0);" class="ref ref196 ref197">(196,197)</a> Additional reviews focused on aminoglycosides are also available.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a></div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structure of common aminoglycosides with 2-deoxystrepatmine (2-DOS) ring highlighted in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Aminoglycosides bind to the A-site of the small subunit in both the bacterial and eukaryotic ribosomes.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> In prokaryotes, paromomycin and similar aminoglycosides such as geneticin (<b>47</b>) that contain a 6′-OH group in ring I interact with A1408 that lies on h44 in the decoding region of the small subunit (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>A). The strong interaction between the 6′-OH group in paromomycin with A1408 in the bacterial 70S ribosome causes significant structural perturbation in codon recognition, leading to an increase in translational error rate and death in bacteria. <sup>199</sup>In eukaryotic ribosomes, A1408 is replaced with G1645, which decreases the <i>K</i><sub>D</sub> for paromomycin from 100 nM in prokaryotic ribosomes to 4 μM in eukaryotes ribosomes.<a onclick="showRef(event, 'ref199 ref200'); return false;" href="javascript:void(0);" class="ref ref199 ref200">(199,200)</a> Although this mutation decreases binding, the 6′-OH group is partially accommodated by G1645 in eukaryotes, reducing the impact on global translation, but sufficient to prevent full engagement of G1645 in tRNA decoding and allow readthrough of PTCs. In contrast, pyranmycin (TC007, <b>48</b>) and gentamicin (<b>49</b>) contain a 6′-NH<sub>2</sub> group that sterically clashes with G1645 in eukaryotic ribosomes. Gentamycin adopts a completely flipped binding orientation in eukaryotic ribosomes, with ring III occupying the region taken up by ring II in the paromomycin binding site (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>B). Indeed, the A1408G mutation in the 30S ribosomal subunit elicits strong resistance toward 6′-NH<sub>2</sub> aminoglycosides.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> Although TC007 has been shown to promote readthrough of PTCs, it is not found to bind at the ribosomal decoding center in cocrystal structures with 80S ribosome complexes but instead is observed to bind in at least two other sites, one proximal to the canonical decoding center and another in the 60S subunit.<a onclick="showRef(event, 'ref202 ref203'); return false;" href="javascript:void(0);" class="ref ref202 ref203">(202,203)</a> This is consistent with single molecule FRET (smFRET) studies of translating ribosome complexes that demonstrate TC007 is able to stabilize two distinct conformational (intersubunit rotated) states, one at ∼2 μM and another at ∼10 μM concentration.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> Therefore, there are potentially multiple and divergent mechanisms by which different aminoglycosides modulate translation in eukaryotes.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structures of aminoglycosides bound to ribosomal A-site in prokaryotes and eukaryotes. (A) X-ray crystal structure of paromomycin (teal) bound to the yeast 80S ribosome (magenta) (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NDV">5NDV</a>) overlaid with X-ray crystal structure of paromomycin (green) bound to the <i>Thermus thermophilus</i> 70S ribosome (gray) (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4V51">4V51</a>). (B) X-ray crystal structure of geneticin (blue) bound to the yeast 80S ribosome (magenta) (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OBM">5OBM</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><i>In vitro</i>, paromomycin and gentamicin have been shown to suppress PTCs, with gentamicin typically displaying ∼2-fold greater potency across translation and viability assays, and across species.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> For example, both paromomycin and gentamicin can suppress PTCs in type VII collagen (C7) and promote production of full-length C7.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> The p.P227X PTC in the GLA gene, which encodes for acid alpha-galactosidase, can also be suppressed by geneticin and gentamicin in fibroblast cultures from Fabry patients.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> Gentamicin has also been shown to induce production of cystic fibrosis transmembrane conductance regulator (CFTR) in <i>ex vivo</i> nasal cells derived from a cystic fibrosis (CF) patient with a G542X mutation.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> In mouse models of CF employing a <i>ctfr–/–</i> human <i>CTFR</i>-G542X mutant, gentamicin dosed at 34 mg/kg daily could induce expression of CTFR in duodenum tissue and was able to rescue CTFR channel activity to ∼10% of <i>ctfr+/–</i> levels.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> In other <i>in vivo</i> studies under a similar dosing regimen, gentamicin has been shown to restore levels of dystrophin protein by 10–20% in mdx mouse models of DMD.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> Gentamicin has also shown positive results in <i>in vivo</i> models of Rett syndrome driven by the R168X mutation in the <i>MECP2</i> gene.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a></div><div class="NLM_p">Gentamicin has undergone multiple clinical trials in diseases driven by nonsense mutations. In a recent phase I clinical study of young male patients with Duchenne’s muscular dystrophy with PTCs in dystrophin, a gentamicin dosing regimen of 7.5 mg/kg daily for 14 days resulted in significant improvements in primary outcome measure (50% reduction in serum creatine kinase). These clinical improvements were only observed in patients with PTCs in dystrophin and not in those with frameshift or other mutations, providing evidence of the on-target mechanism. A clinical trial evaluating the topical and intradermal administration of gentamicin for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) demonstrated increases in type VII collagen production of up to 165%.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> In the topical administration cohort, improvements were observed in dermal–epidermal separation, wound closure, and blister formation. A small study of gentamicin in patients with severe hemophilia caused by nonsense mutations in factor VIII (FVIII) and factor IX (FIX) showed some improvements in factor levels, and some patients showed improvements in their partial thromboplastin time (aPTT).<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> Although, it has been noted that the efficiency of aminoglycoside-mediated readthrough of hemophilia genes is highly mutant specific.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> A comparative clinical study of gentamicin treatment in CF patients with and without nonsense stop mutations in the <i>CTFR</i> gene showed increased CTFR expression in nasal epithelium and CTFR-dependent chloride secretion only in patients harboring the Y112X mutation but not those containing other mutations.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a></div><div class="NLM_p">The main dose-limiting toxicities in clinical application of aminoglycosides are ototoxicity and nephrotoxicity.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> In a systematic review of adverse events associated with single intravenous or intramuscular doses of gentamicin, ∼10% of patients experienced acute kidney injury, although this was reversible in the majority of cases.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> Aminoglycosides accumulate in renal and inner ear epithelial cells, leading to apoptosis and necrosis in that tissue, which can cause hearing loss. This toxicity is a consequence of specific endocytosis of aminoglycosides via interaction with megalin, which is expressed on the surface of epithelial cells of the inner ear and renal tubes. Aminoglycosides may induce apoptosis in these cells by forming aggregates or complexes with proteins and metal ions at high intracellular concentrations or causing the generation of free radicals, but the mechanism is not well understood.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> A potential mechanism of toxicity involves aminoglycoside binding to the mitochondrial ribosome, which shares the A1408 residue observed in prokaryotic ribosome, and so may be more susceptible to aminoglycoside inhibition. In support of this hypothesis, individuals with mutations in the mitochondrial ribosome rRNA genes can be more susceptible to ototoxicity caused by aminoglycosides.<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> In an effort to increase aminoglycoside selectivity for the eukaryotic ribosome and reduce off-target effects, synthetic aminoglycosides have been investigated. Kandasamy and co-workers describe an N1 acylated derivative (<i>S</i>)-11 (<b>50</b>) (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>), which exhibits comparative CFTR-WG542X readthrough activity as geneticin and gentamicin but shows more than 1000 times greater selectivity for inhibition of translation in eukaryotic ribosomes over translation in mitochondrial ribosomes, whereas geneticin and gentamicin show about 2-fold similar translational inhibition activity in both eukaryotic and mitochondrial systems.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> However, this gives rise to only a modest difference in cytotoxicity toward human embryonic kidney HEK293T cells (∼2-fold relative to gentamicin), indicating that additional factors other than binding to mitochondrial ribosomes are responsible for aminoglycoside cytotoxicity <i>in vitro</i>.</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structure synthetic aminoglycoside (<i>S</i>)-11 (<b>50</b>), which displays greater selectivity for the eukaryotic ribosome over mitochondrial ribosome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Finally, several non-aminoglycoside small molecules have also been investigated as TRIDs. PTC124 (Ataluran, <b>51</b>) sold under the trade name Translana, is a dipheyloxadiazole identified using a high-throughput screen of small molecule inducers of UGA nonsense codon readthrough (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>).<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> PTC124 was able to promote readthrough of the UGA luciferase reporter at concentrations down to 10 nM and saturate the readthrough signal at ∼3 μM. PTC124 was also shown to enhance readthrough of UAA and UAG PTCs with similar efficiency. Subsequently, PTC124 underwent <i>in vivo</i> evaluation in a murine mdx model of DMD. When dosed either orally or intraperitoneally, PTC124 was able to increase levels of dystrophin protein in mdx mouse myotubes by 20–25% and improve γ-sarcoglycan, serum creatine kinase, and EDL muscle force biomarkers.<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> PTC124 has also shown efficacy in other <i>in vivo</i> models nonsense mutation disease such as cystic fibrosis, aniridia, and Batten disease.<a onclick="showRef(event, 'ref218 ref219 ref220'); return false;" href="javascript:void(0);" class="ref ref218 ref219 ref220">(218−220)</a> PTC124 has undergone several clinical trials. An open-label phase 2a study of PTC124 in 38 young males with DMD, 28 days of PTC124 treatment of up to 40 mg/kg, orally administered, showed increases in muscle dystrophin levels in 61% of patients and improvements in biomarkers such as serum creatine kinase.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a> Notably, high plasma exposures of PTC124 were achieved, and it was well tolerated at all doses, with gastrointestinal discomfort the only drug-related adverse event reported. In phase III trials of PTC124 in 115 young males with DMD, maximum doses of up to 20 mg/kg showed only moderate improvements in primary end points (6 min walk distance) in some prespecified subgroups, relative to the placebo group (NCT01826487).<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> PTC124 has also undergone clinical trials in CF patients, which also demonstrated improvements in CFTR protein expression and clinical biomarkers.<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> However, in larger follow-up phase III trials in CF patients, PTC124 showed a lack significant therapeutic benefit.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> In 2016, PTC124 was approved for treatment of ambulatory DMD patients in the Europe Medicines Agency. It has yet to be approved by the FDA based on the lack of clinical efficacy observed in recent phase III trials.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structure of small molecules reported to induce PTC readthrough.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">More recently, a number of studies have called into question the mechanism of PTC124 biological activity.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> Since direct binding of PTC124 to the ribosome or other components of the translational machinery have not been established, its mechanism has been inferred based on luciferase reporter and other assay readouts. Several papers have demonstrated the ability of PTC124 to stabilize wild-type firefly luciferase and increase luminescent readouts in an off-target manner, potentially explaining the observed activity of PTC124 in <i>in vitro</i> translation assays.<a onclick="showRef(event, 'ref226 ref227'); return false;" href="javascript:void(0);" class="ref ref226 ref227">(226,227)</a> Indeed, a cocrystal structure of PTC124 bound to firefly luciferase has been solved (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IES">3IES</a>).<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> Currently, an understanding of the molecular details underlying the mechanism of action of PTC124 remains lacking.</div><div class="NLM_p last">Other small molecule chemical scaffolds have also been identified in high-throughput screens for PTC readthrough (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>). A high-throughput enzyme-linked ELISA assay was employed to identify RTC13 (<b>52</b>) as a promoter of PTC readthrough of the ataxia-telangiectasia (A-T) mutated (<i>ATM</i>) gene.<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> In follow-up assays, RTC13 was able to induce expression of full-length ATM protein to similar levels as geneticin and gentamicin. <i>In vivo</i> RTC13 administered to mdx mice via intraperitoneal injection of 30 mg/kg every 5 days for 4 weeks was able to increase dystrophin positive muscle fibers to a greater extent than PCT124 and produce partial recovery of muscle function.<a onclick="showRef(event, 'ref229'); return false;" href="javascript:void(0);" class="ref ref229">(229)</a> Using a similar ELISA screen, triazole GJ072 (<b>53</b>) was also identified as an inducer of ATM protein expression.<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a> Although the preliminary data look promising, the structural features of these compounds, such as the rhodanine-type in RTC13, are known as pan assay interference (PAIN) substructures, and so more work will be required to validate their mechanism of action.<a onclick="showRef(event, 'ref231 ref232'); return false;" href="javascript:void(0);" class="ref ref231 ref232">(231,232)</a> To avoid these potential complications, ribosome affinity binding assays and X-ray crystallographic studies will be highly valuable for the discovery and development of translational readthrough inducing drugs in the future.</div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">3.  Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17386" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17386" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Translation inhibitors have demonstrated great promise as therapeutics. The application of translation inhibitors in medicine has led to two clinical approvals: homoharringtonine for treating CML, and Aplidin (plitidepsin) in combination with dexamethasone for treating multiple myeloma. Ribavirin on the other hand was approved for treating RSV without being recognized as an eIF4E inhibitor at the time. Clinical trials assessing inhibitors of translation initiation, such as Zotatifin, in oncology and antiviral trials have opened the door to alternative modes of therapeutic translation inhibition with clinical potential. However, despite these successes, there remains a lack of drug-like small molecules with optimal pharmacology and ADMET in this space. The observation that plitidepsin has a poor dose-exposure correlation in patients, that its antitumor efficacy is correlated to its plasma half-life, and that it displays essentially irreversible binding to eEF1A suggests molecules targeting eEF1A but with improved pharmacology may be easier to develop and display better efficacy in clinical settings. In addition, eEF1A inhibitor chemotypes that lack off-target activity toward CPT2 may demonstrate lower myotoxicity and larger therapeutic windows.</div><div class="NLM_p">Small molecule modulators of the ribosome are a promising class of novel therapeutics. In addition to the application of HHT in oncology, small molecules that inhibit nascent chain elongation selectively have the potential to significantly lower toxicity. The demonstration of highly mRNA transcript-selective translation inhibition with small molecules, in the form of PF846, offers tantalizing prospects for targeting proteins in indications, such as chronic metabolic disease, that require a larger therapeutic windows and lower off-target risk than cancer and infectious disease often do. Such examples provide a compelling proof-of-concept for nontoxic translation inhibition <i>in vivo</i>, and the next milestone will be demonstrating this in humans. The current challenge is therefore to use drug-like starting points to identify inhibitors of translation with high selectivity for specific disease cell types, or specific transcripts/proteins for diseases without adequate treatment options.</div><div class="NLM_p">The ability to promote nonsense mutation readthrough with small molecules may have a range of therapeutic applications. Aminoglycosides have shown significant promise for increasing protein levels in loss-of-function genetic disease scenarios, such as Duchenne’s muscular dystrophy, cystic fibrosis, and dystrophic epidermolysis bullosa. The off-target cytotoxicity associated with this class of therapeutics suggests new structural classes of PTC readthrough molecules may be less cytotoxic. Indeed, a number of efforts directed toward the discovery of new translational readthrough inducing drugs have been attempted but have been challenged by a lack of tools to interrogate their mechanism of action and optimize their therapeutic effects.</div><div class="NLM_p last">An interesting observation that can be made by surveying the suite of translation inhibitors is that RNA often plays a key role in binding to their target, either through hydrogen bonding or π-stacking interactions. These interactions are often observed in binding pockets formed by rRNA on the ribosome, such as that observed with HHT, AglA, and aminoglycosides. Additionally, interactions with mRNA are critical in the ternary complexes formed by rocaglates, eIF4A, and mRNA polypurine sequences. Structural and chemical biology technologies such as cryo-EM, ribosome profiling, and smFRET will be key to the discovery and understanding of the mechanism of translation inhibitors, driving such molecules toward development as bona fide drugs. As the disease pathways and proteins medicinal chemists are targeting become ever more challenging, we will need to leverage new mechanisms of action and pharmacologic modalities. These exciting emerging data suggest that translation inhibition offers a promising strategy to tackle the next frontier of therapeutic challenges.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01746" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15787" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15787" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Phillip P. Sharp</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4416-2303" title="Orcid link">http://orcid.org/0000-0003-4416-2303</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#64340c0d08080d144a170c05161424090116070f4a070b09"><span class="__cf_email__" data-cfemail="0d5d65646161647d237e656c7f7d4d60687f6e66236e6260">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela Fan</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06521" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06521" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Angela Fan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=BIO-d7e2442-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Angela Fan</b> is an undergraduate student at the University of California, Berkeley, where she is majoring in chemical biology and minoring in nutritional sciences. There, she works on synthesizing organic materials in the T. D. Tilley group. In 2020, Angela was a summer intern at Merck & Co. in South San Francisco where she conducted research into eukaryotic translation inhibitors and DPP-4 inhibitors.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Phillip P. Sharp</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=BIO-d7e2447-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Phillip Patrick Sharp</b> obtained his Ph.D. in organic chemistry from the Australian National University under the supervision of Prof. Martin Banwell. Subsequently, Dr. Sharp undertook postdoctoral research in medical chemistry and chemical biology with Dr. Christopher Burns at the Walter and Eliza Hall Institute of Medical Research in Melbourne, and with Prof. Jack Taunton at University of California, San Francisco, where he developed novel inhibitors of Sec61. Currently Dr. Sharp is Senior Scientist at Merck Research Laboratories in South San Francisco, where his research is focused on the development of novel pharmacologic modalities for treating cancer, immune, and metabolic diseases.</p></figure></div><div class="ack" id="ACK-d7e2455-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36783" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36783" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to acknowledge members of the Merck Research Laboratories in South San Francisco for their helpful suggestions and proofreading.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">aa-tRNA</td><td class="NLM_def"><p class="first last">aminoacyl-tRNA</p></td></tr><tr><td class="NLM_term">ADMET</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, excretion, and toxicity</p></td></tr><tr><td class="NLM_term">ALL</td><td class="NLM_def"><p class="first last">acute lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">APL</td><td class="NLM_def"><p class="first last">acute promyelocytic leukemia</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">CDH1</td><td class="NLM_def"><p class="first last">cadherin-1</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myelogenous leukemia</p></td></tr><tr><td class="NLM_term">CR</td><td class="NLM_def"><p class="first last">complete response</p></td></tr><tr><td class="NLM_term">DOS</td><td class="NLM_def"><p class="first last">deoxystrepatmine</p></td></tr><tr><td class="NLM_term">DMD</td><td class="NLM_def"><p class="first last">Duchenne’s muscular dystrophy</p></td></tr><tr><td class="NLM_term">eIF</td><td class="NLM_def"><p class="first last">eukaryotic initiation factor</p></td></tr><tr><td class="NLM_term">eEF</td><td class="NLM_def"><p class="first last">eukaryotic elongation factor</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial-to-mesenchymal transition</p></td></tr><tr><td class="NLM_term">EM</td><td class="NLM_def"><p class="first last">electron microscopy</p></td></tr><tr><td class="NLM_term">GDP</td><td class="NLM_def"><p class="first last">guanosine diphosphate</p></td></tr><tr><td class="NLM_term">GTP</td><td class="NLM_def"><p class="first last">guanosine triphosphate</p></td></tr><tr><td class="NLM_term">HCC</td><td class="NLM_def"><p class="first last">hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">HUVEC</td><td class="NLM_def"><p class="first last">human umbilical vein endothelial cell</p></td></tr><tr><td class="NLM_term">IFNα</td><td class="NLM_def"><p class="first last">interferon alpha</p></td></tr><tr><td class="NLM_term">LDHB</td><td class="NLM_def"><p class="first last">lactate dehydrogenase B</p></td></tr><tr><td class="NLM_term">LDL</td><td class="NLM_def"><p class="first last">low density lipoprotein</p></td></tr><tr><td class="NLM_term">MDM2</td><td class="NLM_def"><p class="first last">mouse double minute 2</p></td></tr><tr><td class="NLM_term">NDV</td><td class="NLM_def"><p class="first last">Newcastle disease virus</p></td></tr><tr><td class="NLM_term">NTC</td><td class="NLM_def"><p class="first last">normal termination codon</p></td></tr><tr><td class="NLM_term">PABP1</td><td class="NLM_def"><p class="first last">poly(A) tail binding protein 1</p></td></tr><tr><td class="NLM_term">PAINs</td><td class="NLM_def"><p class="first last">pan assay interference compounds</p></td></tr><tr><td class="NLM_term">PEDV</td><td class="NLM_def"><p class="first last">porcine epidemic diarrhea virus</p></td></tr><tr><td class="NLM_term">PCSK9</td><td class="NLM_def"><p class="first last">proprotein convertase subtilisin/kexin type 9</p></td></tr><tr><td class="NLM_term">PFS</td><td class="NLM_def"><p class="first last">progression free survival</p></td></tr><tr><td class="NLM_term">PTC</td><td class="NLM_def"><p class="first last">premature termination codon</p></td></tr><tr><td class="NLM_term">RNC</td><td class="NLM_def"><p class="first last">ribosome nascent chain</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SILAC</td><td class="NLM_def"><p class="first last">stable isotope-labeling of amino acids in cell culture</p></td></tr><tr><td class="NLM_term">TRID</td><td class="NLM_def"><p class="first last">translational read-through inducing drug</p></td></tr><tr><td class="NLM_term">UTR</td><td class="NLM_def"><p class="first last">untranslated region</p></td></tr><tr><td class="NLM_term">VSV</td><td class="NLM_def"><p class="first last">vesicular stomatitis virus</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41084" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41084" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 232 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, N. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentaõ, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, R. B.</span></span> <span> </span><span class="NLM_article-title">Plitidepsin to Treat Multiple Myeloma</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1358/dot.2020.56.5.3135886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1358%2Fdot.2020.56.5.3135886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BB38vmvVahug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=337-347&author=N.+G.+M.+Gomesauthor=P.+Valenta%C3%B5author=P.+B.+Andradeauthor=R.+B.+Pereira&title=Plitidepsin+to+Treat+Multiple+Myeloma&doi=10.1358%2Fdot.2020.56.5.3135886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Plitidepsin to treat multiple myeloma</span></div><div class="casAuthors">Gomes N G M; Valentao P; Andrade P B; Pereira R B</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">337-347</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">While remaining relatively rare, multiple myeloma (MM) accounts for approximately 10% of all hematological malignancies, being an insidious disease with an overall 5-year survival rate of 52%.  In addition to other associated complications, myeloma bone disease further aggravates MM patients, the majority of whom suffer from lytic lesions, leading to pain, fractures, mobility issues and neurological deficits.  Patients not responding or becoming resistant to prior therapies have now a novel therapeutic tool with an unprecedent mode of action, differing from those currently in use.  The anticancer effects of the marine-derived antitumor agent plitidepsin primarily rely on the interaction with elongation factor 1-α 2 (eEF1A2), known to be overexpressed in breast cancer and MM cells, targeting the noncanonical role of the protein and leading to a proapoptotic response.  Following the drug's approval from Australian regulatory authorities, eligible patients will have access to a new first-in-class drug to treat MM, expanding the current anti-MM portfolio.  Plitidepsin (Aplidin; PharmaMar) was approved in combination with the corticosteroid agent dexamethasone, to treat MM patients who failed or became resistant to other therapies, covering the third- and fourth-line treatment setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJU-wjw_aULWlSCSgBhwJFfW6udTcc2eZD9Dmmp-WCCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38vmvVahug%253D%253D&md5=15b7e65e4a4794c5a79a28a1aaa60d38</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1358%2Fdot.2020.56.5.3135886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2020.56.5.3135886%26sid%3Dliteratum%253Aachs%26aulast%3DGomes%26aufirst%3DN.%2BG.%2BM.%26aulast%3DValenta%25C3%25B5%26aufirst%3DP.%26aulast%3DAndrade%26aufirst%3DP.%2BB.%26aulast%3DPereira%26aufirst%3DR.%2BB.%26atitle%3DPlitidepsin%2520to%2520Treat%2520Multiple%2520Myeloma%26jtitle%3DDrugs%2520Today%26date%3D2020%26volume%3D56%26spage%3D337%26epage%3D347%26doi%3D10.1358%2Fdot.2020.56.5.3135886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajasekhar, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanghvi, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavrakis, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roderick, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Meulen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teruya-Feldstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelliher, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speleman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rätsch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendel, H. G.</span></span> <span> </span><span class="NLM_article-title">RNA G-Quadruplexes Cause EIF4A-Dependent Oncogene Translation in Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1038/nature13485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnature13485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25079319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyhurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2014&pages=65-70&author=A.+L.+Wolfeauthor=K.+Singhauthor=Y.+Zhongauthor=P.+Dreweauthor=V.+K.+Rajasekharauthor=V.+R.+Sanghviauthor=K.+J.+Mavrakisauthor=M.+Jiangauthor=J.+E.+Roderickauthor=J.+Van+der+Meulenauthor=J.+H.+Schatzauthor=C.+M.+Rodrigoauthor=C.+Zhaoauthor=P.+Rondouauthor=E.+de+Stanchinaauthor=J.+Teruya-Feldsteinauthor=M.+A.+Kelliherauthor=F.+Spelemanauthor=J.+A.+Porcoauthor=J.+Pelletierauthor=G.+R%C3%A4tschauthor=H.+G.+Wendel&title=RNA+G-Quadruplexes+Cause+EIF4A-Dependent+Oncogene+Translation+in+Cancer&doi=10.1038%2Fnature13485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer</span></div><div class="casAuthors">Wolfe, Andrew L.; Singh, Kamini; Zhong, Yi; Drewe, Philipp; Rajasekhar, Vinagolu K.; Sanghvi, Viraj R.; Mavrakis, Konstantinos J.; Jiang, Man; Roderick, Justine E.; Van der Meulen, Joni; Schatz, Jonathan H.; Rodrigo, Christina M.; Zhao, Chunying; Rondou, Pieter; de Stanchina, Elisa; Teruya-Feldstein, Julie; Kelliher, Michelle A.; Speleman, Frank; Porco, John A.; Pelletier, Jerry; Ratsch, Gunnar; Wendel, Hans-Guido</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue">7516</span>),
    <span class="NLM_cas:pages">65-70</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The translational control of oncoprotein expression is implicated in many cancers.  Here the authors report an eIF4A RNA helicase-dependent mechanism of translational control that contributes to oncogenesis and underlies the anticancer effects of silvestrol and related compds.  For example, eIF4A promotes T-cell acute lymphoblastic leukemia development in vivo and is required for leukemia maintenance.  Accordingly, inhibition of eIF4A with silvestrol has powerful therapeutic effects against murine and human leukemic cells in vitro and in vivo.  The authors use transcriptome-scale ribosome footprinting to identify the hallmarks of eIF4A-dependent transcripts.  These include 5' untranslated region (UTR) sequences such as the 12-nucleotide guanine quartet (CGG)4 motif that can form RNA G-quadruplex structures.  Notably, among the most eIF4A-dependent and silvestrol-sensitive transcripts are a no. of oncogenes, superenhancer-assocd. transcription factors, and epigenetic regulators.  Hence, the 5' UTRs of select cancer genes harbor a targetable requirement for the eIF4A RNA helicase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OIvvYHwn7rVg90H21EOLACvtfcHk0lgKu0Somyucbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyhurvI&md5=8c0a22a542cac567f1ec1340b195680d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature13485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13485%26sid%3Dliteratum%253Aachs%26aulast%3DWolfe%26aufirst%3DA.%2BL.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DDrewe%26aufirst%3DP.%26aulast%3DRajasekhar%26aufirst%3DV.%2BK.%26aulast%3DSanghvi%26aufirst%3DV.%2BR.%26aulast%3DMavrakis%26aufirst%3DK.%2BJ.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DRoderick%26aufirst%3DJ.%2BE.%26aulast%3DVan%2Bder%2BMeulen%26aufirst%3DJ.%26aulast%3DSchatz%26aufirst%3DJ.%2BH.%26aulast%3DRodrigo%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DRondou%26aufirst%3DP.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DTeruya-Feldstein%26aufirst%3DJ.%26aulast%3DKelliher%26aufirst%3DM.%2BA.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DR%25C3%25A4tsch%26aufirst%3DG.%26aulast%3DWendel%26aufirst%3DH.%2BG.%26atitle%3DRNA%2520G-Quadruplexes%2520Cause%2520EIF4A-Dependent%2520Oncogene%2520Translation%2520in%2520Cancer%26jtitle%3DNature%26date%3D2014%26volume%3D513%26spage%3D65%26epage%3D70%26doi%3D10.1038%2Fnature13485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Truitt, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span> <span> </span><span class="NLM_article-title">New Frontiers in Translational Control of the Cancer Genome</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnrc.2016.27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27112207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Omsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=288-304&author=M.+L.+Truittauthor=D.+Ruggero&title=New+Frontiers+in+Translational+Control+of+the+Cancer+Genome&doi=10.1038%2Fnrc.2016.27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">New frontiers in translational control of the cancer genome</span></div><div class="casAuthors">Truitt, Morgan L.; Ruggero, Davide</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">288-304</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past several years have seen dramatic leaps in our understanding of how gene expression is rewired at the translation level during tumorigenesis to support the transformed phenotype.  This work has been driven by an explosion in technol. advances and is revealing previously unimagined regulatory mechanisms that dictate functional expression of the cancer genome.  In this Review we discuss emerging trends and exciting new discoveries that reveal how this translational circuitry contributes to specific aspects of tumorigenesis and cancer cell function, with a particular focus on recent insights into the role of translational control in the adaptive response to oncogenic stress conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWAtdm1QpVuLVg90H21EOLACvtfcHk0licsVnr9iwy2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Omsr0%253D&md5=ed2f746a30588ab8c00022d696861ceb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.27%26sid%3Dliteratum%253Aachs%26aulast%3DTruitt%26aufirst%3DM.%2BL.%26aulast%3DRuggero%26aufirst%3DD.%26atitle%3DNew%2520Frontiers%2520in%2520Translational%2520Control%2520of%2520the%2520Cancer%2520Genome%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D288%26epage%3D304%26doi%3D10.1038%2Fnrc.2016.27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerezo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guemiri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druillennec, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girault, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malka-Mahieu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martineau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agoussi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libenciuc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scoazec, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eychène, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span> <span> </span><span class="NLM_article-title">Translational Control of Tumor Immune Escape via the EIF4F–STAT1–PD-L1 Axis in Melanoma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1877</span>– <span class="NLM_lpage">1886</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0217-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41591-018-0217-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30374200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVCit7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=1877-1886&author=M.+Cerezoauthor=R.+Guemiriauthor=S.+Druillennecauthor=I.+Giraultauthor=H.+Malka-Mahieuauthor=S.+Shenauthor=D.+Allardauthor=S.+Martineauauthor=C.+Welschauthor=S.+Agoussiauthor=C.+Estradaauthor=J.+Adamauthor=C.+Libenciucauthor=E.+Routierauthor=S.+Royauthor=L.+D%C3%A9saubryauthor=A.+M.+Eggermontauthor=N.+Sonenbergauthor=J.+Y.+Scoazecauthor=A.+Eych%C3%A8neauthor=S.+Vagnerauthor=C.+Robert&title=Translational+Control+of+Tumor+Immune+Escape+via+the+EIF4F%E2%80%93STAT1%E2%80%93PD-L1+Axis+in+Melanoma&doi=10.1038%2Fs41591-018-0217-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma</span></div><div class="casAuthors">Cerezo, Michael; Guemiri, Ramdane; Druillennec, Sabine; Girault, Isabelle; Malka-Mahieu, Helene; Shen, Shensi; Allard, Delphine; Martineau, Sylvain; Welsch, Caroline; Agoussi, Sandrine; Estrada, Charlene; Adam, Julien; Libenciuc, Cristina; Routier, Emilie; Roy, Severine; Desaubry, Laurent; Eggermont, Alexander M.; Sonenberg, Nahum; Scoazec, Jean Yves; Eychene, Alain; Vagner, Stephan; Robert, Caroline</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1877-1886</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Preventing the immune escape of tumor cells by blocking inhibitory checkpoints, such as the interaction between programmed death ligand-1 (PD-L1) and programmed death-1 (PD-1) receptor, is a powerful anticancer approach.  However, many patients do not respond to checkpoint blockade.  Tumor PD-L1 expression is a potential efficacy biomarker, but the complex mechanisms underlying its regulation are not completely understood.  Here, we show that the eukaryotic translation initiation complex, eIF4F, which binds the 5' cap of mRNAs, regulates the surface expression of interferon-γ-induced PD-L1 on cancer cells by regulating translation of the mRNA encoding the signal transducer and activator of transcription 1 (STAT1) transcription factor.  EIF4F complex formation correlates with response to immunotherapy in human melanoma.  Pharmacol. inhibition of eIF4A, the RNA helicase component of eIF4F, elicits powerful antitumor immune-mediated effects via PD-L1 downregulation.  Thus, eIF4A inhibitors, in development as anticancer drugs, may also act as cancer immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaq-cWIjgFfrVg90H21EOLACvtfcHk0licsVnr9iwy2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVCit7fI&md5=abce1ed237bb9b9b69b7ecabaf2f711a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0217-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0217-1%26sid%3Dliteratum%253Aachs%26aulast%3DCerezo%26aufirst%3DM.%26aulast%3DGuemiri%26aufirst%3DR.%26aulast%3DDruillennec%26aufirst%3DS.%26aulast%3DGirault%26aufirst%3DI.%26aulast%3DMalka-Mahieu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DAllard%26aufirst%3DD.%26aulast%3DMartineau%26aufirst%3DS.%26aulast%3DWelsch%26aufirst%3DC.%26aulast%3DAgoussi%26aufirst%3DS.%26aulast%3DEstrada%26aufirst%3DC.%26aulast%3DAdam%26aufirst%3DJ.%26aulast%3DLibenciuc%26aufirst%3DC.%26aulast%3DRoutier%26aufirst%3DE.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DScoazec%26aufirst%3DJ.%2BY.%26aulast%3DEych%25C3%25A8ne%26aufirst%3DA.%26aulast%3DVagner%26aufirst%3DS.%26aulast%3DRobert%26aufirst%3DC.%26atitle%3DTranslational%2520Control%2520of%2520Tumor%2520Immune%2520Escape%2520via%2520the%2520EIF4F%25E2%2580%2593STAT1%25E2%2580%2593PD-L1%2520Axis%2520in%2520Melanoma%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D1877%26epage%3D1886%26doi%3D10.1038%2Fs41591-018-0217-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, D.</span></span> <span> </span><span class="NLM_article-title">Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">6462</span>– <span class="NLM_lpage">6473</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01159</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01159" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=6462-6473&author=P.+Fernandesauthor=D.+Pereiraauthor=P.+B.+Watkinsauthor=D.+Bertrand&title=Differentiating+the+Pharmacodynamics+and+Toxicology+of+Macrolide+and+Ketolide+Antibiotics&doi=10.1021%2Facs.jmedchem.9b01159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics</span></div><div class="casAuthors">Fernandes, Prabhavathi; Pereira, David; Watkins, Paul B.; Bertrand, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6462-6473</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This is a review of the macrolide and ketolide field focusing on differentiating the pharmacodynamics and esp. the toxicol. of the macrolides and ketolides.  We emphasize the diversity in pharmacodynamics and toxicity of the macrolides and ketolides, resulting from even small structural changes, which makes it important to consider the various different compds. sep., not necessarily as a class.  The ketolide, telithromycin, was developed because of rising bacterial macrolide resistance, but was withdrawn post-approval after visual disturbances, syncope, Myasthenia Gravis and hepatotoxicity were noted.  These diverse adverse effects could be attributed to inhibition of nicotinic acetylcholine receptors.  Solithromycin, a later generation ketolide, was effective in treating bacterial pneumonia but it was not approved by the U.S. Food and Drug Administration owing, in part, to its structural similarity to telithromycin.  This mini-perspective describes that structurally similar macrolides/ketolides have clearly mechanistically distinct effects.  Understanding these effects could help in developing and securing regulatory approval of a new macrolide/ketolide that is active against macrolide-resistant pathogenic bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBIMPU7y6m_bVg90H21EOLACvtfcHk0lhkryl-vys9mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajt7rK&md5=dbb872200e3f1d79ba7b1012c96d16ac</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01159%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DP.%26aulast%3DPereira%26aufirst%3DD.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DBertrand%26aufirst%3DD.%26atitle%3DDifferentiating%2520the%2520Pharmacodynamics%2520and%2520Toxicology%2520of%2520Macrolide%2520and%2520Ketolide%2520Antibiotics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D6462%26epage%3D6473%26doi%3D10.1021%2Facs.jmedchem.9b01159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jelić, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antolović, R.</span></span> <span> </span><span class="NLM_article-title">From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials</span>. <i>Antibiotics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.3390/antibiotics5030029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fantibiotics5030029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2isrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=29&author=D.+Jeli%C4%87author=R.+Antolovi%C4%87&title=From+Erythromycin+to+Azithromycin+and+New+Potential+Ribosome-Binding+Antimicrobials&doi=10.3390%2Fantibiotics5030029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">From erythromycin to azithromycin and new potential ribosome-binding antimicrobials</span></div><div class="casAuthors">Jelic, Dubravko; Antolovic, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Antibiotics (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">29/1-29/13</span>CODEN:
                <span class="NLM_cas:coden">ABSNC4</span>;
        ISSN:<span class="NLM_cas:issn">2079-6382</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Macrolides, as a class of natural or semisynthetic products, express their antibacterial activity primarily by reversible binding to the bacterial 50S ribosomal subunits and by blocking nascent proteins' progression through their exit tunnel in bacterial protein biosynthesis.  Generally considered to be bacteriostatic, they may also be bactericidal at higher doses.  The discovery of azithromycin from the class of macrolides, as one of the most important new drugs of the 20th century, is presented as an example of a rational medicinal chem. approach to drug design, applying classical structure-activity relationship that will illustrate an impressive drug discovery success story.  However, the microorganisms have developed several mechanisms to acquire resistance to antibiotics, including macrolide antibiotics.  The primary mechanism for acquiring bacterial resistance to macrolides is a mutation of one or more nucleotides from the binding site.  Although azithromycin is reported to show different, two-step process of the inhibition of ribosome function of some species, more detailed elaboration of that specific mode of action is needed.  New macrocyclic derivs., which could be more potent and less prone to escape bacterial resistance mechanisms, are also continuously evaluated.  A novel class of antibiotic compds.-macrolones, which are derived from macrolides and comprise macrocyclic moiety, linker, and either free or esterified quinolone 3-carboxylic group, show excellent antibacterial potency towards key erythromycin-resistant Gram-pos. and Gram-neg. bacterial strains, with possibly decreased potential of bacterial resistance to macrolides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNP2YDfyTwYbVg90H21EOLACvtfcHk0lhkryl-vys9mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2isrbL&md5=f7c62f735cc5bbd2a9c3af18aac50973</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fantibiotics5030029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fantibiotics5030029%26sid%3Dliteratum%253Aachs%26aulast%3DJeli%25C4%2587%26aufirst%3DD.%26aulast%3DAntolovi%25C4%2587%26aufirst%3DR.%26atitle%3DFrom%2520Erythromycin%2520to%2520Azithromycin%2520and%2520New%2520Potential%2520Ribosome-Binding%2520Antimicrobials%26jtitle%3DAntibiotics%26date%3D2016%26volume%3D5%26spage%3D29%26doi%3D10.3390%2Fantibiotics5030029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider-Poetsch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyler, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Eukaryotic Translation Elongation by Cycloheximide and Lactimidomycin</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1038/nchembio.304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnchembio.304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=20118940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ygu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=209-217&author=T.+Schneider-Poetschauthor=J.+Juauthor=D.+E.+Eylerauthor=Y.+Dangauthor=S.+Bhatauthor=W.+C.+Merrickauthor=R.+Greenauthor=B.+Shenauthor=J.+O.+Liu&title=Inhibition+of+Eukaryotic+Translation+Elongation+by+Cycloheximide+and+Lactimidomycin&doi=10.1038%2Fnchembio.304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin</span></div><div class="casAuthors">Schneider-Poetsch, Tilman; Ju, Jianhua; Eyler, Daniel E.; Dang, Yongjun; Bhat, Shridhar; Merrick, William C.; Green, Rachel; Shen, Ben; Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-217</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the protein synthesis inhibitor cycloheximide (CHX) has been known for decades, its precise mechanism of action remains incompletely understood.  The glutarimide portion of CHX is seen in a family of structurally related natural products including migrastatin, isomigrastatin, and lactimidomycin (LTM).  We found that LTM, isomigrastatin, and analogs have a potent antiproliferative effect on tumor cell lines and selectively inhibit translation.  A systematic comparative study of the effects of CHX and LTM on protein synthesis revealed both similarities and differences between the two inhibitors.  Both LTM and CHX were found to block the translocation step in elongation.  Footprinting expts. revealed protection of a single cytidine nucleotide (C3993) in the E-site of the 60S ribosomal subunit, thus defining a common binding pocket for the two inhibitors in the ribosome.  These results shed new light on the mol. mechanism of inhibition of translation elongation by both CHX and LTM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsVhn_TkyD-LVg90H21EOLACvtfcHk0lhkryl-vys9mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ygu7w%253D&md5=77e621c87b496cd697f77299623b9f06</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.304%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider-Poetsch%26aufirst%3DT.%26aulast%3DJu%26aufirst%3DJ.%26aulast%3DEyler%26aufirst%3DD.%2BE.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DInhibition%2520of%2520Eukaryotic%2520Translation%2520Elongation%2520by%2520Cycloheximide%2520and%2520Lactimidomycin%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D209%26epage%3D217%26doi%3D10.1038%2Fnchembio.304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneekloth, J. S.</span></span> <span> </span><span class="NLM_article-title">The Emerging Role of RNA as a Therapeutic Target for Small Molecules</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1077</span>– <span class="NLM_lpage">1090</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.chembiol.2016.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27593111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOqsL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=1077-1090&author=C.+M.+Connellyauthor=M.+H.+Moonauthor=J.+S.+Schneekloth&title=The+Emerging+Role+of+RNA+as+a+Therapeutic+Target+for+Small+Molecules&doi=10.1016%2Fj.chembiol.2016.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Emerging Role of RNA as a Therapeutic Target for Small Molecules</span></div><div class="casAuthors">Connelly, Colleen M.; Moon, Michelle H.; Schneekloth, John S., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1077-1090</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Recent advances in understanding different RNAs and unique features of their biol. have revealed a wealth of information.  However, approaches to identify small mols. that target these newly discovered regulatory elements have been lacking.  The application of new biochem. screening and design-based technologies, coupled with a resurgence of interest in phenotypic screening, has resulted in several compelling successes in targeting RNA.  A no. of recent advances suggest that achieving the long-standing goal of developing drug-like, biol. active small mols. that target RNA is possible.  This review highlights advances and successes in approaches to targeting RNA with diverse small mols., and the potential for these technologies to pave the way to new types of RNA-targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdPbbvOw7jO7Vg90H21EOLACvtfcHk0lgkuA8fwYxwtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOqsL3E&md5=800ffb1879c29aa7ac34940e761b5f7e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DConnelly%26aufirst%3DC.%2BM.%26aulast%3DMoon%26aufirst%3DM.%2BH.%26aulast%3DSchneekloth%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520Emerging%2520Role%2520of%2520RNA%2520as%2520a%2520Therapeutic%2520Target%2520for%2520Small%2520Molecules%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D1077%26epage%3D1090%26doi%3D10.1016%2Fj.chembiol.2016.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulea, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topisirovic, I.</span></span> <span> </span><span class="NLM_article-title">Targeting the Translation Machinery in Cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1038/nrd4505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnrd4505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25743081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFOgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=261-278&author=M.+Bhatauthor=N.+Robichaudauthor=L.+Huleaauthor=N.+Sonenbergauthor=J.+Pelletierauthor=I.+Topisirovic&title=Targeting+the+Translation+Machinery+in+Cancer&doi=10.1038%2Fnrd4505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the translation machinery in cancer</span></div><div class="casAuthors">Bhat, Mamatha; Robichaud, Nathaniel; Hulea, Laura; Sonenberg, Nahum; Pelletier, Jerry; Topisirovic, Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">261-278</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dysregulation of mRNA translation is a frequent feature of neoplasia.  Many oncogenes and tumor suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumor cells, independent of the genetic make-up of the cancer.  Therefore, therapeutic agents that target components of the protein synthesis app. hold promise as novel anticancer drugs that can overcome intra-tumor heterogeneity.  In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7a57QrdxxsbVg90H21EOLACvtfcHk0lgkuA8fwYxwtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFOgs70%253D&md5=51625a521b1d4f18887142383a8d28e8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd4505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4505%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DM.%26aulast%3DRobichaud%26aufirst%3DN.%26aulast%3DHulea%26aufirst%3DL.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DTopisirovic%26aufirst%3DI.%26atitle%3DTargeting%2520the%2520Translation%2520Machinery%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D261%26epage%3D278%26doi%3D10.1038%2Fnrd4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laham-Karam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonen, P.</span></span> <span> </span><span class="NLM_article-title">Transcription and Translation Inhibitors in Cancer Treatment</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">276</span>, <span class="refDoi"> DOI: 10.3389/fchem.2020.00276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3389%2Ffchem.2020.00276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=32373584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGitrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=276&author=N.+Laham-Karamauthor=G.+P.+Pintoauthor=A.+Posoauthor=P.+Kokkonen&title=Transcription+and+Translation+Inhibitors+in+Cancer+Treatment&doi=10.3389%2Ffchem.2020.00276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Transcription and translation inhibitors in cancer treatment</span></div><div class="casAuthors">Laham-Karam, Nihay; Pinto, Gaspar P.; Poso, Antti; Kokkonen, Piia</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">276</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Transcription and translation are fundamental cellular processes that govern the protein prodn. of cells.  These processes are generally up regulated in cancer cells, to maintain the enhanced metab. and proliferative state of these cells.  As such cancerous cells can be susceptible to transcription and translation inhibitors.  There are numerous druggable proteins involved in transcription and translation which make lucrative targets for cancer drug development.  In addn. to proteins, recent years have shown that the "undruggable" transcription factors and RNA mols. can also be targeted to hamper the transcription or translation in cancer.  In this review, we summarize the properties and function of the transcription and translation inhibitors that have been tested and developed, focusing on the advances of the last 5 years.  To complement this, we also discuss some of the recent advances in targeting oncogenes tightly controlling transcription including transcription factors and KRAS.  In addn. to natural and synthetic compds., we review DNA and RNA based approaches to develop cancer drugs.  Finally, we conclude with the outlook to the future of the development of transcription and translation inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqp-guDgqY8rVg90H21EOLACvtfcHk0lgkuA8fwYxwtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGitrzK&md5=e6ad9ae25f9ba15f7fa0ca02485781da</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2020.00276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2020.00276%26sid%3Dliteratum%253Aachs%26aulast%3DLaham-Karam%26aufirst%3DN.%26aulast%3DPinto%26aufirst%3DG.%2BP.%26aulast%3DPoso%26aufirst%3DA.%26aulast%3DKokkonen%26aufirst%3DP.%26atitle%3DTranscription%2520and%2520Translation%2520Inhibitors%2520in%2520Cancer%2520Treatment%26jtitle%3DFront.%2520Chem.%26date%3D2020%26volume%3D8%26spage%3D276%26doi%3D10.3389%2Ffchem.2020.00276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, L.</span></span> <span> </span><span class="NLM_article-title">Determinant of Cistron Specificity in Bacterial Ribosomes</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1038/254034a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2F254034a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=803646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE2MXkt1eltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1975&pages=34-38&author=J.+Shineauthor=L.+Dalgarno&title=Determinant+of+Cistron+Specificity+in+Bacterial+Ribosomes&doi=10.1038%2F254034a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Determinant of cistron specificity in bacterial ribosomes</span></div><div class="casAuthors">Shine, J.; Dalgarno, L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">5495</span>),
    <span class="NLM_cas:pages">34-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The sequence of the 3'-terminus of 16 S rRNA from different species of bacteria was detd.  The complementarity relation between this sequence and that of a purine-rich tract in the ribosome binding site of bacterial mRNA suggests that the intrinsic capacity of ribosomes to translate a particular cistron is detd. by a pyrimidine-rich region at the 3'-end of 16 S RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7IpAtJMJ3Y7Vg90H21EOLACvtfcHk0lgxv2TyLtLvjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXkt1eltbY%253D&md5=3a8771341e1d0fc60295f6b42150137a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2F254034a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F254034a0%26sid%3Dliteratum%253Aachs%26aulast%3DShine%26aufirst%3DJ.%26aulast%3DDalgarno%26aufirst%3DL.%26atitle%3DDeterminant%2520of%2520Cistron%2520Specificity%2520in%2520Bacterial%2520Ribosomes%26jtitle%3DNature%26date%3D1975%26volume%3D254%26spage%3D34%26epage%3D38%26doi%3D10.1038%2F254034a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mokrejš, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vopálenský, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolenatý, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mašek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feketová, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekyrová, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Škaloudová, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kříž, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pospíšek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokrejs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vopálenský, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolenaty, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feketová, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekyrová, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaloudová, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kríz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pospísek, M.</span></span> <span> </span><span class="NLM_article-title">IRESite: The Database of Experimentally Verified IRES Structures (Www.Iresite.Org)</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">D125</span>– <span class="NLM_lpage">D130</span>, <span class="refDoi"> DOI: 10.1093/nar/gkj081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1093%2Fnar%2Fgkj081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16381829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFOqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=D125-D130&author=M.+Mokrej%C5%A1author=V.+Vop%C3%A1lensk%C3%BDauthor=O.+Kolenat%C3%BDauthor=T.+Ma%C5%A1ekauthor=Z.+Feketov%C3%A1author=P.+Sekyrov%C3%A1author=B.+%C5%A0kaloudov%C3%A1author=V.+K%C5%99%C3%AD%C5%BEauthor=M.+Posp%C3%AD%C5%A1ekauthor=M.+Mokrejsauthor=V.+Vop%C3%A1lensk%C3%BDauthor=O.+Kolenatyauthor=T.+Masekauthor=Z.+Feketov%C3%A1author=P.+Sekyrov%C3%A1author=B.+Skaloudov%C3%A1author=V.+Kr%C3%ADzauthor=M.+Posp%C3%ADsek&title=IRESite%3A+The+Database+of+Experimentally+Verified+IRES+Structures+%28Www.Iresite.Org%29&doi=10.1093%2Fnar%2Fgkj081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">IRESite: the database of experimentally verified IRES structures (www.iresite.org)</span></div><div class="casAuthors">Mokrejs, Martin; Vopalensky, Vaclav; Kolenaty, Ondrej; Masek, Tomas; Feketova, Zuzana; Sekyrova, Petra; Skaloudova, Barbora; Kriz, Vitezslav; Pospisek, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">Database</span>),
    <span class="NLM_cas:pages">D125-D130</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">IRESite is an exhaustive, manually annotated non-redundant relational database focused on the IRES elements (Internal Ribosome Entry Site) and contg. information not available in the primary public databases.  IRES elements were originally found in eukaryotic viruses hijacking initiation of translation of their host.  Later on, they were also discovered in 5'-untranslated regions of some eukaryotic mRNA mols.  Currently, IRESite presents up to 92 biol. relevant aspects of every expt., e.g. the nature of an IRES element, its functionality/defectivity, origin, size, sequence, structure, its relative position with respect to surrounding protein coding regions, pos./neg. controls used in the expt., the reporter genes used to monitor IRES activity, the measured reporter protein yields/activities, and refs. to original publications as well as cross-refs. to other databases, and also comments from submitters and our curators.  Furthermore, the site presents the known similarities to rRNA sequences as well as RNA-protein interactions.  Special care is given to the annotation of promoter-like regions.  The annotated data in IRESite are bound to mostly complete, full-length mRNA, and whenever possible, accompanied by original plasmid vector sequences.  New data can be submitted through the publicly available web-based interface at http://www.iresite.org and are curated by a team of lab-experienced biologists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxC_teN9N3krVg90H21EOLACvtfcHk0lgxv2TyLtLvjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFOqtw%253D%253D&md5=54f56e1d50dadc4f29665615aa414cba</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkj081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkj081%26sid%3Dliteratum%253Aachs%26aulast%3DMokrej%25C5%25A1%26aufirst%3DM.%26aulast%3DVop%25C3%25A1lensk%25C3%25BD%26aufirst%3DV.%26aulast%3DKolenat%25C3%25BD%26aufirst%3DO.%26aulast%3DMa%25C5%25A1ek%26aufirst%3DT.%26aulast%3DFeketov%25C3%25A1%26aufirst%3DZ.%26aulast%3DSekyrov%25C3%25A1%26aufirst%3DP.%26aulast%3D%25C5%25A0kaloudov%25C3%25A1%26aufirst%3DB.%26aulast%3DK%25C5%2599%25C3%25AD%25C5%25BE%26aufirst%3DV.%26aulast%3DPosp%25C3%25AD%25C5%25A1ek%26aufirst%3DM.%26aulast%3DMokrejs%26aufirst%3DM.%26aulast%3DVop%25C3%25A1lensk%25C3%25BD%26aufirst%3DV.%26aulast%3DKolenaty%26aufirst%3DO.%26aulast%3DMasek%26aufirst%3DT.%26aulast%3DFeketov%25C3%25A1%26aufirst%3DZ.%26aulast%3DSekyrov%25C3%25A1%26aufirst%3DP.%26aulast%3DSkaloudov%25C3%25A1%26aufirst%3DB.%26aulast%3DKr%25C3%25ADz%26aufirst%3DV.%26aulast%3DPosp%25C3%25ADsek%26aufirst%3DM.%26atitle%3DIRESite%253A%2520The%2520Database%2520of%2520Experimentally%2520Verified%2520IRES%2520Structures%2520%2528Www.Iresite.Org%2529%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2006%26volume%3D34%26spage%3DD125%26epage%3DD130%26doi%3D10.1093%2Fnar%2Fgkj081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortridge, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albin, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cominsky, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varani, G.</span></span> <span> </span><span class="NLM_article-title">Structure of the RNA Specialized Translation Initiation Element That Recruits eIF3 to the 5′-UTR of c-Jun</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>432</i></span>,  <span class="NLM_fpage">1841</span>– <span class="NLM_lpage">1855</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2020.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.jmb.2020.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31953146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktVehsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2020&pages=1841-1855&author=M.+J.+Walkerauthor=M.+D.+Shortridgeauthor=D.+D.+Albinauthor=L.+Y.+Cominskyauthor=G.+Varani&title=Structure+of+the+RNA+Specialized+Translation+Initiation+Element+That+Recruits+eIF3+to+the+5%E2%80%B2-UTR+of+c-Jun&doi=10.1016%2Fj.jmb.2020.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the RNA specialized translation initiation element that recruits eIF3 to the 5'-UTR of c-Jun</span></div><div class="casAuthors">Walker, Matthew J.; Shortridge, Matthew D.; Albin, Dreycey D.; Cominsky, Lauren Y.; Varani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">432</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1841-1855</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Specialized translation initiation is a novel form of regulation of protein synthesis, whereby RNA structures within the 5'-UTR regulate translation rates of specific mRNAs.  Similar to internal ribosome entry sites (IRESs), specialized translation initiation requires the recruitment of eukaryotic initiation factor 3 (eIF3), but also requires cap recognition by eIF3d, a new 5'-m7GTP recognizing protein.  How these RNA structures mediate eIF3 recruitment to affect translation of specific mRNAs remains unclear.  Here, we report the NMR structure of a stem-loop within the c-JUN 5' UTR recognized by eIF3 and essential for specialized translation initiation of this well-known oncogene.  The structure exhibits similarity to eIF3 recognizing motifs found in hepatitis C virus (HCV)-like IRESs, suggesting mechanistic similarities.  This work establishes the RNA structural features involved in c-JUN specialized translation initiation and provides a basis to search for small mol. inhibitors of aberrant expression of the proto-oncogenic c-JUN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZqW62SYA4n7Vg90H21EOLACvtfcHk0lg16kJ8k1dRNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktVehsbg%253D&md5=470093de7ab1efe81f78246e20b2108f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2020.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2020.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DM.%2BJ.%26aulast%3DShortridge%26aufirst%3DM.%2BD.%26aulast%3DAlbin%26aufirst%3DD.%2BD.%26aulast%3DCominsky%26aufirst%3DL.%2BY.%26aulast%3DVarani%26aufirst%3DG.%26atitle%3DStructure%2520of%2520the%2520RNA%2520Specialized%2520Translation%2520Initiation%2520Element%2520That%2520Recruits%2520eIF3%2520to%2520the%25205%25E2%2580%25B2-UTR%2520of%2520c-Jun%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2020%26volume%3D432%26spage%3D1841%26epage%3D1855%26doi%3D10.1016%2Fj.jmb.2020.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pestova, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolupaeva, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomakin, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilipenko, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shatsky, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agol, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellen, C. U. T.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms of Translation Initiation in Eukaryotes</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">7029</span>– <span class="NLM_lpage">7036</span>, <span class="refDoi"> DOI: 10.1073/pnas.111145798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.111145798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=11416183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslWmsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=7029-7036&author=T.+V.+Pestovaauthor=V.+G.+Kolupaevaauthor=I.+B.+Lomakinauthor=E.+V.+Pilipenkoauthor=I.+N.+Shatskyauthor=V.+I.+Agolauthor=C.+U.+T.+Hellen&title=Molecular+Mechanisms+of+Translation+Initiation+in+Eukaryotes&doi=10.1073%2Fpnas.111145798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of translation initiation in eukaryotes</span></div><div class="casAuthors">Pestova, Tatyana V.; Kolupaeva, Victoria G.; Lomakin, Ivan B.; Pilipenko, Evgeny V.; Shatsky, Ivan N.; Agol, Vadim I.; Hellen, Christopher U. T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7029-7036</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A review, with 54 refs.  Translation initiation is a complex process in which initiator tRNA, 40S, and 60S ribosomal subunits are assembled by eukaryotic initiation factors (eIFs) into an 80S ribosome at the initiation codon of mRNA.  The cap-binding complex eIF4F and the factors eIF4A and eIF4B are required for binding of 43S complexes (comprising a 40S subunit, eIF2/GTP/Met-tRNAi and eIF3) to the 5' end of capped mRNA but are not sufficient to promote ribosomal scanning to the initiation codon.  EIF1A enhances the ability of eIF1 to dissoc. aberrantly assembled complexes from mRNA, and these factors synergistically mediate 48S complex assembly at the initiation codon.  Joining of 48S complexes to 60S subunits to form 80S ribosomes requires eIF5B, which has an essential ribosome-dependent GTPase activity and hydrolysis of eIF2-bound GTP induced by eIF5.  Initiation on a few mRNAs is cap-independent and occurs instead by internal ribosomal entry.  Encephalomyocarditis virus (EMCV) and hepatitis C virus epitomize distinct mechanisms of internal ribosomal entry site (IRES)-mediated initiation.  The eIF4A and eIF4G subunits of eIF4F bind immediately upstream of the EMCV initiation codon and promote binding of 43S complexes.  EMCV initiation does not involve scanning and does not require eIF1, eIF1A, and the eIF4E subunit of eIF4F.  Initiation on some EMCV-like IRESs requires addnl. noncanonical initiation factors, which alter IRES conformation and promote binding of eIF4A/4G.  Initiation on the hepatitis C virus IRES is even simpler: 43S complexes contg. only eIF2 and eIF3 bind directly to the initiation codon as a result of specific interaction of the IRES and the 40S subunit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpENj0T2D1NqrVg90H21EOLACvtfcHk0lg16kJ8k1dRNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslWmsLc%253D&md5=49e16cbddc4b187f4a532799e7bd04a3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.111145798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.111145798%26sid%3Dliteratum%253Aachs%26aulast%3DPestova%26aufirst%3DT.%2BV.%26aulast%3DKolupaeva%26aufirst%3DV.%2BG.%26aulast%3DLomakin%26aufirst%3DI.%2BB.%26aulast%3DPilipenko%26aufirst%3DE.%2BV.%26aulast%3DShatsky%26aufirst%3DI.%2BN.%26aulast%3DAgol%26aufirst%3DV.%2BI.%26aulast%3DHellen%26aufirst%3DC.%2BU.%2BT.%26atitle%3DMolecular%2520Mechanisms%2520of%2520Translation%2520Initiation%2520in%2520Eukaryotes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D7029%26epage%3D7036%26doi%3D10.1073%2Fpnas.111145798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzy, T. G.</span></span> <span> </span><span class="NLM_article-title">The Many Roles of the Eukaryotic Elongation Factor 1 Complex</span>. <i>Wiley Interdiscip. Rev. RNA</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1002/wrna.1118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fwrna.1118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22555874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGgsbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=543-555&author=A.+N.+Sasikumarauthor=W.+B.+Perezauthor=T.+G.+Kinzy&title=The+Many+Roles+of+the+Eukaryotic+Elongation+Factor+1+Complex&doi=10.1002%2Fwrna.1118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of the eukaryotic elongation factor 1 complex</span></div><div class="casAuthors">Sasikumar, Arjun N.; Perez, Winder B.; Kinzy, Terri Goss</div><div class="citationInfo"><span class="NLM_cas:title">Wiley Interdisciplinary Reviews: RNA</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">543-555</span>CODEN:
                <span class="NLM_cas:coden">WIRRCU</span>;
        ISSN:<span class="NLM_cas:issn">1757-7012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The vast majority of proteins are believed to have one specific function.  Throughout the course of evolution, however, some proteins have acquired addnl. functions to meet the demands of a complex cellular milieu.  In some cases, changes in RNA or protein processing allow the cell to make the most of what is already encoded in the genome to produce slightly different forms.  The eukaryotic elongation factor 1 (eEF1) complex subunits, however, have acquired such moonlighting functions without alternative forms.  In this article, we discuss the canonical functions of the components of the eEF1 complex in translation elongation as well as the secondary interactions they have with other cellular factors outside of the translational app.  The eEF1 complex itself changes in compn. as the complexity of eukaryotic organisms increases.  Members of the complex are also subject to phosphorylation, a potential modulator of both canonical and non-canonical functions.  Although alternative functions of the eEF1A subunit have been widely reported, recent studies are shedding light on addnl. functions of the eEF1B subunits.  A thorough understanding of these alternate functions of eEF1 is essential for appreciating their biol. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokSwgdh0fzYbVg90H21EOLACvtfcHk0lg16kJ8k1dRNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGgsbrP&md5=8b91d46331db19df59755b893089cf78</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fwrna.1118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwrna.1118%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DA.%2BN.%26aulast%3DPerez%26aufirst%3DW.%2BB.%26aulast%3DKinzy%26aufirst%3DT.%2BG.%26atitle%3DThe%2520Many%2520Roles%2520of%2520the%2520Eukaryotic%2520Elongation%2520Factor%25201%2520Complex%26jtitle%3DWiley%2520Interdiscip.%2520Rev.%2520RNA%26date%3D2012%26volume%3D3%26spage%3D543%26epage%3D555%26doi%3D10.1002%2Fwrna.1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frolova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geballe, A. P.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Translation Termination Mediated by an Interaction of Eukaryotic Release Factor 1 with a Nascent Peptidyl-tRNA</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">8562</span>– <span class="NLM_lpage">8570</span>, <span class="refDoi"> DOI: 10.1128/MCB.22.24.8562-8570.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1128%2FMCB.22.24.8562-8570.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=12446775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlGrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=8562-8570&author=D.+M.+Janzenauthor=L.+Frolovaauthor=A.+P.+Geballe&title=Inhibition+of+Translation+Termination+Mediated+by+an+Interaction+of+Eukaryotic+Release+Factor+1+with+a+Nascent+Peptidyl-tRNA&doi=10.1128%2FMCB.22.24.8562-8570.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of translation termination mediated by an interaction of eukaryotic release factor 1 with a nascent peptidyl-tRNA</span></div><div class="casAuthors">Janzen, Deanna M.; Frolova, Lyudmila; Geballe, Adam P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8562-8570</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Expression of the human cytomegalovirus UL4 gene is inhibited by translation of a 22-codon-upstream open reading frame (uORF2).  The peptide product of uORF2 acts in a sequence-dependent manner to inhibit its own translation termination, resulting in persistence of the uORF2 peptidyl-tRNA linkage.  Consequently, ribosomes stall at the uORF2 termination codon and obstruct downstream translation.  Since termination appears to be the crit. step affected by translation of uORF2, we examd. the role of eukaryotic release factors 1 and 3 (eRF1 and eRF3) in the inhibitory mechanism.  In support of the hypothesis that an interaction between eRF1 and uORF2 contributes to uORF2 inhibitory activity, specific residues in each protein, glycines 183 and 184 of the eRF1 GGQ motif and prolines 21 and 22 of the uORF2 peptide, were found to be necessary for full inhibition of downstream translation.  Immunoblot analyses revealed that eRF1, but not eRF3, accumulated in the uORF2-stalled ribosome complex.  Finally, increased puromycin sensitivity was obsd. after depletion of eRF1 from the stalled ribosome complex, consistent with inhibition of peptidyl-tRNA hydrolysis resulting from an eRF1-uORF2 peptidyl-tRNA interaction.  These results reveal the paradoxical potential for interactions between a nascent peptide and eRF1 to obstruct the translation termination cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCK2GSFB_0vbVg90H21EOLACvtfcHk0lg16kJ8k1dRNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlGrsb4%253D&md5=fc63d5288c0e28a0d087138229261632</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FMCB.22.24.8562-8570.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.22.24.8562-8570.2002%26sid%3Dliteratum%253Aachs%26aulast%3DJanzen%26aufirst%3DD.%2BM.%26aulast%3DFrolova%26aufirst%3DL.%26aulast%3DGeballe%26aufirst%3DA.%2BP.%26atitle%3DInhibition%2520of%2520Translation%2520Termination%2520Mediated%2520by%2520an%2520Interaction%2520of%2520Eukaryotic%2520Release%2520Factor%25201%2520with%2520a%2520Nascent%2520Peptidyl-tRNA%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2002%26volume%3D22%26spage%3D8562%26epage%3D8570%26doi%3D10.1128%2FMCB.22.24.8562-8570.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulygin, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graifer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hountondji, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frolova, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpova, G. G.</span></span> <span> </span><span class="NLM_article-title">Exploring Contacts of ERF1 with the 3′-Terminus of the P Site TRNA and MRNA Stop Signal in the Human Ribosome at Various Translation Termination Steps</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1860</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">793</span>, <span class="refDoi"> DOI: 10.1016/j.bbagrm.2017.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.bbagrm.2017.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28457996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnt1CrtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1860&publication_year=2017&pages=782-793&author=K.+N.+Bulyginauthor=D.+M.+Graiferauthor=C.+Hountondjiauthor=L.+Y.+Frolovaauthor=G.+G.+Karpova&title=Exploring+Contacts+of+ERF1+with+the+3%E2%80%B2-Terminus+of+the+P+Site+TRNA+and+MRNA+Stop+Signal+in+the+Human+Ribosome+at+Various+Translation+Termination+Steps&doi=10.1016%2Fj.bbagrm.2017.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring contacts of eRF1 with the 3'-terminus of the P site tRNA and mRNA stop signal in the human ribosome at various translation termination steps</span></div><div class="casAuthors">Bulygin, Konstantin N.; Graifer, Dmitri M.; Hountondji, Codjo; Frolova, Ludmila Yu.; Karpova, Galina G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1860</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">782-793</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here we employed site-directed crosslinking with the application of tRNA and mRNA analogs bearing an oxidized ribose at the 3'-terminus to investigate mutual arrangement of the main components of translation termination complexes formed on the human 80S ribosome bound with P site deacylated tRNA using eRF1•eRF3•GTP or eRF1 alone.  In addn., we applied a model complex obtained in the same way with eRF1•eRF3•GMPPNP.  We found that eRF3 content in the complexes with GTP and GMPPNP is similar, proving that eRF3 does not leave the ribosome after GTP hydrolysis.  Our crosslinking data allowed detg. locations of the 3'-terminus of the P site tRNA relatively the eRF1 M domain and of the mRNA stop signal toward the N domain and the ribosomal decoding site at the nucleotide-peptide resoln. level.  Our results indicate that locations of these components do not change after peptide release up to post-termination pre-recycling state, and the positioning of the mRNA stop signal remains similar to that when eRF1 recognizes it.  Besides, we found that in all the complexes studied eRF1 shielded the N-terminal part of ribosomal protein eS30 from the interaction with the nucleotide adjacent to stop codon obsd. with pre-termination ribosome free of eRFs.  Altogether, our findings brought important information on contacts of the key structural elements of eRF1, tRNA and mRNA in the ribosomal complexes including those mimicking different translation termination steps, thereby providing a deeper understanding of mol. mechanisms underlying events occurring in the course of protein synthesis termination in mammals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI6DpfHfN7abVg90H21EOLACvtfcHk0ljgxcaUCbAnSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnt1CrtLw%253D&md5=15497645f1d4aea491fe13d2f1820541</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2017.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2017.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DBulygin%26aufirst%3DK.%2BN.%26aulast%3DGraifer%26aufirst%3DD.%2BM.%26aulast%3DHountondji%26aufirst%3DC.%26aulast%3DFrolova%26aufirst%3DL.%2BY.%26aulast%3DKarpova%26aufirst%3DG.%2BG.%26atitle%3DExploring%2520Contacts%2520of%2520ERF1%2520with%2520the%25203%25E2%2580%25B2-Terminus%2520of%2520the%2520P%2520Site%2520TRNA%2520and%2520MRNA%2520Stop%2520Signal%2520in%2520the%2520Human%2520Ribosome%2520at%2520Various%2520Translation%2520Termination%2520Steps%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2017%26volume%3D1860%26spage%3D782%26epage%3D793%26doi%3D10.1016%2Fj.bbagrm.2017.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiel, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaji, A.</span></span> <span> </span><span class="NLM_article-title">Ribosome Recycling: An Essential Process of Protein Synthesis</span>. <i>Biochem. Mol. Biol. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1002/bmb.6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fbmb.6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21591054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=40-44&author=M.+C.+Kielauthor=H.+Kajiauthor=A.+Kaji&title=Ribosome+Recycling%3A+An+Essential+Process+of+Protein+Synthesis&doi=10.1002%2Fbmb.6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosome recycling. An essential process of protein synthesis</span></div><div class="casAuthors">Kiel, Michael C.; Kaji, Hideko; Kaji, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry and Molecular Biology Education</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-44</span>CODEN:
                <span class="NLM_cas:coden">BMBECE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8175</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  A preponderance of textbooks outlines cellular protein synthesis (translation) in three basic steps: initiation, elongation, and termination.  However, researchers in the field of translation accept that a vital fourth step exists; this fourth step is called ribosome recycling.  Ribosome recycling occurs after the nascent polypeptide has been released during the termination step.  Despite the release of the polypeptide, ribosomes remain bound to the mRNA and tRNA.  It is only during the fourth step of translation that ribosomes are ultimately released from the mRNA, split into subunits, and are free to bind new mRNA, thus the term "ribosome recycling.".  This step is essential to the viability of cells.  In bacteria, it is catalyzed by two proteins, elongation factor G and ribosome recycling factor, a near perfect structural mimic of tRNA.  Eukaryotic organelles such as mitochondria and chloroplasts possess ribosome recycling factor and elongation factor G homologs, but the nature of ribosome recycling in eukaryotic cytoplasm is still under investigation.  In this review, the discovery of ribosome recycling and the basic mechanisms involved are discussed so that textbook writers and teachers can include this vital step, which is just as important as the three conventional steps, in sections dealing with protein synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1TwqARcTqzbVg90H21EOLACvtfcHk0ljgxcaUCbAnSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVSisr0%253D&md5=02f9b350a73d131cabdf833578d652ad</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fbmb.6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbmb.6%26sid%3Dliteratum%253Aachs%26aulast%3DKiel%26aufirst%3DM.%2BC.%26aulast%3DKaji%26aufirst%3DH.%26aulast%3DKaji%26aufirst%3DA.%26atitle%3DRibosome%2520Recycling%253A%2520An%2520Essential%2520Process%2520of%2520Protein%2520Synthesis%26jtitle%3DBiochem.%2520Mol.%2520Biol.%2520Educ.%26date%3D2007%26volume%3D35%26spage%3D40%26epage%3D44%26doi%3D10.1002%2Fbmb.6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pisarev, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellen, C. U. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestova, T. V.</span></span> <span> </span><span class="NLM_article-title">Recycling of Eukaryotic Posttermination Ribosomal Complexes</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.08.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.cell.2007.08.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17956730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1KqsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=286-299&author=A.+V.+Pisarevauthor=C.+U.+T.+Hellenauthor=T.+V.+Pestova&title=Recycling+of+Eukaryotic+Posttermination+Ribosomal+Complexes&doi=10.1016%2Fj.cell.2007.08.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Recycling of eukaryotic posttermination ribosomal complexes</span></div><div class="casAuthors">Pisarev, Andrey V.; Hellen, Christopher U. T.; Pestova, Tatyana V.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">286-299</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">After translational termination, mRNA and P site deacylated tRNA remain assocd. with ribosomes in posttermination complexes (post-TCs), which must therefore be recycled by releasing mRNA and deacylated tRNA and by dissocg. ribosomes into subunits.  Recycling of bacterial post-TCs requires elongation factor EF-G and a ribosome recycling factor RRF.  Eukaryotes do not encode a RRF homolog, and their mechanism of ribosomal recycling is unknown.  We investigated eukaryotic recycling using post-TCs assembled on a model mRNA encoding a tetrapeptide followed by a UAA stop codon and report that initiation factors eIF1, eIF1, eIF1A, and eIF3j, a loosely assocd. subunit of eIF3, can promote recycling of eukaryotic post-TCs.  EIF3 is the principal factor that promotes splitting of posttermination ribosomes into 60S subunits and tRNA- and mRNA-bound 40S subunits.  Its activity is enhanced by eIFs 3j, 1, and 1A.  EIF1 also mediates release of P site tRNA, whereas eIF3j ensures subsequent dissocn. of mRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo0SzNZHvsHbVg90H21EOLACvtfcHk0ljgxcaUCbAnSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1KqsbbP&md5=d2f3a3be926631805e46586624a67781</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.08.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.08.041%26sid%3Dliteratum%253Aachs%26aulast%3DPisarev%26aufirst%3DA.%2BV.%26aulast%3DHellen%26aufirst%3DC.%2BU.%2BT.%26aulast%3DPestova%26aufirst%3DT.%2BV.%26atitle%3DRecycling%2520of%2520Eukaryotic%2520Posttermination%2520Ribosomal%2520Complexes%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D286%26epage%3D299%26doi%3D10.1016%2Fj.cell.2007.08.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cargnello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topisirovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">918</span>– <span class="NLM_lpage">933</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2016.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.tcb.2016.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27426745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVynurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=918-933&author=J.+Chuauthor=M.+Cargnelloauthor=I.+Topisirovicauthor=J.+Pelletier&title=Translation+Initiation+Factors%3A+Reprogramming+Protein+Synthesis+in+Cancer&doi=10.1016%2Fj.tcb.2016.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer</span></div><div class="casAuthors">Chu, Jennifer; Cargnello, Marie; Topisirovic, Ivan; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">918-933</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Control of mRNA translation plays a crucial role in the regulation of gene expression and is crit. for cellular homeostasis.  Dysregulation of translation initiation factors has been documented in several pathologies including cancer.  Aberrant function of translation initiation factors leads to translation reprogramming that promotes proliferation, survival, angiogenesis, and metastasis.  In such context, understanding how altered levels (and presumably activity) of initiation factors can contribute to tumor initiation and/or maintenance is of major interest for the development of novel therapeutic strategies.  In this review we provide an overview of translation initiation mechanisms and focus on recent findings describing the role of individual initiation factors and their aberrant activity in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGromGFdRUnWo7Vg90H21EOLACvtfcHk0lj5jj9abcvY4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVynurjJ&md5=3341afaa56564e231571f0f35525490a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2016.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2016.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DCargnello%26aufirst%3DM.%26aulast%3DTopisirovic%26aufirst%3DI.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DTranslation%2520Initiation%2520Factors%253A%2520Reprogramming%2520Protein%2520Synthesis%2520in%2520Cancer%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2016%26volume%3D26%26spage%3D918%26epage%3D933%26doi%3D10.1016%2Fj.tcb.2016.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span> <span> </span><span class="NLM_article-title">eIF4F: A Retrospective</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">24091</span>– <span class="NLM_lpage">24099</span>, <span class="refDoi"> DOI: 10.1074/jbc.R115.675280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1074%2Fjbc.R115.675280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26324716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2kurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=24091-24099&author=W.+C.+Merrick&title=eIF4F%3A+A+Retrospective&doi=10.1074%2Fjbc.R115.675280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">eIF4F: A Retrospective</span></div><div class="casAuthors">Merrick, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">24091-24099</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  The original purifn. of the heterotrimeric eIF4F was published over 30 years ago (Grifo, J. A., Tahara, S. M., Morgan, M. A., Shatkin, A. J., and Merrick, W. C. (1983) J. Biol. Chem. 258, 5804-5810).  Since that time, numerous studies have been performed with the three proteins specifically required for the translation initiation of natural mRNAs, eIF4A, eIF4B, and eIF4F.  These have involved enzymic and structural studies of the proteins and a no. of site-directed mutagenesis studies.  The regulation of translation exhibited through the mammalian target of rapamycin (mTOR) pathway is predominately seen as the phosphorylation of 4E-BP, an inhibitor of protein synthesis that functions by binding to the cap binding subunit of eIF4F (eIF4E).  A hypothesis that requires the disassembly of eIF4F during translation initiation to yield free subunits (eIF4A, eIF4E, and eIF4G) is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFQWuUV9H1Z7Vg90H21EOLACvtfcHk0lj5jj9abcvY4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2kurfP&md5=22603cc62fa11d6d64b3f8b024bdeea8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R115.675280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R115.675280%26sid%3Dliteratum%253Aachs%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26atitle%3DeIF4F%253A%2520A%2520Retrospective%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D24091%26epage%3D24099%26doi%3D10.1074%2Fjbc.R115.675280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Quesne, J.</span></span> <span> </span><span class="NLM_article-title">Translational Dysregulation in Cancer: EIF4A Isoforms and Sequence Determinants of eIF4A Dependence</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1233</span>, <span class="refDoi"> DOI: 10.1042/BST20150163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1042%2FBST20150163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26614665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGntrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=1227-1233&author=F.+Razaauthor=J.+A.+Waldronauthor=J.+Le+Quesne&title=Translational+Dysregulation+in+Cancer%3A+EIF4A+Isoforms+and+Sequence+Determinants+of+eIF4A+Dependence&doi=10.1042%2FBST20150163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Translational dysregulation in cancer: eIF4A isoforms and sequence determinants of eIF4A dependence</span></div><div class="casAuthors">Raza, Farheen; Waldron, Joseph Alexander; Le Quesne, John</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1227-1233</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The malignant phenotype is largely the consequence of dysregulated gene expression.  Transformed cells depend upon not just a global increase in protein synthesis but an altered translational landscape in which pro-oncogenic mRNAs are translationally up-regulated.  Such mRNAs have been shown to possess longer and more structured 5'-UTRs requiring high levels of eukaryotic initiation factor 4A (eIF4A) helicase activity for efficient translation.  As such there is a developing focus on targeting eIF4A as a cancer therapy.  In order for such treatments to be successful, we must develop a detailed understanding of the mechanisms which make specific mRNAs more dependent on eIF4A activity than others.  It is also crucial to fully characterize the potentially distinct roles of eIF4A1 and eIF4A2, which until recently were thought to be functionally interchangeable.  This review will highlight the recent advances made in this field that address these issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa0L1McbYAhrVg90H21EOLACvtfcHk0lj5jj9abcvY4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGntrnF&md5=fd49980ba5a9dd8309bb8b1512c3b05b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1042%2FBST20150163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20150163%26sid%3Dliteratum%253Aachs%26aulast%3DRaza%26aufirst%3DF.%26aulast%3DWaldron%26aufirst%3DJ.%2BA.%26aulast%3DLe%2BQuesne%26aufirst%3DJ.%26atitle%3DTranslational%2520Dysregulation%2520in%2520Cancer%253A%2520EIF4A%2520Isoforms%2520and%2520Sequence%2520Determinants%2520of%2520eIF4A%2520Dependence%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2015%26volume%3D43%26spage%3D1227%26epage%3D1233%26doi%3D10.1042%2FBST20150163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span> <span> </span><span class="NLM_article-title">The Organizing Principles of Eukaryotic Ribosome Recruitment</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1146/annurev-biochem-013118-111042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1146%2Fannurev-biochem-013118-111042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31220979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Wqt7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2019&pages=307-335&author=J.+Pelletierauthor=N.+Sonenberg&title=The+Organizing+Principles+of+Eukaryotic+Ribosome+Recruitment&doi=10.1146%2Fannurev-biochem-013118-111042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Organizing Principles of Eukaryotic Ribosome Recruitment</span></div><div class="casAuthors">Pelletier, Jerry; Sonenberg, Nahum</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">307-335</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The stage at which ribosomes are recruited to mRNAs (mRNAs) is an elaborate and highly regulated phase of protein synthesis.  Upon completion of this step, a ribosome is positioned at an appropriate initiation codon and primed to synthesize the encoded polypeptide product.  In most circumstances, this step commits the ribosome to translate the mRNA.  We summarize the knowledge regarding the initiation factors implicated in this activity as well as review different mechanisms by which this process is conducted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhpAHeWzb93LVg90H21EOLACvtfcHk0lj5jj9abcvY4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Wqt7vM&md5=a93eb98dfec6a13041410081a9ff7962</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-013118-111042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-013118-111042%26sid%3Dliteratum%253Aachs%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DThe%2520Organizing%2520Principles%2520of%2520Eukaryotic%2520Ribosome%2520Recruitment%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2019%26volume%3D88%26spage%3D307%26epage%3D335%26doi%3D10.1146%2Fannurev-biochem-013118-111042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montero, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Gil, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampieri, C. L.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic Initiation Factor 4A (EIF4A) during Viral Infections</span>. <i>Virus Genes</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1007/s11262-019-01641-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs11262-019-01641-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30796742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt12hs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=267-273&author=H.+Monteroauthor=G.+P%C3%A9rez-Gilauthor=C.+L.+Sampieri&title=Eukaryotic+Initiation+Factor+4A+%28EIF4A%29+during+Viral+Infections&doi=10.1007%2Fs11262-019-01641-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic initiation factor 4A (eIF4A) during viral infections</span></div><div class="casAuthors">Montero, Hilda; Perez-Gil, Gustavo; Sampieri, Clara L.</div><div class="citationInfo"><span class="NLM_cas:title">Virus Genes</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-273</span>CODEN:
                <span class="NLM_cas:coden">VIGEET</span>;
        ISSN:<span class="NLM_cas:issn">0920-8569</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The helicase eIF4A is part of the cellular eIF4F translation initiation complex.  The main functions of eIF4A are to remove secondary complex structures within the 5'-untranslated region and to displace proteins attached to mRNA.  As intracellular parasites, viruses regulate the processes involved in protein synthesis, and different mechanisms related to controlling translation factors, such as eIF4A, have been found.  The inhibitors of this factor are currently known; these substances could be used in the near future as part of antiviral pharmacol. therapies in instances of replication cycles in which eIF4A is required.  In this review, the particularities of how some viruses make use of this initiation factor to synthesize their proteins are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtjfqntRIPC7Vg90H21EOLACvtfcHk0lihvfYaUJyjNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt12hs7g%253D&md5=249e2041f1bad3bb9ee69603768c3074</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs11262-019-01641-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11262-019-01641-7%26sid%3Dliteratum%253Aachs%26aulast%3DMontero%26aufirst%3DH.%26aulast%3DP%25C3%25A9rez-Gil%26aufirst%3DG.%26aulast%3DSampieri%26aufirst%3DC.%2BL.%26atitle%3DEukaryotic%2520Initiation%2520Factor%25204A%2520%2528EIF4A%2529%2520during%2520Viral%2520Infections%26jtitle%3DVirus%2520Genes%26date%3D2019%26volume%3D55%26spage%3D267%26epage%3D273%26doi%3D10.1007%2Fs11262-019-01641-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madhugiri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span> <span> </span><span class="NLM_article-title">RNA Structure Analysis of Alphacoronavirus Terminal Genome Regions</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/j.virusres.2014.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.virusres.2014.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25307890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOkt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2014&pages=76-89&author=R.+Madhugiriauthor=M.+Frickeauthor=M.+Marzauthor=J.+Ziebuhr&title=RNA+Structure+Analysis+of+Alphacoronavirus+Terminal+Genome+Regions&doi=10.1016%2Fj.virusres.2014.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">RNA structure analysis of alphacoronavirus terminal genome regions</span></div><div class="casAuthors">Madhugiri, Ramakanth; Fricke, Markus; Marz, Manja; Ziebuhr, John</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-89</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Coronavirus genome replication is mediated by a multi-subunit protein complex that is comprised of more than a dozen virally encoded and several cellular proteins.  Interactions of the viral replicase complex with cis-acting RNA elements located in the 5' and 3'-terminal genome regions ensure the specific replication of viral RNA.  Over the past years, boundaries and structures of cis-acting RNA elements required for coronavirus genome replication have been extensively characterized in betacoronaviruses and, to a lesser extent, other coronavirus genera.  Here, we review our current understanding of coronavirus cis-acting elements located in the terminal genome regions and use a combination of bioinformatic and RNA structure probing studies to identify and characterize putative cis-acting RNA elements in alphacoronaviruses.  The study suggests significant RNA structure conservation among members of the genus Alphacoronavirus but also across genus boundaries.  Overall, the conservation pattern identified for 5' and 3'-terminal RNA structural elements in the genomes of alpha- and betacoronaviruses is in agreement with the widely used replicase polyprotein-based classification of the Coronavirinae, suggesting co-evolution of the coronavirus replication machinery with cognate cis-acting RNA elements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq86f-C5ZahOLVg90H21EOLACvtfcHk0lihvfYaUJyjNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOkt7rM&md5=8569ba1645d445d7339b006b914d0bdb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2014.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2014.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DMadhugiri%26aufirst%3DR.%26aulast%3DFricke%26aufirst%3DM.%26aulast%3DMarz%26aufirst%3DM.%26aulast%3DZiebuhr%26aufirst%3DJ.%26atitle%3DRNA%2520Structure%2520Analysis%2520of%2520Alphacoronavirus%2520Terminal%2520Genome%2520Regions%26jtitle%3DVirus%2520Res.%26date%3D2014%26volume%3D194%26spage%3D76%26epage%3D89%26doi%3D10.1016%2Fj.virusres.2014.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, M. L.</span></span> <span> </span><span class="NLM_article-title">X-Ray Crystal Structure of Rocaglamide, a Novel Antileukemic I H-Cyclopenta[b]Benzofuran from Aglaia Elliptifolia</span>. <i>J. Chem. Soc., Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>260</i></span>,  <span class="NLM_fpage">1150</span>– <span class="NLM_lpage">1151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1039%2Fc39820001150" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1982&pages=1150-1151&author=M.+L.+King&title=X-Ray+Crystal+Structure+of+Rocaglamide%2C+a+Novel+Antileukemic+I+H-Cyclopenta%5Bb%5DBenzofuran+from+Aglaia+Elliptifolia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2Fc39820001150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39820001150%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DM.%2BL.%26atitle%3DX-Ray%2520Crystal%2520Structure%2520of%2520Rocaglamide%252C%2520a%2520Novel%2520Antileukemic%2520I%2520H-Cyclopenta%255Bb%255DBenzofuran%2520from%2520Aglaia%2520Elliptifolia%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1982%26volume%3D260%26spage%3D1150%26epage%3D1151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li-Weber, M.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms and Anti-Cancer Aspects of the Medicinal Phytochemicals Rocaglamides (flavaglines)</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1791</span>– <span class="NLM_lpage">1799</span>, <span class="refDoi"> DOI: 10.1002/ijc.29013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fijc.29013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24895251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFequr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=1791-1799&author=M.+Li-Weber&title=Molecular+Mechanisms+and+Anti-Cancer+Aspects+of+the+Medicinal+Phytochemicals+Rocaglamides+%28flavaglines%29&doi=10.1002%2Fijc.29013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines)</span></div><div class="casAuthors">Li-Weber, Min</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1791-1799</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Rocaglamides (= flavaglines) are potent natural anti-cancer phytochems. that inhibit cancer growth at nanomolar concns. by the following mechanisms: (1) inhibition of translation initiation via inhibition of phosphorylation of the mRNA cap-binding eukaryotic translation initiation factor eIF4E and stabilization of RNA-binding of the translation initiation factor eIF4A in the eIF4F complex; (2) blocking cell cycle progression by activation of the ATM/ATR-Chk1/Chk2 checkpoint pathway; (3) inactivation of the heat shock factor 1 (HSF1) leading to up-regulation of thioredoxin-interacting protein (TXNIP) and consequent redn. of glucose uptake and (4) induction of apoptosis through activation of the MAPK p38 and JNK and inhibition of the Ras-CRaf-MEK-ERK signaling pathway.  Besides the anti-cancer activities, rocaglamides are also shown to protect primary cells from chemotherapy-induced cell death and alleviate inflammation- and drug-induced injury in neuronal tissues.  This review will focus on the recently discovered mol. mechanisms of the actions of rocaglamides and highlights the benefits of using rocaglamides in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3RA3J8dyvL7Vg90H21EOLACvtfcHk0lihvfYaUJyjNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFequr0%253D&md5=ef00b49990d2ddbbb643bd5c9ce353ff</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fijc.29013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29013%26sid%3Dliteratum%253Aachs%26aulast%3DLi-Weber%26aufirst%3DM.%26atitle%3DMolecular%2520Mechanisms%2520and%2520Anti-Cancer%2520Aspects%2520of%2520the%2520Medicinal%2520Phytochemicals%2520Rocaglamides%2520%2528flavaglines%2529%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D137%26spage%3D1791%26epage%3D1799%26doi%3D10.1002%2Fijc.29013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendel, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Suppression of Translation Initiation Modulates Chemosensitivity in a Mouse Lymphoma Model</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">2651</span>– <span class="NLM_lpage">2660</span>, <span class="refDoi"> DOI: 10.1172/JCI34753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1172%2FJCI34753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18551192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1Onu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2008&pages=2651-2660&author=M.+E.+Bordeleauauthor=F.+Robertauthor=B.+Gerardauthor=L.+Lindqvistauthor=S.+M.+H.+Chenauthor=H.+G.+Wendelauthor=B.+Bremauthor=H.+Gregerauthor=S.+W.+Loweauthor=J.+A.+Porcoauthor=J.+Pelletier&title=Therapeutic+Suppression+of+Translation+Initiation+Modulates+Chemosensitivity+in+a+Mouse+Lymphoma+Model&doi=10.1172%2FJCI34753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model</span></div><div class="casAuthors">Bordeleau, Marie-Eve; Robert, Francis; Gerard, Baudouin; Lindqvist, Lisa; Chen, Samuel M. H.; Wendel, Hans-Guido; Brem, Brigitte; Greger, Harald; Lowe, Scott W.; Porco, John A., Jr.; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2651-2660</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Disablement of cell death programs in cancer cells contributes to drug resistance and in some cases has been assocd. with altered translational control.  As eukaryotic translation initiation factor 4E (eIF4E) cooperates with c-Myc during lymphomagenesis, induces drug resistance, and is a genetic modifier of the rapamycin response, we have investigated the effect of dysregulation of the ribosome recruitment phase of translation initiation on tumor progression and chemosensitivity.  The eIF4E is a subunit of eIF4F, a complex that stimulates ribosome recruitment during translation initiation by delivering the DEAD-box RNA helicase eIF4A to the 5' end of mRNAs.  The eIF4A is thought to prep. a ribosome landing pad on mRNA templates for incoming 40S ribosomes (and assocd. factors).  Using small mol. screening, we found that cyclopenta[b]benzofuran flavaglines, a class of natural products, modulate eIF4A activity and inhibit translation initiation.  One member of this class of compds., silvestrol, was able to enhance chemosensitivity in a mouse lymphoma model in which carcinogenesis is driven by phosphatase and tensin homolog (PTEN) inactivation or elevated eIF4E levels.  These results establish that targeting translation initiation can restore drug sensitivity in vivo and provide an approach to modulating chemosensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBHqlb5KiKfLVg90H21EOLACvtfcHk0lgExUrwpExsQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1Onu7Y%253D&md5=74f89a2ff3038033e6d52448555943d0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1172%2FJCI34753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI34753%26sid%3Dliteratum%253Aachs%26aulast%3DBordeleau%26aufirst%3DM.%2BE.%26aulast%3DRobert%26aufirst%3DF.%26aulast%3DGerard%26aufirst%3DB.%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DS.%2BM.%2BH.%26aulast%3DWendel%26aufirst%3DH.%2BG.%26aulast%3DBrem%26aufirst%3DB.%26aulast%3DGreger%26aufirst%3DH.%26aulast%3DLowe%26aufirst%3DS.%2BW.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DTherapeutic%2520Suppression%2520of%2520Translation%2520Initiation%2520Modulates%2520Chemosensitivity%2520in%2520a%2520Mouse%2520Lymphoma%2520Model%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2008%26volume%3D118%26spage%3D2651%26epage%3D2660%26doi%3D10.1172%2FJCI34753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingolia, N. T.</span></span> <span> </span><span class="NLM_article-title">Rocaglates Convert DEAD-Box Protein eIF4A into a Sequence-Selective Translational Repressor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1038/nature17978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnature17978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27309803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSksbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=558-561&author=S.+Iwasakiauthor=S.+N.+Floorauthor=N.+T.+Ingolia&title=Rocaglates+Convert+DEAD-Box+Protein+eIF4A+into+a+Sequence-Selective+Translational+Repressor&doi=10.1038%2Fnature17978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor</span></div><div class="casAuthors">Iwasaki, Shintaro; Floor, Stephen N.; Ingolia, Nicholas T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7608</span>),
    <span class="NLM_cas:pages">558-561</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Rocaglamide A (RocA) typifies a class of protein synthesis inhibitors that selectively kill aneuploid tumor cells and repress translation of specific mRNAs.  RocA targets eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase; its mRNA selectivity is proposed to reflect highly structured 5' untranslated regions that depend strongly on eIF4A-mediated unwinding.  However, rocaglate treatment may not phenocopy the loss of eIF4A activity, as these drugs actually increase the affinity between eIF4A and RNA.  Here we show that secondary structure in 5' untranslated regions is only a minor determinant for RocA selectivity and that RocA does not repress translation by reducing eIF4A availability.  Rather, in vitro and in cells, RocA specifically clamps eIF4A onto polypurine sequences in an ATP-independent manner.  This artificially clamped eIF4A blocks 43S scanning, leading to premature, upstream translation initiation and reducing protein expression from transcripts bearing the RocA-eIF4A target sequence.  In elucidating the mechanism of selective translation repression by this lead anti-cancer compd., we provide an example of a drug stabilizing sequence-selective RNA-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR6CpuR_XHqLVg90H21EOLACvtfcHk0lgExUrwpExsQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSksbjN&md5=8e4735525578a70efe5731e02146c31b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature17978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17978%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DS.%26aulast%3DFloor%26aufirst%3DS.%2BN.%26aulast%3DIngolia%26aufirst%3DN.%2BT.%26atitle%3DRocaglates%2520Convert%2520DEAD-Box%2520Protein%2520eIF4A%2520into%2520a%2520Sequence-Selective%2520Translational%2520Repressor%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D558%26epage%3D561%26doi%3D10.1038%2Fnature17978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicia-Vázquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katigbak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, EIF4A</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2340</span>– <span class="NLM_lpage">2347</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.celrep.2016.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27239032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVSlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2340-2347&author=J.+Chuauthor=G.+Galicia-V%C3%A1zquezauthor=R.+Cencicauthor=J.+R.+Millsauthor=A.+Katigbakauthor=J.+A.+Porcoauthor=J.+Pelletier&title=CRISPR-Mediated+Drug-Target+Validation+Reveals+Selective+Pharmacological+Inhibition+of+the+RNA+Helicase%2C+EIF4A&doi=10.1016%2Fj.celrep.2016.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A</span></div><div class="casAuthors">Chu, Jennifer; Galicia-Vazquez, Gabriela; Cencic, Regina; Mills, John R.; Katigbak, Alexandra; Porco, John A., Jr.; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2340-2347</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Targeting translation initiation is an emerging anti-neoplastic strategy that capitalizes on de-regulated upstream MAPK and PI3K-mTOR signaling pathways in cancers.  A key regulator of translation that controls ribosome recruitment flux is eukaryotic initiation factor (eIF) 4F, a hetero-trimeric complex composed of the cap binding protein eIF4E, the scaffolding protein eIF4G, and the RNA helicase eIF4A.  Small mol. inhibitors targeting eIF4F display promising anti-neoplastic activity in preclin. settings.  Among these are some rocaglate family members that are well tolerated in vivo, deplete eIF4F of its eIF4A helicase subunit, have shown activity as single agents in several xenograft models, and can reverse acquired resistance to MAPK and PI3K-mTOR targeted therapies.  Herein, we highlight the power of using genetic complementation approaches and CRISPR/Cas9-mediated editing for drug-target validation ex vivo and in vivo, linking the anti-tumor properties of rocaglates to eIF4A inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTlJAdKCxSfbVg90H21EOLACvtfcHk0lgExUrwpExsQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVSlt7s%253D&md5=c84a9a808dcb119306303c6a8aa68b5b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DGalicia-V%25C3%25A1zquez%26aufirst%3DG.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DMills%26aufirst%3DJ.%2BR.%26aulast%3DKatigbak%26aufirst%3DA.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DCRISPR-Mediated%2520Drug-Target%2520Validation%2520Reveals%2520Selective%2520Pharmacological%2520Inhibition%2520of%2520the%2520RNA%2520Helicase%252C%2520EIF4A%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D15%26spage%3D2340%26epage%3D2347%26doi%3D10.1016%2Fj.celrep.2016.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shichino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodeoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imataka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuzawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingolia, N. T.</span></span> <span> </span><span class="NLM_article-title">The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2018.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.molcel.2018.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30595437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlyn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2019&pages=738-748&author=S.+Iwasakiauthor=W.+Iwasakiauthor=M.+Takahashiauthor=A.+Sakamotoauthor=C.+Watanabeauthor=Y.+Shichinoauthor=S.+N.+Floorauthor=K.+Fujiwaraauthor=M.+Mitoauthor=K.+Dodoauthor=M.+Sodeokaauthor=H.+Imatakaauthor=T.+Honmaauthor=K.+Fukuzawaauthor=T.+Itoauthor=N.+T.+Ingolia&title=The+Translation+Inhibitor+Rocaglamide+Targets+a+Bimolecular+Cavity+between+eIF4A+and+Polypurine+RNA&doi=10.1016%2Fj.molcel.2018.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA</span></div><div class="casAuthors">Iwasaki, Shintaro; Iwasaki, Wakana; Takahashi, Mari; Sakamoto, Ayako; Watanabe, Chiduru; Shichino, Yuichi; Floor, Stephen N.; Fujiwara, Koichi; Mito, Mari; Dodo, Kosuke; Sodeoka, Mikiko; Imataka, Hiroaki; Honma, Teruki; Fukuzawa, Kaori; Ito, Takuhiro; Ingolia, Nicholas T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">738-748.e9</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A class of translation inhibitors, exemplified by the natural product rocaglamide A (RocA), isolated from Aglaia genus plants, exhibits antitumor activity by clamping eukaryotic translation initiation factor 4A (eIF4A) onto polypurine sequences in mRNAs.  This unusual inhibitory mechanism raises the question of how the drug imposes sequence selectivity onto a general translation factor.  Here, we detd. the crystal structure of the human eIF4A1·ATP analog·RocA·polypurine RNA complex.  RocA targets the "bi-mol. cavity" formed characteristically by eIF4A1 and a sharply bent pair of consecutive purines in the RNA.  Natural amino acid substitutions found in Aglaia eIF4As changed the cavity shape, leading to RocA resistance.  This study provides an example of an RNA-sequence-selective interfacial inhibitor fitting into the space shaped cooperatively by protein and RNA with specific sequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUUblvotYlCLVg90H21EOLACvtfcHk0ljOnZFTWB2Gug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlyn&md5=5a79ee2e73386187b23310837d731645</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2018.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2018.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DS.%26aulast%3DIwasaki%26aufirst%3DW.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSakamoto%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DC.%26aulast%3DShichino%26aufirst%3DY.%26aulast%3DFloor%26aufirst%3DS.%2BN.%26aulast%3DFujiwara%26aufirst%3DK.%26aulast%3DMito%26aufirst%3DM.%26aulast%3DDodo%26aufirst%3DK.%26aulast%3DSodeoka%26aufirst%3DM.%26aulast%3DImataka%26aufirst%3DH.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DFukuzawa%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DIngolia%26aufirst%3DN.%2BT.%26atitle%3DThe%2520Translation%2520Inhibitor%2520Rocaglamide%2520Targets%2520a%2520Bimolecular%2520Cavity%2520between%2520eIF4A%2520and%2520Polypurine%2520RNA%26jtitle%3DMol.%2520Cell%26date%3D2019%26volume%3D73%26spage%3D738%26epage%3D748%26doi%3D10.1016%2Fj.molcel.2018.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kardono, L. B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afriastini, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riswan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarsiero, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairchild, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farnsworth, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordell, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzuto, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinghorn, A. D.</span></span> <span> </span><span class="NLM_article-title">Silvestrol and Episilvestrol, Potential Anticancer Rocaglate Derivatives from Aglaia Silvestris</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">3350</span>– <span class="NLM_lpage">3358</span>, <span class="refDoi"> DOI: 10.1021/jo040120f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo040120f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVSqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=3350-3358&author=B.+Y.+Hwangauthor=B.+N.+Suauthor=H.+Chaiauthor=Q.+Miauthor=L.+B.+S.+Kardonoauthor=J.+J.+Afriastiniauthor=S.+Riswanauthor=B.+D.+Santarsieroauthor=A.+D.+Mesecarauthor=R.+Wildauthor=C.+R.+Fairchildauthor=G.+D.+Viteauthor=W.+C.+Roseauthor=N.+R.+Farnsworthauthor=G.+A.+Cordellauthor=J.+M.+Pezzutoauthor=S.+M.+Swansonauthor=A.+D.+Kinghorn&title=Silvestrol+and+Episilvestrol%2C+Potential+Anticancer+Rocaglate+Derivatives+from+Aglaia+Silvestris&doi=10.1021%2Fjo040120f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris</span></div><div class="casAuthors">Hwang, Bang Yeon; Su, Bao-Ning; Chai, Heebyung; Mi, Qiuwen; Kardono, Leonardus B. S.; Afriastini, Johar J.; Riswan, Soedarsono; Santarsiero, Bernard D.; Mesecar, Andrew D.; Wild, Robert; Fairchild, Craig R.; Vite, Gregory D.; Rose, William C.; Farnsworth, Norman R.; Cordell, Geoffrey A.; Pezzuto, John M.; Swanson, Steven M.; Kinghorn, A. Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3350-3358</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two cytotoxic rocaglate derivs. possessing an unusual dioxanyloxy unit, silvestrol (I) and episilvestrol (II), were isolated from the fruits and twigs of Aglaia silvestris by bioassay-guided fractionation monitored with a human oral epidermoid carcinoma (KB) cell line.  Addnl., two new baccharane-type triterpenoids, 17,24-epoxy-25-hydroxybaccharan-3-one (III) and 17,24-epoxy-25-hydroxy-3-oxobaccharan-21-oic acid (IV), as well as eleven known compds., 1β,6α-dihydroxy-4(15)-eudesmene (5), ferulic acid (6), grasshopper ketone (7), apigenin, cabraleone, chrysoeriol, 1β,4β-dihydroxy-6α,15α-epoxyeudesmane, 4-hydroxy-3-methoxyacetophenone, 4-hydroxyphenethyl alc., ocotillone, and β-sitosterol 3-O-β-D-glucopyranoside, were also isolated and characterized.  The structures of compds. (I-IV) were elucidated by spectroscopic studies and by chem. transformation.  The abs. stereochem. of silvestrol was established by a X-ray diffraction study of its di-p-bromobenzoate deriv., and the structure of 3 was also confirmed by single-crystal X-ray diffraction.  The isolates and chem. transformation products were evaluated for cytotoxicity against several human cancer cell lines, and silvestrol and episilvestrol exhibited potent in vitro cytotoxic activity.  Silvestrol was further evaluated in vivo in the hollow fiber test and in the murine P-388 leukemia model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGremy-QmdRLZbVg90H21EOLACvtfcHk0ljOnZFTWB2Gug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVSqtrw%253D&md5=dff2b5076e06ea4a33f76e4f796b49ec</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjo040120f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo040120f%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DB.%2BY.%26aulast%3DSu%26aufirst%3DB.%2BN.%26aulast%3DChai%26aufirst%3DH.%26aulast%3DMi%26aufirst%3DQ.%26aulast%3DKardono%26aufirst%3DL.%2BB.%2BS.%26aulast%3DAfriastini%26aufirst%3DJ.%2BJ.%26aulast%3DRiswan%26aufirst%3DS.%26aulast%3DSantarsiero%26aufirst%3DB.%2BD.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DFairchild%26aufirst%3DC.%2BR.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DRose%26aufirst%3DW.%2BC.%26aulast%3DFarnsworth%26aufirst%3DN.%2BR.%26aulast%3DCordell%26aufirst%3DG.%2BA.%26aulast%3DPezzuto%26aufirst%3DJ.%2BM.%26aulast%3DSwanson%26aufirst%3DS.%2BM.%26aulast%3DKinghorn%26aufirst%3DA.%2BD.%26atitle%3DSilvestrol%2520and%2520Episilvestrol%252C%2520Potential%2520Anticancer%2520Rocaglate%2520Derivatives%2520from%2520Aglaia%2520Silvestris%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D3350%26epage%3D3358%26doi%3D10.1021%2Fjo040120f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozewski, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goettl, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarjoura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinghorn, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grever, M. R.</span></span> <span> </span><span class="NLM_article-title">The Novel Plant-Derived Agent Silvestrol Has B-Cell Selective Activity in Chronic Lymphocytic Leukemia and Acute Lymphoblastic Leukemia in Vitro and in Vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">4656</span>– <span class="NLM_lpage">4666</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-09-175430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1182%2Fblood-2008-09-175430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19190247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvVyqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4656-4666&author=D.+M.+Lucasauthor=R.+B.+Edwardsauthor=G.+Lozanskiauthor=D.+A.+Westauthor=J.+D.+Shinauthor=M.+A.+Vargoauthor=M.+E.+Davisauthor=D.+M.+Rozewskiauthor=A.+J.+Johnsonauthor=B.+N.+Suauthor=V.+M.+Goettlauthor=N.+A.+Heeremaauthor=T.+S.+Linauthor=A.+Lehmanauthor=X.+Zhangauthor=D.+Jarjouraauthor=D.+J.+Newmanauthor=J.+C.+Byrdauthor=A.+D.+Kinghornauthor=M.+R.+Grever&title=The+Novel+Plant-Derived+Agent+Silvestrol+Has+B-Cell+Selective+Activity+in+Chronic+Lymphocytic+Leukemia+and+Acute+Lymphoblastic+Leukemia+in+Vitro+and+in+Vivo&doi=10.1182%2Fblood-2008-09-175430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo</span></div><div class="casAuthors">Lucas, David M.; Edwards, Ryan B.; Lozanski, Gerard; West, Derek A.; Shin, Jungook D.; Vargo, Melissa A.; Davis, Melanie E.; Rozewski, Darlene M.; Johnson, Amy J.; Su, Bao-Ning; Goettl, Virginia M.; Heerema, Nyla A.; Lin, Thomas S.; Lehman, Amy; Zhang, Xiaoli; Jarjoura, David; Newman, David J.; Byrd, John C.; Kinghorn, A. Douglas; Grever, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4656-4666</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Therapeutic options for advanced B-cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) are limited.  Available treatments can also deplete T lymphocytes, leaving patients at risk of life-threatening infections.  In the National Cancer Institute cell line screen, the structurally unique natural product silvestrol produces an unusual pattern of cytotoxicity that suggests activity in leukemia and selectivity for B cells.  We investigated silvestrol efficacy using primary human B-leukemia cells, established B-leukemia cell lines, and animal models.  In CLL cells, silvestrol LC50 (concn. lethal to 50%) is 6.9 nM at 72 h.  At this concn., there is no difference in sensitivity of cells from patients with or without the del(17p13.1) abnormality.  In isolated cells and whole blood, silvestrol is more cytotoxic toward B cells than T cells.  Silvestrol causes early redn. in Mcl-1 expression due to translational inhibition with subsequent mitochondrial damage, as evidenced by reactive oxygen species generation and membrane depolarization.  In vivo, silvestrol causes significant B-cell redn. in Eμ-Tcl-1 transgenic mice and significantly extends survival of 697 xenograft severe combined immunodeficient (SCID) mice without discernible toxicity.  These data indicate silvestrol has efficacy against B cells in vitro and in vivo and identify translational inhibition as a potential therapeutic target in B-cell leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ws9D3VBlYLVg90H21EOLACvtfcHk0ljOnZFTWB2Gug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvVyqurg%253D&md5=8c43343a06d2b7e2a8633b5c2aa78df4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-09-175430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-09-175430%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DD.%2BM.%26aulast%3DEdwards%26aufirst%3DR.%2BB.%26aulast%3DLozanski%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DD.%2BA.%26aulast%3DShin%26aufirst%3DJ.%2BD.%26aulast%3DVargo%26aufirst%3DM.%2BA.%26aulast%3DDavis%26aufirst%3DM.%2BE.%26aulast%3DRozewski%26aufirst%3DD.%2BM.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSu%26aufirst%3DB.%2BN.%26aulast%3DGoettl%26aufirst%3DV.%2BM.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DLehman%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJarjoura%26aufirst%3DD.%26aulast%3DNewman%26aufirst%3DD.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DKinghorn%26aufirst%3DA.%2BD.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26atitle%3DThe%2520Novel%2520Plant-Derived%2520Agent%2520Silvestrol%2520Has%2520B-Cell%2520Selective%2520Activity%2520in%2520Chronic%2520Lymphocytic%2520Leukemia%2520and%2520Acute%2520Lymphoblastic%2520Leukemia%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D4656%26epage%3D4666%26doi%3D10.1182%2Fblood-2008-09-175430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicia-Vázquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukarieh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teodoro, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity and Mechanism of Action of the Cyclopenta[b]Benzofuran, Silvestrol</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e5223</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0005223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pone.0005223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19401772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BD1MzgvVGntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=e5223&author=R.+Cencicauthor=M.+Carrierauthor=G.+Galicia-V%C3%A1zquezauthor=M.+E.+Bordeleauauthor=R.+Sukariehauthor=A.+Bourdeauauthor=B.+Bremauthor=J.+G.+Teodoroauthor=H.+Gregerauthor=M.+L.+Tremblayauthor=J.+A.+Porcoauthor=J.+Pelletier&title=Antitumor+Activity+and+Mechanism+of+Action+of+the+Cyclopenta%5Bb%5DBenzofuran%2C+Silvestrol&doi=10.1371%2Fjournal.pone.0005223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol</span></div><div class="casAuthors">Cencic Regina; Carrier Marilyn; Galicia-Vazquez Gabriela; Bordeleau Marie-Eve; Sukarieh Rami; Bourdeau Annie; Brem Brigitte; Teodoro Jose G; Greger Harald; Tremblay Michel L; Porco John A Jr; Pelletier Jerry</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e5223</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Flavaglines are a family of natural products from the genus Aglaia that exhibit anti-cancer activity in vitro and in vivo and inhibit translation initiation.  They have been shown to modulate the activity of eIF4A, the DEAD-box RNA helicase subunit of the eukaryotic initiation factor (eIF) 4F complex, a complex that stimulates ribosome recruitment during translation initiation.  One flavagline, silvestrol, is capable of modulating chemosensitivity in a mechanism-based mouse model.  METHODOLOGY/PRINCIPAL FINDINGS:  Among a number of flavagline family members tested herein, we find that silvestrol is the more potent translation inhibitor among these.  We find that silvestrol impairs the ribosome recruitment step of translation initiation by affecting the composition of the eukaryotic initiation factor (eIF) 4F complex.  We show that silvestrol exhibits significant anticancer activity in human breast and prostate cancer xenograft models, and that this is associated with increased apoptosis, decreased proliferation, and inhibition of angiogenesis.  We demonstrate that targeting translation by silvestrol results in preferential inhibition of weakly initiating mRNAs.  CONCLUSIONS/SIGNIFICANCE:  Our results indicate that silvestrol is a potent anti-cancer compound in vivo that exerts its activity by affecting survival pathways as well as angiogenesis.  We propose that silvestrol mediates its effects by preferentially inhibiting translation of malignancy-related mRNAs.  Silvestrol appears to be well tolerated in animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0uaNMC9zaUgaK-_ZudimnfW6udTcc2eYWaF6oWKL2ELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzgvVGntw%253D%253D&md5=48975b3546378c2340d5511d2564399d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0005223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0005223%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DCarrier%26aufirst%3DM.%26aulast%3DGalicia-V%25C3%25A1zquez%26aufirst%3DG.%26aulast%3DBordeleau%26aufirst%3DM.%2BE.%26aulast%3DSukarieh%26aufirst%3DR.%26aulast%3DBourdeau%26aufirst%3DA.%26aulast%3DBrem%26aufirst%3DB.%26aulast%3DTeodoro%26aufirst%3DJ.%2BG.%26aulast%3DGreger%26aufirst%3DH.%26aulast%3DTremblay%26aufirst%3DM.%2BL.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DAntitumor%2520Activity%2520and%2520Mechanism%2520of%2520Action%2520of%2520the%2520Cyclopenta%255Bb%255DBenzofuran%252C%2520Silvestrol%26jtitle%3DPLoS%2520One%26date%3D2009%26volume%3D4%26spage%3De5223%26doi%3D10.1371%2Fjournal.pone.0005223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trnkus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Synergistic Effect of Inhibiting Translation Initiation in Combination with Cytotoxic Agents in Acute Myelogenous Leukemia Cells</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2009.07.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.leukres.2009.07.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19726085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Gmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=535-541&author=R.+Cencicauthor=M.+Carrierauthor=A.+Trnkusauthor=J.+A.+Porcoauthor=M.+Mindenauthor=J.+Pelletier&title=Synergistic+Effect+of+Inhibiting+Translation+Initiation+in+Combination+with+Cytotoxic+Agents+in+Acute+Myelogenous+Leukemia+Cells&doi=10.1016%2Fj.leukres.2009.07.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells</span></div><div class="casAuthors">Cencic, Regina; Carrier, Marilyn; Trnkus, Amanda; Porco, John A.; Minden, Mark; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">535-541</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We have previously shown that inhibition of translation initiation, using the small mol. inhibitor silvestrol, induces apoptosis in a pre-clin. murine lymphoma model when combined with daunorubicin.  Silvestrol blocks ribosome recruitment by targeting the RNA helicase, eIF4A, which is required for this process.  Here we investigate the sensitivity of acute myelogenous leukemia (AML) cell lines to protein synthesis inhibition in combination with the std. cytotoxic agents daunorubicin, etoposide, and cytarabine.  Silvestrol shows synergy with std.-of-care agents in AML cell lines and synergizes with ABT-737, a small mol. inhibitor of Bcl-XL and Bcl-2.  The in vitro synergy between silvestrol and the cytotoxic drugs used in AML therapy provides a basis for in vivo evaluation of these combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdyURmWhIHq7Vg90H21EOLACvtfcHk0ligOH3g59ao1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Gmsrc%253D&md5=32992bda5b2a9218030980c01ae84072</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2009.07.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2009.07.043%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DCarrier%26aufirst%3DM.%26aulast%3DTrnkus%26aufirst%3DA.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DMinden%26aufirst%3DM.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DSynergistic%2520Effect%2520of%2520Inhibiting%2520Translation%2520Initiation%2520in%2520Combination%2520with%2520Cytotoxic%2520Agents%2520in%2520Acute%2520Myelogenous%2520Leukemia%2520Cells%26jtitle%3DLeuk.%2520Res.%26date%3D2010%26volume%3D34%26spage%3D535%26epage%3D541%26doi%3D10.1016%2Fj.leukres.2009.07.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sass, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarjoura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinghorn, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grever, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, D. M.</span></span> <span> </span><span class="NLM_article-title">Resistance to the Translation Initiation Inhibitor Silvestrol Is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">357</span>, <span class="refDoi"> DOI: 10.1208/s12248-011-9276-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1208%2Fs12248-011-9276-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21538216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFKjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=357&author=S.+V.+Guptaauthor=E.+J.+Sassauthor=M.+E.+Davisauthor=R.+B.+Edwardsauthor=G.+Lozanskiauthor=N.+A.+Heeremaauthor=A.+Lehmanauthor=X.+Zhangauthor=D.+Jarjouraauthor=J.+C.+Byrdauthor=L.+Panauthor=K.+K.+Chanauthor=A.+D.+Kinghornauthor=M.+A.+Phelpsauthor=M.+R.+Greverauthor=D.+M.+Lucas&title=Resistance+to+the+Translation+Initiation+Inhibitor+Silvestrol+Is+Mediated+by+ABCB1%2FP-Glycoprotein+Overexpression+in+Acute+Lymphoblastic+Leukemia+Cells&doi=10.1208%2Fs12248-011-9276-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells</span></div><div class="casAuthors">Gupta, Sneha V.; Sass, Ellen J.; Davis, Melanie E.; Edwards, Ryan B.; Lozanski, Gerard; Heerema, Nyla A.; Lehman, Amy; Zhang, Xiaoli; Jarjoura, David; Byrd, John C.; Pan, Li; Chan, Kenneth K.; Kinghorn, A. Douglas; Phelps, Mitch A.; Grever, Michael R.; Lucas, David M.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">357-364</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Protein synthesis is a powerful therapeutic target in leukemias and other cancers, but few pharmacol. viable agents are available that affect this process directly.  The plant-derived agent silvestrol specifically inhibits translation initiation by interfering with eIF4A/mRNA assembly with eIF4F.  Silvestrol has potent in vitro and in vivo activity in multiple cancer models including acute lymphoblastic leukemia (ALL) and is under pre-clin. development by the US National Cancer Institute, but no information is available about potential mechanisms of resistance.  In a sep. report, we showed that i.p. silvestrol is approx. 100% bioavailable systemically, although oral doses were only 1% bioavailable despite an apparent lack of metab.  To explore mechanisms of silvestrol resistance and the possible role of efflux transporters in silvestrol disposition, we characterized multi-drug resistance transporter expression and function in a silvestrol-resistant ALL cell line generated via culture of the 697 ALL cell line in gradually increasing silvestrol concns.  This resistant cell line, 697-R, shows significant upregulation of ABCB1 mRNA and P-glycoprotein (Pgp) as well as cross-resistance to known Pgp substrates vincristine and romidepsin.  Furthermore, 697-R cells readily efflux the fluorescent Pgp substrate rhodamine 123.  This effect is prevented by Pgp inhibitors verapamil and cyclosporin A, as well as siRNA to ABCB1, with concomitant re-sensitization to silvestrol.  Together, these data indicate that silvestrol is a substrate of Pgp, a potential obstacle that must be considered in the development of silvestrol for oral delivery or targeting to tumors protected by Pgp overexpression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj1JyZVHbPo7Vg90H21EOLACvtfcHk0ligOH3g59ao1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFKjtbg%253D&md5=cc9f9f874b6f71720dd673a061418e0a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1208%2Fs12248-011-9276-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-011-9276-7%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DS.%2BV.%26aulast%3DSass%26aufirst%3DE.%2BJ.%26aulast%3DDavis%26aufirst%3DM.%2BE.%26aulast%3DEdwards%26aufirst%3DR.%2BB.%26aulast%3DLozanski%26aufirst%3DG.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DLehman%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJarjoura%26aufirst%3DD.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DK.%2BK.%26aulast%3DKinghorn%26aufirst%3DA.%2BD.%26aulast%3DPhelps%26aufirst%3DM.%2BA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DLucas%26aufirst%3DD.%2BM.%26atitle%3DResistance%2520to%2520the%2520Translation%2520Initiation%2520Inhibitor%2520Silvestrol%2520Is%2520Mediated%2520by%2520ABCB1%252FP-Glycoprotein%2520Overexpression%2520in%2520Acute%2520Lymphoblastic%2520Leukemia%2520Cells%26jtitle%3DAAPS%2520J.%26date%3D2011%26volume%3D13%26spage%3D357%26doi%3D10.1208%2Fs12248-011-9276-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saradhi, U. V. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinghorn, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grever, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. K.</span></span> <span> </span><span class="NLM_article-title">Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography-Tandem Mass Spectrometry</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1208/s12248-011-9273-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1208%2Fs12248-011-9273-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21499689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFKjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=347-356&author=U.+V.+R.+V.+Saradhiauthor=S.+V.+Guptaauthor=M.+Chiuauthor=J.+Wangauthor=Y.+Lingauthor=Z.+Liuauthor=D.+J.+Newmanauthor=J.+M.+Coveyauthor=A.+D.+Kinghornauthor=G.+Marcucciauthor=D.+M.+Lucasauthor=M.+R.+Greverauthor=M.+A.+Phelpsauthor=K.+K.+Chan&title=Characterization+of+Silvestrol+Pharmacokinetics+in+Mice+Using+Liquid+Chromatography-Tandem+Mass+Spectrometry&doi=10.1208%2Fs12248-011-9273-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography-Tandem Mass Spectrometry</span></div><div class="casAuthors">Saradhi, U. V. R. Vijaya; Gupta, Sneha V.; Chiu, Ming; Wang, Jiang; Ling, Yonghua; Liu, Zhongfa; Newman, David J.; Covey, Joseph M.; Kinghorn, A. Douglas; Marcucci, Guido; Lucas, David M.; Grever, Michael R.; Phelps, Mitch A.; Chan, Kenneth K.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-356</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A sensitive and specific liq. chromatog.-tandem mass spectrometry method was developed and validated for the quantification of the plant natural product silvestrol in mice, using ansamitocin P-3 as the internal std.  The method was validated in plasma with a lower limit of quantification of 1 ng/mL, accuracy ranging from 87 to 114%, and precision (coeff. of variation) below 15%.  The validated method was used to characterize pharmacokinetics in C57BL/6 mice and metab. in mouse, human and rat plasma, and liver microsomes.  Mice were dosed with silvestrol formulated in hydroxypropyl-β-cyclodextrin via i.v., i.p., and oral routes followed by blood sampling up to 24 h.  I.p. systemic availability was 100%, but oral administration resulted in only 1.7% bioavailability.  Gradual degrdn. of silvestrol was obsd. in mouse and human plasma, with approx. 60% of the parent drug remaining after 6 h.  In rat plasma, however, silvestrol was completely converted to silvestric acid (SA) within 10 min.  Evaluation in microsomes provided further evidence that the main metabolite formed was SA, which subsequently showed no cytotoxic or cytostatic activity in a silvestrol-sensitive lymphoblastic cell line.  The ability of the anal. assay to measure tissue levels of silvestrol was evaluated in liver, brain, kidney, and spleen.  Results indicated the method was capable of accurately measuring tissue levels of silvestrol and suggested it has a relatively low distribution to brain.  Together, these data suggest an overall favorable pharmacokinetic profile of silvestrol in mice and provide crucial information for its continued development toward potential clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxRcQr8K0Ux7Vg90H21EOLACvtfcHk0lhPTJNZYxlnHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFKjtbs%253D&md5=67657244ab1561c6a61aaeb9496abbbd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1208%2Fs12248-011-9273-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-011-9273-x%26sid%3Dliteratum%253Aachs%26aulast%3DSaradhi%26aufirst%3DU.%2BV.%2BR.%2BV.%26aulast%3DGupta%26aufirst%3DS.%2BV.%26aulast%3DChiu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DNewman%26aufirst%3DD.%2BJ.%26aulast%3DCovey%26aufirst%3DJ.%2BM.%26aulast%3DKinghorn%26aufirst%3DA.%2BD.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DLucas%26aufirst%3DD.%2BM.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DPhelps%26aufirst%3DM.%2BA.%26aulast%3DChan%26aufirst%3DK.%2BK.%26atitle%3DCharacterization%2520of%2520Silvestrol%2520Pharmacokinetics%2520in%2520Mice%2520Using%2520Liquid%2520Chromatography-Tandem%2520Mass%2520Spectrometry%26jtitle%3DAAPS%2520J.%26date%3D2011%26volume%3D13%26spage%3D347%26epage%3D356%26doi%3D10.1208%2Fs12248-011-9273-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, J. H.</span></span> <span> </span><span class="NLM_article-title">EIF4A Inhibition: Ready for Primetime?</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">35515</span>– <span class="NLM_lpage">35516</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.26268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.18632%2Foncotarget.26268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30473746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BB3crksFehsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=35515-35516&author=T.+A.+Cunninghamauthor=E.+Chapmanauthor=J.+H.+Schatz&title=EIF4A+Inhibition%3A+Ready+for+Primetime%3F&doi=10.18632%2Foncotarget.26268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">eIF4A inhibition: ready for primetime?</span></div><div class="casAuthors">Cunningham Tyler A; Chapman Eli; Schatz Jonathan H</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">85</span>),
    <span class="NLM_cas:pages">35515-35516</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSP_Peh7v7xH0EgZCMqtRBifW6udTcc2eYMOADvDLCSrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crksFehsQ%253D%253D&md5=c08ce0ce96db85fcb9af743f659f8431</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.26268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.26268%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DT.%2BA.%26aulast%3DChapman%26aufirst%3DE.%26aulast%3DSchatz%26aufirst%3DJ.%2BH.%26atitle%3DEIF4A%2520Inhibition%253A%2520Ready%2520for%2520Primetime%253F%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D35515%26epage%3D35516%26doi%3D10.18632%2Foncotarget.26268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span> <span> </span><span class="NLM_article-title">Progress in the Total Synthesis of Rocaglamide</span>. <i>ISRN Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.5402/2011/239817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.5402%2F2011%2F239817" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=1-7&author=X.+Caiauthor=B.+Xieauthor=H.+Guo&title=Progress+in+the+Total+Synthesis+of+Rocaglamide&doi=10.5402%2F2011%2F239817"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.5402%2F2011%2F239817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5402%252F2011%252F239817%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DH.%26atitle%3DProgress%2520in%2520the%2520Total%2520Synthesis%2520of%2520Rocaglamide%26jtitle%3DISRN%2520Org.%2520Chem.%26date%3D2011%26volume%3D2011%26spage%3D1%26epage%3D7%26doi%3D10.5402%2F2011%2F239817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Hamdan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Synthesis of Flavaglines, a Family of Potent Bioactive Natural Compounds Originating from Traditional Chinese Medicine</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">5908</span>– <span class="NLM_lpage">5916</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201600437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fejoc.201600437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1CltLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=5908-5916&author=Q.+Zhaoauthor=H.+Abou-Hamdanauthor=L.+D%C3%A9saubry&title=Recent+Advances+in+the+Synthesis+of+Flavaglines%2C+a+Family+of+Potent+Bioactive+Natural+Compounds+Originating+from+Traditional+Chinese+Medicine&doi=10.1002%2Fejoc.201600437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Synthesis of Flavaglines, a Family of Potent Bioactive Natural Compounds Originating from Traditional Chinese Medicine</span></div><div class="casAuthors">Zhao, Qian; Abou-Hamdan, Hussein; Desaubry, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">5908-5916</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Flavaglines constitute a distinctive family of plant metabolites isolated from medicinal plants of the genus Aglaia.  These compds. exhibit a broad spectrum of distinctive pharmacol. properties, including anti-inflammatory, neuroprotective, cardioprotective, and anticancer activities.  These natural cyclopenta[b]benzofurans are characterized by densely functionalized tricyclic frameworks, as exemplified by the structures of rocaglamide or silvestrol, which makes them extremely attractive targets for total synthesis, in addn. to their therapeutic potential.  In this review we describe the various synthetic approaches to the total synthesis of flavaglines, culminating in a new generation of diastereo- and enantioselective total syntheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4fgv5knkhj7Vg90H21EOLACvtfcHk0lhPTJNZYxlnHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1CltLjO&md5=c024d7a3f7142c42d508f4c7867557e4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201600437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201600437%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DAbou-Hamdan%26aufirst%3DH.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Synthesis%2520of%2520Flavaglines%252C%2520a%2520Family%2520of%2520Potent%2520Bioactive%2520Natural%2520Compounds%2520Originating%2520from%2520Traditional%2520Chinese%2520Medicine%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2016%26volume%3D2016%26spage%3D5908%26epage%3D5916%26doi%3D10.1002%2Fejoc.201600437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tius, M. A.</span></span> <span> </span><span class="NLM_article-title">The Evolution of the Total Synthesis of Rocaglamide</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">15929</span>– <span class="NLM_lpage">15936</span>, <span class="refDoi"> DOI: 10.1002/chem.201603312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fchem.201603312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27717051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWqtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=15929-15936&author=Z.+Zhouauthor=D.+D.+Dixonauthor=A.+Jolitauthor=M.+A.+Tius&title=The+Evolution+of+the+Total+Synthesis+of+Rocaglamide&doi=10.1002%2Fchem.201603312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The Evolution of the Total Synthesis of Rocaglamide</span></div><div class="casAuthors">Zhou, Zhe; Dixon, Darryl D.; Jolit, Anais; Tius, Marcus A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">15929-15936</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The complex flavagline, (-)-rocaglamide (I), possesses a synthetically intriguing tricyclic scaffold with five contiguous stereocenters and also exhibits potent anticancer, anti-inflammatory and insecticidal activity.  This full account details distinct approaches to (±)- and (-)-rocaglamide utilizing Bronsted acid catalyzed and asym. Pd0-catalyzed Nazarov chem. developed in our lab., resp.  The successful asym. synthesis revealed unforeseen mechanistic complexity that required adjusting our strategy to overcome an unanticipated racemization process, an unusual reversible ring-cleavage step and a very facile trialkylsilyl group migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpuqXIOS9_dbVg90H21EOLACvtfcHk0liFSZPmHZitCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWqtbfM&md5=fe2d3b17bf8054d58af473b08fb0d82a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fchem.201603312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201603312%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DDixon%26aufirst%3DD.%2BD.%26aulast%3DJolit%26aufirst%3DA.%26aulast%3DTius%26aufirst%3DM.%2BA.%26atitle%3DThe%2520Evolution%2520of%2520the%2520Total%2520Synthesis%2520of%2520Rocaglamide%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2016%26volume%3D22%26spage%3D15929%26epage%3D15936%26doi%3D10.1002%2Fchem.201603312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nhu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzacasa, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span> <span> </span><span class="NLM_article-title">Simplified Silvestrol Analogues with Potent Cytotoxic Activity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1556</span>– <span class="NLM_lpage">1566</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201400024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fcmdc.201400024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24677741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltVSrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1556-1566&author=B.+C.+Hawkinsauthor=L.+M.+Lindqvistauthor=D.+Nhuauthor=P.+P.+Sharpauthor=D.+Segalauthor=A.+K.+Powellauthor=M.+Campbellauthor=E.+Ryanauthor=J.+M.+Chambersauthor=J.+M.+Whiteauthor=M.+A.+Rizzacasaauthor=G.+Lesseneauthor=D.+C.+S.+S.+Huangauthor=C.+J.+Burns&title=Simplified+Silvestrol+Analogues+with+Potent+Cytotoxic+Activity&doi=10.1002%2Fcmdc.201400024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Simplified Silvestrol Analogues with Potent Cytotoxic Activity</span></div><div class="casAuthors">Hawkins, Bill C.; Lindqvist, Lisa M.; Nhu, Duong; Sharp, Phillip P.; Segal, David; Powell, Andrew K.; Campbell, Michael; Ryan, Eileen; Chambers, Jennifer M.; White, Jonathan M.; Rizzacasa, Mark A.; Lessene, Guillaume; Huang, David C. S.; Burns, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1556-1566</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The complex natural products silvestrol (1) and episilvestrol (2) are inhibitors of translation initiation through binding to the DEAD-box helicase eukaryotic initiation factor 4A (eIF4A).  Both compds. are potently cytotoxic to cancer cells in vitro, and 1 has demonstrated efficacy in vivo in several xenograft cancer models.  Here we show that 2 has limited plasma membrane permeability and is metabolized in liver microsomes in a manner consistent with that reported for 1.  In addn., we have prepd. a series of analogs of these compds. where the complex pseudo-sugar at C6 has been replaced with chem. simpler moieties to improve drug-likeness.  Selected compds. from this work possess excellent activity in biochem. and cellular translation assays with potent activity against leukemia cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz75BXieKh5rVg90H21EOLACvtfcHk0liFSZPmHZitCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltVSrtbs%253D&md5=0798d277de73bd89340d5b6df7554f88</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201400024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201400024%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DB.%2BC.%26aulast%3DLindqvist%26aufirst%3DL.%2BM.%26aulast%3DNhu%26aufirst%3DD.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DA.%2BK.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DRyan%26aufirst%3DE.%26aulast%3DChambers%26aufirst%3DJ.%2BM.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DRizzacasa%26aufirst%3DM.%2BA.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%2BS.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26atitle%3DSimplified%2520Silvestrol%2520Analogues%2520with%2520Potent%2520Cytotoxic%2520Activity%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D1556%26epage%3D1566%26doi%3D10.1002%2Fcmdc.201400024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beglov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1586</span>– <span class="NLM_lpage">1593</span>, e3. <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.chembiol.2019.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31519508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslOhur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1586-1593&author=J.+Chuauthor=W.+Zhangauthor=R.+Cencicauthor=W.+G.+Devineauthor=D.+Beglovauthor=T.+Henkelauthor=L.+E.+Brownauthor=S.+Vajdaauthor=J.+A.+Porcoauthor=J.+Pelletier&title=Amidino-Rocaglates%3A+A+Potent+Class+of+eIF4A+Inhibitors&doi=10.1016%2Fj.chembiol.2019.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors</span></div><div class="casAuthors">Chu, Jennifer; Zhang, Wenhan; Cencic, Regina; Devine, William G.; Beglov, Dmitri; Henkel, Thomas; Brown, Lauren E.; Vajda, Sandor; Porco, John A. Jr.; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1586-1593.e3</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Rocaglates share a common cyclopenta[b]benzofuran core that inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase, eIF4A.  Working as interfacial inhibitors, rocaglates stabilize the assocn. between eIF4A and RNA, which can lead to the formation of steric barriers that block initiating ribosomes.  There is significant interest in the development and expansion of rocaglate derivs., as several members of this family have been shown to possess potent anti-neoplastic activity in vitro and in vivo.  To further our understanding of rocaglate diversity and drug design, herein we explore the RNA clamping activity of >200 unique rocaglate derivs.  Through this, we report on the identification and characterization of a potent class of synthetic rocaglates called amidino-rocaglates.  These compds. are among the most potent rocaglates documented to date and, taken together, this work offers important information that will guide the future design of rocaglates with improved biol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIA_4OEeLxs7Vg90H21EOLACvtfcHk0liFSZPmHZitCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslOhur%252FE&md5=f323bd1276dd8142e7f373eaf59d42b3</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DDevine%26aufirst%3DW.%2BG.%26aulast%3DBeglov%26aufirst%3DD.%26aulast%3DHenkel%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DL.%2BE.%26aulast%3DVajda%26aufirst%3DS.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DAmidino-Rocaglates%253A%2520A%2520Potent%2520Class%2520of%2520eIF4A%2520Inhibitors%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D1586%26epage%3D1593%26doi%3D10.1016%2Fj.chembiol.2019.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilewski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegerski, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S. H.</span></span> <span> </span><span class="NLM_article-title">Design of Development Candidate EFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5879</span>– <span class="NLM_lpage">5955</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00182</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00182" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVeis7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=5879-5955&author=J.+T.+Ernstauthor=P.+A.+Thompsonauthor=C.+Nilewskiauthor=P.+A.+Sprengelerauthor=S.+Sperryauthor=G.+Packardauthor=T.+Michelsauthor=A.+Xiangauthor=C.+Tranauthor=C.+J.+Wegerskiauthor=B.+Eamauthor=N.+P.+Youngauthor=S.+Fishauthor=J.+Chenauthor=H.+Howardauthor=J.+Stauntonauthor=J.+Molterauthor=J.+Clarineauthor=A.+Nevarezauthor=G.+G.+Chiangauthor=J.+R.+Applemanauthor=K.+R.+Websterauthor=S.+H.+Reich&title=Design+of+Development+Candidate+EFT226%2C+a+First+in+Class+Inhibitor+of+Eukaryotic+Initiation+Factor+4A+RNA+Helicase&doi=10.1021%2Facs.jmedchem.0c00182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase</span></div><div class="casAuthors">Ernst, Justin T.; Thompson, Peggy A.; Nilewski, Christian; Sprengeler, Paul A.; Sperry, Samuel; Packard, Garrick; Michels, Theodore; Xiang, Alan; Tran, Chinh; Wegerski, Christopher J.; Eam, Boreth; Young, Nathan P.; Fish, Sarah; Chen, Joan; Howard, Haleigh; Staunton, Jocelyn; Molter, Jolene; Clarine, Jeff; Nevarez, Andres; Chiang, Gary G.; Appleman, Jim R.; Webster, Kevin R.; Reich, Siegfried H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5879-5955</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulation of protein translation is a key driver for the pathogenesis of many cancers.  Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a crit. component of the eIF4F complex, which regulates cap-dependent protein synthesis.  The flavagline class of natural products (i.e., rocaglamide A) has been shown to inhibit protein synthesis by stabilizing a translation-incompetent complex for select mRNAs (mRNAs) with eIF4A.  Despite showing promising anticancer phenotypes, the development of flavagline derivs. as therapeutic agents has been hampered because of poor drug-like properties as well as synthetic complexity.  A focused effort was undertaken utilizing a ligand-based design strategy to identify a chemotype with optimized physicochem. properties.  Also, detailed mechanistic studies were undertaken to further elucidate mRNA sequence selectivity, key regulated target genes, and the assocd. antitumor phenotype.  This work led to the design of eFT226 (Zotatifin), I, a compd. with excellent physicochem. properties and significant antitumor activity that supports clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC3keA8h-DArVg90H21EOLACvtfcHk0lgiCNNH3Z9MRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVeis7nE&md5=05271b4aed3a70544777ad61ab66c42d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00182%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DNilewski%26aufirst%3DC.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DPackard%26aufirst%3DG.%26aulast%3DMichels%26aufirst%3DT.%26aulast%3DXiang%26aufirst%3DA.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DWegerski%26aufirst%3DC.%2BJ.%26aulast%3DEam%26aufirst%3DB.%26aulast%3DYoung%26aufirst%3DN.%2BP.%26aulast%3DFish%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHoward%26aufirst%3DH.%26aulast%3DStaunton%26aufirst%3DJ.%26aulast%3DMolter%26aufirst%3DJ.%26aulast%3DClarine%26aufirst%3DJ.%26aulast%3DNevarez%26aufirst%3DA.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26aulast%3DReich%26aufirst%3DS.%2BH.%26atitle%3DDesign%2520of%2520Development%2520Candidate%2520EFT226%252C%2520a%2520First%2520in%2520Class%2520Inhibitor%2520of%2520Eukaryotic%2520Initiation%2520Factor%25204A%2520RNA%2520Helicase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D5879%26epage%3D5955%26doi%3D10.1021%2Facs.jmedchem.0c00182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biedenkopf, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange-Grünweller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weißer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünweller, A.</span></span> <span> </span><span class="NLM_article-title">The Natural Compound Silvestrol Is a Potent Inhibitor of Ebola Virus Replication</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2016.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.antiviral.2016.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27864075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWnsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2017&pages=76-81&author=N.+Biedenkopfauthor=K.+Lange-Gr%C3%BCnwellerauthor=F.+W.+Schulteauthor=A.+Wei%C3%9Ferauthor=C.+M%C3%BCllerauthor=D.+Beckerauthor=S.+Beckerauthor=R.+K.+Hartmannauthor=A.+Gr%C3%BCnweller&title=The+Natural+Compound+Silvestrol+Is+a+Potent+Inhibitor+of+Ebola+Virus+Replication&doi=10.1016%2Fj.antiviral.2016.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The natural compound silvestrol is a potent inhibitor of Ebola virus replication</span></div><div class="casAuthors">Biedenkopf, Nadine; Lange-Gruenweller, Kerstin; Schulte, Falk W.; Weisser, Aileen; Mueller, Christin; Becker, Dirk; Becker, Stephan; Hartmann, Roland K.; Gruenweller, Arnold</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-81</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The DEAD-box RNA helicase eIF4A, which is part of the heterotrimeric translation initiation complex in eukaryotes, is an important novel drug target in cancer research because its helicase activity is required to unwind extended and highly structured 5'-UTRs of several proto-oncogenes.  Silvestrol, a natural compd. isolated from the plant Aglaia foveolata, is a highly efficient, non-toxic and specific inhibitor of eIF4A.  Importantly, 5'-capped viral mRNAs often contain structured 5'-UTRs as well, which may suggest a dependence on eIF4A for their translation by the host protein synthesis machinery.  In view of the recent Ebola virus (EBOV) outbreak in West Africa, the identification of potent antiviral compds. is urgently required.  Since Ebola mRNAs are 5'-capped and harbor RNA secondary structures in their extended 5'-UTRs, we initiated a BSL4 study to analyze silvestrol in EBOV-infected Huh-7 cells and in primary human macrophages for its antiviral activity.  We obsd. that silvestrol inhibits EBOV infection at low nanomolar concns., as inferred from large redns. of viral titers.  This correlated with an almost complete disappearance of EBOV proteins, comparable in effect to the translational shutdown of expression of the proto-oncoprotein PIM1, a cellular kinase known to be affected by silvestrol.  Effective silvestrol concns. were non-toxic in the tested cell systems.  Thus, silvestrol appears to be a promising first-line drug for the treatment of acute EBOV and possibly other viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEUavbaGnxurVg90H21EOLACvtfcHk0lgiCNNH3Z9MRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWnsLnL&md5=ce16ab9595bf6ba47b78057814f279fe</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2016.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2016.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DBiedenkopf%26aufirst%3DN.%26aulast%3DLange-Gr%25C3%25BCnweller%26aufirst%3DK.%26aulast%3DSchulte%26aufirst%3DF.%2BW.%26aulast%3DWei%25C3%259Fer%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DD.%26aulast%3DBecker%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DR.%2BK.%26aulast%3DGr%25C3%25BCnweller%26aufirst%3DA.%26atitle%3DThe%2520Natural%2520Compound%2520Silvestrol%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520Ebola%2520Virus%2520Replication%26jtitle%3DAntiviral%2520Res.%26date%3D2017%26volume%3D137%26spage%3D76%26epage%3D81%26doi%3D10.1016%2Fj.antiviral.2016.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange-Grünweller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhugiri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünweller, A.</span></span> <span> </span><span class="NLM_article-title">Broad-Spectrum Antiviral Activity of the EIF4A Inhibitor Silvestrol against Corona- and Picornaviruses</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2017.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.antiviral.2017.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=29258862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCmtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=123-129&author=C.+M%C3%BCllerauthor=F.+W.+Schulteauthor=K.+Lange-Gr%C3%BCnwellerauthor=W.+Obermannauthor=R.+Madhugiriauthor=S.+Pleschkaauthor=J.+Ziebuhrauthor=R.+K.+Hartmannauthor=A.+Gr%C3%BCnweller&title=Broad-Spectrum+Antiviral+Activity+of+the+EIF4A+Inhibitor+Silvestrol+against+Corona-+and+Picornaviruses&doi=10.1016%2Fj.antiviral.2017.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses</span></div><div class="casAuthors">Mueller, Christin; Schulte, Falk W.; Lange-Gruenweller, Kerstin; Obermann, Wiebke; Madhugiri, Ramakanth; Pleschka, Stephan; Ziebuhr, John; Hartmann, Roland K.; Gruenweller, Arnold</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123-129</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Coronaviruses (CoV) and picornaviruses are plus-strand RNA viruses that use 5' cap-dependent and cap-independent strategies, resp., for viral mRNA translation initiation.  Here, we analyzed the effects of the plant compd. silvestrol, a specific inhibitor of the DEAD-box RNA helicase eIF4A, on viral translation using a dual luciferase assay and virus-infected primary cells.  Silvestrol was recently shown to have potent antiviral activity in Ebola virus-infected human macrophages.  We found that silvestrol is also a potent inhibitor of cap-dependent viral mRNA translation in CoV-infected human embryonic lung fibroblast (MRC-5) cells.  EC50 values of 1.3 nM and 3 nM silvestrol were detd. for MERS-CoV and HCoV-229E, resp.  For the highly pathogenic MERS-CoV, the potent antiviral activities of silvestrol were also confirmed using peripheral blood mononuclear cells (PBMCs) as a second type of human primary cells.  Silvestrol strongly inhibits the expression of CoV structural and nonstructural proteins (N, nsp8) and the formation of viral replication/transcription complexes.  Furthermore, potential antiviral effects against human rhinovirus (HRV) A1 and poliovirus type 1 (PV), representing different species in the genus Enterovirus (family Picornaviridae), were investigated.  The two viruses employ an internal ribosomal entry site (IRES)-mediated translation initiation mechanism.  For PV, which is known to require the activity of eIF4A, an EC50 value of 20 nM silvestrol was detd. in MRC-5 cells.  The higher EC50 value of 100 nM measured for HRV A1 indicates a less crit. role of eIF4A activity in HRV A1 IRES-mediated translation initiation.  Taken together, the data reveal a broad-spectrum antiviral activity of silvestrol in infected primary cells by inhibiting eIF4A-dependent viral mRNA translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ7TqvxcHAr7Vg90H21EOLACvtfcHk0lhhKzpmiKwtvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCmtLvN&md5=5bd9d4639615205e0f68c8813a2885b4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2017.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2017.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DSchulte%26aufirst%3DF.%2BW.%26aulast%3DLange-Gr%25C3%25BCnweller%26aufirst%3DK.%26aulast%3DObermann%26aufirst%3DW.%26aulast%3DMadhugiri%26aufirst%3DR.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DZiebuhr%26aufirst%3DJ.%26aulast%3DHartmann%26aufirst%3DR.%2BK.%26aulast%3DGr%25C3%25BCnweller%26aufirst%3DA.%26atitle%3DBroad-Spectrum%2520Antiviral%2520Activity%2520of%2520the%2520EIF4A%2520Inhibitor%2520Silvestrol%2520against%2520Corona-%2520and%2520Picornaviruses%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D150%26spage%3D123%26epage%3D129%26doi%3D10.1016%2Fj.antiviral.2017.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange-Grünweller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oestereich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elgner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glitscher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendel, H.-G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünweller, A.</span></span> <span> </span><span class="NLM_article-title">Comparison of Broad-Spectrum Antiviral Activities of the Synthetic Rocaglate CR-31-B (−) and the eIF4A-Inhibitor Silvestrol</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">104706</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2020.104706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.antiviral.2020.104706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31931103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslShu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2020&pages=104706&author=C.+M%C3%BCllerauthor=W.+Obermannauthor=F.+W.+Schulteauthor=K.+Lange-Gr%C3%BCnwellerauthor=L.+Oestereichauthor=F.+Elgnerauthor=M.+Glitscherauthor=E.+Hildtauthor=K.+Singhauthor=H.-G.+G.+Wendelauthor=R.+K.+Hartmannauthor=J.+Ziebuhrauthor=A.+Gr%C3%BCnweller&title=Comparison+of+Broad-Spectrum+Antiviral+Activities+of+the+Synthetic+Rocaglate+CR-31-B+%28%E2%88%92%29+and+the+eIF4A-Inhibitor+Silvestrol&doi=10.1016%2Fj.antiviral.2020.104706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol</span></div><div class="casAuthors">Mueller, Christin; Obermann, Wiebke; Schulte, Falk W.; Lange-Gruenweller, Kerstin; Oestereich, Lisa; Elgner, Fabian; Glitscher, Mirco; Hildt, Eberhard; Singh, Kamini; Wendel, Hans-Guido; Hartmann, Roland K.; Ziebuhr, John; Gruenweller, Arnold</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104706</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Rocaglates, a class of natural compds. isolated from plants of the genus Aglaia, are potent inhibitors of translation initiation.  They are proposed to form stacking interactions with polypurine sequences in the 5'-untranslated region (UTR) of selected mRNAs, thereby clamping the RNA substrate onto eIF4A and causing inhibition of the translation initiation complex.  Since virus replication relies on the host translation machinery, it is not surprising that the rocaglate Silvestrol has broad-spectrum antiviral activity.  Unfortunately, synthesis of Silvestrol is sophisticated and time-consuming, thus hampering the prospects for further antiviral drug development.  Here, we present the less complex structured synthetic rocaglate CR-31-B (-) as a novel compd. with potent broad-spectrum antiviral activity in primary cells and in an ex vivo bronchial epithelial cell system.  CR-31-B (-) inhibited the replication of corona-, Zika-, Lassa-, Crimean Congo hemorrhagic fever viruses and, to a lesser extent, hepatitis E virus (HEV) at non-cytotoxic low nanomolar concns.  Since HEV has a polypurine-free 5'-UTR that folds into a stable hairpin structure, we hypothesized that RNA clamping by Silvestrol and its derivs. may also occur in a polypurine-independent but structure-dependent manner.  Interestingly, the HEV 5'-UTR conferred sensitivity towards Silvestrol but not to CR-31-B (-).  However, if an exposed polypurine stretch was introduced into the HEV 5'-UTR, CR-31-B (-) became an active inhibitor comparable to Silvestrol.  Moreover, thermodn. destabilization of the HEV 5'-UTR led to reduced translational inhibition by Silvestrol, suggesting differences between rocaglates in their mode of action, most probably by engaging Silvestrol's addnl. dioxane moiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-syEzl8GTuLVg90H21EOLACvtfcHk0lhhKzpmiKwtvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslShu7k%253D&md5=e803112561be02bbe36611bd8e4a493f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104706%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DObermann%26aufirst%3DW.%26aulast%3DSchulte%26aufirst%3DF.%2BW.%26aulast%3DLange-Gr%25C3%25BCnweller%26aufirst%3DK.%26aulast%3DOestereich%26aufirst%3DL.%26aulast%3DElgner%26aufirst%3DF.%26aulast%3DGlitscher%26aufirst%3DM.%26aulast%3DHildt%26aufirst%3DE.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DWendel%26aufirst%3DH.-G.%2BG.%26aulast%3DHartmann%26aufirst%3DR.%2BK.%26aulast%3DZiebuhr%26aufirst%3DJ.%26aulast%3DGr%25C3%25BCnweller%26aufirst%3DA.%26atitle%3DComparison%2520of%2520Broad-Spectrum%2520Antiviral%2520Activities%2520of%2520the%2520Synthetic%2520Rocaglate%2520CR-31-B%2520%2528%25E2%2588%2592%2529%2520and%2520the%2520eIF4A-Inhibitor%2520Silvestrol%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D175%26spage%3D104706%26doi%3D10.1016%2Fj.antiviral.2020.104706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obernier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezelj, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huettenhain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutuncuoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foussard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polacco, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabius, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucheray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cakir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Kain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miorin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naing, Z. Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorba, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrio-Hernandez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Armenta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathy, C. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perica, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilla, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzberg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calviello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataramanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liboy-Lugo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wankowicz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugur, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savar, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shengjuler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neal, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klippsten, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzuoglu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trenker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavero, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathore, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verba, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agard, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zastrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Enfert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ideker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortemme, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignuzzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogan, N. J.</span></span> <span> </span><span class="NLM_article-title">A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>583</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-2286-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41586-020-2286-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=32353859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=583&publication_year=2020&pages=459-468&author=D.+E.+Gordonauthor=G.+M.+Jangauthor=M.+Bouhaddouauthor=J.+Xuauthor=K.+Obernierauthor=K.+M.+Whiteauthor=M.+J.+O%E2%80%99Mearaauthor=V.+V.+Rezeljauthor=J.+Z.+Guoauthor=D.+L.+Swaneyauthor=T.+A.+Tumminoauthor=R.+Huettenhainauthor=R.+M.+Kaakeauthor=A.+L.+Richardsauthor=B.+Tutuncuogluauthor=H.+Foussardauthor=J.+Batraauthor=K.+Haasauthor=M.+Modakauthor=M.+Kimauthor=P.+Haasauthor=B.+J.+Polaccoauthor=H.+Brabergauthor=J.+M.+Fabiusauthor=M.+Eckhardtauthor=M.+Soucherayauthor=M.+J.+Bennettauthor=M.+Cakirauthor=M.+J.+McGregorauthor=Q.+Liauthor=B.+Meyerauthor=F.+Roeschauthor=T.+Valletauthor=A.+Mac+Kainauthor=L.+Miorinauthor=E.+Morenoauthor=Z.+Z.+C.+Naingauthor=Y.+Zhouauthor=S.+Pengauthor=Y.+Shiauthor=Z.+Zhangauthor=W.+Shenauthor=I.+T.+Kirbyauthor=J.+E.+Melnykauthor=J.+S.+Chorbaauthor=K.+Louauthor=S.+A.+Daiauthor=I.+Barrio-Hernandezauthor=D.+Memonauthor=C.+Hernandez-Armentaauthor=J.+Lyuauthor=C.+J.+P.+Mathyauthor=T.+Pericaauthor=K.+B.+Pillaauthor=S.+J.+Ganesanauthor=D.+J.+Saltzbergauthor=R.+Rakeshauthor=X.+Liuauthor=S.+B.+Rosenthalauthor=L.+Calvielloauthor=S.+Venkataramananauthor=J.+Liboy-Lugoauthor=Y.+Linauthor=X.+P.+Huangauthor=Y.+F.+Liuauthor=S.+A.+Wankowiczauthor=M.+Bohnauthor=M.+Safariauthor=F.+S.+Ugurauthor=C.+Kohauthor=N.+S.+Savarauthor=Q.+D.+Tranauthor=D.+Shengjulerauthor=S.+J.+Fletcherauthor=M.+C.+O%E2%80%99Nealauthor=Y.+Caiauthor=J.+C.+J.+Changauthor=D.+J.+Broadhurstauthor=S.+Klippstenauthor=P.+P.+Sharpauthor=N.+A.+Wenzellauthor=D.+Kuzuogluauthor=H.+Y.+Wangauthor=R.+Trenkerauthor=J.+M.+Youngauthor=D.+A.+Caveroauthor=J.+Hiattauthor=T.+L.+Rothauthor=U.+Rathoreauthor=A.+Subramanianauthor=J.+Noackauthor=M.+Hubertauthor=R.+M.+Stroudauthor=A.+D.+Frankelauthor=O.+S.+Rosenbergauthor=K.+A.+Verbaauthor=D.+A.+Agardauthor=M.+Ottauthor=M.+Emermanauthor=N.+Juraauthor=M.+von+Zastrowauthor=E.+Verdinauthor=A.+Ashworthauthor=O.+Schwartzauthor=C.+d%E2%80%99Enfertauthor=S.+Mukherjeeauthor=M.+Jacobsonauthor=H.+S.+Malikauthor=D.+G.+Fujimoriauthor=T.+Idekerauthor=C.+S.+Craikauthor=S.+N.+Floorauthor=J.+S.+Fraserauthor=J.+D.+Grossauthor=A.+Saliauthor=B.+L.+Rothauthor=D.+Ruggeroauthor=J.+Tauntonauthor=T.+Kortemmeauthor=P.+Beltraoauthor=M.+Vignuzziauthor=A.+Garc%C3%ADa-Sastreauthor=K.+M.+Shokatauthor=B.+K.+Shoichetauthor=N.+J.+Krogan&title=A+SARS-CoV-2+Protein+Interaction+Map+Reveals+Targets+for+Drug+Repurposing&doi=10.1038%2Fs41586-020-2286-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</span></div><div class="casAuthors">Gordon, David E.; Jang, Gwendolyn M.; Bouhaddou, Mehdi; Xu, Jiewei; Obernier, Kirsten; White, Kris M.; O'Meara, Matthew J.; Rezelj, Veronica V.; Guo, Jeffrey Z.; Swaney, Danielle L.; Tummino, Tia A.; Huttenhain, Ruth; Kaake, Robyn M.; Richards, Alicia L.; Tutuncuoglu, Beril; Foussard, Helene; Batra, Jyoti; Haas, Kelsey; Modak, Maya; Kim, Minkyu; Haas, Paige; Polacco, Benjamin J.; Braberg, Hannes; Fabius, Jacqueline M.; Eckhardt, Manon; Soucheray, Margaret; Bennett, Melanie J.; Cakir, Merve; McGregor, Michael J.; Li, Qiongyu; Meyer, Bjoern; Roesch, Ferdinand; Vallet, Thomas; Mac Kain, Alice; Miorin, Lisa; Moreno, Elena; Naing, Zun Zar Chi; Zhou, Yuan; Peng, Shiming; Shi, Ying; Zhang, Ziyang; Shen, Wenqi; Kirby, Ilsa T.; Melnyk, James E.; Chorba, John S.; Lou, Kevin; Dai, Shizhong A.; Barrio-Hernandez, Inigo; Memon, Danish; Hernandez-Armenta, Claudia; Lyu, Jiankun; Mathy, Christopher J. P.; Perica, Tina; Pilla, Kala Bharath; Ganesan, Sai J.; Saltzberg, Daniel J.; Rakesh, Ramachandran; Liu, Xi; Rosenthal, Sara B.; Calviello, Lorenzo; Venkataramanan, Srivats; Liboy-Lugo, Jose; Lin, Yizhu; Huang, Xi-Ping; Liu, YongFeng; Wankowicz, Stephanie A.; Bohn, Markus; Safari, Maliheh; Ugur, Fatima S.; Koh, Cassandra; Savar, Nastaran Sadat; Tran, Quang Dinh; Shengjuler, Djoshkun; Fletcher, Sabrina J.; O'Neal, Michael C.; Cai, Yiming; Chang, Jason C. J.; Broadhurst, David J.; Klippsten, Saker; Sharp, Phillip P.; Wenzell, Nicole A.; Kuzuoglu-Ozturk, Duygu; Wang, Hao-Yuan; Trenker, Raphael; Young, Janet M.; Cavero, Devin A.; Hiatt, Joseph; Roth, Theodore L.; Rathore, Ujjwal; Subramanian, Advait; Noack, Julia; Hubert, Mathieu; Stroud, Robert M.; Frankel, Alan D.; Rosenberg, Oren S.; Verba, Kliment A.; Agard, David A.; Ott, Melanie; Emerman, Michael; Jura, Natalia; von Zastrow, Mark; Verdin, Eric; Ashworth, Alan; Schwartz, Olivier; d'Enfert, Christophe; Mukherjee, Shaeri; Jacobson, Matt; Malik, Harmit S.; Fujimori, Danica G.; Ideker, Trey; Craik, Charles S.; Floor, Stephen N.; Fraser, James S.; Gross, John D.; Sali, Andrej; Roth, Bryan L.; Ruggero, Davide; Taunton, Jack; Kortemme, Tanja; Beltrao, Pedro; Vignuzzi, Marco; Garcia-Sastre, Adolfo; Shokat, Kevan M.; Shoichet, Brian K.; Krogan, Nevan J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">583</span>
        (<span class="NLM_cas:issue">7816</span>),
    <span class="NLM_cas:pages">459-468</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption1,2.  There are no antiviral drugs with proven clin. efficacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the limited knowledge of the mol. details of how SARS-CoV-2 infects cells.  Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that phys. assocd. with each of the SARS-CoV-2 proteins using affinity-purifn. mass spectrometry, identifying 332 high-confidence protein-protein interactions between SARS-CoV-2 and human proteins.  Among these, we identify 66 druggable human proteins or host factors targeted by 69 compds. (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clin. trials and 28 are preclin. compds.).  We screened a subset of these in multiple viral assays and found two sets of pharmacol. agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors.  Further studies of these host-factor-targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDvJUIvi-Ws7Vg90H21EOLACvtfcHk0ljSIDSW9eFW6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtbrI&md5=ce8b172ae73aacd3b3d8bb64877f4435</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2286-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2286-9%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DD.%2BE.%26aulast%3DJang%26aufirst%3DG.%2BM.%26aulast%3DBouhaddou%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DObernier%26aufirst%3DK.%26aulast%3DWhite%26aufirst%3DK.%2BM.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%2BJ.%26aulast%3DRezelj%26aufirst%3DV.%2BV.%26aulast%3DGuo%26aufirst%3DJ.%2BZ.%26aulast%3DSwaney%26aufirst%3DD.%2BL.%26aulast%3DTummino%26aufirst%3DT.%2BA.%26aulast%3DHuettenhain%26aufirst%3DR.%26aulast%3DKaake%26aufirst%3DR.%2BM.%26aulast%3DRichards%26aufirst%3DA.%2BL.%26aulast%3DTutuncuoglu%26aufirst%3DB.%26aulast%3DFoussard%26aufirst%3DH.%26aulast%3DBatra%26aufirst%3DJ.%26aulast%3DHaas%26aufirst%3DK.%26aulast%3DModak%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DHaas%26aufirst%3DP.%26aulast%3DPolacco%26aufirst%3DB.%2BJ.%26aulast%3DBraberg%26aufirst%3DH.%26aulast%3DFabius%26aufirst%3DJ.%2BM.%26aulast%3DEckhardt%26aufirst%3DM.%26aulast%3DSoucheray%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DM.%2BJ.%26aulast%3DCakir%26aufirst%3DM.%26aulast%3DMcGregor%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMeyer%26aufirst%3DB.%26aulast%3DRoesch%26aufirst%3DF.%26aulast%3DVallet%26aufirst%3DT.%26aulast%3DMac%2BKain%26aufirst%3DA.%26aulast%3DMiorin%26aufirst%3DL.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DNaing%26aufirst%3DZ.%2BZ.%2BC.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DKirby%26aufirst%3DI.%2BT.%26aulast%3DMelnyk%26aufirst%3DJ.%2BE.%26aulast%3DChorba%26aufirst%3DJ.%2BS.%26aulast%3DLou%26aufirst%3DK.%26aulast%3DDai%26aufirst%3DS.%2BA.%26aulast%3DBarrio-Hernandez%26aufirst%3DI.%26aulast%3DMemon%26aufirst%3DD.%26aulast%3DHernandez-Armenta%26aufirst%3DC.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DMathy%26aufirst%3DC.%2BJ.%2BP.%26aulast%3DPerica%26aufirst%3DT.%26aulast%3DPilla%26aufirst%3DK.%2BB.%26aulast%3DGanesan%26aufirst%3DS.%2BJ.%26aulast%3DSaltzberg%26aufirst%3DD.%2BJ.%26aulast%3DRakesh%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DRosenthal%26aufirst%3DS.%2BB.%26aulast%3DCalviello%26aufirst%3DL.%26aulast%3DVenkataramanan%26aufirst%3DS.%26aulast%3DLiboy-Lugo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DLiu%26aufirst%3DY.%2BF.%26aulast%3DWankowicz%26aufirst%3DS.%2BA.%26aulast%3DBohn%26aufirst%3DM.%26aulast%3DSafari%26aufirst%3DM.%26aulast%3DUgur%26aufirst%3DF.%2BS.%26aulast%3DKoh%26aufirst%3DC.%26aulast%3DSavar%26aufirst%3DN.%2BS.%26aulast%3DTran%26aufirst%3DQ.%2BD.%26aulast%3DShengjuler%26aufirst%3DD.%26aulast%3DFletcher%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Neal%26aufirst%3DM.%2BC.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DBroadhurst%26aufirst%3DD.%2BJ.%26aulast%3DKlippsten%26aufirst%3DS.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DWenzell%26aufirst%3DN.%2BA.%26aulast%3DKuzuoglu%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DTrenker%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DJ.%2BM.%26aulast%3DCavero%26aufirst%3DD.%2BA.%26aulast%3DHiatt%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DT.%2BL.%26aulast%3DRathore%26aufirst%3DU.%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DNoack%26aufirst%3DJ.%26aulast%3DHubert%26aufirst%3DM.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26aulast%3DFrankel%26aufirst%3DA.%2BD.%26aulast%3DRosenberg%26aufirst%3DO.%2BS.%26aulast%3DVerba%26aufirst%3DK.%2BA.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DEmerman%26aufirst%3DM.%26aulast%3DJura%26aufirst%3DN.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DVerdin%26aufirst%3DE.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3Dd%25E2%2580%2599Enfert%26aufirst%3DC.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DM.%26aulast%3DMalik%26aufirst%3DH.%2BS.%26aulast%3DFujimori%26aufirst%3DD.%2BG.%26aulast%3DIdeker%26aufirst%3DT.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3DFloor%26aufirst%3DS.%2BN.%26aulast%3DFraser%26aufirst%3DJ.%2BS.%26aulast%3DGross%26aufirst%3DJ.%2BD.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DTaunton%26aufirst%3DJ.%26aulast%3DKortemme%26aufirst%3DT.%26aulast%3DBeltrao%26aufirst%3DP.%26aulast%3DVignuzzi%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Sastre%26aufirst%3DA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DKrogan%26aufirst%3DN.%2BJ.%26atitle%3DA%2520SARS-CoV-2%2520Protein%2520Interaction%2520Map%2520Reveals%2520Targets%2520for%2520Drug%2520Repurposing%26jtitle%3DNature%26date%3D2020%26volume%3D583%26spage%3D459%26epage%3D468%26doi%3D10.1038%2Fs41586-020-2286-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Northcote, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blunt, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, M. H. G.</span></span> <span> </span><span class="NLM_article-title">Pateamine: A Potent Cytotoxin from the New Zealand Marine Sponge, Mycale Sp</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">6411</span>– <span class="NLM_lpage">6414</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(91)80182-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2F0040-4039%2891%2980182-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK38XhtVartLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1991&pages=6411-6414&author=P.+T.+Northcoteauthor=J.+W.+Bluntauthor=M.+H.+G.+Munro&title=Pateamine%3A+A+Potent+Cytotoxin+from+the+New+Zealand+Marine+Sponge%2C+Mycale+Sp&doi=10.1016%2F0040-4039%2891%2980182-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pateamine:  a potent cytotoxin from the New Zealand marine sponge, Mycale sp</span></div><div class="casAuthors">Northcote, Peter T.; Blunt, John W.; Munro, Murray H. G.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">6411-14</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    </div><div class="casAbstract">The isolation and structural characterization of pateamine (I), a thiazole-contg. macrolide with the rare dilactone functionality, is reported.  Pateamine is an exceedingly potent, but possibly selective, cytotoxin (P388: IC50 0.15 ng/mL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodXQWsMpklsLVg90H21EOLACvtfcHk0ljBM2ATSJnXgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhtVartLw%253D&md5=78586e5a6b43565a1c94d12bfe0ed01f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2891%2980182-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252891%252980182-6%26sid%3Dliteratum%253Aachs%26aulast%3DNorthcote%26aufirst%3DP.%2BT.%26aulast%3DBlunt%26aufirst%3DJ.%2BW.%26aulast%3DMunro%26aufirst%3DM.%2BH.%2BG.%26atitle%3DPateamine%253A%2520A%2520Potent%2520Cytotoxin%2520from%2520the%2520New%2520Zealand%2520Marine%2520Sponge%252C%2520Mycale%2520Sp%26jtitle%3DTetrahedron%2520Lett.%26date%3D1991%26volume%3D32%26spage%3D6411%26epage%3D6414%26doi%3D10.1016%2F0040-4039%2891%2980182-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Low, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider-Poetsch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Eukaryotic Translation Initiation by the Marine Natural Product Pateamine A</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2005.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.molcel.2005.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16337595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtleqtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=709-722&author=W.+K.+Lowauthor=Y.+Dangauthor=T.+Schneider-Poetschauthor=Z.+Shiauthor=N.+S.+Choiauthor=W.+C.+Merrickauthor=D.+Romoauthor=J.+O.+Liu&title=Inhibition+of+Eukaryotic+Translation+Initiation+by+the+Marine+Natural+Product+Pateamine+A&doi=10.1016%2Fj.molcel.2005.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of eukaryotic translation initiation by the marine natural product pateamine A</span></div><div class="casAuthors">Low, Woon-Kai; Dang, Yongjun; Schneider-Poetsch, Tilman; Shi, Zonggao; Choi, Nam Song; Merrick, William C.; Romo, Daniel; Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">709-722</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Translation initiation in eukaryotes is accomplished through the coordinated and orderly action of a large no. of proteins, including the eIF4 initiation factors.  Herein, we report that pateamine A (PatA), a potent antiproliferative and proapoptotic marine natural product, inhibits cap-dependent eukaryotic translation initiation.  PatA bound to and enhanced the intrinsic enzymic activities of eIF4A, yet it inhibited eIF4A-eIF4G assocn. and promoted the formation of a stable ternary complex between eIF4A and eIF4B.  These changes in eIF4A affinity for its partner proteins upon binding to PatA caused the stalling of initiation complexes on mRNA in vitro and induced stress granule formation in vivo.  These results suggest that PatA will be a valuable mol. probe for future studies of eukaryotic translation initiation and may serve as a lead compd. for the development of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkwxt9CFRLhLVg90H21EOLACvtfcHk0ljBM2ATSJnXgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtleqtb%252FI&md5=4dacc09550c903e2d02470b7a495081d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DW.%2BK.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DSchneider-Poetsch%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DChoi%26aufirst%3DN.%2BS.%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26aulast%3DRomo%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DInhibition%2520of%2520Eukaryotic%2520Translation%2520Initiation%2520by%2520the%2520Marine%2520Natural%2520Product%2520Pateamine%2520A%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D20%26spage%3D709%26epage%3D722%26doi%3D10.1016%2Fj.molcel.2005.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M.-E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojnar, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novac, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowsky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northcote, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teesdale-Spittle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Stimulation of Mammalian Translation Initiation Factor eIF4A Activity by a Small Molecule Inhibitor of Eukaryotic Translation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">10460</span>– <span class="NLM_lpage">10465</span>, <span class="refDoi"> DOI: 10.1073/pnas.0504249102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.0504249102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16030146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVSit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=10460-10465&author=M.-E.+E.+Bordeleauauthor=J.+Matthewsauthor=J.+M.+Wojnarauthor=L.+Lindqvistauthor=O.+Novacauthor=E.+Jankowskyauthor=N.+Sonenbergauthor=P.+Northcoteauthor=P.+Teesdale-Spittleauthor=J.+Pelletier&title=Stimulation+of+Mammalian+Translation+Initiation+Factor+eIF4A+Activity+by+a+Small+Molecule+Inhibitor+of+Eukaryotic+Translation&doi=10.1073%2Fpnas.0504249102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation</span></div><div class="casAuthors">Bordeleau, Marie-Eve; Matthews, James; Wojnar, Joanna M.; Lindqvist, Lisa; Novac, Olivia; Jankowsky, Eckhard; Sonenberg, Nahum; Northcote, Peter; Teesdale-Spittle, Paul; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">10460-10465</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">RNA helicases are the largest group of enzymes in eukaryotic RNA metab.  The DEXD/H-box putative RNA helicases form the helicase superfamily II, whose members are defined by seven highly conserved amino acid motifs, making specific targeting of selected members a challenging pharmacol. problem.  The translation initiation factor eIF4A is the prototypical DEAD-box RNA helicase that works in conjunction with eIF4B and eIF4H and as a subunit of eIF4F to prep. the mRNA template for ribosome binding, possibly by unwinding the secondary structure proximal to the 5' m7GpppN cap structure.  The authors report the identification and characterization of a small mol. inhibitor of eukaryotic translation initiation that acts in an unusual manner by stimulating eIF4A-assocd. activities.  The results suggest that proper control of eIF4A helicase activity is necessary for efficient ribosome binding and demonstrate the feasibility of selectively targeting DEAD-box RNA helicases with small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAEhUC4JFqWbVg90H21EOLACvtfcHk0ljBM2ATSJnXgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVSit7Y%253D&md5=9393ed1b7a46f028340b2b373d8655c0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0504249102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0504249102%26sid%3Dliteratum%253Aachs%26aulast%3DBordeleau%26aufirst%3DM.-E.%2BE.%26aulast%3DMatthews%26aufirst%3DJ.%26aulast%3DWojnar%26aufirst%3DJ.%2BM.%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DNovac%26aufirst%3DO.%26aulast%3DJankowsky%26aufirst%3DE.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DNorthcote%26aufirst%3DP.%26aulast%3DTeesdale-Spittle%26aufirst%3DP.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DStimulation%2520of%2520Mammalian%2520Translation%2520Initiation%2520Factor%2520eIF4A%2520Activity%2520by%2520a%2520Small%2520Molecule%2520Inhibitor%2520of%2520Eukaryotic%2520Translation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D10460%26epage%3D10465%26doi%3D10.1073%2Fpnas.0504249102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Low, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span> <span> </span><span class="NLM_article-title">Substrate-Dependent Targeting of Eukaryotic Translation Initiation Factor 4A by Pateamine A: Negation of Domain-Linker Regulation of Activity</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2007.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.chembiol.2007.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17584618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVOgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=715-727&author=W.+K.+Lowauthor=Y.+Dangauthor=S.+Bhatauthor=D.+Romoauthor=J.+O.+Liu&title=Substrate-Dependent+Targeting+of+Eukaryotic+Translation+Initiation+Factor+4A+by+Pateamine+A%3A+Negation+of+Domain-Linker+Regulation+of+Activity&doi=10.1016%2Fj.chembiol.2007.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate-Dependent Targeting of Eukaryotic Translation Initiation Factor 4A by Pateamine A: Negation of Domain-Linker Regulation of Activity</span></div><div class="casAuthors">Low, Woon-Kai; Dang, Yongjun; Bhat, Shridhar; Romo, Daniel; Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">715-727</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Central to cap-dependent eukaryotic translation initiation is the eIF4F complex, which is composed of the three eukaryotic initiation factors eIF4E, eIF4G, and eIF4A.  Factor eIF4A is an RNA-dependent ATPase and an ATP-dependent helicase that unwinds local secondary structure in mRNA to allow binding of the 43S ribosomal complex.  The marine natural product pateamine A (PatA) has been demonstrated to inhibit cap-dependent initiation by targeting eIF4A and disrupting its protein-protein interactions while increasing its enzymic activities.  Here we demonstrate that the increased activity is caused by the induction of global conformational changes within eIF4A.  Furthermore, binding of PatA is dependent on substrate (RNA and ATP) binding, and the increased activity upon PatA binding is caused by relief of a neg. regulatory function of the eIF4A unique domain linker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoV3zYbusrsLVg90H21EOLACvtfcHk0lj98EyHtmpzlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVOgt7c%253D&md5=e9a769b2bfcc837a58b531fde3d645ad</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DW.%2BK.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DRomo%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DSubstrate-Dependent%2520Targeting%2520of%2520Eukaryotic%2520Translation%2520Initiation%2520Factor%25204A%2520by%2520Pateamine%2520A%253A%2520Negation%2520of%2520Domain-Linker%2520Regulation%2520of%2520Activity%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D715%26epage%3D727%26doi%3D10.1016%2Fj.chembiol.2007.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span> <span> </span><span class="NLM_article-title">Evidence for Separate Binding and Scaffolding Domains in the Immunosuppressive and Antitumor Marine Natural Product, Pateamine A: Design, Synthesis, and Activity Studies Leading to a Potent Simplified Derivative</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">10582</span>– <span class="NLM_lpage">10588</span>, <span class="refDoi"> DOI: 10.1021/ja040065s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja040065s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt12kt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=10582-10588&author=D.+Romoauthor=N.+S.+Choiauthor=S.+Liauthor=I.+Buchlerauthor=Z.+Shiauthor=J.+O.+Liu&title=Evidence+for+Separate+Binding+and+Scaffolding+Domains+in+the+Immunosuppressive+and+Antitumor+Marine+Natural+Product%2C+Pateamine+A%3A+Design%2C+Synthesis%2C+and+Activity+Studies+Leading+to+a+Potent+Simplified+Derivative&doi=10.1021%2Fja040065s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for separate binding and scaffolding domains in the immunosuppressive and antitumor marine natural product, pateamine a: design, synthesis, and activity studies leading to a potent simplified derivative</span></div><div class="casAuthors">Romo, Daniel; Choi, Nam Song; Li, Shukun; Buchler, Ingrid; Shi, Zonggao; Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">10582-10588</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pateamine A (PatA), a marine metabolite from Mycale sp., is a potent inhibitor of the intracellular signal transduction pathway emanating from the T-cell receptor leading to the transcription of cytokines such as interleukin-2 (IL-2).  On the basis of the structure of PatA and initial biol. results, a hypothesis was developed regarding the presence of distinct binding and scaffolding domains in the PatA structure with respect to interactions with its putative cellular receptor(s).  Employing a highly convergent approach involving a Hantzsch coupling strategy, we probed this hypothesis by prepg. a simplified PatA deriv. (desmethyl, desamino PatA, DMDAPatA, 3).  This deriv. was prepd. in 10 fewer synthetic steps relative to PatA and was indeed found to exhibit equal to greater potency (IC50 0.81±0.27 nM) in inhibition of IL-2 prodn. relative to PatA (IC50 4.01±0.94 nM) thus providing support for the binding/scaffolding domain hypothesis.  In addn., as a means to find more stable derivs. and gain further insights into structure-activity relationships, several PatA derivs. were synthesized and assayed in the IL-2 reporter gene assay.  Several of these derivs. displayed lower potency but marked stability relative to the natural product and provide further insights into the nature of the binding domain required for activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXvNluf1DglLVg90H21EOLACvtfcHk0lj98EyHtmpzlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt12kt7Y%253D&md5=ef86db0f97dc4e796a15bf3bb2eb2dfc</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fja040065s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja040065s%26sid%3Dliteratum%253Aachs%26aulast%3DRomo%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DN.%2BS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DBuchler%26aufirst%3DI.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DEvidence%2520for%2520Separate%2520Binding%2520and%2520Scaffolding%2520Domains%2520in%2520the%2520Immunosuppressive%2520and%2520Antitumor%2520Marine%2520Natural%2520Product%252C%2520Pateamine%2520A%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Activity%2520Studies%2520Leading%2520to%2520a%2520Potent%2520Simplified%2520Derivative%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2004%26volume%3D126%26spage%3D10582%26epage%3D10588%26doi%3D10.1021%2Fja040065s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Higa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukitani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, H.</span></span> <span> </span><span class="NLM_article-title">Hippuristanols, Cytotoxic Polyoxygenated Steroids from the Gorgonian <i>Isis Hippuri</i>s</span>. <i>Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1647</span>– <span class="NLM_lpage">1650</span>, <span class="refDoi"> DOI: 10.1246/cl.1981.1647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1246%2Fcl.1981.1647" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1981&pages=1647-1650&author=T.+Higaauthor=J.-i.+Tanakaauthor=T.+Tsukitaniauthor=H.+Kikuchi&title=Hippuristanols%2C+Cytotoxic+Polyoxygenated+Steroids+from+the+Gorgonian+Isis+Hippuris&doi=10.1246%2Fcl.1981.1647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1246%2Fcl.1981.1647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.1981.1647%26sid%3Dliteratum%253Aachs%26aulast%3DHiga%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DJ.-i.%26aulast%3DTsukitani%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DH.%26atitle%3DHippuristanols%252C%2520Cytotoxic%2520Polyoxygenated%2520Steroids%2520from%2520the%2520Gorgonian%2520Isis%2520Hippuris%26jtitle%3DChem.%2520Lett.%26date%3D1981%26volume%3D10%26spage%3D1647%26epage%3D1650%26doi%3D10.1246%2Fcl.1981.1647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chard, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belsham, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Functional Characterization of IRESes by an Inhibitor of the RNA Helicase eIF4A</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1038/nchembio776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnchembio776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16532013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFOnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=213-220&author=M.+E.+Bordeleauauthor=A.+Moriauthor=M.+Obererauthor=L.+Lindqvistauthor=L.+S.+Chardauthor=T.+Higaauthor=G.+J.+Belshamauthor=G.+Wagnerauthor=J.+Tanakaauthor=J.+Pelletier&title=Functional+Characterization+of+IRESes+by+an+Inhibitor+of+the+RNA+Helicase+eIF4A&doi=10.1038%2Fnchembio776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A</span></div><div class="casAuthors">Bordeleau, Marie-Eve; Mori, Ayaka; Oberer, Monika; Lindqvist, Lisa; Chard, Louisa S.; Higa, Tatsuo; Belsham, Graham J.; Wagner, Gerhard; Tanaka, Junichi; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">213-220</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RNA helicases are mol. motors that are involved in virtually all aspects of RNA metab.  Eukaryotic initiation factor (eIF) 4A is the prototypical member of the DEAD-box family of RNA helicases.  It is thought to use energy from ATP hydrolysis to unwind mRNA structure and, in conjunction with other translation factors, it preps. mRNA templates for ribosome recruitment during translation initiation.  In screening marine exts. for new eukaryotic translation initiation inhibitors, we identified the natural product hippuristanol.  We show here that this compd. is a selective and potent inhibitor of eIF4A RNA-binding activity that can be used to distinguish between eIF4A-dependent and -independent modes of translation initiation in vitro and in vivo.  We also show that poliovirus replication is delayed when infected cells are exposed to hippuristanol.  Our study demonstrates the feasibility of selectively targeting members of the DEAD-box helicase family with small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphVpPHxoy7Y7Vg90H21EOLACvtfcHk0lj98EyHtmpzlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFOnsbg%253D&md5=cbeecb6be4f6ab28c47b4c0542ba4d3d</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnchembio776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio776%26sid%3Dliteratum%253Aachs%26aulast%3DBordeleau%26aufirst%3DM.%2BE.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DOberer%26aufirst%3DM.%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DChard%26aufirst%3DL.%2BS.%26aulast%3DHiga%26aufirst%3DT.%26aulast%3DBelsham%26aufirst%3DG.%2BJ.%26aulast%3DWagner%26aufirst%3DG.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DFunctional%2520Characterization%2520of%2520IRESes%2520by%2520an%2520Inhibitor%2520of%2520the%2520RNA%2520Helicase%2520eIF4A%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D213%26epage%3D220%26doi%3D10.1038%2Fnchembio776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span> <span> </span><span class="NLM_article-title">Structural and Stereochemical Requirements of the Spiroketal Group of Hippuristanol for Antiproliferative Activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3112</span>– <span class="NLM_lpage">3115</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.03.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.bmcl.2010.03.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=20409710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFGns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3112-3115&author=W.+Liauthor=Y.+Dangauthor=J.+O.+Liuauthor=B.+Yu&title=Structural+and+Stereochemical+Requirements+of+the+Spiroketal+Group+of+Hippuristanol+for+Antiproliferative+Activity&doi=10.1016%2Fj.bmcl.2010.03.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and stereochemical requirements of the spiroketal group of hippuristanol for antiproliferative activity</span></div><div class="casAuthors">Li, Wei; Dang, Yongjun; Liu, Jun O.; Yu, Biao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3112-3115</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hippuristanol is a natural product that has recently been shown to inhibit eukaryotic translation initiation and tumor cell proliferation.  To investigate the structure and activity relationship of hippuristanol, we synthesized a series of analogs by expanding the size of its F ring and detd. their effects on the proliferation of cancer cell lines.  All changes to the F-ring of hippuristanol resulted in 3-fold to >100-fold decrease in activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYs9eLujY0GLVg90H21EOLACvtfcHk0lh-dCSkBtkKnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFGns7Y%253D&md5=eb9ae51a4d88ba94ffc6a8631d0c9326</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.03.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.03.093%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26aulast%3DYu%26aufirst%3DB.%26atitle%3DStructural%2520and%2520Stereochemical%2520Requirements%2520of%2520the%2520Spiroketal%2520Group%2520of%2520Hippuristanol%2520for%2520Antiproliferative%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3112%26epage%3D3115%26doi%3D10.1016%2Fj.bmcl.2010.03.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reibarkh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marintchev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Selective Pharmacological Targeting of a DEAD Box RNA Helicase</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e1583</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0001583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pone.0001583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18270573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BD1c7htlagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=e1583&author=L.+Lindqvistauthor=M.+Obererauthor=M.+Reibarkhauthor=R.+Cencicauthor=M.+E.+Bordeleauauthor=E.+Vogtauthor=A.+Marintchevauthor=J.+Tanakaauthor=F.+Fagottoauthor=M.+Altmannauthor=G.+Wagnerauthor=J.+Pelletier&title=Selective+Pharmacological+Targeting+of+a+DEAD+Box+RNA+Helicase&doi=10.1371%2Fjournal.pone.0001583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Selective pharmacological targeting of a DEAD box RNA helicase</span></div><div class="casAuthors">Lindqvist Lisa; Oberer Monika; Reibarkh Mikhail; Cencic Regina; Bordeleau Marie-Eve; Vogt Emily; Marintchev Assen; Tanaka Junichi; Fagotto Francois; Altmann Michael; Wagner Gerhard; Pelletier Jerry</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e1583</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RNA helicases represent a large family of proteins implicated in many biological processes including ribosome biogenesis, splicing, translation and mRNA degradation.  However, these proteins have little substrate specificity, making inhibition of selected helicases a challenging problem.  The prototypical DEAD box RNA helicase, eIF4A, works in conjunction with other translation factors to prepare mRNA templates for ribosome recruitment during translation initiation.  Herein, we provide insight into the selectivity of a small molecule inhibitor of eIF4A, hippuristanol.  This coral-derived natural product binds to amino acids adjacent to, and overlapping with, two conserved motifs present in the carboxy-terminal domain of eIF4A.  Mutagenesis of amino acids within this region allowed us to alter the hippuristanol-sensitivity of eIF4A and undertake structure/function studies.  Our results provide an understanding into how selective targeting of RNA helicases for pharmacological intervention can be achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKpFB5Tdsa_tXdcedVHT5tfW6udTcc2eYjQhKHA90mP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c7htlagtg%253D%253D&md5=b29e717681032adca5889d26e11e480d</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0001583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0001583%26sid%3Dliteratum%253Aachs%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DOberer%26aufirst%3DM.%26aulast%3DReibarkh%26aufirst%3DM.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DBordeleau%26aufirst%3DM.%2BE.%26aulast%3DVogt%26aufirst%3DE.%26aulast%3DMarintchev%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DFagotto%26aufirst%3DF.%26aulast%3DAltmann%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DG.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DSelective%2520Pharmacological%2520Targeting%2520of%2520a%2520DEAD%2520Box%2520RNA%2520Helicase%26jtitle%3DPLoS%2520One%26date%3D2008%26volume%3D3%26spage%3De1583%26doi%3D10.1371%2Fjournal.pone.0001583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meller, A.</span></span> <span> </span><span class="NLM_article-title">Single-Molecule Kinetics of the Eukaryotic Initiation Factor 4AI upon RNA Unwinding</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">948</span>, <span class="refDoi"> DOI: 10.1016/j.str.2014.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.str.2014.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24909782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=941-948&author=Y.+Sunauthor=E.+Atasauthor=L.+M.+Lindqvistauthor=N.+Sonenbergauthor=J.+Pelletierauthor=A.+Meller&title=Single-Molecule+Kinetics+of+the+Eukaryotic+Initiation+Factor+4AI+upon+RNA+Unwinding&doi=10.1016%2Fj.str.2014.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Single-Molecule Kinetics of the Eukaryotic Initiation Factor 4AI upon RNA Unwinding</span></div><div class="casAuthors">Sun, Yingjie; Atas, Evrim; Lindqvist, Lisa M.; Sonenberg, Nahum; Pelletier, Jerry; Meller, Amit</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">941-948</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The eukaryotic translation initiation factor 4AI (eIF4AI) is the prototypical DEAD-box RNA helicase.  It has a "dumbbell" structure consisting of 2 domains connected by a flexible linker.  Previous studies demonstrated that eIF4AI, in conjunction with eIF4H, bind to loop structures and repetitively unwind RNA hairpins.  Here, the authors probe the conformational dynamics of eIF4AI in real time using single-mol. FRET.  The authors demonstrate that eIF4AI/eIF4H complex can repetitively unwind RNA hairpins by transitioning between an eIF4AI "open" and a "closed" conformation using the energy derived from ATP hydrolysis.  The authors' expts. directly track the conformational changes in the catalytic cycle of eIF4AI and eIF4H, and this correlates precisely with the kinetics of RNA unwinding.  Furthermore, the authors show that the small-mol. eIF4A inhibitor hippuristanol locks eIF4AI in the closed conformation, thus efficiently inhibiting RNA unwinding.  These results indicate that the large conformational changes undertaken by eIF4A during the helicase catalytic cycle are rate limiting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjkK8RKx0oerVg90H21EOLACvtfcHk0lh-dCSkBtkKnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCmtrk%253D&md5=eda6d7fe5987e4cbc08c601fbed6fa0d</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DAtas%26aufirst%3DE.%26aulast%3DLindqvist%26aufirst%3DL.%2BM.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DMeller%26aufirst%3DA.%26atitle%3DSingle-Molecule%2520Kinetics%2520of%2520the%2520Eukaryotic%2520Initiation%2520Factor%25204AI%2520upon%2520RNA%2520Unwinding%26jtitle%3DStructure%26date%3D2014%26volume%3D22%26spage%3D941%26epage%3D948%26doi%3D10.1016%2Fj.str.2014.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicia-Vázquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somaiah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deslongchamps, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Modifying Chemotherapy Response by Targeted Inhibition of Eukaryotic Initiation Factor 4A</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e128</span>, <span class="refDoi"> DOI: 10.1038/bcj.2013.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fbcj.2013.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=23872707" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=e128&author=R.+Cencicauthor=F.+Robertauthor=G.+Galicia-V%C3%A1zquezauthor=A.+Malinaauthor=K.+Ravindarauthor=R.+Somaiahauthor=P.+Pierreauthor=J.+Tanakaauthor=P.+Deslongchampsauthor=J.+Pelletier&title=Modifying+Chemotherapy+Response+by+Targeted+Inhibition+of+Eukaryotic+Initiation+Factor+4A&doi=10.1038%2Fbcj.2013.25"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2013.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2013.25%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DRobert%26aufirst%3DF.%26aulast%3DGalicia-V%25C3%25A1zquez%26aufirst%3DG.%26aulast%3DMalina%26aufirst%3DA.%26aulast%3DRavindar%26aufirst%3DK.%26aulast%3DSomaiah%26aufirst%3DR.%26aulast%3DPierre%26aufirst%3DP.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DDeslongchamps%26aufirst%3DP.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DModifying%2520Chemotherapy%2520Response%2520by%2520Targeted%2520Inhibition%2520of%2520Eukaryotic%2520Initiation%2520Factor%25204A%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2013%26volume%3D3%26spage%3De128%26doi%3D10.1038%2Fbcj.2013.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, N.</span></span> <span> </span><span class="NLM_article-title">Hippuristanol Reduces the Viability of Primary Effusion Lymphoma Cells Both <i>in Vitro</i> and <i>in Vivo</i></span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3410</span>– <span class="NLM_lpage">3424</span>, <span class="refDoi"> DOI: 10.3390/md11093410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fmd11093410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24018901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVWnsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=3410-3424&author=C.+Ishikawaauthor=J.+Tanakaauthor=H.+Katanoauthor=M.+Senbaauthor=N.+Mori&title=Hippuristanol+Reduces+the+Viability+of+Primary+Effusion+Lymphoma+Cells+Both+in+Vitro+and+in+Vivo&doi=10.3390%2Fmd11093410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Hippuristanol reduces the viability of primary effusion lymphoma cells both in vitro and in vivo</span></div><div class="casAuthors">Ishikawa, Chie; Tanaka, Junichi; Katano, Harutaka; Senba, Masachika; Mori, Naoki</div><div class="citationInfo"><span class="NLM_cas:title">Marine Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3410-3424</span>CODEN:
                <span class="NLM_cas:coden">MDARE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-3397</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Primary effusion lymphoma (PEL) caused by Kaposi's sarcoma-assocd. herpesvirus (also known as human herpesvirus-8) shows serious lymphomatous effusion in body cavities.  PEL is difficult to treat and there is no std. treatment strategy.  Hippuristanol is extd. from Okinawan coral Isis hippuris, and inhibits translational initiation by blocking eukaryotic initiation factor 4A, an ATP-dependent RNA helicase, binding to mRNA.  Recently, there has been much interest in targeting translation initiation as an anticancer therapy.  Here, we show that treatment of PEL cell lines with hippuristanol resulted in cell cycle arrest at G1 phase, and induced caspases activation and apoptosis.  Hippuristanol also reduced the expression of cyclin D2, CDK2, CDK4, CDK6 and prosurvival XIAP and Mcl-1 proteins.  Activation of activator protein-1, signal transducers and activators of transcription protein 3 and Akt pathways plays a crit. role in the survival and growth of PEL cells.  Hippuristanol suppressed the activities of these three pathways by inhibiting the expression of JunB, JunD, c-Fos, signal transducers and activators of transcription protein 3 and Akt proteins.  In a xenograft mouse model that showed ascites and diffused organ invasion of PEL cells, treatment with hippuristanol significantly inhibited the growth and invasion of PEL cells compared with untreated mice.  The results of the in vitro and in vivo expts. underline the potential usefulness of hippuristanol in the treatment of PEL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkZrmV0KYyqrVg90H21EOLACvtfcHk0lhzeM8XsVl7bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVWnsrrP&md5=9e3f47d7d83b82eefdb2d4a2c8b997a1</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.3390%2Fmd11093410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd11093410%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DC.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DKatano%26aufirst%3DH.%26aulast%3DSenba%26aufirst%3DM.%26aulast%3DMori%26aufirst%3DN.%26atitle%3DHippuristanol%2520Reduces%2520the%2520Viability%2520of%2520Primary%2520Effusion%2520Lymphoma%2520Cells%2520Both%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DMar.%2520Drugs%26date%3D2013%26volume%3D11%26spage%3D3410%26epage%3D3424%26doi%3D10.3390%2Fmd11093410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsumuraya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacHijima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakachi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, N.</span></span> <span> </span><span class="NLM_article-title">Effects of Hippuristanol, an Inhibitor of EIF4A, on Adult T-Cell Leukemia</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2010.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.bcp.2010.12.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21219881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXit12jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2011&pages=713-722&author=T.+Tsumurayaauthor=C.+Ishikawaauthor=Y.+MacHijimaauthor=S.+Nakachiauthor=M.+Senbaauthor=J.+Tanakaauthor=N.+Mori&title=Effects+of+Hippuristanol%2C+an+Inhibitor+of+EIF4A%2C+on+Adult+T-Cell+Leukemia&doi=10.1016%2Fj.bcp.2010.12.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia</span></div><div class="casAuthors">Tsumuraya, Tomoyuki; Ishikawa, Chie; Machijima, Yoshiaki; Nakachi, Sawako; Senba, Masachika; Tanaka, Junichi; Mori, Naoki</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">713-722</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We evaluated the anti-adult T-cell leukemia (ATL) effects of hippuristanol, an eukaryotic translation initiation inhibitor from the coral Isis hippuris.  Hippuristanol inhibited proliferation of HTLV-1-infected T-cell lines and ATL cells, but not normal peripheral blood mononuclear cells.  It induced cell cycle arrest during G1 phase by reducing the expression of cyclin D1, cyclin D2, CDK4 and CDK6, and induced apoptosis by reducing the expression of Bcl-xL, c-IAP2, XIAP and c-FLIP.  The induced apoptosis was assocd. with activation of caspase-3, -8 and -9.  Hippuristanol also suppressed IkappaBalpha phosphorylation and depleted IKKalpha, IKKgamma, JunB and JunD, resulting in inactivation of NF-kappaB and AP-1.  It also suppressed carbonic anhydrase type II expression.  In addn. to its in vitro effects, hippuristanol suppressed tumor growth in mice with severe combined immunodeficiency harboring tumors induced by inoculation of HTLV-1-infected T cells.  These preclin. data suggest that hippuristanol could be a potentially useful therapeutic agent for patients with ATL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv0tQeplP_QrVg90H21EOLACvtfcHk0lgWDq-MgbvPPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXit12jtLk%253D&md5=736d7399eb9e024e8fb9c1a33af8b49d</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2010.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2010.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DTsumuraya%26aufirst%3DT.%26aulast%3DIshikawa%26aufirst%3DC.%26aulast%3DMacHijima%26aufirst%3DY.%26aulast%3DNakachi%26aufirst%3DS.%26aulast%3DSenba%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DMori%26aufirst%3DN.%26atitle%3DEffects%2520of%2520Hippuristanol%252C%2520an%2520Inhibitor%2520of%2520EIF4A%252C%2520on%2520Adult%2520T-Cell%2520Leukemia%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D81%26spage%3D713%26epage%3D722%26doi%3D10.1016%2Fj.bcp.2010.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Hippuristanol - A Potent Steroid Inhibitor of Eukaryotic Initiation Factor 4A</span>. <i>Translation</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e1137381</span>, <span class="refDoi"> DOI: 10.1080/21690731.2015.1137381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1080%2F21690731.2015.1137381" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=e1137381&author=R.+Cencicauthor=J.+Pelletier&title=Hippuristanol+-+A+Potent+Steroid+Inhibitor+of+Eukaryotic+Initiation+Factor+4A&doi=10.1080%2F21690731.2015.1137381"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1080%2F21690731.2015.1137381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21690731.2015.1137381%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DHippuristanol%2520-%2520A%2520Potent%2520Steroid%2520Inhibitor%2520of%2520Eukaryotic%2520Initiation%2520Factor%25204A%26jtitle%3DTranslation%26date%3D2016%26volume%3D4%26spage%3De1137381%26doi%3D10.1080%2F21690731.2015.1137381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravindar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deslongchamps, P.</span></span> <span> </span><span class="NLM_article-title">Efficient Synthetic Approach to Potent Antiproliferative Agent Hippuristanol via Hg(II)-Catalyzed Spiroketalization</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">4420</span>– <span class="NLM_lpage">4423</span>, <span class="refDoi"> DOI: 10.1021/ol1019663</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol1019663" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFehurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=4420-4423&author=K.+Ravindarauthor=M.+S.+Reddyauthor=L.+Lindqvistauthor=J.+Pelletierauthor=P.+Deslongchamps&title=Efficient+Synthetic+Approach+to+Potent+Antiproliferative+Agent+Hippuristanol+via+Hg%28II%29-Catalyzed+Spiroketalization&doi=10.1021%2Fol1019663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Synthetic Approach to Potent Antiproliferative Agent Hippuristanol via Hg(II)-Catalyzed Spiroketalization</span></div><div class="casAuthors">Ravindar, Kontham; Reddy, Maddi Sridhar; Lindqvist, Lisa; Pelletier, Jerry; Deslongchamps, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4420-4423</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The steroidal natural product hippuristanol (I) targets eukaryotic translation initiation factor (eIF)4A which plays a pivotal role in translation in eukaryotic cells.  Now an efficient synthesis of I from 11-ketotigogenin is reported.  The synthesis features a rapid construction of a spiroketal unit via Hg(OTf)2-catalyzed oxidn./spiroketalization of the 3-alkyn-1,7-diol motif.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopVHYXkWhrGbVg90H21EOLACvtfcHk0lgWDq-MgbvPPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFehurrJ&md5=ef9bb21d45cb6fc22496fdff5b548adc</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fol1019663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol1019663%26sid%3Dliteratum%253Aachs%26aulast%3DRavindar%26aufirst%3DK.%26aulast%3DReddy%26aufirst%3DM.%2BS.%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DDeslongchamps%26aufirst%3DP.%26atitle%3DEfficient%2520Synthetic%2520Approach%2520to%2520Potent%2520Antiproliferative%2520Agent%2520Hippuristanol%2520via%2520Hg%2528II%2529-Catalyzed%2520Spiroketalization%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D4420%26epage%3D4423%26doi%3D10.1021%2Fol1019663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravindar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deslongchamps, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the Antiproliferative Agent Hippuristanol and Its Analogues via Suárez Cyclizations and Hg(II)-Catalyzed Spiroketalizations</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1269</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1021/jo102054r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo102054r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKgt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=1269-1284&author=K.+Ravindarauthor=M.+S.+Reddyauthor=L.+Lindqvistauthor=J.+Pelletierauthor=P.+Deslongchamps&title=Synthesis+of+the+Antiproliferative+Agent+Hippuristanol+and+Its+Analogues+via+Su%C3%A1rez+Cyclizations+and+Hg%28II%29-Catalyzed+Spiroketalizations&doi=10.1021%2Fjo102054r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of the Antiproliferative Agent Hippuristanol and Its Analogues via Suarez Cyclizations and Hg(II)-Catalyzed Spiroketalizations</span></div><div class="casAuthors">Ravindar, Kontham; Reddy, Maddi Sridhar; Lindqvist, Lisa; Pelletier, Jerry; Deslongchamps, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1269-1284</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A full account of the synthesis of hippuristanol and its analogs is described.  Hecogenin acetate was identified as a suitable and economical starting material for this work, and substrate-controlled stereoselection was obtained throughout the construction of the key spiroketal unit.  Suarez cyclization was first used, but Hg(II)-catalyzed spiroketalization of the 3-alkyne-1,7-diol motif was finally identified as the most convenient strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB-B3L2wB5abVg90H21EOLACvtfcHk0lgWDq-MgbvPPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKgt7k%253D&md5=3852d576c476ce432a664415e0bb79b1</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjo102054r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo102054r%26sid%3Dliteratum%253Aachs%26aulast%3DRavindar%26aufirst%3DK.%26aulast%3DReddy%26aufirst%3DM.%2BS.%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DDeslongchamps%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520the%2520Antiproliferative%2520Agent%2520Hippuristanol%2520and%2520Its%2520Analogues%2520via%2520Su%25C3%25A1rez%2520Cyclizations%2520and%2520Hg%2528II%2529-Catalyzed%2520Spiroketalizations%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26spage%3D1269%26epage%3D1284%26doi%3D10.1021%2Fjo102054r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somaiah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deslongchamps, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the Antiproliferative Agent Hippuristanol and Its Analogues from Hydrocortisone via Hg(II)-Catalyzed Spiroketalization: Structure-Activity Relationship</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2511</span>– <span class="NLM_lpage">2523</span>, <span class="refDoi"> DOI: 10.1021/jm401799j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401799j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlOlu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2511-2523&author=R.+Somaiahauthor=K.+Ravindarauthor=R.+Cencicauthor=J.+Pelletierauthor=P.+Deslongchamps&title=Synthesis+of+the+Antiproliferative+Agent+Hippuristanol+and+Its+Analogues+from+Hydrocortisone+via+Hg%28II%29-Catalyzed+Spiroketalization%3A+Structure-Activity+Relationship&doi=10.1021%2Fjm401799j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of the Antiproliferative Agent Hippuristanol and Its Analogues from Hydrocortisone via Hg(II)-Catalyzed Spiroketalization: Structure-Activity Relationship</span></div><div class="casAuthors">Somaiah, Ragam; Ravindar, Kontham; Cencic, Regina; Pelletier, Jerry; Deslongchamps, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2511-2523</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient synthesis of hippuristanol, a marine-derived highly potent antiproliferative steroidal natural product, and nine closely related analogs has been accomplished from the com. available hydrocortisone utilizing Hg(II)-catalyzed spiroketalization of 3-alkyne-1,7-diol motif as a key strategy.  This practical synthetic sequence furnished hippuristanol in 11% overall yield from hydrocortisone in 15 linear steps.  Modifications to the parent mol. hippuristanol encompassed changing the functional groups on rings A and E.  Each analog was screened for their effects on inhibition of cap-dependent translation, and the assay results were used to establish structure-activity relationships.  These results suggest that the stereochem. and all substituents of spiroketal portion (rings E and F) and C3-α and C11-β hydroxyl functional groups on rings A and C, resp., are crit. for the inhibitory activity of natural product hippuristanol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX_M1TjXp22bVg90H21EOLACvtfcHk0lhQKjejV0nfLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlOlu70%253D&md5=04354eb96c5d5d5010f13f1564b4bf80</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm401799j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401799j%26sid%3Dliteratum%253Aachs%26aulast%3DSomaiah%26aufirst%3DR.%26aulast%3DRavindar%26aufirst%3DK.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DDeslongchamps%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520the%2520Antiproliferative%2520Agent%2520Hippuristanol%2520and%2520Its%2520Analogues%2520from%2520Hydrocortisone%2520via%2520Hg%2528II%2529-Catalyzed%2520Spiroketalization%253A%2520Structure-Activity%2520Relationship%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2511%26epage%3D2523%26doi%3D10.1021%2Fjm401799j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span> <span> </span><span class="NLM_article-title">Expeditious Synthesis of Hippuristanol and Congeners with Potent Antiproliferative Activities</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">10356</span>– <span class="NLM_lpage">10359</span>, <span class="refDoi"> DOI: 10.1002/chem.200901732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fchem.200901732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19746484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Kis7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=10356-10359&author=W.+Liauthor=Y.+Dangauthor=J.+O.+Liuauthor=B.+Yu&title=Expeditious+Synthesis+of+Hippuristanol+and+Congeners+with+Potent+Antiproliferative+Activities&doi=10.1002%2Fchem.200901732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Expeditious Synthesis of Hippuristanol and Congeners with Potent Antiproliferative Activities</span></div><div class="casAuthors">Li, Wei; Dang, Yongjun; Liu, Jun O.; Yu, Biao</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">10356-10359, S10356/1-S10356/74</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Hippuristanol and its congeners with modified E and F rings are prepd.  The effect of hippuristanol and its analogs on HeLa cell proliferation and in vitro translation was detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBRZBR8sT50rVg90H21EOLACvtfcHk0lhQKjejV0nfLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Kis7fI&md5=4462fbcf3275780e6233cb8d0ed2f814</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fchem.200901732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.200901732%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26aulast%3DYu%26aufirst%3DB.%26atitle%3DExpeditious%2520Synthesis%2520of%2520Hippuristanol%2520and%2520Congeners%2520with%2520Potent%2520Antiproliferative%2520Activities%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2009%26volume%3D15%26spage%3D10356%26epage%3D10359%26doi%3D10.1002%2Fchem.200901732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shatkin, A. J.</span></span> <span> </span><span class="NLM_article-title">A Polypeptide in Eukaryotic Initiation Factors That Crosslinks Specifically to the 5′-Terminal Cap in mRNA</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">4843</span>– <span class="NLM_lpage">4847</span>, <span class="refDoi"> DOI: 10.1073/pnas.75.10.4843</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.75.10.4843" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=217002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE1MXhslOrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1978&pages=4843-4847&author=N.+Sonenbergauthor=M.+A.+Morganauthor=W.+C.+Merrickauthor=A.+J.+Shatkin&title=A+Polypeptide+in+Eukaryotic+Initiation+Factors+That+Crosslinks+Specifically+to+the+5%E2%80%B2-Terminal+Cap+in+mRNA&doi=10.1073%2Fpnas.75.10.4843"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">A polypeptide in eukaryotic initiation factors that crosslinks specifically to the 5'-terminal cap in mRNA</span></div><div class="casAuthors">Sonenberg, Nahum; Morgan, Maureen A.; Merrick, William C.; Shatkin, Aaron J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4843-7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Protein formation initiation factors prepd. from rabbit reticulocyte and mouse ascites ribosomes were tested for the ability to crosslink to the 5'-cap of mRNA.  Crosslinking of 1 polypeptide of apparent mol. wt. 24,000 was inhibited by the cap analogs, 7-methyl-GMP and 7-methyl-GDP, indicating a specific interaction with the cap.  Although specific crosslinking of the 24,000-mol.-wt. polypeptide was found with eukaryotic initiation factor 3 and to a lesser extent with initiation factor 4B, both of these factors contained less than stoichiometric amts. of this polypeptide.  The crosslinking method provides a highly sensitive and specific assay for cap-binding proteins and should facilitate their purifn. for functional studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRV1Ykxs1B-7Vg90H21EOLACvtfcHk0lhQKjejV0nfLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXhslOrtw%253D%253D&md5=2ffb987151d81bc60d5d6eb77f89bb2b</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1073%2Fpnas.75.10.4843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.75.10.4843%26sid%3Dliteratum%253Aachs%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DMorgan%26aufirst%3DM.%2BA.%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26aulast%3DShatkin%26aufirst%3DA.%2BJ.%26atitle%3DA%2520Polypeptide%2520in%2520Eukaryotic%2520Initiation%2520Factors%2520That%2520Crosslinks%2520Specifically%2520to%2520the%25205%25E2%2580%25B2-Terminal%2520Cap%2520in%2520mRNA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1978%26volume%3D75%26spage%3D4843%26epage%3D4847%26doi%3D10.1073%2Fpnas.75.10.4843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupprecht, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shatkin, A. J.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic mRNA Cap Binding Protein: Purification by Affinity Chromatography on Sepharose-Coupled m7GDP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">4345</span>– <span class="NLM_lpage">4349</span>, <span class="refDoi"> DOI: 10.1073/pnas.76.9.4345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.76.9.4345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=291969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE1MXlslShu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1979&pages=4345-4349&author=N.+Sonenbergauthor=K.+M.+Rupprechtauthor=S.+M.+Hechtauthor=A.+J.+Shatkin&title=Eukaryotic+mRNA+Cap+Binding+Protein%3A+Purification+by+Affinity+Chromatography+on+Sepharose-Coupled+m7GDP&doi=10.1073%2Fpnas.76.9.4345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic mRNA cap binding protein:  Purification by affinity chromatography on Sepharose-coupled m7GDP</span></div><div class="casAuthors">Sonenberg, Nahum; Rupprecht, Kathleen M.; Hecht, Sidney M.; Shatkin, Aaron J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4345-9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A 24,000-dalton polypeptide that binds strongly and can be specifically crosslinked to the 5'-terminal cap structure m7GpppN (m7G = 7-methylguanine, N = nucleoside base) in eukaryotic mRNAs was detected in protein synthesis initiation factor prepns.  This polypeptide was purified to apparent homogeneity by 1 chromatog. passage through an affinity resin prepd. by coupling the levulinic acid O2',3'-acetal of 7-Me GDP to AH-Sepharose 4B.  Translation in HeLa cell exts. of capped mRNAs, including Sindbis virus, reovirus, and rabbit globin mRNAs, was stimulated by the cap-binding protein under conditions that did not increase translation of noncapped RNAs of encephalomyocarditis virus and satellite tobacco necrosis virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq8b-UTpd86LVg90H21EOLACvtfcHk0lhmfuV7VdGDhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXlslShu7s%253D&md5=abcee2f9b71aafdcb87c7f2c2080cf71</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1073%2Fpnas.76.9.4345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.76.9.4345%26sid%3Dliteratum%253Aachs%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DRupprecht%26aufirst%3DK.%2BM.%26aulast%3DHecht%26aufirst%3DS.%2BM.%26aulast%3DShatkin%26aufirst%3DA.%2BJ.%26atitle%3DEukaryotic%2520mRNA%2520Cap%2520Binding%2520Protein%253A%2520Purification%2520by%2520Affinity%2520Chromatography%2520on%2520Sepharose-Coupled%2520m7GDP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1979%26volume%3D76%26spage%3D4345%26epage%3D4349%26doi%3D10.1073%2Fpnas.76.9.4345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcguire, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span> <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1038/nsb0997-717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnsb0997-717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=9302999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK2sXmtl2qu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Matsuo%2C+H.%3B+Li%2C+H.%3B+Mcguire%2C+A.+M.%3B+Fletcher%2C+C.+M.%3B+Gingras%2C+A.%3B+Sonenberg%2C+N.%3B+Wagner%2C+G.+Nat.+Struct.+Biol.+1997%2C+4%2C+717%E2%80%93724%2C+10.1038%2Fnsb0997-717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of translation factor eIF4E bound to m7GDP and interaction with 4E-binding protein</span></div><div class="casAuthors">Matsuo, Hiroshi; Li, Hanjun; Mcguire, Abigail M.; Fletcher, C. Mark; Gingras, Anne-Claude; Sonenberg, Nahum; Wagner, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">717-724</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">EIF4E, the mRNA cap binding protein, is a master switch that controls eukaryotic translation.  To be active, it must bind eIF4G and form the eIF4F complex, which also contains eIF4A.  Translation is downregulated by assocn. of eIF4E with 4E-BP, which occupies the eIF4G binding site.  Signaling events acting on 4E-BP cause it to dissoc. from eIF4E, and eIF4E is then free to bind eIF4G to form the active eIF4F complex.  We have solved the structure of the yeast eIF4E/m7Gpp complex in a CHAPS micelle.  We detd. the position of the second nucleotide in a complex with m7GpppA, and identified the 4E-BP binding site.  EIF4E has a curved eight-stranded antiparallel β-sheet, decorated with three helixes on the convex face and three smaller helixes inserted in connecting loops.  The m7G of the cap is intercalated into a stack of tryptophans in the concave face.  The 4E-BP binding site is located in a region encompassing one edge of the β-sheet, the adjacent helix a2 and several regions of non-regular secondary structure.  It is adjacent to, but does not overlap the cap-binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoZ0rWyxKYw7Vg90H21EOLACvtfcHk0lhmfuV7VdGDhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmtl2qu7k%253D&md5=c85483815753a9d68cdc6400788037d8</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnsb0997-717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb0997-717%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMcguire%26aufirst%3DA.%2BM.%26aulast%3DFletcher%26aufirst%3DC.%2BM.%26aulast%3DGingras%26aufirst%3DA.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DWagner%26aufirst%3DG.%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D1997%26volume%3D4%26spage%3D717%26epage%3D724%26doi%3D10.1038%2Fnsb0997-717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcotrigiano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burley, S. K.</span></span> <span> </span><span class="NLM_article-title">X-Ray Studies of the Messenger RNA 5′ Cap-Binding Protein (eIF4E) Bound to 7-Methyl-GDP</span>. <i>Nucleic Acids Symp. Ser.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=8-11&author=J.+Marcotrigianoauthor=A.+C.+Gingrasauthor=N.+Sonenbergauthor=S.+K.+Burley&title=X-Ray+Studies+of+the+Messenger+RNA+5%E2%80%B2+Cap-Binding+Protein+%28eIF4E%29+Bound+to+7-Methyl-GDP"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotrigiano%26aufirst%3DJ.%26aulast%3DGingras%26aufirst%3DA.%2BC.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DBurley%26aufirst%3DS.%2BK.%26atitle%3DX-Ray%2520Studies%2520of%2520the%2520Messenger%2520RNA%25205%25E2%2580%25B2%2520Cap-Binding%2520Protein%2520%2528eIF4E%2529%2520Bound%2520to%25207-Methyl-GDP%26jtitle%3DNucleic%2520Acids%2520Symp.%2520Ser.%26date%3D1997%26volume%3D89%26spage%3D8%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, L. O.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic Initiation Factor 4E</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2675</span>– <span class="NLM_lpage">2680</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2007.10.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.biocel.2007.10.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18069043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFaisb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=2675-2680&author=I.+G.+Goodfellowauthor=L.+O.+Roberts&title=Eukaryotic+Initiation+Factor+4E&doi=10.1016%2Fj.biocel.2007.10.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic initiation factor 4E</span></div><div class="casAuthors">Goodfellow, Ian G.; Roberts, Lisa O.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2675-2680</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Eukaryotic translation initiation factor 4E (eIF4E) is perhaps best known for its function in the initiation of protein synthesis on capped mRNAs in the cytoplasm.  However, recent studies have highlighted that eIF4E has many addnl. functions, which include the nuclear export of specific mRNAs as well as roles in aging and the translation of some uncapped viral RNAs.  This review aims to update the reader on recent developments, including the potential of eIF4E as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouxALIroKIqrVg90H21EOLACvtfcHk0lhmfuV7VdGDhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFaisb7O&md5=321d528772f819e9e229fe434a0bfa80</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2007.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2007.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DGoodfellow%26aufirst%3DI.%2BG.%26aulast%3DRoberts%26aufirst%3DL.%2BO.%26atitle%3DEukaryotic%2520Initiation%2520Factor%25204E%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2008%26volume%3D40%26spage%3D2675%26epage%3D2680%26doi%3D10.1016%2Fj.biocel.2007.10.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topisirovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span> <span> </span><span class="NLM_article-title">Controlling Gene Expression through RNA Regulons: The Role of the Eukaryotic Translation Initiation Factor EIF4E</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.4161/cc.6.1.3688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.4161%2Fcc.6.1.3688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17245113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFygtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=65-69&author=B.+Culjkovicauthor=I.+Topisirovicauthor=K.+L.+B.+Borden&title=Controlling+Gene+Expression+through+RNA+Regulons%3A+The+Role+of+the+Eukaryotic+Translation+Initiation+Factor+EIF4E&doi=10.4161%2Fcc.6.1.3688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E</span></div><div class="casAuthors">Culjkovic, Biljana; Topisirovic, Ivan; Borden, Katherine L. B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-69</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  The eukaryotic translation initiation factor eIF4E is a potent oncogene.  In fact, its overexpression in human cancer often correlates with poor prognosis.  Traditionally, eIF4E plays a role in translation initiation where it binds the 5' m7G cap found on mRNAs.  More recent studies indicate that a significant fraction of eIF4E (up to 68%) resides in the nucleus where it regulates the nuclear export of specific mRNAs.  Addnl., eIF4E may play a role in mRNA sequestration and stability in cytoplasmic processing bodies (P-bodies).  Our recent studies suggest that eIF4E governs cell cycle progression and cellular proliferation by coordinately orchestrating the expression of several genes at the post-transcriptional level.  Hence, eIF4E functions as a central node of an RNA regulon (described below), which plays an essential role in normal differentiation and development and is frequently dysregulated in cancer.  Several cellular factors, such as the promyelocytic leukemia protein PML, modulate the function of this regulon by altering the activity of eIF4E.  Here, the physiol. implications of these observations are described and the clin. implications of directly targeting eIF4E, and the related regulon, are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppwYcY9SNNMrVg90H21EOLACvtfcHk0ljJlgeXM4ad1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFygtr4%253D&md5=9b9668885b8ec8dec2bcc8800aba5e4f</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.4161%2Fcc.6.1.3688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.6.1.3688%26sid%3Dliteratum%253Aachs%26aulast%3DCuljkovic%26aufirst%3DB.%26aulast%3DTopisirovic%26aufirst%3DI.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DControlling%2520Gene%2520Expression%2520through%2520RNA%2520Regulons%253A%2520The%2520Role%2520of%2520the%2520Eukaryotic%2520Translation%2520Initiation%2520Factor%2520EIF4E%26jtitle%3DCell%2520Cycle%26date%3D2007%26volume%3D6%26spage%3D65%26epage%3D69%26doi%3D10.4161%2Fcc.6.1.3688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Mnks for Cancer Therapy</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.18632%2Foncotarget.453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22392765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BC383ps1WjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=118-131&author=J.+Houauthor=F.+Lamauthor=C.+Proudauthor=S.+Wang&title=Targeting+Mnks+for+Cancer+Therapy&doi=10.18632%2Foncotarget.453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Mnks for cancer therapy</span></div><div class="casAuthors">Hou Jinqiang; Lam Frankie; Proud Christopher; Wang Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Deregulation of protein synthesis is a common event in human cancer and a key player in translational control is eIF4E.  Elevated expression levels of eIF4E promote cancer development and progression.  Recent findings suggest that eIF4E activity is a key determinant of the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK mediated tumorigenic activity and targeting eIF4E should have a major impact on these pathways in human cancer.  The function of eIF4E is modulated through phosphorylation of a conserved serine (Ser209) by Mnk1 and Mnk2 downstream of ERK.  While the phosphorylation event is necessary for oncogenic transformation, it seems to be dispensable for normal development.  Hence, pharmacologic Mnk inhibitors may provide non-toxic and effective anti-cancer strategy.  Strong circumstantial evidence indicates that Mnk inhibition presents attractive therapeutic potential, but the lack of selective Mnk inhibitors has so far confounded pharmacological target validation and clinical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRs_vEZzPs7B4USrryheKE6fW6udTcc2eagaiLuJ0qDgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383ps1WjsA%253D%253D&md5=b98424025f73526eed531001700584f1</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.453%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DProud%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeting%2520Mnks%2520for%2520Cancer%2520Therapy%26jtitle%3DOncotarget%26date%3D2012%26volume%3D3%26spage%3D118%26epage%3D131%26doi%3D10.18632%2Foncotarget.453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malka-Mahieu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, S.</span></span> <span> </span><span class="NLM_article-title">Molecular Pathways: The EIF4F Translation Initiation Complex-Newopportunities for Cancer Treatment</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1158%2F1078-0432.CCR-14-2362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27789529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1WgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=21-25&author=H.+Malka-Mahieuauthor=M.+Newmanauthor=L.+D%C3%A9saubryauthor=C.+Robertauthor=S.+Vagner&title=Molecular+Pathways%3A+The+EIF4F+Translation+Initiation+Complex-Newopportunities+for+Cancer+Treatment&doi=10.1158%2F1078-0432.CCR-14-2362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment</span></div><div class="casAuthors">Malka-Mahieu, Helene; Newman, Michelle; Desaubry, Laurent; Robert, Caroline; Vagner, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-25</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The eIF4F complex regulates the cap-dependent mRNA translation process.  It is becoming increasingly evident that aberrant activity of this complex is obsd. in many cancers, leading to the selective synthesis of proteins involved in tumor growth and metastasis.  The selective translation of cellular mRNAs controlled by this complex also contributes to resistance to cancer treatments, and downregulation of the eIF4F complex components can restore sensitivity to various cancer therapies.  Here, we review the contribution of the eIF4F complex to tumorigenesis, with a focus on its role in chemoresistance as well as the promising use of new small-mol. inhibitors of the complex, including flavaglines/rocaglates, hippuristanol, and pateamine A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_X1TZoBvLP7Vg90H21EOLACvtfcHk0ljJlgeXM4ad1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1WgsA%253D%253D&md5=8e65b884cc8e3943a83f4965bf600ccd</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2362%26sid%3Dliteratum%253Aachs%26aulast%3DMalka-Mahieu%26aufirst%3DH.%26aulast%3DNewman%26aufirst%3DM.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DVagner%26aufirst%3DS.%26atitle%3DMolecular%2520Pathways%253A%2520The%2520EIF4F%2520Translation%2520Initiation%2520Complex-Newopportunities%2520for%2520Cancer%2520Treatment%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D21%26epage%3D25%26doi%3D10.1158%2F1078-0432.CCR-14-2362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazaris-Karatzas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montine, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span> <span> </span><span class="NLM_article-title">Malignant Transformation by a Eukaryotic Initiation Factor Subunit That Binds to mRNA 5′ Cap</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">544</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1038/345544a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2F345544a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=2348862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK3cXktlygsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=1990&pages=544-547&author=A.+Lazaris-Karatzasauthor=K.+S.+Montineauthor=N.+Sonenberg&title=Malignant+Transformation+by+a+Eukaryotic+Initiation+Factor+Subunit+That+Binds+to+mRNA+5%E2%80%B2+Cap&doi=10.1038%2F345544a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap</span></div><div class="casAuthors">Lazaris-Karatzas, Anthoula; Montine, Kathleen S.; Sonenberg, Nahum</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">6275</span>),
    <span class="NLM_cas:pages">544-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Overexpression of the translation factor eIF-4E from exogenous cDNA in rodent cell lines caused tumorigenic transformation, as detd. by 3 criteria: formation of transformed foci on a monolayer of cells, anchorage-independent growth, and tumor formation in nude mice.  An eIF-4E mutant whose serine 53 codon was mutated to alanine did not cause tumor formation in nude mice.  The mechanism by which eIF-4E transforms cells is not clear.  The expression of certain oncogenes or growth factors might be tightly controlled at the translational level by the availability of eIF-4E.  Increasing the level of eIF-4E might relieve translational repression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC3QZOSYEW5LVg90H21EOLACvtfcHk0lj7ShR3r97SwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktlygsrg%253D&md5=b074e125f2b7c237ba1f646814493064</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2F345544a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F345544a0%26sid%3Dliteratum%253Aachs%26aulast%3DLazaris-Karatzas%26aufirst%3DA.%26aulast%3DMontine%26aufirst%3DK.%2BS.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DMalignant%2520Transformation%2520by%2520a%2520Eukaryotic%2520Initiation%2520Factor%2520Subunit%2520That%2520Binds%2520to%2520mRNA%25205%25E2%2580%25B2%2520Cap%26jtitle%3DNature%26date%3D1990%26volume%3D345%26spage%3D544%26epage%3D547%26doi%3D10.1038%2F345544a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coutinho
de Oliveira, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahardjo, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic-Kraljacic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trahan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span> <span> </span><span class="NLM_article-title">Structural Studies of the EIF4E – VPg Complex Reveal a Direct Competition for Capped RNA : Implications for Translation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">24056</span>– <span class="NLM_lpage">24065</span>, <span class="refDoi"> DOI: 10.1073/pnas.1904752116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.1904752116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31712417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BB3MjnslWqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=24056-24065&author=L.+Coutinho%0Ade+Oliveiraauthor=L.+Volponauthor=A.+K.+Rahardjoauthor=M.+J.+Osborneauthor=B.+Culjkovic-Kraljacicauthor=C.+Trahanauthor=M.+Oeffingerauthor=B.+H.+Kwokauthor=K.+L.+B.+Borden&title=Structural+Studies+of+the+EIF4E+%E2%80%93+VPg+Complex+Reveal+a+Direct+Competition+for+Capped+RNA%E2%80%AF%3A+Implications+for+Translation&doi=10.1073%2Fpnas.1904752116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Structural studies of the eIF4E-VPg complex reveal a direct competition for capped RNA: Implications for translation</span></div><div class="casAuthors">Coutinho de Oliveira Luciana; Volpon Laurent; Rahardjo Amanda K; Osborne Michael J; Culjkovic-Kraljacic Biljana; Kwok Benjamin H; Borden Katherine L B; Trahan Christian; Oeffinger Marlene; Oeffinger Marlene; Oeffinger Marlene</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">24056-24065</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Viruses have transformed our understanding of mammalian RNA processing, including facilitating the discovery of the methyl-7-guanosine (m(7)G) cap on the 5' end of RNAs.  The m(7)G cap is required for RNAs to bind the eukaryotic translation initiation factor eIF4E and associate with the translation machinery across plant and animal kingdoms.  The potyvirus-derived viral genome-linked protein (VPg) is covalently bound to the 5' end of viral genomic RNA (gRNA) and associates with host eIF4E for successful infection.  Divergent models to explain these observations proposed either an unknown mode of eIF4E engagement or a competition of VPg for the m(7)G cap-binding site.  To dissect these possibilities, we resolved the structure of VPg, revealing a previously unknown 3-dimensional (3D) fold, and characterized the VPg-eIF4E complex using NMR and biophysical techniques.  VPg directly bound the cap-binding site of eIF4E and competed for m(7)G cap analog binding.  In human cells, VPg inhibited eIF4E-dependent RNA export, translation, and oncogenic transformation.  Moreover, VPg formed trimeric complexes with eIF4E-eIF4G, eIF4E bound VPg-luciferase RNA conjugates, and these VPg-RNA conjugates were templates for translation.  Informatic analyses revealed structural similarities between VPg and the human kinesin EG5.  Consistently, EG5 directly bound eIF4E in a similar manner to VPg, demonstrating that this form of engagement is relevant beyond potyviruses.  In all, we revealed an unprecedented modality for control and engagement of eIF4E and show that VPg-RNA conjugates functionally engage eIF4E.  As such, potyvirus VPg provides a unique model system to interrogate eIF4E.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4tR5q1L6mjDdblLE_E9PWfW6udTcc2eY_vsJXwCJzdrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjnslWqsQ%253D%253D&md5=399b6d8b5691a5201b4419ddd524c32d</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1904752116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1904752116%26sid%3Dliteratum%253Aachs%26aulast%3DCoutinho%2Bde%2BOliveira%26aufirst%3DL.%26aulast%3DVolpon%26aufirst%3DL.%26aulast%3DRahardjo%26aufirst%3DA.%2BK.%26aulast%3DOsborne%26aufirst%3DM.%2BJ.%26aulast%3DCuljkovic-Kraljacic%26aufirst%3DB.%26aulast%3DTrahan%26aufirst%3DC.%26aulast%3DOeffinger%26aufirst%3DM.%26aulast%3DKwok%26aufirst%3DB.%2BH.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DStructural%2520Studies%2520of%2520the%2520EIF4E%2520%25E2%2580%2593%2520VPg%2520Complex%2520Reveal%2520a%2520Direct%2520Competition%2520for%2520Capped%2520RNA%25E2%2580%25AF%253A%2520Implications%2520for%2520Translation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26spage%3D24056%26epage%3D24065%26doi%3D10.1073%2Fpnas.1904752116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidwell, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, L. N.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Broad Spectrum Antiviral Activity of l-(3-D-Ribofuranosyl-l,2,4-Triazole-3-Carboxamidef and Related Nucleosides</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1972</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1150</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1021/jm00281a014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00281a014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE3sXht1Sgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1972&pages=1150-1154&author=J.+T.+Witkowskiauthor=R.+K.+Robinsauthor=R.+W.+Sidwellauthor=L.+N.+Simon&title=Design%2C+Synthesis%2C+and+Broad+Spectrum+Antiviral+Activity+of+l-%283-D-Ribofuranosyl-l%2C2%2C4-Triazole-3-Carboxamidef+and+Related+Nucleosides&doi=10.1021%2Fjm00281a014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and broad spectrum antiviral activity of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides</span></div><div class="casAuthors">Witkowski, J. T.; Robins, Roland K.; Sidwell, Robert W.; Simon, Lionel N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1972</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1150-4</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (I) [36791-04-5] show high antiviral activity in tissue culture against both DNA and RNA viruses, namely adenovirus, herpes virus types 1 and 2, vaccinia virus, myxoma virus, parainfluenza virus, rhinovirus, coxsackie virus, influenza A2 virus, and influenza B virus.  I was active at concns. as low as 1-32 μg/ml, depending on the viruses utilized.  I was also effective against established infection with DNA and RNA viruses in vivo in lab. animals.  However, I was ineffective against various types of viral encephalitis, presumably due to the inability of I to cross the blood-brain barrier.  I did not induce interferon in mice, and apparently affected macromol. processes of viral replication.  I was synthesized by treatment of the trimethylsilyl deriv. of Me 1,2,4-triazole-3-carboxylate with an acyl-blocked ribofuranosyl bromide in MeCN at room temp., or by acid-catalyzed fusion of Me 1,2,4-triazole-3-carboxylate with a 1,2,3,5-tetra-O-acylribofuranose to yield a mixt. of blocked Me ester nucleosides, which were sepd. by chromatog. on silica gel; the desired isomer was reacted with NH3-MeOH to yield I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAhZCUEbd06rVg90H21EOLACvtfcHk0lj7ShR3r97SwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXht1Sgsg%253D%253D&md5=fdd7b0db555cde9ef08429a4a7542ef0</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fjm00281a014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00281a014%26sid%3Dliteratum%253Aachs%26aulast%3DWitkowski%26aufirst%3DJ.%2BT.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26aulast%3DSidwell%26aufirst%3DR.%2BW.%26aulast%3DSimon%26aufirst%3DL.%2BN.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Broad%2520Spectrum%2520Antiviral%2520Activity%2520of%2520l-%25283-D-Ribofuranosyl-l%252C2%252C4-Triazole-3-Carboxamidef%2520and%2520Related%2520Nucleosides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1972%26volume%3D15%26spage%3D1150%26epage%3D1154%26doi%3D10.1021%2Fjm00281a014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sidwell, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare, L. G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, R. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span> <span> </span><span class="NLM_article-title">Broad-Spectrum Antiviral Activity of Virazole: 1-β-D-Ribofuranosyl-1, 2,4-Triazole-3-Carboxamide</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1972</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1126/science.177.4050.705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1126%2Fscience.177.4050.705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=4340949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE38XlsVOltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=1972&pages=705-706&author=R.+W.+Sidwellauthor=J.+H.+Huffmanauthor=L.+G.+P.+Khareauthor=L.+B.+Allenauthor=R.+J.+T.+Witkowskiauthor=R.+K.+Robins&title=Broad-Spectrum+Antiviral+Activity+of+Virazole%3A+1-%CE%B2-D-Ribofuranosyl-1%2C+2%2C4-Triazole-3-Carboxamide&doi=10.1126%2Fscience.177.4050.705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Broad-spectrum antiviral activity of Virazole. 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide</span></div><div class="casAuthors">Sidwell, Robert W.; Huffman, John H.; Khare, G. P.; Allen, Lois B.; Witkowski, J. T.; Robins, Roland K.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1972</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">4050</span>),
    <span class="NLM_cas:pages">705-6</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Virazole (I) [36791-04-5] is a synthetic nucleoside active in tissue cultures against at least 16 DNA and RNA viruses.  Applied topically it inhibited herpetic keratitis in rabbits and tail lesions induced by herpes, vaccinia, and vesicular stomatitis viruses in mice.  Injected i.p. into mice it inhibited splenomegaly and hepatomegaly induced by Friend leukemia virus and respiratory infections caused by influenza A0, A2, and B viruses and parainfluenza 1 virus.  Oral or aerosol treatment of parainfluenza virus infections was also effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq093yJC1pGwbVg90H21EOLACvtfcHk0li0-de-LIPyzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE38XlsVOltrs%253D&md5=43631ffd66657eaac3c1a836d568779c</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1126%2Fscience.177.4050.705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.177.4050.705%26sid%3Dliteratum%253Aachs%26aulast%3DSidwell%26aufirst%3DR.%2BW.%26aulast%3DHuffman%26aufirst%3DJ.%2BH.%26aulast%3DKhare%26aufirst%3DL.%2BG.%2BP.%26aulast%3DAllen%26aufirst%3DL.%2BB.%26aulast%3DWitkowski%26aufirst%3DR.%2BJ.%2BT.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26atitle%3DBroad-Spectrum%2520Antiviral%2520Activity%2520of%2520Virazole%253A%25201-%25CE%25B2-D-Ribofuranosyl-1%252C%25202%252C4-Triazole-3-Carboxamide%26jtitle%3DScience%26date%3D1972%26volume%3D177%26spage%3D705%26epage%3D706%26doi%3D10.1126%2Fscience.177.4050.705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tam, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Z.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Action of Ribavirin in Antiviral Therapies</span>. <i>Antivir. Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1177/095632020101200501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1177%2F095632020101200501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=11900345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsFeqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=261-272&author=R.+C.+Tamauthor=J.+Y.+N.+Lauauthor=Z.+Hong&title=Mechanisms+of+Action+of+Ribavirin+in+Antiviral+Therapies&doi=10.1177%2F095632020101200501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of action of ribavirin in antiviral therapies</span></div><div class="casAuthors">Tam, Robert C.; Lau, Johnson Y. N.; Hong, Zhi</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">261-272</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">A review.  Although ribavirin was originally synthesized over 30 yr ago and was used to treat viral infections as monotherapy (respiratory syncytial virus and Lassa fever virus) or with interferon-α (IFN-α) as combination therapy (hepatitis C virus), the precise mechanism of its therapeutic activities remains controversial.  In this review the authors focus on 2 main biol. properties of ribavirin: its indirect and direct antiviral activities (with particular emphasis on its efficacy against chronic hepatitis C infection).  Each property could individually or collectively account for its clin. efficacy against viral infections.  First, with emphasis on the evidence for indirect activities of ribavirin, the authors will review the clin. observations that suggest that the immunomodulatory properties of ribavirin can in part account for its antiviral activities in vivo.  The authors will then describe the mode of ribavirin's direct antiviral activities.  These direct activities can be ascribed to several possible mechanisms, including the recently described activity as an RNA mutagen, a property that may be important in driving a rapidly mutating RNA virus over the threshold to "error catastrophe".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2AvIqqfeFX7Vg90H21EOLACvtfcHk0li0-de-LIPyzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsFeqsro%253D&md5=f5b7d6042011b80cd5eb6bc616b2c1ac</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1177%2F095632020101200501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020101200501%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DR.%2BC.%26aulast%3DLau%26aufirst%3DJ.%2BY.%2BN.%26aulast%3DHong%26aufirst%3DZ.%26atitle%3DMechanisms%2520of%2520Action%2520of%2520Ribavirin%2520in%2520Antiviral%2520Therapies%26jtitle%3DAntivir.%2520Chem.%2520Chemother.%26date%3D2001%26volume%3D12%26spage%3D261%26epage%3D272%26doi%3D10.1177%2F095632020101200501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujitaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span> <span> </span><span class="NLM_article-title">The Broad Spectrum Antiviral Agent Ribavirin Inhibits Capping of MRNA</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">830</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(79)91853-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2F0006-291X%2879%2991853-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=226095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE1MXltlCksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1979&pages=830-836&author=B.+B.+Goswamiauthor=E.+Borekauthor=O.+K.+Sharmaauthor=J.+Fujitakiauthor=R.+A.+Smith&title=The+Broad+Spectrum+Antiviral+Agent+Ribavirin+Inhibits+Capping+of+MRNA&doi=10.1016%2F0006-291X%2879%2991853-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The broad spectrum antiviral agent ribavirin inhibits capping of mRNA</span></div><div class="casAuthors">Goswami, Biswendu B.; Borek, Ernest; Sharma, Opendra K.; Fujitaki, James; Smith, Roberts A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">830-6</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Ribavirin (I)  [36791-04-5], a broad spectrum antiviral substance active against a wide range of both DNA and RNA viruses, did not inhibit DNA-dependent RNA synthesis by vaccina virus assocd. polymerase.  However, I triphosphate  [63142-71-2] was a potent competitive inhibitor of the capping guanylation of viral mRNA.  This finding could account for the antiviral potency of the drug against both DNA and RNA viruses and its ineffectiveness against polio virus, a virus in which the mRNAs derived from them are not capped.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5tCmOPyaKCrVg90H21EOLACvtfcHk0li0-de-LIPyzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXltlCksbY%253D&md5=bb9dcca3b5ff4bf5366f08fd645bc721</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2879%2991853-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252879%252991853-9%26sid%3Dliteratum%253Aachs%26aulast%3DGoswami%26aufirst%3DB.%2BB.%26aulast%3DBorek%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DO.%2BK.%26aulast%3DFujitaki%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26atitle%3DThe%2520Broad%2520Spectrum%2520Antiviral%2520Agent%2520Ribavirin%2520Inhibits%2520Capping%2520of%2520MRNA%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1979%26volume%3D89%26spage%3D830%26epage%3D836%26doi%3D10.1016%2F0006-291X%2879%2991853-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgstrand, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misiorny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norén, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philipson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stening, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stridh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberg, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Influenza Virus Ribonucleic Acid Polymerase by Ribavirin Triphosphate</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1128/AAC.11.6.946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1128%2FAAC.11.6.946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=879760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE2sXkvVSgs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1977&pages=946-951&author=B.+Erikssonauthor=E.+Helgstrandauthor=N.+G.+Johanssonauthor=A.+Larssonauthor=A.+Misiornyauthor=J.+O.+Nor%C3%A9nauthor=L.+Philipsonauthor=K.+Stenbergauthor=G.+Steningauthor=S.+Stridhauthor=B.+Oberg&title=Inhibition+of+Influenza+Virus+Ribonucleic+Acid+Polymerase+by+Ribavirin+Triphosphate&doi=10.1128%2FAAC.11.6.946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate</span></div><div class="casAuthors">Eriksson, Bertil; Helgstrand, Erik; Johansson, Nils Gunnar; Larsson, Alf; Misiorny, Alfons; Noren, Jan Olof; Philipson, Lennart; Stenberg, Kjell; Stening, Goran; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">946-51</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">Ribavirin 5'-triphosphate (I), derived from the broad-spectrum antiviral compd., ribavirin (Virazole), selectively inhibited influenza virus RNA polymerase in a cell-free assay.  Neither ribavirin or its 5'-monophosphate had any effect on the viral polymerase.  The inhibition by I was competitive with respect to ATP and GTP.  I also inhibited ApG- and GpC-stimulated influenza virus RNA polymerase.  Since ribavirin is phosphorylated in the cell, the inhibition of influenza multiplication in the cell may also be caused by I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJyStouG8YBrVg90H21EOLACvtfcHk0li0-de-LIPyzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXkvVSgs7o%253D&md5=6679bbc6518c00bd21f565d675d2b213</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1128%2FAAC.11.6.946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.11.6.946%26sid%3Dliteratum%253Aachs%26aulast%3DEriksson%26aufirst%3DB.%26aulast%3DHelgstrand%26aufirst%3DE.%26aulast%3DJohansson%26aufirst%3DN.%2BG.%26aulast%3DLarsson%26aufirst%3DA.%26aulast%3DMisiorny%26aufirst%3DA.%26aulast%3DNor%25C3%25A9n%26aufirst%3DJ.%2BO.%26aulast%3DPhilipson%26aufirst%3DL.%26aulast%3DStenberg%26aufirst%3DK.%26aulast%3DStening%26aufirst%3DG.%26aulast%3DStridh%26aufirst%3DS.%26aulast%3DOberg%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520Influenza%2520Virus%2520Ribonucleic%2520Acid%2520Polymerase%2520by%2520Ribavirin%2520Triphosphate%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1977%26volume%3D11%26spage%3D946%26epage%3D951%26doi%3D10.1128%2FAAC.11.6.946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeprose, R. D.</span></span> <span> </span><span class="NLM_article-title">Metabolism of 5-Amino-1-<i>H</i>-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl-imidazole-4-carboximide and related five-membered heterocycles to 5′-Triphosphates in Human Blood and L5178Y Cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(78)90508-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2F0006-2952%2878%2990508-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=207278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE1cXkvF2ls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1978&pages=709-716&author=T.+P.+Zimmermanauthor=R.+D.+Deeprose&title=Metabolism+of+5-Amino-1-H-d-ribofuranosyl-imidazole-4-carboximide+and+related+five-membered+heterocycles+to+5%E2%80%B2-Triphosphates+in+Human+Blood+and+L5178Y+Cells&doi=10.1016%2F0006-2952%2878%2990508-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of 5-amino-1-β-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5'-triphosphates in human blood and L5178Y cells</span></div><div class="casAuthors">Zimmerman, Thomas P.; Deeprose, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">709-16</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">5-Amino-1-β-D-ribofuranosylimidazole-4-carboxamide (I)  [2627-69-2] and its structural analogs, e.g., ribavirin  [36791-04-5], were metabolized to their corresponding 5'-triphosphates in human blood.  I and ribavirin were metabolized to the 5'-monophosphates mainly (>90%) via a nucleoside kinase  [52350-81-9], whereas 5-fluoro-1-β-D-ribofuranosylimidazole-4-carboxamide (II)  [56766-95-1] appeared to be metabolized to its 5'-monophosphate both via a nucleoside kinase (∼67%) and via phosphorolytic cleavage followed by a phosphoribosyltransferase  [9076-94-2]-mediated reaction (∼33%).  The aglycones of I and II were also metabolized to their corresponding triphosphates.  In addn., ribavirin was metabolized to its 5'-triphosphate in L5178Y cells, but was not incorporated into RNA.  Ribavirin decreased the pool size of GTP  [86-01-1] in L5178Y cells, with a concomitant increase in the pool size of both CTP  [65-47-4] and UTP  [63-39-8].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg-tm2UeE2BLVg90H21EOLACvtfcHk0liB_E5irbfpIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXkvF2ls7s%253D&md5=acf5406304920cc950f34f22d15099e5</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2878%2990508-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252878%252990508-7%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerman%26aufirst%3DT.%2BP.%26aulast%3DDeeprose%26aufirst%3DR.%2BD.%26atitle%3DMetabolism%2520of%25205-Amino-1-H-d-ribofuranosyl-imidazole-4-carboximide%2520and%2520related%2520five-membered%2520heterocycles%2520to%25205%25E2%2580%25B2-Triphosphates%2520in%2520Human%2520Blood%2520and%2520L5178Y%2520Cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1978%26volume%3D27%26spage%3D709%26epage%3D716%26doi%3D10.1016%2F0006-2952%2878%2990508-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casaos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelick, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huq, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lott, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kast, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skuli, N.</span></span> <span> </span><span class="NLM_article-title">The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1185</span>– <span class="NLM_lpage">1194</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-0666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1158%2F1535-7163.MCT-18-0666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31263027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1eru7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=1185-1194&author=J.+Casaosauthor=N.+L.+Gorelickauthor=S.+Huqauthor=J.+Choiauthor=Y.+Xiaauthor=R.+Serraauthor=R.+Felderauthor=T.+Lottauthor=R.+E.+Kastauthor=I.+Sukauthor=H.+Bremauthor=B.+Tylerauthor=N.+Skuli&title=The+Use+of+Ribavirin+as+an+Anticancer+Therapeutic%3A+Will+It+Go+Viral%3F&doi=10.1158%2F1535-7163.MCT-18-0666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">The use of ribavirin as an anticancer therapeutic: will it go viral?</span></div><div class="casAuthors">Casaos, Joshua; Gorelick, Noah L.; Huq, Sakibul; Choi, John; Xia, Yuanxuan; Serra, Riccardo; Felder, Raphael; Lott, Tarik; Kast, Richard E.; Suk, Ian; Brem, Henry; Tyler, Betty; Skuli, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1185-1194</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The growing cost of medical care worldwide, particularly in oncol., has incentivized researchers and physicians to repurpose clin. used drugs to alleviate the financial burden of drug development and offer potential new therapeutics.  Recent works have demonstrated anticancer properties of the FDA-approved drug ribavirin, a synthetic guanosine analog and antiviral mol. used over the past four decades for the treatment of hepatitis C.  The efficacy of ribavirin in cancer has been explored through several preclin. models and ongoing clin. trials in multiple cancers, including acute myeloid leukemia, oropharyngeal squamous cell carcinoma, and metastatic breast cancer.  In this review, we summarize the role of ribavirin as an antiviral medication and focus our attention on its recent use as an antitumoral agent.  We highlight current knowledge of the potential use and mechanisms of action of ribavirin in cancer.  Because current therapeutics for patients with cancer still fail to cure, introducing new forms of treatment is essential.  Converging evidence suggests that ribavirin represents a promising addn. to a generation of newly repurposed safe and effective anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozlolvSKu7LrVg90H21EOLACvtfcHk0liB_E5irbfpIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1eru7vO&md5=2a865efeae91acb0b8afa0fe216021e8</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-0666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-0666%26sid%3Dliteratum%253Aachs%26aulast%3DCasaos%26aufirst%3DJ.%26aulast%3DGorelick%26aufirst%3DN.%2BL.%26aulast%3DHuq%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DSerra%26aufirst%3DR.%26aulast%3DFelder%26aufirst%3DR.%26aulast%3DLott%26aufirst%3DT.%26aulast%3DKast%26aufirst%3DR.%2BE.%26aulast%3DSuk%26aufirst%3DI.%26aulast%3DBrem%26aufirst%3DH.%26aulast%3DTyler%26aufirst%3DB.%26aulast%3DSkuli%26aufirst%3DN.%26atitle%3DThe%2520Use%2520of%2520Ribavirin%2520as%2520an%2520Anticancer%2520Therapeutic%253A%2520Will%2520It%2520Go%2520Viral%253F%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26spage%3D1185%26epage%3D1194%26doi%3D10.1158%2F1535-7163.MCT-18-0666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kentsis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topisirovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span> <span> </span><span class="NLM_article-title">Ribavirin Suppresses eIF4E-Mediated Oncogenic Transformation by Physical Mimicry of the 7-Methyl Guanosine MRNA Cap</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">18105</span>– <span class="NLM_lpage">18110</span>, <span class="refDoi"> DOI: 10.1073/pnas.0406927102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.0406927102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=15601771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsl2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=18105-18110&author=A.+Kentsisauthor=I.+Topisirovicauthor=B.+Culjkovicauthor=L.+Shaoauthor=K.+L.+B.+Borden&title=Ribavirin+Suppresses+eIF4E-Mediated+Oncogenic+Transformation+by+Physical+Mimicry+of+the+7-Methyl+Guanosine+MRNA+Cap&doi=10.1073%2Fpnas.0406927102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap</span></div><div class="casAuthors">Kentsis, Alex; Topisirovic, Ivan; Culjkovic, Biljana; Shao, Ling; Borden, Katherine L. B.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">18105-18110</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The eukaryotic translation initiation factor eIF4E is deregulated in many human cancers, and its overexpression in cells leads to malignant transformation.  Oncogenic properties of eIF4E are directly linked to its ability to bind 7-Me guanosine of the 5' mRNA.  Here, we observe that the antiviral guanosine analog ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-Me guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concns., selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1.  Ribavirin potently suppresses eIF4E-mediated oncogenic transformation of murine cells in vitro, of tumor growth of a mouse model of eIF4E-dependent human squamous cell carcinoma in vivo, and of colony formation of eIF4E-dependent acute myelogenous leukemia cells derived from human patients.  These findings describe a specific, potent, and unforeseen mechanism of action of ribavirin.  Quantum mech. and NMR structural studies offer directions for the development of derivs. with improved cytostatic and antiviral properties.  In all, ribavirin's assocn. with eIF4E may provide a pharmacol. means for the interruption of posttranscriptional networks of oncogenes that maintain and enhance neoplasia and malignancy in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXLIEVbhXRIbVg90H21EOLACvtfcHk0liB_E5irbfpIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsl2mtA%253D%253D&md5=01cfecd677703fb01c0dbd26195bb469</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0406927102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0406927102%26sid%3Dliteratum%253Aachs%26aulast%3DKentsis%26aufirst%3DA.%26aulast%3DTopisirovic%26aufirst%3DI.%26aulast%3DCuljkovic%26aufirst%3DB.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DRibavirin%2520Suppresses%2520eIF4E-Mediated%2520Oncogenic%2520Transformation%2520by%2520Physical%2520Mimicry%2520of%2520the%25207-Methyl%2520Guanosine%2520MRNA%2520Cap%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D18105%26epage%3D18110%26doi%3D10.1073%2Fpnas.0406927102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svitkin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisaillon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Ribavirin Is Not a Functional Mimic of the 7-Methyl Guanosine MRNA Cap</span>. <i>RNA</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1244</span>, <span class="refDoi"> DOI: 10.1261/rna.2930805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1261%2Frna.2930805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16043507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFCgtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1238-1244&author=Y.+Yanauthor=Y.+Svitkinauthor=J.+M.+Leeauthor=M.+Bisaillonauthor=J.+Pelletier&title=Ribavirin+Is+Not+a+Functional+Mimic+of+the+7-Methyl+Guanosine+MRNA+Cap&doi=10.1261%2Frna.2930805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap</span></div><div class="casAuthors">Yan, Yifei; Svitkin, Yuri; Lee, Joseph M.; Bisaillon, Martin; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">RNA</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1238-1244</span>CODEN:
                <span class="NLM_cas:coden">RNARFU</span>;
        ISSN:<span class="NLM_cas:issn">1355-8382</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Ribavirin is a guanosine ribonucleoside analog that displays broad-spectrum anti-viral activity and is currently used for the treatment of some viral infections.  Ribavirin has recently been proposed to also be a mimic of the 7-Me guanosine cap found at the 5' end of mRNAs.  To obtain supporting functional data for this hypothesis, we assessed the ability of ribavirin triphosphate to interfere with the interaction between eIF4E and 7-Me guanosine capped mRNA.  In chem. crosslinking assays, cap-affinity chromatog., and cap-dependent translation assays, ribavirin was unable to function as a cap analog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_zNCMjAS-_7Vg90H21EOLACvtfcHk0ljlFRkSbHlAug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFCgtLs%253D&md5=a7e684246566f5e613d5ffb99428dbf1</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1261%2Frna.2930805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1261%252Frna.2930805%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DY.%26aulast%3DSvitkin%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DBisaillon%26aufirst%3DM.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DRibavirin%2520Is%2520Not%2520a%2520Functional%2520Mimic%2520of%2520the%25207-Methyl%2520Guanosine%2520MRNA%2520Cap%26jtitle%3DRNA%26date%3D2005%26volume%3D11%26spage%3D1238%26epage%3D1244%26doi%3D10.1261%2Frna.2930805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudzien, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuberek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemielity, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolarski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darzynkiewicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhoads, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preiss, T.</span></span> <span> </span><span class="NLM_article-title">The Antiviral Drug Ribavirin Does Not Mimic the 7-Methylguanosine Moiety of the mRNA Cap Structure in Vitro</span>. <i>RNA</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1513</span>, <span class="refDoi"> DOI: 10.1261/rna.2132505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1261%2Frna.2132505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16131589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVygtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1505-1513&author=B.+Westmanauthor=L.+Beerenauthor=E.+Grudzienauthor=J.+Stepinskiauthor=R.+Worchauthor=J.+Zuberekauthor=J.+Jemielityauthor=R.+Stolarskiauthor=E.+Darzynkiewiczauthor=R.+E.+Rhoadsauthor=T.+Preiss&title=The+Antiviral+Drug+Ribavirin+Does+Not+Mimic+the+7-Methylguanosine+Moiety+of+the+mRNA+Cap+Structure+in+Vitro&doi=10.1261%2Frna.2132505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro</span></div><div class="casAuthors">Westman, Belinda; Beeren, Lisa; Grudzien, Ewa; Stepinski, Janusz; Worch, Remigiusz; Zuberek, Joanna; Jemielity, Jacek; Stolarski, Ryszard; Darzynkiewicz, Edward; Rhoads, Robert E.; Preiss, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">RNA</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1505-1513</span>CODEN:
                <span class="NLM_cas:coden">RNARFU</span>;
        ISSN:<span class="NLM_cas:issn">1355-8382</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The eukaryotic initiation factor eIF4E binds the mRNA 5' cap structure and has a central role during translational initiation.  eIF4E And the mechanisms to control its activity have oncogenic properties and thus have become targets for anticancer drug development.  A recent study presented evidence that the antiviral nucleoside ribavirin and its phosphorylated derivs. were structural mimics of the mRNA cap, high-affinity ligands for eIF4E, and potent repressors of eIF4E-mediated cell transformation and tumor growth.  Based on these findings, we tested ribavirin, ribavirin triphosphate (RTP), and the dinucleotide RpppG for their ability to inhibit translation in vitro.  Surprisingly, the ribavirin-based compds. did not affect translation at concns. where canonical cap analogs efficiently block cap-dependent translation.  Using a set of reporter mRNAs that are translated via either cap-dependent or viral internal ribosome entry sites (IRES)-dependent initiation, we found that these ribavirin-contg. compds. did inhibit translation at high (millimolar) concns., but there was no correlation of this inhibition with an eIF4E requirement for translation.  The addn. of a ribavirin-contg. cap to mRNA did not stimulate translation.  Fluorescence titrn. expts. with eIF4E and the nuclear cap-binding complex CBC indicated affinities for RTP and RpppG that were two to four orders of magnitude lower than those of m7GTP and m7GpppG.  We conclude that, at least with respect to translation, ribavirin does not act in vitro as a functional mimic of the mRNA cap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf6dKE-CKVlbVg90H21EOLACvtfcHk0ljlFRkSbHlAug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVygtrbP&md5=9180cec56e6f91320eff2c6ad77b201c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1261%2Frna.2132505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1261%252Frna.2132505%26sid%3Dliteratum%253Aachs%26aulast%3DWestman%26aufirst%3DB.%26aulast%3DBeeren%26aufirst%3DL.%26aulast%3DGrudzien%26aufirst%3DE.%26aulast%3DStepinski%26aufirst%3DJ.%26aulast%3DWorch%26aufirst%3DR.%26aulast%3DZuberek%26aufirst%3DJ.%26aulast%3DJemielity%26aufirst%3DJ.%26aulast%3DStolarski%26aufirst%3DR.%26aulast%3DDarzynkiewicz%26aufirst%3DE.%26aulast%3DRhoads%26aufirst%3DR.%2BE.%26aulast%3DPreiss%26aufirst%3DT.%26atitle%3DThe%2520Antiviral%2520Drug%2520Ribavirin%2520Does%2520Not%2520Mimic%2520the%25207-Methylguanosine%2520Moiety%2520of%2520the%2520mRNA%2520Cap%2520Structure%2520in%2520Vitro%26jtitle%3DRNA%26date%3D2005%26volume%3D11%26spage%3D1505%26epage%3D1513%26doi%3D10.1261%2Frna.2132505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kentsis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topisirovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span> <span> </span><span class="NLM_article-title">Further Evidence That Ribavirin Interacts with eIF4E</span>. <i>RNA</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1762</span>– <span class="NLM_lpage">1766</span>, <span class="refDoi"> DOI: 10.1261/rna.2238705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1261%2Frna.2238705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16251386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlWnu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1762-1766&author=A.+Kentsisauthor=L.+Volponauthor=I.+Topisirovicauthor=C.+E.+Sollauthor=B.+Culjkovicauthor=L.+Shaoauthor=K.+L.+B.+Borden&title=Further+Evidence+That+Ribavirin+Interacts+with+eIF4E&doi=10.1261%2Frna.2238705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Further evidence that ribavirin interacts with eIF4E</span></div><div class="casAuthors">Kentsis, Alex; Volpon, Laurent; Topisirovic, Ivan; Soll, Clifford E.; Culjkovic, Biljana; Shao, Ling; Borden, Katherine L. B.</div><div class="citationInfo"><span class="NLM_cas:title">RNA</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1762-1766</span>CODEN:
                <span class="NLM_cas:coden">RNARFU</span>;
        ISSN:<span class="NLM_cas:issn">1355-8382</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">This commentary discusses the recent reports in RNA by Yan and colleagues and Westman and colleagues of the apparent failure of ribavirin to bind to recombinant eIF4E and inhibit 7-Me guanosine cap-dependent exogenous mRNA translation of cell exts. in vitro.  Measuring binding by using affinity chromatog. of matrix-immobilized proteins and by using protein emission fluorescence spectroscopy in the presence of nucleotide ligands, as well as limitations of using cell exts. for the assessment of mechanisms of mRNA translation are discussed.  Possible reasons for the discordant findings of Yan and colleagues and Westman and colleagues are suggested, and direct observation of the specific binding of ribavirin to eIF4E by using mass spectrometry is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJkZ1EOqgd0LVg90H21EOLACvtfcHk0ljlFRkSbHlAug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlWnu73N&md5=96a8b9153425d43868906ab44cb673b3</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1261%2Frna.2238705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1261%252Frna.2238705%26sid%3Dliteratum%253Aachs%26aulast%3DKentsis%26aufirst%3DA.%26aulast%3DVolpon%26aufirst%3DL.%26aulast%3DTopisirovic%26aufirst%3DI.%26aulast%3DSoll%26aufirst%3DC.%2BE.%26aulast%3DCuljkovic%26aufirst%3DB.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DFurther%2520Evidence%2520That%2520Ribavirin%2520Interacts%2520with%2520eIF4E%26jtitle%3DRNA%26date%3D2005%26volume%3D11%26spage%3D1762%26epage%3D1766%26doi%3D10.1261%2Frna.2238705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
La Cruz-Hernandez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-Blanco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez-Gomez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Cardenas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Fierro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taja-Chayeb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dueñas-Gonzalez, A.</span></span> <span> </span><span class="NLM_article-title">Ribavirin as a Tri-Targeted Antitumor Repositioned Drug</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2384</span>– <span class="NLM_lpage">2392</span>, <span class="refDoi"> DOI: 10.3892/or.2015.3816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3892%2For.2015.3816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25738706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=2384-2392&author=E.+De%0ALa+Cruz-Hernandezauthor=J.+L.+Medina-Francoauthor=J.+Trujilloauthor=A.+Chavez-Blancoauthor=G.+Dominguez-Gomezauthor=E.+Perez-Cardenasauthor=A.+Gonzalez-Fierroauthor=L.+Taja-Chayebauthor=A.+Due%C3%B1as-Gonzalez&title=Ribavirin+as+a+Tri-Targeted+Antitumor+Repositioned+Drug&doi=10.3892%2For.2015.3816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Ribavirin as a tri-targeted antitumor repositioned drug</span></div><div class="casAuthors">De La Cruz-Hernandez, Erick; Medina-Franco, Jose Luis; Trujillo, Jaenai; Chavez-Blanco, Alma; Dominguez-Gomez, Guadalupe; Perez-Cardenas, Enrique; Gonzalez-Fierro, Aurora; Taja-Chayeb, Lucia; Duenas-Gonzalez, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2384-2392</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The aim of the present study was to demonstrate that ribavirin, a known inhibitor of eIF4E and inosine 5'-phosphate dehydrogenase (IMPDH), also inhibits histone methyltransferase zeste homolog 2 (EZH2).  A computational searching revealed that ribavirin has a high structural similarity to 3-deazaneplanocin A (DZNep).  The growth inhibitory effects of ribavirin as well as its effects upon epigenetic enzymes were evaluated in various cancer cell lines. siRNA assays were used to downregulate eIF4E, EZH2 and IMPDH to det. the contribution of these targets to the growth inhibitory effects of ribavirin.  Ribavirin decreased EZH2 expression, inhibited histone methyltransferase activity and decreased H3K27 trimethylation.  Ribavirin induced variable growth inhibition in a no. of cell lines and downregulation of the targets, EZH2, eIF4E and IMPDH1 and 2 by siRNA led to comparable growth inhibition while no significant further redn. in viability was obsd. when siRNA transfected cells were treated with ribavirin.  The results showed that ribavirin inhibits these cancer targets and should thus be studied for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMxpiWdvnXpLVg90H21EOLACvtfcHk0lgomrwH8N8epw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVagtg%253D%253D&md5=bc8d48d9613ab2db23c15cacb9a4de9e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.3892%2For.2015.3816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2015.3816%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLa%2BCruz-Hernandez%26aufirst%3DE.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26aulast%3DTrujillo%26aufirst%3DJ.%26aulast%3DChavez-Blanco%26aufirst%3DA.%26aulast%3DDominguez-Gomez%26aufirst%3DG.%26aulast%3DPerez-Cardenas%26aufirst%3DE.%26aulast%3DGonzalez-Fierro%26aufirst%3DA.%26aulast%3DTaja-Chayeb%26aufirst%3DL.%26aulast%3DDue%25C3%25B1as-Gonzalez%26aufirst%3DA.%26atitle%3DRibavirin%2520as%2520a%2520Tri-Targeted%2520Antitumor%2520Repositioned%2520Drug%26jtitle%3DOncol.%2520Rep.%26date%3D2015%26volume%3D33%26spage%3D2384%26epage%3D2392%26doi%3D10.3892%2For.2015.3816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urtishak, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic-Kraljacic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porazzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teachey, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasian, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seif, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.-M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devidas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyer, Z. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilden, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunger, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willman, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, C. A.</span></span> <span> </span><span class="NLM_article-title">Targeting eIF4E Signaling with Ribavirin in Infant Acute Lymphoblastic Leukemia</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2241</span>– <span class="NLM_lpage">2262</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0567-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41388-018-0567-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30478448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSqsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=2241-2262&author=K.+A.+Urtishakauthor=L.-S.+Wangauthor=B.+Culjkovic-Kraljacicauthor=J.+W.+Davenportauthor=P.+Porazziauthor=T.+L.+Vincentauthor=D.+T.+Teacheyauthor=S.+K.+Tasianauthor=J.+S.+Mooreauthor=A.+E.+Seifauthor=S.+Jinauthor=J.+S.+Barrettauthor=B.+W.+Robinsonauthor=I.-M.+L.+Chenauthor=R.+C.+Harveyauthor=M.+P.+Carrollauthor=A.+J.+Carrollauthor=N.+A.+Heeremaauthor=M.+Devidasauthor=Z.+E.+Dreyerauthor=J.+M.+Hildenauthor=S.+P.+Hungerauthor=C.+L.+Willmanauthor=K.+L.+B.+Bordenauthor=C.+A.+Felix&title=Targeting+eIF4E+Signaling+with+Ribavirin+in+Infant+Acute+Lymphoblastic+Leukemia&doi=10.1038%2Fs41388-018-0567-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia</span></div><div class="casAuthors">Urtishak, Karen A.; Wang, Li-San; Culjkovic-Kraljacic, Biljana; Davenport, James W.; Porazzi, Patrizia; Vincent, Tiffaney L.; Teachey, David T.; Tasian, Sarah K.; Moore, Jonni S.; Seif, Alix E.; Jin, Shenghao; Barrett, Jeffrey S.; Robinson, Blaine W.; Chen, I-Ming L.; Harvey, Richard C.; Carroll, Martin P.; Carroll, Andrew J.; Heerema, Nyla A.; Devidas, Meenakshi; Dreyer, ZoAnn E.; Hilden, Joanne M.; Hunger, Stephen P.; Willman, Cheryl L.; Borden, Katherine L. B.; Felix, Carolyn A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2241-2262</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The poor outcomes in infant acute lymphoblastic leukemia (ALL) necessitate new treatments.  Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has anticancer properties through EIF4E inhibition, as a potential treatment.  We find that ribavirin treatment of actively dividing infant ALL cells on bone marrow stromal cells (BMSCs) at clin. achievable concns. causes robust proliferation inhibition in proportion with EIF4E expression.  Further, we find that ribavirin treatment of KMT2A-rearranged (KMT2A-R) infant ALL cells and the KMT2A-AFF1 cell line RS4:11 inhibits EIF4E, leading to decreases in oncogenic EIF4E-regulated cell growth and survival proteins.  In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5.  Ribavirin-treated RS4:11 cells exhibit impaired EIF4E-dependent nuclear to cytoplasmic export and/or translation of the corresponding mRNAs, as well as reduced phosphorylation of the p-AKT1, p-EIF4EBP1, p-RPS6 and p-EIF4E signaling proteins.  This leads to an S-phase cell cycle arrest in RS4:11 cells corresponding to the decreased proliferation.  Ribavirin causes nuclear EIF4E to re-localize to the cytoplasm in KMT2A-AFF1 infant ALL and RS4:11 cells, providing further evidence for EIF4E inhibition.  Ribavirin slows increases in peripheral blasts in KMT2A-R infant ALL xenograft-bearing mice.  Ribavirin cooperates with chemotherapy, particularly L-asparaginase, in reducing live KMT2A-AFF1 infant ALL cells in BMSC co-cultures.  This work establishes that EIF4E is broadly elevated across infant ALL and that clin. relevant ribavirin exposures have preclin. activity and effectively inhibit EIF4E in KMT2A-R cases, suggesting promise in EIF4E targeting using ribavirin as a means of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD_YsxlZ2LYbVg90H21EOLACvtfcHk0lgomrwH8N8epw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSqsbnN&md5=f643381b62c71813d748f5ef1c241c69</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0567-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0567-7%26sid%3Dliteratum%253Aachs%26aulast%3DUrtishak%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DL.-S.%26aulast%3DCuljkovic-Kraljacic%26aufirst%3DB.%26aulast%3DDavenport%26aufirst%3DJ.%2BW.%26aulast%3DPorazzi%26aufirst%3DP.%26aulast%3DVincent%26aufirst%3DT.%2BL.%26aulast%3DTeachey%26aufirst%3DD.%2BT.%26aulast%3DTasian%26aufirst%3DS.%2BK.%26aulast%3DMoore%26aufirst%3DJ.%2BS.%26aulast%3DSeif%26aufirst%3DA.%2BE.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DBarrett%26aufirst%3DJ.%2BS.%26aulast%3DRobinson%26aufirst%3DB.%2BW.%26aulast%3DChen%26aufirst%3DI.-M.%2BL.%26aulast%3DHarvey%26aufirst%3DR.%2BC.%26aulast%3DCarroll%26aufirst%3DM.%2BP.%26aulast%3DCarroll%26aufirst%3DA.%2BJ.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DDevidas%26aufirst%3DM.%26aulast%3DDreyer%26aufirst%3DZ.%2BE.%26aulast%3DHilden%26aufirst%3DJ.%2BM.%26aulast%3DHunger%26aufirst%3DS.%2BP.%26aulast%3DWillman%26aufirst%3DC.%2BL.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26aulast%3DFelix%26aufirst%3DC.%2BA.%26atitle%3DTargeting%2520eIF4E%2520Signaling%2520with%2520Ribavirin%2520in%2520Infant%2520Acute%2520Lymphoblastic%2520Leukemia%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26spage%3D2241%26epage%3D2262%26doi%3D10.1038%2Fs41388-018-0567-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assouline, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocolakis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beslu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span> <span> </span><span class="NLM_article-title">Molecular Targeting of the Oncogene eIF4E in Acute Myeloid Leukemia (AML): A Proof-of-Principle Clinical Trial with Ribavirin</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-02-205153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1182%2Fblood-2009-02-205153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19433856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovVKmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=257-260&author=S.+Assoulineauthor=B.+Culjkovicauthor=E.+Cocolakisauthor=C.+Rousseauauthor=N.+Besluauthor=A.+Amriauthor=S.+Caplanauthor=B.+Leberauthor=D.+C.+Royauthor=W.+H.+Millerauthor=K.+L.+B.+Borden&title=Molecular+Targeting+of+the+Oncogene+eIF4E+in+Acute+Myeloid+Leukemia+%28AML%29%3A+A+Proof-of-Principle+Clinical+Trial+with+Ribavirin&doi=10.1182%2Fblood-2009-02-205153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin</span></div><div class="casAuthors">Assouline, Sarit; Culjkovic, Biljana; Cocolakis, Eftihia; Rousseau, Caroline; Beslu, Nathalie; Amri, Abdellatif; Caplan, Stephen; Leber, Brian; Roy, Denis-Claude; Miller, Wilson H., Jr.; Borden, Katherine L. B.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-260</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The eukaryotic translation initiation factor eIF4E is elevated in 30% of malignancies including M4/M5 subtypes of acute myeloid leukemia (AML).  The oncogenic potential of eIF4E arises from its ability to bind the 7-Me guanosine (m7G) cap on mRNAs, thereby selectively enhancing eIF4E-dependent nuclear mRNA export and translation.  We tested the clin. efficacy of targeting eIF4E in M4/M5 AML patients with a phys. mimic of the m7G cap, ribavirin.  Among 11 evaluable patients there were 1 complete remission (CR), 2 partial remissions (PRs), 2 blast responses (BRs), 4 stable diseases (SDs), and 2 progressive diseases (PDs).  Ribavirin-induced relocalization of nuclear eIF4E to the cytoplasm and redn. of eIF4E levels were assocd. with clin. response.  Lack of response or relapse coincided with continued or renewed nuclear localization of eIF4E.  This first clin. study to target eIF4E in human malignancy demonstrates clin. activity and assocd. mol. responses in leukemic blasts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwnUgUhzzNTrVg90H21EOLACvtfcHk0litzAYUYuSStw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovVKmu78%253D&md5=36523353e8f24330c7c5de784ea16559</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-02-205153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-02-205153%26sid%3Dliteratum%253Aachs%26aulast%3DAssouline%26aufirst%3DS.%26aulast%3DCuljkovic%26aufirst%3DB.%26aulast%3DCocolakis%26aufirst%3DE.%26aulast%3DRousseau%26aufirst%3DC.%26aulast%3DBeslu%26aufirst%3DN.%26aulast%3DAmri%26aufirst%3DA.%26aulast%3DCaplan%26aufirst%3DS.%26aulast%3DLeber%26aufirst%3DB.%26aulast%3DRoy%26aufirst%3DD.%2BC.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DMolecular%2520Targeting%2520of%2520the%2520Oncogene%2520eIF4E%2520in%2520Acute%2520Myeloid%2520Leukemia%2520%2528AML%2529%253A%2520A%2520Proof-of-Principle%2520Clinical%2520Trial%2520with%2520Ribavirin%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D257%26epage%3D260%26doi%3D10.1182%2Fblood-2009-02-205153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assouline, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic-Kraljacic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocolakis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahreddine, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span> <span> </span><span class="NLM_article-title">A Phase i Trial of Ribavirin and Low-Dose Cytarabine for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia with Elevated eIF4E</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">e7</span>– <span class="NLM_lpage">e9</span>, <span class="refDoi"> DOI: 10.3324/haematol.2014.111245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3324%2Fhaematol.2014.111245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25425688" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=e7-e9&author=S.+Assoulineauthor=B.+Culjkovic-Kraljacicauthor=J.+Bergeronauthor=S.+Caplanauthor=E.+Cocolakisauthor=C.+Lambertauthor=C.+J.+Lauauthor=H.+A.+Zahreddineauthor=W.+H.+Millerauthor=K.+L.+B.+Borden&title=A+Phase+i+Trial+of+Ribavirin+and+Low-Dose+Cytarabine+for+the+Treatment+of+Relapsed+and+Refractory+Acute+Myeloid+Leukemia+with+Elevated+eIF4E&doi=10.3324%2Fhaematol.2014.111245"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2014.111245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2014.111245%26sid%3Dliteratum%253Aachs%26aulast%3DAssouline%26aufirst%3DS.%26aulast%3DCuljkovic-Kraljacic%26aufirst%3DB.%26aulast%3DBergeron%26aufirst%3DJ.%26aulast%3DCaplan%26aufirst%3DS.%26aulast%3DCocolakis%26aufirst%3DE.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DC.%2BJ.%26aulast%3DZahreddine%26aufirst%3DH.%2BA.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DA%2520Phase%2520i%2520Trial%2520of%2520Ribavirin%2520and%2520Low-Dose%2520Cytarabine%2520for%2520the%2520Treatment%2520of%2520Relapsed%2520and%2520Refractory%2520Acute%2520Myeloid%2520Leukemia%2520with%2520Elevated%2520eIF4E%26jtitle%3DHaematologica%26date%3D2015%26volume%3D100%26spage%3De7%26epage%3De9%26doi%3D10.3324%2Fhaematol.2014.111245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagaoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aikata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teraoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatooka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morio, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaoka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiramatsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chayama, K.</span></span> <span> </span><span class="NLM_article-title">The Risks of Hepatocellular Carcinoma Development after HCV Eradication Are Similar between Patients Treated with Peg-Interferon plus Ribavirin and Direct-Acting Antiviral Therapy</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e0182710</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0182710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pone.0182710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28797106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0182710&author=Y.+Nagaokiauthor=M.+Imamuraauthor=H.+Aikataauthor=K.+Daijoauthor=Y.+Teraokaauthor=F.+Hondaauthor=Y.+Nakamuraauthor=M.+Hatookaauthor=R.+Morioauthor=K.+Morioauthor=H.+Kanauthor=H.+Fujinoauthor=T.+Kobayashiauthor=K.+Masakiauthor=A.+Onoauthor=T.+Nakaharaauthor=T.+Kawaokaauthor=M.+Tsugeauthor=A.+Hiramatsuauthor=Y.+Kawakamiauthor=C.+N.+Hayesauthor=D.+Mikiauthor=H.+Ochiauthor=K.+Chayama&title=The+Risks+of+Hepatocellular+Carcinoma+Development+after+HCV+Eradication+Are+Similar+between+Patients+Treated+with+Peg-Interferon+plus+Ribavirin+and+Direct-Acting+Antiviral+Therapy&doi=10.1371%2Fjournal.pone.0182710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy</span></div><div class="casAuthors">Nagaoki, Yuko; Imamura, Michio; Aikata, Hiroshi; Daijo, Kana; Teraoka, Yuji; Honda, Fumi; Nakamura, Yuki; Hatooka, Masahiro; Morio, Reona; Morio, Kei; Kan, Hiromi; Fujino, Hatsue; Kobayashi, Tomoki; Masaki, Keiichi; Ono, Atsushi; Nakahara, Takashi; Kawaoka, Tomokazu; Tsuge, Masataka; Hiramatsu, Akira; Kawakami, Yoshiiku; Hayes, C. Nelson; Miki, Daiki; Ochi, Hidenori; Chayama, Kazuaki</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0182710/1-e0182710/11</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The risk of hepatocellular carcinoma (HCC) development is reduced following viral elimination by interferon therapy in chronic hepatitis C patients.  However, the risk in patients treated with interferon-free direct-acting antivirals (DAAs) is unknown.  We evaluated chronic hepatitis C patients who achieved viral eradication by pegylated-interferon plus ribavirin (PEGIFN/ RBV, n = 244) or daclatasvir plus asunaprevir (DCV/ASV, n = 154) therapy.  None of the patients had prior history of HCC or antiviral therapy.  The median observation period after the end of treatment for the PEG-IFN/RBV and DCV/ASV groups were 96 (range 10-196) and 23 (range 4-78) months, resp.  During the observation period, HCC developed in 13 (5.3%) and 7 (4.5%) patients in the PEG-IFN/RBV and DCV/ASV groups, resp.  The cumulative HCC development rate after 1-, 3- and 5-years (0.4%, 3% and 5% for the PEG-IFN/RBV group and 0.6%, 9% and 9% for the DAA group, resp.) were similar between the two groups.  Propensity score matching anal. also showed no significant difference in HCC development rates between the two groups.  Serum AFP levels decreased to similar levels between PEG-IFN/RBV and DCV/ASV groups following the achievement of viral eradication.  The risk for HCC development following viral eradication by IFN-free DAA therapy may be similar to that in IFN-based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWcmApfKv3X7Vg90H21EOLACvtfcHk0litzAYUYuSStw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOhsLk%253D&md5=353d1780477d468d341c329b42afb158</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0182710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0182710%26sid%3Dliteratum%253Aachs%26aulast%3DNagaoki%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DM.%26aulast%3DAikata%26aufirst%3DH.%26aulast%3DDaijo%26aufirst%3DK.%26aulast%3DTeraoka%26aufirst%3DY.%26aulast%3DHonda%26aufirst%3DF.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DHatooka%26aufirst%3DM.%26aulast%3DMorio%26aufirst%3DR.%26aulast%3DMorio%26aufirst%3DK.%26aulast%3DKan%26aufirst%3DH.%26aulast%3DFujino%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DMasaki%26aufirst%3DK.%26aulast%3DOno%26aufirst%3DA.%26aulast%3DNakahara%26aufirst%3DT.%26aulast%3DKawaoka%26aufirst%3DT.%26aulast%3DTsuge%26aufirst%3DM.%26aulast%3DHiramatsu%26aufirst%3DA.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DHayes%26aufirst%3DC.%2BN.%26aulast%3DMiki%26aufirst%3DD.%26aulast%3DOchi%26aufirst%3DH.%26aulast%3DChayama%26aufirst%3DK.%26atitle%3DThe%2520Risks%2520of%2520Hepatocellular%2520Carcinoma%2520Development%2520after%2520HCV%2520Eradication%2520Are%2520Similar%2520between%2520Patients%2520Treated%2520with%2520Peg-Interferon%2520plus%2520Ribavirin%2520and%2520Direct-Acting%2520Antiviral%2520Therapy%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0182710%26doi%3D10.1371%2Fjournal.pone.0182710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Clinically Relevant Concentration of Anti-Viral Drug Ribavirin Selectively Targets Pediatric Osteosarcoma and Increases Chemosensitivity</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>506</i></span>,  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.10.124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.bbrc.2018.10.124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30454696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVSjurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=506&publication_year=2018&pages=604-610&author=J.+Chenauthor=X.+Xuauthor=J.+Chen&title=Clinically+Relevant+Concentration+of+Anti-Viral+Drug+Ribavirin+Selectively+Targets+Pediatric+Osteosarcoma+and+Increases+Chemosensitivity&doi=10.1016%2Fj.bbrc.2018.10.124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity</span></div><div class="casAuthors">Chen, Jianguo; Xu, Xiaoming; Chen, Junjun</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">506</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">604-610</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using preclin. osteosarcoma cell and xenograft models, we found that ribavirin is active against osteosarcoma bulk and subpopulations with highly proliferative and invasive properties via inhibiting growth, inducing apoptosis and suppressing colony formation.  At the same concns., ribavirin either did not or affected human normal osteoblastic cell and fibroblast cells in a less extent than osteosarcoma cells.  Notably, the combination of ribavirin with doxorubicin resulted in greater efficacy than single drug alone.  The combination completely arrested the osteosarcoma growth in vivo throughout the whole duration of drug treatment.  We further showed that ribavirin acted on osteosarcoma largely via targeting eIF4E.  In addn. to eIF4E, ribavirin also modulated phosphorylation of Erk and expression of EZH2 and Snail without affecting Akt and mTOR.  Lastly, we found that eIF4E expression and phosphorylation were elevated in osteosarcoma compared to normal cells, which might explain the selective anti-osteosarcoma activity of ribavirin. eIF4E depletion mimics the inhibitory effects of ribavirin, further confirm that eIF4E is the essential target of ribavirin in osteosarcoma.  Our work provides fundamental evidence of repurposing ribavirin for the treatment of osteosarcoma.  Our findings also highlight the therapeutic value of inhibiting eIF4E in osteosarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYKuoPqJahs7Vg90H21EOLACvtfcHk0litzAYUYuSStw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVSjurrM&md5=7c7b1bb81577a218c93111b4df15ed04</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.10.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.10.124%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DClinically%2520Relevant%2520Concentration%2520of%2520Anti-Viral%2520Drug%2520Ribavirin%2520Selectively%2520Targets%2520Pediatric%2520Osteosarcoma%2520and%2520Increases%2520Chemosensitivity%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D506%26spage%3D604%26epage%3D610%26doi%3D10.1016%2Fj.bbrc.2018.10.124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G.</span></span> <span> </span><span class="NLM_article-title">Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-NCoV) in Vitro</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">271</span>, <span class="refDoi"> DOI: 10.1038/s41422-020-0282-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41422-020-0282-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=32020029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkt1Ciu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=269-271&author=M.+Wangauthor=R.+Caoauthor=L.+Zhangauthor=X.+Yangauthor=J.+Liuauthor=M.+Xuauthor=Z.+Shiauthor=Z.+Huauthor=W.+Zhongauthor=G.+Xiao&title=Remdesivir+and+Chloroquine+Effectively+Inhibit+the+Recently+Emerged+Novel+Coronavirus+%282019-NCoV%29+in+Vitro&doi=10.1038%2Fs41422-020-0282-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</span></div><div class="casAuthors">Wang, Manli; Cao, Ruiyuan; Zhang, Leike; Yang, Xinglou; Liu, Jia; Xu, Mingyue; Shi, Zhengli; Hu, Zhihong; Zhong, Wu; Xiao, Gengfu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-271</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In Dec. 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million people in central China.  The initial cases were linked to exposures in a seafood market in Wuhan.  The pathogen was soon identified as a novel coronavirus (2019-nCoV), which is closely related to severe acute respiratory syndrome CoV (SARS-CoV).  Currently, there is no specific treatment against the new virus.  Therefore, identifying effective antiviral agents to combat the disease is urgently needed.  In this study, we evaluated the antiviral efficiency of FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir (GS-5734) and favipiravir (T-705) against a clin. isolate of 2019-nCoV in vitro.  Our findings reveal that remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro.  Since these compds. have been used in human patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in human patients suffering from the novel coronavirus disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCnj2tW4TeD7Vg90H21EOLACvtfcHk0lhXl5hI2PGwrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkt1Ciu7k%253D&md5=bdf16b352ebc06bc148ed5c513b7d414</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fs41422-020-0282-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-020-0282-0%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DG.%26atitle%3DRemdesivir%2520and%2520Chloroquine%2520Effectively%2520Inhibit%2520the%2520Recently%2520Emerged%2520Novel%2520Coronavirus%2520%25282019-NCoV%2529%2520in%2520Vitro%26jtitle%3DCell%2520Res.%26date%3D2020%26volume%3D30%26spage%3D269%26epage%3D271%26doi%3D10.1038%2Fs41422-020-0282-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makala, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting Translation: EIF4E as an Emerging Anticancer Drug Target</span>. <i>Expert Rev. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">E2</span>, <span class="refDoi"> DOI: 10.1017/erm.2015.20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1017%2Ferm.2015.20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26775675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVSht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=E2&author=C.+Luauthor=L.+Makalaauthor=D.+Wuauthor=Y.+Cai&title=Targeting+Translation%3A+EIF4E+as+an+Emerging+Anticancer+Drug+Target&doi=10.1017%2Ferm.2015.20"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting translation: eIF4E as an emerging anticancer drug target</span></div><div class="casAuthors">Lu, Chunwan; Makala, Levi; Wu, Daqing; Cai, Yafei</div><div class="citationInfo"><span class="NLM_cas:title">Expert Reviews in Molecular Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e2/1-e2/13</span>CODEN:
                <span class="NLM_cas:coden">ERMMFS</span>;
        ISSN:<span class="NLM_cas:issn">1462-3994</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumor growth, metastasis and therapy resistance.  As an essential regulatory hub in cancer signalling network, many oncogenic signalling pathways appear to converge on eIF4E.  Therefore, targeting eIF4E-mediated cap-dependent translation is considered a promising anticancer strategy.  This paper reviews the strategies that can be used to target eIF4E, highlighting agents that target eIF4E activity at each distinct level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVopkQ3fJ2e7Vg90H21EOLACvtfcHk0lhXl5hI2PGwrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVSht7g%253D&md5=e41aa5dcad1d8914b13e055f9787bc2e</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1017%2Ferm.2015.20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252Ferm.2015.20%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%26aulast%3DMakala%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DY.%26atitle%3DTargeting%2520Translation%253A%2520EIF4E%2520as%2520an%2520Emerging%2520Anticancer%2520Drug%2520Target%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Med.%26date%3D2016%26volume%3D18%26spage%3DE2%26doi%3D10.1017%2Ferm.2015.20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darzynkiewicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekiel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temeriusz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sijuwade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, S. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Eukaryotic Translation by Nucleoside 5 ′-Monophosphate Analogues of mRNA 5 ′-Cap : Changes in N7 Substituent Affect Analogue Activity</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">4771</span>– <span class="NLM_lpage">4778</span>, <span class="refDoi"> DOI: 10.1021/bi00437a038</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00437a038" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaL1MXit1Ohsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1989&pages=4771-4778&author=E.+Darzynkiewiczauthor=J.+Stepinskiauthor=I.+Ekielauthor=C.+Goyerauthor=N.+Sonenbergauthor=A.+Temeriuszauthor=Y.+Jinauthor=T.+Sijuwadeauthor=D.+Haberauthor=S.+M.+Tahara&title=Inhibition+of+Eukaryotic+Translation+by+Nucleoside+5+%E2%80%B2-Monophosphate+Analogues+of+mRNA+5+%E2%80%B2-Cap%E2%80%AF%3A+Changes+in+N7+Substituent+Affect+Analogue+Activity&doi=10.1021%2Fbi00437a038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of eukaryotic translation by nucleoside 5'-monophosphate analogs of mRNA 5'-cap:  changes in N7 substituent affect analog activity</span></div><div class="casAuthors">Darzynkiewicz, Edward; Stepinski, Janusz; Ekiel, Irena; Goyer, Charles; Sonenberg, Nahum; Temeriusz, Andrzej; Jin, Youxin; Sijuwade, Teju; Haber, Dorota; Tahara, Stanley M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4771-8</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">Nucleotide cap analogs of 7-methylguanosine 5'-monophosphate (m7GMP) were synthesized in which the 7-Me moiety was replaced with 7-Et (e7), 7-Pr (p7), 7-isopropyl) (i.p.7), 7-Bu (b7), 7-iso-Bu (ib7), 7-cyclopentyl (cp7), 7-(carboxymethyl) (cm7), 7-benzyl (bn7), 7-(2-phenylethyl) [7-(2-PhEt)], and 7-(1-phenylethyl) [7-(1-PhEt)].  These derivs. were assayed as competitive inhibitors of capped mRNA translation in a reticulocyte lysate.  N7 alkyl and alicyclic substituents larger than Et significantly decreased the inhibitory activity of these cap analogs presumably by decreasing their affinity for cap-binding proteins, which participate in the initiation of translation.  This result defined a max. size for this class of N7 substituents in the nucleotide-binding domain of cap binding proteins.  Like m7GMP, the N7-substituted GMP derivs. synthesized in this study were predominantly in the anti conformation as detd. by 1H NMR analyses.  However, bn7GMP and 7-(2-PhEt)GMP, which have arom. N7 substituents, were more effective than m7GMP as competitive inhibitors of translation.  The increased affinity of bn7GMP for cap-binding proteins was further examd. by synthesis of β-globin mRNA contg. 5'-bn7G, 5'-m7G, or 5'-e7G cap structures.  These modified mRNAs were tested as translation templates.  MRNA capped with bn7G was obsd. to increase the translation activity of the template 1.8-fold relative to that of its m7G-capped mRNA counterpart.  By contrast, e7G-capped mRNA was 25% less active than m7G-capped mRNA.  UV-photocrosslinking of m7G-capped mRNA to cap binding proteins was also inhibited to a greater extent by bn7GMP than by m7GMP or e7GMP.  Thus, from these data the inhibitory effect of bn7GMP was due to its increased affinity for cap binding proteins and not by inhibition at another step of initiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuMgBXQBYumLVg90H21EOLACvtfcHk0lhXl5hI2PGwrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXit1Ohsbo%253D&md5=86f13e891441c287013387807e387ccf</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fbi00437a038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00437a038%26sid%3Dliteratum%253Aachs%26aulast%3DDarzynkiewicz%26aufirst%3DE.%26aulast%3DStepinski%26aufirst%3DJ.%26aulast%3DEkiel%26aufirst%3DI.%26aulast%3DGoyer%26aufirst%3DC.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DTemeriusz%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DSijuwade%26aufirst%3DT.%26aulast%3DHaber%26aufirst%3DD.%26aulast%3DTahara%26aufirst%3DS.%2BM.%26atitle%3DInhibition%2520of%2520Eukaryotic%2520Translation%2520by%2520Nucleoside%25205%2520%25E2%2580%25B2-Monophosphate%2520Analogues%2520of%2520mRNA%25205%2520%25E2%2580%25B2-Cap%25E2%2580%25AF%253A%2520Changes%2520in%2520N7%2520Substituent%2520Affect%2520Analogue%2520Activity%26jtitle%3DBiochemistry%26date%3D1989%26volume%3D28%26spage%3D4771%26epage%3D4778%26doi%3D10.1021%2Fbi00437a038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktas, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahoo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denoyelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabha, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halperin, J. A.</span></span> <span> </span><span class="NLM_article-title">Tumor Suppression by Small Molecule Inhibitorss of Translation Initiation</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.18632%2Foncotarget.598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22935625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BC38bivVCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=869-881&author=L.+Chenauthor=B.+H.+Aktasauthor=Y.+Wangauthor=X.+Heauthor=R.+Sahooauthor=N.+Zhangauthor=S.+Denoyelleauthor=E.+Kabhaauthor=H.+Yangauthor=R.+Y.+Freedmanauthor=J.+G.+Supkoauthor=M.+Chorevauthor=G.+Wagnerauthor=J.+A.+Halperin&title=Tumor+Suppression+by+Small+Molecule+Inhibitorss+of+Translation+Initiation&doi=10.18632%2Foncotarget.598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor suppression by small molecule inhibitors of translation initiation</span></div><div class="casAuthors">Chen Limo; Aktas Bertal H; Wang Yibo; He Xiaoying; Sahoo Rupam; Zhang Nancy; Denoyelle Severine; Kabha Eihab; Yang Hongwei; Freedman Revital Yefidoff; Supko Jeffrey G; Chorev Michael; Wagner Gerhard; Halperin Jose A</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">869-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Translation initiation factors are over-expressed and/or activated in many human cancers and may contribute to their genesis and/or progression.  Removal of physiologic restraints on translation initiation causes malignant transformation.  Conversely, restoration of physiological restrains on translation initiation reverts malignant phenotypes.  Here, we extensively characterize the anti-cancer activity of two small molecule inhibitors of translation initiation: #1181, which targets the eIF2•GTP•Met-tRNAi ternary complex, and 4EGI-1, which targets the eIF4F complex.  In vitro, both molecules inhibit translation initiation, abrogate preferentially translation of mRNAs coding for oncogenic proteins, and inhibit proliferation of human cancer cells.  In vivo, both #1181 and 4EGI-1 strongly inhibit growth of human breast and melanoma cancer xenografts without any apparent macroscopic- or microscopic-toxicity.  Mechanistically, #1181 phosphorylates eIF2α while 4EGI-1 disrupts eIF4G/eIF4E interaction in the tumors excised from mice treated with these agents.  These data indicate that inhibition of translation initiation is a new paradigm in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWEflM3ymwKbYtC3U5jeOifW6udTcc2eZ9zJNZYK0sX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bivVCmsg%253D%253D&md5=eead064f97595ae05a97ed9af42f2c40</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.598%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAktas%26aufirst%3DB.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DSahoo%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DDenoyelle%26aufirst%3DS.%26aulast%3DKabha%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DFreedman%26aufirst%3DR.%2BY.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DChorev%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DG.%26aulast%3DHalperin%26aufirst%3DJ.%2BA.%26atitle%3DTumor%2520Suppression%2520by%2520Small%2520Molecule%2520Inhibitorss%2520of%2520Translation%2520Initiation%26jtitle%3DOncotarget%26date%3D2012%26volume%3D3%26spage%3D869%26epage%3D881%26doi%3D10.18632%2Foncotarget.598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNae, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkinshaw, M. D.</span></span> <span> </span><span class="NLM_article-title">Crystallographic and Mass Spectrometric Characterisation of eIF4E with N7-Alkylated Cap Derivatives</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2007.06.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.jmb.2007.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17631896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFeqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2007&pages=7-15&author=C.+J.+Brownauthor=I.+McNaeauthor=P.+M.+Fischerauthor=M.+D.+Walkinshaw&title=Crystallographic+and+Mass+Spectrometric+Characterisation+of+eIF4E+with+N7-Alkylated+Cap+Derivatives&doi=10.1016%2Fj.jmb.2007.06.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallographic and Mass Spectrometric Characterization of eIF4E with N7-alkylated Cap Derivatives</span></div><div class="casAuthors">Brown, Christopher J.; McNae, Iain; Fischer, Peter M.; Walkinshaw, Malcolm D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-15</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Structural complexes of the eukaryotic translation initiation factor 4E (eIF4E) with a series of N7-alkylated guanosine deriv. mRNA cap analog structures have been characterized.  Mass spectrometry was used to det. apparent gas-phase equil. dissocn. consts. (Kd) values of 0.15 μM, 13.6 μM, and 55.7 μM for eIF4E with 7-methyl-GTP (m7GTP), GTP, and GMP, resp.  For tight and specific binding to the eIF4E mononucleotide binding site, there seems to be a clear requirement for guanosine derivs. to possess both the delocalized pos. charge of the N7-methylated guanine system and at least one phosphate group.  We show that the N7-benzylated monophosphates 7-benzyl-GMP (Bn7GMP) and 7-(p-fluorobenzyl)-GMP (FBn7GMP) bind eIF4E substantially more tightly than non-N7-alkylated guanosine derivs. (Kd values of 7.0 μM and 2.0 μM, resp.).  The eIF4E complex crystal structures with Bn7GMP and FBn7GMP show that addnl. favorable contacts of the benzyl groups with eIF4E contribute binding energy that compensates for loss of the β and γ-phosphates.  The N7-benzyl groups pack into a hydrophobic pocket behind the two tryptophan side-chains that are involved in the cation-π stacking interaction between the cap and the eIF4E mononucleotide binding site.  This pocket is formed by an induced fit in which one of the tryptophan residues involved in cap binding flips through 180° relative to structures with N7-methylated cap derivs.  This and other observations made here will be useful in the design of new families of eIF4E inhibitors, which may have potential therapeutic applications in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIioOMhX9XeLVg90H21EOLACvtfcHk0lh2amGcqisA8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFeqsrc%253D&md5=8d7647bacc756db5265970fb6312e2bd</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2007.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2007.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DC.%2BJ.%26aulast%3DMcNae%26aufirst%3DI.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWalkinshaw%26aufirst%3DM.%2BD.%26atitle%3DCrystallographic%2520and%2520Mass%2520Spectrometric%2520Characterisation%2520of%2520eIF4E%2520with%2520N7-Alkylated%2520Cap%2520Derivatives%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2007%26volume%3D372%26spage%3D7%26epage%3D15%26doi%3D10.1016%2Fj.jmb.2007.06.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benyumov, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdulov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polunovsky, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Nontoxic Chemical Interdiction of the Epithelial-to-Mesenchymal Transition by Targeting Cap-Dependent Translation</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1021/cb9000475</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb9000475" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFKrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=367-377&author=B.+Ghoshauthor=A.+O.+Benyumovauthor=P.+Ghoshauthor=Y.+Jiaauthor=S.+Avdulovauthor=P.+S.+Dahlbergauthor=M.+Petersonauthor=K.+Smithauthor=V.+A.+Polunovskyauthor=P.+B.+Bittermanauthor=C.+R.+Wagner&title=Nontoxic+Chemical+Interdiction+of+the+Epithelial-to-Mesenchymal+Transition+by+Targeting+Cap-Dependent+Translation&doi=10.1021%2Fcb9000475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation</span></div><div class="casAuthors">Ghosh, Brahma; Benyumov, Alexey O.; Ghosh, Phalguni; Jia, Yan; Avdulov, Svetlana; Dahlberg, Peter S.; Peterson, Mark; Smith, Karen; Polunovsky, Vitaly A.; Bitterman, Peter B.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">367-377</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Normal growth and development depends upon high fidelity regulation of cap-dependent translation initiation, a process that is usurped and redirected in cancer to mediate acquisition of malignant properties.  The epithelial-to-mesenchymal transition (EMT) is a key translationally regulated step in the development of epithelial cancers and pathol. tissue fibrosis.  To date, no compds. targeting EMT have been developed.  Here we report the synthesis of a novel class of histidine triad nucleotide binding protein (HINT)-dependent pronucleotides that interdict EMT by neg. regulating the assocn. of eIF4E with the mRNA cap.  Compd. eIF4E inhibitor-1 potently inhibited cap-dependent translation in a dose-dependent manner in zebrafish embryos without causing developmental abnormalities and prevented eIF4E from triggering EMT in zebrafish ectoderm explants without toxicity.  Metab. studies with whole cell lysates demonstrated that the prodrug was rapidly converted into 7-BnGMP.  Thus we have successfully developed the first nontoxic small mol. able to inhibit EMT, a key process in the development of epithelial cancer and tissue fibrosis, by targeting the interaction of eIF4E with the mRNA cap and demonstrated the tractability of zebrafish as a model organism for studying agents that modulate EMT.  Our work provides strong motivation for the continued development of compds. designed to normalize cap-dependent translation as novel chemo-preventive agents and therapeutics for cancer and fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor5zGOqKEr-rVg90H21EOLACvtfcHk0lh2amGcqisA8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFKrtr0%253D&md5=de7ff3316fc7c8fbaba2b9ef52b5376c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fcb9000475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb9000475%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DB.%26aulast%3DBenyumov%26aufirst%3DA.%2BO.%26aulast%3DGhosh%26aufirst%3DP.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DAvdulov%26aufirst%3DS.%26aulast%3DDahlberg%26aufirst%3DP.%2BS.%26aulast%3DPeterson%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DPolunovsky%26aufirst%3DV.%2BA.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DNontoxic%2520Chemical%2520Interdiction%2520of%2520the%2520Epithelial-to-Mesenchymal%2520Transition%2520by%2520Targeting%2520Cap-Dependent%2520Translation%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2009%26volume%3D4%26spage%3D367%26epage%3D377%26doi%3D10.1021%2Fcb9000475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, B.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jefferson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popescu, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, S. H.</span></span> <span> </span><span class="NLM_article-title">Aberrant Gene Expression in Human Non Small Cell Lung Carcinoma Cells Exposed to Demethylating Agent 5-Aza-2′-Deoxycytidine</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1593/neo.03490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1593%2Fneo.03490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=15256063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslWlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=412-419&author=B.-Z.+Yuanauthor=A.+M.+Jeffersonauthor=N.+C.+Popescuauthor=S.+H.+Reynolds&title=Aberrant+Gene+Expression+in+Human+Non+Small+Cell+Lung+Carcinoma+Cells+Exposed+to+Demethylating+Agent+5-Aza-2%E2%80%B2-Deoxycytidine&doi=10.1593%2Fneo.03490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-Aza-2'-deoxycytidine</span></div><div class="casAuthors">Yuan, Bao-Zhu; Jefferson, Amy M.; Popescu, Nicholas C.; Reynolds, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">412-419</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">The identification of genes undergoing genetic or epigenetic alterations and contributing to the development of cancer is crit. to our understanding of the mol. mechanisms of carcinogenesis.  A new approach in identifying alterations of genes that might be relevant to the process of tumor development was used in this study by examg. the gene expression profile in human lung cancer cells exposed to 5-aza-2'-deoxycytidine (5-aza-dC).  A cDNA array anal. was carried out on 5-aza-dC-treated and untreated non small cell lung cancer (NSCLC) cell line NCl-H522.  Sixteen and 14 genes were upregulated and downregulated, resp., by 5-aza-dC treatment.  Among them, downregulation of tyrosine protein kinase ABL2 (ABL2) gene and upregulation of hint/protein kinase C inhibitor 1 (Hint/PKCI-1), DVL1, TIMP-1, and TRP-1 genes were found in expanded observations in two or three of five 5-aza-dC-treated NSCLC cell lines.  Among these genes, we found that cDNA transfer of Hint/PKCl-1 resulted in a significant in vitro growth inhibition in two cell lines exhibiting 5-aza-dC-induced upregulation of Hint/PKCI-1 and significantly reduced in vivo tumorigenicity of one NSCLC cell line.  Hint/PKCl-1, which is the only other characterized human histidine triad (HIT) nucleotide-binding protein in addn. to tumor-suppressor gene FHIT, might be involved in lung carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprJ-4_eHK52LVg90H21EOLACvtfcHk0lh5NrKxI9uHHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslWlu7s%253D&md5=48d6f484b08260d3b61c7ed939f97f15</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1593%2Fneo.03490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.03490%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DB.-Z.%26aulast%3DJefferson%26aufirst%3DA.%2BM.%26aulast%3DPopescu%26aufirst%3DN.%2BC.%26aulast%3DReynolds%26aufirst%3DS.%2BH.%26atitle%3DAberrant%2520Gene%2520Expression%2520in%2520Human%2520Non%2520Small%2520Cell%2520Lung%2520Carcinoma%2520Cells%2520Exposed%2520to%2520Demethylating%2520Agent%25205-Aza-2%25E2%2580%25B2-Deoxycytidine%26jtitle%3DNeoplasia%26date%3D2004%26volume%3D6%26spage%3D412%26epage%3D419%26doi%3D10.1593%2Fneo.03490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdulov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benyumov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hergert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braziunas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borok, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span> <span> </span><span class="NLM_article-title">Transforming Growth Factor-B1 Induced Epithelial Mesenchymal Transition Is Blocked by a Chemical Antagonist of Translation Factor eIF4E</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">18233</span>, <span class="refDoi"> DOI: 10.1038/srep18233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fsrep18233" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=18233&author=K.+A.+Smithauthor=B.+Zhouauthor=S.+Avdulovauthor=A.+Benyumovauthor=M.+Petersonauthor=Y.+Liuauthor=A.+Okonauthor=P.+Hergertauthor=J.+Braziunasauthor=C.+R.+Wagnerauthor=Z.+Borokauthor=P.+B.+Bitterman&title=Transforming+Growth+Factor-B1+Induced+Epithelial+Mesenchymal+Transition+Is+Blocked+by+a+Chemical+Antagonist+of+Translation+Factor+eIF4E&doi=10.1038%2Fsrep18233"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fsrep18233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep18233%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DAvdulov%26aufirst%3DS.%26aulast%3DBenyumov%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DOkon%26aufirst%3DA.%26aulast%3DHergert%26aufirst%3DP.%26aulast%3DBraziunas%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26aulast%3DBorok%26aufirst%3DZ.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26atitle%3DTransforming%2520Growth%2520Factor-B1%2520Induced%2520Epithelial%2520Mesenchymal%2520Transition%2520Is%2520Blocked%2520by%2520a%2520Chemical%2520Antagonist%2520of%2520Translation%2520Factor%2520eIF4E%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D5%26spage%3D18233%26doi%3D10.1038%2Fsrep18233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span> <span> </span><span class="NLM_article-title">Drugs and Targets in Fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">855</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3389%2Ffphar.2017.00855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=29218009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFems77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=855&author=X.+Liauthor=L.+Zhuauthor=B.+Wangauthor=M.+Yuanauthor=R.+Zhu&title=Drugs+and+Targets+in+Fibrosis&doi=10.3389%2Ffphar.2017.00855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs and targets in fibrosis</span></div><div class="casAuthors">Li, Xiaoyi; Zhu, Lixin; Wang, Beibei; Yuan, Meifei; Zhu, Ruixin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">855/1-855/21</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Fibrosis contributes to the development of many diseases and many target mols. are involved in fibrosis.  Currently, the majority of fibrosis treatment strategies are limited to specific diseases or organs.  However, accumulating evidence demonstrates great similarities among fibroproliferative diseases, and more and more drugs are proved to be effective anti-fibrotic therapies across different diseases and organs.  Here we comprehensively review the current knowledge on the pathol. mechanisms of fibrosis, and divide factors mediating fibrosis progression into extracellular and intracellular groups.  Furthermore, we systematically summarize both single and multiple component drugs that target fibrosis.  Future directions of fibrosis drug discovery are also proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYWFKoJKIMZ7Vg90H21EOLACvtfcHk0lh5NrKxI9uHHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFems77P&md5=ce450251ad612e940967fde259549692</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00855%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DR.%26atitle%3DDrugs%2520and%2520Targets%2520in%2520Fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D855%26doi%3D10.3389%2Ffphar.2017.00855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Treatment of Breast and Lung Cancer Cells with a N-7 Benzyl Guanosine Monophosphate Tryptamine Phosphoramidate Pronucleotide (4Ei-1) Results in Chemosensitization to Gemcitabine and Induced EIF4E Proteasomal Degradation</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1021/mp300699d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300699d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=523-531&author=S.+Liauthor=Y.+Jiaauthor=B.+Jacobsonauthor=J.+McCauleyauthor=R.+Kratzkeauthor=P.+B.+Bittermanauthor=C.+R.+Wagner&title=Treatment+of+Breast+and+Lung+Cancer+Cells+with+a+N-7+Benzyl+Guanosine+Monophosphate+Tryptamine+Phosphoramidate+Pronucleotide+%284Ei-1%29+Results+in+Chemosensitization+to+Gemcitabine+and+Induced+EIF4E+Proteasomal+Degradation&doi=10.1021%2Fmp300699d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Breast and Lung Cancer Cells with a N-7 Benzyl Guanosine Monophosphate Tryptamine Phosphoramidate Pronucleotide (4Ei-1) Results in Chemosensitization to Gemcitabine and Induced eIF4E Proteasomal Degradation</span></div><div class="casAuthors">Li, Shui; Jia, Yan; Jacobson, Blake; McCauley, Joel; Kratzke, Robert; Bitterman, Peter B.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">523-531</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of cancer and fibrotic diseases has been shown to be highly dependent on disregulation of cap-dependent translation.  Binding protein eIF4E to N7-methylated guanosine capped mRNA has been found to be the rate-limiting step governing translation initiation, and therefore represents an attractive target for drug discovery.  Our group has found that 7-benzyl guanosine monophosphate (7Bn-GMP) is a potent antagonist of eIF4E cap binding (Kd = 0.8 μM).  Recent X-ray crystallog. studies have revealed that the cap-dependent pocket undergoes a unique structural change in order to accommodate the benzyl group.  Unfortunately, 7Bn-GMP is not cell permeable.  Recently, we have prepd. a tryptamine phosphoramidate prodrug of 7Bn-GMP, 4Ei-1, and shown that it is a substrate for human histidine triad nucleotide binding protein (hHINT1) and inhibits eIF4E initiated epithelial-mesenchymal transition (EMT) by Zebra fish embryo cells.  To assess the intracellular uptake of 4Ei-1 and conversion to 7Bn-GMP by cancer cells, we developed a sensitive assay using LC-ESI-MS/MS for the intracellular quantitation of 4Ei-1 and 7Bn-GMP.  When incubated with the breast cancer cell line MDA-231 or lung cancer cell lines H460, H383 and H2009, 4Ei-1 was found to be rapidly internalized and converted to 7Bn-GMP.  Since oncogenic mRNAs are predicted to have the highest eIF4E requirement for translation, we carried out chemosensitization studies with 4Ei-1.  The prodrug was found to chemosensitize both breast and lung cancer cells to nontoxic levels of gemcitabine.  Further mechanistic studies revealed that the expressed levels of eIF4E were substantially reduced in cells treated with 4Ei-1 in a dose-dependent manner.  The levels of eI4E could be restored by treatment with the proteasome inhibitor MG-132.  Taken together, our results demonstrate that 4Ei-1 is likely to inhibit translation initiation by eIF4E cap binding by both antagonizing eIF4E cap binding and initiating eIF4E proteasomal degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTFyifb06Lu7Vg90H21EOLACvtfcHk0lhH-AOWaOHlGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGgsg%253D%253D&md5=e836b33df2f990b7d42f961a973658c7</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fmp300699d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300699d%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DJacobson%26aufirst%3DB.%26aulast%3DMcCauley%26aufirst%3DJ.%26aulast%3DKratzke%26aufirst%3DR.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DTreatment%2520of%2520Breast%2520and%2520Lung%2520Cancer%2520Cells%2520with%2520a%2520N-7%2520Benzyl%2520Guanosine%2520Monophosphate%2520Tryptamine%2520Phosphoramidate%2520Pronucleotide%2520%25284Ei-1%2529%2520Results%2520in%2520Chemosensitization%2520to%2520Gemcitabine%2520and%2520Induced%2520EIF4E%2520Proteasomal%2520Degradation%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D523%26epage%3D531%26doi%3D10.1021%2Fmp300699d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okon, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, R. A.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Inhibition of Oncogenic Eukaryotic Protein Translation in Mesothelioma Cells</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0076-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs10637-014-0076-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24711125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Whs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=598-603&author=E.+Z.+Chenauthor=B.+A.+Jacobsonauthor=M.+R.+Patelauthor=A.+M.+Okonauthor=S.+Liauthor=K.+Xiongauthor=A.+J.+Vaidyaauthor=P.+B.+Bittermanauthor=C.+R.+Wagnerauthor=R.+A.+Kratzke&title=Small-Molecule+Inhibition+of+Oncogenic+Eukaryotic+Protein+Translation+in+Mesothelioma+Cells&doi=10.1007%2Fs10637-014-0076-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells</span></div><div class="casAuthors">Chen, Esther Z.; Jacobson, Blake A.; Patel, Manish R.; Okon, Aniekan M.; Li, Shui; Xiong, Kerry; Vaidya, Abhishek J.; Bitterman, Peter B.; Wagner, Carston R.; Kratzke, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">598-603</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Deranged cap-mediated translation is implicated in the genesis, maintenance and progression of many human cancers including mesothelioma.  In this study, disrupting the eIF4F complex by antagonizing the eIF4E-mRNA-cap interaction is assessed as a therapy for mesothelioma.  Mesothelioma cells were treated with 4Ei-1, a membrane permeable prodrug that when converted to the active drug, 7-benzyl guanosine monophosphate (7Bn-GMP) displaces capped mRNAs from the eIF4F complex.  Colony formation was measured in mesothelioma treated with 4Ei-1 alone or combined with pemetrexed.  Proliferation was examd. in cells treated with 4Ei-1.  Binding to a synthetic cap-analog was used to study the strength of eIF4F complex activation in lysates exposed to 4Ei-1. 4Ei-1 treatment resulted in a dose dependent decrease in colony formation and cell viability.  Combination therapy of 4Ei-1 with pemetrexed further reduced colony no.  Formation of eIF4F cap-complex decreased in response to 4Ei-1 exposure. 4Ei-1 is a novel prodrug that reduces proliferation, represses colony formation, diminishes assocn. of eIF4F with the mRNA cap, and sensitizes mesothelioma cells to pemetrexed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMe8AjZSME1rVg90H21EOLACvtfcHk0lhH-AOWaOHlGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Whs7vI&md5=7f4419e21132fe7c4ba3fb147194e122</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0076-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0076-7%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DE.%2BZ.%26aulast%3DJacobson%26aufirst%3DB.%2BA.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DOkon%26aufirst%3DA.%2BM.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DXiong%26aufirst%3DK.%26aulast%3DVaidya%26aufirst%3DA.%2BJ.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26aulast%3DKratzke%26aufirst%3DR.%2BA.%26atitle%3DSmall-Molecule%2520Inhibition%2520of%2520Oncogenic%2520Eukaryotic%2520Protein%2520Translation%2520in%2520Mesothelioma%2520Cells%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2014%26volume%3D32%26spage%3D598%26epage%3D603%26doi%3D10.1007%2Fs10637-014-0076-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuesta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balius, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Lysine-Targeted EIF4E Inhibitors through Covalent Docking</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">4960</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b10377</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b10377" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlOksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=4960-4964&author=X.+Wanauthor=T.+Yangauthor=A.+Cuestaauthor=X.+Pangauthor=T.+E.+Baliusauthor=J.+J.+Irwinauthor=B.+K.+Shoichetauthor=J.+Taunton&title=Discovery+of+Lysine-Targeted+EIF4E+Inhibitors+through+Covalent+Docking&doi=10.1021%2Fjacs.9b10377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking</span></div><div class="casAuthors">Wan, Xiaobo; Yang, Tangpo; Cuesta, Adolfo; Pang, Xiaming; Balius, Trent E.; Irwin, John J.; Shoichet, Brian K.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4960-4964</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Eukaryotic translation initiation factor 4E (eIF4E) binds the m7GTP cap structure at the 5'-end of mRNAs, stimulating the translation of proteins implicated in cancer cell growth and metastasis. eIF4E is a notoriously challenging target, and most of the reported inhibitors are neg. charged guanine analogs with negligible cell permeability.  To overcome these challenges, we envisioned a covalent targeting strategy.  As there are no cysteines near the eIF4E cap binding site, we developed a covalent docking approach focused on lysine.  Taking advantage of a "make-on-demand" virtual library, we used covalent docking to identify arylsulfonyl fluorides that target a noncatalytic lysine (Lys162) in eIF4E.  Guided by cocrystal structures, we elaborated arylsulfonyl fluoride 2 to 12, which to our knowledge is the first covalent eIF4E inhibitor with cellular activity.  In addn. to providing a new tool for acutely inactivating eIF4E in cells, our computational approach may offer a general strategy for developing selective lysine-targeted covalent ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8PHp9f-vKHbVg90H21EOLACvtfcHk0lhH-AOWaOHlGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlOksb8%253D&md5=4e014562ef811842104e9999dbe6da67</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b10377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b10377%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DCuesta%26aufirst%3DA.%26aulast%3DPang%26aufirst%3DX.%26aulast%3DBalius%26aufirst%3DT.%2BE.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Lysine-Targeted%2520EIF4E%2520Inhibitors%2520through%2520Covalent%2520Docking%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26spage%3D4960%26epage%3D4964%26doi%3D10.1021%2Fjacs.9b10377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moerke, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reibarkh, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahmy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, J. D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degterev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halperin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.11.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.cell.2006.11.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17254965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=257-267&author=N.+J.+Moerkeauthor=H.+Aktasauthor=H.+Chenauthor=S.+Cantelauthor=M.+Y.+Reibarkhauthor=A.+Fahmyauthor=J.+D.+D.+Grossauthor=A.+Degterevauthor=J.+Yuanauthor=M.+Chorevauthor=J.+A.+Halperinauthor=G.+Wagner&title=Small-Molecule+Inhibition+of+the+Interaction+between+the+Translation+Initiation+Factors+eIF4E+and+eIF4G&doi=10.1016%2Fj.cell.2006.11.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G</span></div><div class="casAuthors">Moerke, Nathan J.; Aktas, Huseyin; Chen, Han; Cantel, Sonia; Reibarkh, Mikhail Y.; Fahmy, Amr; Gross, John D.; Degterev, Alexei; Yuan, Junying; Chorev, Michael; Halperin, Jose A.; Wagner, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-267</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Assembly of the eIF4E/eIF4G complex has a central role in the regulation of gene expression at the level of translation initiation.  This complex is regulated by the 4E-BPs, which compete with eIF4G for binding to eIF4E and which have tumor-suppressor activity.  To pharmacol. mimic 4E-BP function the authors developed a high-throughput screening assay for identifying small-mol. inhibitors of the eIF4E/eIF4G interaction.  The most potent compd. identified, 4EGI-1, binds eIF4E, disrupts eIF4E/eIF4G assocn., and inhibits cap-dependent translation but not initiation factor-independent translation.  While 4EGI-1 displaces eIF4G from eIF4E, it effectively enhances 4E-BP1 assocn. both in vitro and in cells.  4EGI-1 inhibits cellular expression of oncogenic proteins encoded by weak mRNAs, exhibits activity against multiple cancer cell lines, and appears to have a preferential effect on transformed vs. nontransformed cells.  The identification of this compd. provides a new tool for studying translational control and establishes a possible new strategy for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI5WbK0F9CirVg90H21EOLACvtfcHk0li2qy-OQ-6nWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOru7Y%253D&md5=e235725479edd70cd050a104a71b5fe2</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.11.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.11.046%26sid%3Dliteratum%253Aachs%26aulast%3DMoerke%26aufirst%3DN.%2BJ.%26aulast%3DAktas%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCantel%26aufirst%3DS.%26aulast%3DReibarkh%26aufirst%3DM.%2BY.%26aulast%3DFahmy%26aufirst%3DA.%26aulast%3DGross%26aufirst%3DJ.%2BD.%2BD.%26aulast%3DDegterev%26aufirst%3DA.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DChorev%26aufirst%3DM.%26aulast%3DHalperin%26aufirst%3DJ.%2BA.%26aulast%3DWagner%26aufirst%3DG.%26atitle%3DSmall-Molecule%2520Inhibition%2520of%2520the%2520Interaction%2520between%2520the%2520Translation%2520Initiation%2520Factors%2520eIF4E%2520and%2520eIF4G%26jtitle%3DCell%26date%3D2007%26volume%3D128%26spage%3D257%26epage%3D267%26doi%3D10.1016%2Fj.cell.2006.11.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabha, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takrouri, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luna, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthanari, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Mias, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yefidoff-Freedman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktas, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halperin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span> <span> </span><span class="NLM_article-title">Structure of the Eukaryotic Translation Initiation Factor EIF4E in Complex with 4EGI-1 Reveals an Allosteric Mechanism for Dissociating EIF4G</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">E3187</span>, <span class="refDoi"> DOI: 10.1073/pnas.1410250111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.1410250111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25049413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyqtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E3187&author=E.+Papadopoulosauthor=S.+Jenniauthor=E.+Kabhaauthor=K.+J.+Takrouriauthor=T.+Yiauthor=N.+Salviauthor=R.+E.+Lunaauthor=E.+Gavathiotisauthor=P.+Mahalingamauthor=H.+Arthanariauthor=R.+Rodriguez-Miasauthor=R.+Yefidoff-Freedmanauthor=B.+H.+Aktasauthor=M.+Chorevauthor=J.+A.+Halperinauthor=G.+Wagner&title=Structure+of+the+Eukaryotic+Translation+Initiation+Factor+EIF4E+in+Complex+with+4EGI-1+Reveals+an+Allosteric+Mechanism+for+Dissociating+EIF4G&doi=10.1073%2Fpnas.1410250111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G</span></div><div class="casAuthors">Papadopoulos, Evangelos; Jenni, Simon; Kabha, Eihab; Takrouri, Khuloud J.; Yi, Tingfang; Salvi, Nicola; Luna, Rafael E.; Gavathiotis, Evripidis; Mahalingam, Poornachandran; Arthanari, Haribabu; Rodriguez-Mias, Ricard; Yefidoff-Freedman, Revital; Aktas, Bertal H.; Chorev, Michael; Halperin, Jose A.; Wagner, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">E3187-E3195</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The interaction of the eukaryotic translation initiation factor eIF4E with the initiation factor eIF4G recruits the 40S ribosomal particle to the 5' end of mRNAs, facilitates scanning to the AUG start codon, and is crucial for eukaryotic translation of nearly all genes.  Efficient recruitment of the 40S particle is particularly important for translation of mRNAs encoding oncoproteins and growth-promoting factors, which often harbor complex 5' UTRs and require efficient initiation.  Thus, inhibiting the eIF4E/eIF4G interaction has emerged as a previously unpursued route for developing anticancer agents.  Indeed, we discovered small-mol. inhibitors of this eIF4E/eIF4G interaction (4EGIs) that inhibit translation initiation both in vitro and in vivo and were used successfully in numerous cancer-biol. and neurobiol. studies.  However, their detailed mol. mechanism of action has remained elusive.  Here, we show that the eIF4E/eIF4G inhibitor 4EGI-1 acts allosterically by binding to a site on eIF4E distant from the eIF4G binding epitope.  Data from NMR mapping and high-resoln. crystal structures are congruent with this mechanism, where 4EGI-1 attaches to a hydrophobic pocket of eIF4E between β-sheet2 (L60-T68) and α-helix1 (E69-N77), causing localized conformational changes mainly in the H78-L85 region.  It acts by unfolding a short 310-helix (S82-L85) while extending α-helix1 by one turn (H78-S82).  This unusual helix rearrangement has not been seen in any previous eIF4E structure and reveals elements of an allosteric inhibition mechanism leading to the dislocation of eIF4G from eIF4E.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5rQr0p_Vxv7Vg90H21EOLACvtfcHk0li2qy-OQ-6nWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyqtLrN&md5=49e325d40120b071e410c27d78790ebc</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1410250111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1410250111%26sid%3Dliteratum%253Aachs%26aulast%3DPapadopoulos%26aufirst%3DE.%26aulast%3DJenni%26aufirst%3DS.%26aulast%3DKabha%26aufirst%3DE.%26aulast%3DTakrouri%26aufirst%3DK.%2BJ.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DSalvi%26aufirst%3DN.%26aulast%3DLuna%26aufirst%3DR.%2BE.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DMahalingam%26aufirst%3DP.%26aulast%3DArthanari%26aufirst%3DH.%26aulast%3DRodriguez-Mias%26aufirst%3DR.%26aulast%3DYefidoff-Freedman%26aufirst%3DR.%26aulast%3DAktas%26aufirst%3DB.%2BH.%26aulast%3DChorev%26aufirst%3DM.%26aulast%3DHalperin%26aufirst%3DJ.%2BA.%26aulast%3DWagner%26aufirst%3DG.%26atitle%3DStructure%2520of%2520the%2520Eukaryotic%2520Translation%2520Initiation%2520Factor%2520EIF4E%2520in%2520Complex%2520with%25204EGI-1%2520Reveals%2520an%2520Allosteric%2520Mechanism%2520for%2520Dissociating%2520EIF4G%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3DE3187%26doi%3D10.1073%2Fpnas.1410250111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthanari, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Mias, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Léger-Abraham, M.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanism of the Dual Activity of 4EGI-1: Dissociating EIF4G from EIF4E but Stabilizing the Binding of Unphosphorylated 4E-BP1</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">E4036</span>– <span class="NLM_lpage">E4045</span>, <span class="refDoi"> DOI: 10.1073/pnas.1512118112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.1512118112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26170285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFGktr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=E4036-E4045&author=N.+Sekiyamaauthor=H.+Arthanariauthor=E.+Papadopoulosauthor=R.+A.+Rodriguez-Miasauthor=G.+Wagnerauthor=M.+L%C3%A9ger-Abraham&title=Molecular+Mechanism+of+the+Dual+Activity+of+4EGI-1%3A+Dissociating+EIF4G+from+EIF4E+but+Stabilizing+the+Binding+of+Unphosphorylated+4E-BP1&doi=10.1073%2Fpnas.1512118112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of the dual activity of 4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1</span></div><div class="casAuthors">Sekiyama, Naotaka; Arthanari, Haribabu; Papadopoulos, Evangelos; Rodriguez-Mias, Ricard A.; Wagner, Gerhard; Leger-Abraham, Melissa</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">E4036-E4045</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The eIF4E-binding protein (4E-BP) is a phosphorylation-dependent regulator of protein synthesis.  The nonphosphorylated or minimally phosphorylated form binds translation initiation factor 4E (eIF4E), preventing binding of eIF4G and the recruitment of the small ribosomal subunit.  Signaling events stimulate serial phosphorylation of 4E-BP, primarily by mammalian target of rapamycin complex 1 (mTORC1) at residues T37/T46, followed by T70 and S65.  Hyperphosphorylated 4E-BP dissocs. from eIF4E, allowing eIF4E to interact with eIF4G and translation initiation to resume.  Because overexpression of eIF4E is linked to cellular transformation, 4E-BP is a tumor suppressor, and up-regulation of its activity is a goal of interest for cancer therapy.  A recently discovered small mol., eIF4E/eIF4G interaction inhibitor 1 (4EGI-1), disrupts the eIF4E/eIF4G interaction and promotes binding of 4E-BP1 to eIF4E.  Structures of 14- to 16-residue 4E-BP fragments bound to eIF4E contain the eIF4E consensus binding motif, 54YXXXXLΦ60 (motif 1) but lack known phosphorylation sites.  We report here a 2.1-Å crystal structure of mouse eIF4E in complex with m7GTP and with a fragment of human 4E-BP1, extended C-terminally from the consensus-binding motif (4E-BP150-84).  The extension, which includes a proline-turn-helix segment (motif 2) followed by a loop of irregular structure, reveals the location of two phosphorylation sites (S65 and T70).  Our major finding is that the C-terminal extension (motif 3) is crit. to 4E-BP1-mediated cell cycle arrest and that it partially overlaps with the binding site of 4EGI-1.  The binding of 4E-BP1 and 4EGI-1 to eIF4E is therefore not mutually exclusive, and both ligands contribute to shift the equil. toward the inhibition of translation initiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5UX9gpOLePrVg90H21EOLACvtfcHk0li2qy-OQ-6nWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFGktr3K&md5=4b08a4764b5c8b6557f9266402c00dd2</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1512118112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1512118112%26sid%3Dliteratum%253Aachs%26aulast%3DSekiyama%26aufirst%3DN.%26aulast%3DArthanari%26aufirst%3DH.%26aulast%3DPapadopoulos%26aufirst%3DE.%26aulast%3DRodriguez-Mias%26aufirst%3DR.%2BA.%26aulast%3DWagner%26aufirst%3DG.%26aulast%3DL%25C3%25A9ger-Abraham%26aufirst%3DM.%26atitle%3DMolecular%2520Mechanism%2520of%2520the%2520Dual%2520Activity%2520of%25204EGI-1%253A%2520Dissociating%2520EIF4G%2520from%2520EIF4E%2520but%2520Stabilizing%2520the%2520Binding%2520of%2520Unphosphorylated%25204E-BP1%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3DE4036%26epage%3DE4045%26doi%3D10.1073%2Fpnas.1512118112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanggou, S.</span></span> <span> </span><span class="NLM_article-title">Anti-Cancer Effect of Cap-Translation Inhibitor 4EGI-1 in Human Glioma U87 Cells: Involvement of Mitochondrial Dysfunction and ER Stress</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1159/000453158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1159%2F000453158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27941351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSmtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2016&pages=1013-1028&author=M.+Wuauthor=C.+Zhangauthor=X.+J.+Liauthor=Q.+Liuauthor=S.+Wanggou&title=Anti-Cancer+Effect+of+Cap-Translation+Inhibitor+4EGI-1+in+Human+Glioma+U87+Cells%3A+Involvement+of+Mitochondrial+Dysfunction+and+ER+Stress&doi=10.1159%2F000453158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-Cancer Effect of Cap-Translation Inhibitor 4EGI-1 in Human Glioma U87 Cells: Involvement of Mitochondrial Dysfunction and ER Stress</span></div><div class="casAuthors">Wu, Ming; Zhang, Chi; Li, Xue-Jun; Liu, Qing; Wanggou, Siyi</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1013-1028</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Cancer cells are frequently addicted to deregulated oncogenic protein translation that usually arises as a consequence of increased signaling flux from eIF4F activation.  The small mol. 4EG-I, a potent inhibitor of translation initiation through disrupting eIF4E/eIF4G interaction, has been shown to exert anticancer effects in animal models of human cancers.  Methods: Here, we extensively investigated the anticancer activity of 4EGI-1 in human glioma U87 cells.  The anti-cancer effects of 4EGI-1 were measured by cell viability, lactate dehydrogenase (LDH) release, TUNEL staining, flow cytometry and western blot anal. in vitro, and also examd. in a U87 xenograft model in vivo.  The potential underlying mol. mechanisms were investigated by measuring mitochondrial function and ER stress.  Results: We found that 4EGI-1 impaired the assembly of the eIF4F complex and decreased the expression of the eIF4E regulated proteins.  The results of TUNEL staining and flow cytometry showed that 4EGI-1 treatment induced apoptotic cell death in a dose-dependent manner.  Furthermore, 4EGI-1-induced apoptosis in U87 cells was assocd. with mitochondrial dysfunction and activation of the intrinsic mitochondrial pathway, which was dependent on the induction of the pro-apoptotic protein Bax.  In addn., 4EGI-1 treatment triggered ER stress, which was evidenced by morphol. changes of ER lumen and ER calcium release, as well as the dose-dependent increases in the expression of ER stress related proteins.  Moreover, knockdown of the ER chaperone GRP-78 through siRNA was shown to partially reverse the 4EGI-1-induced ER stress in U87 cells.  In vivo, 4EGI-1 strongly inhibited growth of U87 glioma xenografts without any apparent organ related toxicities.  Conclusion: These data indicate that the use of inhibitors that directly target the translation initiation complex eIF4F could represent a potential novel approach for human glioma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomc9VwkFIU-7Vg90H21EOLACvtfcHk0lj_BjWf94T0dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSmtrzL&md5=8aabee0a0716c1c96d988c6d95e21ef4</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1159%2F000453158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000453158%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DX.%2BJ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWanggou%26aufirst%3DS.%26atitle%3DAnti-Cancer%2520Effect%2520of%2520Cap-Translation%2520Inhibitor%25204EGI-1%2520in%2520Human%2520Glioma%2520U87%2520Cells%253A%2520Involvement%2520of%2520Mitochondrial%2520Dysfunction%2520and%2520ER%2520Stress%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2016%26volume%3D40%26spage%3D1013%26epage%3D1028%26doi%3D10.1159%2F000453158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jay-Dixon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadiq, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, R. A.</span></span> <span> </span><span class="NLM_article-title">4EGI-1 Represses Cap-Dependent Translation and Regulates Genome-Wide Translation in Malignant Pleural Mesothelioma</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1007/s10637-017-0535-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs10637-017-0535-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=29116477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2js7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=217-229&author=A.+Deauthor=B.+A.+Jacobsonauthor=M.+S.+Petersonauthor=J.+Jay-Dixonauthor=M.+G.+Kratzkeauthor=A.+A.+Sadiqauthor=M.+R.+Patelauthor=R.+A.+Kratzke&title=4EGI-1+Represses+Cap-Dependent+Translation+and+Regulates+Genome-Wide+Translation+in+Malignant+Pleural+Mesothelioma&doi=10.1007%2Fs10637-017-0535-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma</span></div><div class="casAuthors">De, Arpita; Jacobson, Blake A.; Peterson, Mark S.; Jay-Dixon, Joe; Kratzke, Marian G.; Sadiq, Ahad A.; Patel, Manish R.; Kratzke, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-229</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Deregulation of cap-dependent translation has been implicated in the malignant transformation of numerous human tissues. 4EGI-1, a novel small-mol. inhibitor of cap-dependent translation, disrupts formation of the eukaryotic initiation factor 4F (eIF4F) complex.  The effects of 4EGI-1-mediated inhibition of translation initiation in malignant pleural mesothelioma (MPM) were examd. 4EGI-1 preferentially inhibited cell viability and induced apoptosis in MPM cells compared to normal mesothelial (LP9) cells.  This effect was assocd. with hypophosphorylation of 4E-binding protein 1 (4E-BP1) and decreased protein levels of the cancer-related genes, c-myc and osteopontin. 4EGI-1 showed enhanced cytotoxicity in combination with pemetrexed or gemcitabine.  Translatome-wide polysome microarray anal. revealed a large cohort of genes that were translationally regulated upon treatment with 4EGI-1.  The 4EGI-1-regulated translatome was neg. correlated to a previously published translatome regulated by eIF4E overexpression in human mammary epithelial cells, which is in agreement with the notion that 4EGI-1 inhibits the eIF4F complex.  These data indicate that inhibition of the eIF4F complex by 4EGI-1 or similar translation inhibitors could be a strategy for treating mesothelioma.  Genome wide translational profiling identified a large cohort of promising target genes that should be further evaluated for their potential significance in the treatment of MPM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbtIwZUfu9OrVg90H21EOLACvtfcHk0lj_BjWf94T0dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2js7vE&md5=05712fd65ab5aabe3dd7e51f8eea0855</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1007%2Fs10637-017-0535-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-017-0535-z%26sid%3Dliteratum%253Aachs%26aulast%3DDe%26aufirst%3DA.%26aulast%3DJacobson%26aufirst%3DB.%2BA.%26aulast%3DPeterson%26aufirst%3DM.%2BS.%26aulast%3DJay-Dixon%26aufirst%3DJ.%26aulast%3DKratzke%26aufirst%3DM.%2BG.%26aulast%3DSadiq%26aufirst%3DA.%2BA.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DKratzke%26aufirst%3DR.%2BA.%26atitle%3D4EGI-1%2520Represses%2520Cap-Dependent%2520Translation%2520and%2520Regulates%2520Genome-Wide%2520Translation%2520in%2520Malignant%2520Pleural%2520Mesothelioma%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2018%26volume%3D36%26spage%3D217%26epage%3D229%26doi%3D10.1007%2Fs10637-017-0535-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stelzner, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jay-Dixon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, R. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Oncogenic Cap-Dependent Translation by 4EGI-1 Reduces Growth, Enhances Chemosensitivity and Alters Genome-Wide Translation in Non-Small Cell Lung Cancer</span>. <i>Cancer Gene Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1038/s41417-018-0058-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41417-018-0058-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30420719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Sgur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=157-165&author=A.+Deauthor=B.+A.+Jacobsonauthor=M.+S.+Petersonauthor=M.+E.+Stelznerauthor=J.+Jay-Dixonauthor=M.+G.+Kratzkeauthor=M.+R.+Patelauthor=P.+B.+Bittermanauthor=R.+A.+Kratzke&title=Inhibition+of+Oncogenic+Cap-Dependent+Translation+by+4EGI-1+Reduces+Growth%2C+Enhances+Chemosensitivity+and+Alters+Genome-Wide+Translation+in+Non-Small+Cell+Lung+Cancer&doi=10.1038%2Fs41417-018-0058-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer</span></div><div class="casAuthors">De, Arpita; Jacobson, Blake A.; Peterson, Mark S.; Stelzner, Margaret E.; Jay-Dixon, Joe; Kratzke, Marian G.; Patel, Manish R.; Bitterman, Peter B.; Kratzke, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Gene Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">157-165</span>CODEN:
                <span class="NLM_cas:coden">CGTHEG</span>;
        ISSN:<span class="NLM_cas:issn">0929-1903</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Hyperactivation of eIF4F-mediated translation occurs in many if not all cancers.  As a consequence, cancer cells aberrantly enhance expression of malignancy-related proteins that are involved in cell cycle progression, angiogenesis, growth, and proliferation.  With this in mind eIF4F is a promising mol. target for therapeutics that counteract pathol. eIF4F activity.  Here we used 4EGI-1, a small-mol. inhibitor of cap-mediated translation that disrupts formation of the eukaryotic initiation factor 4F (eIF4F) complex to treat non-small cell lung cancer (NSCLC).  Treatment of cells with 4EGI-1 reduced cell proliferation, decreased cap-dependent complex formation, induced apoptosis, enhanced sensitivity to gemcitabine, and altered global cellular translation.  Suppression of cap-dependent translation by 4EGI-1 resulted in diminished expression of oncogenic proteins c-Myc, Bcl-2, cyclin D1, and survivin, whereas β-actin expression was left unchanged.  In light of these results, small-mol. inhibitors like 4EGI-1 alone or with chemotherapy should be further evaluated in the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK7TURxLzAW7Vg90H21EOLACvtfcHk0lj_BjWf94T0dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Sgur3L&md5=18dc680d7e021e28da7827f03d613e2a</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1038%2Fs41417-018-0058-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41417-018-0058-6%26sid%3Dliteratum%253Aachs%26aulast%3DDe%26aufirst%3DA.%26aulast%3DJacobson%26aufirst%3DB.%2BA.%26aulast%3DPeterson%26aufirst%3DM.%2BS.%26aulast%3DStelzner%26aufirst%3DM.%2BE.%26aulast%3DJay-Dixon%26aufirst%3DJ.%26aulast%3DKratzke%26aufirst%3DM.%2BG.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26aulast%3DKratzke%26aufirst%3DR.%2BA.%26atitle%3DInhibition%2520of%2520Oncogenic%2520Cap-Dependent%2520Translation%2520by%25204EGI-1%2520Reduces%2520Growth%252C%2520Enhances%2520Chemosensitivity%2520and%2520Alters%2520Genome-Wide%2520Translation%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Gene%2520Ther.%26date%3D2019%26volume%3D26%26spage%3D157%26epage%3D165%26doi%3D10.1038%2Fs41417-018-0058-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtkaya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingledine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Reversing Chemoresistance by Small Molecule Inhibition of the Translation Initiation Complex eIF4F</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1073/pnas.1011477108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.1011477108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21191102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlWrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=1046-1051&author=R.+Cencicauthor=D.+R.+Hallauthor=F.+Robertauthor=Y.+Duauthor=J.+Minauthor=L.+Liauthor=M.+Quiauthor=I.+Lewisauthor=S.+Kurtkayaauthor=R.+Dingledineauthor=H.+Fuauthor=D.+Kozakovauthor=S.+Vajdaauthor=J.+Pelletier&title=Reversing+Chemoresistance+by+Small+Molecule+Inhibition+of+the+Translation+Initiation+Complex+eIF4F&doi=10.1073%2Fpnas.1011477108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F</span></div><div class="casAuthors">Cencic, Regina; Hall, David R.; Robert, Francis; Du, Yuhong; Min, Jaeki; Li, Lian; Qui, Min; Lewis, Iestyn; Kurtkaya, Serdar; Dingledine, Ray; Fu, Haian; Kozakov, Dima; Vajda, Sandor; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1046-1051, S1046/1-S1046/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Deregulation of cap-dependent translation is assocd. with cancer initiation and progression.  The rate-limiting step of protein synthesis is the loading of ribosomes onto mRNA templates stimulated by the heterotrimeric complex, eukaryotic initiation factor (elF)4F.  This step represents an attractive target for anticancer drug discovery because it resides at the nexus of the TOR signaling pathway.  We have undertaken an ultra-high-throughput screen to identify inhibitors that prevent assembly of the eIF4F complex.  One of the identified compds. blocks interaction between two subunits of elF4F.  As a consequence, cap-dependent translation is inhibited.  This compd. can reverse tumor chemoresistance in a genetically engineered lymphoma mouse model by sensitizing cells to the proapoptotic action of DNA damage.  Mol. modeling expts. provide insight into the mechanism of action of this small mol. inhibitor.  Our expts. validate targeting the eIF4F complex as a strategy for cancer therapy to modulate chemo-sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp523wPn1DaGbVg90H21EOLACvtfcHk0ljrQJs_y0e5Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlWrsrs%253D&md5=8b9fa0bf7dc5638b9a85e1a8e1556088</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1011477108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1011477108%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DHall%26aufirst%3DD.%2BR.%26aulast%3DRobert%26aufirst%3DF.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DQui%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DI.%26aulast%3DKurtkaya%26aufirst%3DS.%26aulast%3DDingledine%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DKozakov%26aufirst%3DD.%26aulast%3DVajda%26aufirst%3DS.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DReversing%2520Chemoresistance%2520by%2520Small%2520Molecule%2520Inhibition%2520of%2520the%2520Translation%2520Initiation%2520Complex%2520eIF4F%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D1046%26epage%3D1051%26doi%3D10.1073%2Fpnas.1011477108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desforges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingledine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Blocking EIF4E-EIF4G Interaction as a Strategy To Impair Coronavirus Replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">6381</span>– <span class="NLM_lpage">6389</span>, <span class="refDoi"> DOI: 10.1128/JVI.00078-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1128%2FJVI.00078-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21507972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=6381-6389&author=R.+Cencicauthor=M.+Desforgesauthor=D.+R.+Hallauthor=D.+Kozakovauthor=Y.+Duauthor=J.+Minauthor=R.+Dingledineauthor=H.+Fuauthor=S.+Vajdaauthor=P.+J.+Talbotauthor=J.+Pelletier&title=Blocking+EIF4E-EIF4G+Interaction+as+a+Strategy+To+Impair+Coronavirus+Replication&doi=10.1128%2FJVI.00078-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication</span></div><div class="casAuthors">Cencic, Regina; Desforges, Marc; Hall, David R.; Kozakov, Dima; Du, Yuhong; Min, Jaeki; Dingledine, Raymond; Fu, Haian; Vajda, Sandor; Talbot, Pierre J.; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6381-6389</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Coronaviruses are a family of enveloped single-stranded pos.-sense RNA viruses causing respiratory, enteric, and neurol. diseases in mammals and fowl.  Human coronaviruses are recognized to cause up to a third of common colds and are suspected to be involved in enteric and neurol. diseases.  Coronavirus replication involves the generation of nested subgenomic mRNAs (sgmRNAs) with a common capped 5' leader sequence.  The translation of most of the sgmRNAs is thought to be cap dependent and displays a requirement for eukaryotic initiation factor 4F (eIF4F), a heterotrimeric complex needed for the recruitment of 40S ribosomes.  We recently reported on an ultrahigh-throughput screen to discover compds. that inhibit eIF4F activity by blocking the interaction of two of its subunits.  Herein we describe a mol. from this screen that prevents the interaction between eIF4E (the cap-binding protein) and eIF4G (a large scaffolding protein), inhibiting cap-dependent translation.  This inhibitor significantly decreased human coronavirus 229E (HCoV-229E) replication, reducing the percentage of infected cells and intra- and extracellular infectious virus titers.  Our results support the strategy of targeting the eIF4F complex to block coronavirus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmYijWiXmX5LVg90H21EOLACvtfcHk0ljrQJs_y0e5Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOntbY%253D&md5=2825b0855928a3dbbc53ac015dd55d16</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1128%2FJVI.00078-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00078-11%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DDesforges%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DD.%2BR.%26aulast%3DKozakov%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DDingledine%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DVajda%26aufirst%3DS.%26aulast%3DTalbot%26aufirst%3DP.%2BJ.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DBlocking%2520EIF4E-EIF4G%2520Interaction%2520as%2520a%2520Strategy%2520To%2520Impair%2520Coronavirus%2520Replication%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D6381%26epage%3D6389%26doi%3D10.1128%2FJVI.00078-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kardos, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinavahi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. P.</span></span> <span> </span><span class="NLM_article-title">Salubrinal in Combination With 4E1RCat Synergistically Impairs Melanoma Development by Disrupting the Protein Synthetic Machinery</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.3389/fonc.2020.00834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3389%2Ffonc.2020.00834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=32076595" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=1-9&author=G.+R.+Kardosauthor=R.+Gowdaauthor=S.+S.+Dinavahiauthor=S.+Kimballauthor=G.+P.+Robertson&title=Salubrinal+in+Combination+With+4E1RCat+Synergistically+Impairs+Melanoma+Development+by+Disrupting+the+Protein+Synthetic+Machinery&doi=10.3389%2Ffonc.2020.00834"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2020.00834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2020.00834%26sid%3Dliteratum%253Aachs%26aulast%3DKardos%26aufirst%3DG.%2BR.%26aulast%3DGowda%26aufirst%3DR.%26aulast%3DDinavahi%26aufirst%3DS.%2BS.%26aulast%3DKimball%26aufirst%3DS.%26aulast%3DRobertson%26aufirst%3DG.%2BP.%26atitle%3DSalubrinal%2520in%2520Combination%2520With%25204E1RCat%2520Synergistically%2520Impairs%2520Melanoma%2520Development%2520by%2520Disrupting%2520the%2520Protein%2520Synthetic%2520Machinery%26jtitle%3DFront.%2520Oncol.%26date%3D2020%26volume%3D10%26spage%3D1%26epage%3D9%26doi%3D10.3389%2Ffonc.2020.00834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbein, G.</span></span> <span> </span><span class="NLM_article-title">The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral Infections</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">75</span>, <span class="refDoi"> DOI: 10.3389/fonc.2015.00075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3389%2Ffonc.2015.00075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25905039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BC2MjntlGrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=75&author=W.+Abbasauthor=A.+Kumarauthor=G.+Herbein&title=The+eEF1A+Proteins%3A+At+the+Crossroads+of+Oncogenesis%2C+Apoptosis%2C+and+Viral+Infections&doi=10.3389%2Ffonc.2015.00075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral Infections</span></div><div class="casAuthors">Abbas Wasim; Kumar Amit; Herbein Georges</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Eukaryotic translation elongation factors 1 alpha, eEF1A1 and eEF1A2, are not only translation factors but also pleiotropic proteins that are highly expressed in human tumors, including breast cancer, ovarian cancer, and lung cancer. eEF1A1 modulates cytoskeleton, exhibits chaperone-like activity and also controls cell proliferation and cell death.  In contrast, eEF1A2 protein favors oncogenesis as shown by the fact that overexpression of eEF1A2 leads to cellular transformation and gives rise to tumors in nude mice.  The eEF1A2 protein stimulates the phospholipid signaling and activates the Akt-dependent cell migration and actin remodeling that ultimately favors tumorigenesis.  In contrast, inactivation of eEF1A proteins leads to immunodeficiency, neural and muscular defects, and favors apoptosis.  Finally, eEF1A proteins interact with several viral proteins resulting in enhanced viral replication, decreased apoptosis, and increased cellular transformation.  This review summarizes the recent findings on eEF1A proteins indicating that eEF1A proteins play a critical role in numerous human diseases through enhancement of oncogenesis, blockade of apoptosis, and increased viral pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSp9TlOziNGFg8IxFYvehhofW6udTcc2eY1prtBCbtqLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjntlGrug%253D%253D&md5=46d3ba2d08d5b663601d93d52050c4fc</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2015.00075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2015.00075%26sid%3Dliteratum%253Aachs%26aulast%3DAbbas%26aufirst%3DW.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DHerbein%26aufirst%3DG.%26atitle%3DThe%2520eEF1A%2520Proteins%253A%2520At%2520the%2520Crossroads%2520of%2520Oncogenesis%252C%2520Apoptosis%252C%2520and%2520Viral%2520Infections%26jtitle%3DFront.%2520Oncol.%26date%3D2015%26volume%3D5%26spage%3D75%26doi%3D10.3389%2Ffonc.2015.00075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiumi, T.</span></span> <span> </span><span class="NLM_article-title">Switch of the Interactions between the Ribosomal Stalk and EF1A in the GTP- and GDP-Bound Conformations</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">14761</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-51266-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41598-019-51266-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31611569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BB3Mnnslyjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=14761&author=K.+Maruyamaauthor=H.+Imaiauthor=M.+Kawamuraauthor=S.+Ishinoauthor=Y.+Ishinoauthor=K.+Itoauthor=T.+Uchiumi&title=Switch+of+the+Interactions+between+the+Ribosomal+Stalk+and+EF1A+in+the+GTP-+and+GDP-Bound+Conformations&doi=10.1038%2Fs41598-019-51266-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Switch of the interactions between the ribosomal stalk and EF1A in the GTP- and GDP-bound conformations</span></div><div class="casAuthors">Maruyama Kei; Imai Hirotatsu; Kawamura Momoko; Ito Kosuke; Uchiumi Toshio; Ishino Sonoko; Ishino Yoshizumi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14761</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Translation elongation factor EF1A delivers aminoacyl-tRNA to the ribosome in a GTP-bound form, and is released from the ribosome in a GDP-bound form.  This association/dissociation cycle proceeds efficiently via a marked conformational change in EF1A.  EF1A function is dependent on the ribosomal "stalk" protein of the ribosomal large subunit, although the precise mechanism of action of the stalk on EF1A remains unclear.  Here, we clarify the binding mode of archaeal stalk aP1 to GTP-bound aEF1A associated with aPelota.  Intriguingly, the C-terminal domain (CTD) of aP1 binds to aEF1A•GTP with a similar affinity to aEF1A•GDP.  We have also determined the crystal structure of the aP1-CTD•aEF1A•GTP•aPelota complex at 3.0 ÅA resolution.  The structure shows that aP1-CTD binds to a space between domains 1 and 3 of aEF1A.  Biochemical analyses show that this binding is crucial for protein synthesis.  Comparison of the structures of aP1-CTD•aEF1A•GTP and aP1-CTD•aEF1A•GDP demonstrates that the binding mode of aP1 changes markedly upon a conformational switch between the GTP- and GDP-bound forms of aEF1A.  Taking into account biochemical data, we infer that aP1 employs its structural flexibility to bind to aEF1A before and after GTP hydrolysis for efficient protein synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTV1yIRsIeDmRgd2Wuil24tfW6udTcc2eY1prtBCbtqLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mnnslyjsw%253D%253D&md5=e4b3dafd72d99fd8350e88b5622e134a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-51266-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-51266-x%26sid%3Dliteratum%253Aachs%26aulast%3DMaruyama%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DH.%26aulast%3DKawamura%26aufirst%3DM.%26aulast%3DIshino%26aufirst%3DS.%26aulast%3DIshino%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DUchiumi%26aufirst%3DT.%26atitle%3DSwitch%2520of%2520the%2520Interactions%2520between%2520the%2520Ribosomal%2520Stalk%2520and%2520EF1A%2520in%2520the%2520GTP-%2520and%2520GDP-Bound%2520Conformations%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D14761%26doi%3D10.1038%2Fs41598-019-51266-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Condeelis, J.</span></span> <span> </span><span class="NLM_article-title">Elongation Factor 1α, Translation and the Cytoskeleton</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/S0968-0004(00)88998-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2FS0968-0004%2800%2988998-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=7610475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK2MXlslGnsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1995&pages=169-170&author=J.+Condeelis&title=Elongation+Factor+1%CE%B1%2C+Translation+and+the+Cytoskeleton&doi=10.1016%2FS0968-0004%2800%2988998-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Elongation factor 1α, translation and the cytoskeleton</span></div><div class="casAuthors">Condeelis, John</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">169-70</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 29 refs.  Topics discussed include: EF1α assocn. with cytoskeleton; compartmentalization of protein formation in cytoplasm; and regulation and assembly of cytoskeletal compartments by EF1α.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOTAblwkTHxLVg90H21EOLACvtfcHk0lhZ3Fxfz-TcCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXlslGnsrg%253D&md5=614af730c13c7fa12a226a22d38a60e6</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2FS0968-0004%2800%2988998-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0004%252800%252988998-7%26sid%3Dliteratum%253Aachs%26aulast%3DCondeelis%26aufirst%3DJ.%26atitle%3DElongation%2520Factor%25201%25CE%25B1%252C%2520Translation%2520and%2520the%2520Cytoskeleton%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1995%26volume%3D20%26spage%3D169%26epage%3D170%26doi%3D10.1016%2FS0968-0004%2800%2988998-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traugh, J. A.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of Elongation Factor 1 (EF-1) by Protein Kinase C Stimulates GDP/GTP-Exchange Activity</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">550</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1995.550_b.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1111%2Fj.1432-1033.1995.550_b.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=8536702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVSktbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=1995&pages=550-556&author=H.+I.+Petersauthor=Y.+E.+Changauthor=J.+A.+Traugh&title=Phosphorylation+of+Elongation+Factor+1+%28EF-1%29+by+Protein+Kinase+C+Stimulates+GDP%2FGTP-Exchange+Activity&doi=10.1111%2Fj.1432-1033.1995.550_b.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of elongation factor 1 (EF-1) by protein kinase C stimulates GDP/GTP-exchange activity</span></div><div class="casAuthors">Peters, Holme I.; Chang, Yu-Wen; Traugh, Jolinda A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">550-6</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Phosphorylation of the α, β, and δ subunits of EF-1 by protein kinase C (PKC) was previously shown to result in stimulation of elongation activity up to 3-fold both in vivo and in vitro.  The α subunit catalyzes the GTP-dependent binding of amino-acyl-tRNA to the ribosome, whereas the βγ and δ subunits of EF-1 catalyze exchange of the residual GDP on EF-1α for GTP.  To det. whether the change in elongation rate following phosphorylation by PKC is due to stimulation of GDP/GTP exchange activity, EF-1 and EF-1·valyl-tRNA-synthetase were purified from rabbit reticulocytes, phosphorylated in vitro by PKC, and the effect of phosphorylation on nucleotide-exchange activity analyzed.  It was found that the α, β, and δ subunits were phosphorylated only on Ser, and phosphopeptide maps showed distinct phosphopeptides for each subunit.  Following quant. phosphorylation of EF-1 by PKC on the α, β, and δ subunits, a 2-fold enhancement of the rate of nucleotide exchange over the nonphosphorylated controls was obsd. with EF-1 and EF-1·valyl-tRNA synthetase.  Stimulation of nucleotide exchange resulted in a 2-fold increase in the formation of EF-1α·GTP·Phe-tRNA, leading to an increased rate of binding of Phe-tRNA to ribosomes.  The magnitude of stimulation of the exchange rate was similar to that reported previously for the rate of elongation following phosphorylation of EF-1 by PKC.  Thus, the enhancement of EF-1 activity in response to 4β-phorbol 12-myristate 13-acetate appears to be due to stimulation of the rate of GDP/GTP exchange following phosphorylation of EF-1 by PKC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjJpx1oLPlu7Vg90H21EOLACvtfcHk0lhZ3Fxfz-TcCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVSktbbM&md5=d539311bf073cd9b9ba3133d9c4a65a1</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1995.550_b.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1995.550_b.x%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DH.%2BI.%26aulast%3DChang%26aufirst%3DY.%2BE.%26aulast%3DTraugh%26aufirst%3DJ.%2BA.%26atitle%3DPhosphorylation%2520of%2520Elongation%2520Factor%25201%2520%2528EF-1%2529%2520by%2520Protein%2520Kinase%2520C%2520Stimulates%2520GDP%252FGTP-Exchange%2520Activity%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1995%26volume%3D234%26spage%3D550%26epage%3D556%26doi%3D10.1111%2Fj.1432-1033.1995.550_b.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosutti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaja, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanconati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dapas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaggiante, B.</span></span> <span> </span><span class="NLM_article-title">A Rapid and Specific Method to Simultaneously Quantify Eukaryotic Elongation Factor 1A1 and A2 Protein Levels in Cancer Cells</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">112814</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2019.112814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.jpba.2019.112814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31450069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1yht7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=112814&author=A.+Bosuttiauthor=O.+Kalajaauthor=F.+Zanconatiauthor=B.+Dapasauthor=G.+Grassiauthor=S.+Passamontiauthor=B.+Scaggiante&title=A+Rapid+and+Specific+Method+to+Simultaneously+Quantify+Eukaryotic+Elongation+Factor+1A1+and+A2+Protein+Levels+in+Cancer+Cells&doi=10.1016%2Fj.jpba.2019.112814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid and specific method to simultaneously quantify eukaryotic elongation factor 1A1 and A2 protein levels in cancer cells</span></div><div class="casAuthors">Bosutti, Alessandra; Kalaja, Odeta; Zanconati, Fabrizio; Dapas, Barbara; Grassi, Gabriele; Passamonti, Sabina; Scaggiante, Bruna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112814</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The two isoforms of the eukaryotic Elongation Factor 1A (eEF1A1 and eEF1A2), sustain the progression/aggressiveness of cancer cells.  Thus, they are considered promising therapeutic targets and prognostic markers.  It follows that their precise quantification is of utmost relevance in research and development.  The simultaneous quantification of A1 and A2 proteins in the cells helps the comprehension of cancer biol. mechanisms and response to drug treatments.  However, the high homol. at the amino-acidic level (92%) can cause antibodies cross-reaction.  Moreover, the commonly employed western blotting just gives semi-quant. data and does not allow the detection of both protein targets within the same cell.  Thus, we developed an in cell western (ICW) technique to bypass the above limitations.  Firstly, relevant antibodies cross-reaction was excluded by immunohistochem. on normal pancreatic tissue; then eEF1A1-A2 protein levels were quantitated by ICW in prostate and colorectal cancer cell lines in 96 well plates under different conditions, which include: 1) drug treatment, 2) siRNA silencing, 3) cell seeding d.  We show that: 1) eEF1A1-A2 levels vary depending on the cell type following drug treatment, 2) ICW can accurately detect eEF1A1-A2 protein levels following siRNA silencing, 3) cell seeding d. influences eEF1A1-A2 levels, depending on cell type.  ICW is a valuable tool to specifically det. the intracellular level of eEF1A1-A2 proteins thus contributing to better define their role as potential therapeutic targets and prognostic markers in human tumors as well as for drug effects screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSxqfbA0Jf6rVg90H21EOLACvtfcHk0licDFWMOVSQ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1yht7nM&md5=23b49f89e1d94438173a1223140afb4a</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2019.112814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2019.112814%26sid%3Dliteratum%253Aachs%26aulast%3DBosutti%26aufirst%3DA.%26aulast%3DKalaja%26aufirst%3DO.%26aulast%3DZanconati%26aufirst%3DF.%26aulast%3DDapas%26aufirst%3DB.%26aulast%3DGrassi%26aufirst%3DG.%26aulast%3DPassamonti%26aufirst%3DS.%26aulast%3DScaggiante%26aufirst%3DB.%26atitle%3DA%2520Rapid%2520and%2520Specific%2520Method%2520to%2520Simultaneously%2520Quantify%2520Eukaryotic%2520Elongation%2520Factor%25201A1%2520and%2520A2%2520Protein%2520Levels%2520in%2520Cancer%2520Cells%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2019%26volume%3D176%26spage%3D112814%26doi%3D10.1016%2Fj.jpba.2019.112814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. yi</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J. P.</span></span> <span> </span><span class="NLM_article-title">eEF1A1 Overexpression Enhances Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma</span>. <i>Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2017.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.tranon.2017.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=29248802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzit12ltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=125-131&author=S.+L.+Chenauthor=S.+X.+Luauthor=L.+L.+Liuauthor=C.+H.+Wangauthor=X.+Yangauthor=Z.+yi+Zhangauthor=H.+Z.+Zhangauthor=J.+P.+Yun&title=eEF1A1+Overexpression+Enhances+Tumor+Progression+and+Indicates+Poor+Prognosis+in+Hepatocellular+Carcinoma&doi=10.1016%2Fj.tranon.2017.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">eEF1A1 Overexpression Enhances Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma</span></div><div class="casAuthors">Chen Shi-Lu; Lu Shi-Xun; Liu Li-Li; Wang Chun-Hua; Yang Xia; Zhang Zhi-Yi; Zhang Hui-Zhong; Yun Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-131</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">Liver is a major contributor of protein production physiologically.  The aberrant state of protein synthesis leads to tumor progression.  Eukaryotic elongation factor 1 alpha 1 (eEF1A1) is a major member of the eukaryotic elongation factor family that regulates protein synthesis.  Although eEF1A1 plays an essential role in controlling the cell fate, its clinical significance in tumor development and progression has not been reported.  Here, we aimed to uncover the expression and prognostic significance of eEF1A1 in hepatocellular carcinoma (HCC).  Our data indicated that eEF1A1 expression was elevated in HCC cell lines and clinical samples at both the mRNA and protein levels.  Immunohistochemistry revealed that eEF1A1 expression was upregulated in HCC samples compared with corresponding non-tumorous tissues.  In 50 HCC cases with portal vein embolus, higher eEF1A1 immunoreactivity was detected in tumor metastases compared with the primary lesions.  Kaplan-Meier analysis indicated that increased eEF1A1 expression was closely associated with unfavorable post-surgical overall and disease-free survival in 453 HCC patients.  Moreover, multivariate analysis indicated eEF1A1 as an independent predictor for overall and disease-free survival.  Collectively, our study suggests eEF1A1 as a novel prognostic biomarker and potential therapeutic target for HCC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQao6HF1EqhjTQLBVDQn4bCfW6udTcc2eb7qkGcUJNOn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzit12ltg%253D%253D&md5=2aba6588f8f9f1b9a0b7518f5cf3d422</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2017.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2017.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%2BL.%26aulast%3DLu%26aufirst%3DS.%2BX.%26aulast%3DLiu%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DC.%2BH.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%2Byi%26aulast%3DZhang%26aufirst%3DH.%2BZ.%26aulast%3DYun%26aufirst%3DJ.%2BP.%26atitle%3DeEF1A1%2520Overexpression%2520Enhances%2520Tumor%2520Progression%2520and%2520Indicates%2520Poor%2520Prognosis%2520in%2520Hepatocellular%2520Carcinoma%26jtitle%3DTransl.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D125%26epage%3D131%26doi%3D10.1016%2Fj.tranon.2017.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricker, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlow, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgopapadakos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huelskamp, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhimolea, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramkissoon, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spunt, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinski, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, C.</span></span> <span> </span><span class="NLM_article-title">Undifferentiated Small Round Cell Sarcoma in a Young Male: A Case Report</span>. <i>Cold Spring Harb. Mol. Case Stud.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">a004812</span>, <span class="refDoi"> DOI: 10.1101/mcs.a004812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1101%2Fmcs.a004812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=32014859" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=a004812&author=C.+A.+Rickerauthor=N.+E.+Berlowauthor=K.+A.+Crawfordauthor=T.+Georgopapadakosauthor=A.+N.+Huelskampauthor=A.+D.+Woodsauthor=E.+Dhimoleaauthor=S.+H.+Ramkissoonauthor=S.+L.+Spuntauthor=E.+R.+Rudzinskiauthor=C.+Keller&title=Undifferentiated+Small+Round+Cell+Sarcoma+in+a+Young+Male%3A+A+Case+Report&doi=10.1101%2Fmcs.a004812"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1101%2Fmcs.a004812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fmcs.a004812%26sid%3Dliteratum%253Aachs%26aulast%3DRicker%26aufirst%3DC.%2BA.%26aulast%3DBerlow%26aufirst%3DN.%2BE.%26aulast%3DCrawford%26aufirst%3DK.%2BA.%26aulast%3DGeorgopapadakos%26aufirst%3DT.%26aulast%3DHuelskamp%26aufirst%3DA.%2BN.%26aulast%3DWoods%26aufirst%3DA.%2BD.%26aulast%3DDhimolea%26aufirst%3DE.%26aulast%3DRamkissoon%26aufirst%3DS.%2BH.%26aulast%3DSpunt%26aufirst%3DS.%2BL.%26aulast%3DRudzinski%26aufirst%3DE.%2BR.%26aulast%3DKeller%26aufirst%3DC.%26atitle%3DUndifferentiated%2520Small%2520Round%2520Cell%2520Sarcoma%2520in%2520a%2520Young%2520Male%253A%2520A%2520Case%2520Report%26jtitle%3DCold%2520Spring%2520Harb.%2520Mol.%2520Case%2520Stud.%26date%3D2020%26volume%3D6%26spage%3Da004812%26doi%3D10.1101%2Fmcs.a004812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span> <span> </span><span class="NLM_article-title">EF1A Interacting with Nucleocapsid Protein of Transmissible Gastroenteritis Coronavirus and Plays a Role in Virus Replication</span>. <i>Vet. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1016/j.vetmic.2014.05.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.vetmic.2014.05.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24974120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSrur7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2014&pages=443-448&author=X.+Zhangauthor=H.+Shiauthor=J.+Chenauthor=D.+Shiauthor=C.+Liauthor=L.+Feng&title=EF1A+Interacting+with+Nucleocapsid+Protein+of+Transmissible+Gastroenteritis+Coronavirus+and+Plays+a+Role+in+Virus+Replication&doi=10.1016%2Fj.vetmic.2014.05.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">EF1A interacting with nucleocapsid protein of transmissible gastroenteritis coronavirus and plays a role in virus replication</span></div><div class="casAuthors">Zhang, Xin; Shi, Hongyan; Chen, Jianfei; Shi, Da; Li, Changlong; Feng, Li</div><div class="citationInfo"><span class="NLM_cas:title">Veterinary Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">443-448</span>CODEN:
                <span class="NLM_cas:coden">VMICDQ</span>;
        ISSN:<span class="NLM_cas:issn">0378-1135</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Transmissible gastroenteritis coronavirus (TGEV) is an enteropathogenic coronavirus that causes diarrhea in pigs, which is correlated with high morbidity and mortality in suckling piglets.  Using the method of GST pull-down with the nucleocapsid (N), N protein was found to interact with swine testes (ST) cells elongation factor 1-alpha (EF1A), an essential component of the translational machinery with an important role in cells.  In vitro and in virus-infected cells interaction was then confirmed by co-pptn.  Knockdown of EF1A impairs N protein proliferation and TGEV replication in host cell.  It was demonstrated that EF1A plays a role in TGEV replication.  The present study thus provides a protein-related information that should be useful for underlying mechanism of coronavirus replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIT0u6ror6V7Vg90H21EOLACvtfcHk0licDFWMOVSQ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSrur7F&md5=ffa683e84e6636ffb3159869687008ab</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.vetmic.2014.05.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vetmic.2014.05.034%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DL.%26atitle%3DEF1A%2520Interacting%2520with%2520Nucleocapsid%2520Protein%2520of%2520Transmissible%2520Gastroenteritis%2520Coronavirus%2520and%2520Plays%2520a%2520Role%2520in%2520Virus%2520Replication%26jtitle%3DVet.%2520Microbiol.%26date%3D2014%26volume%3D172%26spage%3D443%26epage%3D448%26doi%3D10.1016%2Fj.vetmic.2014.05.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span> <span> </span><span class="NLM_article-title">The Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus Inhibits Cell Cytokinesis and Proliferation by Interacting with Translation Elongation Factor 1α</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">6962</span>– <span class="NLM_lpage">6971</span>, <span class="refDoi"> DOI: 10.1128/JVI.00133-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1128%2FJVI.00133-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18448518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFWmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=6962-6971&author=B.+Zhouauthor=J.+Liuauthor=Q.+Wangauthor=X.+Liuauthor=X.+Liauthor=P.+Liauthor=Q.+Maauthor=C.+Cao&title=The+Nucleocapsid+Protein+of+Severe+Acute+Respiratory+Syndrome+Coronavirus+Inhibits+Cell+Cytokinesis+and+Proliferation+by+Interacting+with+Translation+Elongation+Factor+1%CE%B1&doi=10.1128%2FJVI.00133-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">The nucleocapsid protein of severe acute respiratory syndrome coronavirus inhibits cell cytokinesis and proliferation by interacting with translation elongation factor 1α</span></div><div class="casAuthors">Zhou, Bing; Liu, Junli; Wang, Qiuna; Liu, Xuan; Li, Xiaorong; Li, Ping; Ma, Qingjun; Cao, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6962-6971</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome coronavirus (SARS-CoV) is the etiol. agent of SARS, an emerging disease characterized by atypical pneumonia.  Using a yeast two-hybrid screen with the nucleocapsid (N) protein of SARS-CoV as a bait, the C terminus (amino acids 251 to 422) of the N protein was found to interact with human elongation factor 1-alpha (EF1α), an essential component of the translational machinery with an important role in cytokinesis, promoting the bundling of filamentous actin (F-actin).  In vitro and in vivo interaction was then confirmed by immuno-copptn., far-Western blotting, and surface plasmon resonance.  It was demonstrated that the N protein of SARS-CoV induces aggregation of EF1α, inhibiting protein translation and cytokinesis by blocking F-actin bundling.  Proliferation of human peripheral blood lymphocytes and other human cell lines was significantly inhibited by the infection of recombinant retrovirus expressing SARS-CoV N protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiIRScJzm6N7Vg90H21EOLACvtfcHk0lgs8G70KeOL9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFWmsrw%253D&md5=322cf5b99c4e94f8ee12ad998374809b</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1128%2FJVI.00133-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00133-08%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DCao%26aufirst%3DC.%26atitle%3DThe%2520Nucleocapsid%2520Protein%2520of%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%2520Inhibits%2520Cell%2520Cytokinesis%2520and%2520Proliferation%2520by%2520Interacting%2520with%2520Translation%2520Elongation%2520Factor%25201%25CE%25B1%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D6962%26epage%3D6971%26doi%3D10.1128%2FJVI.00133-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rinehart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renis, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swynenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringfellow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuentzel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Didemnins: Antiviral and Antitumor Depsipeptides from a Caribbean Tunicate</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">933</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1126/science.7233187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1126%2Fscience.7233187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=7233187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaL3MXktlGmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=1981&pages=933-935&author=K.+Rinehartauthor=J.+Gloerauthor=R.+Hughesauthor=H.+Renisauthor=J.+McGovrenauthor=E.+Swynenbergauthor=D.+Stringfellowauthor=S.+Kuentzelauthor=L.+Li&title=Didemnins%3A+Antiviral+and+Antitumor+Depsipeptides+from+a+Caribbean+Tunicate&doi=10.1126%2Fscience.7233187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Didemnins:  antiviral and antitumor depsipeptides from a Caribbean tunicate</span></div><div class="casAuthors">Rinehart, Kenneth L., Jr.; Gloer, James B.; Hughes, Robert G., Jr.; Renis, Harold E.; McGovren, J. Patrick; Swynenberg, Everett B.; Stringfellow, Dale A.; Kuentzel, Sandra L.; Li, Li H.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">4497</span>),
    <span class="NLM_cas:pages">933-5</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Exts. of samples of a Caribbean tunicate (ascidian, sea squirt) of the family Didemnidae inhibit in vitro at low concns. the growth of DNA and RNA viruses as well as L1210 leukemic cells.  The active compds. isolated from the tunicate are didemnin A (I; R = H)  [77327-04-9] didemnin B  [77327-05-0], and didemnin C  [77327-06-1].  Didemnin B (a deriv. of didemnin A) is the component active at the lowest concn. in inhibiting viral replication in vitro and P388 leukemia in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxvIkMzkxqELVg90H21EOLACvtfcHk0lgs8G70KeOL9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXktlGmsLw%253D&md5=8b8ac5f276e3906db1343344c2b7129c</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1126%2Fscience.7233187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.7233187%26sid%3Dliteratum%253Aachs%26aulast%3DRinehart%26aufirst%3DK.%26aulast%3DGloer%26aufirst%3DJ.%26aulast%3DHughes%26aufirst%3DR.%26aulast%3DRenis%26aufirst%3DH.%26aulast%3DMcGovren%26aufirst%3DJ.%26aulast%3DSwynenberg%26aufirst%3DE.%26aulast%3DStringfellow%26aufirst%3DD.%26aulast%3DKuentzel%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26atitle%3DDidemnins%253A%2520Antiviral%2520and%2520Antitumor%2520Depsipeptides%2520from%2520a%2520Caribbean%2520Tunicate%26jtitle%3DScience%26date%3D1981%26volume%3D212%26spage%3D933%26epage%3D935%26doi%3D10.1126%2Fscience.7233187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urdiales, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morata, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Castro, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Jiménez, F.</span></span> <span> </span><span class="NLM_article-title">Antiproliferative Effect of Dehydrodidemnin B (DDB), a Depsipeptide Isolated from Mediterranean Tunicates</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/0304-3835(96)04151-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2F0304-3835%2896%2904151-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=8603376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK28Xhslejurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1996&pages=31-37&author=J.+L.+Urdialesauthor=P.+Morataauthor=I.+N.+De+Castroauthor=F.+S%C3%A1nchez-Jim%C3%A9nez&title=Antiproliferative+Effect+of+Dehydrodidemnin+B+%28DDB%29%2C+a+Depsipeptide+Isolated+from+Mediterranean+Tunicates&doi=10.1016%2F0304-3835%2896%2904151-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates</span></div><div class="casAuthors">Urdiales, Jose L.; Morata, Pilar; Nunez De Castro, Ignacio; Sanchez-Jimenez, Francisca</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">31-7</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The biol. effects of dehydrodidemnin B (DDB), a novel depsipeptide isolated from Aplidium albicans, were studied on Ehrlich carcinoma growing in vivo and in primary cultures, and compared with those reported for Didemnin B (DB).  Daily administration of DB or DDB (2.5 μg/mouse) almost duplicated the animal life-span and total no. of tumor cells decreased by 70-90%.  Results suggest a major effect of DDB when administered in the lag phase of growth.  DDB behaved as a very potent inhibitor of protein synthesis; consequently, ornithine decarboxylase activity (ODC, EC 4.1.1.17) is drastically reduced by the DDB-treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfkvs5GBkoS7Vg90H21EOLACvtfcHk0lgs8G70KeOL9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xhslejurc%253D&md5=e8b33a94cc19d5036368d2ead4ff8556</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2F0304-3835%2896%2904151-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3835%252896%252904151-1%26sid%3Dliteratum%253Aachs%26aulast%3DUrdiales%26aufirst%3DJ.%2BL.%26aulast%3DMorata%26aufirst%3DP.%26aulast%3DDe%2BCastro%26aufirst%3DI.%2BN.%26aulast%3DS%25C3%25A1nchez-Jim%25C3%25A9nez%26aufirst%3DF.%26atitle%3DAntiproliferative%2520Effect%2520of%2520Dehydrodidemnin%2520B%2520%2528DDB%2529%252C%2520a%2520Depsipeptide%2520Isolated%2520from%2520Mediterranean%2520Tunicates%26jtitle%3DCancer%2520Lett.%26date%3D1996%26volume%3D102%26spage%3D31%26epage%3D37%26doi%3D10.1016%2F0304-3835%2896%2904151-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmins, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prairie, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, W. B.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Action of Didemnin B, a Depsipeptide from the Sea</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1016/0304-3835(84)90095-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2F0304-3835%2884%2990095-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=6744252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaL2cXlsVeksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1984&pages=279-288&author=L.+H.+Liauthor=L.+G.+Timminsauthor=T.+L.+Wallaceauthor=W.+C.+Kruegerauthor=M.+D.+Prairieauthor=W.+B.+Im&title=Mechanism+of+Action+of+Didemnin+B%2C+a+Depsipeptide+from+the+Sea&doi=10.1016%2F0304-3835%2884%2990095-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of didemnin B, a depsipeptide from the sea</span></div><div class="casAuthors">Li, Li H.; Timmins, Laura G.; Wallace, Tanya L.; Krueger, William C.; Prairie, Mark D.; Im, Wha B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">279-88</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    </div><div class="casAbstract">With the brush border membrane vesicles prepd. from the rat kidney cortex, didemnin B  [77327-05-0] and its parent compd., didemnin A  [77327-04-9] function neither as a K+-specific ionophore nor as an ionophore for Na+ ions while other depsipeptide antibiotics such as valinomycin and gramicidin promote transmembrane movement of K+ and Na+ ions, resp.  Didemnin B inhibits protein synthesis and DNA synthesis much more than RNA synthesis and is in general more potent than didemnin A.  Time course studies reveal that the action of didemnin B is rapid and cannot be reversed after 2 h in contact with the cells.  The inhibition of protein synthesis is almost superimposable to that of L1210 cells growth.  DNA synthesis is also markedly inhibited.  These results collectively suggest that didemnin B acts differently, at least in part, from other depsipeptide antibiotics and its biol. effect is primarily mediated through its inhibition of protein synthesis and to a lesser extent its inhibition of DNA synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0v0XlDSZJHrVg90H21EOLACvtfcHk0lgOixycZvfkeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXlsVeksrs%253D&md5=631b48381517473de6adc6cceccf444f</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2F0304-3835%2884%2990095-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3835%252884%252990095-8%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%2BH.%26aulast%3DTimmins%26aufirst%3DL.%2BG.%26aulast%3DWallace%26aufirst%3DT.%2BL.%26aulast%3DKrueger%26aufirst%3DW.%2BC.%26aulast%3DPrairie%26aufirst%3DM.%2BD.%26aulast%3DIm%26aufirst%3DW.%2BB.%26atitle%3DMechanism%2520of%2520Action%2520of%2520Didemnin%2520B%252C%2520a%2520Depsipeptide%2520from%2520the%2520Sea%26jtitle%3DCancer%2520Lett.%26date%3D1984%26volume%3D23%26spage%3D279%26epage%3D288%26doi%3D10.1016%2F0304-3835%2884%2990095-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snapper, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">GTP-Dependent Binding of the Antiproliferative Agent Didemnin to Elongation Factor 1α</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">15411</span>– <span class="NLM_lpage">15414</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(17)40692-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2FS0021-9258%2817%2940692-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=8195179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK2cXkvF2htr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=15411-15414&author=C.+M.+Crewsauthor=J.+L.+Collinsauthor=W.+S.+Laneauthor=M.+L.+Snapperauthor=S.+L.+Schreiber&title=GTP-Dependent+Binding+of+the+Antiproliferative+Agent+Didemnin+to+Elongation+Factor+1%CE%B1&doi=10.1016%2FS0021-9258%2817%2940692-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1α</span></div><div class="casAuthors">Crews, Craig M.; Collins, Jon L.; Lane, William S.; Snapper, Marc L.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">15411-14</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The marine natural product, didemnin B, is a 7-amino acid, cyclic depsipeptide that inhibits G1 cell cycle progression at nanomolar concns. by undefined mechanisms.  It has been reported to exhibit immunosuppressive activities in animals and is undergoing clin. trials as a potential antineoplastic drug.  In addn., at higher concns., didemnin B has been shown to inhibit in vivo and in vitro protein synthesis.  However, the mechanisms by which inhibition is achieved are unknown.  To investigate didemnin's various modes of action, an affinity column was synthesized and used to purify didemnin-binding proteins.  The major retained protein was the 49-kDa guanine nucleotide-binding elongation factor, EF-1α, which was identified by peptide sequence anal.  Moreover, didemnin binds EF-1α only in the presence of GTP but does not inhibit the GTPase activity of EF-1α.  Therefore, EF-1α is likely to be the intracellular target responsible for didemnin B's ability to inhibit protein synthesis.  Furthermore, this specificity of didemnin affinity for the GTP-bound conformation of a guanine nucleotide-binding protein with homol. to the Ras superfamily suggests a possible mode of action for didemnin's antiproliferative activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZGve7U4AtzrVg90H21EOLACvtfcHk0lgOixycZvfkeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkvF2htr4%253D&md5=cc1202a47982a21397c04ecab1f4e252</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2817%2940692-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252817%252940692-2%26sid%3Dliteratum%253Aachs%26aulast%3DCrews%26aufirst%3DC.%2BM.%26aulast%3DCollins%26aufirst%3DJ.%2BL.%26aulast%3DLane%26aufirst%3DW.%2BS.%26aulast%3DSnapper%26aufirst%3DM.%2BL.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DGTP-Dependent%2520Binding%2520of%2520the%2520Antiproliferative%2520Agent%2520Didemnin%2520to%2520Elongation%2520Factor%25201%25CE%25B1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D15411%26epage%3D15414%26doi%3D10.1016%2FS0021-9258%2817%2940692-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, R. S.</span></span> <span> </span><span class="NLM_article-title">Decoding Mammalian Ribosome-MRNA States by Translational GTPase Complexes</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1229</span>– <span class="NLM_lpage">1240</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.10.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.cell.2016.10.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27863242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWgu7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2016&pages=1229-1240&author=S.+Shaoauthor=J.+Murrayauthor=A.+Brownauthor=J.+Tauntonauthor=V.+Ramakrishnanauthor=R.+S.+Hegde&title=Decoding+Mammalian+Ribosome-MRNA+States+by+Translational+GTPase+Complexes&doi=10.1016%2Fj.cell.2016.10.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Decoding mammalian ribosome-mRNA states by translational GTPase complexes</span></div><div class="casAuthors">Shao, Sichen; Murray, Jason; Brown, Alan; Taunton, Jack; Ramakrishnan, V.; Hegde, Ramanujan S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1229-1240.e15</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">In eukaryotes, accurate protein synthesis relies on a family of translational GTPases that pair with specific decoding factors to decipher the mRNA code on ribosomes.  We present structures of the mammalian ribosome engaged with decoding factor·GTPase complexes representing intermediates of translation elongation (aminoacyl-tRNA·eEF1A), termination (eRF1·eRF3), and ribosome rescue (Pelota·Hbs1l).  Comparative analyses reveal that each decoding factor exploits the plasticity of the ribosomal decoding center to differentially remodel ribosomal proteins and rRNA.  This leads to varying degrees of large-scale ribosome movements and implies distinct mechanisms for communicating information from the decoding center to each GTPase.  Addnl. structural snapshots of the translation termination pathway reveal the conformational changes that choreograph the accommodation of decoding factors into the peptidyl transferase center.  Our results provide a structural framework for how different states of the mammalian ribosome are selectively recognized by the appropriate decoding factor·GTPase complex to ensure translational fidelity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGoP0I-nUEDLVg90H21EOLACvtfcHk0lgOixycZvfkeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWgu7jF&md5=e1df1f764b28ab554532a0ad6b7228f9</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.10.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.10.046%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DTaunton%26aufirst%3DJ.%26aulast%3DRamakrishnan%26aufirst%3DV.%26aulast%3DHegde%26aufirst%3DR.%2BS.%26atitle%3DDecoding%2520Mammalian%2520Ribosome-MRNA%2520States%2520by%2520Translational%2520GTPase%2520Complexes%26jtitle%3DCell%26date%3D2016%26volume%3D167%26spage%3D1229%26epage%3D1240%26doi%3D10.1016%2Fj.cell.2016.10.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinehart, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faircloth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carney, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namikoshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grávalos, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Quesada, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heid, R. M.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships of the Didemnins</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2819</span>– <span class="NLM_lpage">2834</span>, <span class="refDoi"> DOI: 10.1021/jm960048g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960048g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK28XjsFKmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=2819-2834&author=R.+Sakaiauthor=K.+L.+Rinehartauthor=V.+Kishoreauthor=B.+Kunduauthor=G.+Fairclothauthor=J.+B.+Gloerauthor=J.+R.+Carneyauthor=M.+Namikoshiauthor=F.+Sunauthor=R.+G.+Hughesauthor=D.+G.+Gr%C3%A1valosauthor=T.+G.+De+Quesadaauthor=G.+R.+Wilsonauthor=R.+M.+Heid&title=Structure-Activity+Relationships+of+the+Didemnins&doi=10.1021%2Fjm960048g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships of the Didemnins</span></div><div class="casAuthors">Sakai, Ryuichi; Kishore, Vimal; Kundu, Bijoy; Faircloth, Glynn; Gloer, James B.; Carney, John R.; Namikoshi, Michio; Sun, Furong; Hughes, Robert G., Jr.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2819-2834</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bioactivities of 42 didemnin congeners, either isolated from the marine tunicates Trididemnun solidum and Aplidium albicans or prepd. synthetically and semisynthetically, were compared.  The growth inhibition of various murine and human tumor cells and plaque redn. of HSV-1 and VSV grown on cultured mammalian cells were used to assess cytotoxicity and antiviral activity.  Biochem. assays for macromol. synthesis (protein, DNA, and RNA) and enzyme inhibition (dihydrofolate reductase, thymidylate synthase, DNA polymerase, RNA polymerase, and topoisomerases I and II) were also performed to specify the mechanisms of action of each analog.  Immunosuppressant activity of the didemnins was detd. using a mixed lymphocyte reaction (MLR) assay.  These assays revealed that the native cyclic depsipeptide core is an essential structural requirement for most of the bioactivities of the didemnins, esp. for cytotoxicities and antiviral activities.  The linear side-chain portion of the peptide can be altered with a gain, in some cases, of bioactivities.  In particular, dehydrodidemnin B, tested against several types of tumor cells and in in vivo studies in mice, as well as didemnin M, tested for the mixed lymphocyte reaction and graft vs host reaction in murine systems, showed remarkable gains in their in vitro and in vivo activities compared to didemnin B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6st3hqZo37bVg90H21EOLACvtfcHk0lg19O3n455gxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsFKmurg%253D&md5=5585f7731c3c833f690bd3bb5a0fcfa9</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm960048g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960048g%26sid%3Dliteratum%253Aachs%26aulast%3DSakai%26aufirst%3DR.%26aulast%3DRinehart%26aufirst%3DK.%2BL.%26aulast%3DKishore%26aufirst%3DV.%26aulast%3DKundu%26aufirst%3DB.%26aulast%3DFaircloth%26aufirst%3DG.%26aulast%3DGloer%26aufirst%3DJ.%2BB.%26aulast%3DCarney%26aufirst%3DJ.%2BR.%26aulast%3DNamikoshi%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DR.%2BG.%26aulast%3DGr%25C3%25A1valos%26aufirst%3DD.%2BG.%26aulast%3DDe%2BQuesada%26aufirst%3DT.%2BG.%26aulast%3DWilson%26aufirst%3DG.%2BR.%26aulast%3DHeid%26aufirst%3DR.%2BM.%26atitle%3DStructure-Activity%2520Relationships%2520of%2520the%2520Didemnins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D2819%26epage%3D2834%26doi%3D10.1021%2Fjm960048g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crampton, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuentzel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badiner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhuyan, B. K.</span></span> <span> </span><span class="NLM_article-title">Biochemical and Cellular Effects of Didemnins A and B</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1796</span>– <span class="NLM_lpage">1801</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=6713383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaL2cXitVeht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1984&pages=1796-1801&author=S.+L.+Cramptonauthor=E.+G.+Adamsauthor=S.+L.+Kuentzelauthor=L.+H.+Liauthor=G.+Badinerauthor=B.+K.+Bhuyan&title=Biochemical+and+Cellular+Effects+of+Didemnins+A+and+B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and cellular effects of didemnins A and B</span></div><div class="casAuthors">Crampton, Sheri L.; Adams, Earl G.; Kuentzel, Sandra L.; Li, Li H.; Badiner, Gloria; Bhuyan, Bijoy K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1796-801</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Didemnin B  [77327-05-0] inhibited the in vitro growth of B16 > L1210 > V-79 cells = human foreskin fibroblast = 9L > Chinese hamster ovary cells.  Didemnin B was more lethal to exponentially growing B16 cells (50% LD for a 2-h exposure, 17.5 ng/mL) than to plateau-phase cells (50% LD for a 2-h exposure, 100 ng/mL).  After a 24-h exposure, the 50% LD for exponential- and plateau-phase B16 cells was 8.8 and 59.6 ng/mL, resp.  Chinese hamster ovary cells were not killed even at 25,000 ng/mL.  Mitotic cells were the least sensitive to didemnin B, and cells became more sensitive as they progressed into G1 and S phase.  However, since cells in all phases were killed, didemnin B cannot be considered a phase-specific agent.  Didemnin B inhibited the synthesis of protein more than that of DNA, with much less inhibition of RNA synthesis.  Cell progression studies showed that high doses (300 ng/mL for 2 h or 100 ng/mL for 24 h) of didemnin B "froze" the cells in their resp. phases with complete inhibition of cell progression or growth.  At low doses (10 ng/mL for 2 h or 3 ng/mL for 24 h), the cells were blocked at the G1-S border thereby increasing the percentage of G1 cells and decreasing the percentage of S-phase cells.  Cells continued to progress from S phase to G2 + M and from G2 + M to G1.  The cytotoxicity to different cell lines and inhibition of macromol. synthesis by didemnin A  [77327-04-9] is also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxplaEUYV0VbVg90H21EOLACvtfcHk0lg19O3n455gxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXitVeht7Y%253D&md5=5d88b14ff96960cca01f35035dc910c1</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCrampton%26aufirst%3DS.%2BL.%26aulast%3DAdams%26aufirst%3DE.%2BG.%26aulast%3DKuentzel%26aufirst%3DS.%2BL.%26aulast%3DLi%26aufirst%3DL.%2BH.%26aulast%3DBadiner%26aufirst%3DG.%26aulast%3DBhuyan%26aufirst%3DB.%2BK.%26atitle%3DBiochemical%2520and%2520Cellular%2520Effects%2520of%2520Didemnins%2520A%2520and%2520B%26jtitle%3DCancer%2520Res.%26date%3D1984%26volume%3D44%26spage%3D1796%26epage%3D1801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanjulu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vera, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SirDeshpande, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfizenmayer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abazeed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krosky, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beidler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joullié, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Protein Synthesis by Didemnins: Cell Potency and SAR</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4212</span>– <span class="NLM_lpage">4218</span>, <span class="refDoi"> DOI: 10.1021/jm000168v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000168v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1Ois7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4212-4218&author=D.+Ahujaauthor=A.+Geigerauthor=J.+M.+Ramanjuluauthor=M.+D.+Veraauthor=B.+SirDeshpandeauthor=A.+Pfizenmayerauthor=M.+Abazeedauthor=D.+J.+Kroskyauthor=D.+Beidlerauthor=M.+M.+Joulli%C3%A9author=P.+L.+Toogood&title=Inhibition+of+Protein+Synthesis+by+Didemnins%3A+Cell+Potency+and+SAR&doi=10.1021%2Fjm000168v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of protein synthesis by didemnins: cell potency and SAR</span></div><div class="casAuthors">Ahuja, Deepika; Geiger, Adam; Ramanjulu, Joshi M.; Vera, Matthew D.; Sir Deshpande, Bhagyashri; Pfizenmayer, Amy; Abazeed, Mohamed; Krosky, Daniel J.; Beidler, David; Joullie, Madeleine M.; Toogood, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4212-4218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthetic and naturally occurring didemnins are potent and specific inhibitors of protein synthesis in vitro.  Structure-activity anal. indicates a requirement for the intact macrocycle; however, the smaller ring size represented by the didemnin analog, tamandarin A, is equipotent to didemnin B.  Replacement of the N,O-dimethyltyrosine by a N-methylphenylalanine or N-methylleucine residue is also well-tolerated.  The rank order for inhibition of protein synthesis in vitro appears to be retained in MCF-7 cells, albeit at much higher potency.  This increase in potency is explained for the first time by data indicating that MCF-7 cells can accumulate didemnin B up to 2-3 orders of magnitude compared to the growth medium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrLN_VBE5ycLVg90H21EOLACvtfcHk0lg19O3n455gxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1Ois7c%253D&md5=ab6df5e2873ec2937eaffad9de24ab36</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Fjm000168v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000168v%26sid%3Dliteratum%253Aachs%26aulast%3DAhuja%26aufirst%3DD.%26aulast%3DGeiger%26aufirst%3DA.%26aulast%3DRamanjulu%26aufirst%3DJ.%2BM.%26aulast%3DVera%26aufirst%3DM.%2BD.%26aulast%3DSirDeshpande%26aufirst%3DB.%26aulast%3DPfizenmayer%26aufirst%3DA.%26aulast%3DAbazeed%26aufirst%3DM.%26aulast%3DKrosky%26aufirst%3DD.%2BJ.%26aulast%3DBeidler%26aufirst%3DD.%26aulast%3DJoulli%25C3%25A9%26aufirst%3DM.%2BM.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26atitle%3DInhibition%2520of%2520Protein%2520Synthesis%2520by%2520Didemnins%253A%2520Cell%2520Potency%2520and%2520SAR%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4212%26epage%3D4218%26doi%3D10.1021%2Fjm000168v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Raeve, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepage, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Valckenborgh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Camp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderkerken, K.</span></span> <span> </span><span class="NLM_article-title">Antitumour and Antiangiogenic Effects of Aplidin® in the 5TMM Syngeneic Models of Multiple Myeloma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1966</span>– <span class="NLM_lpage">1974</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6604388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fsj.bjc.6604388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18521088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvV2htLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=1966-1974&author=J.+Caersauthor=E.+Menuauthor=H.+De+Raeveauthor=D.+Lepageauthor=E.+Van+Valckenborghauthor=B.+Van+Campauthor=E.+Alvarezauthor=K.+Vanderkerken&title=Antitumour+and+Antiangiogenic+Effects+of+Aplidin%C2%AE+in+the+5TMM+Syngeneic+Models+of+Multiple+Myeloma&doi=10.1038%2Fsj.bjc.6604388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma</span></div><div class="casAuthors">Caers, J.; Menu, E.; De Raeve, H.; Lepage, D.; Van Valckenborgh, E.; Van Camp, B.; Alvarez, E.; Vanderkerken, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1966-1974</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aplidin is an antitumor drug, currently undergoing phase II evaluation in different haematol. and solid tumors.  In this study, we analyzed the antimyeloma effects of Aplidin in the syngeneic 5T33MM model, which is representable for the human disease.  In vitro, Aplidin inhibited 5T33MMvv DNA synthesis with an IC50 of 3.87 n.  On cell-cycle progression, the drug induced an arrest in transition from G0/G1 to S phase, while Western blot showed a decreased cyclin D1 and CDK4 expression.  Furthermore, Aplidin induced apoptosis by lowering the mitochondrial membrane potential, by inducing cytochrome c release and by activating caspase-9 and caspase-3.  For the in vivo expt., 5T33MM-injected C57Bl/KaLwRij mice were i.p. treated with vehicle or Aplidin (90 μg/kg-1 daily).  Chronic treatment with Aplidin was well tolerated and reduced serum paraprotein concn. by 42% (P<0.001), while BM invasion with myeloma cells was decreased by 35% (P<0.001).  Aplidin also reduced the myeloma-assocd. angiogenesis to basal values.  This antiangiogenic effect was confirmed in vitro and explained by inhibition of endothelial cell proliferation and vessel formation.  These data indicate that Aplidin is well tolerated in vivo and its antitumor and antiangiogenic effects support the use of the drug in multiple myeloma.  British Journal of Cancer (2008) 98, 1966-1974. doi:10.1038/sj.bjc.6604388 www.bjcancer.com Published online 3 June 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXSH4kqhxJC7Vg90H21EOLACvtfcHk0liOl1eMKTXiKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvV2htLw%253D&md5=73d2181640fc9d1e38fe2a8b0f546a3c</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604388%26sid%3Dliteratum%253Aachs%26aulast%3DCaers%26aufirst%3DJ.%26aulast%3DMenu%26aufirst%3DE.%26aulast%3DDe%2BRaeve%26aufirst%3DH.%26aulast%3DLepage%26aufirst%3DD.%26aulast%3DVan%2BValckenborgh%26aufirst%3DE.%26aulast%3DVan%2BCamp%26aufirst%3DB.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DVanderkerken%26aufirst%3DK.%26atitle%3DAntitumour%2520and%2520Antiangiogenic%2520Effects%2520of%2520Aplidin%25C2%25AE%2520in%2520the%25205TMM%2520Syngeneic%2520Models%2520of%2520Multiple%2520Myeloma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D1966%26epage%3D1974%26doi%3D10.1038%2Fsj.bjc.6604388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barboza, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budak-Alpdogan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aracil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertino, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, D.</span></span> <span> </span><span class="NLM_article-title">Plitidepsin (Aplidin) Is a Potent Inhibitor of Diffuse Large Cell and Burkitt Lymphoma and Is Synergistic with Rituximab</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.4161/cbt.13.2.18876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.4161%2Fcbt.13.2.18876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22336911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Oms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=114-122&author=N.+M.+Barbozaauthor=D.+J.+Medinaauthor=T.+Budak-Alpdoganauthor=M.+Aracilauthor=J.+M.+Jimenoauthor=J.+R.+Bertinoauthor=D.+Banerjee&title=Plitidepsin+%28Aplidin%29+Is+a+Potent+Inhibitor+of+Diffuse+Large+Cell+and+Burkitt+Lymphoma+and+Is+Synergistic+with+Rituximab&doi=10.4161%2Fcbt.13.2.18876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab</span></div><div class="casAuthors">Barboza, Nora M.; Medina, Daniel J.; Budak-Alpdogan, Tulin; Aracil, Miguel; Jimeno, Jose M.; Bertino, Joseph R.; Banerjee, Debabrata</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-122</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Plitidepsin (Aplidin), an antitumor agent of marine origin, presently is undergoing phase II/III clin. trials, and has shown promise for the treatment of lymphoma.  Here, we describe the antitumor effects of plitidepsin alone and in combination with rituximab and investigated the effects of each drug and the combination on the cell cycle and mechanism of cell death.  Several Diffuse Large Cell Lymphoma (DLCL) lines and Burkitt cell lines were tested for sensitivity to plitidepsin and rituximab.  All DLCL and Burkitt lymphoma cell lines were inhibited by plitidepsin in nanomolar concns., while rituximab sensitivity varied among different cell lines.  Ramos and the RL cell lines proved sensitive to rituximab and were used to test the effects of each of the two drugs.  The two agents exhibited synergism at all tested concns.  For in vivo studies, irradiated athymic nude mice were engrafted with the Ramos lymphoma.  Treatment was initiated when the tumors were ∼0.5 cm in diam., and toxic and therapeutic effects were monitored.  In the in vivo study, additive effects of the combined two drugs, was demonstrated without an increase in host toxicity.  The in vitro synergy and the in vivo additive antitumor effects without an increase in host toxicity with two relatively non-marrow suppressive agents encourages further development of this combination for treatment of aggressive B-cell lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCZkeiJGxBcbVg90H21EOLACvtfcHk0liOl1eMKTXiKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Oms7k%253D&md5=54d81693e1d711a84c08e4c2be4eff39</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.4161%2Fcbt.13.2.18876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.13.2.18876%26sid%3Dliteratum%253Aachs%26aulast%3DBarboza%26aufirst%3DN.%2BM.%26aulast%3DMedina%26aufirst%3DD.%2BJ.%26aulast%3DBudak-Alpdogan%26aufirst%3DT.%26aulast%3DAracil%26aufirst%3DM.%26aulast%3DJimeno%26aufirst%3DJ.%2BM.%26aulast%3DBertino%26aufirst%3DJ.%2BR.%26aulast%3DBanerjee%26aufirst%3DD.%26atitle%3DPlitidepsin%2520%2528Aplidin%2529%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520Diffuse%2520Large%2520Cell%2520and%2520Burkitt%2520Lymphoma%2520and%2520Is%2520Synergistic%2520with%2520Rituximab%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2012%26volume%3D13%26spage%3D114%26epage%3D122%26doi%3D10.4161%2Fcbt.13.2.18876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Álvarez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Nieto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballero, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateos, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, A.</span></span> <span> </span><span class="NLM_article-title">Plitidepsin: Design, Development, and Potential Place in Therapy</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S94165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.2147%2FDDDT.S94165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28176904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1CltL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=253-264&author=S.+Alonso-%C3%81lvarezauthor=E.+Pardalauthor=D.+S%C3%A1nchez-Nietoauthor=M.+Navarroauthor=M.+D.+Caballeroauthor=M.+V.+Mateosauthor=A.+Mart%C3%ADn&title=Plitidepsin%3A+Design%2C+Development%2C+and+Potential+Place+in+Therapy&doi=10.2147%2FDDDT.S94165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Plitidepsin: design, development, and potential place in therapy</span></div><div class="casAuthors">Alonso-Alvarez, Sara; Pardal, Emilia; Sanchez-Nieto, Diego; Navarro, Miguel; Caballero, Maria Dolores; Mateos, Maria Victoria; Martin, Alejandro</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">253-264</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Plitidepsin is a cyclic depsipeptide that was first isolated from a Mediterranean marine tunicate (Aplidium albicans) and, at present, is manufd. by total synthesis and commercialized as Aplidin.  Its antitumor activity, obsd. in preclin. in vitro and in vivo studies has prompted numerous clin. trials to be conducted over the last 17 years, alone or in combination with other anticancer agents.  Single-agent plitidepsin has shown limited antitumor activity and a tolerable safety profile in several malignancies, such as noncutaneous peripheral T-cell lymphoma, melanoma, and multiple myeloma.  In patients with relapsed or refractory multiple myeloma, plitidepsin activity seems to be enhanced after addn. of dexamethasone while remaining well tolerated, and a Phase III trial comparing plitidepsin plus dexamethasone vs dexamethasone alone is underway.  Addnl. studies are required to better define the role of plitidepsin in combination with other active agents in these indications.  Results of plitidepsin activity in other hematol. malignancies or solid tumors have been disappointing so far.  Further studies analyzing its mechanisms of action and potential biomarkers will help select patients who may benefit most from this drug.  In this review, we critically analyze the published studies on plitidepsin in hematol. malignancies and solid tumors and discuss its current role and future perspectives in treating these malignancies.  We also review its design, pharmaceutical data, and mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLQpZd8DLkQLVg90H21EOLACvtfcHk0liOl1eMKTXiKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1CltL3L&md5=205e3b73fd8e1c2a9cc85a6329d9a0e2</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S94165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S94165%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso-%25C3%2581lvarez%26aufirst%3DS.%26aulast%3DPardal%26aufirst%3DE.%26aulast%3DS%25C3%25A1nchez-Nieto%26aufirst%3DD.%26aulast%3DNavarro%26aufirst%3DM.%26aulast%3DCaballero%26aufirst%3DM.%2BD.%26aulast%3DMateos%26aufirst%3DM.%2BV.%26aulast%3DMart%25C3%25ADn%26aufirst%3DA.%26atitle%3DPlitidepsin%253A%2520Design%252C%2520Development%252C%2520and%2520Potential%2520Place%2520in%2520Therapy%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D253%26epage%3D264%26doi%3D10.2147%2FDDDT.S94165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faivre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chièze, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbaldo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ady-Vago, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Lazaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozahic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pico, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, E.</span></span> <span> </span><span class="NLM_article-title">Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients with Advanced Malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">7871</span>– <span class="NLM_lpage">7880</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.09.357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1200%2FJCO.2005.09.357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16172454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Cqs7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=7871-7880&author=S.+Faivreauthor=S.+Chi%C3%A8zeauthor=C.+Delbaldoauthor=N.+Ady-Vagoauthor=C.+Guzmanauthor=L.+Lopez-Lazaroauthor=S.+Lozahicauthor=J.+Jimenoauthor=F.+Picoauthor=J.+P.+Armandauthor=J.+A.+L.+Martinauthor=E.+Raymond&title=Phase+I+and+Pharmacokinetic+Study+of+Aplidine%2C+a+New+Marine+Cyclodepsipeptide+in+Patients+with+Advanced+Malignancies&doi=10.1200%2FJCO.2005.09.357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies</span></div><div class="casAuthors">Faivre, Sandrine; Chieze, Stephanie; Delbaldo, Catherine; Ady-vago, Nora; Guzman, Cecilia; Lopez-Lazaro, Luis; Lozahic, Stephanie; Jimeno, Jose; Pico, Fernando; Armand, Jean Pierre; Martin, Jose Antonio Lopez; Raymond, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">7871-7880</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To establish the safety, pharmacokinetic parameters, max.-tolerated dose, and recommended dose of aplidine, a novel marine cyclodepsipeptide, in patients with advanced cancer.  Patients and Methods: Using a modified Fibonacci method, we performed a phase I and pharmacokinetic study of aplidine administered as a 24-h i.v. infusion every 2 wk.  Results: Sixty-seven patients received aplidine at a dose ranging from 0.2 to 8 mg/m2.  Dose-limiting myotoxicity corresponding to grade 2 to 3 creatine phosphokinase elevation and grade 1 to 2 myalgia and muscle weakness occurred in two of six patients at 6 mg/m2.  No cardiac toxicity was obsd.  Electron microscopy anal. showed the disappearance of thick filaments of myosin.  Grade 3 muscle toxicity occurred in three of 14 patients at the recommended dose of 5 mg/m2 and seemed to be more readily reversible with oral carnitine (1 g/10 kg).  Therefore, dose escalation was resumed using carnitine prophylactically, allowing an increase in the recommended dose to 7 mg/m2.  Other toxicities were nausea and vomiting, diarrhea, asthenia, and transaminase elevation with mild hematol. toxicity.  Aplidine displayed a long half-life (21 to 44 h), low clearance (45 to 49 L/h), and a high vol. of distribution (1,036 to 1,124 L) with high interpatient variability in plasma, whereas in whole blood, clearance ranged from 3.0 to 6.2 L/h.  Minor responses and prolonged tumor stabilizations were obsd. in patients with medullary thyroid carcinoma.  Conclusion: Muscle toxicity was dose limiting in this study.  Recommended doses of aplidine were 5 and 7 mg/m2 without and with carnitine, resp.  The role of carnitine will be further explored in phase II studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGAxN5YaRqJrVg90H21EOLACvtfcHk0lhOjx_pIWLtMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Cqs7fM&md5=e624d758c5f45858616de980d46130b3</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.09.357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.09.357%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DChi%25C3%25A8ze%26aufirst%3DS.%26aulast%3DDelbaldo%26aufirst%3DC.%26aulast%3DAdy-Vago%26aufirst%3DN.%26aulast%3DGuzman%26aufirst%3DC.%26aulast%3DLopez-Lazaro%26aufirst%3DL.%26aulast%3DLozahic%26aufirst%3DS.%26aulast%3DJimeno%26aufirst%3DJ.%26aulast%3DPico%26aufirst%3DF.%26aulast%3DArmand%26aufirst%3DJ.%2BP.%26aulast%3DMartin%26aufirst%3DJ.%2BA.%2BL.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DPhase%2520I%2520and%2520Pharmacokinetic%2520Study%2520of%2520Aplidine%252C%2520a%2520New%2520Marine%2520Cyclodepsipeptide%2520in%2520Patients%2520with%2520Advanced%2520Malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D7871%26epage%3D7880%26doi%3D10.1200%2FJCO.2005.09.357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Izquierdo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jodrell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Martin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germá, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, J. F.</span></span> <span> </span><span class="NLM_article-title">Phase I Clinical and Pharmacokinetic Study of Plitidepsin as a 1-h Weekly Intravenous Infusion in Patients with Advanced Solid Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3105</span>– <span class="NLM_lpage">3112</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-1652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1158%2F1078-0432.CCR-07-1652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18483378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVCmur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=3105-3112&author=M.+A.+Izquierdoauthor=A.+Bowmanauthor=M.+Garc%C3%ADaauthor=D.+Jodrellauthor=M.+Martinezauthor=B.+Pardoauthor=J.+G%C3%B3mezauthor=J.+A.+L%C3%B3pez-Martinauthor=J.+Jimenoauthor=J.+R.+Germ%C3%A1author=J.+F.+Smyth&title=Phase+I+Clinical+and+Pharmacokinetic+Study+of+Plitidepsin+as+a+1-h+Weekly+Intravenous+Infusion+in+Patients+with+Advanced+Solid+Tumors&doi=10.1158%2F1078-0432.CCR-07-1652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Clinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Izquierdo, Miguel A.; Bowman, Angela; Garcia, Margarita; Jodrell, Duncan; Martinez, Marisa; Pardo, Beatriz; Gomez, Javier; Lopez-Martin, Jose A.; Jimeno, Jose; Germa, Jose R.; Smyth, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3105-3112</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Plitidepsin, given as a 1-h weekly i.v. infusion for 3 consecutive weeks during a 4-wk treatment cycle, was investigated in patients with solid tumors to det. the max. tolerated dose and the recommended dose (RD) using this administration schedule.  Consecutive cohorts of patients with metastatic solid tumors or non-Hodgkin's lymphomas were to be treated at escalating doses of plitidepsin in a conventional phase I study including pharmacokinetic analyses of plitidepsin in plasma, whole blood, and blood cell pellets.  Forty-nine patients with solid tumors were enrolled, and 48 were treated with plitidepsin (doses from 0.133 to 3.6 mg/m2/wk).  Dose-limiting toxicities (defining 3.6 mg/m2/wk as the max. tolerated dose) included myalgia, increased creatine phosphokinase levels, and sustained grade 3/4 increases of hepatic enzyme levels.  The RD was established at 3.2 mg/m2/wk.  The most common toxicities were fatigue, vomiting/nausea, anorexia, injection site reaction, and pain, mostly of mild or moderate severity.  Muscular toxicity manifested by mild-moderate myalgia, weakness, and/or creatine phosphokinase elevations occurred in ∼25% of patients and seemed to be dose related.  Transient transaminase elevations were frequent but achieved grade 3 or 4 in only ∼10% of patients.  Plitidepsin lacked significant hematol. toxicity.  No complete or partial tumor responses were obsd.; however, five patients had disease stabilization (including one patient with medullary thyroid carcinoma with an unconfirmed partial response and one patient with renal carcinoma with major tumor shrinkage in lung metastases).  Pharmacokinetic results for the RD indicated a long plasma half-life give value (16.8 ± 7.7 h) and a high vol. of distribution value (525.2 ± 219.3 L).  The recommended dose for plitidepsin given as a weekly 1-h schedule was 3.2 mg/m2/wk.  Muscular and liver toxicity were dose limiting at 3.6 mg/m2/wk.  Addnl. evaluation of this dose dense schedule is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDy48tEz3dmLVg90H21EOLACvtfcHk0lhOjx_pIWLtMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVCmur4%253D&md5=83458c84c28f4df267c566b65a6c6d38</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1652%26sid%3Dliteratum%253Aachs%26aulast%3DIzquierdo%26aufirst%3DM.%2BA.%26aulast%3DBowman%26aufirst%3DA.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DM.%26aulast%3DJodrell%26aufirst%3DD.%26aulast%3DMartinez%26aufirst%3DM.%26aulast%3DPardo%26aufirst%3DB.%26aulast%3DG%25C3%25B3mez%26aufirst%3DJ.%26aulast%3DL%25C3%25B3pez-Martin%26aufirst%3DJ.%2BA.%26aulast%3DJimeno%26aufirst%3DJ.%26aulast%3DGerm%25C3%25A1%26aufirst%3DJ.%2BR.%26aulast%3DSmyth%26aufirst%3DJ.%2BF.%26atitle%3DPhase%2520I%2520Clinical%2520and%2520Pharmacokinetic%2520Study%2520of%2520Plitidepsin%2520as%2520a%25201-h%2520Weekly%2520Intravenous%2520Infusion%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D3105%26epage%3D3112%26doi%3D10.1158%2F1078-0432.CCR-07-1652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">The Antiproliferative Agent Didemnin B Uncompetitively Inhibits Palmitoyl Protein Thioesterase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">10488</span>– <span class="NLM_lpage">10492</span>, <span class="refDoi"> DOI: 10.1021/bi9804479</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi9804479" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK1cXktFKqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=10488-10492&author=L.+Mengauthor=N.+Sinauthor=C.+M.+Crews&title=The+Antiproliferative+Agent+Didemnin+B+Uncompetitively+Inhibits+Palmitoyl+Protein+Thioesterase&doi=10.1021%2Fbi9804479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The Antiproliferative Agent Didemnin B Uncompetitively Inhibits Palmitoyl Protein Thioesterase</span></div><div class="casAuthors">Meng, Lihao; Sin, Ny; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">10488-10492</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dynamic protein palmitoylation has been proposed to regulate GTP-binding proteins by controlling their membrane assocn. and thus their access to key signaling proteins.  While the palmitoyl protein thioesterase(s) responsible for depalmitoylation of plasma membrane-assocd. signaling proteins has (have) not been identified, the lysosomal palmitoyl protein thioesterase 1 (PPT1) has proven useful in in vitro studies of membrane localization requirements of GTP-binding proteins.  We have previously reported the binding of the antiproliferative cyclic depsipeptide didemnin B to PPT1.  To investigate the nature of this binding and its possible effects on PPT1 enzymic activity, human PPT1 was expressed in an insect cell baculoviral system, and inhibition assays were performed using both [3H]palmitoyl Ha-Ras and myristoyl-CoA as PPT1 substrates.  Didemnin B was shown to inhibit recombinant human PPT1 with a Ki of 92 nM.  Kinetic anal. of this inhibition revealed that didemnin B inhibits PPT1 uncompetitively.  Providing biochem. support for an uncompetitive mode of inhibition, in vitro binding studies of PPT1 and didemnin indicate that the natural product binds preferentially to the enzyme-substrate complex PPT1-palmitoyl-CoA.  As the first described inhibitor of PPT1, didemnin B may prove to be a useful tool in the investigation of protein palmitoylation regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq81qVLF2dKzLVg90H21EOLACvtfcHk0lhYV38IjqxNPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktFKqsLs%253D&md5=84f48ee72d33cdcced2af6386e1b2db3</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fbi9804479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi9804479%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DThe%2520Antiproliferative%2520Agent%2520Didemnin%2520B%2520Uncompetitively%2520Inhibits%2520Palmitoyl%2520Protein%2520Thioesterase%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D10488%26epage%3D10492%26doi%3D10.1021%2Fbi9804479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">Plitidepsin: A Potential New Treatment for Relapsed/Refractory Multiple Myeloma</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.2217/fon-2018-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.2217%2Ffon-2018-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30111169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFGis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=109-120&author=M.+Leischauthor=A.+Egleauthor=R.+Greil&title=Plitidepsin%3A+A+Potential+New+Treatment+for+Relapsed%2FRefractory+Multiple+Myeloma&doi=10.2217%2Ffon-2018-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma</span></div><div class="casAuthors">Leisch, Michael; Egle, Alexander; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-120</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Plitidepsin is a marine-derived anticancer compd. isolated from the Mediterranean tunicate Applidium albicans.  It exerts pleiotropic effects on cancer cells, most likely by binding to the eukaryotic translation eEF1A2.  This ultimately leads to cell-cycle arrest, growth inhibition and induction of apoptosis via multiple pathway alterations.  Recently, a Phase III randomized trial in patients with relapsed/refractory multiple myeloma reported outcomes for plitidepsin plus dexamethasone compared with dexamethasone.  Median progression-free survival was 3.8 mo in the plitidepsin arm and 1.9 mo in the dexamethasone arm (HR: 0.611; p = 0.0048).  Here, we review preclin. data regarding plitidepsins mechanism of action, give an overview of clin. trial results across different tumor types as well as the latest results in multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreQ2wJUJXILbVg90H21EOLACvtfcHk0lhYV38IjqxNPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFGis7k%253D&md5=011f4da81faa52d1a59279093753f05d</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.2217%2Ffon-2018-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2018-0492%26sid%3Dliteratum%253Aachs%26aulast%3DLeisch%26aufirst%3DM.%26aulast%3DEgle%26aufirst%3DA.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DPlitidepsin%253A%2520A%2520Potential%2520New%2520Treatment%2520for%2520Relapsed%252FRefractory%2520Multiple%2520Myeloma%26jtitle%3DFuture%2520Oncol.%26date%3D2019%26volume%3D15%26spage%3D109%26epage%3D120%26doi%3D10.2217%2Ffon-2018-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mateos, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cibeira, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prosper, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oriol, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De La Rubia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahuerta, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sanz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Extremera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szyldergemajn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrado, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bladé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, J.</span></span> <span> </span><span class="NLM_article-title">Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-h Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3260</span>– <span class="NLM_lpage">3269</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-0469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1158%2F1078-0432.CCR-10-0469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=20530693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3260-3269&author=M.+V.+Mateosauthor=M.+T.+Cibeiraauthor=P.+G.+Richardsonauthor=F.+Prosperauthor=A.+Oriolauthor=J.+De+La+Rubiaauthor=J.+J.+Lahuertaauthor=R.+Garc%C3%ADa-Sanzauthor=S.+Extremeraauthor=S.+Szyldergemajnauthor=C.+Corradoauthor=H.+Singerauthor=C.+S.+Mitsiadesauthor=K.+C.+Andersonauthor=J.+Blad%C3%A9author=J.+San+Miguel&title=Phase+II+Clinical+and+Pharmacokinetic+Study+of+Plitidepsin+3-h+Infusion+Every+Two+Weeks+Alone+or+with+Dexamethasone+in+Relapsed+and+Refractory+Multiple+Myeloma&doi=10.1158%2F1078-0432.CCR-10-0469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma</span></div><div class="casAuthors">Mateos, Maria Victoria; Cibeira, Maria Teresa; Richardson, Paul G.; Prosper, Felipe; Oriol, Albert; de la Rubia, Javier; Lahuerta, Juan Jose; Garcia-Sanz, Ramon; Extremera, Sonia; Szyldergemajn, Sergio; Corrado, Claudia; Singer, Harald; Mitsiades, Constantine S.; Anderson, Kenneth C.; Blade, Joan; San Miguel, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3260-3269</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: This trial evaluated the antitumor activity and safety of the marine-derived cyclodepsipeptide plitidepsin in patients with relapsed/refractory multiple myeloma.  Exptl. Design: This was a prospective, multicenter, open-label, single-arm, phase II trial with plitidepsin at 5 mg/m2 as a 3-h i.v. infusion every two weeks.  The protocol was amended to allow patients with suboptimal response to single-agent plitidepsin to add 20 mg/day on days 1 to 4 of oral dexamethasone every two weeks.  RESULTS: Fifty-one patients started treatment with plitidepsin and 47 were evaluable for efficacy.  The overall response rate (complete response plus partial response plus minimal response) was 13% with plitidepsin alone and 22% in the cohort of patients with the addn. of dexamethasone (n = 19, 18 evaluable).  Both plitidepsin alone and with dexamethasone were feasible and well tolerated.  Anemia (29%) and thrombocytopenia (18%) were the most frequent grade 3/4 hematol. toxicities.  Fatigue (16%), muscular toxicity (6%), and transient alanine aminotransferase/aspartate aminotransferase (27%) and creatine phosphokinase (23%) increases were the most relevant nonhematol. side effects.  A prolonged plasma half-life was obsd. in responding patients as compared with nonresponding patients (P = 0.009).  CONCLUSIONS: Single-agent plitidepsin has limited but reproducible activity in relapsed/refractory multiple myeloma patients.  Activity obsd. after dexamethasone addn. merits further study.  Both regimens were well tolerated in this heavily pretreated population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKP3yz58GO9bVg90H21EOLACvtfcHk0lhYV38IjqxNPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKqsrs%253D&md5=3debb134c2651fba943006c99a33837a</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0469%26sid%3Dliteratum%253Aachs%26aulast%3DMateos%26aufirst%3DM.%2BV.%26aulast%3DCibeira%26aufirst%3DM.%2BT.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DProsper%26aufirst%3DF.%26aulast%3DOriol%26aufirst%3DA.%26aulast%3DDe%2BLa%2BRubia%26aufirst%3DJ.%26aulast%3DLahuerta%26aufirst%3DJ.%2BJ.%26aulast%3DGarc%25C3%25ADa-Sanz%26aufirst%3DR.%26aulast%3DExtremera%26aufirst%3DS.%26aulast%3DSzyldergemajn%26aufirst%3DS.%26aulast%3DCorrado%26aufirst%3DC.%26aulast%3DSinger%26aufirst%3DH.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DBlad%25C3%25A9%26aufirst%3DJ.%26aulast%3DSan%2BMiguel%26aufirst%3DJ.%26atitle%3DPhase%2520II%2520Clinical%2520and%2520Pharmacokinetic%2520Study%2520of%2520Plitidepsin%25203-h%2520Infusion%2520Every%2520Two%2520Weeks%2520Alone%2520or%2520with%2520Dexamethasone%2520in%2520Relapsed%2520and%2520Refractory%2520Multiple%2520Myeloma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3260%26epage%3D3269%26doi%3D10.1158%2F1078-0432.CCR-10-0469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geoerger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estlin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearns, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corradini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel, B. De</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prados, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassal, G.</span></span> <span> </span><span class="NLM_article-title">A Phase i and Pharmacokinetic Study of Plitidepsin in Children with Advanced Solid Tumours: An Innovative Therapies for Children with Cancer (ITCC) Study</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2011.10.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.ejca.2011.10.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22119199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=289-296&author=B.+Geoergerauthor=E.+J.+Estlinauthor=I.+Aertsauthor=P.+Kearnsauthor=B.+Gibsonauthor=N.+Corradiniauthor=F.+Dozauthor=P.+Lardelliauthor=B.+De+Miguelauthor=A.+Sotoauthor=R.+Pradosauthor=G.+Vassal&title=A+Phase+i+and+Pharmacokinetic+Study+of+Plitidepsin+in+Children+with+Advanced+Solid+Tumours%3A+An+Innovative+Therapies+for+Children+with+Cancer+%28ITCC%29+Study&doi=10.1016%2Fj.ejca.2011.10.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study</span></div><div class="casAuthors">Geoerger, Birgit; Estlin, Edward J.; Aerts, Isabelle; Kearns, Pamela; Gibson, Brenda; Corradini, Nadege; Doz, Francois; Lardelli, Pilar; De Miguel, Bernardo; Soto, Arturo; Prados, Raquel; Vassal, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-296</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Aims: To det. the max. tolerated dose, the recommended dose (RD) for phase II studies, dose-limiting toxicities and pharmacokinetics (PK) for plitidepsin administered as a 3-h i.v. infusion every 2 wk (one cycle) to children with refractory or relapsed solid tumors.  Methods: Consecutive cohorts of patients were treated according to a std. 3 + 3' design with escalating doses of plitidepsin at 4, 5 and 6 mg/m2.  Addnl. 15 patients were recruited at the RD to further evaluate safety and pharmacokinetic assocns. with respect to age, dose level and toxicity.  Results: Thirty-eight of 41 patients registered received plitidepsin.  Dose-limiting toxicities during the first three treatment cycles related to myalgia, elevated creatine phosphokinase, transaminase increase and nausea/vomiting.  The RD for plitidepsin is 5 mg/m2.  PK analyses revealed high inter-patient variability in plasma, but a similar clearance of plitidepsin in children and adolescents.  One partial response confirmed at 4 wk in a patient with neuroblastoma and one unconfirmed partial response in a pancreatoblastoma were obsd.; four other patients with neuroblastoma, medulloblastoma, glioblastoma and rhabdoid tumor had disease stabilizations lasting ≥3 mo.  Conclusion: Plitidepsin administered to children as a 3-h infusion every 2 wk is received with manageable toxicity for children with cancer, and the RD is 5 mg/m2.  Pharmacokinetic parameters in children and adolescents are comparable to adults.  Future phase II studies of plitidepsin are warranted, and our results suggest that plitidepsin could be appropriately developed in combination with other antitumor where myelosuppression is dose-limiting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8p7iO4pEb8LVg90H21EOLACvtfcHk0liIQ_CM5BSSNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOlsrs%253D&md5=6331b17a17783608e90048aec2fcae00</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2011.10.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2011.10.036%26sid%3Dliteratum%253Aachs%26aulast%3DGeoerger%26aufirst%3DB.%26aulast%3DEstlin%26aufirst%3DE.%2BJ.%26aulast%3DAerts%26aufirst%3DI.%26aulast%3DKearns%26aufirst%3DP.%26aulast%3DGibson%26aufirst%3DB.%26aulast%3DCorradini%26aufirst%3DN.%26aulast%3DDoz%26aufirst%3DF.%26aulast%3DLardelli%26aufirst%3DP.%26aulast%3DMiguel%26aufirst%3DB.%2BDe%26aulast%3DSoto%26aufirst%3DA.%26aulast%3DPrados%26aufirst%3DR.%26aulast%3DVassal%26aufirst%3DG.%26atitle%3DA%2520Phase%2520i%2520and%2520Pharmacokinetic%2520Study%2520of%2520Plitidepsin%2520in%2520Children%2520with%2520Advanced%2520Solid%2520Tumours%253A%2520An%2520Innovative%2520Therapies%2520for%2520Children%2520with%2520Cancer%2520%2528ITCC%2529%2520Study%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2012%26volume%3D48%26spage%3D289%26epage%3D296%26doi%3D10.1016%2Fj.ejca.2011.10.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spicka, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocio, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakervee, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banh, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Rozario, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimopoulos, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Extremera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahatt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfaro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carella, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuleman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hájek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symeonidis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonneveld, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateos, M. V.</span></span> <span> </span><span class="NLM_article-title">Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">2139</span>– <span class="NLM_lpage">2150</span>, <span class="refDoi"> DOI: 10.1007/s00277-019-03739-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs00277-019-03739-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31240472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1KktrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2019&pages=2139-2150&author=I.+Spickaauthor=E.+M.+Ocioauthor=H.+E.+Oakerveeauthor=R.+Greilauthor=R.+H.+Banhauthor=S.+Y.+Huangauthor=J.+M.+D%E2%80%99Rozarioauthor=M.+A.+Dimopoulosauthor=S.+Mart%C3%ADnezauthor=S.+Extremeraauthor=C.+Kahattauthor=V.+Alfaroauthor=A.+M.+Carellaauthor=N.+Meulemanauthor=R.+H%C3%A1jekauthor=A.+Symeonidisauthor=C.+K.+Minauthor=P.+Cannellauthor=H.+Ludwigauthor=P.+Sonneveldauthor=M.+V.+Mateos&title=Randomized+Phase+III+Study+%28ADMYRE%29+of+Plitidepsin+in+Combination+with+Dexamethasone+vs.+Dexamethasone+Alone+in+Patients+with+Relapsed%2FRefractory+Multiple+Myeloma&doi=10.1007%2Fs00277-019-03739-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma</span></div><div class="casAuthors">Spicka, Ivan; Ocio, Enrique M.; Oakervee, Heather E.; Greil, Richard; Banh, Raymond H.; Huang, Shang-Yi; D'Rozario, James M.; Dimopoulos, Meletios A.; Martinez, Sara; Extremera, Sonia; Kahatt, Carmen; Alfaro, Vicente; Carella, Angelo M.; Meuleman, Nathalie; Hajek, Roman; Symeonidis, Argiris; Min, Chang-Ki; Cannell, Paul; Ludwig, Heinz; Sonneveld, Pieter; Mateos, Maria Victoria</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hematology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2139-2150</span>CODEN:
                <span class="NLM_cas:coden">ANHEE8</span>;
        ISSN:<span class="NLM_cas:issn">0939-5555</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) vs. DXM alone in patients with relapsed/refractory multiple myeloma after at least three but not more than six prior regimens, including at least bortezomib and lenalidomide or thalidomide.  Patients were randomly assigned (2:1) to receive plitidepsin 5 mg/m2 on D1 and D15 plus DXM 40 mg on D1, D8, D15, and D22 (arm A, n = 171) or DXM 40 mg on D1, D8, D15, and D22 (arm B, n = 84) q4wk.  The primary endpoint was progression-free survival (PFS).  Median PFS without disease progression (PD) confirmation (IRC assessment) was 2.6 mo (arm A) and 1.7 mo (arm B) (HR = 0.650; p = 0.0054).  Median PFS with PD confirmation (investigator's assessment) was 3.8 mo (arm A) and 1.9 mo (arm B) (HR = 0.611; p = 0.0040).  Median overall survival (OS, intention-to-treat anal.) was 11.6 mo (arm A) and 8.9 mo (arm B) (HR = 0.797; p = 0.1261).  OS improvement favoring arm A was found when discounting a crossover effect (37 patients crossed over from arm B to arm A) (two-stage method; HR = 0.622; p = 0.0015).  The most common grade 3/4 treatment-related adverse events (% of patients arm A/arm B) were fatigue (10.8%/1.2%), myalgia (5.4%/0%), and nausea (3.6%/1.2%), being usually transient and reversible.  The safety profile does not overlap with the toxicity obsd. with other agents used in multiple myeloma.  In conclusion, efficacy data, the reassuring safety profile, and the novel mechanism of action of plitidepsin suggest that this combination can be an alternative option in patients with relapsed/refractory multiple myeloma after at least three prior therapy lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqESyopQh155bVg90H21EOLACvtfcHk0liIQ_CM5BSSNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1KktrnE&md5=4ac511b71ece280fd3675f247075a157</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1007%2Fs00277-019-03739-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-019-03739-2%26sid%3Dliteratum%253Aachs%26aulast%3DSpicka%26aufirst%3DI.%26aulast%3DOcio%26aufirst%3DE.%2BM.%26aulast%3DOakervee%26aufirst%3DH.%2BE.%26aulast%3DGreil%26aufirst%3DR.%26aulast%3DBanh%26aufirst%3DR.%2BH.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DD%25E2%2580%2599Rozario%26aufirst%3DJ.%2BM.%26aulast%3DDimopoulos%26aufirst%3DM.%2BA.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DS.%26aulast%3DExtremera%26aufirst%3DS.%26aulast%3DKahatt%26aufirst%3DC.%26aulast%3DAlfaro%26aufirst%3DV.%26aulast%3DCarella%26aufirst%3DA.%2BM.%26aulast%3DMeuleman%26aufirst%3DN.%26aulast%3DH%25C3%25A1jek%26aufirst%3DR.%26aulast%3DSymeonidis%26aufirst%3DA.%26aulast%3DMin%26aufirst%3DC.%2BK.%26aulast%3DCannell%26aufirst%3DP.%26aulast%3DLudwig%26aufirst%3DH.%26aulast%3DSonneveld%26aufirst%3DP.%26aulast%3DMateos%26aufirst%3DM.%2BV.%26atitle%3DRandomized%2520Phase%2520III%2520Study%2520%2528ADMYRE%2529%2520of%2520Plitidepsin%2520in%2520Combination%2520with%2520Dexamethasone%2520vs.%2520Dexamethasone%2520Alone%2520in%2520Patients%2520with%2520Relapsed%252FRefractory%2520Multiple%2520Myeloma%26jtitle%3DAnn.%2520Hematol.%26date%3D2019%26volume%3D98%26spage%3D2139%26epage%3D2150%26doi%3D10.1007%2Fs00277-019-03739-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyse, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schummer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemke-Jahn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penarier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debussche, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brönstrup, M.</span></span> <span> </span><span class="NLM_article-title">Discovery, Structure Elucidation, and Biological Characterization of Nannocystin A, a Macrocyclic Myxobacterial Metabolite with Potent Antiproliferative Properties</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">10145</span>– <span class="NLM_lpage">10148</span>, <span class="refDoi"> DOI: 10.1002/anie.201411377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fanie.201411377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpt1aqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=10145-10148&author=H.+Hoffmannauthor=H.+Koglerauthor=W.+Heyseauthor=H.+Matterauthor=M.+Caspersauthor=D.+Schummerauthor=C.+Klemke-Jahnauthor=A.+Bauerauthor=G.+Penarierauthor=L.+Debusscheauthor=M.+Br%C3%B6nstrup&title=Discovery%2C+Structure+Elucidation%2C+and+Biological+Characterization+of+Nannocystin+A%2C+a+Macrocyclic+Myxobacterial+Metabolite+with+Potent+Antiproliferative+Properties&doi=10.1002%2Fanie.201411377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, structure elucidation, and biological characterization of nannocystin A, a macrocyclic myxobacterial metabolite with potent antiproliferative properties</span></div><div class="casAuthors">Hoffmann, Holger; Kogler, Herbert; Heyse, Winfried; Matter, Hans; Caspers, Michael; Schummer, Dietmar; Klemke-Jahn, Christine; Bauer, Armin; Penarier, Geraldine; Debussche, Laurent; Broenstrup, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">10145-10148</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Microbial natural products are a rich source of bioactive mols. to serve as drug leads and/or biol. tools.  The authors investigated a little-explored myxobacterial genus, Nannocystis sp., and discovered a novel 21-membered macrocyclic scaffold that is composed of a tripeptide and a polyketide part with an epoxyamide moiety.  The relative and abs. configurations of the nine stereocenters was detd. by NMR spectroscopy, mol. dynamics calcns., chem. degrdn., and X-ray crystallog.  The compd., named nannocystin A (I), was found to inhibit cell proliferation at low nanomolar concns. through the early induction of apoptosis.  The mode of action of I could not be matched to that of std. drugs by transcriptional profiling and biochem. expts.  An initial investigation of the structure-activity relationship based on seven analogs demonstrated the importance of the epoxide moiety for high activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqay0zii-YC1LVg90H21EOLACvtfcHk0liIQ_CM5BSSNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpt1aqtro%253D&md5=d2d35f8ab0531f72c722160781c02c69</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1002%2Fanie.201411377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201411377%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DH.%26aulast%3DKogler%26aufirst%3DH.%26aulast%3DHeyse%26aufirst%3DW.%26aulast%3DMatter%26aufirst%3DH.%26aulast%3DCaspers%26aufirst%3DM.%26aulast%3DSchummer%26aufirst%3DD.%26aulast%3DKlemke-Jahn%26aufirst%3DC.%26aulast%3DBauer%26aufirst%3DA.%26aulast%3DPenarier%26aufirst%3DG.%26aulast%3DDebussche%26aufirst%3DL.%26aulast%3DBr%25C3%25B6nstrup%26aufirst%3DM.%26atitle%3DDiscovery%252C%2520Structure%2520Elucidation%252C%2520and%2520Biological%2520Characterization%2520of%2520Nannocystin%2520A%252C%2520a%2520Macrocyclic%2520Myxobacterial%2520Metabolite%2520with%2520Potent%2520Antiproliferative%2520Properties%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D10145%26epage%3D10148%26doi%3D10.1002%2Fanie.201411377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krastel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roggo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perruccio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspesi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aust, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buntin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estoppey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liechty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mapa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memmert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibaut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoepfner, D.</span></span> <span> </span><span class="NLM_article-title">Nannocystin A: An Elongation Factor 1 Inhibitor from Myxobacteria with Differential Anti-Cancer Properties</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">10149</span>– <span class="NLM_lpage">10154</span>, <span class="refDoi"> DOI: 10.1002/anie.201505069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fanie.201505069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOrtbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=10149-10154&author=P.+Krastelauthor=S.+Roggoauthor=M.+Schirleauthor=N.+T.+Rossauthor=F.+Perruccioauthor=P.+Aspesiauthor=T.+Austauthor=K.+Buntinauthor=D.+Estoppeyauthor=B.+Liechtyauthor=F.+Mapaauthor=K.+Memmertauthor=H.+Millerauthor=X.+Panauthor=R.+Riedlauthor=C.+Thibautauthor=J.+Thomasauthor=T.+Wagnerauthor=E.+Weberauthor=X.+Xieauthor=E.+K.+Schmittauthor=D.+Hoepfner&title=Nannocystin+A%3A+An+Elongation+Factor+1+Inhibitor+from+Myxobacteria+with+Differential+Anti-Cancer+Properties&doi=10.1002%2Fanie.201505069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Nannocystin A: an elongation factor 1 inhibitor from myxobacteria with differential anticancer properties</span></div><div class="casAuthors">Krastel, Philipp; Roggo, Silvio; Schirle, Markus; Ross, Nathan T.; Perruccio, Francesca; Aspesi, Peter, Jr.; Aust, Thomas; Buntin, Kathrin; Estoppey, David; Liechty, Brigitta; Mapa, Felipa; Memmert, Klaus; Miller, Howard; Pan, Xuewen; Riedl, Ralph; Thibaut, Christian; Thomas, Jason; Wagner, Trixie; Weber, Eric; Xie, Xiaobing; Schmitt, Esther K.; Hoepfner, Dominic</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">10149-10154</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cultivation of myxobacteria of the Nannocystis genus led to the isolation and structure elucidation of a class of novel cyclic lactone inhibitors of elongation factor 1.  Whole genome sequence anal. and annotation enabled identification of the putative biosynthetic cluster and synthesis process.  In biol. assays, the compds. displayed antifungal and cytotoxic activity.  Combined genetic and proteomic approaches identified the eukaryotic translation elongation factor 1α (EF-1α) as the primary target for this compd. class.  Nannocystin A (I) displayed differential activity across various cancer cell lines and EEF1A1 expression levels appear to be the main differentiating factor.  Biochem. and genetic evidence support an overlapping binding site of 1 with the anti-cancer compd. didemnin B on EF-1α.  This myxobacterial chemotype thus offers an interesting starting point for further investigations of the potential of therapeutics targeting elongation factor 1.  KT067736 has been submitted to the NCBI/EMBL/DDBJ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5TyLOZkwcUbVg90H21EOLACvtfcHk0lj8_2zXrz98vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOrtbvN&md5=bd120071f530c5d2ba7b0d1464b7bbf1</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1002%2Fanie.201505069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201505069%26sid%3Dliteratum%253Aachs%26aulast%3DKrastel%26aufirst%3DP.%26aulast%3DRoggo%26aufirst%3DS.%26aulast%3DSchirle%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DN.%2BT.%26aulast%3DPerruccio%26aufirst%3DF.%26aulast%3DAspesi%26aufirst%3DP.%26aulast%3DAust%26aufirst%3DT.%26aulast%3DBuntin%26aufirst%3DK.%26aulast%3DEstoppey%26aufirst%3DD.%26aulast%3DLiechty%26aufirst%3DB.%26aulast%3DMapa%26aufirst%3DF.%26aulast%3DMemmert%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DRiedl%26aufirst%3DR.%26aulast%3DThibaut%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWeber%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DSchmitt%26aufirst%3DE.%2BK.%26aulast%3DHoepfner%26aufirst%3DD.%26atitle%3DNannocystin%2520A%253A%2520An%2520Elongation%2520Factor%25201%2520Inhibitor%2520from%2520Myxobacteria%2520with%2520Differential%2520Anti-Cancer%2520Properties%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D10149%26epage%3D10154%26doi%3D10.1002%2Fanie.201505069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Murcia, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés-Cabrera, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gago, F.</span></span> <span> </span><span class="NLM_article-title">Structural Rationale for the Cross-Resistance of Tumor Cells Bearing the A399V Variant of Elongation Factor eEF1A1 to the Structurally Unrelated Didemnin B, Ternatin, Nannocystin A and Ansatrienin B</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">915</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1007/s10822-017-0066-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs10822-017-0066-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28900796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVOrtLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=915-928&author=P.+A.+S%C3%A1nchez-Murciaauthor=%C3%81.+Cort%C3%A9s-Cabreraauthor=F.+Gago&title=Structural+Rationale+for+the+Cross-Resistance+of+Tumor+Cells+Bearing+the+A399V+Variant+of+Elongation+Factor+eEF1A1+to+the+Structurally+Unrelated+Didemnin+B%2C+Ternatin%2C+Nannocystin+A+and+Ansatrienin+B&doi=10.1007%2Fs10822-017-0066-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Structural rationale for the cross-resistance of tumor cells bearing the A399V variant of elongation factor eEF1A1 to the structurally unrelated didemnin B, ternatin, nannocystin A and ansatrienin B</span></div><div class="casAuthors">Sanchez-Murcia, Pedro A.; Cortes-Cabrera, Alvaro; Gago, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">915-928</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">At least four classes of structurally distinct natural products with potent antiproliferative activities target the translation elongation factor eEF1A1, which is best known as the G-protein that delivers amino acyl tRNAs (aa-tRNAs) to ribosomes during mRNA translation.  We present mol. models in at. detail that provide a common structural basis for the high-affinity binding of didemnin B, ternatin, ansatrienin B and nannocystin A to eEF1A1, as well as a rationale based on mol. dynamics results that accounts for the deleterious effect of replacing alanine 399 with valine.  The proposed binding site, at the interface between domains I and III, is eminently hydrophobic and exists only in the GTP-bound conformation.  Drug binding at this site is expected to disrupt neither loading of aa-tRNAs nor GTP hydrolysis but would give rise to stabilization of this particular conformational state, in consonance with reported exptl. findings.  The exptl. soln. of the three-dimensional structure of mammalian eEF1A1 has proved elusive so far and the highly homologous eEF1A2 from rabbit muscle has been crystd. and solved only as a homodimer in a GDP-bound conformation.  Interestingly, in this dimeric structure the large interdomain cavity where the drugs studied are proposed to bind is occupied by a mostly hydrophobic α-helix from domain I of the same monomer.  Since binding of this α-helix and any of these drugs to domain III of eEF1A(1/2) is, therefore, mutually exclusive and involves two distinct protein conformations, one intriguing possibility that emerges from our study is that the potent antiproliferative effect of these natural products may arise not only from inhibition of protein synthesis, which is the current dogma, but also from interference with some other non-canonical functions.  From this standpoint, this type of drugs could be considered antagonists of eEF1A1/2 oligomerization, a hypothesis that opens up novel areas of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmNAOwcCMXJ7Vg90H21EOLACvtfcHk0lj8_2zXrz98vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVOrtLvO&md5=37285ead63e2005f01a4dce718d68175</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1007%2Fs10822-017-0066-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-017-0066-x%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Murcia%26aufirst%3DP.%2BA.%26aulast%3DCort%25C3%25A9s-Cabrera%26aufirst%3D%25C3%2581.%26aulast%3DGago%26aufirst%3DF.%26atitle%3DStructural%2520Rationale%2520for%2520the%2520Cross-Resistance%2520of%2520Tumor%2520Cells%2520Bearing%2520the%2520A399V%2520Variant%2520of%2520Elongation%2520Factor%2520eEF1A1%2520to%2520the%2520Structurally%2520Unrelated%2520Didemnin%2520B%252C%2520Ternatin%252C%2520Nannocystin%2520A%2520and%2520Ansatrienin%2520B%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2017%26volume%3D31%26spage%3D915%26epage%3D928%26doi%3D10.1007%2Fs10822-017-0066-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Total Synthesis of Nannocystin A</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">9217</span>– <span class="NLM_lpage">9222</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.7b01502</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.7b01502" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSitLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2017&pages=9217-9222&author=Q.+Liuauthor=P.+Huauthor=Y.+He&title=Asymmetric+Total+Synthesis+of+Nannocystin+A&doi=10.1021%2Facs.joc.7b01502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric Total Synthesis of Nannocystin A</span></div><div class="casAuthors">Liu, Qiang; Hu, Ping; He, Yun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9217-9222</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nannocystin A is a novel 21-membered macrolactone isolated from myxobacterium Nanocystis sp.  It is a potent elongation factor 1 inhibitor and inhibits cancer cell line growth at nanomolar concns.  In this work, a concise asym. total synthesis of nannocystin A has been developed, which features Sharpless epoxidn., Stille coupling, and final macrolactamization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzwSW30-JuaLVg90H21EOLACvtfcHk0lj9X2mLy3RiBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSitLzI&md5=575ebb7508046c5941fdc385cb1fc0a5</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.7b01502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.7b01502%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DHe%26aufirst%3DY.%26atitle%3DAsymmetric%2520Total%2520Synthesis%2520of%2520Nannocystin%2520A%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2017%26volume%3D82%26spage%3D9217%26epage%3D9222%26doi%3D10.1021%2Facs.joc.7b01502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souillart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monks, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwyler, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fürstner, A.</span></span> <span> </span><span class="NLM_article-title">A “Motif-Oriented” Total Synthesis of Nannocystin Ax. Preparation and Biological Assessment of Analogues</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">6977</span>– <span class="NLM_lpage">6994</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.7b02871</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.7b02871" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVant7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=6977-6994&author=Z.+Mengauthor=L.+Souillartauthor=B.+Monksauthor=N.+Huwylerauthor=J.+Herrmannauthor=R.+M%C3%BCllerauthor=A.+F%C3%BCrstner&title=A+%E2%80%9CMotif-Oriented%E2%80%9D+Total+Synthesis+of+Nannocystin+Ax.+Preparation+and+Biological+Assessment+of+Analogues&doi=10.1021%2Facs.joc.7b02871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">A "Motif-Oriented" Total Synthesis of Nannocystin Ax. Preparation and Biological Assessment of Analogues</span></div><div class="casAuthors">Meng, Zhanchao; Souillart, Laetitia; Monks, Brendan; Huwyler, Nikolas; Herrmann, Jennifer; Mueller, Rolf; Fuerstner, Alois</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6977-6994</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The highly cytotoxic cyclodepsipeptides of the nannocystin family are known to bind to the eukaryotic translation elongation factor 1α (EF-1α).  Anal. of the docking pose, as proposed by a previous in silico study, suggested that the trisubstituted alkene moiety and the neighboring Me ether form a domain that might be closely correlated with biol. activity.  This hypothesis sponsored a synthetic campaign which was designed to be "motif-oriented": specifically, a sequence of ring closing alkyne metathesis (RCAM) followed by hydroxy-directed trans-hydrostannation of the resulting cycloalkyne was conceived, which allowed this potentially anchoring substructure to be systematically addressed at a late stage.  This inherently flexible approach opened access to nannocystin Ax itself as well as to ten non-natural analogs.  While the biol. data confirmed the remarkable potency of this class of compds. and showed that the domain in question is indeed an innate part of the pharmacophore, the specific structure/activity relationships can only partly be reconciled with the original in silico docking study; therefore we conclude that this model needs to be carefully revisited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7gaSUvu2SH7Vg90H21EOLACvtfcHk0lj9X2mLy3RiBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVant7nP&md5=ca254aa5120faddea81e3b37fed4e9ec</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.7b02871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.7b02871%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DSouillart%26aufirst%3DL.%26aulast%3DMonks%26aufirst%3DB.%26aulast%3DHuwyler%26aufirst%3DN.%26aulast%3DHerrmann%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DR.%26aulast%3DF%25C3%25BCrstner%26aufirst%3DA.%26atitle%3DA%2520%25E2%2580%259CMotif-Oriented%25E2%2580%259D%2520Total%2520Synthesis%2520of%2520Nannocystin%2520Ax.%2520Preparation%2520and%2520Biological%2520Assessment%2520of%2520Analogues%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2018%26volume%3D83%26spage%3D6977%26epage%3D6994%26doi%3D10.1021%2Facs.joc.7b02871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">The Chemical Syntheses of Nannocystins</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2252</span>– <span class="NLM_lpage">2260</span>, <span class="refDoi"> DOI: 10.1055/s-0037-1611796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1055%2Fs-0037-1611796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFCrur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=2252-2260&author=Z.+Wang&title=The+Chemical+Syntheses+of+Nannocystins&doi=10.1055%2Fs-0037-1611796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">The chemical syntheses of nannocystins</span></div><div class="casAuthors">Wang, Zhang</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2252-2260</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">1437-210X</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A review.  The broad and potent anticancer activity of the nannocystin family of natural products has attracted significant efforts toward their total syntheses.  Currently, seven total syntheses of different members of the nannocystins have been reported.  In this short review, different synthetic approaches are highlighted.  The reported structure-activity relationship (SAR) studies will also be highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-CyVExyEZ-LVg90H21EOLACvtfcHk0lj9X2mLy3RiBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFCrur0%253D&md5=6b70c4ba5c6b1f09d8c5771207c9547f</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1055%2Fs-0037-1611796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0037-1611796%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DThe%2520Chemical%2520Syntheses%2520of%2520Nannocystins%26jtitle%3DSynthesis%26date%3D2019%26volume%3D51%26spage%3D2252%26epage%3D2260%26doi%3D10.1055%2Fs-0037-1611796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span> <span> </span><span class="NLM_article-title">Novel Nannocystin A Analogues as Anticancer Therapeutics: Synthesis, Biological Evaluations and Structure–activity Relationship Studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.ejmech.2019.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30878835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFCls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2019&pages=99-111&author=Q.+Liuauthor=X.+Yangauthor=J.+Jiauthor=S.+L.+Zhangauthor=Y.+He&title=Novel+Nannocystin+A+Analogues+as+Anticancer+Therapeutics%3A+Synthesis%2C+Biological+Evaluations+and+Structure%E2%80%93activity+Relationship+Studies&doi=10.1016%2Fj.ejmech.2019.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Novel nannocystin A analogs as anticancer therapeutics: Synthesis, biological evaluations and structure-activity relationship studies</span></div><div class="casAuthors">Liu, Qiang; Yang, Xiaohong; Ji, Jie; Zhang, Shao-Lin; He, Yun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">99-111</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Nannocystin A is a novel 21-membered macrocyclic lactam that targets eukaryotic translation elongation factor 1α (eEF1A) and displays potent antiproliferative activities.  Herein, a series of nannocystin A analogs were synthesized and their structure-activity relationship (SAR) were established based on the MTT assay and western blotting anal.  The SAR enabled us to identify a structurally simplified nannocystin A analog LQ18, which exhibited potent antiproliferative activities with IC50 values ranging from 4.3 to 48 nM against the tested cell lines, and inhibited eEF1A1 expression in A549 cell line.  LQ18 arrested cell cycle at G2 phase and induced A549 cell apoptosis via up-regulation of caspase-3, caspase-9 and bax protein expressions in a dose-dependent manner, while it significantly decreased the bcl-2 expression.  Collectively, these data demonstrated that LQ18 could be a promising lead for the development of structurally novel eEF1A1 inhibitor for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmZIvGRZLOsrVg90H21EOLACvtfcHk0ljPg5Nju49mtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFCls7Y%253D&md5=0e7d15caa20c2f9146d0c61045793b8f</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.%2BL.%26aulast%3DHe%26aufirst%3DY.%26atitle%3DNovel%2520Nannocystin%2520A%2520Analogues%2520as%2520Anticancer%2520Therapeutics%253A%2520Synthesis%252C%2520Biological%2520Evaluations%2520and%2520Structure%25E2%2580%2593activity%2520Relationship%2520Studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D170%26spage%3D99%26epage%3D111%26doi%3D10.1016%2Fj.ejmech.2019.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashima, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, D.</span></span> <span> </span><span class="NLM_article-title">Biological Activity, Structural Features, and Synthetic Studies of (−)-Ternatin, a Potent Fat-Accumulation Inhibitor of 3T3-L1 Adipocytes</span>. <i>Chem. - Asian J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1002/asia.200700243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fasia.200700243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18181124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Wjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=438-446&author=K.+Shimokawaauthor=I.+Mashimaauthor=A.+Asaiauthor=T.+Ohnoauthor=K.+Yamadaauthor=M.+Kitaauthor=D.+Uemura&title=Biological+Activity%2C+Structural+Features%2C+and+Synthetic+Studies+of+%28%E2%88%92%29-Ternatin%2C+a+Potent+Fat-Accumulation+Inhibitor+of+3T3-L1+Adipocytes&doi=10.1002%2Fasia.200700243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Biological activity, structural features, and synthetic studies of (-)-ternatin, a potent fat-accumulation inhibitor of 3T3-L1 adipocytes</span></div><div class="casAuthors">Shimokawa, Kenichiro; Mashima, Itsuka; Asai, Akiko; Ohno, Tomohiro; Yamada, Kaoru; Kita, Masaki; Uemura, Daisuke</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - An Asian Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">438-446</span>CODEN:
                <span class="NLM_cas:coden">CAAJBI</span>;
        ISSN:<span class="NLM_cas:issn">1861-4728</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of studies, including preliminary screening, isolation, structure detn., synthesis, and biol. evaluation, of (-)-ternatin (I) are described.  A highly N-methylated cyclic heptapeptide isolated from the mushroom Coriolus versicolor, 1 shows an inhibitory effect on fat accumulation by 3T3-L1 murine adipocytes (EC50 = 0.02 μg mL-1).  Detailed anal. of 1D and 2D NMR spectra, as well as amino acid anal., suggested four stereoisomers as candidates for 1.  For the complete structural elucidation of I, chem. syntheses were carried out by solid phase peptide synthesis.  By comparing the spectroscopic data for the natural product with the data for the synthetic stereoisomers, the structure of I was confirmed to be cyclo[D-allo-Ile1-L-(NMe)Ala2-L-(NMe)Leu3-L-Leu4-L-(NMe)Ala5-D-(NMe)Ala6-(2R,3R)-3-hydroxy-Leu7].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxOWsG8yJybrVg90H21EOLACvtfcHk0ljPg5Nju49mtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Wjtbk%253D&md5=e011c366fd0ac258f17003747bdf71b0</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1002%2Fasia.200700243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fasia.200700243%26sid%3Dliteratum%253Aachs%26aulast%3DShimokawa%26aufirst%3DK.%26aulast%3DMashima%26aufirst%3DI.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DOhno%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DKita%26aufirst%3DM.%26aulast%3DUemura%26aufirst%3DD.%26atitle%3DBiological%2520Activity%252C%2520Structural%2520Features%252C%2520and%2520Synthetic%2520Studies%2520of%2520%2528%25E2%2588%2592%2529-Ternatin%252C%2520a%2520Potent%2520Fat-Accumulation%2520Inhibitor%2520of%25203T3-L1%2520Adipocytes%26jtitle%3DChem.%2520-%2520Asian%2520J.%26date%3D2008%26volume%3D3%26spage%3D438%26epage%3D446%26doi%3D10.1002%2Fasia.200700243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Inhibitory Effect on Fat Accumulation of (−)-Ternatin Derivatives Modified in the β-OH-d-Leu7Moiety</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1039/B714710D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1039%2FB714710D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18075648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVanur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=58-60&author=K.+Shimokawaauthor=Y.+Iwaseauthor=K.+Yamadaauthor=D.+Uemura&title=Synthesis+and+Inhibitory+Effect+on+Fat+Accumulation+of+%28%E2%88%92%29-Ternatin+Derivatives+Modified+in+the+%CE%B2-OH-d-Leu7Moiety&doi=10.1039%2FB714710D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and inhibitory effect on fat accumulation of (-)-ternatin derivatives modified in the β-OH-D-Leu7 moiety</span></div><div class="casAuthors">Shimokawa, Kenichiro; Iwase, Yoshiaki; Yamada, Kaoru; Uemura, Daisuke</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-60</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">An efficient synthesis of (-)-ternatin derivs. directed toward their SAR at the β-OH-D-Leu7 moiety and their biol. activities against 3T3-L1 murine adipocytes are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-uiEvw0JJMbVg90H21EOLACvtfcHk0ljPg5Nju49mtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVanur7P&md5=54345d5f52ff75ebc876913fca251712</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1039%2FB714710D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB714710D%26sid%3Dliteratum%253Aachs%26aulast%3DShimokawa%26aufirst%3DK.%26aulast%3DIwase%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DUemura%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520Inhibitory%2520Effect%2520on%2520Fat%2520Accumulation%2520of%2520%2528%25E2%2588%2592%2529-Ternatin%2520Derivatives%2520Modified%2520in%2520the%2520%25CE%25B2-OH-d-Leu7Moiety%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2008%26volume%3D6%26spage%3D58%26epage%3D60%26doi%3D10.1039%2FB714710D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carelli, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethofer, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Ternatin and Improved Synthetic Variants Kill Cancer Cells by Targeting the Elongation Factor-1A Ternary Complex</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e10222</span>, <span class="refDoi"> DOI: 10.7554/eLife.10222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.7554%2FeLife.10222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26651998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVCmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=e10222&author=J.+D.+Carelliauthor=S.+G.+Sethoferauthor=G.+A.+Smithauthor=H.+R.+Millerauthor=J.+L.+Simardauthor=W.+C.+Merrickauthor=R.+K.+Jainauthor=N.+T.+Rossauthor=J.+Taunton&title=Ternatin+and+Improved+Synthetic+Variants+Kill+Cancer+Cells+by+Targeting+the+Elongation+Factor-1A+Ternary+Complex&doi=10.7554%2FeLife.10222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex</span></div><div class="casAuthors">Carelli, Jordan D.; Sethofer, Steven G.; Smith, Geoffrey A.; Miller, Howard R.; Simard, Jillian L.; Merrick, William C.; Jain, Rishi K.; Ross, Nathan T.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e10222/1-e10222/22</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Cyclic peptide natural products have evolved to exploit diverse protein targets, many of which control essential cellular processes.  Inspired by a series of cyclic peptides with partially elucidated structures, we designed synthetic variants of ternatin, a cytotoxic and anti-adipogenic natural product whose mol. mode of action was unknown.  The new ternatin variants are cytotoxic toward cancer cells, with up to 500-fold greater potency than ternatin itself.  Using a ternatin photo-affinity probe, we identify the translation elongation factor-1A ternary complex (eEF1A & amp; #x00B7;GTP & amp; #x00B7;aminoacyl-tRNA) as a specific target and demonstrate competitive binding by the unrelated natural products, didemnin and cytotrienin.  Mutations in domain III of eEF1A prevent ternatin binding and confer resistance to its cytotoxic effects, implicating the adjacent hydrophobic surface as a functional hot spot for eEF1A modulation.  We conclude that the eukaryotic elongation factor-1A and its ternary complex with GTP and aminoacyl-tRNA are common targets for the evolution of cytotoxic natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojDP-U8yDv77Vg90H21EOLACvtfcHk0lgop2M13SjhUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVCmu7g%253D&md5=72d3537da927c1aaeb08de26669baff3</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.7554%2FeLife.10222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.10222%26sid%3Dliteratum%253Aachs%26aulast%3DCarelli%26aufirst%3DJ.%2BD.%26aulast%3DSethofer%26aufirst%3DS.%2BG.%26aulast%3DSmith%26aufirst%3DG.%2BA.%26aulast%3DMiller%26aufirst%3DH.%2BR.%26aulast%3DSimard%26aufirst%3DJ.%2BL.%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DRoss%26aufirst%3DN.%2BT.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DTernatin%2520and%2520Improved%2520Synthetic%2520Variants%2520Kill%2520Cancer%2520Cells%2520by%2520Targeting%2520the%2520Elongation%2520Factor-1A%2520Ternary%2520Complex%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26spage%3De10222%26doi%3D10.7554%2FeLife.10222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yip, A.</span>; <span class="NLM_string-name">Hann, J.</span>; <span class="NLM_string-name">Bhd, T. S.</span></span> <span> </span><span class="NLM_article-title">Bioactive Compounds</span>. <span class="NLM_patent">WO 2010/062159Al</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=A.+Yip&author=J.+Hann&author=T.+S.+Bhd&title=Bioactive+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYip%26aufirst%3DA.%26atitle%3DBioactive%2520Compounds%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Goietsenoven, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallemand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefranc, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenbussche, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Antwerpen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evidente, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prévost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzy, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornienko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, V.</span></span> <span> </span><span class="NLM_article-title">Targeting of EEF1A with Amaryllidaceae Isocarbostyrils as a Strategy to Combat Melanomas</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4575</span>– <span class="NLM_lpage">4584</span>, <span class="refDoi"> DOI: 10.1096/fj.10-162263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1096%2Ffj.10-162263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=20643906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWqu7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=4575-4584&author=G.+Van%0AGoietsenovenauthor=J.+Huttonauthor=J.+P.+Beckerauthor=B.+Lallemandauthor=F.+Robertauthor=F.+Lefrancauthor=C.+Pirkerauthor=G.+Vandenbusscheauthor=P.+Van+Antwerpenauthor=A.+Evidenteauthor=W.+Bergerauthor=M.+Pr%C3%A9vostauthor=J.+Pelletierauthor=R.+Kissauthor=T.+G.+Kinzyauthor=A.+Kornienkoauthor=V.+Mathieu&title=Targeting+of+EEF1A+with+Amaryllidaceae+Isocarbostyrils+as+a+Strategy+to+Combat+Melanomas&doi=10.1096%2Ffj.10-162263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas</span></div><div class="casAuthors">Van Goietsenoven, Gwendoline; Hutton, Jenna; Becker, Jean-Paul; Lallemand, Benjamin; Robert, Francis; Lefranc, Florence; Pirker, Christine; Vandenbussche, Guy; Van Antwerpen, Pierre; Evidente, Antonio; Berger, Walter; Prevost, Martine; Pelletier, Jerry; Kiss, Robert; Kinzy, Terri Goss; Kornienko, Alexander; Mathieu, Veronique</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4575-4584, 10.1096/fj.10-162263</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Melanomas display poor response rates to adjuvant therapies because of their intrinsic resistance to proapoptotic stimuli.  This study indicates that such resistance can be overcome, at least partly, through the targeting of eEF1A elongation factor with narciclasine, an Amaryllidaceae isocarbostyril controlling plant growth.  Narciclasine displays IC50 growth inhibitory values between 30-100 nM in melanoma cell lines, irresp. of their levels of resistance to proapoptotic stimuli.  Normal noncancerous cell lines are much less affected.  At nontoxic doses, narciclasine also significantly improves (P = 0.004) the survival of mice bearing metastatic apoptosis-resistant melanoma xenografts in their brain.  The eEF1A targeting with narciclasine (50 nM) leads to 1) marked actin cytoskeleton disorganization, resulting in cytokinesis impairment, and 2) protein synthesis impairment (elongation and initiation steps), whereas apoptosis is induced at higher doses only (≥200 nM).  In addn. to mol. docking validation and identification of potential binding sites, we biochem. confirmed that narciclasine directly binds to human recombinant and yeast-purified eEF1A in a nanomolar range, but not to actin or elongation factor 2, and that 5 nM narciclasine is sufficient to impair eEF1A-related actin bundling activity.  EEF1A is thus a potential target to combat melanomas regardless of their apoptosis-sensitivity, and this finding reconciles the pleiotropic cytostatic of narciclasine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowfSWDPcWvSrVg90H21EOLACvtfcHk0lgop2M13SjhUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWqu7nP&md5=7c10cf11667e956546186a532c83c071</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1096%2Ffj.10-162263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.10-162263%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoietsenoven%26aufirst%3DG.%26aulast%3DHutton%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DJ.%2BP.%26aulast%3DLallemand%26aufirst%3DB.%26aulast%3DRobert%26aufirst%3DF.%26aulast%3DLefranc%26aufirst%3DF.%26aulast%3DPirker%26aufirst%3DC.%26aulast%3DVandenbussche%26aufirst%3DG.%26aulast%3DVan%2BAntwerpen%26aufirst%3DP.%26aulast%3DEvidente%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DPr%25C3%25A9vost%26aufirst%3DM.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DKiss%26aufirst%3DR.%26aulast%3DKinzy%26aufirst%3DT.%2BG.%26aulast%3DKornienko%26aufirst%3DA.%26aulast%3DMathieu%26aufirst%3DV.%26atitle%3DTargeting%2520of%2520EEF1A%2520with%2520Amaryllidaceae%2520Isocarbostyrils%2520as%2520a%2520Strategy%2520to%2520Combat%2520Melanomas%26jtitle%3DFASEB%2520J.%26date%3D2010%26volume%3D24%26spage%3D4575%26epage%3D4584%26doi%3D10.1096%2Ffj.10-162263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doudna, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, V. L.</span></span> <span> </span><span class="NLM_article-title">Structure and Function of the Eukaryotic Ribosome: The next Frontier</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(02)00725-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2FS0092-8674%2802%2900725-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=12007402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1ektLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=153-156&author=J.+A.+Doudnaauthor=V.+L.+Rath&title=Structure+and+Function+of+the+Eukaryotic+Ribosome%3A+The+next+Frontier&doi=10.1016%2FS0092-8674%2802%2900725-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of the eukaryotic ribosome: The next frontier</span></div><div class="casAuthors">Doudna, Jennifer A.; Rath, Virginia L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-156</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 12 refs.  As the catalytic and regulatory centers of protein synthesis in cells, ribosomes are central to many aspects of cell and structural biol.  Recent work highlights the unique properties and complexity of eukaryotic ribosomes and their component rRNAs and proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYViixBvJ0e7Vg90H21EOLACvtfcHk0lgop2M13SjhUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1ektLg%253D&md5=1fd9c2b6dca0bb75217f7fd3cc0a7b8c</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900725-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900725-0%26sid%3Dliteratum%253Aachs%26aulast%3DDoudna%26aufirst%3DJ.%2BA.%26aulast%3DRath%26aufirst%3DV.%2BL.%26atitle%3DStructure%2520and%2520Function%2520of%2520the%2520Eukaryotic%2520Ribosome%253A%2520The%2520next%2520Frontier%26jtitle%3DCell%26date%3D2002%26volume%3D109%26spage%3D153%26epage%3D156%26doi%3D10.1016%2FS0092-8674%2802%2900725-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klinge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigts-Hoffmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibundgut, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arpagaus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, N.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Eukaryotic 60S Ribosomal Subunit in Complex with Initiation Factor 6</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">948</span>, <span class="refDoi"> DOI: 10.1126/science.1211204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1126%2Fscience.1211204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22052974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGktL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2011&pages=941-948&author=S.+Klingeauthor=F.+Voigts-Hoffmannauthor=M.+Leibundgutauthor=S.+Arpagausauthor=N.+Ban&title=Crystal+Structure+of+the+Eukaryotic+60S+Ribosomal+Subunit+in+Complex+with+Initiation+Factor+6&doi=10.1126%2Fscience.1211204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the eukaryotic 60S ribosomal subunit in complex with initiation factor 6</span></div><div class="casAuthors">Klinge, Sebastian; Voigts-Hoffmann, Felix; Leibundgut, Marc; Arpagaus, Sofia; Ban, Nenad</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">6058</span>),
    <span class="NLM_cas:pages">941-948</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Protein synthesis in all organisms is catalyzed by ribosomes.  In comparison to their prokaryotic counterparts, eukaryotic ribosomes are considerably larger and are subject to more complex regulation.  The ribosome large subunit (60S) catalyzes peptide bond formation and contains the nascent polypeptide exit tunnel.  Here, the authors present the structure of the ribosome 60S subunit of Tetrahymena thermophila in complex with eukaryotic initiation factor 6 (eIF-6), cocrystd. with the antibiotic, cycloheximide (a eukaryotic-specific inhibitor of protein synthesis), at a resoln. of 3.5 Å.  The structure illustrated the complex functional architecture of the eukaryotic 60S subunit, which comprises an intricate network of interactions between eukaryotic-specific ribosomal protein features and RNA expansion segments.  It revealed the roles of eukaryotic ribosomal protein elements in the stabilization of the active site and the extent of eukaryotic-specific differences in other functional regions of the subunit.  Furthermore, it elucidated the mol. basis of the interaction with eIF-6 and provided a structural framework for further studies of ribosome-assocd. diseases and the role of the 60S subunit in the initiation of protein synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8CoHGTFF0wLVg90H21EOLACvtfcHk0likKBU2SvBiLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGktL%252FI&md5=aada14c4da6f4162ce1bc7b26d059d90</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1126%2Fscience.1211204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1211204%26sid%3Dliteratum%253Aachs%26aulast%3DKlinge%26aufirst%3DS.%26aulast%3DVoigts-Hoffmann%26aufirst%3DF.%26aulast%3DLeibundgut%26aufirst%3DM.%26aulast%3DArpagaus%26aufirst%3DS.%26aulast%3DBan%26aufirst%3DN.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Eukaryotic%252060S%2520Ribosomal%2520Subunit%2520in%2520Complex%2520with%2520Initiation%2520Factor%25206%26jtitle%3DScience%26date%3D2011%26volume%3D334%26spage%3D941%26epage%3D948%26doi%3D10.1126%2Fscience.1211204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budkevich, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesebrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loerke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramrath, D. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrand, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nierhaus, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanbonmatsu, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spahn, C. M. T.</span></span> <span> </span><span class="NLM_article-title">Regulation of the Mammalian Elongation Cycle by Subunit Rolling: A Eukaryotic-Specific Ribosome Rearrangement</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2014.04.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.cell.2014.04.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24995983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWgur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2014&pages=121-131&author=T.+V.+Budkevichauthor=J.+Giesebrechtauthor=E.+Behrmannauthor=J.+Loerkeauthor=D.+J.+F.+Ramrathauthor=T.+Mielkeauthor=J.+Ismerauthor=P.+W.+Hildebrandauthor=C.+S.+Tungauthor=K.+H.+Nierhausauthor=K.+Y.+Sanbonmatsuauthor=C.+M.+T.+Spahn&title=Regulation+of+the+Mammalian+Elongation+Cycle+by+Subunit+Rolling%3A+A+Eukaryotic-Specific+Ribosome+Rearrangement&doi=10.1016%2Fj.cell.2014.04.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the Mammalian Elongation Cycle by Subunit Rolling: A Eukaryotic-Specific Ribosome Rearrangement</span></div><div class="casAuthors">Budkevich, Tatyana V.; Giesebrecht, Jan; Behrmann, Elmar; Loerke, Justus; Ramrath, David J. F.; Mielke, Thorsten; Ismer, Jochen; Hildebrand, Peter W.; Tung, Chang-Shung; Nierhaus, Knud H.; Sanbonmatsu, Karissa Y.; Spahn, Christian M. T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-131</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The extent to which bacterial ribosomes and the significantly larger eukaryotic ribosomes share the same mechanisms of ribosomal elongation is unknown.  Here, we present subnanometer resoln. cryoelectron microscopy maps of the mammalian 80S ribosome in the posttranslocational state and in complex with the eukaryotic eEF1A·Val-tRNA·GMPPNP ternary complex, revealing significant differences in the elongation mechanism between bacteria and mammals.  Surprisingly, and in contrast to bacterial ribosomes, a rotation of the small subunit around its long axis and orthogonal to the well-known intersubunit rotation distinguishes the posttranslocational state from the classical pretranslocational state ribosome.  We term this motion "subunit rolling.".  Correspondingly, a mammalian decoding complex visualized in substates before and after codon recognition reveals structural distinctions from the bacterial system.  These findings suggest how codon recognition leads to GTPase activation in the mammalian system and demonstrate that in mammalia subunit rolling occurs during tRNA selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosg2wAF629QrVg90H21EOLACvtfcHk0likKBU2SvBiLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWgur7L&md5=aa8f09b3e758df780e6391d97e7d3444</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.04.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.04.044%26sid%3Dliteratum%253Aachs%26aulast%3DBudkevich%26aufirst%3DT.%2BV.%26aulast%3DGiesebrecht%26aufirst%3DJ.%26aulast%3DBehrmann%26aufirst%3DE.%26aulast%3DLoerke%26aufirst%3DJ.%26aulast%3DRamrath%26aufirst%3DD.%2BJ.%2BF.%26aulast%3DMielke%26aufirst%3DT.%26aulast%3DIsmer%26aufirst%3DJ.%26aulast%3DHildebrand%26aufirst%3DP.%2BW.%26aulast%3DTung%26aufirst%3DC.%2BS.%26aulast%3DNierhaus%26aufirst%3DK.%2BH.%26aulast%3DSanbonmatsu%26aufirst%3DK.%2BY.%26aulast%3DSpahn%26aufirst%3DC.%2BM.%2BT.%26atitle%3DRegulation%2520of%2520the%2520Mammalian%2520Elongation%2520Cycle%2520by%2520Subunit%2520Rolling%253A%2520A%2520Eukaryotic-Specific%2520Ribosome%2520Rearrangement%26jtitle%3DCell%26date%3D2014%26volume%3D158%26spage%3D121%26epage%3D131%26doi%3D10.1016%2Fj.cell.2014.04.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ban, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steitz, T. A.</span></span> <span> </span><span class="NLM_article-title">The Complete Atomic Structure of the Large Ribosomal Subunit at 2.4 A Resolution</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1126/science.289.5481.905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1126%2Fscience.289.5481.905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10937989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BD3cvgslCgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=905-920&author=N.+Banauthor=P.+Nissenauthor=J.+Hansenauthor=P.+B.+Mooreauthor=T.+A.+Steitz&title=The+Complete+Atomic+Structure+of+the+Large+Ribosomal+Subunit+at+2.4+A+Resolution&doi=10.1126%2Fscience.289.5481.905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">The complete atomic structure of the large ribosomal subunit at 2.4 A resolution</span></div><div class="casAuthors">Ban N; Nissen P; Hansen J; Moore P B; Steitz T A</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5481</span>),
    <span class="NLM_cas:pages">905-20</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The large ribosomal subunit catalyzes peptide bond formation and binds initiation, termination, and elongation factors.  We have determined the crystal structure of the large ribosomal subunit from Haloarcula marismortui at 2.4 angstrom resolution, and it includes 2833 of the subunit's 3045 nucleotides and 27 of its 31 proteins.  The domains of its RNAs all have irregular shapes and fit together in the ribosome like the pieces of a three-dimensional jigsaw puzzle to form a large, monolithic structure.  Proteins are abundant everywhere on its surface except in the active site where peptide bond formation occurs and where it contacts the small subunit.  Most of the proteins stabilize the structure by interacting with several RNA domains, often using idiosyncratically folded extensions that reach into the subunit's interior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5gYgXyiJOxLP3FVUi_gf8fW6udTcc2eZBhmhY0LuEYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvgslCgsA%253D%253D&md5=8c3401c1958c34bd8b81f98a5081d2b7</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5481.905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5481.905%26sid%3Dliteratum%253Aachs%26aulast%3DBan%26aufirst%3DN.%26aulast%3DNissen%26aufirst%3DP.%26aulast%3DHansen%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DP.%2BB.%26aulast%3DSteitz%26aufirst%3DT.%2BA.%26atitle%3DThe%2520Complete%2520Atomic%2520Structure%2520of%2520the%2520Large%2520Ribosomal%2520Subunit%2520at%25202.4%2520A%2520Resolution%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D905%26epage%3D920%26doi%3D10.1126%2Fscience.289.5481.905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalla Venezia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J.-J.</span></span> <span> </span><span class="NLM_article-title">Emerging Role of Eukaryote Ribosomes in Translational Control</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1226</span>, <span class="refDoi"> DOI: 10.3390/ijms20051226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fijms20051226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFOntrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1226&author=N.+Dalla+Veneziaauthor=A.+Vincentauthor=V.+Marcelauthor=F.+Catezauthor=J.-J.+Diaz&title=Emerging+Role+of+Eukaryote+Ribosomes+in+Translational+Control&doi=10.3390%2Fijms20051226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging role of eukaryote ribosomes in translational control</span></div><div class="casAuthors">Dalla Venezia, Nicole; Vincent, Anne; Marcel, Virginie; Catez, Frederic; Diaz, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1226</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Translation is one of the final steps that regulate gene expression.  The ribosome is the effector of translation through to its role in mRNA decoding and protein synthesis.  Many mechanisms have been extensively described accounting for translational regulation.  However it emerged only recently that ribosomes themselves could contribute to this regulation.  Indeed, though it is well-known that the translational efficiency of the cell is linked to ribosome abundance, studies recently demonstrated that the compn. of the ribosome could alter translation of specific mRNAs.  Evidences suggest that according to the status, environment, development, or pathol. conditions, cells produce different populations of ribosomes which differ in their ribosomal protein and/or RNA compn.  Those observations gave rise to the concept of "specialized ribosomes", which proposes that a unique ribosome compn. dets. the translational activity of this ribosome.  The current review will present how technol. advances have participated in the emergence of this concept, and to which extent the literature sustains this concept today.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwCtKPgHXh07Vg90H21EOLACvtfcHk0lgCXgcLLdovCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFOntrrO&md5=abc8a82eae8a987b480672f552273fb7</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.3390%2Fijms20051226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20051226%26sid%3Dliteratum%253Aachs%26aulast%3DDalla%2BVenezia%26aufirst%3DN.%26aulast%3DVincent%26aufirst%3DA.%26aulast%3DMarcel%26aufirst%3DV.%26aulast%3DCatez%26aufirst%3DF.%26aulast%3DDiaz%26aufirst%3DJ.-J.%26atitle%3DEmerging%2520Role%2520of%2520Eukaryote%2520Ribosomes%2520in%2520Translational%2520Control%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1226%26doi%3D10.3390%2Fijms20051226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in Ribosome Profiling for Deciphering Translational Regulation</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/j.ymeth.2019.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.ymeth.2019.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31103613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSqurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2020&pages=46-54&author=Y.+Wangauthor=H.+Zhangauthor=J.+Lu&title=Recent+Advances+in+Ribosome+Profiling+for+Deciphering+Translational+Regulation&doi=10.1016%2Fj.ymeth.2019.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in ribosome profiling for deciphering translational regulation</span></div><div class="casAuthors">Wang, Yirong; Zhang, Hong; Lu, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Methods (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-54</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  MRNA (mRNA) translation is a central step of gene expression.  Translational regulation plays essential roles in various biol. processes.  Ribosome profiling is a powerful technique to study genome-wide translational regulation at a single-codon resoln.  Based on conventional ribosome profiling procedures, many new exptl. methods have recently been developed to investigate the biol. of mRNA translation from different aspects.  These tech. advances have significantly advanced our understanding of translational regulation at genomic scales from the following perspectives: (1) identification of translational initiation sites; (2) characterization of the dynamics of the complete translation cycle; (3) profiling of active ribosomes; (4) tissue-specific translational regulation; (5) translational regulation in subcellular locations; (6) detection of ribosome traffic jams; (7) plastid translatomes; and (8) ribosome heterogeneity and translational preference.  Here, we summarize the key differences between these new techniques and the conventional ribosome profiling approach.  We also review the computational methods designed to analyze ribosome profiling data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEeAKYSWgiQbVg90H21EOLACvtfcHk0lgCXgcLLdovCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSqurbL&md5=5b88eb8855008017ca71f3a0f6046c47</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2019.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2019.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DJ.%26atitle%3DRecent%2520Advances%2520in%2520Ribosome%2520Profiling%2520for%2520Deciphering%2520Translational%2520Regulation%26jtitle%3DMethods%26date%3D2020%26volume%3D176%26spage%3D46%26epage%3D54%26doi%3D10.1016%2Fj.ymeth.2019.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornstein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mela, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gass, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amendolara, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canoll, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, P. A.</span></span> <span> </span><span class="NLM_article-title">Ribosome Profiling Reveals a Cell-Type-Specific Translational Landscape in Brain Tumors</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">10924</span>– <span class="NLM_lpage">10936</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.0084-14.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1523%2FJNEUROSCI.0084-14.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25122893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1equ7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=10924-10936&author=C.+Gonzalezauthor=J.+S.+Simsauthor=N.+Hornsteinauthor=A.+Melaauthor=F.+Garciaauthor=L.+Leiauthor=D.+A.+Gassauthor=B.+Amendolaraauthor=J.+N.+Bruceauthor=P.+Canollauthor=P.+A.+Sims&title=Ribosome+Profiling+Reveals+a+Cell-Type-Specific+Translational+Landscape+in+Brain+Tumors&doi=10.1523%2FJNEUROSCI.0084-14.2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosome profiling reveals a cell-type-specific translational landscape in brain tumors</span></div><div class="casAuthors">Gonzalez, Christian; Sims, Jennifer S.; Hornstein, Nicholas; Mela, Angeliki; Garcia, Franklin; Lei, Liang; Gass, David A.; Amendolara, Benjamin; Bruce, Jeffrey N.; Canoll, Peter; Sims, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">10924-10936, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Glioma growth is driven by signaling that ultimately regulates protein synthesis.  Gliomas are also complex at the cellular level and involve multiple cell types, including transformed and reactive cells in the brain tumor microenvironment.  The distinct functions of the various cell types likely lead to different requirements and regulatory paradigms for protein synthesis.  Proneural gliomas can arise from transformation of glial progenitors that are driven to proliferate via mitogenic signaling that affects translation.  To investigate translational regulation in this system, we developed a RiboTag glioma mouse model that enables cell-type-specific, genome-wide ribosome profiling of tumor tissue.  Infecting glial progenitors with Cre-recombinant retrovirus simultaneously activates expression of tagged ribosomes and delivers a tumor-initiating mutation.  Remarkably, we find that although genes specific to transformed cells are highly translated, their translation efficiencies are low compared with normal brain.  Ribosome positioning reveals sequence-dependent regulation of ribosomal activity in 5'-leaders upstream of annotated start codons, leading to differential translation in glioma compared with normal brain.  Addnl., although transformed cells express a proneural signature, untransformed tumor-assocd. cells, including reactive astrocytes and microglia, express a mesenchymal signature.  Finally, we observe the same phenomena in human disease by combining ribosome profiling of human proneural tumor and non-neoplastic brain tissue with computational deconvolution to assess cell-type-specific translational regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotHY4TaaVZlLVg90H21EOLACvtfcHk0lgCXgcLLdovCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1equ7vK&md5=5375dd6782e05087460e859df52a173c</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0084-14.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0084-14.2014%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez%26aufirst%3DC.%26aulast%3DSims%26aufirst%3DJ.%2BS.%26aulast%3DHornstein%26aufirst%3DN.%26aulast%3DMela%26aufirst%3DA.%26aulast%3DGarcia%26aufirst%3DF.%26aulast%3DLei%26aufirst%3DL.%26aulast%3DGass%26aufirst%3DD.%2BA.%26aulast%3DAmendolara%26aufirst%3DB.%26aulast%3DBruce%26aufirst%3DJ.%2BN.%26aulast%3DCanoll%26aufirst%3DP.%26aulast%3DSims%26aufirst%3DP.%2BA.%26atitle%3DRibosome%2520Profiling%2520Reveals%2520a%2520Cell-Type-Specific%2520Translational%2520Landscape%2520in%2520Brain%2520Tumors%26jtitle%3DJ.%2520Neurosci.%26date%3D2014%26volume%3D34%26spage%3D10924%26epage%3D10936%26doi%3D10.1523%2FJNEUROSCI.0084-14.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span> <span> </span><span class="NLM_article-title">Survey of the Translation Shifts in Hepatocellular Carcinoma with Ribosome Profiling</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4141</span>– <span class="NLM_lpage">4155</span>, <span class="refDoi"> DOI: 10.7150/thno.35033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.7150%2Fthno.35033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31281537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1ert7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=4141-4155&author=Q.+Zouauthor=Z.+Xiaoauthor=R.+Huangauthor=X.+Wangauthor=X.+Wangauthor=H.+Zhaoauthor=X.+Yang&title=Survey+of+the+Translation+Shifts+in+Hepatocellular+Carcinoma+with+Ribosome+Profiling&doi=10.7150%2Fthno.35033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Survey of the translation shifts in hepatocellular carcinoma with ribosome profiling</span></div><div class="casAuthors">Zou, Qin; Xiao, Zhengtao; Huang, Rongyao; Wang, Xin; Wang, Xun; Zhao, Haitao; Yang, Xuerui</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4141-4155</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Despite the crit. position of translation in the multilevel gene expression regulation program, high-resoln. and genome-wide view of the landscape of RNA translation in solid tumors is still limited.  A set of bioinformatics tools was then applied to these data for the mining of novel insights into the translation shifts in HCC.  Results: This is the first translatome data resource for dissecting dysregulated translation in HCC at the sub-codon resoln.  Based on our data, quant. comparisons of mRNA translation rates yielded the genes and processes that were subjected to patient specific or universal dysregulations of translation efficiencies in tumors.  For example, multiple proteins involved in extracellular matrix organization exhibited significant translational upregulation in tumors.  We then exptl. validated the tumor-promoting functions of two such genes as examples: AGRN and VWA1.  In addn., the data was also used for de novo annotation of the translatomes in tumors and normal tissues, including multiple types of novel non-canonical small ORFs, which would be a resource for further functional studies.  Conclusions: The present study generates the first survey of the HCC translatome with ribosome profiling, which is an insightful data resource for dissecting the translatome shift in liver cancer, at sub-codon resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmowvf1xTblrVg90H21EOLACvtfcHk0lhZXV_EEOuNOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1ert7jF&md5=bc79a38554b6ddc5c87c6422126742b0</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.7150%2Fthno.35033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.35033%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DQ.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DX.%26atitle%3DSurvey%2520of%2520the%2520Translation%2520Shifts%2520in%2520Hepatocellular%2520Carcinoma%2520with%2520Ribosome%2520Profiling%26jtitle%3DTheranostics%26date%3D2019%26volume%3D9%26spage%3D4141%26epage%3D4155%26doi%3D10.7150%2Fthno.35033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manfrini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventura, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calamita, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biffo, S.</span></span> <span> </span><span class="NLM_article-title">Ribosome Profiling Unveils Translational Regulation of Metabolic Enzymes in Primary CD4+ Th1 Cells</span>. <i>Dev. Comp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">103697</span>, <span class="refDoi"> DOI: 10.1016/j.dci.2020.103697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.dci.2020.103697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=32330465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXot1Ciurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2020&pages=103697&author=N.+Manfriniauthor=S.+Ricciardiauthor=R.+Alfieriauthor=G.+Venturaauthor=P.+Calamitaauthor=A.+Favalliauthor=S.+Biffo&title=Ribosome+Profiling+Unveils+Translational+Regulation+of+Metabolic+Enzymes+in+Primary+CD4%2B+Th1+Cells&doi=10.1016%2Fj.dci.2020.103697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosome profiling unveils translational regulation of metabolic enzymes in primary CD4+ Th1 cells</span></div><div class="casAuthors">Manfrini, Nicola; Ricciardi, Sara; Alfieri, Roberta; Ventura, Gabriele; Calamita, Piera; Favalli, Andrea; Biffo, Stefano</div><div class="citationInfo"><span class="NLM_cas:title">Developmental & Comparative Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103697</span>CODEN:
                <span class="NLM_cas:coden">DCIMDQ</span>;
        ISSN:<span class="NLM_cas:issn">0145-305X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The transition from a naive to an effector T cell is an essential event that requires metabolic reprogramming.  We have recently demonstrated that the rapid metabolic changes that occur following stimulation of naive T cells require the translation of preexisting mRNAs.  Here, we provide evidence that translation regulates the metabolic asset of effector T cells.  By performing ribosome profiling in human CD4+ Th1 cells, we show that the metab. of glucose, fatty acids and pentose phosphates is regulated at the translational level.  In Th1 cells, each pathway has at least one enzyme regulated at the translational level and selected enzymes have high translational efficiencies. mRNA expression does not predict protein expression.  For instance, PKM2 mRNA is equally present in naive T and Th1 cells, but the protein is abundant only in Th1. 5'-untranslated regions (UTRs) may partly account for this regulation.  Overall we suggest that immunometabolism is controlled by translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLS3bz2OUpBbVg90H21EOLACvtfcHk0lhZXV_EEOuNOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXot1Ciurg%253D&md5=4dfe610d40ba2388b05ae997e92fb35a</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.dci.2020.103697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dci.2020.103697%26sid%3Dliteratum%253Aachs%26aulast%3DManfrini%26aufirst%3DN.%26aulast%3DRicciardi%26aufirst%3DS.%26aulast%3DAlfieri%26aufirst%3DR.%26aulast%3DVentura%26aufirst%3DG.%26aulast%3DCalamita%26aufirst%3DP.%26aulast%3DFavalli%26aufirst%3DA.%26aulast%3DBiffo%26aufirst%3DS.%26atitle%3DRibosome%2520Profiling%2520Unveils%2520Translational%2520Regulation%2520of%2520Metabolic%2520Enzymes%2520in%2520Primary%2520CD4%252B%2520Th1%2520Cells%26jtitle%3DDev.%2520Comp.%2520Immunol.%26date%3D2020%26volume%3D109%26spage%3D103697%26doi%3D10.1016%2Fj.dci.2020.103697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mort, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuzhanova, N. A.</span></span> <span> </span><span class="NLM_article-title">A Meta-Analysis of Nonsense Mutations Causing Human Genetic Disease</span>. <i>Hum. Mutat.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1037</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1002/humu.20763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fhumu.20763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18454449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCqu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=1037-1047&author=M.+Mortauthor=D.+Ivanovauthor=D.+N.+Cooperauthor=N.+A.+Chuzhanova&title=A+Meta-Analysis+of+Nonsense+Mutations+Causing+Human+Genetic+Disease&doi=10.1002%2Fhumu.20763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">A meta-analysis of nonsense mutations causing human genetic disease</span></div><div class="casAuthors">Mort, Matthew; Ivanov, Dobril; Cooper, David N.; Chuzhanova, Nadia A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Mutation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1037-1047</span>CODEN:
                <span class="NLM_cas:coden">HUMUE3</span>;
        ISSN:<span class="NLM_cas:issn">1059-7794</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Nonsense mutations account for ∼11% of all described gene lesions causing human inherited disease and ∼20% of disease-assocd. single-basepair substitutions affecting gene coding regions.  Pathol. nonsense mutations resulting in TGA (38.5%), TAG (40.4%), and TAA (21.1%) occur in different proportions to naturally occurring stop codons.  Of the 23 different nucleotide substitutions giving rise to nonsense mutations, the most frequent are CGA→TGA (21%; resulting from methylation-mediated deamination) and CAG→TAG (19%).  The differing nonsense mutation frequencies are largely explicable in terms of variable nucleotide substitution rates such that it is unnecessary to invoke differential translational termination efficiency or differential codon usage.  Some genes are characterized by numerous nonsense mutations but relatively few if any missense mutations (e.g., CHM) whereas other genes exhibit many missense mutations but few if any nonsense mutations (e.g., PSEN1).  Genes in the latter category have a tendency to encode proteins characterized by multimer formation.  Consistent with the operation of a clin. selection bias, genes exhibiting an excess of nonsense mutations are also likely to display an excess of frameshift mutations.  Tumor suppressor (TS) genes exhibit a disproportionate no. of nonsense mutations while most mutations in oncogenes are missense.  A total of 12% of somatic nonsense mutations in TS genes were found to occur recurrently in the hypermutable CpG dinucleotide.  In a comparison of somatic and germline mutational spectra for 17 TS genes, ∼43% of somatic nonsense mutations had counterparts in the germline (rising to 98% for CpG mutations).  Finally, the proportion of disease-causing nonsense mutations predicted to elicit nonsense-mediated mRNA decay (NMD) is significantly higher (P = 1.56 × 10-9) than among nonobserved (potential) nonsense mutations, implying that nonsense mutations that elicit NMD are more likely to come to clin. attention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqclqgu8RD0S7Vg90H21EOLACvtfcHk0lhZXV_EEOuNOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCqu7vI&md5=ac21ee29de687326330807cbd0017b4a</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2Fhumu.20763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhumu.20763%26sid%3Dliteratum%253Aachs%26aulast%3DMort%26aufirst%3DM.%26aulast%3DIvanov%26aufirst%3DD.%26aulast%3DCooper%26aufirst%3DD.%2BN.%26aulast%3DChuzhanova%26aufirst%3DN.%2BA.%26atitle%3DA%2520Meta-Analysis%2520of%2520Nonsense%2520Mutations%2520Causing%2520Human%2520Genetic%2520Disease%26jtitle%3DHum.%2520Mutat.%26date%3D2008%26volume%3D29%26spage%3D1037%26epage%3D1047%26doi%3D10.1002%2Fhumu.20763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dabrowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukowy-Bieryllo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zietkiewicz, E.</span></span> <span> </span><span class="NLM_article-title">Advances in Therapeutic Use of a Drug-Stimulated Translational Readthrough of Premature Termination Codons</span>. <i>Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi"> DOI: 10.1186/s10020-018-0024-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1186%2Fs10020-018-0024-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30134808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BB3c3gvVSjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=25&author=M.+Dabrowskiauthor=Z.+Bukowy-Bierylloauthor=E.+Zietkiewicz&title=Advances+in+Therapeutic+Use+of+a+Drug-Stimulated+Translational+Readthrough+of+Premature+Termination+Codons&doi=10.1186%2Fs10020-018-0024-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons</span></div><div class="casAuthors">Dabrowski Maciej; Bukowy-Bieryllo Zuzanna; Zietkiewicz Ewa</div><div class="citationInfo"><span class="NLM_cas:title">Molecular medicine (Cambridge, Mass.)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Premature termination codons (PTCs) in the coding regions of mRNA lead to the incorrect termination of translation and generation of non-functional, truncated proteins.  Translational readthrough of PTCs induced by pharmaceutical compounds is a promising way of restoring functional protein expression and reducing disease symptoms, without affecting the genome or transcriptome of the patient.  While in some cases proven effective, the clinical use of readthrough-inducing compounds is still associated with many risks and difficulties.  This review focuses on problems directly associated with compounds used to stimulate PTC readthrough, such as their interactions with the cell and organism, their toxicity and bioavailability (cell permeability; tissue deposition etc.).  Various strategies designed to overcome these problems are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTESyJJ7F50JGlSCSgBhwJFfW6udTcc2eazv74aLgo2ILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3gvVSjtg%253D%253D&md5=a802b3ebc26179642d8941d76281eabb</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1186%2Fs10020-018-0024-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs10020-018-0024-7%26sid%3Dliteratum%253Aachs%26aulast%3DDabrowski%26aufirst%3DM.%26aulast%3DBukowy-Bieryllo%26aufirst%3DZ.%26aulast%3DZietkiewicz%26aufirst%3DE.%26atitle%3DAdvances%2520in%2520Therapeutic%2520Use%2520of%2520a%2520Drug-Stimulated%2520Translational%2520Readthrough%2520of%2520Premature%2520Termination%2520Codons%26jtitle%3DMol.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D25%26doi%3D10.1186%2Fs10020-018-0024-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagel-Wolfrum, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baasov, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfrum, U.</span></span> <span> </span><span class="NLM_article-title">Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs)</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1007/s40259-016-0157-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs40259-016-0157-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26886021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFCit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=49-74&author=K.+Nagel-Wolfrumauthor=F.+M%C3%B6llerauthor=I.+Pennerauthor=T.+Baasovauthor=U.+Wolfrum&title=Targeting+Nonsense+Mutations+in+Diseases+with+Translational+Read-Through-Inducing+Drugs+%28TRIDs%29&doi=10.1007%2Fs40259-016-0157-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs)</span></div><div class="casAuthors">Nagel-Wolfrum, Kerstin; Moeller, Fabian; Penner, Inessa; Baasov, Timor; Wolfrum, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">49-74</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">In recent years, remarkable advances in the ability to diagnose genetic disorders have been made.  The identification of disease-causing genes allows the development of gene-specific therapies with the ultimate goal to develop personalized medicines for each patient according to their own specific genetic defect.  In-depth genotyping of many different genes has revealed that ∼12 % of inherited genetic disorders are caused by in-frame nonsense mutations.  Nonsense (non-coding) mutations are caused by point mutations, which generate premature termination codons (PTCs) that cause premature translational termination of the mRNA, and subsequently inhibit normal full-length protein expression.  Recently, a gene-based therapeutic approach for genetic diseases caused by nonsense mutations has emerged, namely the so-called translational read-through (TR) therapy.  Read-through therapy is based on the discovery that small mols., known as TR-inducing drugs (TRIDs), allow the translation machinery to suppress a nonsense codon, elongate the nascent peptide chain, and consequently result in the synthesis of full-length protein.  Several TRIDs are currently under investigation and research has been performed on several genetic disorders caused by nonsense mutations over the years.  These findings have raised hope for the usage of TR therapy as a gene-based pharmacogenetic therapy for nonsense mutations in various genes responsible for a variety of genetic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMFXoY23VksrVg90H21EOLACvtfcHk0ljyPkSRhZkKkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFCit7k%253D&md5=56a8249101e391d048e1982242099262</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1007%2Fs40259-016-0157-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-016-0157-6%26sid%3Dliteratum%253Aachs%26aulast%3DNagel-Wolfrum%26aufirst%3DK.%26aulast%3DM%25C3%25B6ller%26aufirst%3DF.%26aulast%3DPenner%26aufirst%3DI.%26aulast%3DBaasov%26aufirst%3DT.%26aulast%3DWolfrum%26aufirst%3DU.%26atitle%3DTargeting%2520Nonsense%2520Mutations%2520in%2520Diseases%2520with%2520Translational%2520Read-Through-Inducing%2520Drugs%2520%2528TRIDs%2529%26jtitle%3DBioDrugs%26date%3D2016%26volume%3D30%26spage%3D49%26epage%3D74%26doi%3D10.1007%2Fs40259-016-0157-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kampen, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulima, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vereecke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Keersmaecker, K.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of Ribosomopathies</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1093/nar/gkz637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1093%2Fnar%2Fgkz637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31350888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1OgurfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2020&pages=1013-1028&author=K.+R.+Kampenauthor=S.+O.+Sulimaauthor=S.+Vereeckeauthor=K.+De+Keersmaecker&title=Hallmarks+of+Ribosomopathies&doi=10.1093%2Fnar%2Fgkz637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of ribosomopathies</span></div><div class="casAuthors">Kampen, Kim R.; Sulima, Sergey O.; Vereecke, Stijn; De Keersmaecker, Kim</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1013-1028</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Ribosomopathies are diseases caused by defects in ribosomal constituents or in factors with a role in ribosome assembly.  Intriguingly, congenital ribosomopathies display a paradoxical transition from early symptoms due to cellular hypo-proliferation to an elevated cancer risk later in life.  Another assocn. between ribosome defects and cancer came into view after the recent discovery of somatic mutations in ribosomal proteins and rDNA copy no. changes in a variety of tumor types, giving rise to somatic ribosomopathies.  Despite these clear connections between ribosome defects and cancer, the mol. mechanisms by which defects in this essential cellular machinery are oncogenic only start to emerge.  In this review, the impact of ribosomal defects on the cellular function and their mechanisms of promoting oncogenesis are described.  In particular, we discuss the emerging hallmarks of ribosomopathies such as the appearance of 'onco-ribosomes' that are specialized in translating oncoproteins, dysregulation of translation-independent extra-ribosomal functions of ribosomal proteins, rewired cellular protein and energy metab., and extensive oxidative stress leading to DNA damage.  We end by integrating these findings in a model that can provide an explanation how ribosomopathies could lead to the transition from hypo- to hyper-proliferation in bone marrow failure syndromes with elevated cancer risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgQP1oo3Ap_7Vg90H21EOLACvtfcHk0ljyPkSRhZkKkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1OgurfE&md5=2cd44a5482996d80ca9da5cf5d5bf3b9</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkz637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkz637%26sid%3Dliteratum%253Aachs%26aulast%3DKampen%26aufirst%3DK.%2BR.%26aulast%3DSulima%26aufirst%3DS.%2BO.%26aulast%3DVereecke%26aufirst%3DS.%26aulast%3DDe%2BKeersmaecker%26aufirst%3DK.%26atitle%3DHallmarks%2520of%2520Ribosomopathies%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2020%26volume%3D48%26spage%3D1013%26epage%3D1028%26doi%3D10.1093%2Fnar%2Fgkz637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakhoul, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span> <span> </span><span class="NLM_article-title">Ribosomopathies: Mechanisms of Disease</span>. <i>Clin. Med. Insights Blood Disord.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.4137/CMBD.S16952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.4137%2FCMBD.S16952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25512719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFahsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=7-16&author=H.+Nakhoulauthor=J.+Keauthor=X.+Zhouauthor=W.+Liaoauthor=S.+X.+Zengauthor=H.+Lu&title=Ribosomopathies%3A+Mechanisms+of+Disease&doi=10.4137%2FCMBD.S16952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosomopathies: mechanisms of disease</span></div><div class="casAuthors">Nakhoul, Hani; Ke, Jiangwei; Zhou, Xiang; Liao, Wenjuan; Zeng, Shelya X.; Lu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Medicine Insights: Blood Disorders</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7-16</span>CODEN:
                <span class="NLM_cas:coden">CMIBCH</span>;
        ISSN:<span class="NLM_cas:issn">1179-545X</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica Ltd.</span>)
        </div><div class="casAbstract">A review.  Ribosomopathies are diseases caused by alterations in the structure or function of ribosomal components.  Progress in our understanding of the role of the ribosome in translational and transcriptional regulation has clarified the mechanisms of the ribosomopathies and the relationship between ribosomal dysfunction and other diseases, esp. cancer.  This review aims to discuss these topics with updated information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHrgnGkVB-KbVg90H21EOLACvtfcHk0ljyPkSRhZkKkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFahsbbK&md5=725705ea6ddfd392f8f992d710e21511</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.4137%2FCMBD.S16952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FCMBD.S16952%26sid%3Dliteratum%253Aachs%26aulast%3DNakhoul%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLiao%26aufirst%3DW.%26aulast%3DZeng%26aufirst%3DS.%2BX.%26aulast%3DLu%26aufirst%3DH.%26atitle%3DRibosomopathies%253A%2520Mechanisms%2520of%2520Disease%26jtitle%3DClin.%2520Med.%2520Insights%2520Blood%2520Disord.%26date%3D2014%26volume%3D7%26spage%3D7%26epage%3D16%26doi%3D10.4137%2FCMBD.S16952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frechin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchiar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeffelholz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Holvec, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaval, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winum, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaholz, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyron, J.-F.</span></span> <span> </span><span class="NLM_article-title">Targeting the Human 80S Ribosome in Cancer: From Structure to Function and Drug Design for Innovative Adjuvant Therapeutic Strategies</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">629</span>, <span class="refDoi"> DOI: 10.3390/cells9030629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fcells9030629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVSqt7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=629&author=A.+Gillesauthor=L.+Frechinauthor=K.+Natchiarauthor=G.+Biondaniauthor=O.+Loeffelholzauthor=S.+von+Holvecauthor=J.-L.+Malavalauthor=J.-Y.+Winumauthor=B.+P.+Klaholzauthor=J.-F.+Peyron&title=Targeting+the+Human+80S+Ribosome+in+Cancer%3A+From+Structure+to+Function+and+Drug+Design+for+Innovative+Adjuvant+Therapeutic+Strategies&doi=10.3390%2Fcells9030629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the human 80S ribosome in cancer: from structure to function and drug design for innovative adjuvant therapeutic strategies</span></div><div class="casAuthors">Gilles, Arnaud; Frechin, Leo; Natchiar, Kundhavai; Biondani, Giulia; von Loeffelholz, Ottilie; Holvec, Samuel; Malaval, Julie-Lisa; Winum, Jean-Yves; Klaholz, Bruno P.; Peyron, Jean-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The human 80S ribosome is the cellular nucleoprotein nanomachine in charge of protein synthesis that is profoundly affected during cancer transformation by oncogenic proteins and provides cancerous proliferating cells with proteins and therefore biomass.  Indeed, cancer is assocd. with an increase in ribosome biogenesis and mutations in several ribosomal proteins genes are found in ribosomopathies, which are congenital diseases that display an elevated risk of cancer.  Ribosomes and their biogenesis therefore represent attractive anti-cancer targets and several strategies are being developed to identify efficient and specific drugs.  Homoharringtonine (HHT) is the only direct ribosome inhibitor currently used in clinics for cancer treatments, although many classical chemotherapeutic drugs also appear to impact on protein synthesis.  Here we review the role of the human ribosome as a medical target in cancer, and how functional and structural anal. combined with chem. synthesis of new inhibitors can synergize.  The possible existence of oncoribosomes is also discussed.  The emerging idea is that targeting the human ribosome could not only allow the interference with cancer cell addiction towards protein synthesis and possibly induce their death but may also be highly valuable to decrease the levels of oncogenic proteins that display a high turnover rate (MYC, MCL1).  Cryo-electron microscopy (cryo-EM) is an advanced method that allows the visualization of human ribosome complexes with factors and bound inhibitors to improve our understanding of their functioning mechanisms mode.  Cryo-EM structures could greatly assist the foundation phase of a novel drug-design strategy.  One goal would be to identify new specific and active mols. targeting the ribosome in cancer such as derivs. of cycloheximide, a well-known ribosome inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz64kRp25le7Vg90H21EOLACvtfcHk0liY5Kg0s5Mkmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVSqt7jK&md5=9bf0b6631bcbe83ef4d93d3a7359bcc8</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.3390%2Fcells9030629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9030629%26sid%3Dliteratum%253Aachs%26aulast%3DGilles%26aufirst%3DA.%26aulast%3DFrechin%26aufirst%3DL.%26aulast%3DNatchiar%26aufirst%3DK.%26aulast%3DBiondani%26aufirst%3DG.%26aulast%3DLoeffelholz%26aufirst%3DO.%26aulast%3Dvon%2BHolvec%26aufirst%3DS.%26aulast%3DMalaval%26aufirst%3DJ.-L.%26aulast%3DWinum%26aufirst%3DJ.-Y.%26aulast%3DKlaholz%26aufirst%3DB.%2BP.%26aulast%3DPeyron%26aufirst%3DJ.-F.%26atitle%3DTargeting%2520the%2520Human%252080S%2520Ribosome%2520in%2520Cancer%253A%2520From%2520Structure%2520to%2520Function%2520and%2520Drug%2520Design%2520for%2520Innovative%2520Adjuvant%2520Therapeutic%2520Strategies%26jtitle%3DCells%26date%3D2020%26volume%3D9%26spage%3D629%26doi%3D10.3390%2Fcells9030629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powell, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisleder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, I. A.</span></span> <span> </span><span class="NLM_article-title">Structure of Cephalotaxine and Related Alkaloids</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4081</span>– <span class="NLM_lpage">4084</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)88620-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2FS0040-4039%2801%2988620-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1969&pages=4081-4084&author=R.+G.+Powellauthor=D.+Weislederauthor=C.+R.+Smithauthor=I.+A.+Wolff&title=Structure+of+Cephalotaxine+and+Related+Alkaloids&doi=10.1016%2FS0040-4039%2801%2988620-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2988620-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252988620-2%26sid%3Dliteratum%253Aachs%26aulast%3DPowell%26aufirst%3DR.%2BG.%26aulast%3DWeisleder%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DWolff%26aufirst%3DI.%2BA.%26atitle%3DStructure%2520of%2520Cephalotaxine%2520and%2520Related%2520Alkaloids%26jtitle%3DTetrahedron%2520Lett.%26date%3D1969%26volume%3D10%26spage%3D4081%26epage%3D4084%26doi%3D10.1016%2FS0040-4039%2801%2988620-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fresno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VÁZQUEZ, D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Translation in Eukaryotic Systems by Harringtonine</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1977.tb11256.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1111%2Fj.1432-1033.1977.tb11256.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=319998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE2sXhtleguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1977&pages=323-330&author=M.+Fresnoauthor=A.+Jim%C3%A9nezauthor=D.+V%C3%81ZQUEZ&title=Inhibition+of+Translation+in+Eukaryotic+Systems+by+Harringtonine&doi=10.1111%2Fj.1432-1033.1977.tb11256.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of translation in eukaryotic systems by harringtonine</span></div><div class="casAuthors">Fresno, Manuel; Jimenez, Antonio; Vazquez, David</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">323-30</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    </div><div class="casAbstract">The Cephalotaxus alkaloids harringtonine [26833-85-2], homoharringtonine [26833-87-4] and isoharringtonine [26833-86-3] inhibited protein synthesis in eukaryotic cells.  The alkaloids did not inhibit, in model systems, any of the steps of the initiation process but blocked poly(U)-directed polyphenylalanine [25191-15-5] synthesis as well as peptide bond formation in the fragment reaction assay, the sparsomycin-induced binding of 3H-labeled (C)U-A-C-C-A-Leu-Ac [54867-59-3], and the enzymic and the non-enzymic binding of Phe-tRNA to ribosomes.  These results suggest that the Cephalotaxus alkaloids inhibit the elongation phase of translation by preventing substrate binding to the acceptor site on the 60-S ribosome subunit and therefore block aminoacyl-tRNA binding and peptide bond formation.  However, the Cephalotaxus alkaloids did not inhibit polypeptide synthesis and peptidyl-3H-labeled puromycin formation in polysomes.  Furthermore, these alkaloids strongly inhibited 14C-labeled trichodermin [4682-50-2] binding to free ribosomes but hardly affect the interaction of the antibiotic with yeast polysomes.  Thus, the Cephalotaxus alkaloids cannot interact with polysomes and therefore only inhibit the initial cycles of elongation.  This explains the polysome run off that has been obsd. by some workers in the presence of harringtonine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSRrYoSRnkVbVg90H21EOLACvtfcHk0liY5Kg0s5Mkmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXhtleguro%253D&md5=36cf4b9cd11f243786429704ea8b06ec</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1977.tb11256.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1977.tb11256.x%26sid%3Dliteratum%253Aachs%26aulast%3DFresno%26aufirst%3DM.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DA.%26aulast%3DV%25C3%2581ZQUEZ%26aufirst%3DD.%26atitle%3DInhibition%2520of%2520Translation%2520in%2520Eukaryotic%2520Systems%2520by%2520Harringtonine%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1977%26volume%3D72%26spage%3D323%26epage%3D330%26doi%3D10.1111%2Fj.1432-1033.1977.tb11256.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ingolia, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lareau, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span> <span> </span><span class="NLM_article-title">Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.cell.2011.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22056041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKgsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2011&pages=789-802&author=N.+T.+Ingoliaauthor=L.+F.+Lareauauthor=J.+S.+Weissman&title=Ribosome+Profiling+of+Mouse+Embryonic+Stem+Cells+Reveals+the+Complexity+and+Dynamics+of+Mammalian+Proteomes&doi=10.1016%2Fj.cell.2011.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes</span></div><div class="casAuthors">Ingolia, Nicholas T.; Lareau, Liana F.; Weissman, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">789-802</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The ability to sequence genomes has far outstripped approaches for deciphering the information they encode.  Here we present a suite of techniques, based on ribosome profiling (the deep sequencing of ribosome-protected mRNA fragments), to provide genome-wide maps of protein synthesis as well as a pulse-chase strategy for detg. rates of translation elongation.  We exploit the propensity of harringtonine to cause ribosomes to accumulate at sites of translation initiation together with a machine learning algorithm to define protein products systematically.  Anal. of translation in mouse embryonic stem cells reveals thousands of strong pause sites and unannotated translation products.  These include amino-terminal extensions and truncations and upstream open reading frames with regulatory potential, initiated at both AUG and non-AUG codons, whose translation changes after differentiation.  We also define a class of short, polycistronic ribosome-assocd. coding RNAs (sprcRNAs) that encode small proteins.  Our studies reveal an unanticipated complexity to mammalian proteomes.  A high-resoln. look at mammalian translation reveals unanticipated diversity in the resulting proteome, including peptide products from putative noncoding RNAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo34Hgu2-Dva7Vg90H21EOLACvtfcHk0lhwzmX_0Iuotg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKgsLnJ&md5=07e899f5084ff6912ea3415c53dbe550</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DIngolia%26aufirst%3DN.%2BT.%26aulast%3DLareau%26aufirst%3DL.%2BF.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26atitle%3DRibosome%2520Profiling%2520of%2520Mouse%2520Embryonic%2520Stem%2520Cells%2520Reveals%2520the%2520Complexity%2520and%2520Dynamics%2520of%2520Mammalian%2520Proteomes%26jtitle%3DCell%26date%3D2011%26volume%3D147%26spage%3D789%26epage%3D802%26doi%3D10.1016%2Fj.cell.2011.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, J. F.</span></span> <span> </span><span class="NLM_article-title">Biologic and Pharmacologic Effects of Harringtonine on Human Leukemia-Lymphoma Cells</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1007/BF00258117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2FBF00258117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=3995683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaL2MXltlCmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1985&pages=206-210&author=Y.+Takemuraauthor=T.+Ohnumaauthor=T.+C.+Chouauthor=T.+Okanoauthor=J.+F.+Holland&title=Biologic+and+Pharmacologic+Effects+of+Harringtonine+on+Human+Leukemia-Lymphoma+Cells&doi=10.1007%2FBF00258117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells</span></div><div class="casAuthors">Takemura, Yuzuru; Ohnuma, Takao; Chou, Tingchao; Okano, Tsuyoshi; Holland, James F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">206-10</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">Ten human leukemia-lymphoma cell lines were tested for the growth-inhibitory effects of harringtonine (HT)  [26833-85-2].  HT was most active against HL-60 acute promyelocytic leukemia cells and least active against DND-41 acute lymphoblastic leukemia cells, with a 70-fold differential activity.  Sensitivity of the cell lines was, in decreasing order: HL-60 > RPMI-8402 > DND-39A ≃ ML-2 ≃ MOLT-3 ≃ KG-1 > Daudi ≃ NALL-1 > BALM-2 > DND-41.  The cell lines with rapid cell growth tended to be more sensitive to HT.  To further elucidate the selectivity of the differential sensitivity, uptake and release of HT were compared in HL-60 and DND-41 cells.  Uptake of [3H]HT into HL-60 and DND-41 cells showed no difference; however, the binding of [3H]HT to cellular components was > 16-fold higher in HL-60 cells than DND-41 cells.  There were also minor, but significant differences in the inhibition of [3H]leucine incorporation into proteins of these 2 cell lines in the presence of 1 μg/mL HT.  To test whether the biol. effects of HT are related to the concn. of, or exposure time to, HT, KG-1 cells were exposed to HT for different periods of time and the growth-inhibitory effects were compared.  Increasing exposure time from 1 h to 3 h resulted in a 100-fold decrease in concn. × exposure time (c × t) at ID50; from 3 h to 6 h, in a 20-fold decrease at ID70; and from 6 h to 24 h, in a 16-fold decrease at ID90.  HT was not inactivated by cells up to 24 h.  Apparently, (a) the sensitivity of different cell lines to HT may be related to the degree of HT binding; and (b) the effects of HT are more dependent on exposure time than concn.  Continuous infusion is thus rational for clin. trials of this drug, and the degree of HT binding to leukemic cells may be predictive of clin. response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ohxQVHpxmrVg90H21EOLACvtfcHk0lhwzmX_0Iuotg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltlCmurY%253D&md5=47515bf3cc60be8b90e850eb0554c864</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1007%2FBF00258117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00258117%26sid%3Dliteratum%253Aachs%26aulast%3DTakemura%26aufirst%3DY.%26aulast%3DOhnuma%26aufirst%3DT.%26aulast%3DChou%26aufirst%3DT.%2BC.%26aulast%3DOkano%26aufirst%3DT.%26aulast%3DHolland%26aufirst%3DJ.%2BF.%26atitle%3DBiologic%2520and%2520Pharmacologic%2520Effects%2520of%2520Harringtonine%2520on%2520Human%2520Leukemia-Lymphoma%2520Cells%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1985%26volume%3D14%26spage%3D206%26epage%3D210%26doi%3D10.1007%2FBF00258117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajczak, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisleder, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Cephalotaxine Esters and Correlation of Their Structures with Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1021/jm00213a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00213a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE2sXotlGjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1977&pages=328-332&author=K.+L.+Mikolajczakauthor=C.+R.+Smithauthor=D.+Weisleder&title=Synthesis+of+Cephalotaxine+Esters+and+Correlation+of+Their+Structures+with+Antitumor+Activity&doi=10.1021%2Fjm00213a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of cephalotaxine esters and correlation of their structures with antitumor activity</span></div><div class="casAuthors">Mikolajczak, Kenneth L.; Smith, Cecil R., Jr.; Weisleder, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">328-32</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Of 22 esters of (-)-cephalotaxine [24316-19-6] prepd. and tested for antitumor activity against P388 lymphocytic leukemia in mice, the Me itaconate (I) [61568-74-9], Me fumarate (II) [61568-73-8], L-mandelate trichloroethyl carbonate (III) [61586-85-4], and trichloroethyl carbonate (IV) [61568-75-0] had consistent and significant activity.  Of these compds., I and IV were most active.  The enantiomer of I, (+)-cephalotaxine Me intaconate [61616-07-7], was inactive.  Structure-activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWkdM3XWn9trVg90H21EOLACvtfcHk0lhwzmX_0Iuotg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXotlGjtQ%253D%253D&md5=70b52ba509ce6d8affff62bfb4bdbede</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1021%2Fjm00213a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00213a002%26sid%3Dliteratum%253Aachs%26aulast%3DMikolajczak%26aufirst%3DK.%2BL.%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DWeisleder%26aufirst%3DD.%26atitle%3DSynthesis%2520of%2520Cephalotaxine%2520Esters%2520and%2520Correlation%2520of%2520Their%2520Structures%2520with%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1977%26volume%3D20%26spage%3D328%26epage%3D332%26doi%3D10.1021%2Fjm00213a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span> <span> </span><span class="NLM_article-title">Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval</span>. <i>Clin. Lymphoma, Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">530</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2013.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.clml.2013.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=23790799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVyltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=530-533&author=H.+M.+Kantarjianauthor=S.+O%E2%80%99Brienauthor=J.+Cortes&title=Homoharringtonine%2FOmacetaxine+Mepesuccinate%3A+The+Long+and+Winding+Road+to+Food+and+Drug+Administration+Approval&doi=10.1016%2Fj.clml.2013.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval</span></div><div class="casAuthors">Kantarjian, Hagop M.; O'Brien, Susan; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lymphoma, Myeloma & Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">530-533</span>CODEN:
                <span class="NLM_cas:coden">CLMLCQ</span>;
        ISSN:<span class="NLM_cas:issn">2152-2669</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Homoharringtonine/omacetaxine is a unique agent with a long history of research development.  It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors.  Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsN71Xouy5eLVg90H21EOLACvtfcHk0lhwzmX_0Iuotg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVyltL8%253D&md5=142d6d379d869bc5ea979b1722c0d41a</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2013.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2013.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DHomoharringtonine%252FOmacetaxine%2520Mepesuccinate%253A%2520The%2520Long%2520and%2520Winding%2520Road%2520to%2520Food%2520and%2520Drug%2520Administration%2520Approval%26jtitle%3DClin.%2520Lymphoma%252C%2520Myeloma%2520Leuk.%26date%3D2013%26volume%3D13%26spage%3D530%26epage%3D533%26doi%3D10.1016%2Fj.clml.2013.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murgo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’ Brien, S. M.</span></span> <span> </span><span class="NLM_article-title">Homoharringtonine: History, Current Research, and Future Directions</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1605</span>, <span class="refDoi"> DOI: 10.1002/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=11745238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvVygsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2001&pages=1591-1605&author=M.+H.+Kantarjianauthor=M.+Talpazauthor=V.+Santiniauthor=A.+Murgoauthor=B.+Chesonauthor=S.+M.+O%E2%80%99+Brien&title=Homoharringtonine%3A+History%2C+Current+Research%2C+and+Future+Directions&doi=10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Homoharringtonine: History, current research, and future directions</span></div><div class="casAuthors">Kantarjian, Hagop M.; Talpaz, Moshe; Santini, Valeria; Murgo, Anthony; Cheson, Bruce; O'Brien, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1591-1605</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Cephalotoxine esters, including homoharringtonine (HHT), have shown encouraging activity in leukemia in initial studies in China and in later studies in the U.S.  The authors conducted a review of the literature to examine the studies pertinent to HHT in relation to preclin. studies and Phase I-II trials in patients with hematol. malignancies and solid tumors.  HHT and analogs appear to induce differentiation and apoptosis.  Studies from China reported high response rates in patients with leukemia.  Trials in the U.S. using short HHT infusions (3-4 mg/m2 daily for 5 days) resulted in a high incidence of cardiovascular complications that were reduced using continuous infusion schedules of 3-7 mg/m2 daily for 5-7 days initially, and later lower dose schedules of 2.5 mg/m2 daily for 7-14 days.  Results in solid tumors were neg.  However encouraging results were reported in patients with acute myeloid leukemia, myelodysplastic syndrome, acute promyelocytic leukemia, and, most important, chronic myeloid leukemia (CML).  In CML patients, HHT has been investigated alone and in combination with interferon-α and low-dose cytarabine in late and early chronic phases, with pos. results.  Addnl. areas of interest include the potential use of HHT for the treatment of central nervous system leukemia, polycythemia vera, and other nonmalignant conditions such as malaria.  New semisynthetic prepns. and HHT derivs. that bypass multidrug resistance may improve the efficacy and toxicity profiles, and broaden the range of antitumor efficacy.  HHT and its derivs. appear to have promising activity in hematol. malignancies, a finding that needs to be pursued.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1dQhgTEUcI7Vg90H21EOLACvtfcHk0lgbawmnrHGqNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvVygsrY%253D&md5=ee9e078a86611a4af32064c7b6266bfa</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0142%252820010915%252992%253A6%253C1591%253A%253AAID-CNCR1485%253E3.0.CO%253B2-U%26sid%3Dliteratum%253Aachs%26aulast%3DKantarjian%26aufirst%3DM.%2BH.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DSantini%26aufirst%3DV.%26aulast%3DMurgo%26aufirst%3DA.%26aulast%3DCheson%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599%2BBrien%26aufirst%3DS.%2BM.%26atitle%3DHomoharringtonine%253A%2520History%252C%2520Current%2520Research%252C%2520and%2520Future%2520Directions%26jtitle%3DCancer%26date%3D2001%26volume%3D92%26spage%3D1591%26epage%3D1605%26doi%3D10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vikstrom, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Happo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cluse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kile, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzacasa, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. S.</span></span> <span> </span><span class="NLM_article-title">Translation Inhibitors Induce Cell Death by Multiple Mechanisms and Mcl-1 Reduction Is Only a Minor Contributor</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e409</span>, <span class="refDoi"> DOI: 10.1038/cddis.2012.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fcddis.2012.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=23059828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsV2nuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=e409&author=L.+M.+Lindqvistauthor=I.+Vikstromauthor=J.+M.+Chambersauthor=K.+McArthurauthor=M.+A.+Andersonauthor=K.+J.+Henleyauthor=L.+Happoauthor=L.+Cluseauthor=R.+W.+Johnstoneauthor=A.+W.+Robertsauthor=B.+T.+Kileauthor=B.+A.+Crokerauthor=C.+J.+Burnsauthor=M.+A.+Rizzacasaauthor=A.+Strasserauthor=D.+S.+Huang&title=Translation+Inhibitors+Induce+Cell+Death+by+Multiple+Mechanisms+and+Mcl-1+Reduction+Is+Only+a+Minor+Contributor&doi=10.1038%2Fcddis.2012.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor</span></div><div class="casAuthors">Lindqvist, L. M.; Vikstrom, I.; Chambers, J. M.; McArthur, K.; Ann Anderson, M.; Henley, K. J.; Happo, L.; Cluse, L.; Johnstone, R. W.; Roberts, A. W.; Kile, B. T.; Croker, B. A.; Burns, C. J.; Rizzacasa, M. A.; Strasser, A.; Huang, D. C. S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">Oct.</span>),
    <span class="NLM_cas:pages">e409, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">There is significant interest in treating cancers by blocking protein synthesis, to which hematol. malignancies seem particularly sensitive.  The translation elongation inhibitor homoharringtonine (Omacetaxine mepesuccinate) is undergoing clin. trials for chronic myeloid leukemia, whereas the translation initiation inhibitor silvestrol has shown promise in mouse models of cancer.  Precisely how these compds. induce cell death is unclear, but redn. in Mcl-1, a labile pro-survival Bcl-2 family member, has been proposed to constitute the crit. event.  Moreover, the contribution of translation inhibitors to neutropenia and lymphopenia has not been precisely defined.  Herein, we demonstrate that primary B cells and neutrophils are highly sensitive to translation inhibitors, which trigger the Bax/Bak-mediated apoptotic pathway.  However, contrary to expectations, redn. of Mcl-1 did not significantly enhance cytotoxicity of these compds., suggesting that it does not have a principal role and cautions that strong correlations do not always signify causality.  On the other hand, the killing of T lymphocytes was less dependent on Bax and Bak, indicating that translation inhibitors can also induce cell death via alternative mechanisms.  Indeed, loss of clonogenic survival proved to be independent of the Bax/Bak-mediated apoptosis altogether.  Our findings warn of potential toxicity as these translation inhibitors are cytotoxic to many differentiated non-cycling cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXec6Bnefs-7Vg90H21EOLACvtfcHk0lgbawmnrHGqNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsV2nuw%253D%253D&md5=c38aced51e737b67d433db2b940578ee</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2012.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2012.149%26sid%3Dliteratum%253Aachs%26aulast%3DLindqvist%26aufirst%3DL.%2BM.%26aulast%3DVikstrom%26aufirst%3DI.%26aulast%3DChambers%26aufirst%3DJ.%2BM.%26aulast%3DMcArthur%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DM.%2BA.%26aulast%3DHenley%26aufirst%3DK.%2BJ.%26aulast%3DHappo%26aufirst%3DL.%26aulast%3DCluse%26aufirst%3DL.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26aulast%3DKile%26aufirst%3DB.%2BT.%26aulast%3DCroker%26aufirst%3DB.%2BA.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DRizzacasa%26aufirst%3DM.%2BA.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DD.%2BS.%26atitle%3DTranslation%2520Inhibitors%2520Induce%2520Cell%2520Death%2520by%2520Multiple%2520Mechanisms%2520and%2520Mcl-1%2520Reduction%2520Is%2520Only%2520a%2520Minor%2520Contributor%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2012%26volume%3D3%26spage%3De409%26doi%3D10.1038%2Fcddis.2012.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. J.</span></span> <span> </span><span class="NLM_article-title">The Natural Compound Homoharringtonine Presents Broad Antiviral Activity in Vitro and in Vivo</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">601</span>, <span class="refDoi"> DOI: 10.3390/v10110601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fv10110601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFehtrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=601&author=H.+J.+Dongauthor=Z.+H.+Wangauthor=W.+Mengauthor=C.+C.+Liauthor=Y.+X.+Huauthor=L.+Zhouauthor=X.+J.+Wang&title=The+Natural+Compound+Homoharringtonine+Presents+Broad+Antiviral+Activity+in+Vitro+and+in+Vivo&doi=10.3390%2Fv10110601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">The natural compound homoharringtonine presents broad antiviral activity in vitro and in vivo</span></div><div class="casAuthors">Dong, Hui-Jun; Wang, Zhao-Hua; Meng, Wen; Li, Cui-Cui; Hu, Yan-Xin; Zhou, Lei; Wang, Xiao-Jia</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">601</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">To complement traditional antivirals, natural compds. that act via host targets and present high barriers to resistance are of increasing interest.  In the work reported here, we detected that homoharringtonine (HHT) presents effective antiviral activity.  HHT completely inhibited infections of vesicular stomatitis virus (VSV), Newcastle disease virus (NDV), and porcine epidemic diarrhea virus (PEDV) at concns. of 50, 100, and 500 nM in cell cultures, resp.  Treatment with HHT at doses of 0.05 or 0.2 mg/kg significantly reduced viral load and relieved severe symptoms in PEDV- or NDV-infected animals.  HHT treatment, however, moderately inhibited avian influenza virus (AIV) infection, suggesting its potent antiviral action is restricted to a no. of classes of RNA viruses.  In this study, we also obsd. that HHT actively inhibited herpes simplex virus type 1 (HSV-1) replication with a 50% inhibitory concn. (IC50) of 139 nM; the treatment with HHT at 1000 nM led to redns. of three orders of magnitude.  Moreover, HHT antagonized the phosphorylation level of endogenous and exogenous eukaryotic initiation factor 4E (p-eIF4E), which might regulate the selective translation of specific mRNA (mRNA).  HHT provides a starting point for further progress toward the clin. development of broad-spectrum antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAx4ZQsCsJibVg90H21EOLACvtfcHk0lgbawmnrHGqNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFehtrrK&md5=25c44ce9fed168ca4933eabdf489587d</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.3390%2Fv10110601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv10110601%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DZ.%2BH.%26aulast%3DMeng%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DC.%2BC.%26aulast%3DHu%26aufirst%3DY.%2BX.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%2BJ.%26atitle%3DThe%2520Natural%2520Compound%2520Homoharringtonine%2520Presents%2520Broad%2520Antiviral%2520Activity%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DViruses%26date%3D2018%26volume%3D10%26spage%3D601%26doi%3D10.3390%2Fv10110601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ianevski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstad, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zusinaite, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lysvand, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Løseth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landsem, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmring, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksenych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlandsen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aas, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afset, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordbø, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjørås, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kainov, D. E.</span></span> <span> </span><span class="NLM_article-title">Potential Antiviral Options against SARS-CoV-2 Infection</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">642</span>, <span class="refDoi"> DOI: 10.3390/v12060642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fv12060642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGit73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=642&author=A.+Ianevskiauthor=R.+Yaoauthor=M.+H.+Fenstadauthor=S.+Bizaauthor=E.+Zusinaiteauthor=T.+Reisbergauthor=H.+Lysvandauthor=K.+L%C3%B8sethauthor=V.+M.+Landsemauthor=J.+F.+Malmringauthor=V.+Oksenychauthor=S.+E.+Erlandsenauthor=P.+A.+Aasauthor=L.+Hagenauthor=C.+H.+Pettersenauthor=T.+Tensonauthor=J.+E.+Afsetauthor=S.+A.+Nordb%C3%B8author=M.+Bj%C3%B8r%C3%A5sauthor=D.+E.+Kainov&title=Potential+Antiviral+Options+against+SARS-CoV-2+Infection&doi=10.3390%2Fv12060642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Potential antiviral options against SARS-CoV-2 infection</span></div><div class="casAuthors">Ianevski, Aleksandr; Yao, Rouan; Fenstad, Mona Hoeysaeter; Biza, Svetlana; Zusinaite, Eva; Reisberg, Tuuli; Lysvand, Hilde; Loeseth, Kirsti; Landsem, Veslemoey Malm; Malmring, Janne Fossum; Oksenych, Valentyn; Erlandsen, Sten Even; Aas, Per Arne; Hagen, Lars; Pettersen, Caroline H.; Tenson, Tanel; Afset, Jan Egil; Nordboe, Svein Arne; Bjoeraas, Magnar; Kainov, Denis E.</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">642</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">As of June 2020, the no. of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide.  Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections.  However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly.  Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options.  Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells.  We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients.  We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine.  We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy.  Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr4qdtRfWDabVg90H21EOLACvtfcHk0lh47OxMj4WA-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGit73E&md5=507d1a44014f075da088d01514e9ddd1</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.3390%2Fv12060642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv12060642%26sid%3Dliteratum%253Aachs%26aulast%3DIanevski%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DR.%26aulast%3DFenstad%26aufirst%3DM.%2BH.%26aulast%3DBiza%26aufirst%3DS.%26aulast%3DZusinaite%26aufirst%3DE.%26aulast%3DReisberg%26aufirst%3DT.%26aulast%3DLysvand%26aufirst%3DH.%26aulast%3DL%25C3%25B8seth%26aufirst%3DK.%26aulast%3DLandsem%26aufirst%3DV.%2BM.%26aulast%3DMalmring%26aufirst%3DJ.%2BF.%26aulast%3DOksenych%26aufirst%3DV.%26aulast%3DErlandsen%26aufirst%3DS.%2BE.%26aulast%3DAas%26aufirst%3DP.%2BA.%26aulast%3DHagen%26aufirst%3DL.%26aulast%3DPettersen%26aufirst%3DC.%2BH.%26aulast%3DTenson%26aufirst%3DT.%26aulast%3DAfset%26aufirst%3DJ.%2BE.%26aulast%3DNordb%25C3%25B8%26aufirst%3DS.%2BA.%26aulast%3DBj%25C3%25B8r%25C3%25A5s%26aufirst%3DM.%26aulast%3DKainov%26aufirst%3DD.%2BE.%26atitle%3DPotential%2520Antiviral%2520Options%2520against%2520SARS-CoV-2%2520Infection%26jtitle%3DViruses%26date%3D2020%26volume%3D12%26spage%3D642%26doi%3D10.3390%2Fv12060642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Ambrosio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerriero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debitus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribes, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusset, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietra, F.</span></span> <span> </span><span class="NLM_article-title">Agelastatin A, a New Skeleton Cytotoxic Alkaloid of the Oroidin Family. Isolation from the Axinellid Sponge Agelas Dendromorpha of the Coral Sea</span>. <i>J. Chem. Soc., Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>, (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1306</span>, <span class="refDoi"> DOI: 10.1039/c39930001305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1039%2Fc39930001305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVant7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&pages=1305-1306&issue=16&author=M.+D%E2%80%99Ambrosioauthor=A.+Guerrieroauthor=C.+Debitusauthor=O.+Ribesauthor=J.+Pussetauthor=S.+Leroyauthor=F.+Pietra&title=Agelastatin+A%2C+a+New+Skeleton+Cytotoxic+Alkaloid+of+the+Oroidin+Family.+Isolation+from+the+Axinellid+Sponge+Agelas+Dendromorpha+of+the+Coral+Sea&doi=10.1039%2Fc39930001305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Agelastatin A, a new skeleton cytotoxic alkaloid of the oroidin family. Isolation from the axinellid sponge Agelas dendromorpha of the Coral Sea</span></div><div class="casAuthors">D'Ambrosio, Michele; Guerriero, Antonio; Debitus, Cecile; Ribes, Olivier; Pusset, Jacques; Leroy, Sandrine; Pietra, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Chemical Communications</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1305-6</span>CODEN:
                <span class="NLM_cas:coden">JCCCAT</span>;
        ISSN:<span class="NLM_cas:issn">0022-4936</span>.
    </div><div class="casAbstract">Agelastatin A (I), isolated from the axinellid sponge A. dendromorpha of the Coral Sea, is a new skeleton alkaloid with, unusually for the oroidin family to which it belongs, marked cytotoxicity toward tumor cells in culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH9kgIBHWBbLVg90H21EOLACvtfcHk0lh47OxMj4WA-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVant7c%253D&md5=e121f93fedf1b1b13df356743ef4266a</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1039%2Fc39930001305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39930001305%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DM.%26aulast%3DGuerriero%26aufirst%3DA.%26aulast%3DDebitus%26aufirst%3DC.%26aulast%3DRibes%26aufirst%3DO.%26aulast%3DPusset%26aufirst%3DJ.%26aulast%3DLeroy%26aufirst%3DS.%26aulast%3DPietra%26aufirst%3DF.%26atitle%3DAgelastatin%2520A%252C%2520a%2520New%2520Skeleton%2520Cytotoxic%2520Alkaloid%2520of%2520the%2520Oroidin%2520Family.%2520Isolation%2520from%2520the%2520Axinellid%2520Sponge%2520Agelas%2520Dendromorpha%2520of%2520the%2520Coral%2520Sea%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1993%26issue%3D16%26spage%3D1305%26epage%3D1306%26doi%3D10.1039%2Fc39930001305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarlane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erwin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domostoj, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manaviazar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tanani, M.</span></span> <span> </span><span class="NLM_article-title">Agelastatin A: A Novel Inhibitor of Osteopontin-Mediated Adhesion, Invasion, and Colony Formation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1158%2F1535-7163.MCT-07-2251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18347142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtlWhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=548-558&author=C.+K.+Masonauthor=S.+McFarlaneauthor=P.+G.+Johnstonauthor=P.+Croweauthor=P.+J.+Erwinauthor=M.+M.+Domostojauthor=F.+C.+Campbellauthor=S.+Manaviazarauthor=K.+J.+Haleauthor=M.+El-Tanani&title=Agelastatin+A%3A+A+Novel+Inhibitor+of+Osteopontin-Mediated+Adhesion%2C+Invasion%2C+and+Colony+Formation&doi=10.1158%2F1535-7163.MCT-07-2251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation</span></div><div class="casAuthors">Mason, Charlene K.; McFarlane, Suzanne; Johnston, Patrick G.; Crowe, Paul; Erwin, Pauline J.; Domostoj, Mathias M.; Campbell, F. Charles; Manaviazar, Soraya; Hale, Karl J.; El-Tanani, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">548-558</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Effective inhibitors of osteopontin (OPN)-mediated neoplastic transformation and metastasis are still lacking.  (-)-Agelastatin A is a naturally occurring oroidin alkaloid with powerful antitumor effects that, in many cases, are superior to cisplatin in vitro.  In this regard, past comparative assaying of the two agents against a range of human tumor cell lines has revealed that typically (-)-agelastatin A is 1.5 to 16 times more potent than cisplatin at inhibiting cell growth, its effects being most pronounced against human bladder, skin, colon, and breast carcinomas.  In this study, we have investigated the effects of (-)-agelastatin A on OPN-mediated malignant transformation using mammary epithelial cell lines.  Treatment with (-)-agelastatin A inhibited OPN protein expression and enhanced expression of the cellular OPN inhibitor, Tcf-4.  (-)-Agelastatin A treatment also reduced β-catenin protein expression and reduced anchorage-independent growth, adhesion, and invasion in R37 OPN pBK-CMV and C9 cell lines.  Similar effects were obsd. in MDA-MB-231 and MDA-MB-435s human breast cancer cell lines exposed to (-)-agelastatin A.  Suppression of Tcf-4 by RNA interference (short interfering RNA) induced malignant/invasive transformation in parental benign Rama 37 cells; significantly, these events were reversed by treatment with (-)-agelastatin A.  Our study reveals, for the very first time, that (-)-agelastatin A down-regulates β-catenin expression while simultaneously up-regulating Tcf-4 and that these combined effects cause repression of OPN and inhibition of OPN-mediated malignant cell invasion, adhesion, and colony formation in vitro.  We have also shown that (-)-agelastatin A inhibits cancer cell proliferation by causing cells to accumulate in the G2 phase of cell cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlZ8iSW_fmmrVg90H21EOLACvtfcHk0lh47OxMj4WA-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtlWhu7s%253D&md5=dbfeebaa6bc6c48965d5e9b660492668</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2251%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DC.%2BK.%26aulast%3DMcFarlane%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26aulast%3DCrowe%26aufirst%3DP.%26aulast%3DErwin%26aufirst%3DP.%2BJ.%26aulast%3DDomostoj%26aufirst%3DM.%2BM.%26aulast%3DCampbell%26aufirst%3DF.%2BC.%26aulast%3DManaviazar%26aufirst%3DS.%26aulast%3DHale%26aufirst%3DK.%2BJ.%26aulast%3DEl-Tanani%26aufirst%3DM.%26atitle%3DAgelastatin%2520A%253A%2520A%2520Novel%2520Inhibitor%2520of%2520Osteopontin-Mediated%2520Adhesion%252C%2520Invasion%252C%2520and%2520Colony%2520Formation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D548%26epage%3D558%26doi%3D10.1158%2F1535-7163.MCT-07-2251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hale, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domostoj, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tanani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charles Campbell, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. K.</span></span> <span> </span><span class="NLM_article-title">Chapter 11 Total Synthesis and Mechanism of Action Studies on the Antitumor Alkaloid, (−)-Agelastatin A</span>. <i>Strateg. Tactics Org. Synth.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1016/S1874-6004(05)80034-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2FS1874-6004%2805%2980034-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=352-394&author=K.+J.+Haleauthor=M.+M.+Domostojauthor=M.+El-Tananiauthor=F.+Charles+Campbellauthor=C.+K.+Mason&title=Chapter+11+Total+Synthesis+and+Mechanism+of+Action+Studies+on+the+Antitumor+Alkaloid%2C+%28%E2%88%92%29-Agelastatin+A&doi=10.1016%2FS1874-6004%2805%2980034-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2FS1874-6004%2805%2980034-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1874-6004%252805%252980034-6%26sid%3Dliteratum%253Aachs%26aulast%3DHale%26aufirst%3DK.%2BJ.%26aulast%3DDomostoj%26aufirst%3DM.%2BM.%26aulast%3DEl-Tanani%26aufirst%3DM.%26aulast%3DCharles%2BCampbell%26aufirst%3DF.%26aulast%3DMason%26aufirst%3DC.%2BK.%26atitle%3DChapter%252011%2520Total%2520Synthesis%2520and%2520Mechanism%2520of%2520Action%2520Studies%2520on%2520the%2520Antitumor%2520Alkaloid%252C%2520%2528%25E2%2588%2592%2529-Agelastatin%2520A%26jtitle%3DStrateg.%2520Tactics%2520Org.%2520Synth.%26date%3D2005%26volume%3D6%26spage%3D352%26epage%3D394%26doi%3D10.1016%2FS1874-6004%2805%2980034-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McClary, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinshteyn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouanneau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusupova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, J. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayinde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusupov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Eukaryotic Translation by the Antitumor Natural Product Agelastatin A</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">613</span>, e5. <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.chembiol.2017.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28457705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFSltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=605-613&author=B.+McClaryauthor=B.+Zinshteynauthor=M.+Meyerauthor=M.+Jouanneauauthor=S.+Pellegrinoauthor=G.+Yusupovaauthor=A.+Schullerauthor=J.+C.+P.+Reyesauthor=J.+Luauthor=Z.+Guoauthor=S.+Ayindeauthor=C.+Luoauthor=Y.+Dangauthor=D.+Romoauthor=M.+Yusupovauthor=R.+Greenauthor=J.+O.+Liu&title=Inhibition+of+Eukaryotic+Translation+by+the+Antitumor+Natural+Product+Agelastatin+A&doi=10.1016%2Fj.chembiol.2017.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Eukaryotic Translation by the Antitumor Natural Product Agelastatin A</span></div><div class="casAuthors">McClary, Brandon; Zinshteyn, Boris; Meyer, Melanie; Jouanneau, Morgan; Pellegrino, Simone; Yusupova, Gulnara; Schuller, Anthony; Reyes, Jeremy Chris P.; Lu, Junyan; Guo, Zufeng; Ayinde, Safiat; Luo, Cheng; Dang, Yongjun; Romo, Daniel; Yusupov, Marat; Green, Rachel; Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">605-613.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Protein synthesis plays an essential role in cell proliferation, differentiation, and survival.  Inhibitors of eukaryotic translation have entered the clinic, establishing the translation machinery as a promising target for chemotherapy.  A recently discovered, structurally unique marine sponge-derived brominated alkaloid, (-)-agelastatin A (AglA), possesses potent antitumor activity.  Its underlying mechanism of action, however, has remained unknown.  Using a systematic top-down approach, we show that AglA selectively inhibits protein synthesis.  Using a high-throughput chem. footprinting method, we mapped the AglA-binding site to the ribosomal A site.  A 3.5 Å crystal structure of the 80S eukaryotic ribosome from S. cerevisiae in complex with AglA was obtained, revealing multiple conformational changes of the nucleotide bases in the ribosome accompanying the binding of AglA.  Together, these results have unraveled the mechanism of inhibition of eukaryotic translation by AglA at at. level, paving the way for future structural modifications to develop AglA analogs into novel anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdozB9vaAP57Vg90H21EOLACvtfcHk0lh4oNpc8v6dGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFSltb0%253D&md5=25a42d6159d098efafaf04411840a1bb</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DMcClary%26aufirst%3DB.%26aulast%3DZinshteyn%26aufirst%3DB.%26aulast%3DMeyer%26aufirst%3DM.%26aulast%3DJouanneau%26aufirst%3DM.%26aulast%3DPellegrino%26aufirst%3DS.%26aulast%3DYusupova%26aufirst%3DG.%26aulast%3DSchuller%26aufirst%3DA.%26aulast%3DReyes%26aufirst%3DJ.%2BC.%2BP.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DAyinde%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DRomo%26aufirst%3DD.%26aulast%3DYusupov%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DInhibition%2520of%2520Eukaryotic%2520Translation%2520by%2520the%2520Antitumor%2520Natural%2520Product%2520Agelastatin%2520A%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D605%26epage%3D613%26doi%3D10.1016%2Fj.chembiol.2017.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Total Synthesis of Agelastatins</span>. <i>Pure Appl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">2231</span>– <span class="NLM_lpage">2246</span>, <span class="refDoi"> DOI: 10.1351/PAC-CON-10-08-04</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1351%2FPAC-CON-10-08-04" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFOqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2010&pages=2231-2246&author=G.+Dong&title=Recent+Advances+in+the+Total+Synthesis+of+Agelastatins&doi=10.1351%2FPAC-CON-10-08-04"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the total synthesis of agelastatins</span></div><div class="casAuthors">Dong, Guangbin</div><div class="citationInfo"><span class="NLM_cas:title">Pure and Applied Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2231-2246</span>CODEN:
                <span class="NLM_cas:coden">PACHAS</span>;
        ISSN:<span class="NLM_cas:issn">0033-4545</span>.
    
            (<span class="NLM_cas:orgname">International Union of Pure and Applied Chemistry</span>)
        </div><div class="casAbstract">A review.  Agelastatins represent an important family of marine alkaloids in terms of both exceptional biol. activity and intriguing chem. structure.  In this article, the isolation and biol. activity of agelastatins are reviewed, and proposed biosynthetic pathways are summarized.  The main focus is given to comparative evaluation of recent total syntheses, mainly of agelastatin A.  To date, this has been accomplished by 11 research groups.  Their synthetic routes are analyzed and summarized, with a view to furnishing the reader with insight into different strategic design approaches to assembly of a densely functionalized and compact structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQxVQVSjvP67Vg90H21EOLACvtfcHk0lh4oNpc8v6dGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFOqsbc%253D&md5=7bef89eed87a7abd79c8692f76b2f21d</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1351%2FPAC-CON-10-08-04&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1351%252FPAC-CON-10-08-04%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Total%2520Synthesis%2520of%2520Agelastatins%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D2010%26volume%3D82%26spage%3D2231%26epage%3D2246%26doi%3D10.1351%2FPAC-CON-10-08-04" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hergenrother, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Movassaghi, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Anticancer Activity of All Known (−)-Agelastatin Alkaloids</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">11970</span>– <span class="NLM_lpage">11984</span>, <span class="refDoi"> DOI: 10.1021/jo4020112</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo4020112" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KktbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2013&pages=11970-11984&author=S.+Hanauthor=D.+S.+Siegelauthor=K.+C.+Morrisonauthor=P.+J.+Hergenrotherauthor=M.+Movassaghi&title=Synthesis+and+Anticancer+Activity+of+All+Known+%28%E2%88%92%29-Agelastatin+Alkaloids&doi=10.1021%2Fjo4020112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Anticancer Activity of All Known (-)-Agelastatin Alkaloids</span></div><div class="casAuthors">Han, Sunkyu; Siegel, Dustin S.; Morrison, Karen C.; Hergenrother, Paul J.; Movassaghi, Mohammad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11970-11984</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The full details of our enantioselective total syntheses of (-)-agelastatins A-F, the evolution of a new methodol. for synthesis of substituted azaheterocycles, and the first side-by-side evaluation of all known (-)-agelastatin alkaloids against nine human cancer cell lines are described.  Our concise synthesis of these alkaloids exploits the intrinsic chem. of plausible biosynthetic precursors and capitalizes on a late-stage synthesis of the C-ring.  The crit. copper-mediated cross-coupling reaction was expanded to include guanidine-based systems, offering a versatile prepn. of substituted imidazoles.  The direct comparison of the anticancer activity of all naturally occurring (-)-agelastatins in addn. to eight advanced synthetic intermediates enabled a systematic anal. of the structure-activity relationship within the natural series.  Significantly, (-)-agelastatin A, I (R = Me) is highly potent against six blood cancer cell lines (20-190 nM) without affecting normal red blood cells (>333 μM).  (-)-Agelastatin A and (-)-agelastatin D I (R = H), the two most potent members of this family, induce dose-dependent apoptosis and arrest cells in the G2/M-phase of the cell cycle; however, using confocal microscopy, we have detd. that neither alkaloid affects tubulin dynamics within cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoilGy560IBQbVg90H21EOLACvtfcHk0lh4oNpc8v6dGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KktbzP&md5=cd8e7bc469b46d46e4a6a1963230cd99</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Fjo4020112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo4020112%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%26aulast%3DSiegel%26aufirst%3DD.%2BS.%26aulast%3DMorrison%26aufirst%3DK.%2BC.%26aulast%3DHergenrother%26aufirst%3DP.%2BJ.%26aulast%3DMovassaghi%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520Anticancer%2520Activity%2520of%2520All%2520Known%2520%2528%25E2%2588%2592%2529-Agelastatin%2520Alkaloids%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2013%26volume%3D78%26spage%3D11970%26epage%3D11984%26doi%3D10.1021%2Fjo4020112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stout, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinski, T. F.</span></span> <span> </span><span class="NLM_article-title">Potent Fluorinated Agelastatin Analogues for Chronic Lymphocytic Leukemia: Design, Synthesis, and Pharmacokinetic Studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5085</span>– <span class="NLM_lpage">5093</span>, <span class="refDoi"> DOI: 10.1021/jm4016922</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016922" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5085-5093&author=E.+P.+Stoutauthor=M.+Y.+Choiauthor=J.+E.+Castroauthor=T.+F.+Molinski&title=Potent+Fluorinated+Agelastatin+Analogues+for+Chronic+Lymphocytic+Leukemia%3A+Design%2C+Synthesis%2C+and+Pharmacokinetic+Studies&doi=10.1021%2Fjm4016922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Fluorinated Agelastatin Analogues for Chronic Lymphocytic Leukemia: Design, Synthesis, and Pharmacokinetic Studies</span></div><div class="casAuthors">Stout, E. Paige; Choi, Michael Y.; Castro, Januario E.; Molinski, Tadeusz F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5085-5093</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chronic lymphocytic leukemia (CLL) is the most common lymphoid neoplasia in Western societies and is currently incurable.  Multiple treatment options are practiced, but the available small mol. drugs suffer from dose-limiting toxicity and undesirable side effects.  The need for new, less toxic treatments is a pressing concern.  Here, we demonstrate that (-)-agelastatin A (I, X = Br), a pyrrole-imidazole alkaloid obtained from a marine sponge, exhibits potent in vitro activity against primary cell lines of CLL and disclose the synthesis of several analogs that are equipotent or exceed the potency of the natural product.  The novel synthetic analog, 13-debromo-13-trifluoromethyl agelastatin A I (X = CF3), showed higher activity than the natural product when tested against the same cell lines and is the most potent agelastatin deriv. reported to date.  A detailed in vitro structure-activity relationship of I (X = Br) in CLL compared to that of 22 synthetic analogs is described along with preliminary in vivo pharmacokinetic and metab. studies on the most potent compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD9OSbYEzTfrVg90H21EOLACvtfcHk0ljX21tW69UxgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGmtL8%253D&md5=a10cb2a61a81aca656cfc24d14cfa9f2</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Fjm4016922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016922%26sid%3Dliteratum%253Aachs%26aulast%3DStout%26aufirst%3DE.%2BP.%26aulast%3DChoi%26aufirst%3DM.%2BY.%26aulast%3DCastro%26aufirst%3DJ.%2BE.%26aulast%3DMolinski%26aufirst%3DT.%2BF.%26atitle%3DPotent%2520Fluorinated%2520Agelastatin%2520Analogues%2520for%2520Chronic%2520Lymphocytic%2520Leukemia%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Pharmacokinetic%2520Studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5085%26epage%3D5093%26doi%3D10.1021%2Fjm4016922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dyshlovoy, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinovsky, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shubina, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bokemeyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stonik, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honecker, F.</span></span> <span> </span><span class="NLM_article-title">Mycalamide A Shows Cytotoxic Properties and Prevents EGF-Induced Neoplastic Transformation through Inhibition of Nuclear Factors</span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1212</span>– <span class="NLM_lpage">1224</span>, <span class="refDoi"> DOI: 10.3390/md10061212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fmd10061212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22822368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38Xotlyjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=1212-1224&author=S.+A.+Dyshlovoyauthor=S.+N.+Fedorovauthor=A.+I.+Kalinovskyauthor=L.+K.+Shubinaauthor=C.+Bokemeyerauthor=V.+A.+Stonikauthor=F.+Honecker&title=Mycalamide+A+Shows+Cytotoxic+Properties+and+Prevents+EGF-Induced+Neoplastic+Transformation+through+Inhibition+of+Nuclear+Factors&doi=10.3390%2Fmd10061212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Mycalamide A shows cytotoxic properties and prevents EGF-induced neoplastic transformation through inhibition of nuclear factors</span></div><div class="casAuthors">Dyshlovoy, Sergey A.; Fedorov, Sergey N.; Kalinovsky, Anatoly I.; Shubina, Larisa K.; Bokemeyer, Carsten; Stonik, Valentin A.; Honecker, Friedemann</div><div class="citationInfo"><span class="NLM_cas:title">Marine Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1212-1224</span>CODEN:
                <span class="NLM_cas:coden">MDARE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-3397</span>.
    
            (<span class="NLM_cas:orgname">MDPI Center</span>)
        </div><div class="casAbstract">We report the isolation of mycalamide A from ascidian Polysyncraton sp. as well as investigation of its cancer preventive properties.  In murine JB6 Cl41 P+ cells, mycalamide A inhibited epidermal growth factor (EGF)-induced neoplastic transformation, and induced apoptosis at subnanomolar or nanomolar concns.  The compd. inhibited transcriptional activity of the oncogenic nuclear factors AP-1 and NF-κB, a potential mechanism of its cancer preventive properties.  Induction of phosphorylation of the kinases MAPK p38, JNK, and ERK was also obsd. at high concns. of mycalamide A.  The drug shows promising potential for both cancer prevention and cytotoxic therapy and should be further developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFrdXle0o-tbVg90H21EOLACvtfcHk0ljX21tW69UxgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xotlyjs7g%253D&md5=8ade9a7c7dba8bc28644a183a5c4255c</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.3390%2Fmd10061212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd10061212%26sid%3Dliteratum%253Aachs%26aulast%3DDyshlovoy%26aufirst%3DS.%2BA.%26aulast%3DFedorov%26aufirst%3DS.%2BN.%26aulast%3DKalinovsky%26aufirst%3DA.%2BI.%26aulast%3DShubina%26aufirst%3DL.%2BK.%26aulast%3DBokemeyer%26aufirst%3DC.%26aulast%3DStonik%26aufirst%3DV.%2BA.%26aulast%3DHonecker%26aufirst%3DF.%26atitle%3DMycalamide%2520A%2520Shows%2520Cytotoxic%2520Properties%2520and%2520Prevents%2520EGF-Induced%2520Neoplastic%2520Transformation%2520through%2520Inhibition%2520of%2520Nuclear%2520Factors%26jtitle%3DMar.%2520Drugs%26date%3D2012%26volume%3D10%26spage%3D1212%26epage%3D1224%26doi%3D10.3390%2Fmd10061212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gürel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steitz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. B.</span></span> <span> </span><span class="NLM_article-title">Structures of Triacetyloleandomycin and Mycalamide A Bind to the Large Ribosomal Subunit of Haloarcula Marismortui</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5010</span>– <span class="NLM_lpage">5014</span>, <span class="refDoi"> DOI: 10.1128/AAC.00817-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1128%2FAAC.00817-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19738021" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=5010-5014&author=G.+G%C3%BCrelauthor=G.+Blahaauthor=T.+A.+Steitzauthor=P.+B.+Moore&title=Structures+of+Triacetyloleandomycin+and+Mycalamide+A+Bind+to+the+Large+Ribosomal+Subunit+of+Haloarcula+Marismortui&doi=10.1128%2FAAC.00817-09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1128%2FAAC.00817-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00817-09%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCrel%26aufirst%3DG.%26aulast%3DBlaha%26aufirst%3DG.%26aulast%3DSteitz%26aufirst%3DT.%2BA.%26aulast%3DMoore%26aufirst%3DP.%2BB.%26atitle%3DStructures%2520of%2520Triacetyloleandomycin%2520and%2520Mycalamide%2520A%2520Bind%2520to%2520the%2520Large%2520Ribosomal%2520Subunit%2520of%2520Haloarcula%2520Marismortui%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D5010%26epage%3D5014%26doi%3D10.1128%2FAAC.00817-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruangsiriluk, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocke, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolph, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loria, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpino, P. A.</span></span> <span> </span><span class="NLM_article-title">A Small-Molecule Anti-Secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1362</span>– <span class="NLM_lpage">1371</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.chembiol.2016.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27746128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yqs7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=1362-1371&author=D.+N.+Petersenauthor=J.+Hawkinsauthor=W.+Ruangsirilukauthor=K.+A.+Stevensauthor=B.+A.+Maguireauthor=T.+N.+O%E2%80%99Connellauthor=B.+N.+Rockeauthor=M.+Boehmauthor=R.+B.+Ruggeriauthor=T.+Rolphauthor=D.+Hepworthauthor=P.+M.+Loriaauthor=P.+A.+Carpino&title=A+Small-Molecule+Anti-Secretagogue+of+PCSK9+Targets+the+80S+Ribosome+to+Inhibit+PCSK9+Protein+Translation&doi=10.1016%2Fj.chembiol.2016.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation</span></div><div class="casAuthors">Petersen, Donna N.; Hawkins, Julie; Ruangsiriluk, Wanida; Stevens, Kimberly A.; Maguire, Bruce A.; O'Connell, Thomas N.; Rocke, Benjamin N.; Boehm, Markus; Ruggeri, Roger B.; Rolph, Tim; Hepworth, David; Loria, Paula M.; Carpino, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1362-1371</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that downregulates low-d. lipoprotein (LDL) receptor (LDL-R) levels on the surface of hepatocytes, resulting in decreased clearance of LDL-cholesterol (LDL-C).  Phenotypic screening of a small-mol. compd. collection was used to identify an inhibitor of PCSK9 secretion, (R)-N-(isoquinolin-1-yl)-3-(4-methoxyphenyl)-N-(piperidin-3-yl)propanamide (R-IMPP), which was shown to stimulate uptake of LDL-C in hepatoma cells by increasing LDL-R levels, without altering levels of secreted transferrin.  Systematic investigation of the mode of action revealed that R-IMPP did not decrease PCSK9 transcription or increase PCSK9 degrdn., but instead caused transcript-dependent inhibition of PCSK9 translation.  In support of this surprising mechanism of action, we found that R-IMPP was able to selectively bind to human, but not E. coli, ribosomes.  This study opens a new avenue for the development of drugs that modulate the activity of target proteins by mechanisms involving inhibition of eukaryotic translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbEnbBYD6NKbVg90H21EOLACvtfcHk0ljCb0sUXk8Utw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yqs7%252FJ&md5=c375439e6ed7c49daa4625baff8e4e48</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DD.%2BN.%26aulast%3DHawkins%26aufirst%3DJ.%26aulast%3DRuangsiriluk%26aufirst%3DW.%26aulast%3DStevens%26aufirst%3DK.%2BA.%26aulast%3DMaguire%26aufirst%3DB.%2BA.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DT.%2BN.%26aulast%3DRocke%26aufirst%3DB.%2BN.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DRuggeri%26aufirst%3DR.%2BB.%26aulast%3DRolph%26aufirst%3DT.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26atitle%3DA%2520Small-Molecule%2520Anti-Secretagogue%2520of%2520PCSK9%2520Targets%2520the%252080S%2520Ribosome%2520to%2520Inhibit%2520PCSK9%2520Protein%2520Translation%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D1362%26epage%3D1371%26doi%3D10.1016%2Fj.chembiol.2016.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lintner, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Londregan, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowski, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loria, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolph, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doudna, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dullea, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cate, J. H. D. D.</span></span> <span> </span><span class="NLM_article-title">Selective Stalling of Human Translation through Small-Molecule Engagement of the Ribosome Nascent Chain</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">e2001882</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.2001882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pbio.2001882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28323820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1WqurfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=e2001882&author=N.+G.+Lintnerauthor=K.+F.+McClureauthor=D.+Petersenauthor=A.+T.+Londreganauthor=D.+W.+Piotrowskiauthor=L.+Weiauthor=J.+Xiaoauthor=M.+Boltauthor=P.+M.+Loriaauthor=B.+Maguireauthor=K.+F.+Geogheganauthor=A.+Huangauthor=T.+Rolphauthor=S.+Lirasauthor=J.+A.+Doudnaauthor=R.+G.+Dulleaauthor=J.+H.+D.+D.+Cate&title=Selective+Stalling+of+Human+Translation+through+Small-Molecule+Engagement+of+the+Ribosome+Nascent+Chain&doi=10.1371%2Fjournal.pbio.2001882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain</span></div><div class="casAuthors">Lintner, Nathanael G.; McClure, Kim F.; Petersen, Donna; Londregan, Allyn T.; Piotrowski, David W.; Wei, Liuqing; Xiao, Jun; Bolt, Michael; Loria, Paula M.; Maguire, Bruce; Geoghegan, Kieran F.; Huang, Austin; Rolph, Tim; Liras, Spiros; Doudna, Jennifer A.; Dullea, Robert G.; Cate, Jamie H. D.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e2001882/1-e2001882/36</span>CODEN:
                <span class="NLM_cas:coden">PBLIBG</span>;
        ISSN:<span class="NLM_cas:issn">1545-7885</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating the levels of plasma low-d. lipoprotein cholesterol (LDL-C).  Here, we demonstrate that the compd. PF-06446846 inhibits translation of PCSK9 by inducing the ribosome to stall around codon 34, mediated by the sequence of the nascent chain within the exit tunnel.  We further show that PF-06446846 reduces plasma PCSK9 and total cholesterol levels in rats following oral dosing.  Using ribosome profiling, we demonstrate that PF-06446846 is highly selective for the inhibition of PCSK9 translation.  The mechanism of action employed by PF-06446846 reveals a previously unexpected tunability of the human ribosome that allows small mols. to specifically block translation of individual transcripts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqeQbFLtKlX7Vg90H21EOLACvtfcHk0ljCb0sUXk8Utw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1WqurfE&md5=64f33ee234c2425258154ac8368d2518</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.2001882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.2001882%26sid%3Dliteratum%253Aachs%26aulast%3DLintner%26aufirst%3DN.%2BG.%26aulast%3DMcClure%26aufirst%3DK.%2BF.%26aulast%3DPetersen%26aufirst%3DD.%26aulast%3DLondregan%26aufirst%3DA.%2BT.%26aulast%3DPiotrowski%26aufirst%3DD.%2BW.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DBolt%26aufirst%3DM.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DMaguire%26aufirst%3DB.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DRolph%26aufirst%3DT.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DDoudna%26aufirst%3DJ.%2BA.%26aulast%3DDullea%26aufirst%3DR.%2BG.%26aulast%3DCate%26aufirst%3DJ.%2BH.%2BD.%2BD.%26atitle%3DSelective%2520Stalling%2520of%2520Human%2520Translation%2520through%2520Small-Molecule%2520Engagement%2520of%2520the%2520Ribosome%2520Nascent%2520Chain%26jtitle%3DPLoS%2520Biol.%26date%3D2017%26volume%3D15%26spage%3De2001882%26doi%3D10.1371%2Fjournal.pbio.2001882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liaud, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horlbeck, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjoni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cate, J. H. D.</span></span> <span> </span><span class="NLM_article-title">Cellular Response to Small Molecules That Selectively Stall Protein Synthesis by the Ribosome</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1371/journal.pgen.1008057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pgen.1008057" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=1-30&author=N.+Liaudauthor=M.+A.+Horlbeckauthor=L.+A.+Gilbertauthor=K.+Gjoniauthor=J.+S.+Weissmanauthor=J.+H.+D.+Cate&title=Cellular+Response+to+Small+Molecules+That+Selectively+Stall+Protein+Synthesis+by+the+Ribosome&doi=10.1371%2Fjournal.pgen.1008057"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1008057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1008057%26sid%3Dliteratum%253Aachs%26aulast%3DLiaud%26aufirst%3DN.%26aulast%3DHorlbeck%26aufirst%3DM.%2BA.%26aulast%3DGilbert%26aufirst%3DL.%2BA.%26aulast%3DGjoni%26aufirst%3DK.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26aulast%3DCate%26aufirst%3DJ.%2BH.%2BD.%26atitle%3DCellular%2520Response%2520to%2520Small%2520Molecules%2520That%2520Selectively%2520Stall%2520Protein%2520Synthesis%2520by%2520the%2520Ribosome%26jtitle%3DPLoS%2520Genet.%26date%3D2019%26volume%3D15%26spage%3D1%26epage%3D30%26doi%3D10.1371%2Fjournal.pgen.1008057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montabana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dullea, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cate, J. H. D.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Selective Stalling of Human Ribosome Nascent Chain Complexes by a Drug-like Molecule</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1038/s41594-019-0236-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41594-019-0236-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31160784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2it7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=501-509&author=W.+Liauthor=F.+R.+Wardauthor=K.+F.+McClureauthor=S.+T.+L.+Changauthor=E.+Montabanaauthor=S.+Lirasauthor=R.+G.+Dulleaauthor=J.+H.+D.+Cate&title=Structural+Basis+for+Selective+Stalling+of+Human+Ribosome+Nascent+Chain+Complexes+by+a+Drug-like+Molecule&doi=10.1038%2Fs41594-019-0236-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for selective stalling of human ribosome nascent chain complexes by a drug-like molecule</span></div><div class="casAuthors">Li, Wenfei; Ward, Fred R.; McClure, Kim F.; Chang, Stacey Tsai-Lan; Montabana, Elizabeth; Liras, Spiros; Dullea, Robert G.; Cate, Jamie H. D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">501-509</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The drug-like mol. PF-06446846 (PF846) binds the human ribosome and selectively blocks the translation of a small no. of proteins by an unknown mechanism.  In structures of PF846-stalled human ribosome nascent chain complexes, PF846 binds in the ribosome exit tunnel in a eukaryotic-specific pocket formed by 28S rRNA, and alters the path of the nascent polypeptide chain.  PF846 arrests the translating ribosome in the rotated state of translocation, in which the peptidyl-tRNA 3'-CCA end is improperly docked in the peptidyl transferase center.  Selections of mRNAs from mRNA libraries using translation exts. reveal that PF846 can stall translation elongation, arrest termination or even enhance translation, depending on nascent chain sequence context.  These results illuminate how a small mol. selectively targets translation by the human ribosome, and provides a foundation for developing small mols. that modulate the prodn. of proteins of therapeutic interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGgqVCCdqK77Vg90H21EOLACvtfcHk0ljCb0sUXk8Utw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2it7bN&md5=69dde942a5f86ff7942c94a48d0475a9</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1038%2Fs41594-019-0236-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-019-0236-8%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DWard%26aufirst%3DF.%2BR.%26aulast%3DMcClure%26aufirst%3DK.%2BF.%26aulast%3DChang%26aufirst%3DS.%2BT.%2BL.%26aulast%3DMontabana%26aufirst%3DE.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DDullea%26aufirst%3DR.%2BG.%26aulast%3DCate%26aufirst%3DJ.%2BH.%2BD.%26atitle%3DStructural%2520Basis%2520for%2520Selective%2520Stalling%2520of%2520Human%2520Ribosome%2520Nascent%2520Chain%2520Complexes%2520by%2520a%2520Drug-like%2520Molecule%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D501%26epage%3D509%26doi%3D10.1038%2Fs41594-019-0236-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cate, J. H. D.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Human Translation Termination by a Drug-like Compound</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4941</span>, <span class="refDoi"> DOI: 10.1038/s41467-020-18765-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41467-020-18765-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=33009412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvF2js77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=4941&author=W.+Liauthor=S.+T.+L.+Changauthor=F.+R.+Wardauthor=J.+H.+D.+Cate&title=Selective+Inhibition+of+Human+Translation+Termination+by+a+Drug-like+Compound&doi=10.1038%2Fs41467-020-18765-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of human translation termination by a drug-like compound</span></div><div class="casAuthors">Li, Wenfei; Chang, Stacey Tsai-Lan; Ward, Fred. R.; Cate, Jamie H. D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4941</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Methods to directly inhibit gene expression using small mols. hold promise for the development of new therapeutics targeting proteins that have evaded previous attempts at drug discovery.  Among these, small mols. including the drug-like compd. PF-06446846 (PF846) selectively inhibit the synthesis of specific proteins, by stalling translation elongation.  These mols. also inhibit translation termination by an unknown mechanism.  Using cryo-electron microscopy (cryo-EM) and biochem. approaches, we show that PF846 inhibits translation termination by arresting the nascent chain (NC) in the ribosome exit tunnel.  The arrested NC adopts a compact α-helical conformation that induces 28 S rRNA nucleotide rearrangements that suppress the peptidyl transferase center (PTC) catalytic activity stimulated by eukaryotic release factor 1 (eRF1).  These data support a mechanism of action for a small mol. targeting translation that suppresses peptidyl-tRNA hydrolysis promoted by eRF1, revealing principles of eukaryotic translation termination and laying the foundation for new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2vlgufrovyLVg90H21EOLACvtfcHk0ljyXoJnYOv0ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvF2js77M&md5=4347d287e0ee4ae2caca282df2267b1d</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-18765-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-18765-2%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DChang%26aufirst%3DS.%2BT.%2BL.%26aulast%3DWard%26aufirst%3DF.%2BR.%26aulast%3DCate%26aufirst%3DJ.%2BH.%2BD.%26atitle%3DSelective%2520Inhibition%2520of%2520Human%2520Translation%2520Termination%2520by%2520a%2520Drug-like%2520Compound%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26spage%3D4941%26doi%3D10.1038%2Fs41467-020-18765-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krause, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serio, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, L. E.</span></span> <span> </span><span class="NLM_article-title">Aminoglycosides: An Overview</span>. <i>Cold Spring Harb. Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">a027029</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a027029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1101%2Fcshperspect.a027029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27252397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1ylsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=a027029&author=K.+M.+Krauseauthor=A.+W.+Serioauthor=T.+R.+Kaneauthor=L.+E.+Connolly&title=Aminoglycosides%3A+An+Overview&doi=10.1101%2Fcshperspect.a027029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycosides: an overview</span></div><div class="casAuthors">Krause, Kevin M.; Serio, Alisa W.; Kane, Timothy R.; Connolly, Lynn E.</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">a027029/1-a027029/19</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Aminoglycosides are natural or semisynthetic antibiotics derived from actinomycetes.  They were among the first antibiotics to be introduced for routine clin. use and several examples have been approved for use in humans.  They found widespread use as first-line agents in the early days of antimicrobial chemotherapy, but were eventually replaced in the 1980s with cephalosporins, carbapenems, and fluoroquinolones.  Aminoglycosides synergize with a variety of other antibacterial classes, which, in combination with the continued increase in the rise of multidrug-resistant bacteria and the potential to improve the safety and efficacy of the class through optimized dosing regimens, has led to a renewed interest in these broad-spectrum and rapidly bactericidal antibacterials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_dhgL95KDXbVg90H21EOLACvtfcHk0ljyXoJnYOv0ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1ylsbs%253D&md5=675d7f4c769fdcc681171a121e5aa09e</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a027029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a027029%26sid%3Dliteratum%253Aachs%26aulast%3DKrause%26aufirst%3DK.%2BM.%26aulast%3DSerio%26aufirst%3DA.%2BW.%26aulast%3DKane%26aufirst%3DT.%2BR.%26aulast%3DConnolly%26aufirst%3DL.%2BE.%26atitle%3DAminoglycosides%253A%2520An%2520Overview%26jtitle%3DCold%2520Spring%2520Harb.%2520Perspect.%2520Med.%26date%3D2016%26volume%3D6%26spage%3Da027029%26doi%3D10.1101%2Fcshperspect.a027029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, F.</span></span> <span> </span><span class="NLM_article-title">Phenotypic Suppression of Nonsense Mutants in Yeast by Aminoglycoside Antibiotics</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1038/277148a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2F277148a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=366439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE1MXks12it7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1979&pages=148-150&author=E.+Palmerauthor=J.+M.+Wilhelmauthor=F.+Sherman&title=Phenotypic+Suppression+of+Nonsense+Mutants+in+Yeast+by+Aminoglycoside+Antibiotics&doi=10.1038%2F277148a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics</span></div><div class="casAuthors">Palmer, Edward; Wilhelm, James M.; Sherman, Fred</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5692</span>),
    <span class="NLM_cas:pages">148-50</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Paromomycin (I)  [7542-37-2] (5 mg) phenotypically suppressed the methionine requirement of a yeast (Saccharomyces cerevisiae) strain carrying the amber mutation met8-1.  I suppressed mutations representing lesions in 8 different metabolic paths and in 11 different structural genes.  I could also suppress all 3 nonsense codons, UAG, UAA, and UGA.  I suppressed mutations at concns. as low as 50 μM, the optimal concn. for suppression being ∼100 μM.  In vitro translation expts. studying the incorporation of leucine with a poly(U) template showed that I (0.1-250 μM) stimulated leucine errors but streptomycin  [57-92-1] (0.1-250 μM) had no activity; neomycin  [1404-04-2] (0.1-250 μM) stimulated leucine errors but was less active than I.  I stimulated mistranslation without inhibiting cell-free protein synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRpMEpBxklvLVg90H21EOLACvtfcHk0ljyXoJnYOv0ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXks12it7o%253D&md5=fd09a15094d8ffab9e2040e9f3891cd8</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1038%2F277148a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F277148a0%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DE.%26aulast%3DWilhelm%26aufirst%3DJ.%2BM.%26aulast%3DSherman%26aufirst%3DF.%26atitle%3DPhenotypic%2520Suppression%2520of%2520Nonsense%2520Mutants%2520in%2520Yeast%2520by%2520Aminoglycoside%2520Antibiotics%26jtitle%3DNature%26date%3D1979%26volume%3D277%26spage%3D148%26epage%3D150%26doi%3D10.1038%2F277148a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wangen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span> <span> </span><span class="NLM_article-title">Stop Codon Context Influences Genome-Wide Stimulation of Termination Codon Readthrough by Aminoglycosides</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e52611</span>, <span class="refDoi"> DOI: 10.7554/eLife.52611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.7554%2FeLife.52611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31971508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsF2mtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=e52611&author=J.+R.+Wangenauthor=R.+Green&title=Stop+Codon+Context+Influences+Genome-Wide+Stimulation+of+Termination+Codon+Readthrough+by+Aminoglycosides&doi=10.7554%2FeLife.52611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides</span></div><div class="casAuthors">Wangen, Jamie R.; Green, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e52611</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Stop codon readthrough (SCR) occurs when the ribosome miscodes at a stop codon.  Such readthrough events can be therapeutically desirable when a premature termination codon (PTC) is found in a crit. gene.  To study SCR in vivo in a genome-wide manner, we treated mammalian cells with aminoglycosides and performed ribosome profiling.  We find that in addn. to stimulating readthrough of PTCs, aminoglycosides stimulate readthrough of normal termination codons (NTCs) genome-wide.  Stop codon identity, the nucleotide following the stop codon, and the surrounding mRNA sequence context all influence the likelihood of SCR.  In comparison to NTCs, downstream stop codons in 3'UTRs are recognized less efficiently by ribosomes, suggesting that targeting of crit. stop codons for readthrough may be achievable without general disruption of translation termination.  Finally, we find that G418-induced miscoding alters gene expression with substantial effects on translation of histone genes, selenoprotein genes, and S-adenosylmethionine decarboxylase (AMD1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcLXdaOe4NorVg90H21EOLACvtfcHk0lj3rkNY6Cbmcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsF2mtbbM&md5=486793aaedf36805e1784a95dda726ca</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.7554%2FeLife.52611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.52611%26sid%3Dliteratum%253Aachs%26aulast%3DWangen%26aufirst%3DJ.%2BR.%26aulast%3DGreen%26aufirst%3DR.%26atitle%3DStop%2520Codon%2520Context%2520Influences%2520Genome-Wide%2520Stimulation%2520of%2520Termination%2520Codon%2520Readthrough%2520by%2520Aminoglycosides%26jtitle%3DeLife%26date%3D2020%26volume%3D9%26spage%3De52611%26doi%3D10.7554%2FeLife.52611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howard, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fass, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khatri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesteland, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanigan, K. M.</span></span> <span> </span><span class="NLM_article-title">Readthrough of Dystrophin Stop Codon Mutations Induced by Aminoglycosides</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.1002/ana.20052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fana.20052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=14991821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFKntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2004&pages=422-426&author=M.+T.+Howardauthor=C.+B.+Andersonauthor=U.+Fassauthor=S.+Khatriauthor=R.+F.+Gestelandauthor=J.+F.+Atkinsauthor=K.+M.+Flanigan&title=Readthrough+of+Dystrophin+Stop+Codon+Mutations+Induced+by+Aminoglycosides&doi=10.1002%2Fana.20052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Readthrough of dystrophin stop codon mutations induced by aminoglycosides</span></div><div class="casAuthors">Howard, Michael T.; Anderson, Christine B.; Fass, Uwe; Khatri, Shikha; Gesteland, Raymond F.; Atkins, John F.; Flanigan, Kevin M.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">422-426</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We report the translational readthrough levels induced by the aminoglycosides gentamicin, amikacin, tobramycin, and paromomycin for eight premature stop codon mutations identified in Duchenne's and Becker's muscular dystrophy patients.  In a transient transfection reporter assay, aminoglycoside treatment results show that one stop codon mutation is suppressed significantly better (up to 10% stop codon readthrough) than the others; five show lower but statistically significant suppression (<2% stop codon readthrough); and two appear refractory to aminoglycoside treatment.  Readthrough levels do not substantially vary between different sources of gentamicin, and, for this set of mutations, the efficiency of termination at the premature stop codon mutation does not appear to correlate with disease severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBC-iaCCOrMrVg90H21EOLACvtfcHk0lj3rkNY6Cbmcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFKntbc%253D&md5=84b0ab199baedaf4e338d40e5911b1be</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1002%2Fana.20052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.20052%26sid%3Dliteratum%253Aachs%26aulast%3DHoward%26aufirst%3DM.%2BT.%26aulast%3DAnderson%26aufirst%3DC.%2BB.%26aulast%3DFass%26aufirst%3DU.%26aulast%3DKhatri%26aufirst%3DS.%26aulast%3DGesteland%26aufirst%3DR.%2BF.%26aulast%3DAtkins%26aufirst%3DJ.%2BF.%26aulast%3DFlanigan%26aufirst%3DK.%2BM.%26atitle%3DReadthrough%2520of%2520Dystrophin%2520Stop%2520Codon%2520Mutations%2520Induced%2520by%2520Aminoglycosides%26jtitle%3DAnn.%2520Neurol.%26date%3D2004%26volume%3D55%26spage%3D422%26epage%3D426%26doi%3D10.1002%2Fana.20052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cogan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">South, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodley, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span> <span> </span><span class="NLM_article-title">Aminoglycosides Restore Full-Length Type VII Collagen by Overcoming Premature Termination Codons: Therapeutic Implications for Dystrophic Epidermolysis Bullosa</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1741</span>– <span class="NLM_lpage">1752</span>, <span class="refDoi"> DOI: 10.1038/mt.2014.140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fmt.2014.140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25155989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWktrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=1741-1752&author=J.+Coganauthor=J.+Weinsteinauthor=X.+Wangauthor=Y.+Houauthor=S.+Martinauthor=A.+P.+Southauthor=D.+T.+Woodleyauthor=M.+Chen&title=Aminoglycosides+Restore+Full-Length+Type+VII+Collagen+by+Overcoming+Premature+Termination+Codons%3A+Therapeutic+Implications+for+Dystrophic+Epidermolysis+Bullosa&doi=10.1038%2Fmt.2014.140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycosides Restore Full-length Type VII Collagen by Overcoming Premature Termination Codons: Therapeutic Implications for Dystrophic Epidermolysis Bullosa</span></div><div class="casAuthors">Cogan, Jon; Weinstein, Jacqueline; Wang, Xinyi; Hou, Yingping; Martin, Sabrina; South, Andrew P.; Woodley, David T.; Chen, Mei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1741-1752</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Patients with recessive dystrophic epidermolysis bullosa (RDEB) have severe, incurable skin fragility, blistering, and multiple skin wounds due to mutations in the gene encoding type VII collagen (C7), the major component of anchoring fibrils mediating epidermal-dermal adherence.  Nearly 10-25% of RDEB patients carry nonsense mutations leading to premature stop codons (PTCs) that result in truncated C7.  In this study, we evaluated the feasibility of using aminoglycosides to suppress PTCs and induce C7 expression in two RDEB keratinocyte cell lines (Q251X/Q251X and R578X/R906) and two primary RDEB fibroblasts (R578X/R578X and R163X/R1683X).  Incubation of these cells with aminoglycosides (geneticin, gentamicin, and paromomycin) resulted in the synthesis and secretion of a full-length C7 in a dose-dependent and sustained manner.  Importantly, aminoglycoside-induced C7 reversed the abnormal RDEB cell phenotype and incorporated into the dermal-epidermal junction of skin equiv.  We further demonstrated the general utility of aminoglycoside-mediated readthrough in 293 cells transiently transfected with expression vectors encoding 22 different RDEB nonsense mutations.  This is the first study demonstrating that aminoglycosides can induce PTC readthrough and restore functional C7 in RDEB caused by nonsense mutations.  Therefore, aminoglycosides may have therapeutic potential for RDEB patients and other inherited skin diseases caused by nonsense mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZCDRXfQJBYbVg90H21EOLACvtfcHk0lj3rkNY6Cbmcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWktrrN&md5=cfa3fd6b6335c998db44441b33fadbe1</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1038%2Fmt.2014.140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2014.140%26sid%3Dliteratum%253Aachs%26aulast%3DCogan%26aufirst%3DJ.%26aulast%3DWeinstein%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DSouth%26aufirst%3DA.%2BP.%26aulast%3DWoodley%26aufirst%3DD.%2BT.%26aulast%3DChen%26aufirst%3DM.%26atitle%3DAminoglycosides%2520Restore%2520Full-Length%2520Type%2520VII%2520Collagen%2520by%2520Overcoming%2520Premature%2520Termination%2520Codons%253A%2520Therapeutic%2520Implications%2520for%2520Dystrophic%2520Epidermolysis%2520Bullosa%26jtitle%3DMol.%2520Ther.%26date%3D2014%26volume%3D22%26spage%3D1741%26epage%3D1752%26doi%3D10.1038%2Fmt.2014.140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodersen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan-Warren, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wimberly, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, V.</span></span> <span> </span><span class="NLM_article-title">Functional Insights from the Structure of the 30S Ribosomal Subunit and Its Interactions with Antibiotics</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>407</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1038/35030019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2F35030019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=11014183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFyktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2000&pages=340-348&author=A.+P.+Carterauthor=W.+M.+Clemonsauthor=D.+E.+Brodersenauthor=R.+J.+Morgan-Warrenauthor=B.+T.+Wimberlyauthor=V.+Ramakrishnan&title=Functional+Insights+from+the+Structure+of+the+30S+Ribosomal+Subunit+and+Its+Interactions+with+Antibiotics&doi=10.1038%2F35030019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics</span></div><div class="casAuthors">Carter, Andrew P.; Clemons, William M.; Brodersen, Ditlev E.; Morgan-Warren, Robert J.; Wimberly, Brian T.; Ramakrishnan, V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">6802</span>),
    <span class="NLM_cas:pages">340-348</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The 30S ribosomal subunit has two primary functions in protein synthesis.  It discriminates against aminoacyl tRNAs that do not match the codon of mRNA, thereby ensuring accuracy in translation of the genetic message in a process called decoding.  Also, it works with the 50S subunit to move the tRNAs and assocd. mRNA by precisely one codon, in a process called translocation.  Here we describe the functional implications of the high-resoln. 30S crystal structure presented in the accompanying paper, and infer details of the interactions between the 30S subunit and its tRNA and mRNA ligands.  We also describe the crystal structure of the 30S subunit complexed with the antibiotics paromomycin, streptomycin and spectinomycin, which interfere with decoding and translocation.  This work reveals the structural basis for the action of these antibiotics, and leads to a model for the role of the universally conserved 16S RNA residues A1492 and A1493 in the decoding process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwYnLojpZbJbVg90H21EOLACvtfcHk0lhGLtXDZX0b_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFyktbs%253D&md5=f3e5e6211a5e9951a5f878408c73a434</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1038%2F35030019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35030019%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DA.%2BP.%26aulast%3DClemons%26aufirst%3DW.%2BM.%26aulast%3DBrodersen%26aufirst%3DD.%2BE.%26aulast%3DMorgan-Warren%26aufirst%3DR.%2BJ.%26aulast%3DWimberly%26aufirst%3DB.%2BT.%26aulast%3DRamakrishnan%26aufirst%3DV.%26atitle%3DFunctional%2520Insights%2520from%2520the%2520Structure%2520of%2520the%252030S%2520Ribosomal%2520Subunit%2520and%2520Its%2520Interactions%2520with%2520Antibiotics%26jtitle%3DNature%26date%3D2000%26volume%3D407%26spage%3D340%26epage%3D348%26doi%3D10.1038%2F35030019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puglisi, J. D.</span></span> <span> </span><span class="NLM_article-title">Structural Origins of Aminoglycoside Specificity for Prokaryotic Ribosomes</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">1037</span>– <span class="NLM_lpage">1058</span>, <span class="refDoi"> DOI: 10.1006/jmbi.2000.4420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1006%2Fjmbi.2000.4420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=11237617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsFOhu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2001&pages=1037-1058&author=S.+R.+Lynchauthor=J.+D.+Puglisi&title=Structural+Origins+of+Aminoglycoside+Specificity+for+Prokaryotic+Ribosomes&doi=10.1006%2Fjmbi.2000.4420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Origins of Aminoglycoside Specificity for Prokaryotic Ribosomes</span></div><div class="casAuthors">Lynch, Stephen R.; Puglisi, Joseph D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1037-1058</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Aminoglycoside antibiotics, including paromomycin, neomycin and gentamicin, target a region of highly conserved nucleotides in the decoding region aminoacyl-tRNA site of 16 S rRNA on the 30 S subunit.  Change of a single nucleotide, A1408 to G, reduces the affinity of many aminoglycosides for the ribosome; G1408 distinguishes between prokaryotic and eukaryotic ribosomes.  The structures of a prokaryotic decoding region A-site oligonucleotide free in soln. and bound to the aminoglycosides paromomycin and gentamicin C1a were detd. previously.  Here, the structure of a eukaryotic decoding region A-site oligonucleotide bound to paromomycin has been detd. using NMR spectroscopy and compared to the prokaryotic A-site-paromomycin structure.  A conformational change in three adenosine residues of an internal loop, crit. for high-affinity antibiotic binding, was obsd. in the prokaryotic RNA-paromomycin complex in comparison to its free form.  This conformational change is not obsd. in the eukaryotic RNA-paromomycin complex, disrupting the binding pocket for ring I of the antibiotic.  The lack of the conformational change supports footprinting and titrn. calorimetry data that demonstrate approx. 25-50-fold weaker binding of paromomycin to the eukaryotic decoding-site oligonucleotide.  Neomycin, which is much less active against Escherichia coli ribosomes with an A1408G mutation, binds non-specifically to the oligonucleotide.  These results suggest that eukaryotic rRNA has a shallow binding pocket for aminoglycosides, which accommodates only certain antibiotics.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVlkDMuTq_RbVg90H21EOLACvtfcHk0lhGLtXDZX0b_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsFOhu7g%253D&md5=907edc24d0cfc864d5235be798357dea</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2000.4420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2000.4420%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DS.%2BR.%26aulast%3DPuglisi%26aufirst%3DJ.%2BD.%26atitle%3DStructural%2520Origins%2520of%2520Aminoglycoside%2520Specificity%2520for%2520Prokaryotic%2520Ribosomes%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D306%26spage%3D1037%26epage%3D1058%26doi%3D10.1006%2Fjmbi.2000.4420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Recht, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douthwaite, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlquist, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puglisi, J. D.</span></span> <span> </span><span class="NLM_article-title">Effect of Mutations in the A Site of 16 S RRNA on Aminoglycoside Antibiotic-Ribosome Interaction</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1998.2446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1006%2Fjmbi.1998.2446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=9931247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK1MXhtV2hurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=33-43&author=M.+I.+Rechtauthor=S.+Douthwaiteauthor=K.+D.+Dahlquistauthor=J.+D.+Puglisi&title=Effect+of+Mutations+in+the+A+Site+of+16+S+RRNA+on+Aminoglycoside+Antibiotic-Ribosome+Interaction&doi=10.1006%2Fjmbi.1998.2446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Mutations in the A Site of 16 S rRNA on Aminoglycoside Antibiotic-Ribosome Interaction</span></div><div class="casAuthors">Recht, Michael I.; Douthwaite, Stephen; Dahlquist, Kam D.; Puglisi, Joseph D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-43</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Decoding of genetic information occurs upon interaction of an mRNA codon-tRNA anticodon complex with the small subunit of the ribosome.  The ribosomal decoding region is assocd. with highly conserved sequences near the 3' end of 16 S rRNA.  The decoding process is perturbed by the aminoglycoside antibiotics, which also interact with this region of rRNA.  Mutations of certain nucleotides in rRNA reduce aminoglycoside binding affinity, as previously demonstrated using a model RNA oligonucleotide system.  Here, predictions from the oligonucleotide system were tested in the ribosome by mutation of universally conserved nucleotides at 1406 to 1408 and 1494 to 1495 in the decoding region of plasmid-encoded bacterial 16 S rRNA.  Phenotypic changes range from the benign effect of U1406→A or A1408→G substitutions, to the highly deleterious 1406G and 1495 mutations that assemble into 30 S subunits but are defective in forming functional ribosomes.  Changes in the local conformation of the decoding region caused by these mutations were identified by chem. probing of isolated 30 S subunits.  Ribosomes contg. 16 S rRNA with mutations at positions 1408, 1407+1494, or 1495 had reduced affinity for the aminoglycoside paromomycin, whereas no discernible redn. in affinity was obsd. with 1406 mutant ribosomes.  These data are consistent with prior NMR structural detn. of aminoglycoside interaction with the decoding region, and further our understanding of how aminoglycoside resistance can be conferred.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogeFJ0bC6ambVg90H21EOLACvtfcHk0lhGLtXDZX0b_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtV2hurw%253D&md5=b630e425b105af6a31e75cd6e1e416df</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1998.2446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1998.2446%26sid%3Dliteratum%253Aachs%26aulast%3DRecht%26aufirst%3DM.%2BI.%26aulast%3DDouthwaite%26aufirst%3DS.%26aulast%3DDahlquist%26aufirst%3DK.%2BD.%26aulast%3DPuglisi%26aufirst%3DJ.%2BD.%26atitle%3DEffect%2520of%2520Mutations%2520in%2520the%2520A%2520Site%2520of%252016%2520S%2520RRNA%2520on%2520Aminoglycoside%2520Antibiotic-Ribosome%2520Interaction%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D286%26spage%3D33%26epage%3D43%26doi%3D10.1006%2Fjmbi.1998.2446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinder, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garneau-Tsodikova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doudna Cate, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S. C.</span></span> <span> </span><span class="NLM_article-title">Chemically Related 4,5-Linked Aminoglycoside Antibiotics Drive Subunit Rotation in Opposite Directions</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">7896</span>, <span class="refDoi"> DOI: 10.1038/ncomms8896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fncomms8896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26224058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWgs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=7896&author=M.+R.+Wassermanauthor=A.+Pulkauthor=Z.+Zhouauthor=R.+B.+Altmanauthor=J.+C.+Zinderauthor=K.+D.+Greenauthor=S.+Garneau-Tsodikovaauthor=J.+H.+Doudna+Cateauthor=S.+C.+Blanchard&title=Chemically+Related+4%2C5-Linked+Aminoglycoside+Antibiotics+Drive+Subunit+Rotation+in+Opposite+Directions&doi=10.1038%2Fncomms8896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically related 4,5-linked aminoglycoside antibiotics drive subunit rotation in opposite directions</span></div><div class="casAuthors">Wasserman, Michael R.; Pulk, Arto; Zhou, Zhou; Altman, Roger B.; Zinder, John C.; Green, Keith D.; Garneau-Tsodikova, Sylvie; Doudna Cate, Jamie H.; Blanchard, Scott C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7896</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Dynamic remodelling of intersubunit bridge B2, a conserved RNA domain of the bacterial ribosome connecting helixes 44 (h44) and 69 (H69) of the small and large subunit, resp., impacts translation by controlling intersubunit rotation.  Here we show that aminoglycosides chem. related to neomycin-paromomycin, ribostamycin and neamine-each bind to sites within h44 and H69 to perturb bridge B2 and affect subunit rotation.  Neomycin and paromomycin, which only differ by their ring-I 6'-polar group, drive subunit rotation in opposite directions.  This suggests that their distinct actions hinge on the 6'-substituent and the drug's net pos. charge.  By solving the crystal structure of the paromomycin-ribosome complex, we observe specific contacts between the apical tip of H69 and the 6'-hydroxyl on paromomycin from within the drug's canonical h44-binding site.  These results indicate that aminoglycoside actions must be framed in the context of bridge B2 and their regulation of subunit rotation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLsIpdhw_dd7Vg90H21EOLACvtfcHk0lhGLtXDZX0b_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWgs7rL&md5=592b0846cc6962a8a1303a0b6b938af5</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1038%2Fncomms8896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms8896%26sid%3Dliteratum%253Aachs%26aulast%3DWasserman%26aufirst%3DM.%2BR.%26aulast%3DPulk%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26aulast%3DZinder%26aufirst%3DJ.%2BC.%26aulast%3DGreen%26aufirst%3DK.%2BD.%26aulast%3DGarneau-Tsodikova%26aufirst%3DS.%26aulast%3DDoudna%2BCate%26aufirst%3DJ.%2BH.%26aulast%3DBlanchard%26aufirst%3DS.%2BC.%26atitle%3DChemically%2520Related%25204%252C5-Linked%2520Aminoglycoside%2520Antibiotics%2520Drive%2520Subunit%2520Rotation%2520in%2520Opposite%2520Directions%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D7896%26doi%3D10.1038%2Fncomms8896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattis, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coady, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorson, C. L.</span></span> <span> </span><span class="NLM_article-title">Novel Aminoglycosides Increase SMN Levels in Spinal Muscular Atrophy Fibroblasts</span>. <i>Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">601</span>, <span class="refDoi"> DOI: 10.1007/s00439-006-0245-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs00439-006-0245-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16951947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKmtrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2006&pages=589-601&author=V.+B.+Mattisauthor=R.+Raiauthor=J.+Wangauthor=C.-W.+T.+Changauthor=T.+Coadyauthor=C.+L.+Lorson&title=Novel+Aminoglycosides+Increase+SMN+Levels+in+Spinal+Muscular+Atrophy+Fibroblasts&doi=10.1007%2Fs00439-006-0245-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts</span></div><div class="casAuthors">Mattis, Virginia B.; Rai, Ravi; Wang, Jinhua; Chang, Cheng-Wei T.; Coady, Tristan; Lorson, Christian L.</div><div class="citationInfo"><span class="NLM_cas:title">Human Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-601</span>CODEN:
                <span class="NLM_cas:coden">HUGEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6717</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality.  SMA is caused by the homozygous absence of survival motor neuron-1 (SMN1).  SMN2, a nearly identical copy gene, is retained in all SMA patients and encodes an identical protein as SMN1; however, SMN1 and SMN2 differ by a silent C to T transition which results in the prodn. of an alternatively spliced isoform (SMNΔ7), which encodes a defective protein, demonstrating that the absence of the short peptide encoded by SMN exon 7 is crit. in SMA development.  Previously, we have shown that for some functions heterologous sequences can compensate for the exon 7 peptide, suggesting that the SMN C-terminus functions non-specifically.  Consistent with this hypothesis, we now identify novel aminoglycosides that can induce SMN protein levels in patient fibroblasts.  This hypothesis was supported, in part, by a novel fluorescent SMN read-through assay.  Interestingly, however, through the development of a SMN exon 7-specific antibody, results suggested that levels of normal full-length SMN might also be elevated by aminoglycoside treatment.  These results demonstrate that the compds. that promote read-through may provide an alternative platform for the discovery of compds. that induce SMN protein levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDxozXLlANA7Vg90H21EOLACvtfcHk0liFs5Y8DGIFfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKmtrzM&md5=ebc1b03bc34fe42d6a74adacd8593ca8</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1007%2Fs00439-006-0245-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00439-006-0245-7%26sid%3Dliteratum%253Aachs%26aulast%3DMattis%26aufirst%3DV.%2BB.%26aulast%3DRai%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.-W.%2BT.%26aulast%3DCoady%26aufirst%3DT.%26aulast%3DLorson%26aufirst%3DC.%2BL.%26atitle%3DNovel%2520Aminoglycosides%2520Increase%2520SMN%2520Levels%2520in%2520Spinal%2520Muscular%2520Atrophy%2520Fibroblasts%26jtitle%3DHum.%2520Genet.%26date%3D2006%26volume%3D120%26spage%3D589%26epage%3D601%26doi%3D10.1007%2Fs00439-006-0245-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prokhorova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djumagulov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urzhumtsev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusupov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusupova, G.</span></span> <span> </span><span class="NLM_article-title">Aminoglycoside Interactions and Impacts on the Eukaryotic Ribosome</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">E10899</span>– <span class="NLM_lpage">E10908</span>, <span class="refDoi"> DOI: 10.1073/pnas.1715501114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.1715501114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=29208708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWmtLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=E10899-E10908&author=I.+Prokhorovaauthor=R.+B.+Altmanauthor=M.+Djumagulovauthor=J.+P.+Shresthaauthor=A.+Urzhumtsevauthor=A.+Fergusonauthor=C.-W.+T.+Changauthor=M.+Yusupovauthor=S.+C.+Blanchardauthor=G.+Yusupova&title=Aminoglycoside+Interactions+and+Impacts+on+the+Eukaryotic+Ribosome&doi=10.1073%2Fpnas.1715501114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycoside interactions and impacts on the eukaryotic ribosome</span></div><div class="casAuthors">Prokhorova, Irina; Altman, Roger B.; Djumagulov, Muminjon; Shrestha, Jaya P.; Urzhumtsev, Alexandre; Ferguson, Angelica; Chang, Cheng-Wei Tom; Yusupov, Marat; Blanchard, Scott C.; Yusupova, Gulnara</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">E10899-E10908</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Aminoglycosides are chem. diverse, broad-spectrum antibiotics that target functional centers within the bacterial ribosome to impact all 4 principle stages (initiation, elongation, termination, and recycling) of the translation mechanism.  The propensity of aminoglycosides to induce miscoding errors that suppress the termination of protein synthesis supports their potential as therapeutic interventions in human diseases assocd. with premature termination codons (PTCs).  However, the sites of interaction of aminoglycosides with the eukaryotic ribosome and their modes of action in eukaryotic translation remain largely unexplored.  Here, we used the combination of x-ray crystallog. and single-mol. FRET anal. to reveal the interactions of distinct classes of aminoglycosides with the 80S eukaryotic ribosome.  Crystal structures of the 80S ribosome in complex with paromomycin, geneticin (G418), gentamicin, and TC007, solved at 3.3- to 3.7-Å resoln., revealed multiple aminoglycoside-binding sites within the large and small subunits, wherein the 6'-hydroxyl substituent in ring I served as a key determinant of binding to the canonical eukaryotic ribosomal decoding center.  Multivalent binding interactions with the human ribosome were also evidenced through their capacity to affect large-scale conformational dynamics within the pre-translocation complex that contribute to multiple aspects of the translation mechanism.  The distinct impacts of the aminoglycosides examd. suggested that their chem. compn. and distinct modes of interaction with the ribosome influence PTC read-through efficiency.  These findings provide structural and functional insights into aminoglycoside-induced impacts on the eukaryotic ribosome and implicate pleiotropic mechanisms of action beyond decoding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPUCQMKq_QbVg90H21EOLACvtfcHk0liFs5Y8DGIFfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWmtLrJ&md5=cb086806aff7ff195f63b237a9be682f</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1715501114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1715501114%26sid%3Dliteratum%253Aachs%26aulast%3DProkhorova%26aufirst%3DI.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26aulast%3DDjumagulov%26aufirst%3DM.%26aulast%3DShrestha%26aufirst%3DJ.%2BP.%26aulast%3DUrzhumtsev%26aufirst%3DA.%26aulast%3DFerguson%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DC.-W.%2BT.%26aulast%3DYusupov%26aufirst%3DM.%26aulast%3DBlanchard%26aufirst%3DS.%2BC.%26aulast%3DYusupova%26aufirst%3DG.%26atitle%3DAminoglycoside%2520Interactions%2520and%2520Impacts%2520on%2520the%2520Eukaryotic%2520Ribosome%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3DE10899%26epage%3DE10908%26doi%3D10.1073%2Fpnas.1715501114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kandasamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atia-Glikin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shavit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belakhov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baasov, T.</span></span> <span> </span><span class="NLM_article-title">Increased Selectivity toward Cytoplasmic versus Mitochondrial Ribosome Confers Improved Efficiency of Synthetic Aminoglycosides in Fixing Damaged Genes: A Strategy for Treatment of Genetic Diseases Caused by Nonsense Mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10630</span>– <span class="NLM_lpage">10643</span>, <span class="refDoi"> DOI: 10.1021/jm3012992</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012992" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gru77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10630-10643&author=J.+Kandasamyauthor=D.+Atia-Glikinauthor=E.+Shulmanauthor=K.+Shapiraauthor=M.+Shavitauthor=V.+Belakhovauthor=T.+Baasov&title=Increased+Selectivity+toward+Cytoplasmic+versus+Mitochondrial+Ribosome+Confers+Improved+Efficiency+of+Synthetic+Aminoglycosides+in+Fixing+Damaged+Genes%3A+A+Strategy+for+Treatment+of+Genetic+Diseases+Caused+by+Nonsense+Mutations&doi=10.1021%2Fjm3012992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Increased Selectivity toward Cytoplasmic versus Mitochondrial Ribosome Confers Improved Efficiency of Synthetic Aminoglycosides in Fixing Damaged Genes: A Strategy for Treatment of Genetic Diseases Caused by Nonsense Mutations</span></div><div class="casAuthors">Kandasamy, Jeyakumar; Atia-Glikin, Dana; Shulman, Eli; Shapira, Katya; Shavit, Michal; Belakhov, Valery; Baasov, Timor</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10630-10643</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compelling evidence is now available that gentamicin and Geneticin (G418) can induce the mammalian ribosome to suppress disease-causing nonsense mutations and partially restore the expression of functional proteins.  However, toxicity and relative lack of efficacy at subtoxic doses limit the use of gentamicin for suppression therapy.  Although G418 exhibits the strongest activity, it is very cytotoxic even at low doses.  We describe here the first systematic development of the novel aminoglycoside (S)-11 (I) exhibiting similar in vitro and ex vivo activity to that of G418, while its cell toxicity is significantly lower than those of gentamicin and G418.  Using a series of biochem. assays, we provide proof of principle that antibacterial activity and toxicity of aminoglycosides can be dissected from their suppression activity.  The data further indicate that the increased specificity toward cytoplasmic ribosome correlates with the increased activity and that the decreased specificity toward mitochondrial ribosome confers the lowered cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYhdlMXPmoKrVg90H21EOLACvtfcHk0liFs5Y8DGIFfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gru77N&md5=e028ed13e63ddb0994692fa088998465</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1021%2Fjm3012992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012992%26sid%3Dliteratum%253Aachs%26aulast%3DKandasamy%26aufirst%3DJ.%26aulast%3DAtia-Glikin%26aufirst%3DD.%26aulast%3DShulman%26aufirst%3DE.%26aulast%3DShapira%26aufirst%3DK.%26aulast%3DShavit%26aufirst%3DM.%26aulast%3DBelakhov%26aufirst%3DV.%26aulast%3DBaasov%26aufirst%3DT.%26atitle%3DIncreased%2520Selectivity%2520toward%2520Cytoplasmic%2520versus%2520Mitochondrial%2520Ribosome%2520Confers%2520Improved%2520Efficiency%2520of%2520Synthetic%2520Aminoglycosides%2520in%2520Fixing%2520Damaged%2520Genes%253A%2520A%2520Strategy%2520for%2520Treatment%2520of%2520Genetic%2520Diseases%2520Caused%2520by%2520Nonsense%2520Mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10630%26epage%3D10643%26doi%3D10.1021%2Fjm3012992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dündar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biberoglu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okur, İ.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tümer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezgü, F. S.</span></span> <span> </span><span class="NLM_article-title">In Vitro Translational Readthrough by Gentamicin and Geneticin Improves GLA Activity in Fabry Disease</span>. <i>Mol. Genet. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">S43</span>, <span class="refDoi"> DOI: 10.1016/j.ymgme.2016.11.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.ymgme.2016.11.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2017&pages=S43&author=H.+D%C3%BCndarauthor=G.+Biberogluauthor=%C4%B0.+Okurauthor=L.+T%C3%BCmerauthor=F.+S.+Ezg%C3%BC&title=In+Vitro+Translational+Readthrough+by+Gentamicin+and+Geneticin+Improves+GLA+Activity+in+Fabry+Disease&doi=10.1016%2Fj.ymgme.2016.11.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1016%2Fj.ymgme.2016.11.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymgme.2016.11.087%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25BCndar%26aufirst%3DH.%26aulast%3DBiberoglu%26aufirst%3DG.%26aulast%3DOkur%26aufirst%3D%25C4%25B0.%26aulast%3DT%25C3%25BCmer%26aufirst%3DL.%26aulast%3DEzg%25C3%25BC%26aufirst%3DF.%2BS.%26atitle%3DIn%2520Vitro%2520Translational%2520Readthrough%2520by%2520Gentamicin%2520and%2520Geneticin%2520Improves%2520GLA%2520Activity%2520in%2520Fabry%2520Disease%26jtitle%3DMol.%2520Genet.%2520Metab.%26date%3D2017%26volume%3D120%26spage%3DS43%26doi%3D10.1016%2Fj.ymgme.2016.11.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebök, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyrene, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorscher, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedwell, D. M.</span></span> <span> </span><span class="NLM_article-title">Evidence That Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic Fibrosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">1683</span>– <span class="NLM_lpage">1692</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.163.7.2004001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1164%2Fajrccm.163.7.2004001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=11401894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BD3MvgsVSquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2001&pages=1683-1692&author=J.+P.+Clancyauthor=Z.+Beb%C3%B6kauthor=F.+Ruizauthor=C.+Kingauthor=J.+Jonesauthor=L.+Walkerauthor=H.+Greerauthor=J.+Hongauthor=L.+Wingauthor=M.+Macalusoauthor=R.+Lyreneauthor=E.+J.+Sorscherauthor=D.+M.+Bedwell&title=Evidence+That+Systemic+Gentamicin+Suppresses+Premature+Stop+Mutations+in+Patients+with+Cystic+Fibrosis&doi=10.1164%2Fajrccm.163.7.2004001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis</span></div><div class="casAuthors">Clancy J P; Bebok Z; Ruiz F; King C; Jones J; Walker L; Greer H; Hong J; Wing L; Macaluso M; Lyrene R; Sorscher E J; Bedwell D M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1683-92</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Here we report the effects of gentamicin treatment on cystic fibrosis transmembrane regulator (CFTR) production and function in CF airway cells and patients with CF with premature stop mutations.  Using immunocytochemical and functional [6-methoxy-N- (3-sulfopropyl) quinolinium (SPQ)-based] techniques, ex vivo exposure of airway cells from stop mutation CF patients led to the identification of surface-localized CFTR in a dose-dependent fashion.  Next, five patients with CF with stop mutations and five CF control subjects were treated with parenteral gentamicin for 1 wk, and underwent repeated in vivo measures of CFTR function (nasal potential difference [PD] measurements and sweat chloride [Cl(-)] testing).  During the treatment period, the number of nasal PD readings in the direction of Cl(-) secretion was increased approximately 3-fold in the stop mutation patient group compared with controls (p < 0.001), and four of five stop mutation patients with CF had at least one reading during gentamicin treatment with a Cl(-) secretory response of more than -5 mV (hyperpolarized).  A response of this magnitude was not seen in any of the CF control subjects (p < 0.05).  In an independent series of experiments designed to test the ability of repeat nasal PDs to detect wild-type CFTR function, evidence of Cl(-) secretion was seen in 88% of control (non-CF) nasal PDs, and 71% were more than -5 mV hyperpolarized.  Together, these results suggest that gentamicin treatment can suppress premature stop mutations in airway cells from patients with CF, and produce small increases in CFTR Cl(-) conductance (as measured by the nasal PD) in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkuB1AyaLPjT69zv1FsJFMfW6udTcc2ebCa6KQ1nryALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvgsVSquw%253D%253D&md5=d773a4fc291c3883ced2a2829f849828</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.163.7.2004001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.163.7.2004001%26sid%3Dliteratum%253Aachs%26aulast%3DClancy%26aufirst%3DJ.%2BP.%26aulast%3DBeb%25C3%25B6k%26aufirst%3DZ.%26aulast%3DRuiz%26aufirst%3DF.%26aulast%3DKing%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DL.%26aulast%3DGreer%26aufirst%3DH.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DWing%26aufirst%3DL.%26aulast%3DMacaluso%26aufirst%3DM.%26aulast%3DLyrene%26aufirst%3DR.%26aulast%3DSorscher%26aufirst%3DE.%2BJ.%26aulast%3DBedwell%26aufirst%3DD.%2BM.%26atitle%3DEvidence%2520That%2520Systemic%2520Gentamicin%2520Suppresses%2520Premature%2520Stop%2520Mutations%2520in%2520Patients%2520with%2520Cystic%2520Fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2001%26volume%3D163%26spage%3D1683%26epage%3D1692%26doi%3D10.1164%2Fajrccm.163.7.2004001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tousson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebök, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitsett, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colledge, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorscher, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedwell, D. M.</span></span> <span> </span><span class="NLM_article-title">Aminoglycoside Suppression of a Premature Stop Mutation in a Cftr–/– Mouse Carrying a Human CFTR-G542X Transgene</span>. <i>J. Mol. Med. (Heidelberg, Ger.)</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1007/s00109-002-0363-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs00109-002-0363-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=12226741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFWktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2002&pages=595-604&author=M.+Duauthor=J.+R.+Jonesauthor=J.+Lanierauthor=K.+M.+Keelingauthor=J.+R.+Lindseyauthor=A.+Toussonauthor=Z.+Beb%C3%B6kauthor=J.+A.+Whitsettauthor=C.+R.+Deyauthor=W.+H.+Colledgeauthor=M.+J.+Evansauthor=E.+J.+Sorscherauthor=D.+M.+Bedwell&title=Aminoglycoside+Suppression+of+a+Premature+Stop+Mutation+in+a+Cftr%E2%80%93%2F%E2%80%93+Mouse+Carrying+a+Human+CFTR-G542X+Transgene&doi=10.1007%2Fs00109-002-0363-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene</span></div><div class="casAuthors">Du, Ming; Jones, Julie R.; Lanier, Jessica; Keeling, Kim M.; Lindsey, J. Russell; Tousson, Albert; Bebok, Zsuzsa; Whitsett, Jeffrey A.; Dey, Chitta R.; Colledge, William H.; Evans, Martin J.; Sorscher, Eric J.; Bedwell, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">595-604</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein.  Since ∼5% of all mutant CF alleles are stop mutations, it can be calcd. that ∼10% of CF patients carry a premature stop mutation in at least one copy of the CFTR gene.  Certain ethnic groups, such as the Ashkenazi Jewish population, carry a much higher percentage of CF stop mutations.  Consequently, a therapeutic strategy aimed at suppressing this class of mutation would be highly desirable for the treatment of this common genetic disease.  We have shown previously that aminoglycoside antibiotics can suppress premature stop mutations in the CFTR gene in a bronchial epithelial cell line [Nat Med (1997) 3:1280].  To address whether aminoglycosides can suppress a CFTR premature stop mutation in an animal model, we constructed a transgenic mouse with a null mutation in the endogenous CFTR locus (Cftr-/-) that also expressed a human CFTR-G542X cDNA under control of the intestinal fatty acid binding protein promoter.  We then investigated whether the daily administration of the aminoglycoside antibiotics gentamicin or tobramycin could restore the expression of a detectable level of CFTR protein.  Immunofluorescence staining of intestinal tissues from Cftr-/- hCFTR-G542X mice revealed that gentamicin treatment resulted in the appearance of hCFTR protein at the apical surface of the glands of treated mice.  Weaker staining was also obsd. in the intestinal glands following tobramycin treatment.  Short-circuit current measurements made on intestinal tissues from these mice demonstrated that a significant no. of pos. cAMP-stimulated transepithelial chloride current measurements could be obsd. following gentamicin treatment (P=0.008) and a near significant no. following tobramycin treatment (P=0.052).  When taken together, these results indicate that gentamicin, and to a lesser extent tobramycin, can restore the synthesis of functional hCFTR protein by suppressing the hCFTR-G542X premature stop mutation in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSLJYvlzwj6rVg90H21EOLACvtfcHk0lh7GY93scI43A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFWktbc%253D&md5=17729b95ae1d83d560eacef495968c37</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1007%2Fs00109-002-0363-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-002-0363-1%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DJ.%2BR.%26aulast%3DLanier%26aufirst%3DJ.%26aulast%3DKeeling%26aufirst%3DK.%2BM.%26aulast%3DLindsey%26aufirst%3DJ.%2BR.%26aulast%3DTousson%26aufirst%3DA.%26aulast%3DBeb%25C3%25B6k%26aufirst%3DZ.%26aulast%3DWhitsett%26aufirst%3DJ.%2BA.%26aulast%3DDey%26aufirst%3DC.%2BR.%26aulast%3DColledge%26aufirst%3DW.%2BH.%26aulast%3DEvans%26aufirst%3DM.%2BJ.%26aulast%3DSorscher%26aufirst%3DE.%2BJ.%26aulast%3DBedwell%26aufirst%3DD.%2BM.%26atitle%3DAminoglycoside%2520Suppression%2520of%2520a%2520Premature%2520Stop%2520Mutation%2520in%2520a%2520Cftr%25E2%2580%2593%252F%25E2%2580%2593%2520Mouse%2520Carrying%2520a%2520Human%2520CFTR-G542X%2520Transgene%26jtitle%3DJ.%2520Mol.%2520Med.%2520%2528Heidelberg%252C%2520Ger.%2529%26date%3D2002%26volume%3D80%26spage%3D595%26epage%3D604%26doi%3D10.1007%2Fs00109-002-0363-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barton-Davis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoturma, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leland, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, H. L.</span></span> <span> </span><span class="NLM_article-title">Aminoglycoside Antibiotics Restore Dystrophin Function to Skeletal Muscles of Mdx Mice</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1172/JCI7866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1172%2FJCI7866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10449429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK1MXltlektbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=375-381&author=E.+R.+Barton-Davisauthor=L.+Cordierauthor=D.+I.+Shoturmaauthor=S.+E.+Lelandauthor=H.+L.+Sweeney&title=Aminoglycoside+Antibiotics+Restore+Dystrophin+Function+to+Skeletal+Muscles+of+Mdx+Mice&doi=10.1172%2FJCI7866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice</span></div><div class="casAuthors">Barton-Davis, Elisabeth R.; Cordier, Laurence; Shoturma, Daria I.; Leland, Stuart E.; Sweeney, H. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">375-381</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, leading to the absence of the dystrophin protein in striated muscle.  A significant no. of these mutations are premature stop codons.  On the basis of the observation that aminoglycoside treatment can suppress stop codons in cultured cells, we tested the effect of gentamicin on cultured muscle cells from the mdx mouse - an animal model for DMD that possesses a premature stop codon in the dystrophin gene.  Exposure of mdx myotubes to gentamicin led to the expression and localization of dystrophin to the cell membrane.  We then evaluated the effects of differing dosages of gentamicin on expression and functional protection of the muscles of mdx mice.  We identified a treatment regimen that resulted in the presence of dystrophin in the cell membrane in all striated muscles examd. and that provided functional protection against muscular injury.  To our knowledge, our results are the first to demonstrate that aminoglycosides can suppress stop codons not only in vitro but also in vivo.  Furthermore, these results raise the possibility of a novel treatment regimen for muscular dystrophy and other diseases caused by premature stop codon mutations.  This treatment could prove effective in up to 15% of patients with DMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraj2EpBjywyrVg90H21EOLACvtfcHk0ljU3wIe7-0XmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltlektbo%253D&md5=1df883f4c95a9381df3a7801ec5bd08c</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1172%2FJCI7866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI7866%26sid%3Dliteratum%253Aachs%26aulast%3DBarton-Davis%26aufirst%3DE.%2BR.%26aulast%3DCordier%26aufirst%3DL.%26aulast%3DShoturma%26aufirst%3DD.%2BI.%26aulast%3DLeland%26aufirst%3DS.%2BE.%26aulast%3DSweeney%26aufirst%3DH.%2BL.%26atitle%3DAminoglycoside%2520Antibiotics%2520Restore%2520Dystrophin%2520Function%2520to%2520Skeletal%2520Muscles%2520of%2520Mdx%2520Mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1999%26volume%3D104%26spage%3D375%26epage%3D381%26doi%3D10.1172%2FJCI7866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brendel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belakhov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gärtner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nudelman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baasov, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huppke, P.</span></span> <span> </span><span class="NLM_article-title">Readthrough of Nonsense Mutations in Rett Syndrome: Evaluation of Novel Aminoglycosides and Generation of a New Mouse Model</span>. <i>J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1007/s00109-010-0704-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs00109-010-0704-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21120444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFSntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=389-398&author=C.+Brendelauthor=V.+Belakhovauthor=H.+Wernerauthor=E.+Wegenerauthor=J.+G%C3%A4rtnerauthor=I.+Nudelmanauthor=T.+Baasovauthor=P.+Huppke&title=Readthrough+of+Nonsense+Mutations+in+Rett+Syndrome%3A+Evaluation+of+Novel+Aminoglycosides+and+Generation+of+a+New+Mouse+Model&doi=10.1007%2Fs00109-010-0704-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model</span></div><div class="casAuthors">Brendel, Cornelia; Belakhov, Valery; Werner, Hauke; Wegener, Eike; Gaertner, Jutta; Nudelman, Igor; Baasov, Timor; Huppke, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">389-398</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">35% Of patients with Rett syndrome carry nonsense mutations in the MECP2 gene.  We have recently shown in transfected HeLa cells that readthrough of nonsense mutations in the MECP2 gene can be achieved by treatment with gentamicin and geneticin.  This study was performed to test if readthrough can also be achieved in cells endogenously expressing mutant MeCP2 and to evaluate potentially more effective readthrough compds.  A mouse model was generated carrying the R168X mutation in the MECP2 gene.  Transfected HeLa cells expressing mutated MeCP2 fusion proteins and mouse ear fibroblasts isolated from the new mouse model were treated with gentamicin and the novel aminoglycosides NB30, NB54, and NB84.  The localization of the readthrough product was tested by immunofluorescence.  Readthrough of the R168X mutation in mouse ear fibroblasts using gentamicin was detected but at lower level than in HeLa cells.  As expected, the readthrough product, full-length Mecp2 protein, was located in the nucleus.  NB54 and NB84 induced readthrough more effectively than gentamicin, while NB30 was less effective.  Readthrough of nonsense mutations can be achieved not only in transfected HeLa cells but also in fibroblasts of the newly generated Mecp2R168X mouse model.  NB54 and NB84 were more effective than gentamicin and are therefore promising candidates for readthrough therapy in Rett syndrome patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU2XsdLCdFSrVg90H21EOLACvtfcHk0ljU3wIe7-0XmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFSntbg%253D&md5=f22d74f345c5c322ecf8c2c94035ccf4</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1007%2Fs00109-010-0704-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-010-0704-4%26sid%3Dliteratum%253Aachs%26aulast%3DBrendel%26aufirst%3DC.%26aulast%3DBelakhov%26aufirst%3DV.%26aulast%3DWerner%26aufirst%3DH.%26aulast%3DWegener%26aufirst%3DE.%26aulast%3DG%25C3%25A4rtner%26aufirst%3DJ.%26aulast%3DNudelman%26aufirst%3DI.%26aulast%3DBaasov%26aufirst%3DT.%26aulast%3DHuppke%26aufirst%3DP.%26atitle%3DReadthrough%2520of%2520Nonsense%2520Mutations%2520in%2520Rett%2520Syndrome%253A%2520Evaluation%2520of%2520Novel%2520Aminoglycosides%2520and%2520Generation%2520of%2520a%2520New%2520Mouse%2520Model%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2011%26volume%3D89%26spage%3D389%26epage%3D398%26doi%3D10.1007%2Fs00109-010-0704-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodley, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinkovich, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keene, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span> <span> </span><span class="NLM_article-title">Gentamicin Induces Functional Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa Patients</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">3028</span>– <span class="NLM_lpage">3038</span>, <span class="refDoi"> DOI: 10.1172/JCI92707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1172%2FJCI92707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28691931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlvF2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=3028-3038&author=D.+T.+Woodleyauthor=J.+Coganauthor=Y.+Houauthor=C.+Lyuauthor=M.+P.+Marinkovichauthor=D.+Keeneauthor=M.+Chen&title=Gentamicin+Induces+Functional+Type+VII+Collagen+in+Recessive+Dystrophic+Epidermolysis+Bullosa+Patients&doi=10.1172%2FJCI92707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients</span></div><div class="casAuthors">Woodley David T; Cogan Jon; Hou Yingping; Lyu Chao; Chen Mei; Marinkovich M Peter; Marinkovich M Peter; Keene Douglas</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3028-3038</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable disease caused by mutations in the gene encoding type VII collagen, the major component of anchoring fibrils (AF).  We previously demonstrated that gentamicin produced functional type VII collagen in RDEB cells harboring nonsense mutations.  Herein, we determined whether topical or intradermal gentamicin administration induces type VII collagen and AFs in RDEB patients.  METHODS:  A double-blind, placebo-controlled pilot trial assessed safety and efficacy of topical and intradermal gentamicin in 5 RDEB patients with nonsense mutations.  The topical arm tested 0.1% gentamicin ointment or placebo application 3 times daily at 2 open erosion sites for 2 weeks.  The intradermal arm tested daily intradermal injection of gentamicin solution (8 mg) or placebo into 2 intact skin sites for 2 days in 4 of 5 patients.  Primary outcomes were induction of type VII collagen and AFs at the test sites and safety assessment.  A secondary outcome assessed wound closure of topically treated erosions.  RESULTS:  Both topical and intradermal gentamicin administration induced type VII collagen and AFs at the dermal-epidermal junction of treatment sites.  Newly created type VII collagen varied from 20% to 165% of that expressed in normal human skin and persisted for 3 months.  Topical gentamicin corrected dermal-epidermal separation, improved wound closure, and reduced blister formation.  There were no untoward side effects from gentamicin treatments.  Type VII collagen induction did not generate anti-type VII collagen autoantibodies in patients' blood or skin.  CONCLUSION:  Topical and intradermal gentamicin suppresses nonsense mutations and induces type VII collagen and AFs in RDEB patients.  Gentamicin therapy may provide a readily available treatment for RDEB patients with nonsense mutations.  TRIAL REGISTRATION:  ClinicalTrials.gov NCT02698735.  FUNDING:  Epidermolysis Bullosa Research Partnership, Epidermolysis Bullosa Medical Research Foundation, NIH, and VA Merit Award.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXoJ0sTrmDnD0O18WR3iAofW6udTcc2eaXBgdIYVxdG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlvF2gtA%253D%253D&md5=aea7ab7324f450b0ce8c92ac4552a799</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1172%2FJCI92707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI92707%26sid%3Dliteratum%253Aachs%26aulast%3DWoodley%26aufirst%3DD.%2BT.%26aulast%3DCogan%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DLyu%26aufirst%3DC.%26aulast%3DMarinkovich%26aufirst%3DM.%2BP.%26aulast%3DKeene%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DM.%26atitle%3DGentamicin%2520Induces%2520Functional%2520Type%2520VII%2520Collagen%2520in%2520Recessive%2520Dystrophic%2520Epidermolysis%2520Bullosa%2520Patients%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D3028%26epage%3D3038%26doi%3D10.1172%2FJCI92707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">James, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillicrap, D.</span></span> <span> </span><span class="NLM_article-title">Aminoglycoside Suppression of Nonsense Mutations in Severe Hemophilia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">3043</span>– <span class="NLM_lpage">3048</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-03-1307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1182%2Fblood-2005-03-1307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16051741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Wntr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=3043-3048&author=P.+D.+Jamesauthor=S.+Rautauthor=G.+E.+Rivardauthor=M.+C.+Poonauthor=M.+Warnerauthor=S.+McKennaauthor=J.+Leggoauthor=D.+Lillicrap&title=Aminoglycoside+Suppression+of+Nonsense+Mutations+in+Severe+Hemophilia&doi=10.1182%2Fblood-2005-03-1307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycoside suppression of nonsense mutations in severe hemophilia</span></div><div class="casAuthors">James, Paula D.; Raut, Sanj; Rivard, Georges E.; Poon, Man-Chiu; Warner, Margaret; McKenna, Susan; Leggo, Jayne; Lillicrap, David</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3043-3048</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Aminoglycoside antibiotics exhibit their bactericidal effect by interfering with normal ribosomal activity.  In this pilot study, we have evaluated the effect of the aminoglycoside antibiotic gentamicin on the factor VIII (FVIII) and IX levels of severe hemophiliacs with known nonsense mutations.  Five patients were enrolled and each patients was given 3 consecutive days of gentamicin at a dose of 7 mg/kg i.v. every 24 h.  Two patients (patient no. 1: hemophilia A, Ser1395Stop; and patient no. 5: hemophilia B, Arg333Stop) showed a decrease in their activated partial thromboplastin time (aPTT), an increase in their FVIII (0.016 IU/mL, 1.6%) or FIX (0.02 IU/mL, 2%) levels, and an increase in thrombin generation.  The remaining 3 patients (patient no. 2: hemophilia B, Arg252Stop; patient no. 3: hemophilia A, Arg2116Stop; and patient no. 4: hemophilia A, Arg427Stop) showed no response in the aPTTs or factor levels, but one (patient no. 2: hemophilia B, Arg252Stop) showed an increase in the factor IX antigen level (2% - 5.5%) that persisted throughout the period of the study and was concordant with an increase in thrombin generation.  Gentamicin is unlikely to be an effective treatment for severe hemophilia due to its potential toxicities and the minimal response documented in this report.  This study, however, does provide a proof of principle, suggesting that ribosomal interference with a less toxic agent may be a potential therapeutic mechanism for severe hemophilia patients with nonsense mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9gNUVX1ORO7Vg90H21EOLACvtfcHk0lhXrJytozEEHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Wntr%252FF&md5=b5ff28adaaab7e0286bd3832d73b7159</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-03-1307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-03-1307%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DP.%2BD.%26aulast%3DRaut%26aufirst%3DS.%26aulast%3DRivard%26aufirst%3DG.%2BE.%26aulast%3DPoon%26aufirst%3DM.%2BC.%26aulast%3DWarner%26aufirst%3DM.%26aulast%3DMcKenna%26aufirst%3DS.%26aulast%3DLeggo%26aufirst%3DJ.%26aulast%3DLillicrap%26aufirst%3DD.%26atitle%3DAminoglycoside%2520Suppression%2520of%2520Nonsense%2520Mutations%2520in%2520Severe%2520Hemophilia%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D3043%26epage%3D3048%26doi%3D10.1182%2Fblood-2005-03-1307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martorell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barquinero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, F.</span></span> <span> </span><span class="NLM_article-title">Variable Readthrough Responsiveness of Nonsense Mutations in Hemophilia A</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.3324/haematol.2018.212118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3324%2Fhaematol.2018.212118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31197069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVartL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2020&pages=508-518&author=L.+Martorellauthor=V.+Cortinaauthor=R.+Parraauthor=J.+Barquineroauthor=F.+Vidal&title=Variable+Readthrough+Responsiveness+of+Nonsense+Mutations+in+Hemophilia+A&doi=10.3324%2Fhaematol.2018.212118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Variable readthrough responsiveness of nonsense mutations in hemophilia A</span></div><div class="casAuthors">Martorell, Lluis; Cortina, Vicente; Parra, Rafael; Barquinero, Jordi; Vidal, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">508-518</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Readthrough therapy relies on the use of small mols. that enable premature termination codons in mRNA open reading frames to be misinterpreted by the translation machinery, thus allowing the generation of full-length, potentially functional proteins from mRNA carrying nonsense mutations.  In patients with hemophilia A, nonsense mutations potentially sensitive to readthrough agents represent approx. 16% of the point mutations.  The aim of this study was to measure the readthrough effect of different compds. and to analyze the influence of premature termination codon context in selected nonsense mutations causing hemophilia A.  To this end, primary fibroblasts from three patients with hemophilia A caused by nonsense mutations (p.W1586X, p.Q1636X and p.R1960X) and Chinese hamster ovary (CHO) cells transfected with 12 different plasmids encoding mutated F8 (p.Q462X, p.Q1705X, p.Q1764X, p.W274X, p.W1726X, p.W2015X, p.W2131X, p.R1715X, p.R1822X, p.R1960X, p.R2071X and p.R2228X) were treated with gentamicin, geneticin, PTC124, RTC13 or RTC14.  Responses were assessed by analyzing not only F8 mRNA expression and FVIII biosynthesis (FVIII antigen by ELISA, western blot and immunofluorescence) but also the FVIII activity (by chromogenic assay).  In the patients' fibroblasts, readthrough agents neither stabilized F8 mRNA nor increased FVIII protein or activity to detectable levels.  In CHO cells, only in five of the 12 F8 variants, readthrough treatment increased both FVIII antigen and activity levels, which was assocd. with a redn. in intracellular accumulation of truncated forms and an increase in full-length proteins.  These results provide exptl. evidence of genetic context dependence of nonsense suppression by readthrough agents and of factors predicting responsiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1avzpFJ00r7Vg90H21EOLACvtfcHk0lhXrJytozEEHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVartL7L&md5=187226504e5758ec335ec769fafaa5d4</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2018.212118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2018.212118%26sid%3Dliteratum%253Aachs%26aulast%3DMartorell%26aufirst%3DL.%26aulast%3DCortina%26aufirst%3DV.%26aulast%3DParra%26aufirst%3DR.%26aulast%3DBarquinero%26aufirst%3DJ.%26aulast%3DVidal%26aufirst%3DF.%26atitle%3DVariable%2520Readthrough%2520Responsiveness%2520of%2520Nonsense%2520Mutations%2520in%2520Hemophilia%2520A%26jtitle%3DHaematologica%26date%3D2020%26volume%3D105%26spage%3D508%26epage%3D518%26doi%3D10.3324%2Fhaematol.2018.212118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sermet-Gaudelus, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renouil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fajac, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parbaille, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierrot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bismuth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesure, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousset, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, A.</span></span> <span> </span><span class="NLM_article-title">In Vitro Prediction of Stop-Codon Suppression by Intravenous Gentamicin in Patients with Cystic Fibrosis: A Pilot Study</span>. <i>BMC Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5</span>, <span class="refDoi"> DOI: 10.1186/1741-7015-5-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1186%2F1741-7015-5-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17394637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BD2s3isVaqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=5&author=I.+Sermet-Gaudelusauthor=M.+Renouilauthor=A.+Fajacauthor=L.+Bidouauthor=B.+Parbailleauthor=S.+Pierrotauthor=N.+Davyauthor=E.+Bismuthauthor=P.+Reinertauthor=G.+Lenoirauthor=J.+F.+Lesureauthor=J.+P.+Roussetauthor=A.+Edelman&title=In+Vitro+Prediction+of+Stop-Codon+Suppression+by+Intravenous+Gentamicin+in+Patients+with+Cystic+Fibrosis%3A+A+Pilot+Study&doi=10.1186%2F1741-7015-5-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study</span></div><div class="casAuthors">Sermet-Gaudelus Isabelle; Renouil Michel; Fajac Anne; Bidou Laure; Parbaille Bastien; Pierrot Sebastien; Davy Nolwen; Bismuth Elise; Reinert Philippe; Lenoir Gerard; Lesure Jean Francois; Rousset Jean Pierre; Edelman Aleksander</div><div class="citationInfo"><span class="NLM_cas:title">BMC medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which acts as a chloride channel activated by cyclic AMP (cAMP).  The most frequent mutation found in 70% of CF patients is F508del, while premature stop mutations are found in about 10% of patients.  In vitro aminoglycoside antibiotics (e.g. gentamicin) suppress nonsense mutations located in CFTR permitting translation to continue to the natural termination codon.  Pharmacologic suppression of stop mutations within the CFTR may be of benefit to a significant number of patients.  Our pilot study was conducted to determine whether intravenous gentamicin suppresses stop codons in CF patients and whether it has clinical benefits.  METHODS:  A dual gene reporter system was used to determine the gentamicin-induced readthrough level of the most frequent stop mutations within the CFTR in the French population.  We investigated readthrough efficiency in response to 10 mg/kg once-daily intravenous gentamicin perfusions in patients with and without stop mutations.  Respiratory function, sweat chloride concentration, nasal potential difference (NPD) and CFTR expression in nasal epithelial cells were measured at baseline and after 15 days of treatment.  RESULTS:  After in vitro gentamicin incubation, the readthrough efficiency for the Y122X mutation was at least five times higher than that for G542X, R1162X, and W1282X.  In six of the nine patients with the Y122X mutation, CFTR immunodetection showed protein at the membrane of the nasal epithelial cells and the CFTR-dependent Cl- secretion in NPD measurements increased significantly.  Respiratory status also improved in these patients, irrespective of the gentamicin sensitivity of the bacteria present in the sputum.  Mean sweat chloride concentration decreased significantly and normalised in two patients.  Clinical status, NPD and sweat Cl- values did not change in the Y122X patients with no protein expression, in patients with the other stop mutations investigated in vitro and those without stop mutations.  CONCLUSION:  Suppression of stop mutations in the CFTR gene with parenteral gentamicin can be predicted in vitro and is associated with clinical benefit and significant modification of the CFTR-mediated Cl- transport in nasal and sweat gland epithelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVYdCWSD9Hn5Pq5LRczm8ffW6udTcc2ead23V_arnSzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3isVaqsw%253D%253D&md5=ebab098cbb11bbc01cc129f4a33a4f98</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1186%2F1741-7015-5-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7015-5-5%26sid%3Dliteratum%253Aachs%26aulast%3DSermet-Gaudelus%26aufirst%3DI.%26aulast%3DRenouil%26aufirst%3DM.%26aulast%3DFajac%26aufirst%3DA.%26aulast%3DBidou%26aufirst%3DL.%26aulast%3DParbaille%26aufirst%3DB.%26aulast%3DPierrot%26aufirst%3DS.%26aulast%3DDavy%26aufirst%3DN.%26aulast%3DBismuth%26aufirst%3DE.%26aulast%3DReinert%26aufirst%3DP.%26aulast%3DLenoir%26aufirst%3DG.%26aulast%3DLesure%26aufirst%3DJ.%2BF.%26aulast%3DRousset%26aufirst%3DJ.%2BP.%26aulast%3DEdelman%26aufirst%3DA.%26atitle%3DIn%2520Vitro%2520Prediction%2520of%2520Stop-Codon%2520Suppression%2520by%2520Intravenous%2520Gentamicin%2520in%2520Patients%2520with%2520Cystic%2520Fibrosis%253A%2520A%2520Pilot%2520Study%26jtitle%3DBMC%2520Med.%26date%3D2007%26volume%3D5%26spage%3D5%26doi%3D10.1186%2F1741-7015-5-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selimoglu, E.</span></span> <span> </span><span class="NLM_article-title">Aminoglycoside-Induced Ototoxicity</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.2174/138161207779313731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.2174%2F138161207779313731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17266591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Wjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=119-126&author=E.+Selimoglu&title=Aminoglycoside-Induced+Ototoxicity&doi=10.2174%2F138161207779313731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycoside-induced ototoxicity</span></div><div class="casAuthors">Selimoglu, Erol</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-126</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has long been known that the major irreversible toxicity of aminoglycosides is ototoxicity.  Among them, streptomycin and gentamicin are primarily vestibulotoxic, whereas amikacin, neomycin, dihydrosterptomycin, and kanamycin are primarily cochleotoxic.  Cochlear damage can produce permanent hearing loss, and damage to the vestibular app. results in dizziness, ataxia, and(or) nystagmus.  Aminoglycosides appear to generate free radicals within the inner car, with subsequent permanent damage to sensory cells and neurons, resulting in permanent hearing loss.  Two mutations in the mitochondrial 12 S rRNA gene have been previously reported to predispose carriers to aminoglycoside-induced ototoxicity.  As aminoglycosides are indispensable agents both in the treatment of infections and Meniere's disease, a great effort has been made to develop strategies to prevent aminoglycoside ototoxicity.  Anti-free radical agents, such as salicylate, have been shown to attenuate the ototoxic effects of aminoglycosides.  In this paper, incidence, predisposition, mechanism, and prevention of aminoglycoside-induced ototoxicity is discussed in the light of literature data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN-qswAWEgqLVg90H21EOLACvtfcHk0ljODxdFlLL3bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Wjs78%253D&md5=8196d5701e29edf5e259bad9a284596c</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.2174%2F138161207779313731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161207779313731%26sid%3Dliteratum%253Aachs%26aulast%3DSelimoglu%26aufirst%3DE.%26atitle%3DAminoglycoside-Induced%2520Ototoxicity%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2007%26volume%3D13%26spage%3D119%26epage%3D126%26doi%3D10.2174%2F138161207779313731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molloy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Land, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longcroft-Neal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. D. C.</span></span> <span> </span><span class="NLM_article-title">Adverse Effects of a Single Dose of Gentamicin in Adults: A Systematic Review</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1111/bcp.13439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1111%2Fbcp.13439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28940715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Ois7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=223-238&author=R.+S.+Haywardauthor=J.+Hardingauthor=R.+Molloyauthor=L.+Landauthor=K.+Longcroft-Nealauthor=D.+Mooreauthor=J.+D.+C.+Ross&title=Adverse+Effects+of+a+Single+Dose+of+Gentamicin+in+Adults%3A+A+Systematic+Review&doi=10.1111%2Fbcp.13439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effects of a single dose of gentamicin in adults: a systematic review</span></div><div class="casAuthors">Hayward, Rachel S.; Harding, Jan; Molloy, Rob; Land, Lucy; Longcroft-Neal, Kate; Moore, David; Ross, Jonathan D. C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-238</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : To systematically review the frequency and type of adverse events assocd. with a single dose of i.v. or i.m. gentamicin in adults, for any indication, in studies where a comparator was available.  Methods : A review protocol was developed and registered (PROSPERO: CRD42013003229).  Studies were eligible for review if they: recruited participants aged ≥16 years; used gentamicin i.m. or i.v. as a single one-off dose; compared gentamicin to another medication or placebo; and monitored adverse events.  MEDLINE, EMBASE, Cochrane Library, trial registries, conference proceedings and other relevant databases were searched up to Nov. 2016.  Risk of bias was assessed on all included studies.  Results : In total, 15 522 records were identified.  After removal of duplicates, screening of title/abstrs. for relevance and independent selection of full texts by two reviewers, 36 studies were included.  Across all the included studies, 24 107 participants received a single one-off dose of gentamicin (doses ranged from 1 mg kg-1 to 480 mg per dose).  Acute kidney injury was described in 2520 participants receiving gentamicin.  The large majority of cases were reversible.  There were no cases of ototoxicity reported in patients receiving gentamicin.  A meta-anal. was not performed due to study heterogeneity.  Conclusions : A significant no. of patients saw a transient rise in creatinine after a single dose of gentamicin at doses up to 480 mg.  Persistent renal impairment and other adverse events were relatively rare.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3-N_DuC0C6bVg90H21EOLACvtfcHk0ljODxdFlLL3bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Ois7w%253D&md5=97139451036ca458debaf8de94874fa0</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13439%26sid%3Dliteratum%253Aachs%26aulast%3DHayward%26aufirst%3DR.%2BS.%26aulast%3DHarding%26aufirst%3DJ.%26aulast%3DMolloy%26aufirst%3DR.%26aulast%3DLand%26aufirst%3DL.%26aulast%3DLongcroft-Neal%26aufirst%3DK.%26aulast%3DMoore%26aufirst%3DD.%26aulast%3DRoss%26aufirst%3DJ.%2BD.%2BC.%26atitle%3DAdverse%2520Effects%2520of%2520a%2520Single%2520Dose%2520of%2520Gentamicin%2520in%2520Adults%253A%2520A%2520Systematic%2520Review%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D84%26spage%3D223%26epage%3D238%26doi%3D10.1111%2Fbcp.13439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, M.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial DNA Mutations Associated with Aminoglycoside Induced Ototoxicity</span>. <i>J. Otol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.joto.2017.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.joto.2017.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=29937831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fhtleqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1-8&author=Z.+Gaoauthor=Y.+Chenauthor=M.+Guan&title=Mitochondrial+DNA+Mutations+Associated+with+Aminoglycoside+Induced+Ototoxicity&doi=10.1016%2Fj.joto.2017.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial DNA mutations associated with aminoglycoside induced ototoxicity</span></div><div class="casAuthors">Gao Zewen; Chen Ye; Guan Min-Xin; Gao Zewen; Chen Ye; Guan Min-Xin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of otology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aminoglycosides (AmAn) are widely used for their great efficiency against gram-negative bacterial infections.  However, they can also induce ototoxic hearing loss, which has affected millions of people around the world.  As previously reported, individuals bearing mitochondrial DNA mutations in the 12S rRNA gene, such as m.1555A>G and m.1494C>T, are more prone to AmAn-induced ototoxicity.  These mutations cause human mitochondrial ribosomes to more closely resemble bacterial ribosomes and enable a stronger aminoglycoside interaction.  Consequently, exposure to AmAn can induce or worsen hearing loss in these individuals.  Furthermore, a wide range of severity and penetrance of hearing loss was observed among families carrying these mutations.  Studies have revealed that these mitochondria mutations are the primary molecular mechanism of genetic susceptibility to AmAn ototoxicity, though nuclear modifier genes and mitochondrial haplotypes are known to modulate the phenotypic manifestation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTusxX5zh2Y9tXdcedVHT5tfW6udTcc2ebIYcpss51kwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fhtleqtg%253D%253D&md5=85bf2742534289c23e34cb6c83156bb9</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1016%2Fj.joto.2017.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.joto.2017.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGuan%26aufirst%3DM.%26atitle%3DMitochondrial%2520DNA%2520Mutations%2520Associated%2520with%2520Aminoglycoside%2520Induced%2520Ototoxicity%26jtitle%3DJ.%2520Otol.%26date%3D2017%26volume%3D12%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.joto.2017.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Welch, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomizawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifillis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paushkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotta, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilde, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasugi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpoff, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almstead, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weetall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branstrom, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colacino, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babiak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northcutt, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spatrick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, H. L.</span></span> <span> </span><span class="NLM_article-title">PTC124 Targets Genetic Disorders Caused by Nonsense Mutations</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>447</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1038/nature05756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnature05756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17450125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvVaju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2007&pages=87-91&author=E.+M.+Welchauthor=E.+R.+Bartonauthor=J.+Zhuoauthor=Y.+Tomizawaauthor=W.+J.+Friesenauthor=P.+Trifillisauthor=S.+Paushkinauthor=M.+Patelauthor=C.+R.+Trottaauthor=S.+Hwangauthor=R.+G.+Wildeauthor=G.+Karpauthor=J.+Takasugiauthor=G.+Chenauthor=S.+Jonesauthor=H.+Renauthor=Y.+C.+Moonauthor=D.+Corsonauthor=A.+A.+Turpoffauthor=J.+A.+Campbellauthor=M.+M.+Connauthor=A.+Khanauthor=N.+G.+Almsteadauthor=J.+Hedrickauthor=A.+Mollinauthor=N.+Risherauthor=M.+Weetallauthor=S.+Yehauthor=A.+A.+Branstromauthor=J.+M.+Colacinoauthor=J.+Babiakauthor=W.+D.+Juauthor=S.+Hirawatauthor=V.+J.+Northcuttauthor=L.+L.+Millerauthor=P.+Spatrickauthor=F.+Heauthor=M.+Kawanaauthor=H.+Fengauthor=A.+Jacobsonauthor=S.+W.+Peltzauthor=H.+L.+Sweeney&title=PTC124+Targets+Genetic+Disorders+Caused+by+Nonsense+Mutations&doi=10.1038%2Fnature05756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">PTC124 targets genetic disorders caused by nonsense mutations</span></div><div class="casAuthors">Welch, Ellen M.; Barton, Elisabeth R.; Zhuo, Jin; Tomizawa, Yuki; Friesen, Westley J.; Trifillis, Panayiota; Paushkin, Sergey; Patel, Meenal; Trotta, Christopher R.; Hwang, Seongwoo; Wilde, Richard G.; Karp, Gary; Takasugi, James; Chen, Guangming; Jones, Stephen; Ren, Hongyu; Moon, Young-Choon; Corson, Donald; Turpoff, Anthony A.; Campbell, Jeffrey A.; Conn, M. Morgan; Khan, Atiyya; Almstead, Neil G.; Hedrick, Jean; Mollin, Anna; Risher, Nicole; Weetall, Marla; Yeh, Shirley; Branstrom, Arthur A.; Colacino, Joseph M.; Babiak, John; Ju, William D.; Hirawat, Samit; Northcutt, Valerie J.; Miller, Langdon L.; Spatrick, Phyllis; He, Feng; Kawana, Masataka; Feng, Huisheng; Jacobson, Allan; Peltz, Stuart W.; Sweeney, H. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">7140</span>),
    <span class="NLM_cas:pages">87-91</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nonsense mutations promote premature translational termination and cause anywhere from 5-70% of the individual cases of most inherited diseases.  Studies on nonsense-mediated cystic fibrosis have indicated that boosting specific protein synthesis from <1% to as little as 5% of normal levels may greatly reduce the severity or eliminate the principal manifestations of disease.  To address the need for a drug capable of suppressing premature termination, we identified PTC124-a new chem. entity that selectively induces ribosomal readthrough of premature but not normal termination codons.  PTC124 activity, optimized using nonsense-contg. reporters, promoted dystrophin prodn. in primary muscle cells from humans and mdx mice expressing dystrophin nonsense alleles, and rescued striated muscle function in mdx mice within 2-8 wk of drug exposure.  PTC124 was well tolerated in animals at plasma exposures substantially in excess of those required for nonsense suppression.  The selectivity of PTC124 for premature termination codons, its well characterized activity profile, oral bioavailability and pharmacol. properties indicate that this drug may have broad clin. potential for the treatment of a large group of genetic disorders with limited or no therapeutic options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-j-BIHWRRyLVg90H21EOLACvtfcHk0lgrMeNCf1d6iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvVaju7o%253D&md5=c4eecae6e36e8d128a1dc8af8d472e7c</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1038%2Fnature05756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05756%26sid%3Dliteratum%253Aachs%26aulast%3DWelch%26aufirst%3DE.%2BM.%26aulast%3DBarton%26aufirst%3DE.%2BR.%26aulast%3DZhuo%26aufirst%3DJ.%26aulast%3DTomizawa%26aufirst%3DY.%26aulast%3DFriesen%26aufirst%3DW.%2BJ.%26aulast%3DTrifillis%26aufirst%3DP.%26aulast%3DPaushkin%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DTrotta%26aufirst%3DC.%2BR.%26aulast%3DHwang%26aufirst%3DS.%26aulast%3DWilde%26aufirst%3DR.%2BG.%26aulast%3DKarp%26aufirst%3DG.%26aulast%3DTakasugi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DMoon%26aufirst%3DY.%2BC.%26aulast%3DCorson%26aufirst%3DD.%26aulast%3DTurpoff%26aufirst%3DA.%2BA.%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26aulast%3DConn%26aufirst%3DM.%2BM.%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DAlmstead%26aufirst%3DN.%2BG.%26aulast%3DHedrick%26aufirst%3DJ.%26aulast%3DMollin%26aufirst%3DA.%26aulast%3DRisher%26aufirst%3DN.%26aulast%3DWeetall%26aufirst%3DM.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DBranstrom%26aufirst%3DA.%2BA.%26aulast%3DColacino%26aufirst%3DJ.%2BM.%26aulast%3DBabiak%26aufirst%3DJ.%26aulast%3DJu%26aufirst%3DW.%2BD.%26aulast%3DHirawat%26aufirst%3DS.%26aulast%3DNorthcutt%26aufirst%3DV.%2BJ.%26aulast%3DMiller%26aufirst%3DL.%2BL.%26aulast%3DSpatrick%26aufirst%3DP.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DKawana%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DJacobson%26aufirst%3DA.%26aulast%3DPeltz%26aufirst%3DS.%2BW.%26aulast%3DSweeney%26aufirst%3DH.%2BL.%26atitle%3DPTC124%2520Targets%2520Genetic%2520Disorders%2520Caused%2520by%2520Nonsense%2520Mutations%26jtitle%3DNature%26date%3D2007%26volume%3D447%26spage%3D87%26epage%3D91%26doi%3D10.1038%2Fnature05756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedwell, D. M.</span></span> <span> </span><span class="NLM_article-title">PTC124 Is an Orally Bioavailable Compound That Promotes Suppression of the Human CFTR-G542X Nonsense Allele in a CF Mouse Model</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2064</span>– <span class="NLM_lpage">2069</span>, <span class="refDoi"> DOI: 10.1073/pnas.0711795105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.0711795105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18272502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2064-2069&author=M.+Duauthor=X.+Liuauthor=E.+M.+Welchauthor=S.+Hirawatauthor=S.+W.+Peltzauthor=D.+M.+Bedwell&title=PTC124+Is+an+Orally+Bioavailable+Compound+That+Promotes+Suppression+of+the+Human+CFTR-G542X+Nonsense+Allele+in+a+CF+Mouse+Model&doi=10.1073%2Fpnas.0711795105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model</span></div><div class="casAuthors">Du, Ming; Liu, Xiaoli; Welch, Ellen M.; Hirawat, Samit; Peltz, Stuart W.; Bedwwell, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2064-2069</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonsense mutations inactivate gene function and are the underlying cause of a large percentage of the individual cases of many genetic disorders.  PTC124 is an orally bioavailable compd. that promotes readthrough of premature translation termination codons, suggesting that it may have the potential to treat genetic diseases caused by nonsense mutations.  Using a mouse model for cystic fibrosis (CF), we show that s.c. injection or oral administration of PTC124 to Cftr-/- mice expressing a human CFTR-G542X transgene suppressed the G542X nonsense mutation and restored a significant amt. of human (h)CFTR protein and function.  Translational readthrough of the premature stop codon was demonstrated in this mouse model in two ways.  First, immunofluorescence staining showed that PTC124 treatment resulted in the appearance of hCFTR protein at the apical surface of intestinal glands in Cftr-/- hCFTR-GS42X mice.  In addn., functional assays demonstrated that PTC124 treatment restored 24-29% of the av. cAMP-stimulated transepithelial chloride currents obsd. in wild-type mice.  These results indicate that PTC124 can effectively suppress the hCFTR-G542X nonsense mutation in vivo.  In light of its oral bioavailability, safety toxicol. profile in animal studies, and efficacy with other nonsense alleles, PTC124 has the potential to be an important therapeutic agent for the treatment of inherited diseases caused by nonsense mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogGIOgesV_abVg90H21EOLACvtfcHk0lgrMeNCf1d6iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7g%253D&md5=61692496750638a95a3b688e486a4653</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711795105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711795105%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWelch%26aufirst%3DE.%2BM.%26aulast%3DHirawat%26aufirst%3DS.%26aulast%3DPeltz%26aufirst%3DS.%2BW.%26aulast%3DBedwell%26aufirst%3DD.%2BM.%26atitle%3DPTC124%2520Is%2520an%2520Orally%2520Bioavailable%2520Compound%2520That%2520Promotes%2520Suppression%2520of%2520the%2520Human%2520CFTR-G542X%2520Nonsense%2520Allele%2520in%2520a%2520CF%2520Mouse%2520Model%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2064%26epage%3D2069%26doi%3D10.1073%2Fpnas.0711795105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregory-evans, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory-Evans, K.</span></span> <span> </span><span class="NLM_article-title">Postnatal Manipulation of Pax6 Dosage Reverses Congenital Tissue Malformation Defects</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1172/JCI70462</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1172%2FJCI70462" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24355924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFeiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=111-116&author=C.+Y.+Gregory-evansauthor=X.+Wangauthor=K.+M.+Wasanauthor=J.+Zhaoauthor=A.+L.+Metcalfeauthor=K.+Gregory-Evans&title=Postnatal+Manipulation+of+Pax6+Dosage+Reverses+Congenital+Tissue+Malformation+Defects&doi=10.1172%2FJCI70462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects</span></div><div class="casAuthors">Gregory-Evans, Cheryl Y.; Wang, Xia; Wasan, Kishor M.; Zhao, Jinying; Metcalfe, Andrew L.; Gregory-Evans, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-116</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Aniridia is a congenital and progressive panocular condition with poor visual prognosis that is assocd. with brain, olfactory, and pancreatic abnormalities.  Development of aniridia is linked with nonsense mutations that result in paired box 6 (PAX6) haploinsufficiency.  Here, we used a mouse model of aniridia to test the hypothesis that manipulation of Pax6 dosage through a mutation-independent nonsense mutation suppression strategy would limit progressive, postnatal damage in the eye.  We focused on the nonsense suppression drugs 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid (ataluren) and gentamicin.  Remarkably, we demonstrated that nonsense suppression not only inhibited disease progression but also stably reversed corneal, lens, and retinal malformation defects and restored elec. and behavioral responses of the retina.  The most successful results were achieved through topical application of the drug formulation START (0.9% sodium chloride, 1% Tween 80, 1% powd. ataluren, 1% CM-cellulose), which was designed to enhance particle dispersion and to increase suspension viscosity.  These observations suggest that the eye retains marked developmental plasticity into the postnatal period and remains sensitive to mol. remodeling.  Furthermore, these data indicate that other neurol. developmental anomalies assocd. with dosage-sensitive genetic mutations may be reversible through nonsense suppression therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMqjOU_Vfk67Vg90H21EOLACvtfcHk0lgrMeNCf1d6iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFeiug%253D%253D&md5=8bd96b6898e5f0c2a466db6253714f59</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1172%2FJCI70462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI70462%26sid%3Dliteratum%253Aachs%26aulast%3DGregory-evans%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWasan%26aufirst%3DK.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMetcalfe%26aufirst%3DA.%2BL.%26aulast%3DGregory-Evans%26aufirst%3DK.%26atitle%3DPostnatal%2520Manipulation%2520of%2520Pax6%2520Dosage%2520Reverses%2520Congenital%2520Tissue%2520Malformation%2520Defects%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D111%26epage%3D116%26doi%3D10.1172%2FJCI70462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovács, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, D. A.</span></span> <span> </span><span class="NLM_article-title">The Novel Cln1R151X Mouse Model of Infantile Neuronal Ceroid Lipofuscinosis (INCL) for Testing Nonsense Suppression Therapy</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddu428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1093%2Fhmg%2Fddu428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25205113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitl2gt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=185-196&author=J.+N.+Millerauthor=A.+D.+Kov%C3%A1csauthor=D.+A.+Pearce&title=The+Novel+Cln1R151X+Mouse+Model+of+Infantile+Neuronal+Ceroid+Lipofuscinosis+%28INCL%29+for+Testing+Nonsense+Suppression+Therapy&doi=10.1093%2Fhmg%2Fddu428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">The novel Cln1R151X mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy</span></div><div class="casAuthors">Miller, Jake N.; Kovacs, Attila D.; Pearce, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-196</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease, are a group of autosomal recessive neurodegenerative disorders in children characterized by the progressive onset of seizures, blindness, motor and cognitive decline and premature death.  Patients with mutations in CLN1 primarily manifest with infantile NCL (INCL or Haltia-Santavuori disease), which is second only to congenital NCL for its age of onset and devastating progression.  CLN1 encodes a lysosomal enzyme, palmitoyl-protein thioesterase 1 (PPT1).  Nonsense mutations in CLN1 account for 52.3% of all disease causing alleles in infantile NCL, the most common of which worldwide is the p.R151X mutation.  Previously, we have shown how nonsense-mediated decay is involved in the degrdn. of CLN1 mRNA transcripts contg. the p.R151X mutation in human lymphoblast cell lines.  We have also shown how the read-through drugs gentamicin and ataluren (PTC124) increase CLN1 (PPT1) enzyme activity.  Here, we provide the initial characterization of the novel Cln1R151X mouse model of infantile neuronal ceroid lipofuscinosis that we have generated.  This nonsense mutation model recapitulates the mol., histol. and behavioral phenotypes of the human disease.  Cln1R151X mice showed a significant decrease in Cln1 mRNA level and PPT1 enzyme activity, accumulation of autofluorescent storage material, astrocytosis and microglial activation in the brain.  Behavioral characterization of Cln1R151X mice at 3 and 5 mo of age revealed significant motor deficits as measured by the vertical pole and rotarod tests.  We also show how the read-through compd. ataluren (PTC124) increases PPT1 enzyme activity and protein level in Cln1R151X mice in a proof-of-principle study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-UfjtGsCSCLVg90H21EOLACvtfcHk0lgi7AZ0LeCn0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitl2gt7s%253D&md5=ab3153c6871564b86be93ccb87fb0f2a</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddu428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddu428%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DJ.%2BN.%26aulast%3DKov%25C3%25A1cs%26aufirst%3DA.%2BD.%26aulast%3DPearce%26aufirst%3DD.%2BA.%26atitle%3DThe%2520Novel%2520Cln1R151X%2520Mouse%2520Model%2520of%2520Infantile%2520Neuronal%2520Ceroid%2520Lipofuscinosis%2520%2528INCL%2529%2520for%2520Testing%2520Nonsense%2520Suppression%2520Therapy%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2015%26volume%3D24%26spage%3D185%26epage%3D196%26doi%3D10.1093%2Fhmg%2Fddu428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finkel, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanigan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnemann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northcutt, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elfring, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, S. W.</span></span> <span> </span><span class="NLM_article-title">Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e81302</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0081302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pone.0081302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24349052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsVOmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e81302&author=R.+S.+Finkelauthor=K.+M.+Flaniganauthor=B.+Wongauthor=C.+Bonnemannauthor=J.+Sampsonauthor=H.+L.+Sweeneyauthor=A.+Rehaauthor=V.+J.+Northcuttauthor=G.+Elfringauthor=J.+Barthauthor=S.+W.+Peltz&title=Phase+2a+Study+of+Ataluren-Mediated+Dystrophin+Production+in+Patients+with+Nonsense+Mutation+Duchenne+Muscular+Dystrophy&doi=10.1371%2Fjournal.pone.0081302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy</span></div><div class="casAuthors">Finkel, Richard S.; Flanigan, Kevin M.; Wong, Brenda; Bonnemann, Carsten; Sampson, Jacinda; Sweeney, H. Lee; Reha, Allen; Northcutt, Valerie J.; Elfring, Gary; Barth, Jay; Peltz, Stuart W.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e81302/1-e81302/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Approx. 13% of boys with Duchenne muscular dystrophy (DMD) have a nonsense mutation in the dystrophin gene, resulting in a premature stop codon in the corresponding mRNA and failure to generate a functional protein.  Ataluren (PTC124) enables ribosomal readthrough of premature stop codons, leading to prodn. of full-length, functional proteins.  Methods: This Phase 2a open-label, sequential dose-ranging trial recruited 38 boys with nonsense mutation DMD.  The first cohort (n = 6) received ataluren three times per day at morning, midday, and evening doses of 4, 4, and 8 mg/kg; the second cohort (n = 20) was dosed at 10, 10, 20 mg/kg; and the third cohort (n = 12) was dosed at 20, 20, 40 mg/kg.  Treatment duration was 28 days.  Change in full-length dystrophin expression, as assessed by immunostaining in pre- and post-treatment muscle biopsy specimens, was the primary endpoint.  Findings: Twenty three of 38 (61%) subjects demonstrated increases in post-treatment dystrophin expression in a quant. anal. assessing the ratio of dystrophin/spectrin.  A qual. anal. also showed pos. changes in dystrophin expression.  Expression was not assocd. with nonsense mutation type or exon location.  Ataluren trough plasma concns. active in the mdx mouse model were consistently achieved at the mid- and high-dose levels in participants.  Ataluren was generally well tolerated.  Interpretation: Ataluren showed activity and safety in this short-term study, supporting evaluation of ataluren 10, 10, 20 mg/kg and 20, 20, 40 mg/kg in a Phase 2b, double-blind, long-term study in nonsense mutation DMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquxNJecOocsbVg90H21EOLACvtfcHk0lgi7AZ0LeCn0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsVOmtrw%253D&md5=c7198497eed795894e094ae044d35624</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0081302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0081302%26sid%3Dliteratum%253Aachs%26aulast%3DFinkel%26aufirst%3DR.%2BS.%26aulast%3DFlanigan%26aufirst%3DK.%2BM.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DBonnemann%26aufirst%3DC.%26aulast%3DSampson%26aufirst%3DJ.%26aulast%3DSweeney%26aufirst%3DH.%2BL.%26aulast%3DReha%26aufirst%3DA.%26aulast%3DNorthcutt%26aufirst%3DV.%2BJ.%26aulast%3DElfring%26aufirst%3DG.%26aulast%3DBarth%26aufirst%3DJ.%26aulast%3DPeltz%26aufirst%3DS.%2BW.%26atitle%3DPhase%25202a%2520Study%2520of%2520Ataluren-Mediated%2520Dystrophin%2520Production%2520in%2520Patients%2520with%2520Nonsense%2520Mutation%2520Duchenne%2520Muscular%2520Dystrophy%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De81302%26doi%3D10.1371%2Fjournal.pone.0081302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, C. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torricelli, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkel, R. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanigan, K. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goemans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydemann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muntoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osorio, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schara, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sejersen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, P. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, H L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topaloglu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulinius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilchez, J. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elfring, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riebling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, R. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, S. W</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercuri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfano, L. N</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eagle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayhew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzone, E. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Hamid, H. Z</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apkon, S. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barohn, R. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloetzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vaud, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, R. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabrol, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jongno-gu, D.-r.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comi, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darras, B. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastgir, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desguerre, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, R. G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finanger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannaccone, S. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karachunski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotze, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, J. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Queiroz
Campos Araujo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renfroe, J B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Resende, M. B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tennekoon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vita, G.</span></span> <span> </span><span class="NLM_article-title">Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">1489</span>– <span class="NLM_lpage">1498</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)31611-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2FS0140-6736%2817%2931611-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28728956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtF2hsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=1489-1498&author=C.+M+McDonaldauthor=C.+Campbellauthor=R.+E.+Torricelliauthor=R.+S+Finkelauthor=K.+M+Flaniganauthor=N.+Goemansauthor=P.+Heydemannauthor=A.+Kaminskaauthor=J.+Kirschnerauthor=F.+Muntoniauthor=A.+N.+Osorioauthor=U.+Scharaauthor=T.+Sejersenauthor=P.+B+Shiehauthor=H+L.+Sweeneyauthor=H.+Topalogluauthor=M.+Tuliniusauthor=J.+J+Vilchezauthor=T.+Voitauthor=B.+Wongauthor=G.+Elfringauthor=H.+Krogerauthor=X.+Luoauthor=J.+McIntoshauthor=T.+Ongauthor=P.+Rieblingauthor=M.+Souzaauthor=R.+J+Spiegelauthor=S.+W+Peltzauthor=E.+Mercuriauthor=L.+N+Alfanoauthor=M.+Eagleauthor=M.+K+Jamesauthor=L.+Lowesauthor=A.+Mayhewauthor=E.+S+Mazzoneauthor=L.+Nelsonauthor=K.+J+Roseauthor=H.+Z+Abdel-Hamidauthor=S.+D+Apkonauthor=R.+J+Barohnauthor=E.+Bertiniauthor=C.+Bloetzerauthor=L.+C.+de+Vaudauthor=R.+J+Butterfieldauthor=B.+Chabrolauthor=J.-H.+Chaeauthor=D.-r.+Jongno-guauthor=G.+P.+Comiauthor=B.+T+Darrasauthor=J.+Dastgirauthor=I.+Desguerreauthor=R.+G+Escobarauthor=E.+Finangerauthor=M.+Guglieriauthor=I.+Hughesauthor=S.+T+Iannacconeauthor=K.+J+Jonesauthor=P.+Karachunskiauthor=M.+Kudrauthor=T.+Lotzeauthor=J.+K+Mahauthor=K.+Mathewsauthor=Y.+Nevoauthor=J.+Parsonsauthor=Y.+Pereonauthor=A.+P.+de+Queiroz%0ACampos+Araujoauthor=J+B.+Renfroeauthor=M.+B.+D.+de+Resendeauthor=M.+Ryanauthor=K.+Selbyauthor=G.+Tennekoonauthor=G.+Vita&title=Ataluren+in+Patients+with+Nonsense+Mutation+Duchenne+Muscular+Dystrophy+%28ACT+DMD%29%3A+A+Multicentre%2C+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C+Phase+3+Trial&doi=10.1016%2FS0140-6736%2817%2931611-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial</span></div><div class="casAuthors">McDonald, Craig M.; Campbell, Craig; Torricelli, Ricardo Erazo; Finkel, Richard S.; Flanigan, Kevin M.; Goemans, Nathalie; Heydemann, Peter; Kaminska, Anna; Kirschner, Janbernd; Muntoni, Francesco; Osorio, Andres Nascimento; Schara, Ulrike; Sejersen, Thomas; Shieh, Perry B.; Sweeney, H. Lee; Topaloglu, Haluk; Tulinius, Mar; Vilchez, Juan J.; Voit, Thomas; Wong, Brenda; Elfring, Gary; Kroger, Hans; Luo, Xiaohui; McIntosh, Joseph; Ong, Tuyen; Riebling, Peter; Souza, Marcio; Spiegel, Robert J.; Peltz, Stuart W.; Mercuri, Eugenio</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">10101</span>),
    <span class="NLM_cas:pages">1489-1498</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Duchenne muscular dystrophy (DMD) is a severe, progressive, and rare neuromuscular, X-linked recessive disease.  Dystrophin deficiency is the underlying cause of disease; therefore, mutation-specific therapies aimed at restoring dystrophin protein prodn. are being explored.  We aimed to assess the efficacy and safety of ataluren in ambulatory boys with nonsense mutation DMD.  We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 54 sites in 18 countries located in North America, Europe, the Asia-Pacific region, and Latin America.  Boys aged 7-16 years with nonsense mutation DMD and a baseline 6-min walk distance (6MWD) of 150 m or more and 80% or less of the predicted normal value for age and height were randomly assigned (1:1), via permuted block randomisation (block size of four) using an interactive voice-response or web-response system, to receive ataluren orally three times daily (40 mg/kg per day) or matching placebo.  Randomisation was stratified by age (<9 years vs ≥9 years), duration of previous corticosteroid use (6 mo to <12 mo vs ≥12 mo), and baseline 6MWD (<350 m vs ≥350 m).  Patients, parents and caregivers, investigational site personnel, PTC Therapeutics employees, and all other study personnel were masked to group allocation until after database lock.  The primary endpoint was change in 6MWD from baseline to week 48.  We addnl. did a prespecified subgroup anal. of the primary endpoint, based on baseline 6MWD, which is reflective of anticipated rates of disease progression over 1 yr.  The primary anal. was by intention to treat.  This study is registered with ClinicalTrials.gov, no. NCT01826487.  Between March 26, 2013, and Aug 26, 2014, we randomly assigned 230 patients to receive ataluren (n=115) or placebo (n=115); 228 patients comprised the intention-to-treat population.  The least-squares mean change in 6MWD from baseline to week 48 was -47·7 m (SE 9·3) for ataluren-treated patients and -60·7 m (9·3) for placebo-treated patients (difference 13·0 m [SE 10·4], 95% CI -7·4 to 33·4; p=0·213).  The least-squares mean change for ataluren vs. placebo in the prespecified subgroups was -7·7 m (SE 24·1, 95% CI -54·9 to 39·5; p=0·749) in the group with a 6MWD of less than 300 m, 42·9 m (15·9, 11·8-74·0; p=0·007) in the group with a 6MWD of 300 m or more to less than 400 m, and -9·5 m (17·2, -43·2 to 24·2; p=0·580) in the group with a 6MWD of 400 m or more.  Ataluren was generally well tolerated and most treatment-emergent adverse events were mild to moderate in severity.  Eight (3%) patients (n=4 per group) reported serious adverse events; all except one event in the placebo group (abnormal hepatic function deemed possibly related to treatment) were deemed unrelated to treatment.  Change in 6MWD did not differ significantly between patients in the ataluren group and those in the placebo group, neither in the intention-to-treat population nor in the prespecified subgroups with a baseline 6MWD of less than 300 m or 400 m or more.  However, we recorded a significant effect of ataluren in the prespecified subgroup of patients with a baseline 6MWD of 300 m or more to less than 400 m.  Baseline 6MWD values within this range were assocd. with a more predictable rate of decline over 1 yr; this finding has implications for the design of future DMD trials with the 6-min walk test as the endpoint.PTC Therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrdEeegEaHJLVg90H21EOLACvtfcHk0lhAKFMeSRl8oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtF2hsL3N&md5=25ae69e359455aca9d716e964aa09015</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2931611-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252931611-2%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonald%26aufirst%3DC.%2BM%26aulast%3DCampbell%26aufirst%3DC.%26aulast%3DTorricelli%26aufirst%3DR.%2BE.%26aulast%3DFinkel%26aufirst%3DR.%2BS%26aulast%3DFlanigan%26aufirst%3DK.%2BM%26aulast%3DGoemans%26aufirst%3DN.%26aulast%3DHeydemann%26aufirst%3DP.%26aulast%3DKaminska%26aufirst%3DA.%26aulast%3DKirschner%26aufirst%3DJ.%26aulast%3DMuntoni%26aufirst%3DF.%26aulast%3DOsorio%26aufirst%3DA.%2BN.%26aulast%3DSchara%26aufirst%3DU.%26aulast%3DSejersen%26aufirst%3DT.%26aulast%3DShieh%26aufirst%3DP.%2BB%26aulast%3DSweeney%26aufirst%3DH%2BL.%26aulast%3DTopaloglu%26aufirst%3DH.%26aulast%3DTulinius%26aufirst%3DM.%26aulast%3DVilchez%26aufirst%3DJ.%2BJ%26aulast%3DVoit%26aufirst%3DT.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DElfring%26aufirst%3DG.%26aulast%3DKroger%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DOng%26aufirst%3DT.%26aulast%3DRiebling%26aufirst%3DP.%26aulast%3DSouza%26aufirst%3DM.%26aulast%3DSpiegel%26aufirst%3DR.%2BJ%26aulast%3DPeltz%26aufirst%3DS.%2BW%26aulast%3DMercuri%26aufirst%3DE.%26aulast%3DAlfano%26aufirst%3DL.%2BN%26aulast%3DEagle%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DM.%2BK%26aulast%3DLowes%26aufirst%3DL.%26aulast%3DMayhew%26aufirst%3DA.%26aulast%3DMazzone%26aufirst%3DE.%2BS%26aulast%3DNelson%26aufirst%3DL.%26aulast%3DRose%26aufirst%3DK.%2BJ%26aulast%3DAbdel-Hamid%26aufirst%3DH.%2BZ%26aulast%3DApkon%26aufirst%3DS.%2BD%26aulast%3DBarohn%26aufirst%3DR.%2BJ%26aulast%3DBertini%26aufirst%3DE.%26aulast%3DBloetzer%26aufirst%3DC.%26aulast%3Dde%2BVaud%26aufirst%3DL.%2BC.%26aulast%3DButterfield%26aufirst%3DR.%2BJ%26aulast%3DChabrol%26aufirst%3DB.%26aulast%3DChae%26aufirst%3DJ.-H.%26aulast%3DJongno-gu%26aufirst%3DD.-r.%26aulast%3DComi%26aufirst%3DG.%2BP.%26aulast%3DDarras%26aufirst%3DB.%2BT%26aulast%3DDastgir%26aufirst%3DJ.%26aulast%3DDesguerre%26aufirst%3DI.%26aulast%3DEscobar%26aufirst%3DR.%2BG%26aulast%3DFinanger%26aufirst%3DE.%26aulast%3DGuglieri%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DI.%26aulast%3DIannaccone%26aufirst%3DS.%2BT%26aulast%3DJones%26aufirst%3DK.%2BJ%26aulast%3DKarachunski%26aufirst%3DP.%26aulast%3DKudr%26aufirst%3DM.%26aulast%3DLotze%26aufirst%3DT.%26aulast%3DMah%26aufirst%3DJ.%2BK%26aulast%3DMathews%26aufirst%3DK.%26aulast%3DNevo%26aufirst%3DY.%26aulast%3DParsons%26aufirst%3DJ.%26aulast%3DPereon%26aufirst%3DY.%26aulast%3Dde%2BQueiroz%2BCampos%2BAraujo%26aufirst%3DA.%2BP.%26aulast%3DRenfroe%26aufirst%3DJ%2BB.%26aulast%3Dde%2BResende%26aufirst%3DM.%2BB.%2BD.%26aulast%3DRyan%26aufirst%3DM.%26aulast%3DSelby%26aufirst%3DK.%26aulast%3DTennekoon%26aufirst%3DG.%26aulast%3DVita%26aufirst%3DG.%26atitle%3DAtaluren%2520in%2520Patients%2520with%2520Nonsense%2520Mutation%2520Duchenne%2520Muscular%2520Dystrophy%2520%2528ACT%2520DMD%2529%253A%2520A%2520Multicentre%252C%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26spage%3D1489%26epage%3D1498%26doi%3D10.1016%2FS0140-6736%2817%2931611-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sermet-Gaudelus, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeck, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimir, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeulen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogenet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanssens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajayi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elfring, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. L.</span></span> <span> </span><span class="NLM_article-title">Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">1262</span>– <span class="NLM_lpage">1272</span>, <span class="refDoi"> DOI: 10.1164/rccm.201001-0137OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1164%2Frccm.201001-0137OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=20622033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1eqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=1262-1272&author=I.+Sermet-Gaudelusauthor=K.+D.+Boeckauthor=G.+J.+Casimirauthor=F.+Vermeulenauthor=T.+Lealauthor=A.+Mogenetauthor=D.+Rousselauthor=J.+Fritschauthor=L.+Hanssensauthor=S.+Hirawatauthor=N.+L.+Millerauthor=S.+Constantineauthor=A.+Rehaauthor=T.+Ajayiauthor=G.+L.+Elfringauthor=L.+L.+Miller&title=Ataluren+%28PTC124%29+Induces+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Protein+Expression+and+Activity+in+Children+with+Nonsense+Mutation+Cystic+Fibrosis&doi=10.1164%2Frccm.201001-0137OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis</span></div><div class="casAuthors">Sermet-Gaudelus, Isabelle; de Boeck, Kris; Casimir, Georges J.; Vermeulen, Francois; Leal, Teresinha; Mogenet, Agnes; Roussel, Delphine; Fritsch, Janine; Hanssens, Laurence; Hirawat, Samit; Miller, Nilsen L.; Constantine, Scott; Reha, Allen; Ajayi, Temitayo; Elfring, Gary L.; Miller, Langdon L.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1262-1272</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Nonsense (premature stop codon) mutations in mRNA for the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis (CF) in approx. 10% of patients.  Ataluren (PTC124) is an oral drug that permits ribosomes to readthrough premature stop codons in mRNA to produce functional protein.  Objectives: To evaluate ataluren activity, safety, and pharmacokinetics in children with nonsense mutation CF.  Methods: Patients were assessed in two 28-day cycles, comprising 14 days on and 14 days off ataluren.  Patients took ataluren three times per day (morning, midday, and evening) with randomization to the order of receiving a lower dose (4, 4, and 8 mg/kg) and a higher dose (10, 10, and 20 mg/kg) in the two cycles.  Measurements and Main Results: The study enrolled 30 patients (16 male and 14 female, ages 6 through 18 yr) with a nonsense mutation in at least one allele of the CFTR gene, a classical CF phenotype, and abnormal baseline nasal epithelial chloride transport.  Ataluren induced a nasal chloride transport response (at least a -5-mV improvement) or hyperpolarization (value more elec. neg. than -5 mV) in 50% and 47% of patients, resp., with more hyperpolarizations at the higher dose.  Improvements were seen in seven of nine nonsense mutation genotypes represented.  Ataluren significantly increased the proportion of nasal epithelial cells expressing apical full-length CFTR protein.  Adverse events and lab. abnormalities were infrequent and usually mild.  Ataluren pharmacokinetics were similar to those in adults.  Conclusions: In children with nonsense mutation CF, ataluren can induce functional CFTR prodn. and is well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYmpNckBQweLVg90H21EOLACvtfcHk0lhAKFMeSRl8oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1eqsg%253D%253D&md5=bc4306006e48f8ae7a96e1c8227feebb</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1164%2Frccm.201001-0137OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201001-0137OC%26sid%3Dliteratum%253Aachs%26aulast%3DSermet-Gaudelus%26aufirst%3DI.%26aulast%3DBoeck%26aufirst%3DK.%2BD.%26aulast%3DCasimir%26aufirst%3DG.%2BJ.%26aulast%3DVermeulen%26aufirst%3DF.%26aulast%3DLeal%26aufirst%3DT.%26aulast%3DMogenet%26aufirst%3DA.%26aulast%3DRoussel%26aufirst%3DD.%26aulast%3DFritsch%26aufirst%3DJ.%26aulast%3DHanssens%26aufirst%3DL.%26aulast%3DHirawat%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DN.%2BL.%26aulast%3DConstantine%26aufirst%3DS.%26aulast%3DReha%26aufirst%3DA.%26aulast%3DAjayi%26aufirst%3DT.%26aulast%3DElfring%26aufirst%3DG.%2BL.%26aulast%3DMiller%26aufirst%3DL.%2BL.%26atitle%3DAtaluren%2520%2528PTC124%2529%2520Induces%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Protein%2520Expression%2520and%2520Activity%2520in%2520Children%2520with%2520Nonsense%2520Mutation%2520Cystic%2520Fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26spage%3D1262%26epage%3D1272%26doi%3D10.1164%2Frccm.201001-0137OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aslam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, I. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southern, K. W</span></span> <span> </span><span class="NLM_article-title">Ataluren and Similar Compounds (Specific Therapies for Premature Termination Codon Class I Mutations) for Cystic Fibrosis</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_fpage">CD012040</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD012040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2F14651858.CD012040" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=CD012040&author=A.+Aslamauthor=I.+P+Sinhaauthor=K.+W+Southern&title=Ataluren+and+Similar+Compounds+%28Specific+Therapies+for+Premature+Termination+Codon+Class+I+Mutations%29+for+Cystic+Fibrosis&doi=10.1002%2F14651858.CD012040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD012040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD012040%26sid%3Dliteratum%253Aachs%26aulast%3DAslam%26aufirst%3DA.%26aulast%3DSinha%26aufirst%3DI.%2BP%26aulast%3DSouthern%26aufirst%3DK.%2BW%26atitle%3DAtaluren%2520and%2520Similar%2520Compounds%2520%2528Specific%2520Therapies%2520for%2520Premature%2520Termination%2520Codon%2520Class%2520I%2520Mutations%2529%2520for%2520Cystic%2520Fibrosis%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2016%26spage%3DCD012040%26doi%3D10.1002%2F14651858.CD012040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mcelroy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrie, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warbrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, W. H. I.</span></span> <span> </span><span class="NLM_article-title">A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e1001593</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.1001593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pbio.1001593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=23824517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFGjsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=e1001593&author=S.+P.+Mcelroyauthor=T.+Nomuraauthor=L.+S.+Torrieauthor=E.+Warbrickauthor=U.+Gartnerauthor=G.+Woodauthor=W.+H.+I.+McLean&title=A+Lack+of+Premature+Termination+Codon+Read-Through+Efficacy+of+PTC124+%28Ataluren%29+in+a+Diverse+Array+of+Reporter+Assays&doi=10.1371%2Fjournal.pbio.1001593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays</span></div><div class="casAuthors">McElroy, Stuart P.; Nomura, Toshifumi; Torrie, Leah S.; Warbrick, Emma; Gartner, Ulrike; Wood, Gavin; McLean, W. H. Irwin</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1001593</span>CODEN:
                <span class="NLM_cas:coden">PBLIBG</span>;
        ISSN:<span class="NLM_cas:issn">1545-7885</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The drug mol. PTC124 (Ataluren) has been described as a read-through agent, capable of suppressing premature termination codons (PTCs) and restoring functional protein prodn. from genes disrupted by nonsense mutations.  Following the discovery of PTC124 there was some controversy regarding its mechanism of action with two reports attributing its activity to an off-target effect on the Firefly luciferase (FLuc) reporter used in the development of the mol.  Despite questions remaining as to its mechanism of action, development of PTC124 continued into the clinic and it is being actively pursued as a potential nonsense mutation therapy.  To thoroughly test the ability of PTC124 to read through nonsense mutations, we conducted a detailed assessment comparing the efficacy of PTC124 with the classical aminoglycoside antibiotic read-through agent geneticin (G418) across a diverse range of in vitro reporter assays.  We can confirm the off-target FLuc activity of PTC124 but found that, while G418 exhibits varying activity in every read-through assay, there is no evidence of activity for PTC124.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLzPdUkQVuG7Vg90H21EOLACvtfcHk0lihYCbqCFSx6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFGjsLzK&md5=f611a69f45a185ea002f4073da436a7e</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1001593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1001593%26sid%3Dliteratum%253Aachs%26aulast%3DMcelroy%26aufirst%3DS.%2BP.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DTorrie%26aufirst%3DL.%2BS.%26aulast%3DWarbrick%26aufirst%3DE.%26aulast%3DGartner%26aufirst%3DU.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DMcLean%26aufirst%3DW.%2BH.%2BI.%26atitle%3DA%2520Lack%2520of%2520Premature%2520Termination%2520Codon%2520Read-Through%2520Efficacy%2520of%2520PTC124%2520%2528Ataluren%2529%2520in%2520a%2520Diverse%2520Array%2520of%2520Reporter%2520Assays%26jtitle%3DPLoS%2520Biol.%26date%3D2013%26volume%3D11%26spage%3De1001593%26doi%3D10.1371%2Fjournal.pbio.1001593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Auld, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorne, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lea, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaile, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanzlik, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglese, J.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis for the High-Affinity Binding and Stabilization of Firefly Luciferase by PTC124</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">4878</span>– <span class="NLM_lpage">4883</span>, <span class="refDoi"> DOI: 10.1073/pnas.0909141107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.0909141107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=20194791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFaqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=4878-4883&author=D.+S.+Auldauthor=S.+Lovellauthor=N.+Thorneauthor=W.+A.+Leaauthor=D.+J.+Maloneyauthor=M.+Shenauthor=G.+Raiauthor=K.+P.+Battaileauthor=C.+J.+Thomasauthor=A.+Simeonovauthor=R.+P.+Hanzlikauthor=J.+Inglese&title=Molecular+Basis+for+the+High-Affinity+Binding+and+Stabilization+of+Firefly+Luciferase+by+PTC124&doi=10.1073%2Fpnas.0909141107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124</span></div><div class="casAuthors">Auld, Douglas S.; Lovell, Scott; Thorne, Natasha; Lea, Wendy A.; Maloney, David J.; Shen, Min; Rai, Ganesha; Battaile, Kevin P.; Thomas, Craig J.; Simeonov, Anton; Hanzlik, Robert P.; Inglese, James</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4878-4883, S4878/1-S4878/14</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Firefly luciferase (FLuc), an ATP-dependent bioluminescent reporter enzyme, is broadly used in chem. biol. and drug discovery assays.  PTC124 (Ataluren; (3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid)) discovered in an FLuc-based assay targeting nonsense codon suppression, is an unusually potent FLuc-inhibitor.  Paradoxically, PTC124 and related analogs increase cellular FLuc activity levels by posttranslational stabilization.  In this study, we show that FLuc inhibition and stabilization is the result of an inhibitory product formed during the FLuc-catalyzed reaction between its natural substrate, ATP, and PTC124.  A 2.0 Å cocrystal structure revealed the inhibitor to be the acyl-AMP mixed-anhydride adduct PTC124-AMP, which was subsequently synthesized and shown to be a high-affinity multisubstrate adduct inhibitor (MAI; KD = 120 pM) of FLuc.  Biochem. assays, liq. chromatog./mass spectrometry, and near-attack conformer modeling demonstrate that formation of this novel MAI is absolutely dependent upon the precise positioning and reactivity of a key meta-carboxylate of PTC124 within the FLuc active site.  We also demonstrate that the inhibitory activity of PTC124-AMP is relieved by free CoA, a component present at high concns. in luciferase detection reagents used for cell-based assays.  This explains why PTC124 can appear to increase, instead of inhibit, FLuc activity in cell-based reporter gene assays.  To our knowledge, this is an unusual example in which the "off-target" effect of a small mol. is mediated by an MAI mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIPfC1eBndl7Vg90H21EOLACvtfcHk0lihYCbqCFSx6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFaqsbo%253D&md5=e22180fb96672f3fa7cdc907b7ada4fe</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0909141107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0909141107%26sid%3Dliteratum%253Aachs%26aulast%3DAuld%26aufirst%3DD.%2BS.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DThorne%26aufirst%3DN.%26aulast%3DLea%26aufirst%3DW.%2BA.%26aulast%3DMaloney%26aufirst%3DD.%2BJ.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DRai%26aufirst%3DG.%26aulast%3DBattaile%26aufirst%3DK.%2BP.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DHanzlik%26aufirst%3DR.%2BP.%26aulast%3DInglese%26aufirst%3DJ.%26atitle%3DMolecular%2520Basis%2520for%2520the%2520High-Affinity%2520Binding%2520and%2520Stabilization%2520of%2520Firefly%2520Luciferase%2520by%2520PTC124%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D4878%26epage%3D4883%26doi%3D10.1073%2Fpnas.0909141107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melfi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leonardo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo
Piccionello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pibiri, I.</span></span> <span> </span><span class="NLM_article-title">Toward a Rationale for the PTC124 (Ataluren) Promoted Readthrough of Premature Stop Codons: A Computational Approach and GFP-Reporter Cell-Based Assay</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1021/mp400230s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400230s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsF2mtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=653-664&author=L.+Lentiniauthor=R.+Melfiauthor=A.+Di+Leonardoauthor=A.+Spinelloauthor=G.+Baroneauthor=A.+Paceauthor=A.+Palumbo%0APiccionelloauthor=I.+Pibiri&title=Toward+a+Rationale+for+the+PTC124+%28Ataluren%29+Promoted+Readthrough+of+Premature+Stop+Codons%3A+A+Computational+Approach+and+GFP-Reporter+Cell-Based+Assay&doi=10.1021%2Fmp400230s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay</span></div><div class="casAuthors">Lentini, Laura; Melfi, Raffaella; Di Leonardo, Aldo; Spinello, Angelo; Barone, Giampaolo; Pace, Andrea; Palumbo Piccionello, Antonio; Pibiri, Ivana</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">653-664</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The presence in the mRNA of premature stop codons (PTCs) results in protein truncation responsible for several inherited (genetic) diseases.  A well-known example of these diseases is cystic fibrosis (CF), where approx. 10% (worldwide) of patients have nonsense mutations in the CF transmembrane regulator (CFTR) gene.  PTC124 (3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-benzoic acid), also known as Ataluren, is a small mol. that has been suggested to allow PTC readthrough even though its target has yet to be identified.  In the lack of a general consensus about its mechanism of action, we exptl. tested the ability of PTC124 to promote the readthrough of premature termination codons by using a new reporter.  The reporter vector was based on a plasmid harboring the H2B histone coding sequence fused in frame with the green fluorescent protein (GFP) cDNA, and a TGA stop codon was introduced in the H2B-GFP gene by site-directed mutagenesis.  Addnl., an unprecedented computational study on the putative supramol. interaction between PTC124 and an 11-codon (33-nucleotides) sequence corresponding to a CFTR mRNA fragment contg. a central UGA nonsense mutation showed a specific interaction between PTC124 and the UGA codon.  Altogether, the H2B-GFP-opal based assay and the mol. dynamics (MD) simulation support the hypothesis that PTC124 is able to promote the specific readthrough of internal TGA premature stop codons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoMyq0NCLi-rVg90H21EOLACvtfcHk0lihYCbqCFSx6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsF2mtrg%253D&md5=9db7ec531aa57c1e0c376d05612bfd2f</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1021%2Fmp400230s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400230s%26sid%3Dliteratum%253Aachs%26aulast%3DLentini%26aufirst%3DL.%26aulast%3DMelfi%26aufirst%3DR.%26aulast%3DDi%2BLeonardo%26aufirst%3DA.%26aulast%3DSpinello%26aufirst%3DA.%26aulast%3DBarone%26aufirst%3DG.%26aulast%3DPace%26aufirst%3DA.%26aulast%3DPalumbo%2BPiccionello%26aufirst%3DA.%26aulast%3DPibiri%26aufirst%3DI.%26atitle%3DToward%2520a%2520Rationale%2520for%2520the%2520PTC124%2520%2528Ataluren%2529%2520Promoted%2520Readthrough%2520of%2520Premature%2520Stop%2520Codons%253A%2520A%2520Computational%2520Approach%2520and%2520GFP-Reporter%2520Cell-Based%2520Assay%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D653%26epage%3D664%26doi%3D10.1021%2Fmp400230s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damoiseaux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henning, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, R. A.</span></span> <span> </span><span class="NLM_article-title">Nonaminoglycoside Compounds Induce Readthrough of Nonsense Mutations</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>206</i></span>,  <span class="NLM_fpage">2285</span>– <span class="NLM_lpage">2297</span>, <span class="refDoi"> DOI: 10.1084/jem.20081940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1084%2Fjem.20081940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19770270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1SrtbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=2009&pages=2285-2297&author=L.+Duauthor=R.+Damoiseauxauthor=S.+Nahasauthor=K.+Gaoauthor=H.+Huauthor=J.+M.+Pollardauthor=J.+Goldstineauthor=M.+E.+Jungauthor=S.+M.+Henningauthor=C.+Bertoniauthor=R.+A.+Gatti&title=Nonaminoglycoside+Compounds+Induce+Readthrough+of+Nonsense+Mutations&doi=10.1084%2Fjem.20081940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Nonaminoglycoside compounds induce readthrough of nonsense mutations</span></div><div class="casAuthors">Du, Liutao; Damoiseaux, Robert; Nahas, Shareef; Gao, Kun; Hu, Hailiang; Pollard, Julianne M.; Goldstine, Jimena; Jung, Michael E.; Henning, Susanne M.; Bertoni, Carmen; Gatti, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2285-2297</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Large nos. of genetic disorders are caused by nonsense mutations for which compd.-induced readthrough of premature termination codons (PTCs) might be exploited as a potential treatment strategy.  We have successfully developed a sensitive and quant. high-throughput screening (HTS) assay, protein transcription/translation (PTT)-ELISA, for identifying novel PTC-readthrough compds. using ataxia-telangiectasia (A-T) as a genetic disease model.  This HTS PTT-ELISA assay is based on a coupled PTT that uses plasmid templates contg. prototypic A-T mutated (ATM) mutations for HTS.  The assay is luciferase independent.  We screened ∼34,000 compds. and identified 12 low-mol.-mass nonaminoglycosides with potential PTC-readthrough activity.  From these, two leading compds. consistently induced functional ATM protein in ATM-deficient cells contg. disease-causing nonsense mutations, as demonstrated by direct measurement of ATM protein, restored ATM kinase activity, and colony survival assays for cellular radiosensitivity.  The two compds. also demonstrated readthrough activity in mdx mouse myotube cells carrying a nonsense mutation and induced significant amts. of dystrophin protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpsc57CownCbVg90H21EOLACvtfcHk0ljrNmyz_C6csw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1SrtbnI&md5=4bc19a6fde2c6fa1e66130ff622bd894</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1084%2Fjem.20081940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20081940%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DL.%26aulast%3DDamoiseaux%26aufirst%3DR.%26aulast%3DNahas%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DPollard%26aufirst%3DJ.%2BM.%26aulast%3DGoldstine%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DHenning%26aufirst%3DS.%2BM.%26aulast%3DBertoni%26aufirst%3DC.%26aulast%3DGatti%26aufirst%3DR.%2BA.%26atitle%3DNonaminoglycoside%2520Compounds%2520Induce%2520Readthrough%2520of%2520Nonsense%2520Mutations%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2009%26volume%3D206%26spage%3D2285%26epage%3D2297%26doi%3D10.1084%2Fjem.20081940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kayali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khitrov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prikhodko, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, C.</span></span> <span> </span><span class="NLM_article-title">Read-through Compound 13 Restores Dystrophin Expression and Improves Muscle Function in the Mdx Mouse Model for Duchenne Muscular Dystrophy</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4007</span>– <span class="NLM_lpage">4020</span>, <span class="refDoi"> DOI: 10.1093/hmg/dds223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1093%2Fhmg%2Fdds223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22692682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yntr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=4007-4020&author=R.+Kayaliauthor=J.-M.+Kuauthor=G.+Khitrovauthor=M.+E.+Jungauthor=O.+Prikhodkoauthor=C.+Bertoni&title=Read-through+Compound+13+Restores+Dystrophin+Expression+and+Improves+Muscle+Function+in+the+Mdx+Mouse+Model+for+Duchenne+Muscular+Dystrophy&doi=10.1093%2Fhmg%2Fdds223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy</span></div><div class="casAuthors">Kayali, Refik; Ku, Jin-Mo; Khitrov, Gregory; Jung, Michael E.; Prikhodko, Olga; Bertoni, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4007-4020</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Mols. that induce ribosomal read-through of nonsense mutations in mRNA and allow prodn. of a full-length functional protein hold great therapeutic potential for the treatment of many genetic disorders.  Two such read-through compds., RTC13 and RTC14, were recently identified by a luciferase-independent high-throughput screening assay and were shown to have potential therapeutic functions in the treatment of nonsense mutations in the ATM and the dystrophin genes.  We have now tested the ability of RTC13 and RTC14 to restore dystrophin expression into skeletal muscles of the mdx mouse model for Duchenne muscular dystrophy (DMD).  Direct i.m. injection of compd. RTC14 did not result in significant read-through activity in vivo and demonstrated the levels of dystrophin protein similar to those detected using gentamicin.  In contrast, significant higher amts. of dystrophin were detected after i.m. injection of RTC13.  When administered systemically, RTC13 was shown to partially restore dystrophin protein in different muscle groups, including diaphragm and heart, and improved muscle function.  An increase in muscle strength was detected in all treated animals and was accompanied by a significant decrease in creatine kinase levels.  These studies establish the therapeutic potential of RTC13 in vivo and advance this newly identified compd. into preclin. application for DMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa4PAhMiCO-bVg90H21EOLACvtfcHk0ljrNmyz_C6csw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yntr3L&md5=75c2b41df1bb6d0465e75b518143578f</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fdds223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fdds223%26sid%3Dliteratum%253Aachs%26aulast%3DKayali%26aufirst%3DR.%26aulast%3DKu%26aufirst%3DJ.-M.%26aulast%3DKhitrov%26aufirst%3DG.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DPrikhodko%26aufirst%3DO.%26aulast%3DBertoni%26aufirst%3DC.%26atitle%3DRead-through%2520Compound%252013%2520Restores%2520Dystrophin%2520Expression%2520and%2520Improves%2520Muscle%2520Function%2520in%2520the%2520Mdx%2520Mouse%2520Model%2520for%2520Duchenne%2520Muscular%2520Dystrophy%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2012%26volume%3D21%26spage%3D4007%26epage%3D4020%26doi%3D10.1093%2Fhmg%2Fdds223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damoiseaux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Completo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fike, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, R. A.</span></span> <span> </span><span class="NLM_article-title">A New Series of Small Molecular Weight Compounds Induce Read through of All Three Types of Nonsense Mutations in the ATM Gene</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1653</span>– <span class="NLM_lpage">1660</span>, <span class="refDoi"> DOI: 10.1038/mt.2013.150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fmt.2013.150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=23774824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12is7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=1653-1660&author=L.+Duauthor=M.+E.+Jungauthor=R.+Damoiseauxauthor=G.+Completoauthor=F.+Fikeauthor=J.+M.+Kuauthor=S.+Nahasauthor=C.+Piaoauthor=H.+Huauthor=R.+A.+Gatti&title=A+New+Series+of+Small+Molecular+Weight+Compounds+Induce+Read+through+of+All+Three+Types+of+Nonsense+Mutations+in+the+ATM+Gene&doi=10.1038%2Fmt.2013.150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">A New Series of Small Molecular Weight Compounds Induce Read Through of All Three Types of Nonsense Mutations in the ATM Gene</span></div><div class="casAuthors">Du, Liutao; Jung, Michael E.; Damoiseaux, Robert; Completo, Gladys; Fike, Francesca; Ku, Jin-Mo; Nahas, Shareef; Piao, Cijing; Hu, Hailiang; Gatti, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1653-1660</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chem.-induced read through of premature stop codons might be exploited as a potential treatment strategy for genetic disorders caused by nonsense mutations.  Despite the promise of this approach, only a few read-through compds. (RTCs) have been discovered to date.  These include aminoglycosides (e.g., gentamicin and G418) and nonaminoglycosides (e.g., PTC124 and RTC13).  The therapeutic benefits of these RTCs remain to be detd.  In an effort to find new RTCs, we screened an addnl. ∼36,000 small mol. wt. compds. using a high-throughput screening (HTS) assay that we had previously developed and identified two novel RTCs, GJ071, and GJ072.  The activity of these two compds. was confirmed in cells derived from ataxia telangiectasia (A-T) patients with three different types of nonsense mutation in the ATM gene.  Both compds. showed activity comparable to stop codons (TGA, TAG, and TAA) PTC124 and RTC13.  Early structure-activity relationship studies generated eight active analogs of GJ072.  Most of those analogs were effective on all three stop codons.  GJ071 and GJ072, and some of the GJ072 analogs, appeared to be well tolerated by A-T cells.  We also identified another two active RTCs in the primary screen, RTC204 and RTC219, which share a key structural feature with GJ072 and its analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7y6ey8JUWZ7Vg90H21EOLACvtfcHk0ljrNmyz_C6csw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12is7%252FK&md5=f012fa596ae8f63c503a255d7e1ba046</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1038%2Fmt.2013.150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2013.150%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DL.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DDamoiseaux%26aufirst%3DR.%26aulast%3DCompleto%26aufirst%3DG.%26aulast%3DFike%26aufirst%3DF.%26aulast%3DKu%26aufirst%3DJ.%2BM.%26aulast%3DNahas%26aufirst%3DS.%26aulast%3DPiao%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DGatti%26aufirst%3DR.%2BA.%26atitle%3DA%2520New%2520Series%2520of%2520Small%2520Molecular%2520Weight%2520Compounds%2520Induce%2520Read%2520through%2520of%2520All%2520Three%2520Types%2520of%2520Nonsense%2520Mutations%2520in%2520the%2520ATM%2520Gene%26jtitle%3DMol.%2520Ther.%26date%3D2013%26volume%3D21%26spage%3D1653%26epage%3D1660%26doi%3D10.1038%2Fmt.2013.150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomašić, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterlin Mašič, L.</span></span> <span> </span><span class="NLM_article-title">Rhodanine as a Scaffold in Drug Discovery: A Critical Review of Its Biological Activities and Mechanisms of Target Modulation</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">560</span>, <span class="refDoi"> DOI: 10.1517/17460441.2012.688743</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1517%2F17460441.2012.688743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22607309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38XptFWmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=549-560&author=T.+Toma%C5%A1i%C4%87author=L.+Peterlin+Ma%C5%A1i%C4%8D&title=Rhodanine+as+a+Scaffold+in+Drug+Discovery%3A+A+Critical+Review+of+Its+Biological+Activities+and+Mechanisms+of+Target+Modulation&doi=10.1517%2F17460441.2012.688743"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation</span></div><div class="casAuthors">Tomasic, Tihomir; Peterlin Masic, Lucija</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">549-560</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Rhodanine-based compds. have been assocd. with numerous biol. activities.  After many years of research in drug discovery, they have gained a reputation as being pan assay interference compds. (PAINS) and frequent hitters in screening campaigns.  Rhodanine-based compds. are also aggregators that can non-specifically interact with target proteins as well as Michael acceptors and interfere photometrically in biol. assays due to their color.Areas covered: The authors review the recently reported biol. activities of rhodanine-based compds.  Furthermore, the article provides details of their synthesis and occurrence in compd. libraries through high-throughput screening (HTS) and virtual high-throughput screening (VHTS).  Addnl., the authors provide the reader with possible mechanisms of non-specific target modulation, anal. of the crystal structures of enzyme-rhodanine complexes and a comparison of rhodanine and thiazolidine-2,4-dione moieties.Expert opinion: The biol. activity of compds. possessing a rhodanine moiety should be considered very critically despite the convincing data obtained in biol. assays.  In addn. to the lack of selectivity, unusual structure-activity relationship profiles and safety and specificity problems mean that rhodanines are generally not optimizable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorolVH32PdC7Vg90H21EOLACvtfcHk0lhjB8Qcvo758A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptFWmtLw%253D&md5=a02e78c0c7788aaeb044f3753c901117</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1517%2F17460441.2012.688743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2012.688743%26sid%3Dliteratum%253Aachs%26aulast%3DToma%25C5%25A1i%25C4%2587%26aufirst%3DT.%26aulast%3DPeterlin%2BMa%25C5%25A1i%25C4%258D%26aufirst%3DL.%26atitle%3DRhodanine%2520as%2520a%2520Scaffold%2520in%2520Drug%2520Discovery%253A%2520A%2520Critical%2520Review%2520of%2520Its%2520Biological%2520Activities%2520and%2520Mechanisms%2520of%2520Target%2520Modulation%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D549%26epage%3D560%26doi%3D10.1517%2F17460441.2012.688743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+Screening+Libraries+and+for+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lhjB8Qcvo758A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalia  Kleczewska</span>, <span class="hlFld-ContribAuthor ">Pawel J.  Sikorski</span>, <span class="hlFld-ContribAuthor ">Zofia  Warminska</span>, <span class="hlFld-ContribAuthor ">Lukasz  Markiewicz</span>, <span class="hlFld-ContribAuthor ">Renata  Kasprzyk</span>, <span class="hlFld-ContribAuthor ">Natalia  Baran</span>, <span class="hlFld-ContribAuthor ">Karina  Kwapiszewska</span>, <span class="hlFld-ContribAuthor ">Aneta  Karpinska</span>, <span class="hlFld-ContribAuthor ">Jaroslaw  Michalski</span>, <span class="hlFld-ContribAuthor ">Robert  Holyst</span>, <span class="hlFld-ContribAuthor ">Joanna  Kowalska</span>, <span class="hlFld-ContribAuthor ">Jacek  Jemielity</span>. </span><span class="cited-content_cbyCitation_article-title">Cellular delivery of dinucleotides by conjugation with small molecules: targeting translation initiation for anticancer applications. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2021,</strong> <em>162 </em><a href="https://doi.org/10.1039/D1SC02143E" title="DOI URL">https://doi.org/10.1039/D1SC02143E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1SC02143E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1SC02143E%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DCellular%252Bdelivery%252Bof%252Bdinucleotides%252Bby%252Bconjugation%252Bwith%252Bsmall%252Bmolecules%25253A%252Btargeting%252Btranslation%252Binitiation%252Bfor%252Banticancer%252Bapplications%26aulast%3DKleczewska%26aufirst%3DNatalia%26date%3D2021%26date%3D2021%26volume%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected translation inhibitors with various mechanisms of action and species selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Eukaryotic translation initiation and subsequent translation elongation cycle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Peptidyl transfer in the ribosome during eukaryotic translation elongation. eEF1A delivers amino acyl-tRNA to the A-site of the 80S ribosome complex. GTP is hydrolyzed, and eEF1A is released. Peptidyl transfer takes place, during which the nucleophilic tRNA in the A-site attacks the electrophilic peptidyl-tRNA in the P-site. eEF2 mediates transposition of the tRNAs during which GTP is hydrolyzed. Once the stop codon has been reached, ERFs bind in the A-site and assist with release of the completed peptide chain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Structure of rocaglamide A (<b>7</b>). (B) Co-crystal structure of the eIF4A·AMPPNP·RocA·polypurine complex (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZC9">5ZC9</a>). (C) Co-crystal structure of the eIF4A·AMPPNP·RocA·polypurine complex highlighting key binding interactions. Gray = rRNA base; green = eIF4A protein; teal = RocA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of synthetic rocaglamide analogues CR-1-31-B (<b>10</b>), CMLD012612 (<b>11</b>), Zotatifin (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of eIF1A inhibitors pateamine A (PatA, <b>11</b>), synthetic analogue of PatA DMDAPatA (<b>12</b>), and hippuristanol (<b>13</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Chemical structure of mRNA 5′-7-methylguanylate (m7G) cap. (B) <i>In vivo</i> transformation of ribavirin (<b>15</b>) to predicted active metabolite RTP (<b>16</b>). (C) Cocrystal structure of m7G bound to eIF4E (PDB: IL8B). (C) eIF4E inhibitors ribavirin (<b>15</b>) and ribavirin triphosphate (RTP, <b>16</b>) and (D) Rib4C (<b>17</b>) and tiazafurin (<b>18</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Structures of synthetic 5′-7-methylguanosine cap mimetics <b>19</b> and <b>20</b>. (B) Cocrystal structure of eIF4A with 7Bn-GMP (<b>19</b>) (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V8X">2V8X</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Structures of covalent eIF4E inhibitors. (B) Cocrystal structure of <b>21</b> bound to eIF4E via covalent bond to Lys162 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UO9">6UO9</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of synthetic eIF4E inhibitors 4EGI-1 (<b>23</b>), 4E1RCat (<b>24</b>), and 4E2RCat (<b>25</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Cocrystal structure of 4EGI-1 bound to eIF4E (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4TPW">4TPW</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Molecular structures of members of the didemnin class of natural products didemnin A (<b>26</b>), didemnin B (<b>27</b>), <b>28</b>, and dehydrodidemnin B (plitidepsin) (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structures of didemnin B bound to eEF1A (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LZS">5LZS</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structure of nannocyctin A (<b>29</b>) and synthetic derivative LQ18 (<b>30</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Ternatin (<b>31</b>) and synthetic derivative (<b>32</b>) with improved antiproliferative activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Other potential eEF1A binding molecules ansatrienin A (<b>33</b>) and nasiclasine (<b>34</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Eukaryotic 80S ribosome complex during elongation (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4UJE">4UJE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Base-catalyzed mechanism of peptidyl transfer in the peptidyl transfer center of the ribosome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. (A) Structure of naturally occurring cephalotaxine natural products and clinical used analogue HHT (<b>1</b>). (B) Cryo-EM structure indicating the binding site and key interactions with rRNA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. (A) Structure of naturally occurring alegestatin A (<b>39</b>) and synthetic analogue <b>40</b>. (B) Cryo-EM structure indicating the binding site and key interactions with rRNA (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MEI">5MEI</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structure of naturally occurring translation inhibitors mycalamide A (<b>41</b>) and mycalamide B (<b>42</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Structures of transcript-selective ribosome binding small molecules.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structures of PF846 bound to ribosome-RNC complexes. (A) PCSK9 nascent chain residues Pro25-Ala26 interacting with PF846 at the dipeptide (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OM0">6OM0</a>). (B) CDH1 nascent chain residues Leu721-ILeu723 interacting with PF846 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OLE">6OLE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structure of common aminoglycosides with 2-deoxystrepatmine (2-DOS) ring highlighted in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structures of aminoglycosides bound to ribosomal A-site in prokaryotes and eukaryotes. (A) X-ray crystal structure of paromomycin (teal) bound to the yeast 80S ribosome (magenta) (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NDV">5NDV</a>) overlaid with X-ray crystal structure of paromomycin (green) bound to the <i>Thermus thermophilus</i> 70S ribosome (gray) (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4V51">4V51</a>). (B) X-ray crystal structure of geneticin (blue) bound to the yeast 80S ribosome (magenta) (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OBM">5OBM</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structure synthetic aminoglycoside (<i>S</i>)-11 (<b>50</b>), which displays greater selectivity for the eukaryotic ribosome over mitochondrial ribosome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/medium/jm0c01746_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structure of small molecules reported to induce PTC readthrough.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01746/20210305/images/large/jm0c01746_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01746&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i27">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33178" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33178" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 232 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, N. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentaõ, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, R. B.</span></span> <span> </span><span class="NLM_article-title">Plitidepsin to Treat Multiple Myeloma</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1358/dot.2020.56.5.3135886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1358%2Fdot.2020.56.5.3135886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BB38vmvVahug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=337-347&author=N.+G.+M.+Gomesauthor=P.+Valenta%C3%B5author=P.+B.+Andradeauthor=R.+B.+Pereira&title=Plitidepsin+to+Treat+Multiple+Myeloma&doi=10.1358%2Fdot.2020.56.5.3135886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Plitidepsin to treat multiple myeloma</span></div><div class="casAuthors">Gomes N G M; Valentao P; Andrade P B; Pereira R B</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">337-347</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">While remaining relatively rare, multiple myeloma (MM) accounts for approximately 10% of all hematological malignancies, being an insidious disease with an overall 5-year survival rate of 52%.  In addition to other associated complications, myeloma bone disease further aggravates MM patients, the majority of whom suffer from lytic lesions, leading to pain, fractures, mobility issues and neurological deficits.  Patients not responding or becoming resistant to prior therapies have now a novel therapeutic tool with an unprecedent mode of action, differing from those currently in use.  The anticancer effects of the marine-derived antitumor agent plitidepsin primarily rely on the interaction with elongation factor 1-α 2 (eEF1A2), known to be overexpressed in breast cancer and MM cells, targeting the noncanonical role of the protein and leading to a proapoptotic response.  Following the drug's approval from Australian regulatory authorities, eligible patients will have access to a new first-in-class drug to treat MM, expanding the current anti-MM portfolio.  Plitidepsin (Aplidin; PharmaMar) was approved in combination with the corticosteroid agent dexamethasone, to treat MM patients who failed or became resistant to other therapies, covering the third- and fourth-line treatment setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJU-wjw_aULWlSCSgBhwJFfW6udTcc2eYg9ZrWedn2rrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38vmvVahug%253D%253D&md5=15b7e65e4a4794c5a79a28a1aaa60d38</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1358%2Fdot.2020.56.5.3135886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2020.56.5.3135886%26sid%3Dliteratum%253Aachs%26aulast%3DGomes%26aufirst%3DN.%2BG.%2BM.%26aulast%3DValenta%25C3%25B5%26aufirst%3DP.%26aulast%3DAndrade%26aufirst%3DP.%2BB.%26aulast%3DPereira%26aufirst%3DR.%2BB.%26atitle%3DPlitidepsin%2520to%2520Treat%2520Multiple%2520Myeloma%26jtitle%3DDrugs%2520Today%26date%3D2020%26volume%3D56%26spage%3D337%26epage%3D347%26doi%3D10.1358%2Fdot.2020.56.5.3135886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajasekhar, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanghvi, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavrakis, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roderick, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Meulen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teruya-Feldstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelliher, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speleman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rätsch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendel, H. G.</span></span> <span> </span><span class="NLM_article-title">RNA G-Quadruplexes Cause EIF4A-Dependent Oncogene Translation in Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1038/nature13485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnature13485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25079319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyhurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2014&pages=65-70&author=A.+L.+Wolfeauthor=K.+Singhauthor=Y.+Zhongauthor=P.+Dreweauthor=V.+K.+Rajasekharauthor=V.+R.+Sanghviauthor=K.+J.+Mavrakisauthor=M.+Jiangauthor=J.+E.+Roderickauthor=J.+Van+der+Meulenauthor=J.+H.+Schatzauthor=C.+M.+Rodrigoauthor=C.+Zhaoauthor=P.+Rondouauthor=E.+de+Stanchinaauthor=J.+Teruya-Feldsteinauthor=M.+A.+Kelliherauthor=F.+Spelemanauthor=J.+A.+Porcoauthor=J.+Pelletierauthor=G.+R%C3%A4tschauthor=H.+G.+Wendel&title=RNA+G-Quadruplexes+Cause+EIF4A-Dependent+Oncogene+Translation+in+Cancer&doi=10.1038%2Fnature13485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer</span></div><div class="casAuthors">Wolfe, Andrew L.; Singh, Kamini; Zhong, Yi; Drewe, Philipp; Rajasekhar, Vinagolu K.; Sanghvi, Viraj R.; Mavrakis, Konstantinos J.; Jiang, Man; Roderick, Justine E.; Van der Meulen, Joni; Schatz, Jonathan H.; Rodrigo, Christina M.; Zhao, Chunying; Rondou, Pieter; de Stanchina, Elisa; Teruya-Feldstein, Julie; Kelliher, Michelle A.; Speleman, Frank; Porco, John A.; Pelletier, Jerry; Ratsch, Gunnar; Wendel, Hans-Guido</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue">7516</span>),
    <span class="NLM_cas:pages">65-70</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The translational control of oncoprotein expression is implicated in many cancers.  Here the authors report an eIF4A RNA helicase-dependent mechanism of translational control that contributes to oncogenesis and underlies the anticancer effects of silvestrol and related compds.  For example, eIF4A promotes T-cell acute lymphoblastic leukemia development in vivo and is required for leukemia maintenance.  Accordingly, inhibition of eIF4A with silvestrol has powerful therapeutic effects against murine and human leukemic cells in vitro and in vivo.  The authors use transcriptome-scale ribosome footprinting to identify the hallmarks of eIF4A-dependent transcripts.  These include 5' untranslated region (UTR) sequences such as the 12-nucleotide guanine quartet (CGG)4 motif that can form RNA G-quadruplex structures.  Notably, among the most eIF4A-dependent and silvestrol-sensitive transcripts are a no. of oncogenes, superenhancer-assocd. transcription factors, and epigenetic regulators.  Hence, the 5' UTRs of select cancer genes harbor a targetable requirement for the eIF4A RNA helicase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OIvvYHwn7rVg90H21EOLACvtfcHk0lguNAaJmxD1tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyhurvI&md5=8c0a22a542cac567f1ec1340b195680d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature13485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13485%26sid%3Dliteratum%253Aachs%26aulast%3DWolfe%26aufirst%3DA.%2BL.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DDrewe%26aufirst%3DP.%26aulast%3DRajasekhar%26aufirst%3DV.%2BK.%26aulast%3DSanghvi%26aufirst%3DV.%2BR.%26aulast%3DMavrakis%26aufirst%3DK.%2BJ.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DRoderick%26aufirst%3DJ.%2BE.%26aulast%3DVan%2Bder%2BMeulen%26aufirst%3DJ.%26aulast%3DSchatz%26aufirst%3DJ.%2BH.%26aulast%3DRodrigo%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DRondou%26aufirst%3DP.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DTeruya-Feldstein%26aufirst%3DJ.%26aulast%3DKelliher%26aufirst%3DM.%2BA.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DR%25C3%25A4tsch%26aufirst%3DG.%26aulast%3DWendel%26aufirst%3DH.%2BG.%26atitle%3DRNA%2520G-Quadruplexes%2520Cause%2520EIF4A-Dependent%2520Oncogene%2520Translation%2520in%2520Cancer%26jtitle%3DNature%26date%3D2014%26volume%3D513%26spage%3D65%26epage%3D70%26doi%3D10.1038%2Fnature13485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Truitt, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span> <span> </span><span class="NLM_article-title">New Frontiers in Translational Control of the Cancer Genome</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnrc.2016.27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27112207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Omsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=288-304&author=M.+L.+Truittauthor=D.+Ruggero&title=New+Frontiers+in+Translational+Control+of+the+Cancer+Genome&doi=10.1038%2Fnrc.2016.27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">New frontiers in translational control of the cancer genome</span></div><div class="casAuthors">Truitt, Morgan L.; Ruggero, Davide</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">288-304</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past several years have seen dramatic leaps in our understanding of how gene expression is rewired at the translation level during tumorigenesis to support the transformed phenotype.  This work has been driven by an explosion in technol. advances and is revealing previously unimagined regulatory mechanisms that dictate functional expression of the cancer genome.  In this Review we discuss emerging trends and exciting new discoveries that reveal how this translational circuitry contributes to specific aspects of tumorigenesis and cancer cell function, with a particular focus on recent insights into the role of translational control in the adaptive response to oncogenic stress conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWAtdm1QpVuLVg90H21EOLACvtfcHk0lguNAaJmxD1tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Omsr0%253D&md5=ed2f746a30588ab8c00022d696861ceb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.27%26sid%3Dliteratum%253Aachs%26aulast%3DTruitt%26aufirst%3DM.%2BL.%26aulast%3DRuggero%26aufirst%3DD.%26atitle%3DNew%2520Frontiers%2520in%2520Translational%2520Control%2520of%2520the%2520Cancer%2520Genome%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D288%26epage%3D304%26doi%3D10.1038%2Fnrc.2016.27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerezo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guemiri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druillennec, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girault, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malka-Mahieu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martineau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agoussi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libenciuc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scoazec, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eychène, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span> <span> </span><span class="NLM_article-title">Translational Control of Tumor Immune Escape via the EIF4F–STAT1–PD-L1 Axis in Melanoma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1877</span>– <span class="NLM_lpage">1886</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0217-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41591-018-0217-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30374200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVCit7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=1877-1886&author=M.+Cerezoauthor=R.+Guemiriauthor=S.+Druillennecauthor=I.+Giraultauthor=H.+Malka-Mahieuauthor=S.+Shenauthor=D.+Allardauthor=S.+Martineauauthor=C.+Welschauthor=S.+Agoussiauthor=C.+Estradaauthor=J.+Adamauthor=C.+Libenciucauthor=E.+Routierauthor=S.+Royauthor=L.+D%C3%A9saubryauthor=A.+M.+Eggermontauthor=N.+Sonenbergauthor=J.+Y.+Scoazecauthor=A.+Eych%C3%A8neauthor=S.+Vagnerauthor=C.+Robert&title=Translational+Control+of+Tumor+Immune+Escape+via+the+EIF4F%E2%80%93STAT1%E2%80%93PD-L1+Axis+in+Melanoma&doi=10.1038%2Fs41591-018-0217-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma</span></div><div class="casAuthors">Cerezo, Michael; Guemiri, Ramdane; Druillennec, Sabine; Girault, Isabelle; Malka-Mahieu, Helene; Shen, Shensi; Allard, Delphine; Martineau, Sylvain; Welsch, Caroline; Agoussi, Sandrine; Estrada, Charlene; Adam, Julien; Libenciuc, Cristina; Routier, Emilie; Roy, Severine; Desaubry, Laurent; Eggermont, Alexander M.; Sonenberg, Nahum; Scoazec, Jean Yves; Eychene, Alain; Vagner, Stephan; Robert, Caroline</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1877-1886</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Preventing the immune escape of tumor cells by blocking inhibitory checkpoints, such as the interaction between programmed death ligand-1 (PD-L1) and programmed death-1 (PD-1) receptor, is a powerful anticancer approach.  However, many patients do not respond to checkpoint blockade.  Tumor PD-L1 expression is a potential efficacy biomarker, but the complex mechanisms underlying its regulation are not completely understood.  Here, we show that the eukaryotic translation initiation complex, eIF4F, which binds the 5' cap of mRNAs, regulates the surface expression of interferon-γ-induced PD-L1 on cancer cells by regulating translation of the mRNA encoding the signal transducer and activator of transcription 1 (STAT1) transcription factor.  EIF4F complex formation correlates with response to immunotherapy in human melanoma.  Pharmacol. inhibition of eIF4A, the RNA helicase component of eIF4F, elicits powerful antitumor immune-mediated effects via PD-L1 downregulation.  Thus, eIF4A inhibitors, in development as anticancer drugs, may also act as cancer immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaq-cWIjgFfrVg90H21EOLACvtfcHk0lhsDZL2uR2AZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVCit7fI&md5=abce1ed237bb9b9b69b7ecabaf2f711a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0217-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0217-1%26sid%3Dliteratum%253Aachs%26aulast%3DCerezo%26aufirst%3DM.%26aulast%3DGuemiri%26aufirst%3DR.%26aulast%3DDruillennec%26aufirst%3DS.%26aulast%3DGirault%26aufirst%3DI.%26aulast%3DMalka-Mahieu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DAllard%26aufirst%3DD.%26aulast%3DMartineau%26aufirst%3DS.%26aulast%3DWelsch%26aufirst%3DC.%26aulast%3DAgoussi%26aufirst%3DS.%26aulast%3DEstrada%26aufirst%3DC.%26aulast%3DAdam%26aufirst%3DJ.%26aulast%3DLibenciuc%26aufirst%3DC.%26aulast%3DRoutier%26aufirst%3DE.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DScoazec%26aufirst%3DJ.%2BY.%26aulast%3DEych%25C3%25A8ne%26aufirst%3DA.%26aulast%3DVagner%26aufirst%3DS.%26aulast%3DRobert%26aufirst%3DC.%26atitle%3DTranslational%2520Control%2520of%2520Tumor%2520Immune%2520Escape%2520via%2520the%2520EIF4F%25E2%2580%2593STAT1%25E2%2580%2593PD-L1%2520Axis%2520in%2520Melanoma%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D1877%26epage%3D1886%26doi%3D10.1038%2Fs41591-018-0217-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, D.</span></span> <span> </span><span class="NLM_article-title">Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">6462</span>– <span class="NLM_lpage">6473</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01159</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01159" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=6462-6473&author=P.+Fernandesauthor=D.+Pereiraauthor=P.+B.+Watkinsauthor=D.+Bertrand&title=Differentiating+the+Pharmacodynamics+and+Toxicology+of+Macrolide+and+Ketolide+Antibiotics&doi=10.1021%2Facs.jmedchem.9b01159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics</span></div><div class="casAuthors">Fernandes, Prabhavathi; Pereira, David; Watkins, Paul B.; Bertrand, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6462-6473</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This is a review of the macrolide and ketolide field focusing on differentiating the pharmacodynamics and esp. the toxicol. of the macrolides and ketolides.  We emphasize the diversity in pharmacodynamics and toxicity of the macrolides and ketolides, resulting from even small structural changes, which makes it important to consider the various different compds. sep., not necessarily as a class.  The ketolide, telithromycin, was developed because of rising bacterial macrolide resistance, but was withdrawn post-approval after visual disturbances, syncope, Myasthenia Gravis and hepatotoxicity were noted.  These diverse adverse effects could be attributed to inhibition of nicotinic acetylcholine receptors.  Solithromycin, a later generation ketolide, was effective in treating bacterial pneumonia but it was not approved by the U.S. Food and Drug Administration owing, in part, to its structural similarity to telithromycin.  This mini-perspective describes that structurally similar macrolides/ketolides have clearly mechanistically distinct effects.  Understanding these effects could help in developing and securing regulatory approval of a new macrolide/ketolide that is active against macrolide-resistant pathogenic bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBIMPU7y6m_bVg90H21EOLACvtfcHk0lhsDZL2uR2AZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajt7rK&md5=dbb872200e3f1d79ba7b1012c96d16ac</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01159%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DP.%26aulast%3DPereira%26aufirst%3DD.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DBertrand%26aufirst%3DD.%26atitle%3DDifferentiating%2520the%2520Pharmacodynamics%2520and%2520Toxicology%2520of%2520Macrolide%2520and%2520Ketolide%2520Antibiotics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D6462%26epage%3D6473%26doi%3D10.1021%2Facs.jmedchem.9b01159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jelić, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antolović, R.</span></span> <span> </span><span class="NLM_article-title">From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials</span>. <i>Antibiotics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.3390/antibiotics5030029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fantibiotics5030029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2isrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=29&author=D.+Jeli%C4%87author=R.+Antolovi%C4%87&title=From+Erythromycin+to+Azithromycin+and+New+Potential+Ribosome-Binding+Antimicrobials&doi=10.3390%2Fantibiotics5030029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">From erythromycin to azithromycin and new potential ribosome-binding antimicrobials</span></div><div class="casAuthors">Jelic, Dubravko; Antolovic, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Antibiotics (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">29/1-29/13</span>CODEN:
                <span class="NLM_cas:coden">ABSNC4</span>;
        ISSN:<span class="NLM_cas:issn">2079-6382</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Macrolides, as a class of natural or semisynthetic products, express their antibacterial activity primarily by reversible binding to the bacterial 50S ribosomal subunits and by blocking nascent proteins' progression through their exit tunnel in bacterial protein biosynthesis.  Generally considered to be bacteriostatic, they may also be bactericidal at higher doses.  The discovery of azithromycin from the class of macrolides, as one of the most important new drugs of the 20th century, is presented as an example of a rational medicinal chem. approach to drug design, applying classical structure-activity relationship that will illustrate an impressive drug discovery success story.  However, the microorganisms have developed several mechanisms to acquire resistance to antibiotics, including macrolide antibiotics.  The primary mechanism for acquiring bacterial resistance to macrolides is a mutation of one or more nucleotides from the binding site.  Although azithromycin is reported to show different, two-step process of the inhibition of ribosome function of some species, more detailed elaboration of that specific mode of action is needed.  New macrocyclic derivs., which could be more potent and less prone to escape bacterial resistance mechanisms, are also continuously evaluated.  A novel class of antibiotic compds.-macrolones, which are derived from macrolides and comprise macrocyclic moiety, linker, and either free or esterified quinolone 3-carboxylic group, show excellent antibacterial potency towards key erythromycin-resistant Gram-pos. and Gram-neg. bacterial strains, with possibly decreased potential of bacterial resistance to macrolides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNP2YDfyTwYbVg90H21EOLACvtfcHk0lhsDZL2uR2AZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2isrbL&md5=f7c62f735cc5bbd2a9c3af18aac50973</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fantibiotics5030029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fantibiotics5030029%26sid%3Dliteratum%253Aachs%26aulast%3DJeli%25C4%2587%26aufirst%3DD.%26aulast%3DAntolovi%25C4%2587%26aufirst%3DR.%26atitle%3DFrom%2520Erythromycin%2520to%2520Azithromycin%2520and%2520New%2520Potential%2520Ribosome-Binding%2520Antimicrobials%26jtitle%3DAntibiotics%26date%3D2016%26volume%3D5%26spage%3D29%26doi%3D10.3390%2Fantibiotics5030029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider-Poetsch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyler, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Eukaryotic Translation Elongation by Cycloheximide and Lactimidomycin</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1038/nchembio.304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnchembio.304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=20118940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ygu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=209-217&author=T.+Schneider-Poetschauthor=J.+Juauthor=D.+E.+Eylerauthor=Y.+Dangauthor=S.+Bhatauthor=W.+C.+Merrickauthor=R.+Greenauthor=B.+Shenauthor=J.+O.+Liu&title=Inhibition+of+Eukaryotic+Translation+Elongation+by+Cycloheximide+and+Lactimidomycin&doi=10.1038%2Fnchembio.304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin</span></div><div class="casAuthors">Schneider-Poetsch, Tilman; Ju, Jianhua; Eyler, Daniel E.; Dang, Yongjun; Bhat, Shridhar; Merrick, William C.; Green, Rachel; Shen, Ben; Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-217</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the protein synthesis inhibitor cycloheximide (CHX) has been known for decades, its precise mechanism of action remains incompletely understood.  The glutarimide portion of CHX is seen in a family of structurally related natural products including migrastatin, isomigrastatin, and lactimidomycin (LTM).  We found that LTM, isomigrastatin, and analogs have a potent antiproliferative effect on tumor cell lines and selectively inhibit translation.  A systematic comparative study of the effects of CHX and LTM on protein synthesis revealed both similarities and differences between the two inhibitors.  Both LTM and CHX were found to block the translocation step in elongation.  Footprinting expts. revealed protection of a single cytidine nucleotide (C3993) in the E-site of the 60S ribosomal subunit, thus defining a common binding pocket for the two inhibitors in the ribosome.  These results shed new light on the mol. mechanism of inhibition of translation elongation by both CHX and LTM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsVhn_TkyD-LVg90H21EOLACvtfcHk0ljAOqxUNae42g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ygu7w%253D&md5=77e621c87b496cd697f77299623b9f06</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.304%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider-Poetsch%26aufirst%3DT.%26aulast%3DJu%26aufirst%3DJ.%26aulast%3DEyler%26aufirst%3DD.%2BE.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DInhibition%2520of%2520Eukaryotic%2520Translation%2520Elongation%2520by%2520Cycloheximide%2520and%2520Lactimidomycin%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D209%26epage%3D217%26doi%3D10.1038%2Fnchembio.304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneekloth, J. S.</span></span> <span> </span><span class="NLM_article-title">The Emerging Role of RNA as a Therapeutic Target for Small Molecules</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1077</span>– <span class="NLM_lpage">1090</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.chembiol.2016.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27593111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOqsL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=1077-1090&author=C.+M.+Connellyauthor=M.+H.+Moonauthor=J.+S.+Schneekloth&title=The+Emerging+Role+of+RNA+as+a+Therapeutic+Target+for+Small+Molecules&doi=10.1016%2Fj.chembiol.2016.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Emerging Role of RNA as a Therapeutic Target for Small Molecules</span></div><div class="casAuthors">Connelly, Colleen M.; Moon, Michelle H.; Schneekloth, John S., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1077-1090</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Recent advances in understanding different RNAs and unique features of their biol. have revealed a wealth of information.  However, approaches to identify small mols. that target these newly discovered regulatory elements have been lacking.  The application of new biochem. screening and design-based technologies, coupled with a resurgence of interest in phenotypic screening, has resulted in several compelling successes in targeting RNA.  A no. of recent advances suggest that achieving the long-standing goal of developing drug-like, biol. active small mols. that target RNA is possible.  This review highlights advances and successes in approaches to targeting RNA with diverse small mols., and the potential for these technologies to pave the way to new types of RNA-targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdPbbvOw7jO7Vg90H21EOLACvtfcHk0ljAOqxUNae42g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOqsL3E&md5=800ffb1879c29aa7ac34940e761b5f7e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DConnelly%26aufirst%3DC.%2BM.%26aulast%3DMoon%26aufirst%3DM.%2BH.%26aulast%3DSchneekloth%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520Emerging%2520Role%2520of%2520RNA%2520as%2520a%2520Therapeutic%2520Target%2520for%2520Small%2520Molecules%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D1077%26epage%3D1090%26doi%3D10.1016%2Fj.chembiol.2016.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulea, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topisirovic, I.</span></span> <span> </span><span class="NLM_article-title">Targeting the Translation Machinery in Cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1038/nrd4505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnrd4505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25743081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFOgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=261-278&author=M.+Bhatauthor=N.+Robichaudauthor=L.+Huleaauthor=N.+Sonenbergauthor=J.+Pelletierauthor=I.+Topisirovic&title=Targeting+the+Translation+Machinery+in+Cancer&doi=10.1038%2Fnrd4505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the translation machinery in cancer</span></div><div class="casAuthors">Bhat, Mamatha; Robichaud, Nathaniel; Hulea, Laura; Sonenberg, Nahum; Pelletier, Jerry; Topisirovic, Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">261-278</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dysregulation of mRNA translation is a frequent feature of neoplasia.  Many oncogenes and tumor suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumor cells, independent of the genetic make-up of the cancer.  Therefore, therapeutic agents that target components of the protein synthesis app. hold promise as novel anticancer drugs that can overcome intra-tumor heterogeneity.  In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7a57QrdxxsbVg90H21EOLACvtfcHk0ljAOqxUNae42g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFOgs70%253D&md5=51625a521b1d4f18887142383a8d28e8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd4505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4505%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DM.%26aulast%3DRobichaud%26aufirst%3DN.%26aulast%3DHulea%26aufirst%3DL.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DTopisirovic%26aufirst%3DI.%26atitle%3DTargeting%2520the%2520Translation%2520Machinery%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D261%26epage%3D278%26doi%3D10.1038%2Fnrd4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laham-Karam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonen, P.</span></span> <span> </span><span class="NLM_article-title">Transcription and Translation Inhibitors in Cancer Treatment</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">276</span>, <span class="refDoi"> DOI: 10.3389/fchem.2020.00276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3389%2Ffchem.2020.00276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=32373584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGitrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=276&author=N.+Laham-Karamauthor=G.+P.+Pintoauthor=A.+Posoauthor=P.+Kokkonen&title=Transcription+and+Translation+Inhibitors+in+Cancer+Treatment&doi=10.3389%2Ffchem.2020.00276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Transcription and translation inhibitors in cancer treatment</span></div><div class="casAuthors">Laham-Karam, Nihay; Pinto, Gaspar P.; Poso, Antti; Kokkonen, Piia</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">276</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Transcription and translation are fundamental cellular processes that govern the protein prodn. of cells.  These processes are generally up regulated in cancer cells, to maintain the enhanced metab. and proliferative state of these cells.  As such cancerous cells can be susceptible to transcription and translation inhibitors.  There are numerous druggable proteins involved in transcription and translation which make lucrative targets for cancer drug development.  In addn. to proteins, recent years have shown that the "undruggable" transcription factors and RNA mols. can also be targeted to hamper the transcription or translation in cancer.  In this review, we summarize the properties and function of the transcription and translation inhibitors that have been tested and developed, focusing on the advances of the last 5 years.  To complement this, we also discuss some of the recent advances in targeting oncogenes tightly controlling transcription including transcription factors and KRAS.  In addn. to natural and synthetic compds., we review DNA and RNA based approaches to develop cancer drugs.  Finally, we conclude with the outlook to the future of the development of transcription and translation inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqp-guDgqY8rVg90H21EOLACvtfcHk0lg0EThKRJscZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGitrzK&md5=e6ad9ae25f9ba15f7fa0ca02485781da</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2020.00276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2020.00276%26sid%3Dliteratum%253Aachs%26aulast%3DLaham-Karam%26aufirst%3DN.%26aulast%3DPinto%26aufirst%3DG.%2BP.%26aulast%3DPoso%26aufirst%3DA.%26aulast%3DKokkonen%26aufirst%3DP.%26atitle%3DTranscription%2520and%2520Translation%2520Inhibitors%2520in%2520Cancer%2520Treatment%26jtitle%3DFront.%2520Chem.%26date%3D2020%26volume%3D8%26spage%3D276%26doi%3D10.3389%2Ffchem.2020.00276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, L.</span></span> <span> </span><span class="NLM_article-title">Determinant of Cistron Specificity in Bacterial Ribosomes</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1038/254034a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2F254034a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=803646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE2MXkt1eltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1975&pages=34-38&author=J.+Shineauthor=L.+Dalgarno&title=Determinant+of+Cistron+Specificity+in+Bacterial+Ribosomes&doi=10.1038%2F254034a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Determinant of cistron specificity in bacterial ribosomes</span></div><div class="casAuthors">Shine, J.; Dalgarno, L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">5495</span>),
    <span class="NLM_cas:pages">34-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The sequence of the 3'-terminus of 16 S rRNA from different species of bacteria was detd.  The complementarity relation between this sequence and that of a purine-rich tract in the ribosome binding site of bacterial mRNA suggests that the intrinsic capacity of ribosomes to translate a particular cistron is detd. by a pyrimidine-rich region at the 3'-end of 16 S RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7IpAtJMJ3Y7Vg90H21EOLACvtfcHk0lg0EThKRJscZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXkt1eltbY%253D&md5=3a8771341e1d0fc60295f6b42150137a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2F254034a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F254034a0%26sid%3Dliteratum%253Aachs%26aulast%3DShine%26aufirst%3DJ.%26aulast%3DDalgarno%26aufirst%3DL.%26atitle%3DDeterminant%2520of%2520Cistron%2520Specificity%2520in%2520Bacterial%2520Ribosomes%26jtitle%3DNature%26date%3D1975%26volume%3D254%26spage%3D34%26epage%3D38%26doi%3D10.1038%2F254034a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mokrejš, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vopálenský, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolenatý, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mašek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feketová, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekyrová, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Škaloudová, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kříž, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pospíšek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokrejs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vopálenský, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolenaty, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feketová, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekyrová, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaloudová, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kríz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pospísek, M.</span></span> <span> </span><span class="NLM_article-title">IRESite: The Database of Experimentally Verified IRES Structures (Www.Iresite.Org)</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">D125</span>– <span class="NLM_lpage">D130</span>, <span class="refDoi"> DOI: 10.1093/nar/gkj081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1093%2Fnar%2Fgkj081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16381829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFOqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=D125-D130&author=M.+Mokrej%C5%A1author=V.+Vop%C3%A1lensk%C3%BDauthor=O.+Kolenat%C3%BDauthor=T.+Ma%C5%A1ekauthor=Z.+Feketov%C3%A1author=P.+Sekyrov%C3%A1author=B.+%C5%A0kaloudov%C3%A1author=V.+K%C5%99%C3%AD%C5%BEauthor=M.+Posp%C3%AD%C5%A1ekauthor=M.+Mokrejsauthor=V.+Vop%C3%A1lensk%C3%BDauthor=O.+Kolenatyauthor=T.+Masekauthor=Z.+Feketov%C3%A1author=P.+Sekyrov%C3%A1author=B.+Skaloudov%C3%A1author=V.+Kr%C3%ADzauthor=M.+Posp%C3%ADsek&title=IRESite%3A+The+Database+of+Experimentally+Verified+IRES+Structures+%28Www.Iresite.Org%29&doi=10.1093%2Fnar%2Fgkj081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">IRESite: the database of experimentally verified IRES structures (www.iresite.org)</span></div><div class="casAuthors">Mokrejs, Martin; Vopalensky, Vaclav; Kolenaty, Ondrej; Masek, Tomas; Feketova, Zuzana; Sekyrova, Petra; Skaloudova, Barbora; Kriz, Vitezslav; Pospisek, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">Database</span>),
    <span class="NLM_cas:pages">D125-D130</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">IRESite is an exhaustive, manually annotated non-redundant relational database focused on the IRES elements (Internal Ribosome Entry Site) and contg. information not available in the primary public databases.  IRES elements were originally found in eukaryotic viruses hijacking initiation of translation of their host.  Later on, they were also discovered in 5'-untranslated regions of some eukaryotic mRNA mols.  Currently, IRESite presents up to 92 biol. relevant aspects of every expt., e.g. the nature of an IRES element, its functionality/defectivity, origin, size, sequence, structure, its relative position with respect to surrounding protein coding regions, pos./neg. controls used in the expt., the reporter genes used to monitor IRES activity, the measured reporter protein yields/activities, and refs. to original publications as well as cross-refs. to other databases, and also comments from submitters and our curators.  Furthermore, the site presents the known similarities to rRNA sequences as well as RNA-protein interactions.  Special care is given to the annotation of promoter-like regions.  The annotated data in IRESite are bound to mostly complete, full-length mRNA, and whenever possible, accompanied by original plasmid vector sequences.  New data can be submitted through the publicly available web-based interface at http://www.iresite.org and are curated by a team of lab-experienced biologists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxC_teN9N3krVg90H21EOLACvtfcHk0lg0EThKRJscZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFOqtw%253D%253D&md5=54f56e1d50dadc4f29665615aa414cba</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkj081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkj081%26sid%3Dliteratum%253Aachs%26aulast%3DMokrej%25C5%25A1%26aufirst%3DM.%26aulast%3DVop%25C3%25A1lensk%25C3%25BD%26aufirst%3DV.%26aulast%3DKolenat%25C3%25BD%26aufirst%3DO.%26aulast%3DMa%25C5%25A1ek%26aufirst%3DT.%26aulast%3DFeketov%25C3%25A1%26aufirst%3DZ.%26aulast%3DSekyrov%25C3%25A1%26aufirst%3DP.%26aulast%3D%25C5%25A0kaloudov%25C3%25A1%26aufirst%3DB.%26aulast%3DK%25C5%2599%25C3%25AD%25C5%25BE%26aufirst%3DV.%26aulast%3DPosp%25C3%25AD%25C5%25A1ek%26aufirst%3DM.%26aulast%3DMokrejs%26aufirst%3DM.%26aulast%3DVop%25C3%25A1lensk%25C3%25BD%26aufirst%3DV.%26aulast%3DKolenaty%26aufirst%3DO.%26aulast%3DMasek%26aufirst%3DT.%26aulast%3DFeketov%25C3%25A1%26aufirst%3DZ.%26aulast%3DSekyrov%25C3%25A1%26aufirst%3DP.%26aulast%3DSkaloudov%25C3%25A1%26aufirst%3DB.%26aulast%3DKr%25C3%25ADz%26aufirst%3DV.%26aulast%3DPosp%25C3%25ADsek%26aufirst%3DM.%26atitle%3DIRESite%253A%2520The%2520Database%2520of%2520Experimentally%2520Verified%2520IRES%2520Structures%2520%2528Www.Iresite.Org%2529%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2006%26volume%3D34%26spage%3DD125%26epage%3DD130%26doi%3D10.1093%2Fnar%2Fgkj081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortridge, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albin, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cominsky, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varani, G.</span></span> <span> </span><span class="NLM_article-title">Structure of the RNA Specialized Translation Initiation Element That Recruits eIF3 to the 5′-UTR of c-Jun</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>432</i></span>,  <span class="NLM_fpage">1841</span>– <span class="NLM_lpage">1855</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2020.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.jmb.2020.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31953146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktVehsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2020&pages=1841-1855&author=M.+J.+Walkerauthor=M.+D.+Shortridgeauthor=D.+D.+Albinauthor=L.+Y.+Cominskyauthor=G.+Varani&title=Structure+of+the+RNA+Specialized+Translation+Initiation+Element+That+Recruits+eIF3+to+the+5%E2%80%B2-UTR+of+c-Jun&doi=10.1016%2Fj.jmb.2020.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the RNA specialized translation initiation element that recruits eIF3 to the 5'-UTR of c-Jun</span></div><div class="casAuthors">Walker, Matthew J.; Shortridge, Matthew D.; Albin, Dreycey D.; Cominsky, Lauren Y.; Varani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">432</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1841-1855</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Specialized translation initiation is a novel form of regulation of protein synthesis, whereby RNA structures within the 5'-UTR regulate translation rates of specific mRNAs.  Similar to internal ribosome entry sites (IRESs), specialized translation initiation requires the recruitment of eukaryotic initiation factor 3 (eIF3), but also requires cap recognition by eIF3d, a new 5'-m7GTP recognizing protein.  How these RNA structures mediate eIF3 recruitment to affect translation of specific mRNAs remains unclear.  Here, we report the NMR structure of a stem-loop within the c-JUN 5' UTR recognized by eIF3 and essential for specialized translation initiation of this well-known oncogene.  The structure exhibits similarity to eIF3 recognizing motifs found in hepatitis C virus (HCV)-like IRESs, suggesting mechanistic similarities.  This work establishes the RNA structural features involved in c-JUN specialized translation initiation and provides a basis to search for small mol. inhibitors of aberrant expression of the proto-oncogenic c-JUN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZqW62SYA4n7Vg90H21EOLACvtfcHk0lg-q9Mzpx7-yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktVehsbg%253D&md5=470093de7ab1efe81f78246e20b2108f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2020.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2020.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DM.%2BJ.%26aulast%3DShortridge%26aufirst%3DM.%2BD.%26aulast%3DAlbin%26aufirst%3DD.%2BD.%26aulast%3DCominsky%26aufirst%3DL.%2BY.%26aulast%3DVarani%26aufirst%3DG.%26atitle%3DStructure%2520of%2520the%2520RNA%2520Specialized%2520Translation%2520Initiation%2520Element%2520That%2520Recruits%2520eIF3%2520to%2520the%25205%25E2%2580%25B2-UTR%2520of%2520c-Jun%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2020%26volume%3D432%26spage%3D1841%26epage%3D1855%26doi%3D10.1016%2Fj.jmb.2020.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pestova, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolupaeva, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomakin, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilipenko, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shatsky, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agol, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellen, C. U. T.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms of Translation Initiation in Eukaryotes</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">7029</span>– <span class="NLM_lpage">7036</span>, <span class="refDoi"> DOI: 10.1073/pnas.111145798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.111145798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=11416183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslWmsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=7029-7036&author=T.+V.+Pestovaauthor=V.+G.+Kolupaevaauthor=I.+B.+Lomakinauthor=E.+V.+Pilipenkoauthor=I.+N.+Shatskyauthor=V.+I.+Agolauthor=C.+U.+T.+Hellen&title=Molecular+Mechanisms+of+Translation+Initiation+in+Eukaryotes&doi=10.1073%2Fpnas.111145798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of translation initiation in eukaryotes</span></div><div class="casAuthors">Pestova, Tatyana V.; Kolupaeva, Victoria G.; Lomakin, Ivan B.; Pilipenko, Evgeny V.; Shatsky, Ivan N.; Agol, Vadim I.; Hellen, Christopher U. T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7029-7036</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A review, with 54 refs.  Translation initiation is a complex process in which initiator tRNA, 40S, and 60S ribosomal subunits are assembled by eukaryotic initiation factors (eIFs) into an 80S ribosome at the initiation codon of mRNA.  The cap-binding complex eIF4F and the factors eIF4A and eIF4B are required for binding of 43S complexes (comprising a 40S subunit, eIF2/GTP/Met-tRNAi and eIF3) to the 5' end of capped mRNA but are not sufficient to promote ribosomal scanning to the initiation codon.  EIF1A enhances the ability of eIF1 to dissoc. aberrantly assembled complexes from mRNA, and these factors synergistically mediate 48S complex assembly at the initiation codon.  Joining of 48S complexes to 60S subunits to form 80S ribosomes requires eIF5B, which has an essential ribosome-dependent GTPase activity and hydrolysis of eIF2-bound GTP induced by eIF5.  Initiation on a few mRNAs is cap-independent and occurs instead by internal ribosomal entry.  Encephalomyocarditis virus (EMCV) and hepatitis C virus epitomize distinct mechanisms of internal ribosomal entry site (IRES)-mediated initiation.  The eIF4A and eIF4G subunits of eIF4F bind immediately upstream of the EMCV initiation codon and promote binding of 43S complexes.  EMCV initiation does not involve scanning and does not require eIF1, eIF1A, and the eIF4E subunit of eIF4F.  Initiation on some EMCV-like IRESs requires addnl. noncanonical initiation factors, which alter IRES conformation and promote binding of eIF4A/4G.  Initiation on the hepatitis C virus IRES is even simpler: 43S complexes contg. only eIF2 and eIF3 bind directly to the initiation codon as a result of specific interaction of the IRES and the 40S subunit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpENj0T2D1NqrVg90H21EOLACvtfcHk0lg-q9Mzpx7-yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslWmsLc%253D&md5=49e16cbddc4b187f4a532799e7bd04a3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.111145798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.111145798%26sid%3Dliteratum%253Aachs%26aulast%3DPestova%26aufirst%3DT.%2BV.%26aulast%3DKolupaeva%26aufirst%3DV.%2BG.%26aulast%3DLomakin%26aufirst%3DI.%2BB.%26aulast%3DPilipenko%26aufirst%3DE.%2BV.%26aulast%3DShatsky%26aufirst%3DI.%2BN.%26aulast%3DAgol%26aufirst%3DV.%2BI.%26aulast%3DHellen%26aufirst%3DC.%2BU.%2BT.%26atitle%3DMolecular%2520Mechanisms%2520of%2520Translation%2520Initiation%2520in%2520Eukaryotes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D7029%26epage%3D7036%26doi%3D10.1073%2Fpnas.111145798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzy, T. G.</span></span> <span> </span><span class="NLM_article-title">The Many Roles of the Eukaryotic Elongation Factor 1 Complex</span>. <i>Wiley Interdiscip. Rev. RNA</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1002/wrna.1118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fwrna.1118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22555874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGgsbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=543-555&author=A.+N.+Sasikumarauthor=W.+B.+Perezauthor=T.+G.+Kinzy&title=The+Many+Roles+of+the+Eukaryotic+Elongation+Factor+1+Complex&doi=10.1002%2Fwrna.1118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of the eukaryotic elongation factor 1 complex</span></div><div class="casAuthors">Sasikumar, Arjun N.; Perez, Winder B.; Kinzy, Terri Goss</div><div class="citationInfo"><span class="NLM_cas:title">Wiley Interdisciplinary Reviews: RNA</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">543-555</span>CODEN:
                <span class="NLM_cas:coden">WIRRCU</span>;
        ISSN:<span class="NLM_cas:issn">1757-7012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The vast majority of proteins are believed to have one specific function.  Throughout the course of evolution, however, some proteins have acquired addnl. functions to meet the demands of a complex cellular milieu.  In some cases, changes in RNA or protein processing allow the cell to make the most of what is already encoded in the genome to produce slightly different forms.  The eukaryotic elongation factor 1 (eEF1) complex subunits, however, have acquired such moonlighting functions without alternative forms.  In this article, we discuss the canonical functions of the components of the eEF1 complex in translation elongation as well as the secondary interactions they have with other cellular factors outside of the translational app.  The eEF1 complex itself changes in compn. as the complexity of eukaryotic organisms increases.  Members of the complex are also subject to phosphorylation, a potential modulator of both canonical and non-canonical functions.  Although alternative functions of the eEF1A subunit have been widely reported, recent studies are shedding light on addnl. functions of the eEF1B subunits.  A thorough understanding of these alternate functions of eEF1 is essential for appreciating their biol. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokSwgdh0fzYbVg90H21EOLACvtfcHk0lg-q9Mzpx7-yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGgsbrP&md5=8b91d46331db19df59755b893089cf78</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fwrna.1118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwrna.1118%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DA.%2BN.%26aulast%3DPerez%26aufirst%3DW.%2BB.%26aulast%3DKinzy%26aufirst%3DT.%2BG.%26atitle%3DThe%2520Many%2520Roles%2520of%2520the%2520Eukaryotic%2520Elongation%2520Factor%25201%2520Complex%26jtitle%3DWiley%2520Interdiscip.%2520Rev.%2520RNA%26date%3D2012%26volume%3D3%26spage%3D543%26epage%3D555%26doi%3D10.1002%2Fwrna.1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frolova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geballe, A. P.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Translation Termination Mediated by an Interaction of Eukaryotic Release Factor 1 with a Nascent Peptidyl-tRNA</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">8562</span>– <span class="NLM_lpage">8570</span>, <span class="refDoi"> DOI: 10.1128/MCB.22.24.8562-8570.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1128%2FMCB.22.24.8562-8570.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=12446775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlGrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=8562-8570&author=D.+M.+Janzenauthor=L.+Frolovaauthor=A.+P.+Geballe&title=Inhibition+of+Translation+Termination+Mediated+by+an+Interaction+of+Eukaryotic+Release+Factor+1+with+a+Nascent+Peptidyl-tRNA&doi=10.1128%2FMCB.22.24.8562-8570.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of translation termination mediated by an interaction of eukaryotic release factor 1 with a nascent peptidyl-tRNA</span></div><div class="casAuthors">Janzen, Deanna M.; Frolova, Lyudmila; Geballe, Adam P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8562-8570</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Expression of the human cytomegalovirus UL4 gene is inhibited by translation of a 22-codon-upstream open reading frame (uORF2).  The peptide product of uORF2 acts in a sequence-dependent manner to inhibit its own translation termination, resulting in persistence of the uORF2 peptidyl-tRNA linkage.  Consequently, ribosomes stall at the uORF2 termination codon and obstruct downstream translation.  Since termination appears to be the crit. step affected by translation of uORF2, we examd. the role of eukaryotic release factors 1 and 3 (eRF1 and eRF3) in the inhibitory mechanism.  In support of the hypothesis that an interaction between eRF1 and uORF2 contributes to uORF2 inhibitory activity, specific residues in each protein, glycines 183 and 184 of the eRF1 GGQ motif and prolines 21 and 22 of the uORF2 peptide, were found to be necessary for full inhibition of downstream translation.  Immunoblot analyses revealed that eRF1, but not eRF3, accumulated in the uORF2-stalled ribosome complex.  Finally, increased puromycin sensitivity was obsd. after depletion of eRF1 from the stalled ribosome complex, consistent with inhibition of peptidyl-tRNA hydrolysis resulting from an eRF1-uORF2 peptidyl-tRNA interaction.  These results reveal the paradoxical potential for interactions between a nascent peptide and eRF1 to obstruct the translation termination cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCK2GSFB_0vbVg90H21EOLACvtfcHk0ljzlNVATdh2Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlGrsb4%253D&md5=fc63d5288c0e28a0d087138229261632</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FMCB.22.24.8562-8570.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.22.24.8562-8570.2002%26sid%3Dliteratum%253Aachs%26aulast%3DJanzen%26aufirst%3DD.%2BM.%26aulast%3DFrolova%26aufirst%3DL.%26aulast%3DGeballe%26aufirst%3DA.%2BP.%26atitle%3DInhibition%2520of%2520Translation%2520Termination%2520Mediated%2520by%2520an%2520Interaction%2520of%2520Eukaryotic%2520Release%2520Factor%25201%2520with%2520a%2520Nascent%2520Peptidyl-tRNA%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2002%26volume%3D22%26spage%3D8562%26epage%3D8570%26doi%3D10.1128%2FMCB.22.24.8562-8570.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulygin, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graifer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hountondji, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frolova, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpova, G. G.</span></span> <span> </span><span class="NLM_article-title">Exploring Contacts of ERF1 with the 3′-Terminus of the P Site TRNA and MRNA Stop Signal in the Human Ribosome at Various Translation Termination Steps</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1860</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">793</span>, <span class="refDoi"> DOI: 10.1016/j.bbagrm.2017.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.bbagrm.2017.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28457996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnt1CrtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1860&publication_year=2017&pages=782-793&author=K.+N.+Bulyginauthor=D.+M.+Graiferauthor=C.+Hountondjiauthor=L.+Y.+Frolovaauthor=G.+G.+Karpova&title=Exploring+Contacts+of+ERF1+with+the+3%E2%80%B2-Terminus+of+the+P+Site+TRNA+and+MRNA+Stop+Signal+in+the+Human+Ribosome+at+Various+Translation+Termination+Steps&doi=10.1016%2Fj.bbagrm.2017.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring contacts of eRF1 with the 3'-terminus of the P site tRNA and mRNA stop signal in the human ribosome at various translation termination steps</span></div><div class="casAuthors">Bulygin, Konstantin N.; Graifer, Dmitri M.; Hountondji, Codjo; Frolova, Ludmila Yu.; Karpova, Galina G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1860</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">782-793</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here we employed site-directed crosslinking with the application of tRNA and mRNA analogs bearing an oxidized ribose at the 3'-terminus to investigate mutual arrangement of the main components of translation termination complexes formed on the human 80S ribosome bound with P site deacylated tRNA using eRF1•eRF3•GTP or eRF1 alone.  In addn., we applied a model complex obtained in the same way with eRF1•eRF3•GMPPNP.  We found that eRF3 content in the complexes with GTP and GMPPNP is similar, proving that eRF3 does not leave the ribosome after GTP hydrolysis.  Our crosslinking data allowed detg. locations of the 3'-terminus of the P site tRNA relatively the eRF1 M domain and of the mRNA stop signal toward the N domain and the ribosomal decoding site at the nucleotide-peptide resoln. level.  Our results indicate that locations of these components do not change after peptide release up to post-termination pre-recycling state, and the positioning of the mRNA stop signal remains similar to that when eRF1 recognizes it.  Besides, we found that in all the complexes studied eRF1 shielded the N-terminal part of ribosomal protein eS30 from the interaction with the nucleotide adjacent to stop codon obsd. with pre-termination ribosome free of eRFs.  Altogether, our findings brought important information on contacts of the key structural elements of eRF1, tRNA and mRNA in the ribosomal complexes including those mimicking different translation termination steps, thereby providing a deeper understanding of mol. mechanisms underlying events occurring in the course of protein synthesis termination in mammals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI6DpfHfN7abVg90H21EOLACvtfcHk0ljzlNVATdh2Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnt1CrtLw%253D&md5=15497645f1d4aea491fe13d2f1820541</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2017.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2017.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DBulygin%26aufirst%3DK.%2BN.%26aulast%3DGraifer%26aufirst%3DD.%2BM.%26aulast%3DHountondji%26aufirst%3DC.%26aulast%3DFrolova%26aufirst%3DL.%2BY.%26aulast%3DKarpova%26aufirst%3DG.%2BG.%26atitle%3DExploring%2520Contacts%2520of%2520ERF1%2520with%2520the%25203%25E2%2580%25B2-Terminus%2520of%2520the%2520P%2520Site%2520TRNA%2520and%2520MRNA%2520Stop%2520Signal%2520in%2520the%2520Human%2520Ribosome%2520at%2520Various%2520Translation%2520Termination%2520Steps%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2017%26volume%3D1860%26spage%3D782%26epage%3D793%26doi%3D10.1016%2Fj.bbagrm.2017.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiel, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaji, A.</span></span> <span> </span><span class="NLM_article-title">Ribosome Recycling: An Essential Process of Protein Synthesis</span>. <i>Biochem. Mol. Biol. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1002/bmb.6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fbmb.6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21591054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=40-44&author=M.+C.+Kielauthor=H.+Kajiauthor=A.+Kaji&title=Ribosome+Recycling%3A+An+Essential+Process+of+Protein+Synthesis&doi=10.1002%2Fbmb.6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosome recycling. An essential process of protein synthesis</span></div><div class="casAuthors">Kiel, Michael C.; Kaji, Hideko; Kaji, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry and Molecular Biology Education</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-44</span>CODEN:
                <span class="NLM_cas:coden">BMBECE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8175</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  A preponderance of textbooks outlines cellular protein synthesis (translation) in three basic steps: initiation, elongation, and termination.  However, researchers in the field of translation accept that a vital fourth step exists; this fourth step is called ribosome recycling.  Ribosome recycling occurs after the nascent polypeptide has been released during the termination step.  Despite the release of the polypeptide, ribosomes remain bound to the mRNA and tRNA.  It is only during the fourth step of translation that ribosomes are ultimately released from the mRNA, split into subunits, and are free to bind new mRNA, thus the term "ribosome recycling.".  This step is essential to the viability of cells.  In bacteria, it is catalyzed by two proteins, elongation factor G and ribosome recycling factor, a near perfect structural mimic of tRNA.  Eukaryotic organelles such as mitochondria and chloroplasts possess ribosome recycling factor and elongation factor G homologs, but the nature of ribosome recycling in eukaryotic cytoplasm is still under investigation.  In this review, the discovery of ribosome recycling and the basic mechanisms involved are discussed so that textbook writers and teachers can include this vital step, which is just as important as the three conventional steps, in sections dealing with protein synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1TwqARcTqzbVg90H21EOLACvtfcHk0ljzlNVATdh2Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVSisr0%253D&md5=02f9b350a73d131cabdf833578d652ad</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fbmb.6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbmb.6%26sid%3Dliteratum%253Aachs%26aulast%3DKiel%26aufirst%3DM.%2BC.%26aulast%3DKaji%26aufirst%3DH.%26aulast%3DKaji%26aufirst%3DA.%26atitle%3DRibosome%2520Recycling%253A%2520An%2520Essential%2520Process%2520of%2520Protein%2520Synthesis%26jtitle%3DBiochem.%2520Mol.%2520Biol.%2520Educ.%26date%3D2007%26volume%3D35%26spage%3D40%26epage%3D44%26doi%3D10.1002%2Fbmb.6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pisarev, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellen, C. U. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestova, T. V.</span></span> <span> </span><span class="NLM_article-title">Recycling of Eukaryotic Posttermination Ribosomal Complexes</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.08.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.cell.2007.08.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17956730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1KqsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=286-299&author=A.+V.+Pisarevauthor=C.+U.+T.+Hellenauthor=T.+V.+Pestova&title=Recycling+of+Eukaryotic+Posttermination+Ribosomal+Complexes&doi=10.1016%2Fj.cell.2007.08.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Recycling of eukaryotic posttermination ribosomal complexes</span></div><div class="casAuthors">Pisarev, Andrey V.; Hellen, Christopher U. T.; Pestova, Tatyana V.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">286-299</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">After translational termination, mRNA and P site deacylated tRNA remain assocd. with ribosomes in posttermination complexes (post-TCs), which must therefore be recycled by releasing mRNA and deacylated tRNA and by dissocg. ribosomes into subunits.  Recycling of bacterial post-TCs requires elongation factor EF-G and a ribosome recycling factor RRF.  Eukaryotes do not encode a RRF homolog, and their mechanism of ribosomal recycling is unknown.  We investigated eukaryotic recycling using post-TCs assembled on a model mRNA encoding a tetrapeptide followed by a UAA stop codon and report that initiation factors eIF1, eIF1, eIF1A, and eIF3j, a loosely assocd. subunit of eIF3, can promote recycling of eukaryotic post-TCs.  EIF3 is the principal factor that promotes splitting of posttermination ribosomes into 60S subunits and tRNA- and mRNA-bound 40S subunits.  Its activity is enhanced by eIFs 3j, 1, and 1A.  EIF1 also mediates release of P site tRNA, whereas eIF3j ensures subsequent dissocn. of mRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo0SzNZHvsHbVg90H21EOLACvtfcHk0lgr6mYEuxx4AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1KqsbbP&md5=d2f3a3be926631805e46586624a67781</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.08.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.08.041%26sid%3Dliteratum%253Aachs%26aulast%3DPisarev%26aufirst%3DA.%2BV.%26aulast%3DHellen%26aufirst%3DC.%2BU.%2BT.%26aulast%3DPestova%26aufirst%3DT.%2BV.%26atitle%3DRecycling%2520of%2520Eukaryotic%2520Posttermination%2520Ribosomal%2520Complexes%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D286%26epage%3D299%26doi%3D10.1016%2Fj.cell.2007.08.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cargnello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topisirovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">918</span>– <span class="NLM_lpage">933</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2016.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.tcb.2016.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27426745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVynurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=918-933&author=J.+Chuauthor=M.+Cargnelloauthor=I.+Topisirovicauthor=J.+Pelletier&title=Translation+Initiation+Factors%3A+Reprogramming+Protein+Synthesis+in+Cancer&doi=10.1016%2Fj.tcb.2016.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer</span></div><div class="casAuthors">Chu, Jennifer; Cargnello, Marie; Topisirovic, Ivan; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">918-933</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Control of mRNA translation plays a crucial role in the regulation of gene expression and is crit. for cellular homeostasis.  Dysregulation of translation initiation factors has been documented in several pathologies including cancer.  Aberrant function of translation initiation factors leads to translation reprogramming that promotes proliferation, survival, angiogenesis, and metastasis.  In such context, understanding how altered levels (and presumably activity) of initiation factors can contribute to tumor initiation and/or maintenance is of major interest for the development of novel therapeutic strategies.  In this review we provide an overview of translation initiation mechanisms and focus on recent findings describing the role of individual initiation factors and their aberrant activity in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGromGFdRUnWo7Vg90H21EOLACvtfcHk0lgr6mYEuxx4AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVynurjJ&md5=3341afaa56564e231571f0f35525490a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2016.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2016.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DCargnello%26aufirst%3DM.%26aulast%3DTopisirovic%26aufirst%3DI.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DTranslation%2520Initiation%2520Factors%253A%2520Reprogramming%2520Protein%2520Synthesis%2520in%2520Cancer%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2016%26volume%3D26%26spage%3D918%26epage%3D933%26doi%3D10.1016%2Fj.tcb.2016.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span> <span> </span><span class="NLM_article-title">eIF4F: A Retrospective</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">24091</span>– <span class="NLM_lpage">24099</span>, <span class="refDoi"> DOI: 10.1074/jbc.R115.675280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1074%2Fjbc.R115.675280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26324716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2kurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=24091-24099&author=W.+C.+Merrick&title=eIF4F%3A+A+Retrospective&doi=10.1074%2Fjbc.R115.675280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">eIF4F: A Retrospective</span></div><div class="casAuthors">Merrick, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">24091-24099</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  The original purifn. of the heterotrimeric eIF4F was published over 30 years ago (Grifo, J. A., Tahara, S. M., Morgan, M. A., Shatkin, A. J., and Merrick, W. C. (1983) J. Biol. Chem. 258, 5804-5810).  Since that time, numerous studies have been performed with the three proteins specifically required for the translation initiation of natural mRNAs, eIF4A, eIF4B, and eIF4F.  These have involved enzymic and structural studies of the proteins and a no. of site-directed mutagenesis studies.  The regulation of translation exhibited through the mammalian target of rapamycin (mTOR) pathway is predominately seen as the phosphorylation of 4E-BP, an inhibitor of protein synthesis that functions by binding to the cap binding subunit of eIF4F (eIF4E).  A hypothesis that requires the disassembly of eIF4F during translation initiation to yield free subunits (eIF4A, eIF4E, and eIF4G) is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFQWuUV9H1Z7Vg90H21EOLACvtfcHk0lgr6mYEuxx4AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2kurfP&md5=22603cc62fa11d6d64b3f8b024bdeea8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R115.675280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R115.675280%26sid%3Dliteratum%253Aachs%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26atitle%3DeIF4F%253A%2520A%2520Retrospective%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D24091%26epage%3D24099%26doi%3D10.1074%2Fjbc.R115.675280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Quesne, J.</span></span> <span> </span><span class="NLM_article-title">Translational Dysregulation in Cancer: EIF4A Isoforms and Sequence Determinants of eIF4A Dependence</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1233</span>, <span class="refDoi"> DOI: 10.1042/BST20150163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1042%2FBST20150163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26614665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGntrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=1227-1233&author=F.+Razaauthor=J.+A.+Waldronauthor=J.+Le+Quesne&title=Translational+Dysregulation+in+Cancer%3A+EIF4A+Isoforms+and+Sequence+Determinants+of+eIF4A+Dependence&doi=10.1042%2FBST20150163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Translational dysregulation in cancer: eIF4A isoforms and sequence determinants of eIF4A dependence</span></div><div class="casAuthors">Raza, Farheen; Waldron, Joseph Alexander; Le Quesne, John</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1227-1233</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The malignant phenotype is largely the consequence of dysregulated gene expression.  Transformed cells depend upon not just a global increase in protein synthesis but an altered translational landscape in which pro-oncogenic mRNAs are translationally up-regulated.  Such mRNAs have been shown to possess longer and more structured 5'-UTRs requiring high levels of eukaryotic initiation factor 4A (eIF4A) helicase activity for efficient translation.  As such there is a developing focus on targeting eIF4A as a cancer therapy.  In order for such treatments to be successful, we must develop a detailed understanding of the mechanisms which make specific mRNAs more dependent on eIF4A activity than others.  It is also crucial to fully characterize the potentially distinct roles of eIF4A1 and eIF4A2, which until recently were thought to be functionally interchangeable.  This review will highlight the recent advances made in this field that address these issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa0L1McbYAhrVg90H21EOLACvtfcHk0lipOeOnsl0kkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGntrnF&md5=fd49980ba5a9dd8309bb8b1512c3b05b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1042%2FBST20150163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20150163%26sid%3Dliteratum%253Aachs%26aulast%3DRaza%26aufirst%3DF.%26aulast%3DWaldron%26aufirst%3DJ.%2BA.%26aulast%3DLe%2BQuesne%26aufirst%3DJ.%26atitle%3DTranslational%2520Dysregulation%2520in%2520Cancer%253A%2520EIF4A%2520Isoforms%2520and%2520Sequence%2520Determinants%2520of%2520eIF4A%2520Dependence%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2015%26volume%3D43%26spage%3D1227%26epage%3D1233%26doi%3D10.1042%2FBST20150163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span> <span> </span><span class="NLM_article-title">The Organizing Principles of Eukaryotic Ribosome Recruitment</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1146/annurev-biochem-013118-111042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1146%2Fannurev-biochem-013118-111042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31220979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Wqt7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2019&pages=307-335&author=J.+Pelletierauthor=N.+Sonenberg&title=The+Organizing+Principles+of+Eukaryotic+Ribosome+Recruitment&doi=10.1146%2Fannurev-biochem-013118-111042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Organizing Principles of Eukaryotic Ribosome Recruitment</span></div><div class="casAuthors">Pelletier, Jerry; Sonenberg, Nahum</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">307-335</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The stage at which ribosomes are recruited to mRNAs (mRNAs) is an elaborate and highly regulated phase of protein synthesis.  Upon completion of this step, a ribosome is positioned at an appropriate initiation codon and primed to synthesize the encoded polypeptide product.  In most circumstances, this step commits the ribosome to translate the mRNA.  We summarize the knowledge regarding the initiation factors implicated in this activity as well as review different mechanisms by which this process is conducted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhpAHeWzb93LVg90H21EOLACvtfcHk0lipOeOnsl0kkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Wqt7vM&md5=a93eb98dfec6a13041410081a9ff7962</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-013118-111042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-013118-111042%26sid%3Dliteratum%253Aachs%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DThe%2520Organizing%2520Principles%2520of%2520Eukaryotic%2520Ribosome%2520Recruitment%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2019%26volume%3D88%26spage%3D307%26epage%3D335%26doi%3D10.1146%2Fannurev-biochem-013118-111042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montero, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Gil, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampieri, C. L.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic Initiation Factor 4A (EIF4A) during Viral Infections</span>. <i>Virus Genes</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1007/s11262-019-01641-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs11262-019-01641-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30796742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt12hs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=267-273&author=H.+Monteroauthor=G.+P%C3%A9rez-Gilauthor=C.+L.+Sampieri&title=Eukaryotic+Initiation+Factor+4A+%28EIF4A%29+during+Viral+Infections&doi=10.1007%2Fs11262-019-01641-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic initiation factor 4A (eIF4A) during viral infections</span></div><div class="casAuthors">Montero, Hilda; Perez-Gil, Gustavo; Sampieri, Clara L.</div><div class="citationInfo"><span class="NLM_cas:title">Virus Genes</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-273</span>CODEN:
                <span class="NLM_cas:coden">VIGEET</span>;
        ISSN:<span class="NLM_cas:issn">0920-8569</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The helicase eIF4A is part of the cellular eIF4F translation initiation complex.  The main functions of eIF4A are to remove secondary complex structures within the 5'-untranslated region and to displace proteins attached to mRNA.  As intracellular parasites, viruses regulate the processes involved in protein synthesis, and different mechanisms related to controlling translation factors, such as eIF4A, have been found.  The inhibitors of this factor are currently known; these substances could be used in the near future as part of antiviral pharmacol. therapies in instances of replication cycles in which eIF4A is required.  In this review, the particularities of how some viruses make use of this initiation factor to synthesize their proteins are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtjfqntRIPC7Vg90H21EOLACvtfcHk0lipOeOnsl0kkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt12hs7g%253D&md5=249e2041f1bad3bb9ee69603768c3074</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs11262-019-01641-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11262-019-01641-7%26sid%3Dliteratum%253Aachs%26aulast%3DMontero%26aufirst%3DH.%26aulast%3DP%25C3%25A9rez-Gil%26aufirst%3DG.%26aulast%3DSampieri%26aufirst%3DC.%2BL.%26atitle%3DEukaryotic%2520Initiation%2520Factor%25204A%2520%2528EIF4A%2529%2520during%2520Viral%2520Infections%26jtitle%3DVirus%2520Genes%26date%3D2019%26volume%3D55%26spage%3D267%26epage%3D273%26doi%3D10.1007%2Fs11262-019-01641-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madhugiri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span> <span> </span><span class="NLM_article-title">RNA Structure Analysis of Alphacoronavirus Terminal Genome Regions</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/j.virusres.2014.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.virusres.2014.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25307890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOkt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2014&pages=76-89&author=R.+Madhugiriauthor=M.+Frickeauthor=M.+Marzauthor=J.+Ziebuhr&title=RNA+Structure+Analysis+of+Alphacoronavirus+Terminal+Genome+Regions&doi=10.1016%2Fj.virusres.2014.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">RNA structure analysis of alphacoronavirus terminal genome regions</span></div><div class="casAuthors">Madhugiri, Ramakanth; Fricke, Markus; Marz, Manja; Ziebuhr, John</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-89</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Coronavirus genome replication is mediated by a multi-subunit protein complex that is comprised of more than a dozen virally encoded and several cellular proteins.  Interactions of the viral replicase complex with cis-acting RNA elements located in the 5' and 3'-terminal genome regions ensure the specific replication of viral RNA.  Over the past years, boundaries and structures of cis-acting RNA elements required for coronavirus genome replication have been extensively characterized in betacoronaviruses and, to a lesser extent, other coronavirus genera.  Here, we review our current understanding of coronavirus cis-acting elements located in the terminal genome regions and use a combination of bioinformatic and RNA structure probing studies to identify and characterize putative cis-acting RNA elements in alphacoronaviruses.  The study suggests significant RNA structure conservation among members of the genus Alphacoronavirus but also across genus boundaries.  Overall, the conservation pattern identified for 5' and 3'-terminal RNA structural elements in the genomes of alpha- and betacoronaviruses is in agreement with the widely used replicase polyprotein-based classification of the Coronavirinae, suggesting co-evolution of the coronavirus replication machinery with cognate cis-acting RNA elements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq86f-C5ZahOLVg90H21EOLACvtfcHk0lipOeOnsl0kkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOkt7rM&md5=8569ba1645d445d7339b006b914d0bdb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2014.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2014.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DMadhugiri%26aufirst%3DR.%26aulast%3DFricke%26aufirst%3DM.%26aulast%3DMarz%26aufirst%3DM.%26aulast%3DZiebuhr%26aufirst%3DJ.%26atitle%3DRNA%2520Structure%2520Analysis%2520of%2520Alphacoronavirus%2520Terminal%2520Genome%2520Regions%26jtitle%3DVirus%2520Res.%26date%3D2014%26volume%3D194%26spage%3D76%26epage%3D89%26doi%3D10.1016%2Fj.virusres.2014.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, M. L.</span></span> <span> </span><span class="NLM_article-title">X-Ray Crystal Structure of Rocaglamide, a Novel Antileukemic I H-Cyclopenta[b]Benzofuran from Aglaia Elliptifolia</span>. <i>J. Chem. Soc., Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>260</i></span>,  <span class="NLM_fpage">1150</span>– <span class="NLM_lpage">1151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1039%2Fc39820001150" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1982&pages=1150-1151&author=M.+L.+King&title=X-Ray+Crystal+Structure+of+Rocaglamide%2C+a+Novel+Antileukemic+I+H-Cyclopenta%5Bb%5DBenzofuran+from+Aglaia+Elliptifolia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2Fc39820001150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39820001150%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DM.%2BL.%26atitle%3DX-Ray%2520Crystal%2520Structure%2520of%2520Rocaglamide%252C%2520a%2520Novel%2520Antileukemic%2520I%2520H-Cyclopenta%255Bb%255DBenzofuran%2520from%2520Aglaia%2520Elliptifolia%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1982%26volume%3D260%26spage%3D1150%26epage%3D1151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li-Weber, M.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms and Anti-Cancer Aspects of the Medicinal Phytochemicals Rocaglamides (flavaglines)</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1791</span>– <span class="NLM_lpage">1799</span>, <span class="refDoi"> DOI: 10.1002/ijc.29013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fijc.29013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24895251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFequr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=1791-1799&author=M.+Li-Weber&title=Molecular+Mechanisms+and+Anti-Cancer+Aspects+of+the+Medicinal+Phytochemicals+Rocaglamides+%28flavaglines%29&doi=10.1002%2Fijc.29013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines)</span></div><div class="casAuthors">Li-Weber, Min</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1791-1799</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Rocaglamides (= flavaglines) are potent natural anti-cancer phytochems. that inhibit cancer growth at nanomolar concns. by the following mechanisms: (1) inhibition of translation initiation via inhibition of phosphorylation of the mRNA cap-binding eukaryotic translation initiation factor eIF4E and stabilization of RNA-binding of the translation initiation factor eIF4A in the eIF4F complex; (2) blocking cell cycle progression by activation of the ATM/ATR-Chk1/Chk2 checkpoint pathway; (3) inactivation of the heat shock factor 1 (HSF1) leading to up-regulation of thioredoxin-interacting protein (TXNIP) and consequent redn. of glucose uptake and (4) induction of apoptosis through activation of the MAPK p38 and JNK and inhibition of the Ras-CRaf-MEK-ERK signaling pathway.  Besides the anti-cancer activities, rocaglamides are also shown to protect primary cells from chemotherapy-induced cell death and alleviate inflammation- and drug-induced injury in neuronal tissues.  This review will focus on the recently discovered mol. mechanisms of the actions of rocaglamides and highlights the benefits of using rocaglamides in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3RA3J8dyvL7Vg90H21EOLACvtfcHk0lhYZTn-lf7NUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFequr0%253D&md5=ef00b49990d2ddbbb643bd5c9ce353ff</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fijc.29013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29013%26sid%3Dliteratum%253Aachs%26aulast%3DLi-Weber%26aufirst%3DM.%26atitle%3DMolecular%2520Mechanisms%2520and%2520Anti-Cancer%2520Aspects%2520of%2520the%2520Medicinal%2520Phytochemicals%2520Rocaglamides%2520%2528flavaglines%2529%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D137%26spage%3D1791%26epage%3D1799%26doi%3D10.1002%2Fijc.29013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendel, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Suppression of Translation Initiation Modulates Chemosensitivity in a Mouse Lymphoma Model</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">2651</span>– <span class="NLM_lpage">2660</span>, <span class="refDoi"> DOI: 10.1172/JCI34753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1172%2FJCI34753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18551192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1Onu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2008&pages=2651-2660&author=M.+E.+Bordeleauauthor=F.+Robertauthor=B.+Gerardauthor=L.+Lindqvistauthor=S.+M.+H.+Chenauthor=H.+G.+Wendelauthor=B.+Bremauthor=H.+Gregerauthor=S.+W.+Loweauthor=J.+A.+Porcoauthor=J.+Pelletier&title=Therapeutic+Suppression+of+Translation+Initiation+Modulates+Chemosensitivity+in+a+Mouse+Lymphoma+Model&doi=10.1172%2FJCI34753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model</span></div><div class="casAuthors">Bordeleau, Marie-Eve; Robert, Francis; Gerard, Baudouin; Lindqvist, Lisa; Chen, Samuel M. H.; Wendel, Hans-Guido; Brem, Brigitte; Greger, Harald; Lowe, Scott W.; Porco, John A., Jr.; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2651-2660</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Disablement of cell death programs in cancer cells contributes to drug resistance and in some cases has been assocd. with altered translational control.  As eukaryotic translation initiation factor 4E (eIF4E) cooperates with c-Myc during lymphomagenesis, induces drug resistance, and is a genetic modifier of the rapamycin response, we have investigated the effect of dysregulation of the ribosome recruitment phase of translation initiation on tumor progression and chemosensitivity.  The eIF4E is a subunit of eIF4F, a complex that stimulates ribosome recruitment during translation initiation by delivering the DEAD-box RNA helicase eIF4A to the 5' end of mRNAs.  The eIF4A is thought to prep. a ribosome landing pad on mRNA templates for incoming 40S ribosomes (and assocd. factors).  Using small mol. screening, we found that cyclopenta[b]benzofuran flavaglines, a class of natural products, modulate eIF4A activity and inhibit translation initiation.  One member of this class of compds., silvestrol, was able to enhance chemosensitivity in a mouse lymphoma model in which carcinogenesis is driven by phosphatase and tensin homolog (PTEN) inactivation or elevated eIF4E levels.  These results establish that targeting translation initiation can restore drug sensitivity in vivo and provide an approach to modulating chemosensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBHqlb5KiKfLVg90H21EOLACvtfcHk0lhYZTn-lf7NUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1Onu7Y%253D&md5=74f89a2ff3038033e6d52448555943d0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1172%2FJCI34753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI34753%26sid%3Dliteratum%253Aachs%26aulast%3DBordeleau%26aufirst%3DM.%2BE.%26aulast%3DRobert%26aufirst%3DF.%26aulast%3DGerard%26aufirst%3DB.%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DS.%2BM.%2BH.%26aulast%3DWendel%26aufirst%3DH.%2BG.%26aulast%3DBrem%26aufirst%3DB.%26aulast%3DGreger%26aufirst%3DH.%26aulast%3DLowe%26aufirst%3DS.%2BW.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DTherapeutic%2520Suppression%2520of%2520Translation%2520Initiation%2520Modulates%2520Chemosensitivity%2520in%2520a%2520Mouse%2520Lymphoma%2520Model%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2008%26volume%3D118%26spage%3D2651%26epage%3D2660%26doi%3D10.1172%2FJCI34753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingolia, N. T.</span></span> <span> </span><span class="NLM_article-title">Rocaglates Convert DEAD-Box Protein eIF4A into a Sequence-Selective Translational Repressor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1038/nature17978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnature17978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27309803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSksbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=558-561&author=S.+Iwasakiauthor=S.+N.+Floorauthor=N.+T.+Ingolia&title=Rocaglates+Convert+DEAD-Box+Protein+eIF4A+into+a+Sequence-Selective+Translational+Repressor&doi=10.1038%2Fnature17978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor</span></div><div class="casAuthors">Iwasaki, Shintaro; Floor, Stephen N.; Ingolia, Nicholas T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7608</span>),
    <span class="NLM_cas:pages">558-561</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Rocaglamide A (RocA) typifies a class of protein synthesis inhibitors that selectively kill aneuploid tumor cells and repress translation of specific mRNAs.  RocA targets eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase; its mRNA selectivity is proposed to reflect highly structured 5' untranslated regions that depend strongly on eIF4A-mediated unwinding.  However, rocaglate treatment may not phenocopy the loss of eIF4A activity, as these drugs actually increase the affinity between eIF4A and RNA.  Here we show that secondary structure in 5' untranslated regions is only a minor determinant for RocA selectivity and that RocA does not repress translation by reducing eIF4A availability.  Rather, in vitro and in cells, RocA specifically clamps eIF4A onto polypurine sequences in an ATP-independent manner.  This artificially clamped eIF4A blocks 43S scanning, leading to premature, upstream translation initiation and reducing protein expression from transcripts bearing the RocA-eIF4A target sequence.  In elucidating the mechanism of selective translation repression by this lead anti-cancer compd., we provide an example of a drug stabilizing sequence-selective RNA-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR6CpuR_XHqLVg90H21EOLACvtfcHk0lhYZTn-lf7NUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSksbjN&md5=8e4735525578a70efe5731e02146c31b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature17978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17978%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DS.%26aulast%3DFloor%26aufirst%3DS.%2BN.%26aulast%3DIngolia%26aufirst%3DN.%2BT.%26atitle%3DRocaglates%2520Convert%2520DEAD-Box%2520Protein%2520eIF4A%2520into%2520a%2520Sequence-Selective%2520Translational%2520Repressor%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D558%26epage%3D561%26doi%3D10.1038%2Fnature17978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicia-Vázquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katigbak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, EIF4A</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2340</span>– <span class="NLM_lpage">2347</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.celrep.2016.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27239032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVSlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2340-2347&author=J.+Chuauthor=G.+Galicia-V%C3%A1zquezauthor=R.+Cencicauthor=J.+R.+Millsauthor=A.+Katigbakauthor=J.+A.+Porcoauthor=J.+Pelletier&title=CRISPR-Mediated+Drug-Target+Validation+Reveals+Selective+Pharmacological+Inhibition+of+the+RNA+Helicase%2C+EIF4A&doi=10.1016%2Fj.celrep.2016.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A</span></div><div class="casAuthors">Chu, Jennifer; Galicia-Vazquez, Gabriela; Cencic, Regina; Mills, John R.; Katigbak, Alexandra; Porco, John A., Jr.; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2340-2347</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Targeting translation initiation is an emerging anti-neoplastic strategy that capitalizes on de-regulated upstream MAPK and PI3K-mTOR signaling pathways in cancers.  A key regulator of translation that controls ribosome recruitment flux is eukaryotic initiation factor (eIF) 4F, a hetero-trimeric complex composed of the cap binding protein eIF4E, the scaffolding protein eIF4G, and the RNA helicase eIF4A.  Small mol. inhibitors targeting eIF4F display promising anti-neoplastic activity in preclin. settings.  Among these are some rocaglate family members that are well tolerated in vivo, deplete eIF4F of its eIF4A helicase subunit, have shown activity as single agents in several xenograft models, and can reverse acquired resistance to MAPK and PI3K-mTOR targeted therapies.  Herein, we highlight the power of using genetic complementation approaches and CRISPR/Cas9-mediated editing for drug-target validation ex vivo and in vivo, linking the anti-tumor properties of rocaglates to eIF4A inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTlJAdKCxSfbVg90H21EOLACvtfcHk0lgCWbESZ_o_5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVSlt7s%253D&md5=c84a9a808dcb119306303c6a8aa68b5b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DGalicia-V%25C3%25A1zquez%26aufirst%3DG.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DMills%26aufirst%3DJ.%2BR.%26aulast%3DKatigbak%26aufirst%3DA.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DCRISPR-Mediated%2520Drug-Target%2520Validation%2520Reveals%2520Selective%2520Pharmacological%2520Inhibition%2520of%2520the%2520RNA%2520Helicase%252C%2520EIF4A%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D15%26spage%3D2340%26epage%3D2347%26doi%3D10.1016%2Fj.celrep.2016.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shichino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodeoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imataka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuzawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingolia, N. T.</span></span> <span> </span><span class="NLM_article-title">The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2018.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.molcel.2018.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30595437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlyn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2019&pages=738-748&author=S.+Iwasakiauthor=W.+Iwasakiauthor=M.+Takahashiauthor=A.+Sakamotoauthor=C.+Watanabeauthor=Y.+Shichinoauthor=S.+N.+Floorauthor=K.+Fujiwaraauthor=M.+Mitoauthor=K.+Dodoauthor=M.+Sodeokaauthor=H.+Imatakaauthor=T.+Honmaauthor=K.+Fukuzawaauthor=T.+Itoauthor=N.+T.+Ingolia&title=The+Translation+Inhibitor+Rocaglamide+Targets+a+Bimolecular+Cavity+between+eIF4A+and+Polypurine+RNA&doi=10.1016%2Fj.molcel.2018.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA</span></div><div class="casAuthors">Iwasaki, Shintaro; Iwasaki, Wakana; Takahashi, Mari; Sakamoto, Ayako; Watanabe, Chiduru; Shichino, Yuichi; Floor, Stephen N.; Fujiwara, Koichi; Mito, Mari; Dodo, Kosuke; Sodeoka, Mikiko; Imataka, Hiroaki; Honma, Teruki; Fukuzawa, Kaori; Ito, Takuhiro; Ingolia, Nicholas T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">738-748.e9</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A class of translation inhibitors, exemplified by the natural product rocaglamide A (RocA), isolated from Aglaia genus plants, exhibits antitumor activity by clamping eukaryotic translation initiation factor 4A (eIF4A) onto polypurine sequences in mRNAs.  This unusual inhibitory mechanism raises the question of how the drug imposes sequence selectivity onto a general translation factor.  Here, we detd. the crystal structure of the human eIF4A1·ATP analog·RocA·polypurine RNA complex.  RocA targets the "bi-mol. cavity" formed characteristically by eIF4A1 and a sharply bent pair of consecutive purines in the RNA.  Natural amino acid substitutions found in Aglaia eIF4As changed the cavity shape, leading to RocA resistance.  This study provides an example of an RNA-sequence-selective interfacial inhibitor fitting into the space shaped cooperatively by protein and RNA with specific sequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUUblvotYlCLVg90H21EOLACvtfcHk0lgCWbESZ_o_5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlyn&md5=5a79ee2e73386187b23310837d731645</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2018.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2018.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DS.%26aulast%3DIwasaki%26aufirst%3DW.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSakamoto%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DC.%26aulast%3DShichino%26aufirst%3DY.%26aulast%3DFloor%26aufirst%3DS.%2BN.%26aulast%3DFujiwara%26aufirst%3DK.%26aulast%3DMito%26aufirst%3DM.%26aulast%3DDodo%26aufirst%3DK.%26aulast%3DSodeoka%26aufirst%3DM.%26aulast%3DImataka%26aufirst%3DH.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DFukuzawa%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DIngolia%26aufirst%3DN.%2BT.%26atitle%3DThe%2520Translation%2520Inhibitor%2520Rocaglamide%2520Targets%2520a%2520Bimolecular%2520Cavity%2520between%2520eIF4A%2520and%2520Polypurine%2520RNA%26jtitle%3DMol.%2520Cell%26date%3D2019%26volume%3D73%26spage%3D738%26epage%3D748%26doi%3D10.1016%2Fj.molcel.2018.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kardono, L. B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afriastini, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riswan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarsiero, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairchild, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farnsworth, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordell, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzuto, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinghorn, A. D.</span></span> <span> </span><span class="NLM_article-title">Silvestrol and Episilvestrol, Potential Anticancer Rocaglate Derivatives from Aglaia Silvestris</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">3350</span>– <span class="NLM_lpage">3358</span>, <span class="refDoi"> DOI: 10.1021/jo040120f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo040120f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVSqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=3350-3358&author=B.+Y.+Hwangauthor=B.+N.+Suauthor=H.+Chaiauthor=Q.+Miauthor=L.+B.+S.+Kardonoauthor=J.+J.+Afriastiniauthor=S.+Riswanauthor=B.+D.+Santarsieroauthor=A.+D.+Mesecarauthor=R.+Wildauthor=C.+R.+Fairchildauthor=G.+D.+Viteauthor=W.+C.+Roseauthor=N.+R.+Farnsworthauthor=G.+A.+Cordellauthor=J.+M.+Pezzutoauthor=S.+M.+Swansonauthor=A.+D.+Kinghorn&title=Silvestrol+and+Episilvestrol%2C+Potential+Anticancer+Rocaglate+Derivatives+from+Aglaia+Silvestris&doi=10.1021%2Fjo040120f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris</span></div><div class="casAuthors">Hwang, Bang Yeon; Su, Bao-Ning; Chai, Heebyung; Mi, Qiuwen; Kardono, Leonardus B. S.; Afriastini, Johar J.; Riswan, Soedarsono; Santarsiero, Bernard D.; Mesecar, Andrew D.; Wild, Robert; Fairchild, Craig R.; Vite, Gregory D.; Rose, William C.; Farnsworth, Norman R.; Cordell, Geoffrey A.; Pezzuto, John M.; Swanson, Steven M.; Kinghorn, A. Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3350-3358</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two cytotoxic rocaglate derivs. possessing an unusual dioxanyloxy unit, silvestrol (I) and episilvestrol (II), were isolated from the fruits and twigs of Aglaia silvestris by bioassay-guided fractionation monitored with a human oral epidermoid carcinoma (KB) cell line.  Addnl., two new baccharane-type triterpenoids, 17,24-epoxy-25-hydroxybaccharan-3-one (III) and 17,24-epoxy-25-hydroxy-3-oxobaccharan-21-oic acid (IV), as well as eleven known compds., 1β,6α-dihydroxy-4(15)-eudesmene (5), ferulic acid (6), grasshopper ketone (7), apigenin, cabraleone, chrysoeriol, 1β,4β-dihydroxy-6α,15α-epoxyeudesmane, 4-hydroxy-3-methoxyacetophenone, 4-hydroxyphenethyl alc., ocotillone, and β-sitosterol 3-O-β-D-glucopyranoside, were also isolated and characterized.  The structures of compds. (I-IV) were elucidated by spectroscopic studies and by chem. transformation.  The abs. stereochem. of silvestrol was established by a X-ray diffraction study of its di-p-bromobenzoate deriv., and the structure of 3 was also confirmed by single-crystal X-ray diffraction.  The isolates and chem. transformation products were evaluated for cytotoxicity against several human cancer cell lines, and silvestrol and episilvestrol exhibited potent in vitro cytotoxic activity.  Silvestrol was further evaluated in vivo in the hollow fiber test and in the murine P-388 leukemia model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGremy-QmdRLZbVg90H21EOLACvtfcHk0lgCWbESZ_o_5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVSqtrw%253D&md5=dff2b5076e06ea4a33f76e4f796b49ec</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjo040120f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo040120f%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DB.%2BY.%26aulast%3DSu%26aufirst%3DB.%2BN.%26aulast%3DChai%26aufirst%3DH.%26aulast%3DMi%26aufirst%3DQ.%26aulast%3DKardono%26aufirst%3DL.%2BB.%2BS.%26aulast%3DAfriastini%26aufirst%3DJ.%2BJ.%26aulast%3DRiswan%26aufirst%3DS.%26aulast%3DSantarsiero%26aufirst%3DB.%2BD.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26aulast%3DWild%26aufirst%3DR.%26aulast%3DFairchild%26aufirst%3DC.%2BR.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DRose%26aufirst%3DW.%2BC.%26aulast%3DFarnsworth%26aufirst%3DN.%2BR.%26aulast%3DCordell%26aufirst%3DG.%2BA.%26aulast%3DPezzuto%26aufirst%3DJ.%2BM.%26aulast%3DSwanson%26aufirst%3DS.%2BM.%26aulast%3DKinghorn%26aufirst%3DA.%2BD.%26atitle%3DSilvestrol%2520and%2520Episilvestrol%252C%2520Potential%2520Anticancer%2520Rocaglate%2520Derivatives%2520from%2520Aglaia%2520Silvestris%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D3350%26epage%3D3358%26doi%3D10.1021%2Fjo040120f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozewski, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goettl, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarjoura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinghorn, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grever, M. R.</span></span> <span> </span><span class="NLM_article-title">The Novel Plant-Derived Agent Silvestrol Has B-Cell Selective Activity in Chronic Lymphocytic Leukemia and Acute Lymphoblastic Leukemia in Vitro and in Vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">4656</span>– <span class="NLM_lpage">4666</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-09-175430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1182%2Fblood-2008-09-175430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19190247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvVyqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4656-4666&author=D.+M.+Lucasauthor=R.+B.+Edwardsauthor=G.+Lozanskiauthor=D.+A.+Westauthor=J.+D.+Shinauthor=M.+A.+Vargoauthor=M.+E.+Davisauthor=D.+M.+Rozewskiauthor=A.+J.+Johnsonauthor=B.+N.+Suauthor=V.+M.+Goettlauthor=N.+A.+Heeremaauthor=T.+S.+Linauthor=A.+Lehmanauthor=X.+Zhangauthor=D.+Jarjouraauthor=D.+J.+Newmanauthor=J.+C.+Byrdauthor=A.+D.+Kinghornauthor=M.+R.+Grever&title=The+Novel+Plant-Derived+Agent+Silvestrol+Has+B-Cell+Selective+Activity+in+Chronic+Lymphocytic+Leukemia+and+Acute+Lymphoblastic+Leukemia+in+Vitro+and+in+Vivo&doi=10.1182%2Fblood-2008-09-175430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo</span></div><div class="casAuthors">Lucas, David M.; Edwards, Ryan B.; Lozanski, Gerard; West, Derek A.; Shin, Jungook D.; Vargo, Melissa A.; Davis, Melanie E.; Rozewski, Darlene M.; Johnson, Amy J.; Su, Bao-Ning; Goettl, Virginia M.; Heerema, Nyla A.; Lin, Thomas S.; Lehman, Amy; Zhang, Xiaoli; Jarjoura, David; Newman, David J.; Byrd, John C.; Kinghorn, A. Douglas; Grever, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4656-4666</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Therapeutic options for advanced B-cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) are limited.  Available treatments can also deplete T lymphocytes, leaving patients at risk of life-threatening infections.  In the National Cancer Institute cell line screen, the structurally unique natural product silvestrol produces an unusual pattern of cytotoxicity that suggests activity in leukemia and selectivity for B cells.  We investigated silvestrol efficacy using primary human B-leukemia cells, established B-leukemia cell lines, and animal models.  In CLL cells, silvestrol LC50 (concn. lethal to 50%) is 6.9 nM at 72 h.  At this concn., there is no difference in sensitivity of cells from patients with or without the del(17p13.1) abnormality.  In isolated cells and whole blood, silvestrol is more cytotoxic toward B cells than T cells.  Silvestrol causes early redn. in Mcl-1 expression due to translational inhibition with subsequent mitochondrial damage, as evidenced by reactive oxygen species generation and membrane depolarization.  In vivo, silvestrol causes significant B-cell redn. in Eμ-Tcl-1 transgenic mice and significantly extends survival of 697 xenograft severe combined immunodeficient (SCID) mice without discernible toxicity.  These data indicate silvestrol has efficacy against B cells in vitro and in vivo and identify translational inhibition as a potential therapeutic target in B-cell leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ws9D3VBlYLVg90H21EOLACvtfcHk0lh0ikDIvCTxoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvVyqurg%253D&md5=8c43343a06d2b7e2a8633b5c2aa78df4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-09-175430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-09-175430%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DD.%2BM.%26aulast%3DEdwards%26aufirst%3DR.%2BB.%26aulast%3DLozanski%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DD.%2BA.%26aulast%3DShin%26aufirst%3DJ.%2BD.%26aulast%3DVargo%26aufirst%3DM.%2BA.%26aulast%3DDavis%26aufirst%3DM.%2BE.%26aulast%3DRozewski%26aufirst%3DD.%2BM.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSu%26aufirst%3DB.%2BN.%26aulast%3DGoettl%26aufirst%3DV.%2BM.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DLehman%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJarjoura%26aufirst%3DD.%26aulast%3DNewman%26aufirst%3DD.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DKinghorn%26aufirst%3DA.%2BD.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26atitle%3DThe%2520Novel%2520Plant-Derived%2520Agent%2520Silvestrol%2520Has%2520B-Cell%2520Selective%2520Activity%2520in%2520Chronic%2520Lymphocytic%2520Leukemia%2520and%2520Acute%2520Lymphoblastic%2520Leukemia%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D4656%26epage%3D4666%26doi%3D10.1182%2Fblood-2008-09-175430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicia-Vázquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukarieh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teodoro, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Antitumor Activity and Mechanism of Action of the Cyclopenta[b]Benzofuran, Silvestrol</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e5223</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0005223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pone.0005223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19401772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BD1MzgvVGntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=e5223&author=R.+Cencicauthor=M.+Carrierauthor=G.+Galicia-V%C3%A1zquezauthor=M.+E.+Bordeleauauthor=R.+Sukariehauthor=A.+Bourdeauauthor=B.+Bremauthor=J.+G.+Teodoroauthor=H.+Gregerauthor=M.+L.+Tremblayauthor=J.+A.+Porcoauthor=J.+Pelletier&title=Antitumor+Activity+and+Mechanism+of+Action+of+the+Cyclopenta%5Bb%5DBenzofuran%2C+Silvestrol&doi=10.1371%2Fjournal.pone.0005223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol</span></div><div class="casAuthors">Cencic Regina; Carrier Marilyn; Galicia-Vazquez Gabriela; Bordeleau Marie-Eve; Sukarieh Rami; Bourdeau Annie; Brem Brigitte; Teodoro Jose G; Greger Harald; Tremblay Michel L; Porco John A Jr; Pelletier Jerry</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e5223</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Flavaglines are a family of natural products from the genus Aglaia that exhibit anti-cancer activity in vitro and in vivo and inhibit translation initiation.  They have been shown to modulate the activity of eIF4A, the DEAD-box RNA helicase subunit of the eukaryotic initiation factor (eIF) 4F complex, a complex that stimulates ribosome recruitment during translation initiation.  One flavagline, silvestrol, is capable of modulating chemosensitivity in a mechanism-based mouse model.  METHODOLOGY/PRINCIPAL FINDINGS:  Among a number of flavagline family members tested herein, we find that silvestrol is the more potent translation inhibitor among these.  We find that silvestrol impairs the ribosome recruitment step of translation initiation by affecting the composition of the eukaryotic initiation factor (eIF) 4F complex.  We show that silvestrol exhibits significant anticancer activity in human breast and prostate cancer xenograft models, and that this is associated with increased apoptosis, decreased proliferation, and inhibition of angiogenesis.  We demonstrate that targeting translation by silvestrol results in preferential inhibition of weakly initiating mRNAs.  CONCLUSIONS/SIGNIFICANCE:  Our results indicate that silvestrol is a potent anti-cancer compound in vivo that exerts its activity by affecting survival pathways as well as angiogenesis.  We propose that silvestrol mediates its effects by preferentially inhibiting translation of malignancy-related mRNAs.  Silvestrol appears to be well tolerated in animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0uaNMC9zaUgaK-_ZudimnfW6udTcc2eYMsFaHpJfko7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzgvVGntw%253D%253D&md5=48975b3546378c2340d5511d2564399d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0005223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0005223%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DCarrier%26aufirst%3DM.%26aulast%3DGalicia-V%25C3%25A1zquez%26aufirst%3DG.%26aulast%3DBordeleau%26aufirst%3DM.%2BE.%26aulast%3DSukarieh%26aufirst%3DR.%26aulast%3DBourdeau%26aufirst%3DA.%26aulast%3DBrem%26aufirst%3DB.%26aulast%3DTeodoro%26aufirst%3DJ.%2BG.%26aulast%3DGreger%26aufirst%3DH.%26aulast%3DTremblay%26aufirst%3DM.%2BL.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DAntitumor%2520Activity%2520and%2520Mechanism%2520of%2520Action%2520of%2520the%2520Cyclopenta%255Bb%255DBenzofuran%252C%2520Silvestrol%26jtitle%3DPLoS%2520One%26date%3D2009%26volume%3D4%26spage%3De5223%26doi%3D10.1371%2Fjournal.pone.0005223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trnkus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Synergistic Effect of Inhibiting Translation Initiation in Combination with Cytotoxic Agents in Acute Myelogenous Leukemia Cells</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2009.07.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.leukres.2009.07.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19726085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Gmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=535-541&author=R.+Cencicauthor=M.+Carrierauthor=A.+Trnkusauthor=J.+A.+Porcoauthor=M.+Mindenauthor=J.+Pelletier&title=Synergistic+Effect+of+Inhibiting+Translation+Initiation+in+Combination+with+Cytotoxic+Agents+in+Acute+Myelogenous+Leukemia+Cells&doi=10.1016%2Fj.leukres.2009.07.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells</span></div><div class="casAuthors">Cencic, Regina; Carrier, Marilyn; Trnkus, Amanda; Porco, John A.; Minden, Mark; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">535-541</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We have previously shown that inhibition of translation initiation, using the small mol. inhibitor silvestrol, induces apoptosis in a pre-clin. murine lymphoma model when combined with daunorubicin.  Silvestrol blocks ribosome recruitment by targeting the RNA helicase, eIF4A, which is required for this process.  Here we investigate the sensitivity of acute myelogenous leukemia (AML) cell lines to protein synthesis inhibition in combination with the std. cytotoxic agents daunorubicin, etoposide, and cytarabine.  Silvestrol shows synergy with std.-of-care agents in AML cell lines and synergizes with ABT-737, a small mol. inhibitor of Bcl-XL and Bcl-2.  The in vitro synergy between silvestrol and the cytotoxic drugs used in AML therapy provides a basis for in vivo evaluation of these combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdyURmWhIHq7Vg90H21EOLACvtfcHk0li68A6y_IocEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Gmsrc%253D&md5=32992bda5b2a9218030980c01ae84072</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2009.07.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2009.07.043%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DCarrier%26aufirst%3DM.%26aulast%3DTrnkus%26aufirst%3DA.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DMinden%26aufirst%3DM.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DSynergistic%2520Effect%2520of%2520Inhibiting%2520Translation%2520Initiation%2520in%2520Combination%2520with%2520Cytotoxic%2520Agents%2520in%2520Acute%2520Myelogenous%2520Leukemia%2520Cells%26jtitle%3DLeuk.%2520Res.%26date%3D2010%26volume%3D34%26spage%3D535%26epage%3D541%26doi%3D10.1016%2Fj.leukres.2009.07.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sass, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarjoura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinghorn, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grever, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, D. M.</span></span> <span> </span><span class="NLM_article-title">Resistance to the Translation Initiation Inhibitor Silvestrol Is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">357</span>, <span class="refDoi"> DOI: 10.1208/s12248-011-9276-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1208%2Fs12248-011-9276-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21538216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFKjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=357&author=S.+V.+Guptaauthor=E.+J.+Sassauthor=M.+E.+Davisauthor=R.+B.+Edwardsauthor=G.+Lozanskiauthor=N.+A.+Heeremaauthor=A.+Lehmanauthor=X.+Zhangauthor=D.+Jarjouraauthor=J.+C.+Byrdauthor=L.+Panauthor=K.+K.+Chanauthor=A.+D.+Kinghornauthor=M.+A.+Phelpsauthor=M.+R.+Greverauthor=D.+M.+Lucas&title=Resistance+to+the+Translation+Initiation+Inhibitor+Silvestrol+Is+Mediated+by+ABCB1%2FP-Glycoprotein+Overexpression+in+Acute+Lymphoblastic+Leukemia+Cells&doi=10.1208%2Fs12248-011-9276-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells</span></div><div class="casAuthors">Gupta, Sneha V.; Sass, Ellen J.; Davis, Melanie E.; Edwards, Ryan B.; Lozanski, Gerard; Heerema, Nyla A.; Lehman, Amy; Zhang, Xiaoli; Jarjoura, David; Byrd, John C.; Pan, Li; Chan, Kenneth K.; Kinghorn, A. Douglas; Phelps, Mitch A.; Grever, Michael R.; Lucas, David M.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">357-364</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Protein synthesis is a powerful therapeutic target in leukemias and other cancers, but few pharmacol. viable agents are available that affect this process directly.  The plant-derived agent silvestrol specifically inhibits translation initiation by interfering with eIF4A/mRNA assembly with eIF4F.  Silvestrol has potent in vitro and in vivo activity in multiple cancer models including acute lymphoblastic leukemia (ALL) and is under pre-clin. development by the US National Cancer Institute, but no information is available about potential mechanisms of resistance.  In a sep. report, we showed that i.p. silvestrol is approx. 100% bioavailable systemically, although oral doses were only 1% bioavailable despite an apparent lack of metab.  To explore mechanisms of silvestrol resistance and the possible role of efflux transporters in silvestrol disposition, we characterized multi-drug resistance transporter expression and function in a silvestrol-resistant ALL cell line generated via culture of the 697 ALL cell line in gradually increasing silvestrol concns.  This resistant cell line, 697-R, shows significant upregulation of ABCB1 mRNA and P-glycoprotein (Pgp) as well as cross-resistance to known Pgp substrates vincristine and romidepsin.  Furthermore, 697-R cells readily efflux the fluorescent Pgp substrate rhodamine 123.  This effect is prevented by Pgp inhibitors verapamil and cyclosporin A, as well as siRNA to ABCB1, with concomitant re-sensitization to silvestrol.  Together, these data indicate that silvestrol is a substrate of Pgp, a potential obstacle that must be considered in the development of silvestrol for oral delivery or targeting to tumors protected by Pgp overexpression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj1JyZVHbPo7Vg90H21EOLACvtfcHk0li68A6y_IocEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFKjtbg%253D&md5=cc9f9f874b6f71720dd673a061418e0a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1208%2Fs12248-011-9276-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-011-9276-7%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DS.%2BV.%26aulast%3DSass%26aufirst%3DE.%2BJ.%26aulast%3DDavis%26aufirst%3DM.%2BE.%26aulast%3DEdwards%26aufirst%3DR.%2BB.%26aulast%3DLozanski%26aufirst%3DG.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DLehman%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJarjoura%26aufirst%3DD.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DK.%2BK.%26aulast%3DKinghorn%26aufirst%3DA.%2BD.%26aulast%3DPhelps%26aufirst%3DM.%2BA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DLucas%26aufirst%3DD.%2BM.%26atitle%3DResistance%2520to%2520the%2520Translation%2520Initiation%2520Inhibitor%2520Silvestrol%2520Is%2520Mediated%2520by%2520ABCB1%252FP-Glycoprotein%2520Overexpression%2520in%2520Acute%2520Lymphoblastic%2520Leukemia%2520Cells%26jtitle%3DAAPS%2520J.%26date%3D2011%26volume%3D13%26spage%3D357%26doi%3D10.1208%2Fs12248-011-9276-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saradhi, U. V. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinghorn, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grever, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. K.</span></span> <span> </span><span class="NLM_article-title">Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography-Tandem Mass Spectrometry</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1208/s12248-011-9273-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1208%2Fs12248-011-9273-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21499689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFKjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=347-356&author=U.+V.+R.+V.+Saradhiauthor=S.+V.+Guptaauthor=M.+Chiuauthor=J.+Wangauthor=Y.+Lingauthor=Z.+Liuauthor=D.+J.+Newmanauthor=J.+M.+Coveyauthor=A.+D.+Kinghornauthor=G.+Marcucciauthor=D.+M.+Lucasauthor=M.+R.+Greverauthor=M.+A.+Phelpsauthor=K.+K.+Chan&title=Characterization+of+Silvestrol+Pharmacokinetics+in+Mice+Using+Liquid+Chromatography-Tandem+Mass+Spectrometry&doi=10.1208%2Fs12248-011-9273-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography-Tandem Mass Spectrometry</span></div><div class="casAuthors">Saradhi, U. V. R. Vijaya; Gupta, Sneha V.; Chiu, Ming; Wang, Jiang; Ling, Yonghua; Liu, Zhongfa; Newman, David J.; Covey, Joseph M.; Kinghorn, A. Douglas; Marcucci, Guido; Lucas, David M.; Grever, Michael R.; Phelps, Mitch A.; Chan, Kenneth K.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-356</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A sensitive and specific liq. chromatog.-tandem mass spectrometry method was developed and validated for the quantification of the plant natural product silvestrol in mice, using ansamitocin P-3 as the internal std.  The method was validated in plasma with a lower limit of quantification of 1 ng/mL, accuracy ranging from 87 to 114%, and precision (coeff. of variation) below 15%.  The validated method was used to characterize pharmacokinetics in C57BL/6 mice and metab. in mouse, human and rat plasma, and liver microsomes.  Mice were dosed with silvestrol formulated in hydroxypropyl-β-cyclodextrin via i.v., i.p., and oral routes followed by blood sampling up to 24 h.  I.p. systemic availability was 100%, but oral administration resulted in only 1.7% bioavailability.  Gradual degrdn. of silvestrol was obsd. in mouse and human plasma, with approx. 60% of the parent drug remaining after 6 h.  In rat plasma, however, silvestrol was completely converted to silvestric acid (SA) within 10 min.  Evaluation in microsomes provided further evidence that the main metabolite formed was SA, which subsequently showed no cytotoxic or cytostatic activity in a silvestrol-sensitive lymphoblastic cell line.  The ability of the anal. assay to measure tissue levels of silvestrol was evaluated in liver, brain, kidney, and spleen.  Results indicated the method was capable of accurately measuring tissue levels of silvestrol and suggested it has a relatively low distribution to brain.  Together, these data suggest an overall favorable pharmacokinetic profile of silvestrol in mice and provide crucial information for its continued development toward potential clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxRcQr8K0Ux7Vg90H21EOLACvtfcHk0lgD4vLWfRXedA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFKjtbs%253D&md5=67657244ab1561c6a61aaeb9496abbbd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1208%2Fs12248-011-9273-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-011-9273-x%26sid%3Dliteratum%253Aachs%26aulast%3DSaradhi%26aufirst%3DU.%2BV.%2BR.%2BV.%26aulast%3DGupta%26aufirst%3DS.%2BV.%26aulast%3DChiu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DNewman%26aufirst%3DD.%2BJ.%26aulast%3DCovey%26aufirst%3DJ.%2BM.%26aulast%3DKinghorn%26aufirst%3DA.%2BD.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DLucas%26aufirst%3DD.%2BM.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DPhelps%26aufirst%3DM.%2BA.%26aulast%3DChan%26aufirst%3DK.%2BK.%26atitle%3DCharacterization%2520of%2520Silvestrol%2520Pharmacokinetics%2520in%2520Mice%2520Using%2520Liquid%2520Chromatography-Tandem%2520Mass%2520Spectrometry%26jtitle%3DAAPS%2520J.%26date%3D2011%26volume%3D13%26spage%3D347%26epage%3D356%26doi%3D10.1208%2Fs12248-011-9273-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, J. H.</span></span> <span> </span><span class="NLM_article-title">EIF4A Inhibition: Ready for Primetime?</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">35515</span>– <span class="NLM_lpage">35516</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.26268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.18632%2Foncotarget.26268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30473746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BB3crksFehsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=35515-35516&author=T.+A.+Cunninghamauthor=E.+Chapmanauthor=J.+H.+Schatz&title=EIF4A+Inhibition%3A+Ready+for+Primetime%3F&doi=10.18632%2Foncotarget.26268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">eIF4A inhibition: ready for primetime?</span></div><div class="casAuthors">Cunningham Tyler A; Chapman Eli; Schatz Jonathan H</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">85</span>),
    <span class="NLM_cas:pages">35515-35516</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSP_Peh7v7xH0EgZCMqtRBifW6udTcc2eYo29k3qq8JPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crksFehsQ%253D%253D&md5=c08ce0ce96db85fcb9af743f659f8431</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.26268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.26268%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DT.%2BA.%26aulast%3DChapman%26aufirst%3DE.%26aulast%3DSchatz%26aufirst%3DJ.%2BH.%26atitle%3DEIF4A%2520Inhibition%253A%2520Ready%2520for%2520Primetime%253F%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D35515%26epage%3D35516%26doi%3D10.18632%2Foncotarget.26268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span> <span> </span><span class="NLM_article-title">Progress in the Total Synthesis of Rocaglamide</span>. <i>ISRN Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.5402/2011/239817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.5402%2F2011%2F239817" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=1-7&author=X.+Caiauthor=B.+Xieauthor=H.+Guo&title=Progress+in+the+Total+Synthesis+of+Rocaglamide&doi=10.5402%2F2011%2F239817"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.5402%2F2011%2F239817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5402%252F2011%252F239817%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DH.%26atitle%3DProgress%2520in%2520the%2520Total%2520Synthesis%2520of%2520Rocaglamide%26jtitle%3DISRN%2520Org.%2520Chem.%26date%3D2011%26volume%3D2011%26spage%3D1%26epage%3D7%26doi%3D10.5402%2F2011%2F239817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Hamdan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Synthesis of Flavaglines, a Family of Potent Bioactive Natural Compounds Originating from Traditional Chinese Medicine</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">5908</span>– <span class="NLM_lpage">5916</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201600437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fejoc.201600437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1CltLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=5908-5916&author=Q.+Zhaoauthor=H.+Abou-Hamdanauthor=L.+D%C3%A9saubry&title=Recent+Advances+in+the+Synthesis+of+Flavaglines%2C+a+Family+of+Potent+Bioactive+Natural+Compounds+Originating+from+Traditional+Chinese+Medicine&doi=10.1002%2Fejoc.201600437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Synthesis of Flavaglines, a Family of Potent Bioactive Natural Compounds Originating from Traditional Chinese Medicine</span></div><div class="casAuthors">Zhao, Qian; Abou-Hamdan, Hussein; Desaubry, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">5908-5916</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Flavaglines constitute a distinctive family of plant metabolites isolated from medicinal plants of the genus Aglaia.  These compds. exhibit a broad spectrum of distinctive pharmacol. properties, including anti-inflammatory, neuroprotective, cardioprotective, and anticancer activities.  These natural cyclopenta[b]benzofurans are characterized by densely functionalized tricyclic frameworks, as exemplified by the structures of rocaglamide or silvestrol, which makes them extremely attractive targets for total synthesis, in addn. to their therapeutic potential.  In this review we describe the various synthetic approaches to the total synthesis of flavaglines, culminating in a new generation of diastereo- and enantioselective total syntheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4fgv5knkhj7Vg90H21EOLACvtfcHk0lgD4vLWfRXedA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1CltLjO&md5=c024d7a3f7142c42d508f4c7867557e4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201600437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201600437%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DAbou-Hamdan%26aufirst%3DH.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Synthesis%2520of%2520Flavaglines%252C%2520a%2520Family%2520of%2520Potent%2520Bioactive%2520Natural%2520Compounds%2520Originating%2520from%2520Traditional%2520Chinese%2520Medicine%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2016%26volume%3D2016%26spage%3D5908%26epage%3D5916%26doi%3D10.1002%2Fejoc.201600437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tius, M. A.</span></span> <span> </span><span class="NLM_article-title">The Evolution of the Total Synthesis of Rocaglamide</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">15929</span>– <span class="NLM_lpage">15936</span>, <span class="refDoi"> DOI: 10.1002/chem.201603312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fchem.201603312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27717051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWqtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=15929-15936&author=Z.+Zhouauthor=D.+D.+Dixonauthor=A.+Jolitauthor=M.+A.+Tius&title=The+Evolution+of+the+Total+Synthesis+of+Rocaglamide&doi=10.1002%2Fchem.201603312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The Evolution of the Total Synthesis of Rocaglamide</span></div><div class="casAuthors">Zhou, Zhe; Dixon, Darryl D.; Jolit, Anais; Tius, Marcus A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">15929-15936</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The complex flavagline, (-)-rocaglamide (I), possesses a synthetically intriguing tricyclic scaffold with five contiguous stereocenters and also exhibits potent anticancer, anti-inflammatory and insecticidal activity.  This full account details distinct approaches to (±)- and (-)-rocaglamide utilizing Bronsted acid catalyzed and asym. Pd0-catalyzed Nazarov chem. developed in our lab., resp.  The successful asym. synthesis revealed unforeseen mechanistic complexity that required adjusting our strategy to overcome an unanticipated racemization process, an unusual reversible ring-cleavage step and a very facile trialkylsilyl group migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpuqXIOS9_dbVg90H21EOLACvtfcHk0lhIaL1qct6k6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWqtbfM&md5=fe2d3b17bf8054d58af473b08fb0d82a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fchem.201603312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201603312%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DDixon%26aufirst%3DD.%2BD.%26aulast%3DJolit%26aufirst%3DA.%26aulast%3DTius%26aufirst%3DM.%2BA.%26atitle%3DThe%2520Evolution%2520of%2520the%2520Total%2520Synthesis%2520of%2520Rocaglamide%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2016%26volume%3D22%26spage%3D15929%26epage%3D15936%26doi%3D10.1002%2Fchem.201603312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nhu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzacasa, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span> <span> </span><span class="NLM_article-title">Simplified Silvestrol Analogues with Potent Cytotoxic Activity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1556</span>– <span class="NLM_lpage">1566</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201400024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fcmdc.201400024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24677741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltVSrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1556-1566&author=B.+C.+Hawkinsauthor=L.+M.+Lindqvistauthor=D.+Nhuauthor=P.+P.+Sharpauthor=D.+Segalauthor=A.+K.+Powellauthor=M.+Campbellauthor=E.+Ryanauthor=J.+M.+Chambersauthor=J.+M.+Whiteauthor=M.+A.+Rizzacasaauthor=G.+Lesseneauthor=D.+C.+S.+S.+Huangauthor=C.+J.+Burns&title=Simplified+Silvestrol+Analogues+with+Potent+Cytotoxic+Activity&doi=10.1002%2Fcmdc.201400024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Simplified Silvestrol Analogues with Potent Cytotoxic Activity</span></div><div class="casAuthors">Hawkins, Bill C.; Lindqvist, Lisa M.; Nhu, Duong; Sharp, Phillip P.; Segal, David; Powell, Andrew K.; Campbell, Michael; Ryan, Eileen; Chambers, Jennifer M.; White, Jonathan M.; Rizzacasa, Mark A.; Lessene, Guillaume; Huang, David C. S.; Burns, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1556-1566</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The complex natural products silvestrol (1) and episilvestrol (2) are inhibitors of translation initiation through binding to the DEAD-box helicase eukaryotic initiation factor 4A (eIF4A).  Both compds. are potently cytotoxic to cancer cells in vitro, and 1 has demonstrated efficacy in vivo in several xenograft cancer models.  Here we show that 2 has limited plasma membrane permeability and is metabolized in liver microsomes in a manner consistent with that reported for 1.  In addn., we have prepd. a series of analogs of these compds. where the complex pseudo-sugar at C6 has been replaced with chem. simpler moieties to improve drug-likeness.  Selected compds. from this work possess excellent activity in biochem. and cellular translation assays with potent activity against leukemia cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz75BXieKh5rVg90H21EOLACvtfcHk0lhIaL1qct6k6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltVSrtbs%253D&md5=0798d277de73bd89340d5b6df7554f88</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201400024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201400024%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DB.%2BC.%26aulast%3DLindqvist%26aufirst%3DL.%2BM.%26aulast%3DNhu%26aufirst%3DD.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DA.%2BK.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DRyan%26aufirst%3DE.%26aulast%3DChambers%26aufirst%3DJ.%2BM.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DRizzacasa%26aufirst%3DM.%2BA.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%2BS.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26atitle%3DSimplified%2520Silvestrol%2520Analogues%2520with%2520Potent%2520Cytotoxic%2520Activity%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D1556%26epage%3D1566%26doi%3D10.1002%2Fcmdc.201400024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beglov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1586</span>– <span class="NLM_lpage">1593</span>, e3. <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.chembiol.2019.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31519508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslOhur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1586-1593&author=J.+Chuauthor=W.+Zhangauthor=R.+Cencicauthor=W.+G.+Devineauthor=D.+Beglovauthor=T.+Henkelauthor=L.+E.+Brownauthor=S.+Vajdaauthor=J.+A.+Porcoauthor=J.+Pelletier&title=Amidino-Rocaglates%3A+A+Potent+Class+of+eIF4A+Inhibitors&doi=10.1016%2Fj.chembiol.2019.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors</span></div><div class="casAuthors">Chu, Jennifer; Zhang, Wenhan; Cencic, Regina; Devine, William G.; Beglov, Dmitri; Henkel, Thomas; Brown, Lauren E.; Vajda, Sandor; Porco, John A. Jr.; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1586-1593.e3</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Rocaglates share a common cyclopenta[b]benzofuran core that inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase, eIF4A.  Working as interfacial inhibitors, rocaglates stabilize the assocn. between eIF4A and RNA, which can lead to the formation of steric barriers that block initiating ribosomes.  There is significant interest in the development and expansion of rocaglate derivs., as several members of this family have been shown to possess potent anti-neoplastic activity in vitro and in vivo.  To further our understanding of rocaglate diversity and drug design, herein we explore the RNA clamping activity of >200 unique rocaglate derivs.  Through this, we report on the identification and characterization of a potent class of synthetic rocaglates called amidino-rocaglates.  These compds. are among the most potent rocaglates documented to date and, taken together, this work offers important information that will guide the future design of rocaglates with improved biol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIA_4OEeLxs7Vg90H21EOLACvtfcHk0lhIaL1qct6k6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslOhur%252FE&md5=f323bd1276dd8142e7f373eaf59d42b3</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DDevine%26aufirst%3DW.%2BG.%26aulast%3DBeglov%26aufirst%3DD.%26aulast%3DHenkel%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DL.%2BE.%26aulast%3DVajda%26aufirst%3DS.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DAmidino-Rocaglates%253A%2520A%2520Potent%2520Class%2520of%2520eIF4A%2520Inhibitors%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D1586%26epage%3D1593%26doi%3D10.1016%2Fj.chembiol.2019.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilewski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegerski, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S. H.</span></span> <span> </span><span class="NLM_article-title">Design of Development Candidate EFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5879</span>– <span class="NLM_lpage">5955</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00182</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00182" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVeis7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=5879-5955&author=J.+T.+Ernstauthor=P.+A.+Thompsonauthor=C.+Nilewskiauthor=P.+A.+Sprengelerauthor=S.+Sperryauthor=G.+Packardauthor=T.+Michelsauthor=A.+Xiangauthor=C.+Tranauthor=C.+J.+Wegerskiauthor=B.+Eamauthor=N.+P.+Youngauthor=S.+Fishauthor=J.+Chenauthor=H.+Howardauthor=J.+Stauntonauthor=J.+Molterauthor=J.+Clarineauthor=A.+Nevarezauthor=G.+G.+Chiangauthor=J.+R.+Applemanauthor=K.+R.+Websterauthor=S.+H.+Reich&title=Design+of+Development+Candidate+EFT226%2C+a+First+in+Class+Inhibitor+of+Eukaryotic+Initiation+Factor+4A+RNA+Helicase&doi=10.1021%2Facs.jmedchem.0c00182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase</span></div><div class="casAuthors">Ernst, Justin T.; Thompson, Peggy A.; Nilewski, Christian; Sprengeler, Paul A.; Sperry, Samuel; Packard, Garrick; Michels, Theodore; Xiang, Alan; Tran, Chinh; Wegerski, Christopher J.; Eam, Boreth; Young, Nathan P.; Fish, Sarah; Chen, Joan; Howard, Haleigh; Staunton, Jocelyn; Molter, Jolene; Clarine, Jeff; Nevarez, Andres; Chiang, Gary G.; Appleman, Jim R.; Webster, Kevin R.; Reich, Siegfried H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5879-5955</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulation of protein translation is a key driver for the pathogenesis of many cancers.  Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a crit. component of the eIF4F complex, which regulates cap-dependent protein synthesis.  The flavagline class of natural products (i.e., rocaglamide A) has been shown to inhibit protein synthesis by stabilizing a translation-incompetent complex for select mRNAs (mRNAs) with eIF4A.  Despite showing promising anticancer phenotypes, the development of flavagline derivs. as therapeutic agents has been hampered because of poor drug-like properties as well as synthetic complexity.  A focused effort was undertaken utilizing a ligand-based design strategy to identify a chemotype with optimized physicochem. properties.  Also, detailed mechanistic studies were undertaken to further elucidate mRNA sequence selectivity, key regulated target genes, and the assocd. antitumor phenotype.  This work led to the design of eFT226 (Zotatifin), I, a compd. with excellent physicochem. properties and significant antitumor activity that supports clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC3keA8h-DArVg90H21EOLACvtfcHk0liEXuwHeMxuNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVeis7nE&md5=05271b4aed3a70544777ad61ab66c42d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00182%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DNilewski%26aufirst%3DC.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DPackard%26aufirst%3DG.%26aulast%3DMichels%26aufirst%3DT.%26aulast%3DXiang%26aufirst%3DA.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DWegerski%26aufirst%3DC.%2BJ.%26aulast%3DEam%26aufirst%3DB.%26aulast%3DYoung%26aufirst%3DN.%2BP.%26aulast%3DFish%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHoward%26aufirst%3DH.%26aulast%3DStaunton%26aufirst%3DJ.%26aulast%3DMolter%26aufirst%3DJ.%26aulast%3DClarine%26aufirst%3DJ.%26aulast%3DNevarez%26aufirst%3DA.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26aulast%3DReich%26aufirst%3DS.%2BH.%26atitle%3DDesign%2520of%2520Development%2520Candidate%2520EFT226%252C%2520a%2520First%2520in%2520Class%2520Inhibitor%2520of%2520Eukaryotic%2520Initiation%2520Factor%25204A%2520RNA%2520Helicase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D5879%26epage%3D5955%26doi%3D10.1021%2Facs.jmedchem.0c00182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biedenkopf, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange-Grünweller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weißer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünweller, A.</span></span> <span> </span><span class="NLM_article-title">The Natural Compound Silvestrol Is a Potent Inhibitor of Ebola Virus Replication</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2016.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.antiviral.2016.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27864075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWnsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2017&pages=76-81&author=N.+Biedenkopfauthor=K.+Lange-Gr%C3%BCnwellerauthor=F.+W.+Schulteauthor=A.+Wei%C3%9Ferauthor=C.+M%C3%BCllerauthor=D.+Beckerauthor=S.+Beckerauthor=R.+K.+Hartmannauthor=A.+Gr%C3%BCnweller&title=The+Natural+Compound+Silvestrol+Is+a+Potent+Inhibitor+of+Ebola+Virus+Replication&doi=10.1016%2Fj.antiviral.2016.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The natural compound silvestrol is a potent inhibitor of Ebola virus replication</span></div><div class="casAuthors">Biedenkopf, Nadine; Lange-Gruenweller, Kerstin; Schulte, Falk W.; Weisser, Aileen; Mueller, Christin; Becker, Dirk; Becker, Stephan; Hartmann, Roland K.; Gruenweller, Arnold</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-81</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The DEAD-box RNA helicase eIF4A, which is part of the heterotrimeric translation initiation complex in eukaryotes, is an important novel drug target in cancer research because its helicase activity is required to unwind extended and highly structured 5'-UTRs of several proto-oncogenes.  Silvestrol, a natural compd. isolated from the plant Aglaia foveolata, is a highly efficient, non-toxic and specific inhibitor of eIF4A.  Importantly, 5'-capped viral mRNAs often contain structured 5'-UTRs as well, which may suggest a dependence on eIF4A for their translation by the host protein synthesis machinery.  In view of the recent Ebola virus (EBOV) outbreak in West Africa, the identification of potent antiviral compds. is urgently required.  Since Ebola mRNAs are 5'-capped and harbor RNA secondary structures in their extended 5'-UTRs, we initiated a BSL4 study to analyze silvestrol in EBOV-infected Huh-7 cells and in primary human macrophages for its antiviral activity.  We obsd. that silvestrol inhibits EBOV infection at low nanomolar concns., as inferred from large redns. of viral titers.  This correlated with an almost complete disappearance of EBOV proteins, comparable in effect to the translational shutdown of expression of the proto-oncoprotein PIM1, a cellular kinase known to be affected by silvestrol.  Effective silvestrol concns. were non-toxic in the tested cell systems.  Thus, silvestrol appears to be a promising first-line drug for the treatment of acute EBOV and possibly other viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEUavbaGnxurVg90H21EOLACvtfcHk0liEXuwHeMxuNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWnsLnL&md5=ce16ab9595bf6ba47b78057814f279fe</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2016.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2016.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DBiedenkopf%26aufirst%3DN.%26aulast%3DLange-Gr%25C3%25BCnweller%26aufirst%3DK.%26aulast%3DSchulte%26aufirst%3DF.%2BW.%26aulast%3DWei%25C3%259Fer%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DD.%26aulast%3DBecker%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DR.%2BK.%26aulast%3DGr%25C3%25BCnweller%26aufirst%3DA.%26atitle%3DThe%2520Natural%2520Compound%2520Silvestrol%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520Ebola%2520Virus%2520Replication%26jtitle%3DAntiviral%2520Res.%26date%3D2017%26volume%3D137%26spage%3D76%26epage%3D81%26doi%3D10.1016%2Fj.antiviral.2016.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange-Grünweller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhugiri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünweller, A.</span></span> <span> </span><span class="NLM_article-title">Broad-Spectrum Antiviral Activity of the EIF4A Inhibitor Silvestrol against Corona- and Picornaviruses</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2017.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.antiviral.2017.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=29258862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCmtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=123-129&author=C.+M%C3%BCllerauthor=F.+W.+Schulteauthor=K.+Lange-Gr%C3%BCnwellerauthor=W.+Obermannauthor=R.+Madhugiriauthor=S.+Pleschkaauthor=J.+Ziebuhrauthor=R.+K.+Hartmannauthor=A.+Gr%C3%BCnweller&title=Broad-Spectrum+Antiviral+Activity+of+the+EIF4A+Inhibitor+Silvestrol+against+Corona-+and+Picornaviruses&doi=10.1016%2Fj.antiviral.2017.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses</span></div><div class="casAuthors">Mueller, Christin; Schulte, Falk W.; Lange-Gruenweller, Kerstin; Obermann, Wiebke; Madhugiri, Ramakanth; Pleschka, Stephan; Ziebuhr, John; Hartmann, Roland K.; Gruenweller, Arnold</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123-129</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Coronaviruses (CoV) and picornaviruses are plus-strand RNA viruses that use 5' cap-dependent and cap-independent strategies, resp., for viral mRNA translation initiation.  Here, we analyzed the effects of the plant compd. silvestrol, a specific inhibitor of the DEAD-box RNA helicase eIF4A, on viral translation using a dual luciferase assay and virus-infected primary cells.  Silvestrol was recently shown to have potent antiviral activity in Ebola virus-infected human macrophages.  We found that silvestrol is also a potent inhibitor of cap-dependent viral mRNA translation in CoV-infected human embryonic lung fibroblast (MRC-5) cells.  EC50 values of 1.3 nM and 3 nM silvestrol were detd. for MERS-CoV and HCoV-229E, resp.  For the highly pathogenic MERS-CoV, the potent antiviral activities of silvestrol were also confirmed using peripheral blood mononuclear cells (PBMCs) as a second type of human primary cells.  Silvestrol strongly inhibits the expression of CoV structural and nonstructural proteins (N, nsp8) and the formation of viral replication/transcription complexes.  Furthermore, potential antiviral effects against human rhinovirus (HRV) A1 and poliovirus type 1 (PV), representing different species in the genus Enterovirus (family Picornaviridae), were investigated.  The two viruses employ an internal ribosomal entry site (IRES)-mediated translation initiation mechanism.  For PV, which is known to require the activity of eIF4A, an EC50 value of 20 nM silvestrol was detd. in MRC-5 cells.  The higher EC50 value of 100 nM measured for HRV A1 indicates a less crit. role of eIF4A activity in HRV A1 IRES-mediated translation initiation.  Taken together, the data reveal a broad-spectrum antiviral activity of silvestrol in infected primary cells by inhibiting eIF4A-dependent viral mRNA translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ7TqvxcHAr7Vg90H21EOLACvtfcHk0liEXuwHeMxuNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCmtLvN&md5=5bd9d4639615205e0f68c8813a2885b4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2017.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2017.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DSchulte%26aufirst%3DF.%2BW.%26aulast%3DLange-Gr%25C3%25BCnweller%26aufirst%3DK.%26aulast%3DObermann%26aufirst%3DW.%26aulast%3DMadhugiri%26aufirst%3DR.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DZiebuhr%26aufirst%3DJ.%26aulast%3DHartmann%26aufirst%3DR.%2BK.%26aulast%3DGr%25C3%25BCnweller%26aufirst%3DA.%26atitle%3DBroad-Spectrum%2520Antiviral%2520Activity%2520of%2520the%2520EIF4A%2520Inhibitor%2520Silvestrol%2520against%2520Corona-%2520and%2520Picornaviruses%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D150%26spage%3D123%26epage%3D129%26doi%3D10.1016%2Fj.antiviral.2017.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange-Grünweller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oestereich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elgner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glitscher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendel, H.-G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünweller, A.</span></span> <span> </span><span class="NLM_article-title">Comparison of Broad-Spectrum Antiviral Activities of the Synthetic Rocaglate CR-31-B (−) and the eIF4A-Inhibitor Silvestrol</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">104706</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2020.104706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.antiviral.2020.104706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31931103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslShu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2020&pages=104706&author=C.+M%C3%BCllerauthor=W.+Obermannauthor=F.+W.+Schulteauthor=K.+Lange-Gr%C3%BCnwellerauthor=L.+Oestereichauthor=F.+Elgnerauthor=M.+Glitscherauthor=E.+Hildtauthor=K.+Singhauthor=H.-G.+G.+Wendelauthor=R.+K.+Hartmannauthor=J.+Ziebuhrauthor=A.+Gr%C3%BCnweller&title=Comparison+of+Broad-Spectrum+Antiviral+Activities+of+the+Synthetic+Rocaglate+CR-31-B+%28%E2%88%92%29+and+the+eIF4A-Inhibitor+Silvestrol&doi=10.1016%2Fj.antiviral.2020.104706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol</span></div><div class="casAuthors">Mueller, Christin; Obermann, Wiebke; Schulte, Falk W.; Lange-Gruenweller, Kerstin; Oestereich, Lisa; Elgner, Fabian; Glitscher, Mirco; Hildt, Eberhard; Singh, Kamini; Wendel, Hans-Guido; Hartmann, Roland K.; Ziebuhr, John; Gruenweller, Arnold</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104706</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Rocaglates, a class of natural compds. isolated from plants of the genus Aglaia, are potent inhibitors of translation initiation.  They are proposed to form stacking interactions with polypurine sequences in the 5'-untranslated region (UTR) of selected mRNAs, thereby clamping the RNA substrate onto eIF4A and causing inhibition of the translation initiation complex.  Since virus replication relies on the host translation machinery, it is not surprising that the rocaglate Silvestrol has broad-spectrum antiviral activity.  Unfortunately, synthesis of Silvestrol is sophisticated and time-consuming, thus hampering the prospects for further antiviral drug development.  Here, we present the less complex structured synthetic rocaglate CR-31-B (-) as a novel compd. with potent broad-spectrum antiviral activity in primary cells and in an ex vivo bronchial epithelial cell system.  CR-31-B (-) inhibited the replication of corona-, Zika-, Lassa-, Crimean Congo hemorrhagic fever viruses and, to a lesser extent, hepatitis E virus (HEV) at non-cytotoxic low nanomolar concns.  Since HEV has a polypurine-free 5'-UTR that folds into a stable hairpin structure, we hypothesized that RNA clamping by Silvestrol and its derivs. may also occur in a polypurine-independent but structure-dependent manner.  Interestingly, the HEV 5'-UTR conferred sensitivity towards Silvestrol but not to CR-31-B (-).  However, if an exposed polypurine stretch was introduced into the HEV 5'-UTR, CR-31-B (-) became an active inhibitor comparable to Silvestrol.  Moreover, thermodn. destabilization of the HEV 5'-UTR led to reduced translational inhibition by Silvestrol, suggesting differences between rocaglates in their mode of action, most probably by engaging Silvestrol's addnl. dioxane moiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-syEzl8GTuLVg90H21EOLACvtfcHk0lhSvqUrNvo6cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslShu7k%253D&md5=e803112561be02bbe36611bd8e4a493f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104706%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DObermann%26aufirst%3DW.%26aulast%3DSchulte%26aufirst%3DF.%2BW.%26aulast%3DLange-Gr%25C3%25BCnweller%26aufirst%3DK.%26aulast%3DOestereich%26aufirst%3DL.%26aulast%3DElgner%26aufirst%3DF.%26aulast%3DGlitscher%26aufirst%3DM.%26aulast%3DHildt%26aufirst%3DE.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DWendel%26aufirst%3DH.-G.%2BG.%26aulast%3DHartmann%26aufirst%3DR.%2BK.%26aulast%3DZiebuhr%26aufirst%3DJ.%26aulast%3DGr%25C3%25BCnweller%26aufirst%3DA.%26atitle%3DComparison%2520of%2520Broad-Spectrum%2520Antiviral%2520Activities%2520of%2520the%2520Synthetic%2520Rocaglate%2520CR-31-B%2520%2528%25E2%2588%2592%2529%2520and%2520the%2520eIF4A-Inhibitor%2520Silvestrol%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D175%26spage%3D104706%26doi%3D10.1016%2Fj.antiviral.2020.104706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obernier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezelj, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huettenhain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutuncuoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foussard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polacco, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabius, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucheray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cakir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Kain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miorin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naing, Z. Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorba, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrio-Hernandez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Armenta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathy, C. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perica, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilla, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzberg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calviello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataramanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liboy-Lugo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wankowicz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugur, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savar, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shengjuler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neal, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klippsten, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzuoglu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trenker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavero, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathore, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verba, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agard, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zastrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Enfert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ideker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortemme, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignuzzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogan, N. J.</span></span> <span> </span><span class="NLM_article-title">A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>583</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-2286-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41586-020-2286-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=32353859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=583&publication_year=2020&pages=459-468&author=D.+E.+Gordonauthor=G.+M.+Jangauthor=M.+Bouhaddouauthor=J.+Xuauthor=K.+Obernierauthor=K.+M.+Whiteauthor=M.+J.+O%E2%80%99Mearaauthor=V.+V.+Rezeljauthor=J.+Z.+Guoauthor=D.+L.+Swaneyauthor=T.+A.+Tumminoauthor=R.+Huettenhainauthor=R.+M.+Kaakeauthor=A.+L.+Richardsauthor=B.+Tutuncuogluauthor=H.+Foussardauthor=J.+Batraauthor=K.+Haasauthor=M.+Modakauthor=M.+Kimauthor=P.+Haasauthor=B.+J.+Polaccoauthor=H.+Brabergauthor=J.+M.+Fabiusauthor=M.+Eckhardtauthor=M.+Soucherayauthor=M.+J.+Bennettauthor=M.+Cakirauthor=M.+J.+McGregorauthor=Q.+Liauthor=B.+Meyerauthor=F.+Roeschauthor=T.+Valletauthor=A.+Mac+Kainauthor=L.+Miorinauthor=E.+Morenoauthor=Z.+Z.+C.+Naingauthor=Y.+Zhouauthor=S.+Pengauthor=Y.+Shiauthor=Z.+Zhangauthor=W.+Shenauthor=I.+T.+Kirbyauthor=J.+E.+Melnykauthor=J.+S.+Chorbaauthor=K.+Louauthor=S.+A.+Daiauthor=I.+Barrio-Hernandezauthor=D.+Memonauthor=C.+Hernandez-Armentaauthor=J.+Lyuauthor=C.+J.+P.+Mathyauthor=T.+Pericaauthor=K.+B.+Pillaauthor=S.+J.+Ganesanauthor=D.+J.+Saltzbergauthor=R.+Rakeshauthor=X.+Liuauthor=S.+B.+Rosenthalauthor=L.+Calvielloauthor=S.+Venkataramananauthor=J.+Liboy-Lugoauthor=Y.+Linauthor=X.+P.+Huangauthor=Y.+F.+Liuauthor=S.+A.+Wankowiczauthor=M.+Bohnauthor=M.+Safariauthor=F.+S.+Ugurauthor=C.+Kohauthor=N.+S.+Savarauthor=Q.+D.+Tranauthor=D.+Shengjulerauthor=S.+J.+Fletcherauthor=M.+C.+O%E2%80%99Nealauthor=Y.+Caiauthor=J.+C.+J.+Changauthor=D.+J.+Broadhurstauthor=S.+Klippstenauthor=P.+P.+Sharpauthor=N.+A.+Wenzellauthor=D.+Kuzuogluauthor=H.+Y.+Wangauthor=R.+Trenkerauthor=J.+M.+Youngauthor=D.+A.+Caveroauthor=J.+Hiattauthor=T.+L.+Rothauthor=U.+Rathoreauthor=A.+Subramanianauthor=J.+Noackauthor=M.+Hubertauthor=R.+M.+Stroudauthor=A.+D.+Frankelauthor=O.+S.+Rosenbergauthor=K.+A.+Verbaauthor=D.+A.+Agardauthor=M.+Ottauthor=M.+Emermanauthor=N.+Juraauthor=M.+von+Zastrowauthor=E.+Verdinauthor=A.+Ashworthauthor=O.+Schwartzauthor=C.+d%E2%80%99Enfertauthor=S.+Mukherjeeauthor=M.+Jacobsonauthor=H.+S.+Malikauthor=D.+G.+Fujimoriauthor=T.+Idekerauthor=C.+S.+Craikauthor=S.+N.+Floorauthor=J.+S.+Fraserauthor=J.+D.+Grossauthor=A.+Saliauthor=B.+L.+Rothauthor=D.+Ruggeroauthor=J.+Tauntonauthor=T.+Kortemmeauthor=P.+Beltraoauthor=M.+Vignuzziauthor=A.+Garc%C3%ADa-Sastreauthor=K.+M.+Shokatauthor=B.+K.+Shoichetauthor=N.+J.+Krogan&title=A+SARS-CoV-2+Protein+Interaction+Map+Reveals+Targets+for+Drug+Repurposing&doi=10.1038%2Fs41586-020-2286-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</span></div><div class="casAuthors">Gordon, David E.; Jang, Gwendolyn M.; Bouhaddou, Mehdi; Xu, Jiewei; Obernier, Kirsten; White, Kris M.; O'Meara, Matthew J.; Rezelj, Veronica V.; Guo, Jeffrey Z.; Swaney, Danielle L.; Tummino, Tia A.; Huttenhain, Ruth; Kaake, Robyn M.; Richards, Alicia L.; Tutuncuoglu, Beril; Foussard, Helene; Batra, Jyoti; Haas, Kelsey; Modak, Maya; Kim, Minkyu; Haas, Paige; Polacco, Benjamin J.; Braberg, Hannes; Fabius, Jacqueline M.; Eckhardt, Manon; Soucheray, Margaret; Bennett, Melanie J.; Cakir, Merve; McGregor, Michael J.; Li, Qiongyu; Meyer, Bjoern; Roesch, Ferdinand; Vallet, Thomas; Mac Kain, Alice; Miorin, Lisa; Moreno, Elena; Naing, Zun Zar Chi; Zhou, Yuan; Peng, Shiming; Shi, Ying; Zhang, Ziyang; Shen, Wenqi; Kirby, Ilsa T.; Melnyk, James E.; Chorba, John S.; Lou, Kevin; Dai, Shizhong A.; Barrio-Hernandez, Inigo; Memon, Danish; Hernandez-Armenta, Claudia; Lyu, Jiankun; Mathy, Christopher J. P.; Perica, Tina; Pilla, Kala Bharath; Ganesan, Sai J.; Saltzberg, Daniel J.; Rakesh, Ramachandran; Liu, Xi; Rosenthal, Sara B.; Calviello, Lorenzo; Venkataramanan, Srivats; Liboy-Lugo, Jose; Lin, Yizhu; Huang, Xi-Ping; Liu, YongFeng; Wankowicz, Stephanie A.; Bohn, Markus; Safari, Maliheh; Ugur, Fatima S.; Koh, Cassandra; Savar, Nastaran Sadat; Tran, Quang Dinh; Shengjuler, Djoshkun; Fletcher, Sabrina J.; O'Neal, Michael C.; Cai, Yiming; Chang, Jason C. J.; Broadhurst, David J.; Klippsten, Saker; Sharp, Phillip P.; Wenzell, Nicole A.; Kuzuoglu-Ozturk, Duygu; Wang, Hao-Yuan; Trenker, Raphael; Young, Janet M.; Cavero, Devin A.; Hiatt, Joseph; Roth, Theodore L.; Rathore, Ujjwal; Subramanian, Advait; Noack, Julia; Hubert, Mathieu; Stroud, Robert M.; Frankel, Alan D.; Rosenberg, Oren S.; Verba, Kliment A.; Agard, David A.; Ott, Melanie; Emerman, Michael; Jura, Natalia; von Zastrow, Mark; Verdin, Eric; Ashworth, Alan; Schwartz, Olivier; d'Enfert, Christophe; Mukherjee, Shaeri; Jacobson, Matt; Malik, Harmit S.; Fujimori, Danica G.; Ideker, Trey; Craik, Charles S.; Floor, Stephen N.; Fraser, James S.; Gross, John D.; Sali, Andrej; Roth, Bryan L.; Ruggero, Davide; Taunton, Jack; Kortemme, Tanja; Beltrao, Pedro; Vignuzzi, Marco; Garcia-Sastre, Adolfo; Shokat, Kevan M.; Shoichet, Brian K.; Krogan, Nevan J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">583</span>
        (<span class="NLM_cas:issue">7816</span>),
    <span class="NLM_cas:pages">459-468</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption1,2.  There are no antiviral drugs with proven clin. efficacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the limited knowledge of the mol. details of how SARS-CoV-2 infects cells.  Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that phys. assocd. with each of the SARS-CoV-2 proteins using affinity-purifn. mass spectrometry, identifying 332 high-confidence protein-protein interactions between SARS-CoV-2 and human proteins.  Among these, we identify 66 druggable human proteins or host factors targeted by 69 compds. (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clin. trials and 28 are preclin. compds.).  We screened a subset of these in multiple viral assays and found two sets of pharmacol. agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors.  Further studies of these host-factor-targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDvJUIvi-Ws7Vg90H21EOLACvtfcHk0lhSvqUrNvo6cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtbrI&md5=ce8b172ae73aacd3b3d8bb64877f4435</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2286-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2286-9%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DD.%2BE.%26aulast%3DJang%26aufirst%3DG.%2BM.%26aulast%3DBouhaddou%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DObernier%26aufirst%3DK.%26aulast%3DWhite%26aufirst%3DK.%2BM.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%2BJ.%26aulast%3DRezelj%26aufirst%3DV.%2BV.%26aulast%3DGuo%26aufirst%3DJ.%2BZ.%26aulast%3DSwaney%26aufirst%3DD.%2BL.%26aulast%3DTummino%26aufirst%3DT.%2BA.%26aulast%3DHuettenhain%26aufirst%3DR.%26aulast%3DKaake%26aufirst%3DR.%2BM.%26aulast%3DRichards%26aufirst%3DA.%2BL.%26aulast%3DTutuncuoglu%26aufirst%3DB.%26aulast%3DFoussard%26aufirst%3DH.%26aulast%3DBatra%26aufirst%3DJ.%26aulast%3DHaas%26aufirst%3DK.%26aulast%3DModak%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DHaas%26aufirst%3DP.%26aulast%3DPolacco%26aufirst%3DB.%2BJ.%26aulast%3DBraberg%26aufirst%3DH.%26aulast%3DFabius%26aufirst%3DJ.%2BM.%26aulast%3DEckhardt%26aufirst%3DM.%26aulast%3DSoucheray%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DM.%2BJ.%26aulast%3DCakir%26aufirst%3DM.%26aulast%3DMcGregor%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMeyer%26aufirst%3DB.%26aulast%3DRoesch%26aufirst%3DF.%26aulast%3DVallet%26aufirst%3DT.%26aulast%3DMac%2BKain%26aufirst%3DA.%26aulast%3DMiorin%26aufirst%3DL.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DNaing%26aufirst%3DZ.%2BZ.%2BC.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DKirby%26aufirst%3DI.%2BT.%26aulast%3DMelnyk%26aufirst%3DJ.%2BE.%26aulast%3DChorba%26aufirst%3DJ.%2BS.%26aulast%3DLou%26aufirst%3DK.%26aulast%3DDai%26aufirst%3DS.%2BA.%26aulast%3DBarrio-Hernandez%26aufirst%3DI.%26aulast%3DMemon%26aufirst%3DD.%26aulast%3DHernandez-Armenta%26aufirst%3DC.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DMathy%26aufirst%3DC.%2BJ.%2BP.%26aulast%3DPerica%26aufirst%3DT.%26aulast%3DPilla%26aufirst%3DK.%2BB.%26aulast%3DGanesan%26aufirst%3DS.%2BJ.%26aulast%3DSaltzberg%26aufirst%3DD.%2BJ.%26aulast%3DRakesh%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DRosenthal%26aufirst%3DS.%2BB.%26aulast%3DCalviello%26aufirst%3DL.%26aulast%3DVenkataramanan%26aufirst%3DS.%26aulast%3DLiboy-Lugo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DLiu%26aufirst%3DY.%2BF.%26aulast%3DWankowicz%26aufirst%3DS.%2BA.%26aulast%3DBohn%26aufirst%3DM.%26aulast%3DSafari%26aufirst%3DM.%26aulast%3DUgur%26aufirst%3DF.%2BS.%26aulast%3DKoh%26aufirst%3DC.%26aulast%3DSavar%26aufirst%3DN.%2BS.%26aulast%3DTran%26aufirst%3DQ.%2BD.%26aulast%3DShengjuler%26aufirst%3DD.%26aulast%3DFletcher%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Neal%26aufirst%3DM.%2BC.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DBroadhurst%26aufirst%3DD.%2BJ.%26aulast%3DKlippsten%26aufirst%3DS.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DWenzell%26aufirst%3DN.%2BA.%26aulast%3DKuzuoglu%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DTrenker%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DJ.%2BM.%26aulast%3DCavero%26aufirst%3DD.%2BA.%26aulast%3DHiatt%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DT.%2BL.%26aulast%3DRathore%26aufirst%3DU.%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DNoack%26aufirst%3DJ.%26aulast%3DHubert%26aufirst%3DM.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26aulast%3DFrankel%26aufirst%3DA.%2BD.%26aulast%3DRosenberg%26aufirst%3DO.%2BS.%26aulast%3DVerba%26aufirst%3DK.%2BA.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DEmerman%26aufirst%3DM.%26aulast%3DJura%26aufirst%3DN.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DVerdin%26aufirst%3DE.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3Dd%25E2%2580%2599Enfert%26aufirst%3DC.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DM.%26aulast%3DMalik%26aufirst%3DH.%2BS.%26aulast%3DFujimori%26aufirst%3DD.%2BG.%26aulast%3DIdeker%26aufirst%3DT.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3DFloor%26aufirst%3DS.%2BN.%26aulast%3DFraser%26aufirst%3DJ.%2BS.%26aulast%3DGross%26aufirst%3DJ.%2BD.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DTaunton%26aufirst%3DJ.%26aulast%3DKortemme%26aufirst%3DT.%26aulast%3DBeltrao%26aufirst%3DP.%26aulast%3DVignuzzi%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Sastre%26aufirst%3DA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DKrogan%26aufirst%3DN.%2BJ.%26atitle%3DA%2520SARS-CoV-2%2520Protein%2520Interaction%2520Map%2520Reveals%2520Targets%2520for%2520Drug%2520Repurposing%26jtitle%3DNature%26date%3D2020%26volume%3D583%26spage%3D459%26epage%3D468%26doi%3D10.1038%2Fs41586-020-2286-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Northcote, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blunt, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, M. H. G.</span></span> <span> </span><span class="NLM_article-title">Pateamine: A Potent Cytotoxin from the New Zealand Marine Sponge, Mycale Sp</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">6411</span>– <span class="NLM_lpage">6414</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(91)80182-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2F0040-4039%2891%2980182-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK38XhtVartLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1991&pages=6411-6414&author=P.+T.+Northcoteauthor=J.+W.+Bluntauthor=M.+H.+G.+Munro&title=Pateamine%3A+A+Potent+Cytotoxin+from+the+New+Zealand+Marine+Sponge%2C+Mycale+Sp&doi=10.1016%2F0040-4039%2891%2980182-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pateamine:  a potent cytotoxin from the New Zealand marine sponge, Mycale sp</span></div><div class="casAuthors">Northcote, Peter T.; Blunt, John W.; Munro, Murray H. G.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">6411-14</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    </div><div class="casAbstract">The isolation and structural characterization of pateamine (I), a thiazole-contg. macrolide with the rare dilactone functionality, is reported.  Pateamine is an exceedingly potent, but possibly selective, cytotoxin (P388: IC50 0.15 ng/mL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodXQWsMpklsLVg90H21EOLACvtfcHk0lgXsFO_faPyVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhtVartLw%253D&md5=78586e5a6b43565a1c94d12bfe0ed01f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2891%2980182-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252891%252980182-6%26sid%3Dliteratum%253Aachs%26aulast%3DNorthcote%26aufirst%3DP.%2BT.%26aulast%3DBlunt%26aufirst%3DJ.%2BW.%26aulast%3DMunro%26aufirst%3DM.%2BH.%2BG.%26atitle%3DPateamine%253A%2520A%2520Potent%2520Cytotoxin%2520from%2520the%2520New%2520Zealand%2520Marine%2520Sponge%252C%2520Mycale%2520Sp%26jtitle%3DTetrahedron%2520Lett.%26date%3D1991%26volume%3D32%26spage%3D6411%26epage%3D6414%26doi%3D10.1016%2F0040-4039%2891%2980182-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Low, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider-Poetsch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Eukaryotic Translation Initiation by the Marine Natural Product Pateamine A</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2005.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.molcel.2005.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16337595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtleqtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=709-722&author=W.+K.+Lowauthor=Y.+Dangauthor=T.+Schneider-Poetschauthor=Z.+Shiauthor=N.+S.+Choiauthor=W.+C.+Merrickauthor=D.+Romoauthor=J.+O.+Liu&title=Inhibition+of+Eukaryotic+Translation+Initiation+by+the+Marine+Natural+Product+Pateamine+A&doi=10.1016%2Fj.molcel.2005.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of eukaryotic translation initiation by the marine natural product pateamine A</span></div><div class="casAuthors">Low, Woon-Kai; Dang, Yongjun; Schneider-Poetsch, Tilman; Shi, Zonggao; Choi, Nam Song; Merrick, William C.; Romo, Daniel; Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">709-722</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Translation initiation in eukaryotes is accomplished through the coordinated and orderly action of a large no. of proteins, including the eIF4 initiation factors.  Herein, we report that pateamine A (PatA), a potent antiproliferative and proapoptotic marine natural product, inhibits cap-dependent eukaryotic translation initiation.  PatA bound to and enhanced the intrinsic enzymic activities of eIF4A, yet it inhibited eIF4A-eIF4G assocn. and promoted the formation of a stable ternary complex between eIF4A and eIF4B.  These changes in eIF4A affinity for its partner proteins upon binding to PatA caused the stalling of initiation complexes on mRNA in vitro and induced stress granule formation in vivo.  These results suggest that PatA will be a valuable mol. probe for future studies of eukaryotic translation initiation and may serve as a lead compd. for the development of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkwxt9CFRLhLVg90H21EOLACvtfcHk0lgXsFO_faPyVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtleqtb%252FI&md5=4dacc09550c903e2d02470b7a495081d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DW.%2BK.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DSchneider-Poetsch%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DChoi%26aufirst%3DN.%2BS.%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26aulast%3DRomo%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DInhibition%2520of%2520Eukaryotic%2520Translation%2520Initiation%2520by%2520the%2520Marine%2520Natural%2520Product%2520Pateamine%2520A%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D20%26spage%3D709%26epage%3D722%26doi%3D10.1016%2Fj.molcel.2005.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M.-E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojnar, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novac, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowsky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northcote, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teesdale-Spittle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Stimulation of Mammalian Translation Initiation Factor eIF4A Activity by a Small Molecule Inhibitor of Eukaryotic Translation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">10460</span>– <span class="NLM_lpage">10465</span>, <span class="refDoi"> DOI: 10.1073/pnas.0504249102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.0504249102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16030146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVSit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=10460-10465&author=M.-E.+E.+Bordeleauauthor=J.+Matthewsauthor=J.+M.+Wojnarauthor=L.+Lindqvistauthor=O.+Novacauthor=E.+Jankowskyauthor=N.+Sonenbergauthor=P.+Northcoteauthor=P.+Teesdale-Spittleauthor=J.+Pelletier&title=Stimulation+of+Mammalian+Translation+Initiation+Factor+eIF4A+Activity+by+a+Small+Molecule+Inhibitor+of+Eukaryotic+Translation&doi=10.1073%2Fpnas.0504249102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation</span></div><div class="casAuthors">Bordeleau, Marie-Eve; Matthews, James; Wojnar, Joanna M.; Lindqvist, Lisa; Novac, Olivia; Jankowsky, Eckhard; Sonenberg, Nahum; Northcote, Peter; Teesdale-Spittle, Paul; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">10460-10465</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">RNA helicases are the largest group of enzymes in eukaryotic RNA metab.  The DEXD/H-box putative RNA helicases form the helicase superfamily II, whose members are defined by seven highly conserved amino acid motifs, making specific targeting of selected members a challenging pharmacol. problem.  The translation initiation factor eIF4A is the prototypical DEAD-box RNA helicase that works in conjunction with eIF4B and eIF4H and as a subunit of eIF4F to prep. the mRNA template for ribosome binding, possibly by unwinding the secondary structure proximal to the 5' m7GpppN cap structure.  The authors report the identification and characterization of a small mol. inhibitor of eukaryotic translation initiation that acts in an unusual manner by stimulating eIF4A-assocd. activities.  The results suggest that proper control of eIF4A helicase activity is necessary for efficient ribosome binding and demonstrate the feasibility of selectively targeting DEAD-box RNA helicases with small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAEhUC4JFqWbVg90H21EOLACvtfcHk0lgzG_W4Q7He4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVSit7Y%253D&md5=9393ed1b7a46f028340b2b373d8655c0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0504249102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0504249102%26sid%3Dliteratum%253Aachs%26aulast%3DBordeleau%26aufirst%3DM.-E.%2BE.%26aulast%3DMatthews%26aufirst%3DJ.%26aulast%3DWojnar%26aufirst%3DJ.%2BM.%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DNovac%26aufirst%3DO.%26aulast%3DJankowsky%26aufirst%3DE.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DNorthcote%26aufirst%3DP.%26aulast%3DTeesdale-Spittle%26aufirst%3DP.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DStimulation%2520of%2520Mammalian%2520Translation%2520Initiation%2520Factor%2520eIF4A%2520Activity%2520by%2520a%2520Small%2520Molecule%2520Inhibitor%2520of%2520Eukaryotic%2520Translation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D10460%26epage%3D10465%26doi%3D10.1073%2Fpnas.0504249102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Low, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span> <span> </span><span class="NLM_article-title">Substrate-Dependent Targeting of Eukaryotic Translation Initiation Factor 4A by Pateamine A: Negation of Domain-Linker Regulation of Activity</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2007.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.chembiol.2007.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17584618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVOgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=715-727&author=W.+K.+Lowauthor=Y.+Dangauthor=S.+Bhatauthor=D.+Romoauthor=J.+O.+Liu&title=Substrate-Dependent+Targeting+of+Eukaryotic+Translation+Initiation+Factor+4A+by+Pateamine+A%3A+Negation+of+Domain-Linker+Regulation+of+Activity&doi=10.1016%2Fj.chembiol.2007.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate-Dependent Targeting of Eukaryotic Translation Initiation Factor 4A by Pateamine A: Negation of Domain-Linker Regulation of Activity</span></div><div class="casAuthors">Low, Woon-Kai; Dang, Yongjun; Bhat, Shridhar; Romo, Daniel; Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">715-727</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Central to cap-dependent eukaryotic translation initiation is the eIF4F complex, which is composed of the three eukaryotic initiation factors eIF4E, eIF4G, and eIF4A.  Factor eIF4A is an RNA-dependent ATPase and an ATP-dependent helicase that unwinds local secondary structure in mRNA to allow binding of the 43S ribosomal complex.  The marine natural product pateamine A (PatA) has been demonstrated to inhibit cap-dependent initiation by targeting eIF4A and disrupting its protein-protein interactions while increasing its enzymic activities.  Here we demonstrate that the increased activity is caused by the induction of global conformational changes within eIF4A.  Furthermore, binding of PatA is dependent on substrate (RNA and ATP) binding, and the increased activity upon PatA binding is caused by relief of a neg. regulatory function of the eIF4A unique domain linker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoV3zYbusrsLVg90H21EOLACvtfcHk0lgzG_W4Q7He4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVOgt7c%253D&md5=e9a769b2bfcc837a58b531fde3d645ad</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DW.%2BK.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DRomo%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DSubstrate-Dependent%2520Targeting%2520of%2520Eukaryotic%2520Translation%2520Initiation%2520Factor%25204A%2520by%2520Pateamine%2520A%253A%2520Negation%2520of%2520Domain-Linker%2520Regulation%2520of%2520Activity%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D715%26epage%3D727%26doi%3D10.1016%2Fj.chembiol.2007.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span> <span> </span><span class="NLM_article-title">Evidence for Separate Binding and Scaffolding Domains in the Immunosuppressive and Antitumor Marine Natural Product, Pateamine A: Design, Synthesis, and Activity Studies Leading to a Potent Simplified Derivative</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">10582</span>– <span class="NLM_lpage">10588</span>, <span class="refDoi"> DOI: 10.1021/ja040065s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja040065s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt12kt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=10582-10588&author=D.+Romoauthor=N.+S.+Choiauthor=S.+Liauthor=I.+Buchlerauthor=Z.+Shiauthor=J.+O.+Liu&title=Evidence+for+Separate+Binding+and+Scaffolding+Domains+in+the+Immunosuppressive+and+Antitumor+Marine+Natural+Product%2C+Pateamine+A%3A+Design%2C+Synthesis%2C+and+Activity+Studies+Leading+to+a+Potent+Simplified+Derivative&doi=10.1021%2Fja040065s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for separate binding and scaffolding domains in the immunosuppressive and antitumor marine natural product, pateamine a: design, synthesis, and activity studies leading to a potent simplified derivative</span></div><div class="casAuthors">Romo, Daniel; Choi, Nam Song; Li, Shukun; Buchler, Ingrid; Shi, Zonggao; Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">10582-10588</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pateamine A (PatA), a marine metabolite from Mycale sp., is a potent inhibitor of the intracellular signal transduction pathway emanating from the T-cell receptor leading to the transcription of cytokines such as interleukin-2 (IL-2).  On the basis of the structure of PatA and initial biol. results, a hypothesis was developed regarding the presence of distinct binding and scaffolding domains in the PatA structure with respect to interactions with its putative cellular receptor(s).  Employing a highly convergent approach involving a Hantzsch coupling strategy, we probed this hypothesis by prepg. a simplified PatA deriv. (desmethyl, desamino PatA, DMDAPatA, 3).  This deriv. was prepd. in 10 fewer synthetic steps relative to PatA and was indeed found to exhibit equal to greater potency (IC50 0.81±0.27 nM) in inhibition of IL-2 prodn. relative to PatA (IC50 4.01±0.94 nM) thus providing support for the binding/scaffolding domain hypothesis.  In addn., as a means to find more stable derivs. and gain further insights into structure-activity relationships, several PatA derivs. were synthesized and assayed in the IL-2 reporter gene assay.  Several of these derivs. displayed lower potency but marked stability relative to the natural product and provide further insights into the nature of the binding domain required for activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXvNluf1DglLVg90H21EOLACvtfcHk0lgzG_W4Q7He4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt12kt7Y%253D&md5=ef86db0f97dc4e796a15bf3bb2eb2dfc</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fja040065s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja040065s%26sid%3Dliteratum%253Aachs%26aulast%3DRomo%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DN.%2BS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DBuchler%26aufirst%3DI.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DEvidence%2520for%2520Separate%2520Binding%2520and%2520Scaffolding%2520Domains%2520in%2520the%2520Immunosuppressive%2520and%2520Antitumor%2520Marine%2520Natural%2520Product%252C%2520Pateamine%2520A%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Activity%2520Studies%2520Leading%2520to%2520a%2520Potent%2520Simplified%2520Derivative%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2004%26volume%3D126%26spage%3D10582%26epage%3D10588%26doi%3D10.1021%2Fja040065s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Higa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukitani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, H.</span></span> <span> </span><span class="NLM_article-title">Hippuristanols, Cytotoxic Polyoxygenated Steroids from the Gorgonian <i>Isis Hippuri</i>s</span>. <i>Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1647</span>– <span class="NLM_lpage">1650</span>, <span class="refDoi"> DOI: 10.1246/cl.1981.1647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1246%2Fcl.1981.1647" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1981&pages=1647-1650&author=T.+Higaauthor=J.-i.+Tanakaauthor=T.+Tsukitaniauthor=H.+Kikuchi&title=Hippuristanols%2C+Cytotoxic+Polyoxygenated+Steroids+from+the+Gorgonian+Isis+Hippuris&doi=10.1246%2Fcl.1981.1647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1246%2Fcl.1981.1647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.1981.1647%26sid%3Dliteratum%253Aachs%26aulast%3DHiga%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DJ.-i.%26aulast%3DTsukitani%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DH.%26atitle%3DHippuristanols%252C%2520Cytotoxic%2520Polyoxygenated%2520Steroids%2520from%2520the%2520Gorgonian%2520Isis%2520Hippuris%26jtitle%3DChem.%2520Lett.%26date%3D1981%26volume%3D10%26spage%3D1647%26epage%3D1650%26doi%3D10.1246%2Fcl.1981.1647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chard, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belsham, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Functional Characterization of IRESes by an Inhibitor of the RNA Helicase eIF4A</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1038/nchembio776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnchembio776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16532013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFOnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=213-220&author=M.+E.+Bordeleauauthor=A.+Moriauthor=M.+Obererauthor=L.+Lindqvistauthor=L.+S.+Chardauthor=T.+Higaauthor=G.+J.+Belshamauthor=G.+Wagnerauthor=J.+Tanakaauthor=J.+Pelletier&title=Functional+Characterization+of+IRESes+by+an+Inhibitor+of+the+RNA+Helicase+eIF4A&doi=10.1038%2Fnchembio776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A</span></div><div class="casAuthors">Bordeleau, Marie-Eve; Mori, Ayaka; Oberer, Monika; Lindqvist, Lisa; Chard, Louisa S.; Higa, Tatsuo; Belsham, Graham J.; Wagner, Gerhard; Tanaka, Junichi; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">213-220</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RNA helicases are mol. motors that are involved in virtually all aspects of RNA metab.  Eukaryotic initiation factor (eIF) 4A is the prototypical member of the DEAD-box family of RNA helicases.  It is thought to use energy from ATP hydrolysis to unwind mRNA structure and, in conjunction with other translation factors, it preps. mRNA templates for ribosome recruitment during translation initiation.  In screening marine exts. for new eukaryotic translation initiation inhibitors, we identified the natural product hippuristanol.  We show here that this compd. is a selective and potent inhibitor of eIF4A RNA-binding activity that can be used to distinguish between eIF4A-dependent and -independent modes of translation initiation in vitro and in vivo.  We also show that poliovirus replication is delayed when infected cells are exposed to hippuristanol.  Our study demonstrates the feasibility of selectively targeting members of the DEAD-box helicase family with small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphVpPHxoy7Y7Vg90H21EOLACvtfcHk0linoPJnbZUKhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFOnsbg%253D&md5=cbeecb6be4f6ab28c47b4c0542ba4d3d</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnchembio776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio776%26sid%3Dliteratum%253Aachs%26aulast%3DBordeleau%26aufirst%3DM.%2BE.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DOberer%26aufirst%3DM.%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DChard%26aufirst%3DL.%2BS.%26aulast%3DHiga%26aufirst%3DT.%26aulast%3DBelsham%26aufirst%3DG.%2BJ.%26aulast%3DWagner%26aufirst%3DG.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DFunctional%2520Characterization%2520of%2520IRESes%2520by%2520an%2520Inhibitor%2520of%2520the%2520RNA%2520Helicase%2520eIF4A%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D213%26epage%3D220%26doi%3D10.1038%2Fnchembio776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span> <span> </span><span class="NLM_article-title">Structural and Stereochemical Requirements of the Spiroketal Group of Hippuristanol for Antiproliferative Activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3112</span>– <span class="NLM_lpage">3115</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.03.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.bmcl.2010.03.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=20409710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFGns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3112-3115&author=W.+Liauthor=Y.+Dangauthor=J.+O.+Liuauthor=B.+Yu&title=Structural+and+Stereochemical+Requirements+of+the+Spiroketal+Group+of+Hippuristanol+for+Antiproliferative+Activity&doi=10.1016%2Fj.bmcl.2010.03.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and stereochemical requirements of the spiroketal group of hippuristanol for antiproliferative activity</span></div><div class="casAuthors">Li, Wei; Dang, Yongjun; Liu, Jun O.; Yu, Biao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3112-3115</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hippuristanol is a natural product that has recently been shown to inhibit eukaryotic translation initiation and tumor cell proliferation.  To investigate the structure and activity relationship of hippuristanol, we synthesized a series of analogs by expanding the size of its F ring and detd. their effects on the proliferation of cancer cell lines.  All changes to the F-ring of hippuristanol resulted in 3-fold to >100-fold decrease in activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYs9eLujY0GLVg90H21EOLACvtfcHk0linoPJnbZUKhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFGns7Y%253D&md5=eb9ae51a4d88ba94ffc6a8631d0c9326</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.03.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.03.093%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26aulast%3DYu%26aufirst%3DB.%26atitle%3DStructural%2520and%2520Stereochemical%2520Requirements%2520of%2520the%2520Spiroketal%2520Group%2520of%2520Hippuristanol%2520for%2520Antiproliferative%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3112%26epage%3D3115%26doi%3D10.1016%2Fj.bmcl.2010.03.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reibarkh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marintchev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Selective Pharmacological Targeting of a DEAD Box RNA Helicase</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e1583</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0001583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pone.0001583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18270573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BD1c7htlagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=e1583&author=L.+Lindqvistauthor=M.+Obererauthor=M.+Reibarkhauthor=R.+Cencicauthor=M.+E.+Bordeleauauthor=E.+Vogtauthor=A.+Marintchevauthor=J.+Tanakaauthor=F.+Fagottoauthor=M.+Altmannauthor=G.+Wagnerauthor=J.+Pelletier&title=Selective+Pharmacological+Targeting+of+a+DEAD+Box+RNA+Helicase&doi=10.1371%2Fjournal.pone.0001583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Selective pharmacological targeting of a DEAD box RNA helicase</span></div><div class="casAuthors">Lindqvist Lisa; Oberer Monika; Reibarkh Mikhail; Cencic Regina; Bordeleau Marie-Eve; Vogt Emily; Marintchev Assen; Tanaka Junichi; Fagotto Francois; Altmann Michael; Wagner Gerhard; Pelletier Jerry</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e1583</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RNA helicases represent a large family of proteins implicated in many biological processes including ribosome biogenesis, splicing, translation and mRNA degradation.  However, these proteins have little substrate specificity, making inhibition of selected helicases a challenging problem.  The prototypical DEAD box RNA helicase, eIF4A, works in conjunction with other translation factors to prepare mRNA templates for ribosome recruitment during translation initiation.  Herein, we provide insight into the selectivity of a small molecule inhibitor of eIF4A, hippuristanol.  This coral-derived natural product binds to amino acids adjacent to, and overlapping with, two conserved motifs present in the carboxy-terminal domain of eIF4A.  Mutagenesis of amino acids within this region allowed us to alter the hippuristanol-sensitivity of eIF4A and undertake structure/function studies.  Our results provide an understanding into how selective targeting of RNA helicases for pharmacological intervention can be achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKpFB5Tdsa_tXdcedVHT5tfW6udTcc2eZNQj1WFOgGS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c7htlagtg%253D%253D&md5=b29e717681032adca5889d26e11e480d</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0001583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0001583%26sid%3Dliteratum%253Aachs%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DOberer%26aufirst%3DM.%26aulast%3DReibarkh%26aufirst%3DM.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DBordeleau%26aufirst%3DM.%2BE.%26aulast%3DVogt%26aufirst%3DE.%26aulast%3DMarintchev%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DFagotto%26aufirst%3DF.%26aulast%3DAltmann%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DG.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DSelective%2520Pharmacological%2520Targeting%2520of%2520a%2520DEAD%2520Box%2520RNA%2520Helicase%26jtitle%3DPLoS%2520One%26date%3D2008%26volume%3D3%26spage%3De1583%26doi%3D10.1371%2Fjournal.pone.0001583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meller, A.</span></span> <span> </span><span class="NLM_article-title">Single-Molecule Kinetics of the Eukaryotic Initiation Factor 4AI upon RNA Unwinding</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">948</span>, <span class="refDoi"> DOI: 10.1016/j.str.2014.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.str.2014.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24909782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=941-948&author=Y.+Sunauthor=E.+Atasauthor=L.+M.+Lindqvistauthor=N.+Sonenbergauthor=J.+Pelletierauthor=A.+Meller&title=Single-Molecule+Kinetics+of+the+Eukaryotic+Initiation+Factor+4AI+upon+RNA+Unwinding&doi=10.1016%2Fj.str.2014.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Single-Molecule Kinetics of the Eukaryotic Initiation Factor 4AI upon RNA Unwinding</span></div><div class="casAuthors">Sun, Yingjie; Atas, Evrim; Lindqvist, Lisa M.; Sonenberg, Nahum; Pelletier, Jerry; Meller, Amit</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">941-948</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The eukaryotic translation initiation factor 4AI (eIF4AI) is the prototypical DEAD-box RNA helicase.  It has a "dumbbell" structure consisting of 2 domains connected by a flexible linker.  Previous studies demonstrated that eIF4AI, in conjunction with eIF4H, bind to loop structures and repetitively unwind RNA hairpins.  Here, the authors probe the conformational dynamics of eIF4AI in real time using single-mol. FRET.  The authors demonstrate that eIF4AI/eIF4H complex can repetitively unwind RNA hairpins by transitioning between an eIF4AI "open" and a "closed" conformation using the energy derived from ATP hydrolysis.  The authors' expts. directly track the conformational changes in the catalytic cycle of eIF4AI and eIF4H, and this correlates precisely with the kinetics of RNA unwinding.  Furthermore, the authors show that the small-mol. eIF4A inhibitor hippuristanol locks eIF4AI in the closed conformation, thus efficiently inhibiting RNA unwinding.  These results indicate that the large conformational changes undertaken by eIF4A during the helicase catalytic cycle are rate limiting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjkK8RKx0oerVg90H21EOLACvtfcHk0liyEway86hGug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCmtrk%253D&md5=eda6d7fe5987e4cbc08c601fbed6fa0d</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DAtas%26aufirst%3DE.%26aulast%3DLindqvist%26aufirst%3DL.%2BM.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DMeller%26aufirst%3DA.%26atitle%3DSingle-Molecule%2520Kinetics%2520of%2520the%2520Eukaryotic%2520Initiation%2520Factor%25204AI%2520upon%2520RNA%2520Unwinding%26jtitle%3DStructure%26date%3D2014%26volume%3D22%26spage%3D941%26epage%3D948%26doi%3D10.1016%2Fj.str.2014.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicia-Vázquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somaiah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deslongchamps, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Modifying Chemotherapy Response by Targeted Inhibition of Eukaryotic Initiation Factor 4A</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e128</span>, <span class="refDoi"> DOI: 10.1038/bcj.2013.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fbcj.2013.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=23872707" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=e128&author=R.+Cencicauthor=F.+Robertauthor=G.+Galicia-V%C3%A1zquezauthor=A.+Malinaauthor=K.+Ravindarauthor=R.+Somaiahauthor=P.+Pierreauthor=J.+Tanakaauthor=P.+Deslongchampsauthor=J.+Pelletier&title=Modifying+Chemotherapy+Response+by+Targeted+Inhibition+of+Eukaryotic+Initiation+Factor+4A&doi=10.1038%2Fbcj.2013.25"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2013.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2013.25%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DRobert%26aufirst%3DF.%26aulast%3DGalicia-V%25C3%25A1zquez%26aufirst%3DG.%26aulast%3DMalina%26aufirst%3DA.%26aulast%3DRavindar%26aufirst%3DK.%26aulast%3DSomaiah%26aufirst%3DR.%26aulast%3DPierre%26aufirst%3DP.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DDeslongchamps%26aufirst%3DP.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DModifying%2520Chemotherapy%2520Response%2520by%2520Targeted%2520Inhibition%2520of%2520Eukaryotic%2520Initiation%2520Factor%25204A%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2013%26volume%3D3%26spage%3De128%26doi%3D10.1038%2Fbcj.2013.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, N.</span></span> <span> </span><span class="NLM_article-title">Hippuristanol Reduces the Viability of Primary Effusion Lymphoma Cells Both <i>in Vitro</i> and <i>in Vivo</i></span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3410</span>– <span class="NLM_lpage">3424</span>, <span class="refDoi"> DOI: 10.3390/md11093410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fmd11093410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24018901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVWnsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=3410-3424&author=C.+Ishikawaauthor=J.+Tanakaauthor=H.+Katanoauthor=M.+Senbaauthor=N.+Mori&title=Hippuristanol+Reduces+the+Viability+of+Primary+Effusion+Lymphoma+Cells+Both+in+Vitro+and+in+Vivo&doi=10.3390%2Fmd11093410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Hippuristanol reduces the viability of primary effusion lymphoma cells both in vitro and in vivo</span></div><div class="casAuthors">Ishikawa, Chie; Tanaka, Junichi; Katano, Harutaka; Senba, Masachika; Mori, Naoki</div><div class="citationInfo"><span class="NLM_cas:title">Marine Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3410-3424</span>CODEN:
                <span class="NLM_cas:coden">MDARE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-3397</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Primary effusion lymphoma (PEL) caused by Kaposi's sarcoma-assocd. herpesvirus (also known as human herpesvirus-8) shows serious lymphomatous effusion in body cavities.  PEL is difficult to treat and there is no std. treatment strategy.  Hippuristanol is extd. from Okinawan coral Isis hippuris, and inhibits translational initiation by blocking eukaryotic initiation factor 4A, an ATP-dependent RNA helicase, binding to mRNA.  Recently, there has been much interest in targeting translation initiation as an anticancer therapy.  Here, we show that treatment of PEL cell lines with hippuristanol resulted in cell cycle arrest at G1 phase, and induced caspases activation and apoptosis.  Hippuristanol also reduced the expression of cyclin D2, CDK2, CDK4, CDK6 and prosurvival XIAP and Mcl-1 proteins.  Activation of activator protein-1, signal transducers and activators of transcription protein 3 and Akt pathways plays a crit. role in the survival and growth of PEL cells.  Hippuristanol suppressed the activities of these three pathways by inhibiting the expression of JunB, JunD, c-Fos, signal transducers and activators of transcription protein 3 and Akt proteins.  In a xenograft mouse model that showed ascites and diffused organ invasion of PEL cells, treatment with hippuristanol significantly inhibited the growth and invasion of PEL cells compared with untreated mice.  The results of the in vitro and in vivo expts. underline the potential usefulness of hippuristanol in the treatment of PEL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkZrmV0KYyqrVg90H21EOLACvtfcHk0ljOFlBcBYGOSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVWnsrrP&md5=9e3f47d7d83b82eefdb2d4a2c8b997a1</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.3390%2Fmd11093410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd11093410%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DC.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DKatano%26aufirst%3DH.%26aulast%3DSenba%26aufirst%3DM.%26aulast%3DMori%26aufirst%3DN.%26atitle%3DHippuristanol%2520Reduces%2520the%2520Viability%2520of%2520Primary%2520Effusion%2520Lymphoma%2520Cells%2520Both%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DMar.%2520Drugs%26date%3D2013%26volume%3D11%26spage%3D3410%26epage%3D3424%26doi%3D10.3390%2Fmd11093410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsumuraya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacHijima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakachi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, N.</span></span> <span> </span><span class="NLM_article-title">Effects of Hippuristanol, an Inhibitor of EIF4A, on Adult T-Cell Leukemia</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2010.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.bcp.2010.12.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21219881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXit12jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2011&pages=713-722&author=T.+Tsumurayaauthor=C.+Ishikawaauthor=Y.+MacHijimaauthor=S.+Nakachiauthor=M.+Senbaauthor=J.+Tanakaauthor=N.+Mori&title=Effects+of+Hippuristanol%2C+an+Inhibitor+of+EIF4A%2C+on+Adult+T-Cell+Leukemia&doi=10.1016%2Fj.bcp.2010.12.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia</span></div><div class="casAuthors">Tsumuraya, Tomoyuki; Ishikawa, Chie; Machijima, Yoshiaki; Nakachi, Sawako; Senba, Masachika; Tanaka, Junichi; Mori, Naoki</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">713-722</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We evaluated the anti-adult T-cell leukemia (ATL) effects of hippuristanol, an eukaryotic translation initiation inhibitor from the coral Isis hippuris.  Hippuristanol inhibited proliferation of HTLV-1-infected T-cell lines and ATL cells, but not normal peripheral blood mononuclear cells.  It induced cell cycle arrest during G1 phase by reducing the expression of cyclin D1, cyclin D2, CDK4 and CDK6, and induced apoptosis by reducing the expression of Bcl-xL, c-IAP2, XIAP and c-FLIP.  The induced apoptosis was assocd. with activation of caspase-3, -8 and -9.  Hippuristanol also suppressed IkappaBalpha phosphorylation and depleted IKKalpha, IKKgamma, JunB and JunD, resulting in inactivation of NF-kappaB and AP-1.  It also suppressed carbonic anhydrase type II expression.  In addn. to its in vitro effects, hippuristanol suppressed tumor growth in mice with severe combined immunodeficiency harboring tumors induced by inoculation of HTLV-1-infected T cells.  These preclin. data suggest that hippuristanol could be a potentially useful therapeutic agent for patients with ATL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv0tQeplP_QrVg90H21EOLACvtfcHk0ljOFlBcBYGOSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXit12jtLk%253D&md5=736d7399eb9e024e8fb9c1a33af8b49d</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2010.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2010.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DTsumuraya%26aufirst%3DT.%26aulast%3DIshikawa%26aufirst%3DC.%26aulast%3DMacHijima%26aufirst%3DY.%26aulast%3DNakachi%26aufirst%3DS.%26aulast%3DSenba%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DMori%26aufirst%3DN.%26atitle%3DEffects%2520of%2520Hippuristanol%252C%2520an%2520Inhibitor%2520of%2520EIF4A%252C%2520on%2520Adult%2520T-Cell%2520Leukemia%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D81%26spage%3D713%26epage%3D722%26doi%3D10.1016%2Fj.bcp.2010.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Hippuristanol - A Potent Steroid Inhibitor of Eukaryotic Initiation Factor 4A</span>. <i>Translation</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e1137381</span>, <span class="refDoi"> DOI: 10.1080/21690731.2015.1137381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1080%2F21690731.2015.1137381" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=e1137381&author=R.+Cencicauthor=J.+Pelletier&title=Hippuristanol+-+A+Potent+Steroid+Inhibitor+of+Eukaryotic+Initiation+Factor+4A&doi=10.1080%2F21690731.2015.1137381"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1080%2F21690731.2015.1137381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21690731.2015.1137381%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DHippuristanol%2520-%2520A%2520Potent%2520Steroid%2520Inhibitor%2520of%2520Eukaryotic%2520Initiation%2520Factor%25204A%26jtitle%3DTranslation%26date%3D2016%26volume%3D4%26spage%3De1137381%26doi%3D10.1080%2F21690731.2015.1137381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravindar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deslongchamps, P.</span></span> <span> </span><span class="NLM_article-title">Efficient Synthetic Approach to Potent Antiproliferative Agent Hippuristanol via Hg(II)-Catalyzed Spiroketalization</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">4420</span>– <span class="NLM_lpage">4423</span>, <span class="refDoi"> DOI: 10.1021/ol1019663</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol1019663" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFehurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=4420-4423&author=K.+Ravindarauthor=M.+S.+Reddyauthor=L.+Lindqvistauthor=J.+Pelletierauthor=P.+Deslongchamps&title=Efficient+Synthetic+Approach+to+Potent+Antiproliferative+Agent+Hippuristanol+via+Hg%28II%29-Catalyzed+Spiroketalization&doi=10.1021%2Fol1019663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Synthetic Approach to Potent Antiproliferative Agent Hippuristanol via Hg(II)-Catalyzed Spiroketalization</span></div><div class="casAuthors">Ravindar, Kontham; Reddy, Maddi Sridhar; Lindqvist, Lisa; Pelletier, Jerry; Deslongchamps, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4420-4423</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The steroidal natural product hippuristanol (I) targets eukaryotic translation initiation factor (eIF)4A which plays a pivotal role in translation in eukaryotic cells.  Now an efficient synthesis of I from 11-ketotigogenin is reported.  The synthesis features a rapid construction of a spiroketal unit via Hg(OTf)2-catalyzed oxidn./spiroketalization of the 3-alkyn-1,7-diol motif.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopVHYXkWhrGbVg90H21EOLACvtfcHk0ljOFlBcBYGOSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFehurrJ&md5=ef9bb21d45cb6fc22496fdff5b548adc</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fol1019663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol1019663%26sid%3Dliteratum%253Aachs%26aulast%3DRavindar%26aufirst%3DK.%26aulast%3DReddy%26aufirst%3DM.%2BS.%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DDeslongchamps%26aufirst%3DP.%26atitle%3DEfficient%2520Synthetic%2520Approach%2520to%2520Potent%2520Antiproliferative%2520Agent%2520Hippuristanol%2520via%2520Hg%2528II%2529-Catalyzed%2520Spiroketalization%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D4420%26epage%3D4423%26doi%3D10.1021%2Fol1019663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravindar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deslongchamps, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the Antiproliferative Agent Hippuristanol and Its Analogues via Suárez Cyclizations and Hg(II)-Catalyzed Spiroketalizations</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1269</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1021/jo102054r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo102054r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKgt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=1269-1284&author=K.+Ravindarauthor=M.+S.+Reddyauthor=L.+Lindqvistauthor=J.+Pelletierauthor=P.+Deslongchamps&title=Synthesis+of+the+Antiproliferative+Agent+Hippuristanol+and+Its+Analogues+via+Su%C3%A1rez+Cyclizations+and+Hg%28II%29-Catalyzed+Spiroketalizations&doi=10.1021%2Fjo102054r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of the Antiproliferative Agent Hippuristanol and Its Analogues via Suarez Cyclizations and Hg(II)-Catalyzed Spiroketalizations</span></div><div class="casAuthors">Ravindar, Kontham; Reddy, Maddi Sridhar; Lindqvist, Lisa; Pelletier, Jerry; Deslongchamps, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1269-1284</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A full account of the synthesis of hippuristanol and its analogs is described.  Hecogenin acetate was identified as a suitable and economical starting material for this work, and substrate-controlled stereoselection was obtained throughout the construction of the key spiroketal unit.  Suarez cyclization was first used, but Hg(II)-catalyzed spiroketalization of the 3-alkyne-1,7-diol motif was finally identified as the most convenient strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB-B3L2wB5abVg90H21EOLACvtfcHk0li459O8-OyMHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKgt7k%253D&md5=3852d576c476ce432a664415e0bb79b1</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjo102054r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo102054r%26sid%3Dliteratum%253Aachs%26aulast%3DRavindar%26aufirst%3DK.%26aulast%3DReddy%26aufirst%3DM.%2BS.%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DDeslongchamps%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520the%2520Antiproliferative%2520Agent%2520Hippuristanol%2520and%2520Its%2520Analogues%2520via%2520Su%25C3%25A1rez%2520Cyclizations%2520and%2520Hg%2528II%2529-Catalyzed%2520Spiroketalizations%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26spage%3D1269%26epage%3D1284%26doi%3D10.1021%2Fjo102054r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somaiah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravindar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deslongchamps, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the Antiproliferative Agent Hippuristanol and Its Analogues from Hydrocortisone via Hg(II)-Catalyzed Spiroketalization: Structure-Activity Relationship</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2511</span>– <span class="NLM_lpage">2523</span>, <span class="refDoi"> DOI: 10.1021/jm401799j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401799j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlOlu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2511-2523&author=R.+Somaiahauthor=K.+Ravindarauthor=R.+Cencicauthor=J.+Pelletierauthor=P.+Deslongchamps&title=Synthesis+of+the+Antiproliferative+Agent+Hippuristanol+and+Its+Analogues+from+Hydrocortisone+via+Hg%28II%29-Catalyzed+Spiroketalization%3A+Structure-Activity+Relationship&doi=10.1021%2Fjm401799j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of the Antiproliferative Agent Hippuristanol and Its Analogues from Hydrocortisone via Hg(II)-Catalyzed Spiroketalization: Structure-Activity Relationship</span></div><div class="casAuthors">Somaiah, Ragam; Ravindar, Kontham; Cencic, Regina; Pelletier, Jerry; Deslongchamps, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2511-2523</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient synthesis of hippuristanol, a marine-derived highly potent antiproliferative steroidal natural product, and nine closely related analogs has been accomplished from the com. available hydrocortisone utilizing Hg(II)-catalyzed spiroketalization of 3-alkyne-1,7-diol motif as a key strategy.  This practical synthetic sequence furnished hippuristanol in 11% overall yield from hydrocortisone in 15 linear steps.  Modifications to the parent mol. hippuristanol encompassed changing the functional groups on rings A and E.  Each analog was screened for their effects on inhibition of cap-dependent translation, and the assay results were used to establish structure-activity relationships.  These results suggest that the stereochem. and all substituents of spiroketal portion (rings E and F) and C3-α and C11-β hydroxyl functional groups on rings A and C, resp., are crit. for the inhibitory activity of natural product hippuristanol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX_M1TjXp22bVg90H21EOLACvtfcHk0li459O8-OyMHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlOlu70%253D&md5=04354eb96c5d5d5010f13f1564b4bf80</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm401799j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401799j%26sid%3Dliteratum%253Aachs%26aulast%3DSomaiah%26aufirst%3DR.%26aulast%3DRavindar%26aufirst%3DK.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DDeslongchamps%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520the%2520Antiproliferative%2520Agent%2520Hippuristanol%2520and%2520Its%2520Analogues%2520from%2520Hydrocortisone%2520via%2520Hg%2528II%2529-Catalyzed%2520Spiroketalization%253A%2520Structure-Activity%2520Relationship%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2511%26epage%3D2523%26doi%3D10.1021%2Fjm401799j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span> <span> </span><span class="NLM_article-title">Expeditious Synthesis of Hippuristanol and Congeners with Potent Antiproliferative Activities</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">10356</span>– <span class="NLM_lpage">10359</span>, <span class="refDoi"> DOI: 10.1002/chem.200901732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fchem.200901732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19746484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Kis7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=10356-10359&author=W.+Liauthor=Y.+Dangauthor=J.+O.+Liuauthor=B.+Yu&title=Expeditious+Synthesis+of+Hippuristanol+and+Congeners+with+Potent+Antiproliferative+Activities&doi=10.1002%2Fchem.200901732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Expeditious Synthesis of Hippuristanol and Congeners with Potent Antiproliferative Activities</span></div><div class="casAuthors">Li, Wei; Dang, Yongjun; Liu, Jun O.; Yu, Biao</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">10356-10359, S10356/1-S10356/74</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Hippuristanol and its congeners with modified E and F rings are prepd.  The effect of hippuristanol and its analogs on HeLa cell proliferation and in vitro translation was detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBRZBR8sT50rVg90H21EOLACvtfcHk0li459O8-OyMHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Kis7fI&md5=4462fbcf3275780e6233cb8d0ed2f814</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fchem.200901732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.200901732%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26aulast%3DYu%26aufirst%3DB.%26atitle%3DExpeditious%2520Synthesis%2520of%2520Hippuristanol%2520and%2520Congeners%2520with%2520Potent%2520Antiproliferative%2520Activities%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2009%26volume%3D15%26spage%3D10356%26epage%3D10359%26doi%3D10.1002%2Fchem.200901732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shatkin, A. J.</span></span> <span> </span><span class="NLM_article-title">A Polypeptide in Eukaryotic Initiation Factors That Crosslinks Specifically to the 5′-Terminal Cap in mRNA</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">4843</span>– <span class="NLM_lpage">4847</span>, <span class="refDoi"> DOI: 10.1073/pnas.75.10.4843</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.75.10.4843" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=217002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE1MXhslOrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1978&pages=4843-4847&author=N.+Sonenbergauthor=M.+A.+Morganauthor=W.+C.+Merrickauthor=A.+J.+Shatkin&title=A+Polypeptide+in+Eukaryotic+Initiation+Factors+That+Crosslinks+Specifically+to+the+5%E2%80%B2-Terminal+Cap+in+mRNA&doi=10.1073%2Fpnas.75.10.4843"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">A polypeptide in eukaryotic initiation factors that crosslinks specifically to the 5'-terminal cap in mRNA</span></div><div class="casAuthors">Sonenberg, Nahum; Morgan, Maureen A.; Merrick, William C.; Shatkin, Aaron J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4843-7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Protein formation initiation factors prepd. from rabbit reticulocyte and mouse ascites ribosomes were tested for the ability to crosslink to the 5'-cap of mRNA.  Crosslinking of 1 polypeptide of apparent mol. wt. 24,000 was inhibited by the cap analogs, 7-methyl-GMP and 7-methyl-GDP, indicating a specific interaction with the cap.  Although specific crosslinking of the 24,000-mol.-wt. polypeptide was found with eukaryotic initiation factor 3 and to a lesser extent with initiation factor 4B, both of these factors contained less than stoichiometric amts. of this polypeptide.  The crosslinking method provides a highly sensitive and specific assay for cap-binding proteins and should facilitate their purifn. for functional studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRV1Ykxs1B-7Vg90H21EOLACvtfcHk0lhy6ODnL2TVXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXhslOrtw%253D%253D&md5=2ffb987151d81bc60d5d6eb77f89bb2b</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1073%2Fpnas.75.10.4843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.75.10.4843%26sid%3Dliteratum%253Aachs%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DMorgan%26aufirst%3DM.%2BA.%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26aulast%3DShatkin%26aufirst%3DA.%2BJ.%26atitle%3DA%2520Polypeptide%2520in%2520Eukaryotic%2520Initiation%2520Factors%2520That%2520Crosslinks%2520Specifically%2520to%2520the%25205%25E2%2580%25B2-Terminal%2520Cap%2520in%2520mRNA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1978%26volume%3D75%26spage%3D4843%26epage%3D4847%26doi%3D10.1073%2Fpnas.75.10.4843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupprecht, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shatkin, A. J.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic mRNA Cap Binding Protein: Purification by Affinity Chromatography on Sepharose-Coupled m7GDP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">4345</span>– <span class="NLM_lpage">4349</span>, <span class="refDoi"> DOI: 10.1073/pnas.76.9.4345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.76.9.4345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=291969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE1MXlslShu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1979&pages=4345-4349&author=N.+Sonenbergauthor=K.+M.+Rupprechtauthor=S.+M.+Hechtauthor=A.+J.+Shatkin&title=Eukaryotic+mRNA+Cap+Binding+Protein%3A+Purification+by+Affinity+Chromatography+on+Sepharose-Coupled+m7GDP&doi=10.1073%2Fpnas.76.9.4345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic mRNA cap binding protein:  Purification by affinity chromatography on Sepharose-coupled m7GDP</span></div><div class="casAuthors">Sonenberg, Nahum; Rupprecht, Kathleen M.; Hecht, Sidney M.; Shatkin, Aaron J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4345-9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A 24,000-dalton polypeptide that binds strongly and can be specifically crosslinked to the 5'-terminal cap structure m7GpppN (m7G = 7-methylguanine, N = nucleoside base) in eukaryotic mRNAs was detected in protein synthesis initiation factor prepns.  This polypeptide was purified to apparent homogeneity by 1 chromatog. passage through an affinity resin prepd. by coupling the levulinic acid O2',3'-acetal of 7-Me GDP to AH-Sepharose 4B.  Translation in HeLa cell exts. of capped mRNAs, including Sindbis virus, reovirus, and rabbit globin mRNAs, was stimulated by the cap-binding protein under conditions that did not increase translation of noncapped RNAs of encephalomyocarditis virus and satellite tobacco necrosis virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq8b-UTpd86LVg90H21EOLACvtfcHk0lhy6ODnL2TVXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXlslShu7s%253D&md5=abcee2f9b71aafdcb87c7f2c2080cf71</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1073%2Fpnas.76.9.4345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.76.9.4345%26sid%3Dliteratum%253Aachs%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DRupprecht%26aufirst%3DK.%2BM.%26aulast%3DHecht%26aufirst%3DS.%2BM.%26aulast%3DShatkin%26aufirst%3DA.%2BJ.%26atitle%3DEukaryotic%2520mRNA%2520Cap%2520Binding%2520Protein%253A%2520Purification%2520by%2520Affinity%2520Chromatography%2520on%2520Sepharose-Coupled%2520m7GDP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1979%26volume%3D76%26spage%3D4345%26epage%3D4349%26doi%3D10.1073%2Fpnas.76.9.4345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcguire, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span> <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1038/nsb0997-717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnsb0997-717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=9302999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK2sXmtl2qu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Matsuo%2C+H.%3B+Li%2C+H.%3B+Mcguire%2C+A.+M.%3B+Fletcher%2C+C.+M.%3B+Gingras%2C+A.%3B+Sonenberg%2C+N.%3B+Wagner%2C+G.+Nat.+Struct.+Biol.+1997%2C+4%2C+717%E2%80%93724%2C+10.1038%2Fnsb0997-717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of translation factor eIF4E bound to m7GDP and interaction with 4E-binding protein</span></div><div class="casAuthors">Matsuo, Hiroshi; Li, Hanjun; Mcguire, Abigail M.; Fletcher, C. Mark; Gingras, Anne-Claude; Sonenberg, Nahum; Wagner, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">717-724</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">EIF4E, the mRNA cap binding protein, is a master switch that controls eukaryotic translation.  To be active, it must bind eIF4G and form the eIF4F complex, which also contains eIF4A.  Translation is downregulated by assocn. of eIF4E with 4E-BP, which occupies the eIF4G binding site.  Signaling events acting on 4E-BP cause it to dissoc. from eIF4E, and eIF4E is then free to bind eIF4G to form the active eIF4F complex.  We have solved the structure of the yeast eIF4E/m7Gpp complex in a CHAPS micelle.  We detd. the position of the second nucleotide in a complex with m7GpppA, and identified the 4E-BP binding site.  EIF4E has a curved eight-stranded antiparallel β-sheet, decorated with three helixes on the convex face and three smaller helixes inserted in connecting loops.  The m7G of the cap is intercalated into a stack of tryptophans in the concave face.  The 4E-BP binding site is located in a region encompassing one edge of the β-sheet, the adjacent helix a2 and several regions of non-regular secondary structure.  It is adjacent to, but does not overlap the cap-binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoZ0rWyxKYw7Vg90H21EOLACvtfcHk0lhy6ODnL2TVXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmtl2qu7k%253D&md5=c85483815753a9d68cdc6400788037d8</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnsb0997-717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb0997-717%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMcguire%26aufirst%3DA.%2BM.%26aulast%3DFletcher%26aufirst%3DC.%2BM.%26aulast%3DGingras%26aufirst%3DA.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DWagner%26aufirst%3DG.%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D1997%26volume%3D4%26spage%3D717%26epage%3D724%26doi%3D10.1038%2Fnsb0997-717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcotrigiano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burley, S. K.</span></span> <span> </span><span class="NLM_article-title">X-Ray Studies of the Messenger RNA 5′ Cap-Binding Protein (eIF4E) Bound to 7-Methyl-GDP</span>. <i>Nucleic Acids Symp. Ser.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=8-11&author=J.+Marcotrigianoauthor=A.+C.+Gingrasauthor=N.+Sonenbergauthor=S.+K.+Burley&title=X-Ray+Studies+of+the+Messenger+RNA+5%E2%80%B2+Cap-Binding+Protein+%28eIF4E%29+Bound+to+7-Methyl-GDP"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotrigiano%26aufirst%3DJ.%26aulast%3DGingras%26aufirst%3DA.%2BC.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DBurley%26aufirst%3DS.%2BK.%26atitle%3DX-Ray%2520Studies%2520of%2520the%2520Messenger%2520RNA%25205%25E2%2580%25B2%2520Cap-Binding%2520Protein%2520%2528eIF4E%2529%2520Bound%2520to%25207-Methyl-GDP%26jtitle%3DNucleic%2520Acids%2520Symp.%2520Ser.%26date%3D1997%26volume%3D89%26spage%3D8%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, L. O.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic Initiation Factor 4E</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2675</span>– <span class="NLM_lpage">2680</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2007.10.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.biocel.2007.10.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18069043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFaisb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=2675-2680&author=I.+G.+Goodfellowauthor=L.+O.+Roberts&title=Eukaryotic+Initiation+Factor+4E&doi=10.1016%2Fj.biocel.2007.10.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic initiation factor 4E</span></div><div class="casAuthors">Goodfellow, Ian G.; Roberts, Lisa O.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2675-2680</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Eukaryotic translation initiation factor 4E (eIF4E) is perhaps best known for its function in the initiation of protein synthesis on capped mRNAs in the cytoplasm.  However, recent studies have highlighted that eIF4E has many addnl. functions, which include the nuclear export of specific mRNAs as well as roles in aging and the translation of some uncapped viral RNAs.  This review aims to update the reader on recent developments, including the potential of eIF4E as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouxALIroKIqrVg90H21EOLACvtfcHk0liMqJkBMQ4KqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFaisb7O&md5=321d528772f819e9e229fe434a0bfa80</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2007.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2007.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DGoodfellow%26aufirst%3DI.%2BG.%26aulast%3DRoberts%26aufirst%3DL.%2BO.%26atitle%3DEukaryotic%2520Initiation%2520Factor%25204E%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2008%26volume%3D40%26spage%3D2675%26epage%3D2680%26doi%3D10.1016%2Fj.biocel.2007.10.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topisirovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span> <span> </span><span class="NLM_article-title">Controlling Gene Expression through RNA Regulons: The Role of the Eukaryotic Translation Initiation Factor EIF4E</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.4161/cc.6.1.3688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.4161%2Fcc.6.1.3688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17245113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFygtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=65-69&author=B.+Culjkovicauthor=I.+Topisirovicauthor=K.+L.+B.+Borden&title=Controlling+Gene+Expression+through+RNA+Regulons%3A+The+Role+of+the+Eukaryotic+Translation+Initiation+Factor+EIF4E&doi=10.4161%2Fcc.6.1.3688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E</span></div><div class="casAuthors">Culjkovic, Biljana; Topisirovic, Ivan; Borden, Katherine L. B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-69</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  The eukaryotic translation initiation factor eIF4E is a potent oncogene.  In fact, its overexpression in human cancer often correlates with poor prognosis.  Traditionally, eIF4E plays a role in translation initiation where it binds the 5' m7G cap found on mRNAs.  More recent studies indicate that a significant fraction of eIF4E (up to 68%) resides in the nucleus where it regulates the nuclear export of specific mRNAs.  Addnl., eIF4E may play a role in mRNA sequestration and stability in cytoplasmic processing bodies (P-bodies).  Our recent studies suggest that eIF4E governs cell cycle progression and cellular proliferation by coordinately orchestrating the expression of several genes at the post-transcriptional level.  Hence, eIF4E functions as a central node of an RNA regulon (described below), which plays an essential role in normal differentiation and development and is frequently dysregulated in cancer.  Several cellular factors, such as the promyelocytic leukemia protein PML, modulate the function of this regulon by altering the activity of eIF4E.  Here, the physiol. implications of these observations are described and the clin. implications of directly targeting eIF4E, and the related regulon, are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppwYcY9SNNMrVg90H21EOLACvtfcHk0liMqJkBMQ4KqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFygtr4%253D&md5=9b9668885b8ec8dec2bcc8800aba5e4f</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.4161%2Fcc.6.1.3688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.6.1.3688%26sid%3Dliteratum%253Aachs%26aulast%3DCuljkovic%26aufirst%3DB.%26aulast%3DTopisirovic%26aufirst%3DI.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DControlling%2520Gene%2520Expression%2520through%2520RNA%2520Regulons%253A%2520The%2520Role%2520of%2520the%2520Eukaryotic%2520Translation%2520Initiation%2520Factor%2520EIF4E%26jtitle%3DCell%2520Cycle%26date%3D2007%26volume%3D6%26spage%3D65%26epage%3D69%26doi%3D10.4161%2Fcc.6.1.3688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Mnks for Cancer Therapy</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.18632%2Foncotarget.453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22392765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BC383ps1WjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=118-131&author=J.+Houauthor=F.+Lamauthor=C.+Proudauthor=S.+Wang&title=Targeting+Mnks+for+Cancer+Therapy&doi=10.18632%2Foncotarget.453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Mnks for cancer therapy</span></div><div class="casAuthors">Hou Jinqiang; Lam Frankie; Proud Christopher; Wang Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Deregulation of protein synthesis is a common event in human cancer and a key player in translational control is eIF4E.  Elevated expression levels of eIF4E promote cancer development and progression.  Recent findings suggest that eIF4E activity is a key determinant of the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK mediated tumorigenic activity and targeting eIF4E should have a major impact on these pathways in human cancer.  The function of eIF4E is modulated through phosphorylation of a conserved serine (Ser209) by Mnk1 and Mnk2 downstream of ERK.  While the phosphorylation event is necessary for oncogenic transformation, it seems to be dispensable for normal development.  Hence, pharmacologic Mnk inhibitors may provide non-toxic and effective anti-cancer strategy.  Strong circumstantial evidence indicates that Mnk inhibition presents attractive therapeutic potential, but the lack of selective Mnk inhibitors has so far confounded pharmacological target validation and clinical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRs_vEZzPs7B4USrryheKE6fW6udTcc2eZdPIEEGJK2j7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383ps1WjsA%253D%253D&md5=b98424025f73526eed531001700584f1</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.453%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DProud%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeting%2520Mnks%2520for%2520Cancer%2520Therapy%26jtitle%3DOncotarget%26date%3D2012%26volume%3D3%26spage%3D118%26epage%3D131%26doi%3D10.18632%2Foncotarget.453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malka-Mahieu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, S.</span></span> <span> </span><span class="NLM_article-title">Molecular Pathways: The EIF4F Translation Initiation Complex-Newopportunities for Cancer Treatment</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1158%2F1078-0432.CCR-14-2362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27789529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1WgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=21-25&author=H.+Malka-Mahieuauthor=M.+Newmanauthor=L.+D%C3%A9saubryauthor=C.+Robertauthor=S.+Vagner&title=Molecular+Pathways%3A+The+EIF4F+Translation+Initiation+Complex-Newopportunities+for+Cancer+Treatment&doi=10.1158%2F1078-0432.CCR-14-2362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment</span></div><div class="casAuthors">Malka-Mahieu, Helene; Newman, Michelle; Desaubry, Laurent; Robert, Caroline; Vagner, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-25</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The eIF4F complex regulates the cap-dependent mRNA translation process.  It is becoming increasingly evident that aberrant activity of this complex is obsd. in many cancers, leading to the selective synthesis of proteins involved in tumor growth and metastasis.  The selective translation of cellular mRNAs controlled by this complex also contributes to resistance to cancer treatments, and downregulation of the eIF4F complex components can restore sensitivity to various cancer therapies.  Here, we review the contribution of the eIF4F complex to tumorigenesis, with a focus on its role in chemoresistance as well as the promising use of new small-mol. inhibitors of the complex, including flavaglines/rocaglates, hippuristanol, and pateamine A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_X1TZoBvLP7Vg90H21EOLACvtfcHk0liMqJkBMQ4KqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1WgsA%253D%253D&md5=8e65b884cc8e3943a83f4965bf600ccd</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2362%26sid%3Dliteratum%253Aachs%26aulast%3DMalka-Mahieu%26aufirst%3DH.%26aulast%3DNewman%26aufirst%3DM.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DVagner%26aufirst%3DS.%26atitle%3DMolecular%2520Pathways%253A%2520The%2520EIF4F%2520Translation%2520Initiation%2520Complex-Newopportunities%2520for%2520Cancer%2520Treatment%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D21%26epage%3D25%26doi%3D10.1158%2F1078-0432.CCR-14-2362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazaris-Karatzas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montine, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span> <span> </span><span class="NLM_article-title">Malignant Transformation by a Eukaryotic Initiation Factor Subunit That Binds to mRNA 5′ Cap</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">544</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1038/345544a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2F345544a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=2348862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK3cXktlygsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=1990&pages=544-547&author=A.+Lazaris-Karatzasauthor=K.+S.+Montineauthor=N.+Sonenberg&title=Malignant+Transformation+by+a+Eukaryotic+Initiation+Factor+Subunit+That+Binds+to+mRNA+5%E2%80%B2+Cap&doi=10.1038%2F345544a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap</span></div><div class="casAuthors">Lazaris-Karatzas, Anthoula; Montine, Kathleen S.; Sonenberg, Nahum</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">6275</span>),
    <span class="NLM_cas:pages">544-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Overexpression of the translation factor eIF-4E from exogenous cDNA in rodent cell lines caused tumorigenic transformation, as detd. by 3 criteria: formation of transformed foci on a monolayer of cells, anchorage-independent growth, and tumor formation in nude mice.  An eIF-4E mutant whose serine 53 codon was mutated to alanine did not cause tumor formation in nude mice.  The mechanism by which eIF-4E transforms cells is not clear.  The expression of certain oncogenes or growth factors might be tightly controlled at the translational level by the availability of eIF-4E.  Increasing the level of eIF-4E might relieve translational repression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC3QZOSYEW5LVg90H21EOLACvtfcHk0ljsXF2MCVQHkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktlygsrg%253D&md5=b074e125f2b7c237ba1f646814493064</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2F345544a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F345544a0%26sid%3Dliteratum%253Aachs%26aulast%3DLazaris-Karatzas%26aufirst%3DA.%26aulast%3DMontine%26aufirst%3DK.%2BS.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DMalignant%2520Transformation%2520by%2520a%2520Eukaryotic%2520Initiation%2520Factor%2520Subunit%2520That%2520Binds%2520to%2520mRNA%25205%25E2%2580%25B2%2520Cap%26jtitle%3DNature%26date%3D1990%26volume%3D345%26spage%3D544%26epage%3D547%26doi%3D10.1038%2F345544a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coutinho
de Oliveira, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahardjo, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic-Kraljacic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trahan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span> <span> </span><span class="NLM_article-title">Structural Studies of the EIF4E – VPg Complex Reveal a Direct Competition for Capped RNA : Implications for Translation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">24056</span>– <span class="NLM_lpage">24065</span>, <span class="refDoi"> DOI: 10.1073/pnas.1904752116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.1904752116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31712417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BB3MjnslWqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=24056-24065&author=L.+Coutinho%0Ade+Oliveiraauthor=L.+Volponauthor=A.+K.+Rahardjoauthor=M.+J.+Osborneauthor=B.+Culjkovic-Kraljacicauthor=C.+Trahanauthor=M.+Oeffingerauthor=B.+H.+Kwokauthor=K.+L.+B.+Borden&title=Structural+Studies+of+the+EIF4E+%E2%80%93+VPg+Complex+Reveal+a+Direct+Competition+for+Capped+RNA%E2%80%AF%3A+Implications+for+Translation&doi=10.1073%2Fpnas.1904752116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Structural studies of the eIF4E-VPg complex reveal a direct competition for capped RNA: Implications for translation</span></div><div class="casAuthors">Coutinho de Oliveira Luciana; Volpon Laurent; Rahardjo Amanda K; Osborne Michael J; Culjkovic-Kraljacic Biljana; Kwok Benjamin H; Borden Katherine L B; Trahan Christian; Oeffinger Marlene; Oeffinger Marlene; Oeffinger Marlene</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">24056-24065</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Viruses have transformed our understanding of mammalian RNA processing, including facilitating the discovery of the methyl-7-guanosine (m(7)G) cap on the 5' end of RNAs.  The m(7)G cap is required for RNAs to bind the eukaryotic translation initiation factor eIF4E and associate with the translation machinery across plant and animal kingdoms.  The potyvirus-derived viral genome-linked protein (VPg) is covalently bound to the 5' end of viral genomic RNA (gRNA) and associates with host eIF4E for successful infection.  Divergent models to explain these observations proposed either an unknown mode of eIF4E engagement or a competition of VPg for the m(7)G cap-binding site.  To dissect these possibilities, we resolved the structure of VPg, revealing a previously unknown 3-dimensional (3D) fold, and characterized the VPg-eIF4E complex using NMR and biophysical techniques.  VPg directly bound the cap-binding site of eIF4E and competed for m(7)G cap analog binding.  In human cells, VPg inhibited eIF4E-dependent RNA export, translation, and oncogenic transformation.  Moreover, VPg formed trimeric complexes with eIF4E-eIF4G, eIF4E bound VPg-luciferase RNA conjugates, and these VPg-RNA conjugates were templates for translation.  Informatic analyses revealed structural similarities between VPg and the human kinesin EG5.  Consistently, EG5 directly bound eIF4E in a similar manner to VPg, demonstrating that this form of engagement is relevant beyond potyviruses.  In all, we revealed an unprecedented modality for control and engagement of eIF4E and show that VPg-RNA conjugates functionally engage eIF4E.  As such, potyvirus VPg provides a unique model system to interrogate eIF4E.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4tR5q1L6mjDdblLE_E9PWfW6udTcc2ea8FUyt_L-C57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjnslWqsQ%253D%253D&md5=399b6d8b5691a5201b4419ddd524c32d</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1904752116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1904752116%26sid%3Dliteratum%253Aachs%26aulast%3DCoutinho%2Bde%2BOliveira%26aufirst%3DL.%26aulast%3DVolpon%26aufirst%3DL.%26aulast%3DRahardjo%26aufirst%3DA.%2BK.%26aulast%3DOsborne%26aufirst%3DM.%2BJ.%26aulast%3DCuljkovic-Kraljacic%26aufirst%3DB.%26aulast%3DTrahan%26aufirst%3DC.%26aulast%3DOeffinger%26aufirst%3DM.%26aulast%3DKwok%26aufirst%3DB.%2BH.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DStructural%2520Studies%2520of%2520the%2520EIF4E%2520%25E2%2580%2593%2520VPg%2520Complex%2520Reveal%2520a%2520Direct%2520Competition%2520for%2520Capped%2520RNA%25E2%2580%25AF%253A%2520Implications%2520for%2520Translation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26spage%3D24056%26epage%3D24065%26doi%3D10.1073%2Fpnas.1904752116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidwell, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, L. N.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Broad Spectrum Antiviral Activity of l-(3-D-Ribofuranosyl-l,2,4-Triazole-3-Carboxamidef and Related Nucleosides</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1972</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1150</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1021/jm00281a014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00281a014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE3sXht1Sgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1972&pages=1150-1154&author=J.+T.+Witkowskiauthor=R.+K.+Robinsauthor=R.+W.+Sidwellauthor=L.+N.+Simon&title=Design%2C+Synthesis%2C+and+Broad+Spectrum+Antiviral+Activity+of+l-%283-D-Ribofuranosyl-l%2C2%2C4-Triazole-3-Carboxamidef+and+Related+Nucleosides&doi=10.1021%2Fjm00281a014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and broad spectrum antiviral activity of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides</span></div><div class="casAuthors">Witkowski, J. T.; Robins, Roland K.; Sidwell, Robert W.; Simon, Lionel N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1972</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1150-4</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (I) [36791-04-5] show high antiviral activity in tissue culture against both DNA and RNA viruses, namely adenovirus, herpes virus types 1 and 2, vaccinia virus, myxoma virus, parainfluenza virus, rhinovirus, coxsackie virus, influenza A2 virus, and influenza B virus.  I was active at concns. as low as 1-32 μg/ml, depending on the viruses utilized.  I was also effective against established infection with DNA and RNA viruses in vivo in lab. animals.  However, I was ineffective against various types of viral encephalitis, presumably due to the inability of I to cross the blood-brain barrier.  I did not induce interferon in mice, and apparently affected macromol. processes of viral replication.  I was synthesized by treatment of the trimethylsilyl deriv. of Me 1,2,4-triazole-3-carboxylate with an acyl-blocked ribofuranosyl bromide in MeCN at room temp., or by acid-catalyzed fusion of Me 1,2,4-triazole-3-carboxylate with a 1,2,3,5-tetra-O-acylribofuranose to yield a mixt. of blocked Me ester nucleosides, which were sepd. by chromatog. on silica gel; the desired isomer was reacted with NH3-MeOH to yield I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAhZCUEbd06rVg90H21EOLACvtfcHk0ljsXF2MCVQHkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXht1Sgsg%253D%253D&md5=fdd7b0db555cde9ef08429a4a7542ef0</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fjm00281a014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00281a014%26sid%3Dliteratum%253Aachs%26aulast%3DWitkowski%26aufirst%3DJ.%2BT.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26aulast%3DSidwell%26aufirst%3DR.%2BW.%26aulast%3DSimon%26aufirst%3DL.%2BN.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Broad%2520Spectrum%2520Antiviral%2520Activity%2520of%2520l-%25283-D-Ribofuranosyl-l%252C2%252C4-Triazole-3-Carboxamidef%2520and%2520Related%2520Nucleosides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1972%26volume%3D15%26spage%3D1150%26epage%3D1154%26doi%3D10.1021%2Fjm00281a014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sidwell, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare, L. G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, R. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span> <span> </span><span class="NLM_article-title">Broad-Spectrum Antiviral Activity of Virazole: 1-β-D-Ribofuranosyl-1, 2,4-Triazole-3-Carboxamide</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1972</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1126/science.177.4050.705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1126%2Fscience.177.4050.705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=4340949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE38XlsVOltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=1972&pages=705-706&author=R.+W.+Sidwellauthor=J.+H.+Huffmanauthor=L.+G.+P.+Khareauthor=L.+B.+Allenauthor=R.+J.+T.+Witkowskiauthor=R.+K.+Robins&title=Broad-Spectrum+Antiviral+Activity+of+Virazole%3A+1-%CE%B2-D-Ribofuranosyl-1%2C+2%2C4-Triazole-3-Carboxamide&doi=10.1126%2Fscience.177.4050.705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Broad-spectrum antiviral activity of Virazole. 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide</span></div><div class="casAuthors">Sidwell, Robert W.; Huffman, John H.; Khare, G. P.; Allen, Lois B.; Witkowski, J. T.; Robins, Roland K.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1972</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">4050</span>),
    <span class="NLM_cas:pages">705-6</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Virazole (I) [36791-04-5] is a synthetic nucleoside active in tissue cultures against at least 16 DNA and RNA viruses.  Applied topically it inhibited herpetic keratitis in rabbits and tail lesions induced by herpes, vaccinia, and vesicular stomatitis viruses in mice.  Injected i.p. into mice it inhibited splenomegaly and hepatomegaly induced by Friend leukemia virus and respiratory infections caused by influenza A0, A2, and B viruses and parainfluenza 1 virus.  Oral or aerosol treatment of parainfluenza virus infections was also effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq093yJC1pGwbVg90H21EOLACvtfcHk0lgcrULlkoYEfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE38XlsVOltrs%253D&md5=43631ffd66657eaac3c1a836d568779c</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1126%2Fscience.177.4050.705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.177.4050.705%26sid%3Dliteratum%253Aachs%26aulast%3DSidwell%26aufirst%3DR.%2BW.%26aulast%3DHuffman%26aufirst%3DJ.%2BH.%26aulast%3DKhare%26aufirst%3DL.%2BG.%2BP.%26aulast%3DAllen%26aufirst%3DL.%2BB.%26aulast%3DWitkowski%26aufirst%3DR.%2BJ.%2BT.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26atitle%3DBroad-Spectrum%2520Antiviral%2520Activity%2520of%2520Virazole%253A%25201-%25CE%25B2-D-Ribofuranosyl-1%252C%25202%252C4-Triazole-3-Carboxamide%26jtitle%3DScience%26date%3D1972%26volume%3D177%26spage%3D705%26epage%3D706%26doi%3D10.1126%2Fscience.177.4050.705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tam, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Z.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Action of Ribavirin in Antiviral Therapies</span>. <i>Antivir. Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1177/095632020101200501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1177%2F095632020101200501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=11900345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsFeqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=261-272&author=R.+C.+Tamauthor=J.+Y.+N.+Lauauthor=Z.+Hong&title=Mechanisms+of+Action+of+Ribavirin+in+Antiviral+Therapies&doi=10.1177%2F095632020101200501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of action of ribavirin in antiviral therapies</span></div><div class="casAuthors">Tam, Robert C.; Lau, Johnson Y. N.; Hong, Zhi</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">261-272</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">A review.  Although ribavirin was originally synthesized over 30 yr ago and was used to treat viral infections as monotherapy (respiratory syncytial virus and Lassa fever virus) or with interferon-α (IFN-α) as combination therapy (hepatitis C virus), the precise mechanism of its therapeutic activities remains controversial.  In this review the authors focus on 2 main biol. properties of ribavirin: its indirect and direct antiviral activities (with particular emphasis on its efficacy against chronic hepatitis C infection).  Each property could individually or collectively account for its clin. efficacy against viral infections.  First, with emphasis on the evidence for indirect activities of ribavirin, the authors will review the clin. observations that suggest that the immunomodulatory properties of ribavirin can in part account for its antiviral activities in vivo.  The authors will then describe the mode of ribavirin's direct antiviral activities.  These direct activities can be ascribed to several possible mechanisms, including the recently described activity as an RNA mutagen, a property that may be important in driving a rapidly mutating RNA virus over the threshold to "error catastrophe".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2AvIqqfeFX7Vg90H21EOLACvtfcHk0lgcrULlkoYEfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsFeqsro%253D&md5=f5b7d6042011b80cd5eb6bc616b2c1ac</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1177%2F095632020101200501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020101200501%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DR.%2BC.%26aulast%3DLau%26aufirst%3DJ.%2BY.%2BN.%26aulast%3DHong%26aufirst%3DZ.%26atitle%3DMechanisms%2520of%2520Action%2520of%2520Ribavirin%2520in%2520Antiviral%2520Therapies%26jtitle%3DAntivir.%2520Chem.%2520Chemother.%26date%3D2001%26volume%3D12%26spage%3D261%26epage%3D272%26doi%3D10.1177%2F095632020101200501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujitaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span> <span> </span><span class="NLM_article-title">The Broad Spectrum Antiviral Agent Ribavirin Inhibits Capping of MRNA</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">830</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(79)91853-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2F0006-291X%2879%2991853-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=226095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE1MXltlCksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1979&pages=830-836&author=B.+B.+Goswamiauthor=E.+Borekauthor=O.+K.+Sharmaauthor=J.+Fujitakiauthor=R.+A.+Smith&title=The+Broad+Spectrum+Antiviral+Agent+Ribavirin+Inhibits+Capping+of+MRNA&doi=10.1016%2F0006-291X%2879%2991853-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The broad spectrum antiviral agent ribavirin inhibits capping of mRNA</span></div><div class="casAuthors">Goswami, Biswendu B.; Borek, Ernest; Sharma, Opendra K.; Fujitaki, James; Smith, Roberts A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">830-6</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Ribavirin (I)  [36791-04-5], a broad spectrum antiviral substance active against a wide range of both DNA and RNA viruses, did not inhibit DNA-dependent RNA synthesis by vaccina virus assocd. polymerase.  However, I triphosphate  [63142-71-2] was a potent competitive inhibitor of the capping guanylation of viral mRNA.  This finding could account for the antiviral potency of the drug against both DNA and RNA viruses and its ineffectiveness against polio virus, a virus in which the mRNAs derived from them are not capped.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5tCmOPyaKCrVg90H21EOLACvtfcHk0lgcrULlkoYEfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXltlCksbY%253D&md5=bb9dcca3b5ff4bf5366f08fd645bc721</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2879%2991853-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252879%252991853-9%26sid%3Dliteratum%253Aachs%26aulast%3DGoswami%26aufirst%3DB.%2BB.%26aulast%3DBorek%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DO.%2BK.%26aulast%3DFujitaki%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26atitle%3DThe%2520Broad%2520Spectrum%2520Antiviral%2520Agent%2520Ribavirin%2520Inhibits%2520Capping%2520of%2520MRNA%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1979%26volume%3D89%26spage%3D830%26epage%3D836%26doi%3D10.1016%2F0006-291X%2879%2991853-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgstrand, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misiorny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norén, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philipson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stening, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stridh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberg, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Influenza Virus Ribonucleic Acid Polymerase by Ribavirin Triphosphate</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1128/AAC.11.6.946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1128%2FAAC.11.6.946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=879760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE2sXkvVSgs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1977&pages=946-951&author=B.+Erikssonauthor=E.+Helgstrandauthor=N.+G.+Johanssonauthor=A.+Larssonauthor=A.+Misiornyauthor=J.+O.+Nor%C3%A9nauthor=L.+Philipsonauthor=K.+Stenbergauthor=G.+Steningauthor=S.+Stridhauthor=B.+Oberg&title=Inhibition+of+Influenza+Virus+Ribonucleic+Acid+Polymerase+by+Ribavirin+Triphosphate&doi=10.1128%2FAAC.11.6.946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate</span></div><div class="casAuthors">Eriksson, Bertil; Helgstrand, Erik; Johansson, Nils Gunnar; Larsson, Alf; Misiorny, Alfons; Noren, Jan Olof; Philipson, Lennart; Stenberg, Kjell; Stening, Goran; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">946-51</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">Ribavirin 5'-triphosphate (I), derived from the broad-spectrum antiviral compd., ribavirin (Virazole), selectively inhibited influenza virus RNA polymerase in a cell-free assay.  Neither ribavirin or its 5'-monophosphate had any effect on the viral polymerase.  The inhibition by I was competitive with respect to ATP and GTP.  I also inhibited ApG- and GpC-stimulated influenza virus RNA polymerase.  Since ribavirin is phosphorylated in the cell, the inhibition of influenza multiplication in the cell may also be caused by I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJyStouG8YBrVg90H21EOLACvtfcHk0lgiM10UWgLhBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXkvVSgs7o%253D&md5=6679bbc6518c00bd21f565d675d2b213</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1128%2FAAC.11.6.946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.11.6.946%26sid%3Dliteratum%253Aachs%26aulast%3DEriksson%26aufirst%3DB.%26aulast%3DHelgstrand%26aufirst%3DE.%26aulast%3DJohansson%26aufirst%3DN.%2BG.%26aulast%3DLarsson%26aufirst%3DA.%26aulast%3DMisiorny%26aufirst%3DA.%26aulast%3DNor%25C3%25A9n%26aufirst%3DJ.%2BO.%26aulast%3DPhilipson%26aufirst%3DL.%26aulast%3DStenberg%26aufirst%3DK.%26aulast%3DStening%26aufirst%3DG.%26aulast%3DStridh%26aufirst%3DS.%26aulast%3DOberg%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520Influenza%2520Virus%2520Ribonucleic%2520Acid%2520Polymerase%2520by%2520Ribavirin%2520Triphosphate%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1977%26volume%3D11%26spage%3D946%26epage%3D951%26doi%3D10.1128%2FAAC.11.6.946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeprose, R. D.</span></span> <span> </span><span class="NLM_article-title">Metabolism of 5-Amino-1-<i>H</i>-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl-imidazole-4-carboximide and related five-membered heterocycles to 5′-Triphosphates in Human Blood and L5178Y Cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(78)90508-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2F0006-2952%2878%2990508-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=207278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE1cXkvF2ls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1978&pages=709-716&author=T.+P.+Zimmermanauthor=R.+D.+Deeprose&title=Metabolism+of+5-Amino-1-H-d-ribofuranosyl-imidazole-4-carboximide+and+related+five-membered+heterocycles+to+5%E2%80%B2-Triphosphates+in+Human+Blood+and+L5178Y+Cells&doi=10.1016%2F0006-2952%2878%2990508-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of 5-amino-1-β-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5'-triphosphates in human blood and L5178Y cells</span></div><div class="casAuthors">Zimmerman, Thomas P.; Deeprose, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">709-16</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">5-Amino-1-β-D-ribofuranosylimidazole-4-carboxamide (I)  [2627-69-2] and its structural analogs, e.g., ribavirin  [36791-04-5], were metabolized to their corresponding 5'-triphosphates in human blood.  I and ribavirin were metabolized to the 5'-monophosphates mainly (>90%) via a nucleoside kinase  [52350-81-9], whereas 5-fluoro-1-β-D-ribofuranosylimidazole-4-carboxamide (II)  [56766-95-1] appeared to be metabolized to its 5'-monophosphate both via a nucleoside kinase (∼67%) and via phosphorolytic cleavage followed by a phosphoribosyltransferase  [9076-94-2]-mediated reaction (∼33%).  The aglycones of I and II were also metabolized to their corresponding triphosphates.  In addn., ribavirin was metabolized to its 5'-triphosphate in L5178Y cells, but was not incorporated into RNA.  Ribavirin decreased the pool size of GTP  [86-01-1] in L5178Y cells, with a concomitant increase in the pool size of both CTP  [65-47-4] and UTP  [63-39-8].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg-tm2UeE2BLVg90H21EOLACvtfcHk0lgiM10UWgLhBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXkvF2ls7s%253D&md5=acf5406304920cc950f34f22d15099e5</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2878%2990508-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252878%252990508-7%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerman%26aufirst%3DT.%2BP.%26aulast%3DDeeprose%26aufirst%3DR.%2BD.%26atitle%3DMetabolism%2520of%25205-Amino-1-H-d-ribofuranosyl-imidazole-4-carboximide%2520and%2520related%2520five-membered%2520heterocycles%2520to%25205%25E2%2580%25B2-Triphosphates%2520in%2520Human%2520Blood%2520and%2520L5178Y%2520Cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1978%26volume%3D27%26spage%3D709%26epage%3D716%26doi%3D10.1016%2F0006-2952%2878%2990508-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casaos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelick, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huq, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lott, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kast, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skuli, N.</span></span> <span> </span><span class="NLM_article-title">The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1185</span>– <span class="NLM_lpage">1194</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-0666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1158%2F1535-7163.MCT-18-0666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31263027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1eru7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=1185-1194&author=J.+Casaosauthor=N.+L.+Gorelickauthor=S.+Huqauthor=J.+Choiauthor=Y.+Xiaauthor=R.+Serraauthor=R.+Felderauthor=T.+Lottauthor=R.+E.+Kastauthor=I.+Sukauthor=H.+Bremauthor=B.+Tylerauthor=N.+Skuli&title=The+Use+of+Ribavirin+as+an+Anticancer+Therapeutic%3A+Will+It+Go+Viral%3F&doi=10.1158%2F1535-7163.MCT-18-0666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">The use of ribavirin as an anticancer therapeutic: will it go viral?</span></div><div class="casAuthors">Casaos, Joshua; Gorelick, Noah L.; Huq, Sakibul; Choi, John; Xia, Yuanxuan; Serra, Riccardo; Felder, Raphael; Lott, Tarik; Kast, Richard E.; Suk, Ian; Brem, Henry; Tyler, Betty; Skuli, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1185-1194</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The growing cost of medical care worldwide, particularly in oncol., has incentivized researchers and physicians to repurpose clin. used drugs to alleviate the financial burden of drug development and offer potential new therapeutics.  Recent works have demonstrated anticancer properties of the FDA-approved drug ribavirin, a synthetic guanosine analog and antiviral mol. used over the past four decades for the treatment of hepatitis C.  The efficacy of ribavirin in cancer has been explored through several preclin. models and ongoing clin. trials in multiple cancers, including acute myeloid leukemia, oropharyngeal squamous cell carcinoma, and metastatic breast cancer.  In this review, we summarize the role of ribavirin as an antiviral medication and focus our attention on its recent use as an antitumoral agent.  We highlight current knowledge of the potential use and mechanisms of action of ribavirin in cancer.  Because current therapeutics for patients with cancer still fail to cure, introducing new forms of treatment is essential.  Converging evidence suggests that ribavirin represents a promising addn. to a generation of newly repurposed safe and effective anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozlolvSKu7LrVg90H21EOLACvtfcHk0lgiM10UWgLhBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1eru7vO&md5=2a865efeae91acb0b8afa0fe216021e8</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-0666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-0666%26sid%3Dliteratum%253Aachs%26aulast%3DCasaos%26aufirst%3DJ.%26aulast%3DGorelick%26aufirst%3DN.%2BL.%26aulast%3DHuq%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DSerra%26aufirst%3DR.%26aulast%3DFelder%26aufirst%3DR.%26aulast%3DLott%26aufirst%3DT.%26aulast%3DKast%26aufirst%3DR.%2BE.%26aulast%3DSuk%26aufirst%3DI.%26aulast%3DBrem%26aufirst%3DH.%26aulast%3DTyler%26aufirst%3DB.%26aulast%3DSkuli%26aufirst%3DN.%26atitle%3DThe%2520Use%2520of%2520Ribavirin%2520as%2520an%2520Anticancer%2520Therapeutic%253A%2520Will%2520It%2520Go%2520Viral%253F%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26spage%3D1185%26epage%3D1194%26doi%3D10.1158%2F1535-7163.MCT-18-0666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kentsis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topisirovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span> <span> </span><span class="NLM_article-title">Ribavirin Suppresses eIF4E-Mediated Oncogenic Transformation by Physical Mimicry of the 7-Methyl Guanosine MRNA Cap</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">18105</span>– <span class="NLM_lpage">18110</span>, <span class="refDoi"> DOI: 10.1073/pnas.0406927102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.0406927102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=15601771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsl2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=18105-18110&author=A.+Kentsisauthor=I.+Topisirovicauthor=B.+Culjkovicauthor=L.+Shaoauthor=K.+L.+B.+Borden&title=Ribavirin+Suppresses+eIF4E-Mediated+Oncogenic+Transformation+by+Physical+Mimicry+of+the+7-Methyl+Guanosine+MRNA+Cap&doi=10.1073%2Fpnas.0406927102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap</span></div><div class="casAuthors">Kentsis, Alex; Topisirovic, Ivan; Culjkovic, Biljana; Shao, Ling; Borden, Katherine L. B.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">18105-18110</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The eukaryotic translation initiation factor eIF4E is deregulated in many human cancers, and its overexpression in cells leads to malignant transformation.  Oncogenic properties of eIF4E are directly linked to its ability to bind 7-Me guanosine of the 5' mRNA.  Here, we observe that the antiviral guanosine analog ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-Me guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concns., selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1.  Ribavirin potently suppresses eIF4E-mediated oncogenic transformation of murine cells in vitro, of tumor growth of a mouse model of eIF4E-dependent human squamous cell carcinoma in vivo, and of colony formation of eIF4E-dependent acute myelogenous leukemia cells derived from human patients.  These findings describe a specific, potent, and unforeseen mechanism of action of ribavirin.  Quantum mech. and NMR structural studies offer directions for the development of derivs. with improved cytostatic and antiviral properties.  In all, ribavirin's assocn. with eIF4E may provide a pharmacol. means for the interruption of posttranscriptional networks of oncogenes that maintain and enhance neoplasia and malignancy in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXLIEVbhXRIbVg90H21EOLACvtfcHk0liIlpvaCY8o-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsl2mtA%253D%253D&md5=01cfecd677703fb01c0dbd26195bb469</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0406927102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0406927102%26sid%3Dliteratum%253Aachs%26aulast%3DKentsis%26aufirst%3DA.%26aulast%3DTopisirovic%26aufirst%3DI.%26aulast%3DCuljkovic%26aufirst%3DB.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DRibavirin%2520Suppresses%2520eIF4E-Mediated%2520Oncogenic%2520Transformation%2520by%2520Physical%2520Mimicry%2520of%2520the%25207-Methyl%2520Guanosine%2520MRNA%2520Cap%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D18105%26epage%3D18110%26doi%3D10.1073%2Fpnas.0406927102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svitkin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisaillon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Ribavirin Is Not a Functional Mimic of the 7-Methyl Guanosine MRNA Cap</span>. <i>RNA</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1244</span>, <span class="refDoi"> DOI: 10.1261/rna.2930805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1261%2Frna.2930805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16043507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFCgtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1238-1244&author=Y.+Yanauthor=Y.+Svitkinauthor=J.+M.+Leeauthor=M.+Bisaillonauthor=J.+Pelletier&title=Ribavirin+Is+Not+a+Functional+Mimic+of+the+7-Methyl+Guanosine+MRNA+Cap&doi=10.1261%2Frna.2930805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap</span></div><div class="casAuthors">Yan, Yifei; Svitkin, Yuri; Lee, Joseph M.; Bisaillon, Martin; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">RNA</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1238-1244</span>CODEN:
                <span class="NLM_cas:coden">RNARFU</span>;
        ISSN:<span class="NLM_cas:issn">1355-8382</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Ribavirin is a guanosine ribonucleoside analog that displays broad-spectrum anti-viral activity and is currently used for the treatment of some viral infections.  Ribavirin has recently been proposed to also be a mimic of the 7-Me guanosine cap found at the 5' end of mRNAs.  To obtain supporting functional data for this hypothesis, we assessed the ability of ribavirin triphosphate to interfere with the interaction between eIF4E and 7-Me guanosine capped mRNA.  In chem. crosslinking assays, cap-affinity chromatog., and cap-dependent translation assays, ribavirin was unable to function as a cap analog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_zNCMjAS-_7Vg90H21EOLACvtfcHk0liIlpvaCY8o-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFCgtLs%253D&md5=a7e684246566f5e613d5ffb99428dbf1</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1261%2Frna.2930805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1261%252Frna.2930805%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DY.%26aulast%3DSvitkin%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DBisaillon%26aufirst%3DM.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DRibavirin%2520Is%2520Not%2520a%2520Functional%2520Mimic%2520of%2520the%25207-Methyl%2520Guanosine%2520MRNA%2520Cap%26jtitle%3DRNA%26date%3D2005%26volume%3D11%26spage%3D1238%26epage%3D1244%26doi%3D10.1261%2Frna.2930805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudzien, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuberek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemielity, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolarski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darzynkiewicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhoads, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preiss, T.</span></span> <span> </span><span class="NLM_article-title">The Antiviral Drug Ribavirin Does Not Mimic the 7-Methylguanosine Moiety of the mRNA Cap Structure in Vitro</span>. <i>RNA</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1513</span>, <span class="refDoi"> DOI: 10.1261/rna.2132505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1261%2Frna.2132505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16131589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVygtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1505-1513&author=B.+Westmanauthor=L.+Beerenauthor=E.+Grudzienauthor=J.+Stepinskiauthor=R.+Worchauthor=J.+Zuberekauthor=J.+Jemielityauthor=R.+Stolarskiauthor=E.+Darzynkiewiczauthor=R.+E.+Rhoadsauthor=T.+Preiss&title=The+Antiviral+Drug+Ribavirin+Does+Not+Mimic+the+7-Methylguanosine+Moiety+of+the+mRNA+Cap+Structure+in+Vitro&doi=10.1261%2Frna.2132505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro</span></div><div class="casAuthors">Westman, Belinda; Beeren, Lisa; Grudzien, Ewa; Stepinski, Janusz; Worch, Remigiusz; Zuberek, Joanna; Jemielity, Jacek; Stolarski, Ryszard; Darzynkiewicz, Edward; Rhoads, Robert E.; Preiss, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">RNA</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1505-1513</span>CODEN:
                <span class="NLM_cas:coden">RNARFU</span>;
        ISSN:<span class="NLM_cas:issn">1355-8382</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The eukaryotic initiation factor eIF4E binds the mRNA 5' cap structure and has a central role during translational initiation.  eIF4E And the mechanisms to control its activity have oncogenic properties and thus have become targets for anticancer drug development.  A recent study presented evidence that the antiviral nucleoside ribavirin and its phosphorylated derivs. were structural mimics of the mRNA cap, high-affinity ligands for eIF4E, and potent repressors of eIF4E-mediated cell transformation and tumor growth.  Based on these findings, we tested ribavirin, ribavirin triphosphate (RTP), and the dinucleotide RpppG for their ability to inhibit translation in vitro.  Surprisingly, the ribavirin-based compds. did not affect translation at concns. where canonical cap analogs efficiently block cap-dependent translation.  Using a set of reporter mRNAs that are translated via either cap-dependent or viral internal ribosome entry sites (IRES)-dependent initiation, we found that these ribavirin-contg. compds. did inhibit translation at high (millimolar) concns., but there was no correlation of this inhibition with an eIF4E requirement for translation.  The addn. of a ribavirin-contg. cap to mRNA did not stimulate translation.  Fluorescence titrn. expts. with eIF4E and the nuclear cap-binding complex CBC indicated affinities for RTP and RpppG that were two to four orders of magnitude lower than those of m7GTP and m7GpppG.  We conclude that, at least with respect to translation, ribavirin does not act in vitro as a functional mimic of the mRNA cap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf6dKE-CKVlbVg90H21EOLACvtfcHk0liIlpvaCY8o-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVygtrbP&md5=9180cec56e6f91320eff2c6ad77b201c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1261%2Frna.2132505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1261%252Frna.2132505%26sid%3Dliteratum%253Aachs%26aulast%3DWestman%26aufirst%3DB.%26aulast%3DBeeren%26aufirst%3DL.%26aulast%3DGrudzien%26aufirst%3DE.%26aulast%3DStepinski%26aufirst%3DJ.%26aulast%3DWorch%26aufirst%3DR.%26aulast%3DZuberek%26aufirst%3DJ.%26aulast%3DJemielity%26aufirst%3DJ.%26aulast%3DStolarski%26aufirst%3DR.%26aulast%3DDarzynkiewicz%26aufirst%3DE.%26aulast%3DRhoads%26aufirst%3DR.%2BE.%26aulast%3DPreiss%26aufirst%3DT.%26atitle%3DThe%2520Antiviral%2520Drug%2520Ribavirin%2520Does%2520Not%2520Mimic%2520the%25207-Methylguanosine%2520Moiety%2520of%2520the%2520mRNA%2520Cap%2520Structure%2520in%2520Vitro%26jtitle%3DRNA%26date%3D2005%26volume%3D11%26spage%3D1505%26epage%3D1513%26doi%3D10.1261%2Frna.2132505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kentsis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topisirovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span> <span> </span><span class="NLM_article-title">Further Evidence That Ribavirin Interacts with eIF4E</span>. <i>RNA</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1762</span>– <span class="NLM_lpage">1766</span>, <span class="refDoi"> DOI: 10.1261/rna.2238705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1261%2Frna.2238705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16251386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlWnu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1762-1766&author=A.+Kentsisauthor=L.+Volponauthor=I.+Topisirovicauthor=C.+E.+Sollauthor=B.+Culjkovicauthor=L.+Shaoauthor=K.+L.+B.+Borden&title=Further+Evidence+That+Ribavirin+Interacts+with+eIF4E&doi=10.1261%2Frna.2238705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Further evidence that ribavirin interacts with eIF4E</span></div><div class="casAuthors">Kentsis, Alex; Volpon, Laurent; Topisirovic, Ivan; Soll, Clifford E.; Culjkovic, Biljana; Shao, Ling; Borden, Katherine L. B.</div><div class="citationInfo"><span class="NLM_cas:title">RNA</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1762-1766</span>CODEN:
                <span class="NLM_cas:coden">RNARFU</span>;
        ISSN:<span class="NLM_cas:issn">1355-8382</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">This commentary discusses the recent reports in RNA by Yan and colleagues and Westman and colleagues of the apparent failure of ribavirin to bind to recombinant eIF4E and inhibit 7-Me guanosine cap-dependent exogenous mRNA translation of cell exts. in vitro.  Measuring binding by using affinity chromatog. of matrix-immobilized proteins and by using protein emission fluorescence spectroscopy in the presence of nucleotide ligands, as well as limitations of using cell exts. for the assessment of mechanisms of mRNA translation are discussed.  Possible reasons for the discordant findings of Yan and colleagues and Westman and colleagues are suggested, and direct observation of the specific binding of ribavirin to eIF4E by using mass spectrometry is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJkZ1EOqgd0LVg90H21EOLACvtfcHk0liIlpvaCY8o-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlWnu73N&md5=96a8b9153425d43868906ab44cb673b3</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1261%2Frna.2238705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1261%252Frna.2238705%26sid%3Dliteratum%253Aachs%26aulast%3DKentsis%26aufirst%3DA.%26aulast%3DVolpon%26aufirst%3DL.%26aulast%3DTopisirovic%26aufirst%3DI.%26aulast%3DSoll%26aufirst%3DC.%2BE.%26aulast%3DCuljkovic%26aufirst%3DB.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DFurther%2520Evidence%2520That%2520Ribavirin%2520Interacts%2520with%2520eIF4E%26jtitle%3DRNA%26date%3D2005%26volume%3D11%26spage%3D1762%26epage%3D1766%26doi%3D10.1261%2Frna.2238705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
La Cruz-Hernandez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-Blanco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez-Gomez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Cardenas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Fierro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taja-Chayeb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dueñas-Gonzalez, A.</span></span> <span> </span><span class="NLM_article-title">Ribavirin as a Tri-Targeted Antitumor Repositioned Drug</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2384</span>– <span class="NLM_lpage">2392</span>, <span class="refDoi"> DOI: 10.3892/or.2015.3816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3892%2For.2015.3816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25738706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=2384-2392&author=E.+De%0ALa+Cruz-Hernandezauthor=J.+L.+Medina-Francoauthor=J.+Trujilloauthor=A.+Chavez-Blancoauthor=G.+Dominguez-Gomezauthor=E.+Perez-Cardenasauthor=A.+Gonzalez-Fierroauthor=L.+Taja-Chayebauthor=A.+Due%C3%B1as-Gonzalez&title=Ribavirin+as+a+Tri-Targeted+Antitumor+Repositioned+Drug&doi=10.3892%2For.2015.3816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Ribavirin as a tri-targeted antitumor repositioned drug</span></div><div class="casAuthors">De La Cruz-Hernandez, Erick; Medina-Franco, Jose Luis; Trujillo, Jaenai; Chavez-Blanco, Alma; Dominguez-Gomez, Guadalupe; Perez-Cardenas, Enrique; Gonzalez-Fierro, Aurora; Taja-Chayeb, Lucia; Duenas-Gonzalez, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2384-2392</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The aim of the present study was to demonstrate that ribavirin, a known inhibitor of eIF4E and inosine 5'-phosphate dehydrogenase (IMPDH), also inhibits histone methyltransferase zeste homolog 2 (EZH2).  A computational searching revealed that ribavirin has a high structural similarity to 3-deazaneplanocin A (DZNep).  The growth inhibitory effects of ribavirin as well as its effects upon epigenetic enzymes were evaluated in various cancer cell lines. siRNA assays were used to downregulate eIF4E, EZH2 and IMPDH to det. the contribution of these targets to the growth inhibitory effects of ribavirin.  Ribavirin decreased EZH2 expression, inhibited histone methyltransferase activity and decreased H3K27 trimethylation.  Ribavirin induced variable growth inhibition in a no. of cell lines and downregulation of the targets, EZH2, eIF4E and IMPDH1 and 2 by siRNA led to comparable growth inhibition while no significant further redn. in viability was obsd. when siRNA transfected cells were treated with ribavirin.  The results showed that ribavirin inhibits these cancer targets and should thus be studied for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMxpiWdvnXpLVg90H21EOLACvtfcHk0li1Y3SXtOdBBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVagtg%253D%253D&md5=bc8d48d9613ab2db23c15cacb9a4de9e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.3892%2For.2015.3816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2015.3816%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLa%2BCruz-Hernandez%26aufirst%3DE.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26aulast%3DTrujillo%26aufirst%3DJ.%26aulast%3DChavez-Blanco%26aufirst%3DA.%26aulast%3DDominguez-Gomez%26aufirst%3DG.%26aulast%3DPerez-Cardenas%26aufirst%3DE.%26aulast%3DGonzalez-Fierro%26aufirst%3DA.%26aulast%3DTaja-Chayeb%26aufirst%3DL.%26aulast%3DDue%25C3%25B1as-Gonzalez%26aufirst%3DA.%26atitle%3DRibavirin%2520as%2520a%2520Tri-Targeted%2520Antitumor%2520Repositioned%2520Drug%26jtitle%3DOncol.%2520Rep.%26date%3D2015%26volume%3D33%26spage%3D2384%26epage%3D2392%26doi%3D10.3892%2For.2015.3816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urtishak, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic-Kraljacic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porazzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teachey, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasian, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seif, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.-M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devidas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyer, Z. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilden, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunger, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willman, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, C. A.</span></span> <span> </span><span class="NLM_article-title">Targeting eIF4E Signaling with Ribavirin in Infant Acute Lymphoblastic Leukemia</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2241</span>– <span class="NLM_lpage">2262</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0567-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41388-018-0567-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30478448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSqsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=2241-2262&author=K.+A.+Urtishakauthor=L.-S.+Wangauthor=B.+Culjkovic-Kraljacicauthor=J.+W.+Davenportauthor=P.+Porazziauthor=T.+L.+Vincentauthor=D.+T.+Teacheyauthor=S.+K.+Tasianauthor=J.+S.+Mooreauthor=A.+E.+Seifauthor=S.+Jinauthor=J.+S.+Barrettauthor=B.+W.+Robinsonauthor=I.-M.+L.+Chenauthor=R.+C.+Harveyauthor=M.+P.+Carrollauthor=A.+J.+Carrollauthor=N.+A.+Heeremaauthor=M.+Devidasauthor=Z.+E.+Dreyerauthor=J.+M.+Hildenauthor=S.+P.+Hungerauthor=C.+L.+Willmanauthor=K.+L.+B.+Bordenauthor=C.+A.+Felix&title=Targeting+eIF4E+Signaling+with+Ribavirin+in+Infant+Acute+Lymphoblastic+Leukemia&doi=10.1038%2Fs41388-018-0567-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia</span></div><div class="casAuthors">Urtishak, Karen A.; Wang, Li-San; Culjkovic-Kraljacic, Biljana; Davenport, James W.; Porazzi, Patrizia; Vincent, Tiffaney L.; Teachey, David T.; Tasian, Sarah K.; Moore, Jonni S.; Seif, Alix E.; Jin, Shenghao; Barrett, Jeffrey S.; Robinson, Blaine W.; Chen, I-Ming L.; Harvey, Richard C.; Carroll, Martin P.; Carroll, Andrew J.; Heerema, Nyla A.; Devidas, Meenakshi; Dreyer, ZoAnn E.; Hilden, Joanne M.; Hunger, Stephen P.; Willman, Cheryl L.; Borden, Katherine L. B.; Felix, Carolyn A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2241-2262</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The poor outcomes in infant acute lymphoblastic leukemia (ALL) necessitate new treatments.  Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has anticancer properties through EIF4E inhibition, as a potential treatment.  We find that ribavirin treatment of actively dividing infant ALL cells on bone marrow stromal cells (BMSCs) at clin. achievable concns. causes robust proliferation inhibition in proportion with EIF4E expression.  Further, we find that ribavirin treatment of KMT2A-rearranged (KMT2A-R) infant ALL cells and the KMT2A-AFF1 cell line RS4:11 inhibits EIF4E, leading to decreases in oncogenic EIF4E-regulated cell growth and survival proteins.  In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5.  Ribavirin-treated RS4:11 cells exhibit impaired EIF4E-dependent nuclear to cytoplasmic export and/or translation of the corresponding mRNAs, as well as reduced phosphorylation of the p-AKT1, p-EIF4EBP1, p-RPS6 and p-EIF4E signaling proteins.  This leads to an S-phase cell cycle arrest in RS4:11 cells corresponding to the decreased proliferation.  Ribavirin causes nuclear EIF4E to re-localize to the cytoplasm in KMT2A-AFF1 infant ALL and RS4:11 cells, providing further evidence for EIF4E inhibition.  Ribavirin slows increases in peripheral blasts in KMT2A-R infant ALL xenograft-bearing mice.  Ribavirin cooperates with chemotherapy, particularly L-asparaginase, in reducing live KMT2A-AFF1 infant ALL cells in BMSC co-cultures.  This work establishes that EIF4E is broadly elevated across infant ALL and that clin. relevant ribavirin exposures have preclin. activity and effectively inhibit EIF4E in KMT2A-R cases, suggesting promise in EIF4E targeting using ribavirin as a means of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD_YsxlZ2LYbVg90H21EOLACvtfcHk0li1Y3SXtOdBBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSqsbnN&md5=f643381b62c71813d748f5ef1c241c69</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0567-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0567-7%26sid%3Dliteratum%253Aachs%26aulast%3DUrtishak%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DL.-S.%26aulast%3DCuljkovic-Kraljacic%26aufirst%3DB.%26aulast%3DDavenport%26aufirst%3DJ.%2BW.%26aulast%3DPorazzi%26aufirst%3DP.%26aulast%3DVincent%26aufirst%3DT.%2BL.%26aulast%3DTeachey%26aufirst%3DD.%2BT.%26aulast%3DTasian%26aufirst%3DS.%2BK.%26aulast%3DMoore%26aufirst%3DJ.%2BS.%26aulast%3DSeif%26aufirst%3DA.%2BE.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DBarrett%26aufirst%3DJ.%2BS.%26aulast%3DRobinson%26aufirst%3DB.%2BW.%26aulast%3DChen%26aufirst%3DI.-M.%2BL.%26aulast%3DHarvey%26aufirst%3DR.%2BC.%26aulast%3DCarroll%26aufirst%3DM.%2BP.%26aulast%3DCarroll%26aufirst%3DA.%2BJ.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DDevidas%26aufirst%3DM.%26aulast%3DDreyer%26aufirst%3DZ.%2BE.%26aulast%3DHilden%26aufirst%3DJ.%2BM.%26aulast%3DHunger%26aufirst%3DS.%2BP.%26aulast%3DWillman%26aufirst%3DC.%2BL.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26aulast%3DFelix%26aufirst%3DC.%2BA.%26atitle%3DTargeting%2520eIF4E%2520Signaling%2520with%2520Ribavirin%2520in%2520Infant%2520Acute%2520Lymphoblastic%2520Leukemia%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26spage%3D2241%26epage%3D2262%26doi%3D10.1038%2Fs41388-018-0567-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assouline, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocolakis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beslu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span> <span> </span><span class="NLM_article-title">Molecular Targeting of the Oncogene eIF4E in Acute Myeloid Leukemia (AML): A Proof-of-Principle Clinical Trial with Ribavirin</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-02-205153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1182%2Fblood-2009-02-205153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19433856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovVKmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=257-260&author=S.+Assoulineauthor=B.+Culjkovicauthor=E.+Cocolakisauthor=C.+Rousseauauthor=N.+Besluauthor=A.+Amriauthor=S.+Caplanauthor=B.+Leberauthor=D.+C.+Royauthor=W.+H.+Millerauthor=K.+L.+B.+Borden&title=Molecular+Targeting+of+the+Oncogene+eIF4E+in+Acute+Myeloid+Leukemia+%28AML%29%3A+A+Proof-of-Principle+Clinical+Trial+with+Ribavirin&doi=10.1182%2Fblood-2009-02-205153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin</span></div><div class="casAuthors">Assouline, Sarit; Culjkovic, Biljana; Cocolakis, Eftihia; Rousseau, Caroline; Beslu, Nathalie; Amri, Abdellatif; Caplan, Stephen; Leber, Brian; Roy, Denis-Claude; Miller, Wilson H., Jr.; Borden, Katherine L. B.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-260</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The eukaryotic translation initiation factor eIF4E is elevated in 30% of malignancies including M4/M5 subtypes of acute myeloid leukemia (AML).  The oncogenic potential of eIF4E arises from its ability to bind the 7-Me guanosine (m7G) cap on mRNAs, thereby selectively enhancing eIF4E-dependent nuclear mRNA export and translation.  We tested the clin. efficacy of targeting eIF4E in M4/M5 AML patients with a phys. mimic of the m7G cap, ribavirin.  Among 11 evaluable patients there were 1 complete remission (CR), 2 partial remissions (PRs), 2 blast responses (BRs), 4 stable diseases (SDs), and 2 progressive diseases (PDs).  Ribavirin-induced relocalization of nuclear eIF4E to the cytoplasm and redn. of eIF4E levels were assocd. with clin. response.  Lack of response or relapse coincided with continued or renewed nuclear localization of eIF4E.  This first clin. study to target eIF4E in human malignancy demonstrates clin. activity and assocd. mol. responses in leukemic blasts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwnUgUhzzNTrVg90H21EOLACvtfcHk0lhzc_6qsWk6kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovVKmu78%253D&md5=36523353e8f24330c7c5de784ea16559</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-02-205153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-02-205153%26sid%3Dliteratum%253Aachs%26aulast%3DAssouline%26aufirst%3DS.%26aulast%3DCuljkovic%26aufirst%3DB.%26aulast%3DCocolakis%26aufirst%3DE.%26aulast%3DRousseau%26aufirst%3DC.%26aulast%3DBeslu%26aufirst%3DN.%26aulast%3DAmri%26aufirst%3DA.%26aulast%3DCaplan%26aufirst%3DS.%26aulast%3DLeber%26aufirst%3DB.%26aulast%3DRoy%26aufirst%3DD.%2BC.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DMolecular%2520Targeting%2520of%2520the%2520Oncogene%2520eIF4E%2520in%2520Acute%2520Myeloid%2520Leukemia%2520%2528AML%2529%253A%2520A%2520Proof-of-Principle%2520Clinical%2520Trial%2520with%2520Ribavirin%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D257%26epage%3D260%26doi%3D10.1182%2Fblood-2009-02-205153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assouline, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culjkovic-Kraljacic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocolakis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahreddine, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borden, K. L. B.</span></span> <span> </span><span class="NLM_article-title">A Phase i Trial of Ribavirin and Low-Dose Cytarabine for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia with Elevated eIF4E</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">e7</span>– <span class="NLM_lpage">e9</span>, <span class="refDoi"> DOI: 10.3324/haematol.2014.111245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3324%2Fhaematol.2014.111245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25425688" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=e7-e9&author=S.+Assoulineauthor=B.+Culjkovic-Kraljacicauthor=J.+Bergeronauthor=S.+Caplanauthor=E.+Cocolakisauthor=C.+Lambertauthor=C.+J.+Lauauthor=H.+A.+Zahreddineauthor=W.+H.+Millerauthor=K.+L.+B.+Borden&title=A+Phase+i+Trial+of+Ribavirin+and+Low-Dose+Cytarabine+for+the+Treatment+of+Relapsed+and+Refractory+Acute+Myeloid+Leukemia+with+Elevated+eIF4E&doi=10.3324%2Fhaematol.2014.111245"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2014.111245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2014.111245%26sid%3Dliteratum%253Aachs%26aulast%3DAssouline%26aufirst%3DS.%26aulast%3DCuljkovic-Kraljacic%26aufirst%3DB.%26aulast%3DBergeron%26aufirst%3DJ.%26aulast%3DCaplan%26aufirst%3DS.%26aulast%3DCocolakis%26aufirst%3DE.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DC.%2BJ.%26aulast%3DZahreddine%26aufirst%3DH.%2BA.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DBorden%26aufirst%3DK.%2BL.%2BB.%26atitle%3DA%2520Phase%2520i%2520Trial%2520of%2520Ribavirin%2520and%2520Low-Dose%2520Cytarabine%2520for%2520the%2520Treatment%2520of%2520Relapsed%2520and%2520Refractory%2520Acute%2520Myeloid%2520Leukemia%2520with%2520Elevated%2520eIF4E%26jtitle%3DHaematologica%26date%3D2015%26volume%3D100%26spage%3De7%26epage%3De9%26doi%3D10.3324%2Fhaematol.2014.111245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagaoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aikata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teraoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatooka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morio, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaoka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiramatsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chayama, K.</span></span> <span> </span><span class="NLM_article-title">The Risks of Hepatocellular Carcinoma Development after HCV Eradication Are Similar between Patients Treated with Peg-Interferon plus Ribavirin and Direct-Acting Antiviral Therapy</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e0182710</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0182710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pone.0182710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28797106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0182710&author=Y.+Nagaokiauthor=M.+Imamuraauthor=H.+Aikataauthor=K.+Daijoauthor=Y.+Teraokaauthor=F.+Hondaauthor=Y.+Nakamuraauthor=M.+Hatookaauthor=R.+Morioauthor=K.+Morioauthor=H.+Kanauthor=H.+Fujinoauthor=T.+Kobayashiauthor=K.+Masakiauthor=A.+Onoauthor=T.+Nakaharaauthor=T.+Kawaokaauthor=M.+Tsugeauthor=A.+Hiramatsuauthor=Y.+Kawakamiauthor=C.+N.+Hayesauthor=D.+Mikiauthor=H.+Ochiauthor=K.+Chayama&title=The+Risks+of+Hepatocellular+Carcinoma+Development+after+HCV+Eradication+Are+Similar+between+Patients+Treated+with+Peg-Interferon+plus+Ribavirin+and+Direct-Acting+Antiviral+Therapy&doi=10.1371%2Fjournal.pone.0182710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy</span></div><div class="casAuthors">Nagaoki, Yuko; Imamura, Michio; Aikata, Hiroshi; Daijo, Kana; Teraoka, Yuji; Honda, Fumi; Nakamura, Yuki; Hatooka, Masahiro; Morio, Reona; Morio, Kei; Kan, Hiromi; Fujino, Hatsue; Kobayashi, Tomoki; Masaki, Keiichi; Ono, Atsushi; Nakahara, Takashi; Kawaoka, Tomokazu; Tsuge, Masataka; Hiramatsu, Akira; Kawakami, Yoshiiku; Hayes, C. Nelson; Miki, Daiki; Ochi, Hidenori; Chayama, Kazuaki</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0182710/1-e0182710/11</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The risk of hepatocellular carcinoma (HCC) development is reduced following viral elimination by interferon therapy in chronic hepatitis C patients.  However, the risk in patients treated with interferon-free direct-acting antivirals (DAAs) is unknown.  We evaluated chronic hepatitis C patients who achieved viral eradication by pegylated-interferon plus ribavirin (PEGIFN/ RBV, n = 244) or daclatasvir plus asunaprevir (DCV/ASV, n = 154) therapy.  None of the patients had prior history of HCC or antiviral therapy.  The median observation period after the end of treatment for the PEG-IFN/RBV and DCV/ASV groups were 96 (range 10-196) and 23 (range 4-78) months, resp.  During the observation period, HCC developed in 13 (5.3%) and 7 (4.5%) patients in the PEG-IFN/RBV and DCV/ASV groups, resp.  The cumulative HCC development rate after 1-, 3- and 5-years (0.4%, 3% and 5% for the PEG-IFN/RBV group and 0.6%, 9% and 9% for the DAA group, resp.) were similar between the two groups.  Propensity score matching anal. also showed no significant difference in HCC development rates between the two groups.  Serum AFP levels decreased to similar levels between PEG-IFN/RBV and DCV/ASV groups following the achievement of viral eradication.  The risk for HCC development following viral eradication by IFN-free DAA therapy may be similar to that in IFN-based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWcmApfKv3X7Vg90H21EOLACvtfcHk0lhzc_6qsWk6kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOhsLk%253D&md5=353d1780477d468d341c329b42afb158</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0182710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0182710%26sid%3Dliteratum%253Aachs%26aulast%3DNagaoki%26aufirst%3DY.%26aulast%3DImamura%26aufirst%3DM.%26aulast%3DAikata%26aufirst%3DH.%26aulast%3DDaijo%26aufirst%3DK.%26aulast%3DTeraoka%26aufirst%3DY.%26aulast%3DHonda%26aufirst%3DF.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DHatooka%26aufirst%3DM.%26aulast%3DMorio%26aufirst%3DR.%26aulast%3DMorio%26aufirst%3DK.%26aulast%3DKan%26aufirst%3DH.%26aulast%3DFujino%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DMasaki%26aufirst%3DK.%26aulast%3DOno%26aufirst%3DA.%26aulast%3DNakahara%26aufirst%3DT.%26aulast%3DKawaoka%26aufirst%3DT.%26aulast%3DTsuge%26aufirst%3DM.%26aulast%3DHiramatsu%26aufirst%3DA.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DHayes%26aufirst%3DC.%2BN.%26aulast%3DMiki%26aufirst%3DD.%26aulast%3DOchi%26aufirst%3DH.%26aulast%3DChayama%26aufirst%3DK.%26atitle%3DThe%2520Risks%2520of%2520Hepatocellular%2520Carcinoma%2520Development%2520after%2520HCV%2520Eradication%2520Are%2520Similar%2520between%2520Patients%2520Treated%2520with%2520Peg-Interferon%2520plus%2520Ribavirin%2520and%2520Direct-Acting%2520Antiviral%2520Therapy%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0182710%26doi%3D10.1371%2Fjournal.pone.0182710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Clinically Relevant Concentration of Anti-Viral Drug Ribavirin Selectively Targets Pediatric Osteosarcoma and Increases Chemosensitivity</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>506</i></span>,  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.10.124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.bbrc.2018.10.124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30454696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVSjurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=506&publication_year=2018&pages=604-610&author=J.+Chenauthor=X.+Xuauthor=J.+Chen&title=Clinically+Relevant+Concentration+of+Anti-Viral+Drug+Ribavirin+Selectively+Targets+Pediatric+Osteosarcoma+and+Increases+Chemosensitivity&doi=10.1016%2Fj.bbrc.2018.10.124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity</span></div><div class="casAuthors">Chen, Jianguo; Xu, Xiaoming; Chen, Junjun</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">506</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">604-610</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using preclin. osteosarcoma cell and xenograft models, we found that ribavirin is active against osteosarcoma bulk and subpopulations with highly proliferative and invasive properties via inhibiting growth, inducing apoptosis and suppressing colony formation.  At the same concns., ribavirin either did not or affected human normal osteoblastic cell and fibroblast cells in a less extent than osteosarcoma cells.  Notably, the combination of ribavirin with doxorubicin resulted in greater efficacy than single drug alone.  The combination completely arrested the osteosarcoma growth in vivo throughout the whole duration of drug treatment.  We further showed that ribavirin acted on osteosarcoma largely via targeting eIF4E.  In addn. to eIF4E, ribavirin also modulated phosphorylation of Erk and expression of EZH2 and Snail without affecting Akt and mTOR.  Lastly, we found that eIF4E expression and phosphorylation were elevated in osteosarcoma compared to normal cells, which might explain the selective anti-osteosarcoma activity of ribavirin. eIF4E depletion mimics the inhibitory effects of ribavirin, further confirm that eIF4E is the essential target of ribavirin in osteosarcoma.  Our work provides fundamental evidence of repurposing ribavirin for the treatment of osteosarcoma.  Our findings also highlight the therapeutic value of inhibiting eIF4E in osteosarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYKuoPqJahs7Vg90H21EOLACvtfcHk0lhzc_6qsWk6kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVSjurrM&md5=7c7b1bb81577a218c93111b4df15ed04</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.10.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.10.124%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DClinically%2520Relevant%2520Concentration%2520of%2520Anti-Viral%2520Drug%2520Ribavirin%2520Selectively%2520Targets%2520Pediatric%2520Osteosarcoma%2520and%2520Increases%2520Chemosensitivity%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D506%26spage%3D604%26epage%3D610%26doi%3D10.1016%2Fj.bbrc.2018.10.124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G.</span></span> <span> </span><span class="NLM_article-title">Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-NCoV) in Vitro</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">271</span>, <span class="refDoi"> DOI: 10.1038/s41422-020-0282-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41422-020-0282-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=32020029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkt1Ciu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=269-271&author=M.+Wangauthor=R.+Caoauthor=L.+Zhangauthor=X.+Yangauthor=J.+Liuauthor=M.+Xuauthor=Z.+Shiauthor=Z.+Huauthor=W.+Zhongauthor=G.+Xiao&title=Remdesivir+and+Chloroquine+Effectively+Inhibit+the+Recently+Emerged+Novel+Coronavirus+%282019-NCoV%29+in+Vitro&doi=10.1038%2Fs41422-020-0282-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</span></div><div class="casAuthors">Wang, Manli; Cao, Ruiyuan; Zhang, Leike; Yang, Xinglou; Liu, Jia; Xu, Mingyue; Shi, Zhengli; Hu, Zhihong; Zhong, Wu; Xiao, Gengfu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-271</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In Dec. 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million people in central China.  The initial cases were linked to exposures in a seafood market in Wuhan.  The pathogen was soon identified as a novel coronavirus (2019-nCoV), which is closely related to severe acute respiratory syndrome CoV (SARS-CoV).  Currently, there is no specific treatment against the new virus.  Therefore, identifying effective antiviral agents to combat the disease is urgently needed.  In this study, we evaluated the antiviral efficiency of FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir (GS-5734) and favipiravir (T-705) against a clin. isolate of 2019-nCoV in vitro.  Our findings reveal that remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro.  Since these compds. have been used in human patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in human patients suffering from the novel coronavirus disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCnj2tW4TeD7Vg90H21EOLACvtfcHk0lh0bCwtw0O6AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkt1Ciu7k%253D&md5=bdf16b352ebc06bc148ed5c513b7d414</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fs41422-020-0282-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-020-0282-0%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DG.%26atitle%3DRemdesivir%2520and%2520Chloroquine%2520Effectively%2520Inhibit%2520the%2520Recently%2520Emerged%2520Novel%2520Coronavirus%2520%25282019-NCoV%2529%2520in%2520Vitro%26jtitle%3DCell%2520Res.%26date%3D2020%26volume%3D30%26spage%3D269%26epage%3D271%26doi%3D10.1038%2Fs41422-020-0282-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makala, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting Translation: EIF4E as an Emerging Anticancer Drug Target</span>. <i>Expert Rev. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">E2</span>, <span class="refDoi"> DOI: 10.1017/erm.2015.20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1017%2Ferm.2015.20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26775675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVSht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=E2&author=C.+Luauthor=L.+Makalaauthor=D.+Wuauthor=Y.+Cai&title=Targeting+Translation%3A+EIF4E+as+an+Emerging+Anticancer+Drug+Target&doi=10.1017%2Ferm.2015.20"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting translation: eIF4E as an emerging anticancer drug target</span></div><div class="casAuthors">Lu, Chunwan; Makala, Levi; Wu, Daqing; Cai, Yafei</div><div class="citationInfo"><span class="NLM_cas:title">Expert Reviews in Molecular Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e2/1-e2/13</span>CODEN:
                <span class="NLM_cas:coden">ERMMFS</span>;
        ISSN:<span class="NLM_cas:issn">1462-3994</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumor growth, metastasis and therapy resistance.  As an essential regulatory hub in cancer signalling network, many oncogenic signalling pathways appear to converge on eIF4E.  Therefore, targeting eIF4E-mediated cap-dependent translation is considered a promising anticancer strategy.  This paper reviews the strategies that can be used to target eIF4E, highlighting agents that target eIF4E activity at each distinct level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVopkQ3fJ2e7Vg90H21EOLACvtfcHk0lh0bCwtw0O6AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVSht7g%253D&md5=e41aa5dcad1d8914b13e055f9787bc2e</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1017%2Ferm.2015.20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252Ferm.2015.20%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%26aulast%3DMakala%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DY.%26atitle%3DTargeting%2520Translation%253A%2520EIF4E%2520as%2520an%2520Emerging%2520Anticancer%2520Drug%2520Target%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Med.%26date%3D2016%26volume%3D18%26spage%3DE2%26doi%3D10.1017%2Ferm.2015.20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darzynkiewicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekiel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temeriusz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sijuwade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, S. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Eukaryotic Translation by Nucleoside 5 ′-Monophosphate Analogues of mRNA 5 ′-Cap : Changes in N7 Substituent Affect Analogue Activity</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">4771</span>– <span class="NLM_lpage">4778</span>, <span class="refDoi"> DOI: 10.1021/bi00437a038</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00437a038" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaL1MXit1Ohsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1989&pages=4771-4778&author=E.+Darzynkiewiczauthor=J.+Stepinskiauthor=I.+Ekielauthor=C.+Goyerauthor=N.+Sonenbergauthor=A.+Temeriuszauthor=Y.+Jinauthor=T.+Sijuwadeauthor=D.+Haberauthor=S.+M.+Tahara&title=Inhibition+of+Eukaryotic+Translation+by+Nucleoside+5+%E2%80%B2-Monophosphate+Analogues+of+mRNA+5+%E2%80%B2-Cap%E2%80%AF%3A+Changes+in+N7+Substituent+Affect+Analogue+Activity&doi=10.1021%2Fbi00437a038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of eukaryotic translation by nucleoside 5'-monophosphate analogs of mRNA 5'-cap:  changes in N7 substituent affect analog activity</span></div><div class="casAuthors">Darzynkiewicz, Edward; Stepinski, Janusz; Ekiel, Irena; Goyer, Charles; Sonenberg, Nahum; Temeriusz, Andrzej; Jin, Youxin; Sijuwade, Teju; Haber, Dorota; Tahara, Stanley M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4771-8</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">Nucleotide cap analogs of 7-methylguanosine 5'-monophosphate (m7GMP) were synthesized in which the 7-Me moiety was replaced with 7-Et (e7), 7-Pr (p7), 7-isopropyl) (i.p.7), 7-Bu (b7), 7-iso-Bu (ib7), 7-cyclopentyl (cp7), 7-(carboxymethyl) (cm7), 7-benzyl (bn7), 7-(2-phenylethyl) [7-(2-PhEt)], and 7-(1-phenylethyl) [7-(1-PhEt)].  These derivs. were assayed as competitive inhibitors of capped mRNA translation in a reticulocyte lysate.  N7 alkyl and alicyclic substituents larger than Et significantly decreased the inhibitory activity of these cap analogs presumably by decreasing their affinity for cap-binding proteins, which participate in the initiation of translation.  This result defined a max. size for this class of N7 substituents in the nucleotide-binding domain of cap binding proteins.  Like m7GMP, the N7-substituted GMP derivs. synthesized in this study were predominantly in the anti conformation as detd. by 1H NMR analyses.  However, bn7GMP and 7-(2-PhEt)GMP, which have arom. N7 substituents, were more effective than m7GMP as competitive inhibitors of translation.  The increased affinity of bn7GMP for cap-binding proteins was further examd. by synthesis of β-globin mRNA contg. 5'-bn7G, 5'-m7G, or 5'-e7G cap structures.  These modified mRNAs were tested as translation templates.  MRNA capped with bn7G was obsd. to increase the translation activity of the template 1.8-fold relative to that of its m7G-capped mRNA counterpart.  By contrast, e7G-capped mRNA was 25% less active than m7G-capped mRNA.  UV-photocrosslinking of m7G-capped mRNA to cap binding proteins was also inhibited to a greater extent by bn7GMP than by m7GMP or e7GMP.  Thus, from these data the inhibitory effect of bn7GMP was due to its increased affinity for cap binding proteins and not by inhibition at another step of initiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuMgBXQBYumLVg90H21EOLACvtfcHk0lh0bCwtw0O6AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXit1Ohsbo%253D&md5=86f13e891441c287013387807e387ccf</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fbi00437a038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00437a038%26sid%3Dliteratum%253Aachs%26aulast%3DDarzynkiewicz%26aufirst%3DE.%26aulast%3DStepinski%26aufirst%3DJ.%26aulast%3DEkiel%26aufirst%3DI.%26aulast%3DGoyer%26aufirst%3DC.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DTemeriusz%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DSijuwade%26aufirst%3DT.%26aulast%3DHaber%26aufirst%3DD.%26aulast%3DTahara%26aufirst%3DS.%2BM.%26atitle%3DInhibition%2520of%2520Eukaryotic%2520Translation%2520by%2520Nucleoside%25205%2520%25E2%2580%25B2-Monophosphate%2520Analogues%2520of%2520mRNA%25205%2520%25E2%2580%25B2-Cap%25E2%2580%25AF%253A%2520Changes%2520in%2520N7%2520Substituent%2520Affect%2520Analogue%2520Activity%26jtitle%3DBiochemistry%26date%3D1989%26volume%3D28%26spage%3D4771%26epage%3D4778%26doi%3D10.1021%2Fbi00437a038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktas, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahoo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denoyelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabha, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halperin, J. A.</span></span> <span> </span><span class="NLM_article-title">Tumor Suppression by Small Molecule Inhibitorss of Translation Initiation</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.18632%2Foncotarget.598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22935625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BC38bivVCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=869-881&author=L.+Chenauthor=B.+H.+Aktasauthor=Y.+Wangauthor=X.+Heauthor=R.+Sahooauthor=N.+Zhangauthor=S.+Denoyelleauthor=E.+Kabhaauthor=H.+Yangauthor=R.+Y.+Freedmanauthor=J.+G.+Supkoauthor=M.+Chorevauthor=G.+Wagnerauthor=J.+A.+Halperin&title=Tumor+Suppression+by+Small+Molecule+Inhibitorss+of+Translation+Initiation&doi=10.18632%2Foncotarget.598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor suppression by small molecule inhibitors of translation initiation</span></div><div class="casAuthors">Chen Limo; Aktas Bertal H; Wang Yibo; He Xiaoying; Sahoo Rupam; Zhang Nancy; Denoyelle Severine; Kabha Eihab; Yang Hongwei; Freedman Revital Yefidoff; Supko Jeffrey G; Chorev Michael; Wagner Gerhard; Halperin Jose A</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">869-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Translation initiation factors are over-expressed and/or activated in many human cancers and may contribute to their genesis and/or progression.  Removal of physiologic restraints on translation initiation causes malignant transformation.  Conversely, restoration of physiological restrains on translation initiation reverts malignant phenotypes.  Here, we extensively characterize the anti-cancer activity of two small molecule inhibitors of translation initiation: #1181, which targets the eIF2•GTP•Met-tRNAi ternary complex, and 4EGI-1, which targets the eIF4F complex.  In vitro, both molecules inhibit translation initiation, abrogate preferentially translation of mRNAs coding for oncogenic proteins, and inhibit proliferation of human cancer cells.  In vivo, both #1181 and 4EGI-1 strongly inhibit growth of human breast and melanoma cancer xenografts without any apparent macroscopic- or microscopic-toxicity.  Mechanistically, #1181 phosphorylates eIF2α while 4EGI-1 disrupts eIF4G/eIF4E interaction in the tumors excised from mice treated with these agents.  These data indicate that inhibition of translation initiation is a new paradigm in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWEflM3ymwKbYtC3U5jeOifW6udTcc2eZtsAuWDuxIPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bivVCmsg%253D%253D&md5=eead064f97595ae05a97ed9af42f2c40</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.598%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAktas%26aufirst%3DB.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DSahoo%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DDenoyelle%26aufirst%3DS.%26aulast%3DKabha%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DFreedman%26aufirst%3DR.%2BY.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DChorev%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DG.%26aulast%3DHalperin%26aufirst%3DJ.%2BA.%26atitle%3DTumor%2520Suppression%2520by%2520Small%2520Molecule%2520Inhibitorss%2520of%2520Translation%2520Initiation%26jtitle%3DOncotarget%26date%3D2012%26volume%3D3%26spage%3D869%26epage%3D881%26doi%3D10.18632%2Foncotarget.598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNae, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkinshaw, M. D.</span></span> <span> </span><span class="NLM_article-title">Crystallographic and Mass Spectrometric Characterisation of eIF4E with N7-Alkylated Cap Derivatives</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2007.06.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.jmb.2007.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17631896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFeqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2007&pages=7-15&author=C.+J.+Brownauthor=I.+McNaeauthor=P.+M.+Fischerauthor=M.+D.+Walkinshaw&title=Crystallographic+and+Mass+Spectrometric+Characterisation+of+eIF4E+with+N7-Alkylated+Cap+Derivatives&doi=10.1016%2Fj.jmb.2007.06.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallographic and Mass Spectrometric Characterization of eIF4E with N7-alkylated Cap Derivatives</span></div><div class="casAuthors">Brown, Christopher J.; McNae, Iain; Fischer, Peter M.; Walkinshaw, Malcolm D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-15</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Structural complexes of the eukaryotic translation initiation factor 4E (eIF4E) with a series of N7-alkylated guanosine deriv. mRNA cap analog structures have been characterized.  Mass spectrometry was used to det. apparent gas-phase equil. dissocn. consts. (Kd) values of 0.15 μM, 13.6 μM, and 55.7 μM for eIF4E with 7-methyl-GTP (m7GTP), GTP, and GMP, resp.  For tight and specific binding to the eIF4E mononucleotide binding site, there seems to be a clear requirement for guanosine derivs. to possess both the delocalized pos. charge of the N7-methylated guanine system and at least one phosphate group.  We show that the N7-benzylated monophosphates 7-benzyl-GMP (Bn7GMP) and 7-(p-fluorobenzyl)-GMP (FBn7GMP) bind eIF4E substantially more tightly than non-N7-alkylated guanosine derivs. (Kd values of 7.0 μM and 2.0 μM, resp.).  The eIF4E complex crystal structures with Bn7GMP and FBn7GMP show that addnl. favorable contacts of the benzyl groups with eIF4E contribute binding energy that compensates for loss of the β and γ-phosphates.  The N7-benzyl groups pack into a hydrophobic pocket behind the two tryptophan side-chains that are involved in the cation-π stacking interaction between the cap and the eIF4E mononucleotide binding site.  This pocket is formed by an induced fit in which one of the tryptophan residues involved in cap binding flips through 180° relative to structures with N7-methylated cap derivs.  This and other observations made here will be useful in the design of new families of eIF4E inhibitors, which may have potential therapeutic applications in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIioOMhX9XeLVg90H21EOLACvtfcHk0lhAEZ1dV841CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFeqsrc%253D&md5=8d7647bacc756db5265970fb6312e2bd</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2007.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2007.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DC.%2BJ.%26aulast%3DMcNae%26aufirst%3DI.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWalkinshaw%26aufirst%3DM.%2BD.%26atitle%3DCrystallographic%2520and%2520Mass%2520Spectrometric%2520Characterisation%2520of%2520eIF4E%2520with%2520N7-Alkylated%2520Cap%2520Derivatives%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2007%26volume%3D372%26spage%3D7%26epage%3D15%26doi%3D10.1016%2Fj.jmb.2007.06.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benyumov, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdulov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polunovsky, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Nontoxic Chemical Interdiction of the Epithelial-to-Mesenchymal Transition by Targeting Cap-Dependent Translation</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1021/cb9000475</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb9000475" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFKrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=367-377&author=B.+Ghoshauthor=A.+O.+Benyumovauthor=P.+Ghoshauthor=Y.+Jiaauthor=S.+Avdulovauthor=P.+S.+Dahlbergauthor=M.+Petersonauthor=K.+Smithauthor=V.+A.+Polunovskyauthor=P.+B.+Bittermanauthor=C.+R.+Wagner&title=Nontoxic+Chemical+Interdiction+of+the+Epithelial-to-Mesenchymal+Transition+by+Targeting+Cap-Dependent+Translation&doi=10.1021%2Fcb9000475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation</span></div><div class="casAuthors">Ghosh, Brahma; Benyumov, Alexey O.; Ghosh, Phalguni; Jia, Yan; Avdulov, Svetlana; Dahlberg, Peter S.; Peterson, Mark; Smith, Karen; Polunovsky, Vitaly A.; Bitterman, Peter B.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">367-377</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Normal growth and development depends upon high fidelity regulation of cap-dependent translation initiation, a process that is usurped and redirected in cancer to mediate acquisition of malignant properties.  The epithelial-to-mesenchymal transition (EMT) is a key translationally regulated step in the development of epithelial cancers and pathol. tissue fibrosis.  To date, no compds. targeting EMT have been developed.  Here we report the synthesis of a novel class of histidine triad nucleotide binding protein (HINT)-dependent pronucleotides that interdict EMT by neg. regulating the assocn. of eIF4E with the mRNA cap.  Compd. eIF4E inhibitor-1 potently inhibited cap-dependent translation in a dose-dependent manner in zebrafish embryos without causing developmental abnormalities and prevented eIF4E from triggering EMT in zebrafish ectoderm explants without toxicity.  Metab. studies with whole cell lysates demonstrated that the prodrug was rapidly converted into 7-BnGMP.  Thus we have successfully developed the first nontoxic small mol. able to inhibit EMT, a key process in the development of epithelial cancer and tissue fibrosis, by targeting the interaction of eIF4E with the mRNA cap and demonstrated the tractability of zebrafish as a model organism for studying agents that modulate EMT.  Our work provides strong motivation for the continued development of compds. designed to normalize cap-dependent translation as novel chemo-preventive agents and therapeutics for cancer and fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor5zGOqKEr-rVg90H21EOLACvtfcHk0lhAEZ1dV841CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFKrtr0%253D&md5=de7ff3316fc7c8fbaba2b9ef52b5376c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fcb9000475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb9000475%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DB.%26aulast%3DBenyumov%26aufirst%3DA.%2BO.%26aulast%3DGhosh%26aufirst%3DP.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DAvdulov%26aufirst%3DS.%26aulast%3DDahlberg%26aufirst%3DP.%2BS.%26aulast%3DPeterson%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DPolunovsky%26aufirst%3DV.%2BA.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DNontoxic%2520Chemical%2520Interdiction%2520of%2520the%2520Epithelial-to-Mesenchymal%2520Transition%2520by%2520Targeting%2520Cap-Dependent%2520Translation%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2009%26volume%3D4%26spage%3D367%26epage%3D377%26doi%3D10.1021%2Fcb9000475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, B.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jefferson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popescu, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, S. H.</span></span> <span> </span><span class="NLM_article-title">Aberrant Gene Expression in Human Non Small Cell Lung Carcinoma Cells Exposed to Demethylating Agent 5-Aza-2′-Deoxycytidine</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1593/neo.03490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1593%2Fneo.03490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=15256063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslWlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=412-419&author=B.-Z.+Yuanauthor=A.+M.+Jeffersonauthor=N.+C.+Popescuauthor=S.+H.+Reynolds&title=Aberrant+Gene+Expression+in+Human+Non+Small+Cell+Lung+Carcinoma+Cells+Exposed+to+Demethylating+Agent+5-Aza-2%E2%80%B2-Deoxycytidine&doi=10.1593%2Fneo.03490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-Aza-2'-deoxycytidine</span></div><div class="casAuthors">Yuan, Bao-Zhu; Jefferson, Amy M.; Popescu, Nicholas C.; Reynolds, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">412-419</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">The identification of genes undergoing genetic or epigenetic alterations and contributing to the development of cancer is crit. to our understanding of the mol. mechanisms of carcinogenesis.  A new approach in identifying alterations of genes that might be relevant to the process of tumor development was used in this study by examg. the gene expression profile in human lung cancer cells exposed to 5-aza-2'-deoxycytidine (5-aza-dC).  A cDNA array anal. was carried out on 5-aza-dC-treated and untreated non small cell lung cancer (NSCLC) cell line NCl-H522.  Sixteen and 14 genes were upregulated and downregulated, resp., by 5-aza-dC treatment.  Among them, downregulation of tyrosine protein kinase ABL2 (ABL2) gene and upregulation of hint/protein kinase C inhibitor 1 (Hint/PKCI-1), DVL1, TIMP-1, and TRP-1 genes were found in expanded observations in two or three of five 5-aza-dC-treated NSCLC cell lines.  Among these genes, we found that cDNA transfer of Hint/PKCl-1 resulted in a significant in vitro growth inhibition in two cell lines exhibiting 5-aza-dC-induced upregulation of Hint/PKCI-1 and significantly reduced in vivo tumorigenicity of one NSCLC cell line.  Hint/PKCl-1, which is the only other characterized human histidine triad (HIT) nucleotide-binding protein in addn. to tumor-suppressor gene FHIT, might be involved in lung carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprJ-4_eHK52LVg90H21EOLACvtfcHk0lheH2i8jfjARg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslWlu7s%253D&md5=48d6f484b08260d3b61c7ed939f97f15</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1593%2Fneo.03490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.03490%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DB.-Z.%26aulast%3DJefferson%26aufirst%3DA.%2BM.%26aulast%3DPopescu%26aufirst%3DN.%2BC.%26aulast%3DReynolds%26aufirst%3DS.%2BH.%26atitle%3DAberrant%2520Gene%2520Expression%2520in%2520Human%2520Non%2520Small%2520Cell%2520Lung%2520Carcinoma%2520Cells%2520Exposed%2520to%2520Demethylating%2520Agent%25205-Aza-2%25E2%2580%25B2-Deoxycytidine%26jtitle%3DNeoplasia%26date%3D2004%26volume%3D6%26spage%3D412%26epage%3D419%26doi%3D10.1593%2Fneo.03490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdulov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benyumov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hergert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braziunas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borok, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span> <span> </span><span class="NLM_article-title">Transforming Growth Factor-B1 Induced Epithelial Mesenchymal Transition Is Blocked by a Chemical Antagonist of Translation Factor eIF4E</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">18233</span>, <span class="refDoi"> DOI: 10.1038/srep18233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fsrep18233" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=18233&author=K.+A.+Smithauthor=B.+Zhouauthor=S.+Avdulovauthor=A.+Benyumovauthor=M.+Petersonauthor=Y.+Liuauthor=A.+Okonauthor=P.+Hergertauthor=J.+Braziunasauthor=C.+R.+Wagnerauthor=Z.+Borokauthor=P.+B.+Bitterman&title=Transforming+Growth+Factor-B1+Induced+Epithelial+Mesenchymal+Transition+Is+Blocked+by+a+Chemical+Antagonist+of+Translation+Factor+eIF4E&doi=10.1038%2Fsrep18233"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fsrep18233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep18233%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DAvdulov%26aufirst%3DS.%26aulast%3DBenyumov%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DOkon%26aufirst%3DA.%26aulast%3DHergert%26aufirst%3DP.%26aulast%3DBraziunas%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26aulast%3DBorok%26aufirst%3DZ.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26atitle%3DTransforming%2520Growth%2520Factor-B1%2520Induced%2520Epithelial%2520Mesenchymal%2520Transition%2520Is%2520Blocked%2520by%2520a%2520Chemical%2520Antagonist%2520of%2520Translation%2520Factor%2520eIF4E%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D5%26spage%3D18233%26doi%3D10.1038%2Fsrep18233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span> <span> </span><span class="NLM_article-title">Drugs and Targets in Fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">855</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3389%2Ffphar.2017.00855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=29218009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFems77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=855&author=X.+Liauthor=L.+Zhuauthor=B.+Wangauthor=M.+Yuanauthor=R.+Zhu&title=Drugs+and+Targets+in+Fibrosis&doi=10.3389%2Ffphar.2017.00855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs and targets in fibrosis</span></div><div class="casAuthors">Li, Xiaoyi; Zhu, Lixin; Wang, Beibei; Yuan, Meifei; Zhu, Ruixin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">855/1-855/21</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Fibrosis contributes to the development of many diseases and many target mols. are involved in fibrosis.  Currently, the majority of fibrosis treatment strategies are limited to specific diseases or organs.  However, accumulating evidence demonstrates great similarities among fibroproliferative diseases, and more and more drugs are proved to be effective anti-fibrotic therapies across different diseases and organs.  Here we comprehensively review the current knowledge on the pathol. mechanisms of fibrosis, and divide factors mediating fibrosis progression into extracellular and intracellular groups.  Furthermore, we systematically summarize both single and multiple component drugs that target fibrosis.  Future directions of fibrosis drug discovery are also proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYWFKoJKIMZ7Vg90H21EOLACvtfcHk0lheH2i8jfjARg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFems77P&md5=ce450251ad612e940967fde259549692</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00855%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DR.%26atitle%3DDrugs%2520and%2520Targets%2520in%2520Fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D855%26doi%3D10.3389%2Ffphar.2017.00855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Treatment of Breast and Lung Cancer Cells with a N-7 Benzyl Guanosine Monophosphate Tryptamine Phosphoramidate Pronucleotide (4Ei-1) Results in Chemosensitization to Gemcitabine and Induced EIF4E Proteasomal Degradation</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1021/mp300699d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300699d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=523-531&author=S.+Liauthor=Y.+Jiaauthor=B.+Jacobsonauthor=J.+McCauleyauthor=R.+Kratzkeauthor=P.+B.+Bittermanauthor=C.+R.+Wagner&title=Treatment+of+Breast+and+Lung+Cancer+Cells+with+a+N-7+Benzyl+Guanosine+Monophosphate+Tryptamine+Phosphoramidate+Pronucleotide+%284Ei-1%29+Results+in+Chemosensitization+to+Gemcitabine+and+Induced+EIF4E+Proteasomal+Degradation&doi=10.1021%2Fmp300699d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Breast and Lung Cancer Cells with a N-7 Benzyl Guanosine Monophosphate Tryptamine Phosphoramidate Pronucleotide (4Ei-1) Results in Chemosensitization to Gemcitabine and Induced eIF4E Proteasomal Degradation</span></div><div class="casAuthors">Li, Shui; Jia, Yan; Jacobson, Blake; McCauley, Joel; Kratzke, Robert; Bitterman, Peter B.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">523-531</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of cancer and fibrotic diseases has been shown to be highly dependent on disregulation of cap-dependent translation.  Binding protein eIF4E to N7-methylated guanosine capped mRNA has been found to be the rate-limiting step governing translation initiation, and therefore represents an attractive target for drug discovery.  Our group has found that 7-benzyl guanosine monophosphate (7Bn-GMP) is a potent antagonist of eIF4E cap binding (Kd = 0.8 μM).  Recent X-ray crystallog. studies have revealed that the cap-dependent pocket undergoes a unique structural change in order to accommodate the benzyl group.  Unfortunately, 7Bn-GMP is not cell permeable.  Recently, we have prepd. a tryptamine phosphoramidate prodrug of 7Bn-GMP, 4Ei-1, and shown that it is a substrate for human histidine triad nucleotide binding protein (hHINT1) and inhibits eIF4E initiated epithelial-mesenchymal transition (EMT) by Zebra fish embryo cells.  To assess the intracellular uptake of 4Ei-1 and conversion to 7Bn-GMP by cancer cells, we developed a sensitive assay using LC-ESI-MS/MS for the intracellular quantitation of 4Ei-1 and 7Bn-GMP.  When incubated with the breast cancer cell line MDA-231 or lung cancer cell lines H460, H383 and H2009, 4Ei-1 was found to be rapidly internalized and converted to 7Bn-GMP.  Since oncogenic mRNAs are predicted to have the highest eIF4E requirement for translation, we carried out chemosensitization studies with 4Ei-1.  The prodrug was found to chemosensitize both breast and lung cancer cells to nontoxic levels of gemcitabine.  Further mechanistic studies revealed that the expressed levels of eIF4E were substantially reduced in cells treated with 4Ei-1 in a dose-dependent manner.  The levels of eI4E could be restored by treatment with the proteasome inhibitor MG-132.  Taken together, our results demonstrate that 4Ei-1 is likely to inhibit translation initiation by eIF4E cap binding by both antagonizing eIF4E cap binding and initiating eIF4E proteasomal degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTFyifb06Lu7Vg90H21EOLACvtfcHk0ljvIoElJyv4lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGgsg%253D%253D&md5=e836b33df2f990b7d42f961a973658c7</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fmp300699d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300699d%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DJacobson%26aufirst%3DB.%26aulast%3DMcCauley%26aufirst%3DJ.%26aulast%3DKratzke%26aufirst%3DR.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DTreatment%2520of%2520Breast%2520and%2520Lung%2520Cancer%2520Cells%2520with%2520a%2520N-7%2520Benzyl%2520Guanosine%2520Monophosphate%2520Tryptamine%2520Phosphoramidate%2520Pronucleotide%2520%25284Ei-1%2529%2520Results%2520in%2520Chemosensitization%2520to%2520Gemcitabine%2520and%2520Induced%2520EIF4E%2520Proteasomal%2520Degradation%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D523%26epage%3D531%26doi%3D10.1021%2Fmp300699d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okon, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, R. A.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Inhibition of Oncogenic Eukaryotic Protein Translation in Mesothelioma Cells</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0076-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs10637-014-0076-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24711125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Whs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=598-603&author=E.+Z.+Chenauthor=B.+A.+Jacobsonauthor=M.+R.+Patelauthor=A.+M.+Okonauthor=S.+Liauthor=K.+Xiongauthor=A.+J.+Vaidyaauthor=P.+B.+Bittermanauthor=C.+R.+Wagnerauthor=R.+A.+Kratzke&title=Small-Molecule+Inhibition+of+Oncogenic+Eukaryotic+Protein+Translation+in+Mesothelioma+Cells&doi=10.1007%2Fs10637-014-0076-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells</span></div><div class="casAuthors">Chen, Esther Z.; Jacobson, Blake A.; Patel, Manish R.; Okon, Aniekan M.; Li, Shui; Xiong, Kerry; Vaidya, Abhishek J.; Bitterman, Peter B.; Wagner, Carston R.; Kratzke, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">598-603</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Deranged cap-mediated translation is implicated in the genesis, maintenance and progression of many human cancers including mesothelioma.  In this study, disrupting the eIF4F complex by antagonizing the eIF4E-mRNA-cap interaction is assessed as a therapy for mesothelioma.  Mesothelioma cells were treated with 4Ei-1, a membrane permeable prodrug that when converted to the active drug, 7-benzyl guanosine monophosphate (7Bn-GMP) displaces capped mRNAs from the eIF4F complex.  Colony formation was measured in mesothelioma treated with 4Ei-1 alone or combined with pemetrexed.  Proliferation was examd. in cells treated with 4Ei-1.  Binding to a synthetic cap-analog was used to study the strength of eIF4F complex activation in lysates exposed to 4Ei-1. 4Ei-1 treatment resulted in a dose dependent decrease in colony formation and cell viability.  Combination therapy of 4Ei-1 with pemetrexed further reduced colony no.  Formation of eIF4F cap-complex decreased in response to 4Ei-1 exposure. 4Ei-1 is a novel prodrug that reduces proliferation, represses colony formation, diminishes assocn. of eIF4F with the mRNA cap, and sensitizes mesothelioma cells to pemetrexed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMe8AjZSME1rVg90H21EOLACvtfcHk0ljvIoElJyv4lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Whs7vI&md5=7f4419e21132fe7c4ba3fb147194e122</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0076-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0076-7%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DE.%2BZ.%26aulast%3DJacobson%26aufirst%3DB.%2BA.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DOkon%26aufirst%3DA.%2BM.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DXiong%26aufirst%3DK.%26aulast%3DVaidya%26aufirst%3DA.%2BJ.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26aulast%3DKratzke%26aufirst%3DR.%2BA.%26atitle%3DSmall-Molecule%2520Inhibition%2520of%2520Oncogenic%2520Eukaryotic%2520Protein%2520Translation%2520in%2520Mesothelioma%2520Cells%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2014%26volume%3D32%26spage%3D598%26epage%3D603%26doi%3D10.1007%2Fs10637-014-0076-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuesta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balius, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Lysine-Targeted EIF4E Inhibitors through Covalent Docking</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">4960</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b10377</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b10377" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlOksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=4960-4964&author=X.+Wanauthor=T.+Yangauthor=A.+Cuestaauthor=X.+Pangauthor=T.+E.+Baliusauthor=J.+J.+Irwinauthor=B.+K.+Shoichetauthor=J.+Taunton&title=Discovery+of+Lysine-Targeted+EIF4E+Inhibitors+through+Covalent+Docking&doi=10.1021%2Fjacs.9b10377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking</span></div><div class="casAuthors">Wan, Xiaobo; Yang, Tangpo; Cuesta, Adolfo; Pang, Xiaming; Balius, Trent E.; Irwin, John J.; Shoichet, Brian K.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4960-4964</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Eukaryotic translation initiation factor 4E (eIF4E) binds the m7GTP cap structure at the 5'-end of mRNAs, stimulating the translation of proteins implicated in cancer cell growth and metastasis. eIF4E is a notoriously challenging target, and most of the reported inhibitors are neg. charged guanine analogs with negligible cell permeability.  To overcome these challenges, we envisioned a covalent targeting strategy.  As there are no cysteines near the eIF4E cap binding site, we developed a covalent docking approach focused on lysine.  Taking advantage of a "make-on-demand" virtual library, we used covalent docking to identify arylsulfonyl fluorides that target a noncatalytic lysine (Lys162) in eIF4E.  Guided by cocrystal structures, we elaborated arylsulfonyl fluoride 2 to 12, which to our knowledge is the first covalent eIF4E inhibitor with cellular activity.  In addn. to providing a new tool for acutely inactivating eIF4E in cells, our computational approach may offer a general strategy for developing selective lysine-targeted covalent ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8PHp9f-vKHbVg90H21EOLACvtfcHk0ljvIoElJyv4lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlOksb8%253D&md5=4e014562ef811842104e9999dbe6da67</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b10377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b10377%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DCuesta%26aufirst%3DA.%26aulast%3DPang%26aufirst%3DX.%26aulast%3DBalius%26aufirst%3DT.%2BE.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Lysine-Targeted%2520EIF4E%2520Inhibitors%2520through%2520Covalent%2520Docking%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26spage%3D4960%26epage%3D4964%26doi%3D10.1021%2Fjacs.9b10377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moerke, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reibarkh, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahmy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, J. D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degterev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halperin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.11.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.cell.2006.11.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17254965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=257-267&author=N.+J.+Moerkeauthor=H.+Aktasauthor=H.+Chenauthor=S.+Cantelauthor=M.+Y.+Reibarkhauthor=A.+Fahmyauthor=J.+D.+D.+Grossauthor=A.+Degterevauthor=J.+Yuanauthor=M.+Chorevauthor=J.+A.+Halperinauthor=G.+Wagner&title=Small-Molecule+Inhibition+of+the+Interaction+between+the+Translation+Initiation+Factors+eIF4E+and+eIF4G&doi=10.1016%2Fj.cell.2006.11.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G</span></div><div class="casAuthors">Moerke, Nathan J.; Aktas, Huseyin; Chen, Han; Cantel, Sonia; Reibarkh, Mikhail Y.; Fahmy, Amr; Gross, John D.; Degterev, Alexei; Yuan, Junying; Chorev, Michael; Halperin, Jose A.; Wagner, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-267</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Assembly of the eIF4E/eIF4G complex has a central role in the regulation of gene expression at the level of translation initiation.  This complex is regulated by the 4E-BPs, which compete with eIF4G for binding to eIF4E and which have tumor-suppressor activity.  To pharmacol. mimic 4E-BP function the authors developed a high-throughput screening assay for identifying small-mol. inhibitors of the eIF4E/eIF4G interaction.  The most potent compd. identified, 4EGI-1, binds eIF4E, disrupts eIF4E/eIF4G assocn., and inhibits cap-dependent translation but not initiation factor-independent translation.  While 4EGI-1 displaces eIF4G from eIF4E, it effectively enhances 4E-BP1 assocn. both in vitro and in cells.  4EGI-1 inhibits cellular expression of oncogenic proteins encoded by weak mRNAs, exhibits activity against multiple cancer cell lines, and appears to have a preferential effect on transformed vs. nontransformed cells.  The identification of this compd. provides a new tool for studying translational control and establishes a possible new strategy for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI5WbK0F9CirVg90H21EOLACvtfcHk0liZhqVKthHesw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOru7Y%253D&md5=e235725479edd70cd050a104a71b5fe2</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.11.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.11.046%26sid%3Dliteratum%253Aachs%26aulast%3DMoerke%26aufirst%3DN.%2BJ.%26aulast%3DAktas%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCantel%26aufirst%3DS.%26aulast%3DReibarkh%26aufirst%3DM.%2BY.%26aulast%3DFahmy%26aufirst%3DA.%26aulast%3DGross%26aufirst%3DJ.%2BD.%2BD.%26aulast%3DDegterev%26aufirst%3DA.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DChorev%26aufirst%3DM.%26aulast%3DHalperin%26aufirst%3DJ.%2BA.%26aulast%3DWagner%26aufirst%3DG.%26atitle%3DSmall-Molecule%2520Inhibition%2520of%2520the%2520Interaction%2520between%2520the%2520Translation%2520Initiation%2520Factors%2520eIF4E%2520and%2520eIF4G%26jtitle%3DCell%26date%3D2007%26volume%3D128%26spage%3D257%26epage%3D267%26doi%3D10.1016%2Fj.cell.2006.11.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabha, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takrouri, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luna, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthanari, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Mias, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yefidoff-Freedman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktas, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halperin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span> <span> </span><span class="NLM_article-title">Structure of the Eukaryotic Translation Initiation Factor EIF4E in Complex with 4EGI-1 Reveals an Allosteric Mechanism for Dissociating EIF4G</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">E3187</span>, <span class="refDoi"> DOI: 10.1073/pnas.1410250111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.1410250111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25049413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyqtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E3187&author=E.+Papadopoulosauthor=S.+Jenniauthor=E.+Kabhaauthor=K.+J.+Takrouriauthor=T.+Yiauthor=N.+Salviauthor=R.+E.+Lunaauthor=E.+Gavathiotisauthor=P.+Mahalingamauthor=H.+Arthanariauthor=R.+Rodriguez-Miasauthor=R.+Yefidoff-Freedmanauthor=B.+H.+Aktasauthor=M.+Chorevauthor=J.+A.+Halperinauthor=G.+Wagner&title=Structure+of+the+Eukaryotic+Translation+Initiation+Factor+EIF4E+in+Complex+with+4EGI-1+Reveals+an+Allosteric+Mechanism+for+Dissociating+EIF4G&doi=10.1073%2Fpnas.1410250111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G</span></div><div class="casAuthors">Papadopoulos, Evangelos; Jenni, Simon; Kabha, Eihab; Takrouri, Khuloud J.; Yi, Tingfang; Salvi, Nicola; Luna, Rafael E.; Gavathiotis, Evripidis; Mahalingam, Poornachandran; Arthanari, Haribabu; Rodriguez-Mias, Ricard; Yefidoff-Freedman, Revital; Aktas, Bertal H.; Chorev, Michael; Halperin, Jose A.; Wagner, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">E3187-E3195</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The interaction of the eukaryotic translation initiation factor eIF4E with the initiation factor eIF4G recruits the 40S ribosomal particle to the 5' end of mRNAs, facilitates scanning to the AUG start codon, and is crucial for eukaryotic translation of nearly all genes.  Efficient recruitment of the 40S particle is particularly important for translation of mRNAs encoding oncoproteins and growth-promoting factors, which often harbor complex 5' UTRs and require efficient initiation.  Thus, inhibiting the eIF4E/eIF4G interaction has emerged as a previously unpursued route for developing anticancer agents.  Indeed, we discovered small-mol. inhibitors of this eIF4E/eIF4G interaction (4EGIs) that inhibit translation initiation both in vitro and in vivo and were used successfully in numerous cancer-biol. and neurobiol. studies.  However, their detailed mol. mechanism of action has remained elusive.  Here, we show that the eIF4E/eIF4G inhibitor 4EGI-1 acts allosterically by binding to a site on eIF4E distant from the eIF4G binding epitope.  Data from NMR mapping and high-resoln. crystal structures are congruent with this mechanism, where 4EGI-1 attaches to a hydrophobic pocket of eIF4E between β-sheet2 (L60-T68) and α-helix1 (E69-N77), causing localized conformational changes mainly in the H78-L85 region.  It acts by unfolding a short 310-helix (S82-L85) while extending α-helix1 by one turn (H78-S82).  This unusual helix rearrangement has not been seen in any previous eIF4E structure and reveals elements of an allosteric inhibition mechanism leading to the dislocation of eIF4G from eIF4E.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5rQr0p_Vxv7Vg90H21EOLACvtfcHk0li0sxfCaR9mKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyqtLrN&md5=49e325d40120b071e410c27d78790ebc</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1410250111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1410250111%26sid%3Dliteratum%253Aachs%26aulast%3DPapadopoulos%26aufirst%3DE.%26aulast%3DJenni%26aufirst%3DS.%26aulast%3DKabha%26aufirst%3DE.%26aulast%3DTakrouri%26aufirst%3DK.%2BJ.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DSalvi%26aufirst%3DN.%26aulast%3DLuna%26aufirst%3DR.%2BE.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DMahalingam%26aufirst%3DP.%26aulast%3DArthanari%26aufirst%3DH.%26aulast%3DRodriguez-Mias%26aufirst%3DR.%26aulast%3DYefidoff-Freedman%26aufirst%3DR.%26aulast%3DAktas%26aufirst%3DB.%2BH.%26aulast%3DChorev%26aufirst%3DM.%26aulast%3DHalperin%26aufirst%3DJ.%2BA.%26aulast%3DWagner%26aufirst%3DG.%26atitle%3DStructure%2520of%2520the%2520Eukaryotic%2520Translation%2520Initiation%2520Factor%2520EIF4E%2520in%2520Complex%2520with%25204EGI-1%2520Reveals%2520an%2520Allosteric%2520Mechanism%2520for%2520Dissociating%2520EIF4G%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3DE3187%26doi%3D10.1073%2Fpnas.1410250111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthanari, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Mias, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Léger-Abraham, M.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanism of the Dual Activity of 4EGI-1: Dissociating EIF4G from EIF4E but Stabilizing the Binding of Unphosphorylated 4E-BP1</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">E4036</span>– <span class="NLM_lpage">E4045</span>, <span class="refDoi"> DOI: 10.1073/pnas.1512118112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.1512118112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26170285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFGktr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=E4036-E4045&author=N.+Sekiyamaauthor=H.+Arthanariauthor=E.+Papadopoulosauthor=R.+A.+Rodriguez-Miasauthor=G.+Wagnerauthor=M.+L%C3%A9ger-Abraham&title=Molecular+Mechanism+of+the+Dual+Activity+of+4EGI-1%3A+Dissociating+EIF4G+from+EIF4E+but+Stabilizing+the+Binding+of+Unphosphorylated+4E-BP1&doi=10.1073%2Fpnas.1512118112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of the dual activity of 4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1</span></div><div class="casAuthors">Sekiyama, Naotaka; Arthanari, Haribabu; Papadopoulos, Evangelos; Rodriguez-Mias, Ricard A.; Wagner, Gerhard; Leger-Abraham, Melissa</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">E4036-E4045</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The eIF4E-binding protein (4E-BP) is a phosphorylation-dependent regulator of protein synthesis.  The nonphosphorylated or minimally phosphorylated form binds translation initiation factor 4E (eIF4E), preventing binding of eIF4G and the recruitment of the small ribosomal subunit.  Signaling events stimulate serial phosphorylation of 4E-BP, primarily by mammalian target of rapamycin complex 1 (mTORC1) at residues T37/T46, followed by T70 and S65.  Hyperphosphorylated 4E-BP dissocs. from eIF4E, allowing eIF4E to interact with eIF4G and translation initiation to resume.  Because overexpression of eIF4E is linked to cellular transformation, 4E-BP is a tumor suppressor, and up-regulation of its activity is a goal of interest for cancer therapy.  A recently discovered small mol., eIF4E/eIF4G interaction inhibitor 1 (4EGI-1), disrupts the eIF4E/eIF4G interaction and promotes binding of 4E-BP1 to eIF4E.  Structures of 14- to 16-residue 4E-BP fragments bound to eIF4E contain the eIF4E consensus binding motif, 54YXXXXLΦ60 (motif 1) but lack known phosphorylation sites.  We report here a 2.1-Å crystal structure of mouse eIF4E in complex with m7GTP and with a fragment of human 4E-BP1, extended C-terminally from the consensus-binding motif (4E-BP150-84).  The extension, which includes a proline-turn-helix segment (motif 2) followed by a loop of irregular structure, reveals the location of two phosphorylation sites (S65 and T70).  Our major finding is that the C-terminal extension (motif 3) is crit. to 4E-BP1-mediated cell cycle arrest and that it partially overlaps with the binding site of 4EGI-1.  The binding of 4E-BP1 and 4EGI-1 to eIF4E is therefore not mutually exclusive, and both ligands contribute to shift the equil. toward the inhibition of translation initiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5UX9gpOLePrVg90H21EOLACvtfcHk0ljCsACDSDPoOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFGktr3K&md5=4b08a4764b5c8b6557f9266402c00dd2</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1512118112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1512118112%26sid%3Dliteratum%253Aachs%26aulast%3DSekiyama%26aufirst%3DN.%26aulast%3DArthanari%26aufirst%3DH.%26aulast%3DPapadopoulos%26aufirst%3DE.%26aulast%3DRodriguez-Mias%26aufirst%3DR.%2BA.%26aulast%3DWagner%26aufirst%3DG.%26aulast%3DL%25C3%25A9ger-Abraham%26aufirst%3DM.%26atitle%3DMolecular%2520Mechanism%2520of%2520the%2520Dual%2520Activity%2520of%25204EGI-1%253A%2520Dissociating%2520EIF4G%2520from%2520EIF4E%2520but%2520Stabilizing%2520the%2520Binding%2520of%2520Unphosphorylated%25204E-BP1%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3DE4036%26epage%3DE4045%26doi%3D10.1073%2Fpnas.1512118112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanggou, S.</span></span> <span> </span><span class="NLM_article-title">Anti-Cancer Effect of Cap-Translation Inhibitor 4EGI-1 in Human Glioma U87 Cells: Involvement of Mitochondrial Dysfunction and ER Stress</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1159/000453158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1159%2F000453158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27941351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSmtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2016&pages=1013-1028&author=M.+Wuauthor=C.+Zhangauthor=X.+J.+Liauthor=Q.+Liuauthor=S.+Wanggou&title=Anti-Cancer+Effect+of+Cap-Translation+Inhibitor+4EGI-1+in+Human+Glioma+U87+Cells%3A+Involvement+of+Mitochondrial+Dysfunction+and+ER+Stress&doi=10.1159%2F000453158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-Cancer Effect of Cap-Translation Inhibitor 4EGI-1 in Human Glioma U87 Cells: Involvement of Mitochondrial Dysfunction and ER Stress</span></div><div class="casAuthors">Wu, Ming; Zhang, Chi; Li, Xue-Jun; Liu, Qing; Wanggou, Siyi</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1013-1028</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Cancer cells are frequently addicted to deregulated oncogenic protein translation that usually arises as a consequence of increased signaling flux from eIF4F activation.  The small mol. 4EG-I, a potent inhibitor of translation initiation through disrupting eIF4E/eIF4G interaction, has been shown to exert anticancer effects in animal models of human cancers.  Methods: Here, we extensively investigated the anticancer activity of 4EGI-1 in human glioma U87 cells.  The anti-cancer effects of 4EGI-1 were measured by cell viability, lactate dehydrogenase (LDH) release, TUNEL staining, flow cytometry and western blot anal. in vitro, and also examd. in a U87 xenograft model in vivo.  The potential underlying mol. mechanisms were investigated by measuring mitochondrial function and ER stress.  Results: We found that 4EGI-1 impaired the assembly of the eIF4F complex and decreased the expression of the eIF4E regulated proteins.  The results of TUNEL staining and flow cytometry showed that 4EGI-1 treatment induced apoptotic cell death in a dose-dependent manner.  Furthermore, 4EGI-1-induced apoptosis in U87 cells was assocd. with mitochondrial dysfunction and activation of the intrinsic mitochondrial pathway, which was dependent on the induction of the pro-apoptotic protein Bax.  In addn., 4EGI-1 treatment triggered ER stress, which was evidenced by morphol. changes of ER lumen and ER calcium release, as well as the dose-dependent increases in the expression of ER stress related proteins.  Moreover, knockdown of the ER chaperone GRP-78 through siRNA was shown to partially reverse the 4EGI-1-induced ER stress in U87 cells.  In vivo, 4EGI-1 strongly inhibited growth of U87 glioma xenografts without any apparent organ related toxicities.  Conclusion: These data indicate that the use of inhibitors that directly target the translation initiation complex eIF4F could represent a potential novel approach for human glioma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomc9VwkFIU-7Vg90H21EOLACvtfcHk0ljCsACDSDPoOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSmtrzL&md5=8aabee0a0716c1c96d988c6d95e21ef4</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1159%2F000453158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000453158%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DX.%2BJ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWanggou%26aufirst%3DS.%26atitle%3DAnti-Cancer%2520Effect%2520of%2520Cap-Translation%2520Inhibitor%25204EGI-1%2520in%2520Human%2520Glioma%2520U87%2520Cells%253A%2520Involvement%2520of%2520Mitochondrial%2520Dysfunction%2520and%2520ER%2520Stress%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2016%26volume%3D40%26spage%3D1013%26epage%3D1028%26doi%3D10.1159%2F000453158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jay-Dixon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadiq, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, R. A.</span></span> <span> </span><span class="NLM_article-title">4EGI-1 Represses Cap-Dependent Translation and Regulates Genome-Wide Translation in Malignant Pleural Mesothelioma</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1007/s10637-017-0535-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs10637-017-0535-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=29116477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2js7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=217-229&author=A.+Deauthor=B.+A.+Jacobsonauthor=M.+S.+Petersonauthor=J.+Jay-Dixonauthor=M.+G.+Kratzkeauthor=A.+A.+Sadiqauthor=M.+R.+Patelauthor=R.+A.+Kratzke&title=4EGI-1+Represses+Cap-Dependent+Translation+and+Regulates+Genome-Wide+Translation+in+Malignant+Pleural+Mesothelioma&doi=10.1007%2Fs10637-017-0535-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma</span></div><div class="casAuthors">De, Arpita; Jacobson, Blake A.; Peterson, Mark S.; Jay-Dixon, Joe; Kratzke, Marian G.; Sadiq, Ahad A.; Patel, Manish R.; Kratzke, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-229</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Deregulation of cap-dependent translation has been implicated in the malignant transformation of numerous human tissues. 4EGI-1, a novel small-mol. inhibitor of cap-dependent translation, disrupts formation of the eukaryotic initiation factor 4F (eIF4F) complex.  The effects of 4EGI-1-mediated inhibition of translation initiation in malignant pleural mesothelioma (MPM) were examd. 4EGI-1 preferentially inhibited cell viability and induced apoptosis in MPM cells compared to normal mesothelial (LP9) cells.  This effect was assocd. with hypophosphorylation of 4E-binding protein 1 (4E-BP1) and decreased protein levels of the cancer-related genes, c-myc and osteopontin. 4EGI-1 showed enhanced cytotoxicity in combination with pemetrexed or gemcitabine.  Translatome-wide polysome microarray anal. revealed a large cohort of genes that were translationally regulated upon treatment with 4EGI-1.  The 4EGI-1-regulated translatome was neg. correlated to a previously published translatome regulated by eIF4E overexpression in human mammary epithelial cells, which is in agreement with the notion that 4EGI-1 inhibits the eIF4F complex.  These data indicate that inhibition of the eIF4F complex by 4EGI-1 or similar translation inhibitors could be a strategy for treating mesothelioma.  Genome wide translational profiling identified a large cohort of promising target genes that should be further evaluated for their potential significance in the treatment of MPM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbtIwZUfu9OrVg90H21EOLACvtfcHk0ljCsACDSDPoOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2js7vE&md5=05712fd65ab5aabe3dd7e51f8eea0855</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1007%2Fs10637-017-0535-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-017-0535-z%26sid%3Dliteratum%253Aachs%26aulast%3DDe%26aufirst%3DA.%26aulast%3DJacobson%26aufirst%3DB.%2BA.%26aulast%3DPeterson%26aufirst%3DM.%2BS.%26aulast%3DJay-Dixon%26aufirst%3DJ.%26aulast%3DKratzke%26aufirst%3DM.%2BG.%26aulast%3DSadiq%26aufirst%3DA.%2BA.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DKratzke%26aufirst%3DR.%2BA.%26atitle%3D4EGI-1%2520Represses%2520Cap-Dependent%2520Translation%2520and%2520Regulates%2520Genome-Wide%2520Translation%2520in%2520Malignant%2520Pleural%2520Mesothelioma%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2018%26volume%3D36%26spage%3D217%26epage%3D229%26doi%3D10.1007%2Fs10637-017-0535-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stelzner, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jay-Dixon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, R. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Oncogenic Cap-Dependent Translation by 4EGI-1 Reduces Growth, Enhances Chemosensitivity and Alters Genome-Wide Translation in Non-Small Cell Lung Cancer</span>. <i>Cancer Gene Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1038/s41417-018-0058-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41417-018-0058-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30420719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Sgur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=157-165&author=A.+Deauthor=B.+A.+Jacobsonauthor=M.+S.+Petersonauthor=M.+E.+Stelznerauthor=J.+Jay-Dixonauthor=M.+G.+Kratzkeauthor=M.+R.+Patelauthor=P.+B.+Bittermanauthor=R.+A.+Kratzke&title=Inhibition+of+Oncogenic+Cap-Dependent+Translation+by+4EGI-1+Reduces+Growth%2C+Enhances+Chemosensitivity+and+Alters+Genome-Wide+Translation+in+Non-Small+Cell+Lung+Cancer&doi=10.1038%2Fs41417-018-0058-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer</span></div><div class="casAuthors">De, Arpita; Jacobson, Blake A.; Peterson, Mark S.; Stelzner, Margaret E.; Jay-Dixon, Joe; Kratzke, Marian G.; Patel, Manish R.; Bitterman, Peter B.; Kratzke, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Gene Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">157-165</span>CODEN:
                <span class="NLM_cas:coden">CGTHEG</span>;
        ISSN:<span class="NLM_cas:issn">0929-1903</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Hyperactivation of eIF4F-mediated translation occurs in many if not all cancers.  As a consequence, cancer cells aberrantly enhance expression of malignancy-related proteins that are involved in cell cycle progression, angiogenesis, growth, and proliferation.  With this in mind eIF4F is a promising mol. target for therapeutics that counteract pathol. eIF4F activity.  Here we used 4EGI-1, a small-mol. inhibitor of cap-mediated translation that disrupts formation of the eukaryotic initiation factor 4F (eIF4F) complex to treat non-small cell lung cancer (NSCLC).  Treatment of cells with 4EGI-1 reduced cell proliferation, decreased cap-dependent complex formation, induced apoptosis, enhanced sensitivity to gemcitabine, and altered global cellular translation.  Suppression of cap-dependent translation by 4EGI-1 resulted in diminished expression of oncogenic proteins c-Myc, Bcl-2, cyclin D1, and survivin, whereas β-actin expression was left unchanged.  In light of these results, small-mol. inhibitors like 4EGI-1 alone or with chemotherapy should be further evaluated in the treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK7TURxLzAW7Vg90H21EOLACvtfcHk0li9MjD0m2OwNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Sgur3L&md5=18dc680d7e021e28da7827f03d613e2a</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1038%2Fs41417-018-0058-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41417-018-0058-6%26sid%3Dliteratum%253Aachs%26aulast%3DDe%26aufirst%3DA.%26aulast%3DJacobson%26aufirst%3DB.%2BA.%26aulast%3DPeterson%26aufirst%3DM.%2BS.%26aulast%3DStelzner%26aufirst%3DM.%2BE.%26aulast%3DJay-Dixon%26aufirst%3DJ.%26aulast%3DKratzke%26aufirst%3DM.%2BG.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26aulast%3DKratzke%26aufirst%3DR.%2BA.%26atitle%3DInhibition%2520of%2520Oncogenic%2520Cap-Dependent%2520Translation%2520by%25204EGI-1%2520Reduces%2520Growth%252C%2520Enhances%2520Chemosensitivity%2520and%2520Alters%2520Genome-Wide%2520Translation%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Gene%2520Ther.%26date%3D2019%26volume%3D26%26spage%3D157%26epage%3D165%26doi%3D10.1038%2Fs41417-018-0058-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtkaya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingledine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Reversing Chemoresistance by Small Molecule Inhibition of the Translation Initiation Complex eIF4F</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1073/pnas.1011477108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.1011477108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21191102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlWrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=1046-1051&author=R.+Cencicauthor=D.+R.+Hallauthor=F.+Robertauthor=Y.+Duauthor=J.+Minauthor=L.+Liauthor=M.+Quiauthor=I.+Lewisauthor=S.+Kurtkayaauthor=R.+Dingledineauthor=H.+Fuauthor=D.+Kozakovauthor=S.+Vajdaauthor=J.+Pelletier&title=Reversing+Chemoresistance+by+Small+Molecule+Inhibition+of+the+Translation+Initiation+Complex+eIF4F&doi=10.1073%2Fpnas.1011477108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F</span></div><div class="casAuthors">Cencic, Regina; Hall, David R.; Robert, Francis; Du, Yuhong; Min, Jaeki; Li, Lian; Qui, Min; Lewis, Iestyn; Kurtkaya, Serdar; Dingledine, Ray; Fu, Haian; Kozakov, Dima; Vajda, Sandor; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1046-1051, S1046/1-S1046/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Deregulation of cap-dependent translation is assocd. with cancer initiation and progression.  The rate-limiting step of protein synthesis is the loading of ribosomes onto mRNA templates stimulated by the heterotrimeric complex, eukaryotic initiation factor (elF)4F.  This step represents an attractive target for anticancer drug discovery because it resides at the nexus of the TOR signaling pathway.  We have undertaken an ultra-high-throughput screen to identify inhibitors that prevent assembly of the eIF4F complex.  One of the identified compds. blocks interaction between two subunits of elF4F.  As a consequence, cap-dependent translation is inhibited.  This compd. can reverse tumor chemoresistance in a genetically engineered lymphoma mouse model by sensitizing cells to the proapoptotic action of DNA damage.  Mol. modeling expts. provide insight into the mechanism of action of this small mol. inhibitor.  Our expts. validate targeting the eIF4F complex as a strategy for cancer therapy to modulate chemo-sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp523wPn1DaGbVg90H21EOLACvtfcHk0li9MjD0m2OwNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlWrsrs%253D&md5=8b9fa0bf7dc5638b9a85e1a8e1556088</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1011477108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1011477108%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DHall%26aufirst%3DD.%2BR.%26aulast%3DRobert%26aufirst%3DF.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DQui%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DI.%26aulast%3DKurtkaya%26aufirst%3DS.%26aulast%3DDingledine%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DKozakov%26aufirst%3DD.%26aulast%3DVajda%26aufirst%3DS.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DReversing%2520Chemoresistance%2520by%2520Small%2520Molecule%2520Inhibition%2520of%2520the%2520Translation%2520Initiation%2520Complex%2520eIF4F%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D1046%26epage%3D1051%26doi%3D10.1073%2Fpnas.1011477108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desforges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingledine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Blocking EIF4E-EIF4G Interaction as a Strategy To Impair Coronavirus Replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">6381</span>– <span class="NLM_lpage">6389</span>, <span class="refDoi"> DOI: 10.1128/JVI.00078-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1128%2FJVI.00078-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21507972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=6381-6389&author=R.+Cencicauthor=M.+Desforgesauthor=D.+R.+Hallauthor=D.+Kozakovauthor=Y.+Duauthor=J.+Minauthor=R.+Dingledineauthor=H.+Fuauthor=S.+Vajdaauthor=P.+J.+Talbotauthor=J.+Pelletier&title=Blocking+EIF4E-EIF4G+Interaction+as+a+Strategy+To+Impair+Coronavirus+Replication&doi=10.1128%2FJVI.00078-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication</span></div><div class="casAuthors">Cencic, Regina; Desforges, Marc; Hall, David R.; Kozakov, Dima; Du, Yuhong; Min, Jaeki; Dingledine, Raymond; Fu, Haian; Vajda, Sandor; Talbot, Pierre J.; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6381-6389</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Coronaviruses are a family of enveloped single-stranded pos.-sense RNA viruses causing respiratory, enteric, and neurol. diseases in mammals and fowl.  Human coronaviruses are recognized to cause up to a third of common colds and are suspected to be involved in enteric and neurol. diseases.  Coronavirus replication involves the generation of nested subgenomic mRNAs (sgmRNAs) with a common capped 5' leader sequence.  The translation of most of the sgmRNAs is thought to be cap dependent and displays a requirement for eukaryotic initiation factor 4F (eIF4F), a heterotrimeric complex needed for the recruitment of 40S ribosomes.  We recently reported on an ultrahigh-throughput screen to discover compds. that inhibit eIF4F activity by blocking the interaction of two of its subunits.  Herein we describe a mol. from this screen that prevents the interaction between eIF4E (the cap-binding protein) and eIF4G (a large scaffolding protein), inhibiting cap-dependent translation.  This inhibitor significantly decreased human coronavirus 229E (HCoV-229E) replication, reducing the percentage of infected cells and intra- and extracellular infectious virus titers.  Our results support the strategy of targeting the eIF4F complex to block coronavirus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmYijWiXmX5LVg90H21EOLACvtfcHk0li9MjD0m2OwNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOntbY%253D&md5=2825b0855928a3dbbc53ac015dd55d16</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1128%2FJVI.00078-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00078-11%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DDesforges%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DD.%2BR.%26aulast%3DKozakov%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DDingledine%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DVajda%26aufirst%3DS.%26aulast%3DTalbot%26aufirst%3DP.%2BJ.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DBlocking%2520EIF4E-EIF4G%2520Interaction%2520as%2520a%2520Strategy%2520To%2520Impair%2520Coronavirus%2520Replication%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D6381%26epage%3D6389%26doi%3D10.1128%2FJVI.00078-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kardos, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinavahi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, G. P.</span></span> <span> </span><span class="NLM_article-title">Salubrinal in Combination With 4E1RCat Synergistically Impairs Melanoma Development by Disrupting the Protein Synthetic Machinery</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.3389/fonc.2020.00834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3389%2Ffonc.2020.00834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=32076595" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=1-9&author=G.+R.+Kardosauthor=R.+Gowdaauthor=S.+S.+Dinavahiauthor=S.+Kimballauthor=G.+P.+Robertson&title=Salubrinal+in+Combination+With+4E1RCat+Synergistically+Impairs+Melanoma+Development+by+Disrupting+the+Protein+Synthetic+Machinery&doi=10.3389%2Ffonc.2020.00834"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2020.00834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2020.00834%26sid%3Dliteratum%253Aachs%26aulast%3DKardos%26aufirst%3DG.%2BR.%26aulast%3DGowda%26aufirst%3DR.%26aulast%3DDinavahi%26aufirst%3DS.%2BS.%26aulast%3DKimball%26aufirst%3DS.%26aulast%3DRobertson%26aufirst%3DG.%2BP.%26atitle%3DSalubrinal%2520in%2520Combination%2520With%25204E1RCat%2520Synergistically%2520Impairs%2520Melanoma%2520Development%2520by%2520Disrupting%2520the%2520Protein%2520Synthetic%2520Machinery%26jtitle%3DFront.%2520Oncol.%26date%3D2020%26volume%3D10%26spage%3D1%26epage%3D9%26doi%3D10.3389%2Ffonc.2020.00834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbein, G.</span></span> <span> </span><span class="NLM_article-title">The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral Infections</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">75</span>, <span class="refDoi"> DOI: 10.3389/fonc.2015.00075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3389%2Ffonc.2015.00075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25905039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BC2MjntlGrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=75&author=W.+Abbasauthor=A.+Kumarauthor=G.+Herbein&title=The+eEF1A+Proteins%3A+At+the+Crossroads+of+Oncogenesis%2C+Apoptosis%2C+and+Viral+Infections&doi=10.3389%2Ffonc.2015.00075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral Infections</span></div><div class="casAuthors">Abbas Wasim; Kumar Amit; Herbein Georges</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Eukaryotic translation elongation factors 1 alpha, eEF1A1 and eEF1A2, are not only translation factors but also pleiotropic proteins that are highly expressed in human tumors, including breast cancer, ovarian cancer, and lung cancer. eEF1A1 modulates cytoskeleton, exhibits chaperone-like activity and also controls cell proliferation and cell death.  In contrast, eEF1A2 protein favors oncogenesis as shown by the fact that overexpression of eEF1A2 leads to cellular transformation and gives rise to tumors in nude mice.  The eEF1A2 protein stimulates the phospholipid signaling and activates the Akt-dependent cell migration and actin remodeling that ultimately favors tumorigenesis.  In contrast, inactivation of eEF1A proteins leads to immunodeficiency, neural and muscular defects, and favors apoptosis.  Finally, eEF1A proteins interact with several viral proteins resulting in enhanced viral replication, decreased apoptosis, and increased cellular transformation.  This review summarizes the recent findings on eEF1A proteins indicating that eEF1A proteins play a critical role in numerous human diseases through enhancement of oncogenesis, blockade of apoptosis, and increased viral pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSp9TlOziNGFg8IxFYvehhofW6udTcc2eacabVNn2u027ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjntlGrug%253D%253D&md5=46d3ba2d08d5b663601d93d52050c4fc</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2015.00075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2015.00075%26sid%3Dliteratum%253Aachs%26aulast%3DAbbas%26aufirst%3DW.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DHerbein%26aufirst%3DG.%26atitle%3DThe%2520eEF1A%2520Proteins%253A%2520At%2520the%2520Crossroads%2520of%2520Oncogenesis%252C%2520Apoptosis%252C%2520and%2520Viral%2520Infections%26jtitle%3DFront.%2520Oncol.%26date%3D2015%26volume%3D5%26spage%3D75%26doi%3D10.3389%2Ffonc.2015.00075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiumi, T.</span></span> <span> </span><span class="NLM_article-title">Switch of the Interactions between the Ribosomal Stalk and EF1A in the GTP- and GDP-Bound Conformations</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">14761</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-51266-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41598-019-51266-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31611569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BB3Mnnslyjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=14761&author=K.+Maruyamaauthor=H.+Imaiauthor=M.+Kawamuraauthor=S.+Ishinoauthor=Y.+Ishinoauthor=K.+Itoauthor=T.+Uchiumi&title=Switch+of+the+Interactions+between+the+Ribosomal+Stalk+and+EF1A+in+the+GTP-+and+GDP-Bound+Conformations&doi=10.1038%2Fs41598-019-51266-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Switch of the interactions between the ribosomal stalk and EF1A in the GTP- and GDP-bound conformations</span></div><div class="casAuthors">Maruyama Kei; Imai Hirotatsu; Kawamura Momoko; Ito Kosuke; Uchiumi Toshio; Ishino Sonoko; Ishino Yoshizumi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14761</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Translation elongation factor EF1A delivers aminoacyl-tRNA to the ribosome in a GTP-bound form, and is released from the ribosome in a GDP-bound form.  This association/dissociation cycle proceeds efficiently via a marked conformational change in EF1A.  EF1A function is dependent on the ribosomal "stalk" protein of the ribosomal large subunit, although the precise mechanism of action of the stalk on EF1A remains unclear.  Here, we clarify the binding mode of archaeal stalk aP1 to GTP-bound aEF1A associated with aPelota.  Intriguingly, the C-terminal domain (CTD) of aP1 binds to aEF1A•GTP with a similar affinity to aEF1A•GDP.  We have also determined the crystal structure of the aP1-CTD•aEF1A•GTP•aPelota complex at 3.0 ÅA resolution.  The structure shows that aP1-CTD binds to a space between domains 1 and 3 of aEF1A.  Biochemical analyses show that this binding is crucial for protein synthesis.  Comparison of the structures of aP1-CTD•aEF1A•GTP and aP1-CTD•aEF1A•GDP demonstrates that the binding mode of aP1 changes markedly upon a conformational switch between the GTP- and GDP-bound forms of aEF1A.  Taking into account biochemical data, we infer that aP1 employs its structural flexibility to bind to aEF1A before and after GTP hydrolysis for efficient protein synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTV1yIRsIeDmRgd2Wuil24tfW6udTcc2eacabVNn2u027ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mnnslyjsw%253D%253D&md5=e4b3dafd72d99fd8350e88b5622e134a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-51266-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-51266-x%26sid%3Dliteratum%253Aachs%26aulast%3DMaruyama%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DH.%26aulast%3DKawamura%26aufirst%3DM.%26aulast%3DIshino%26aufirst%3DS.%26aulast%3DIshino%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DUchiumi%26aufirst%3DT.%26atitle%3DSwitch%2520of%2520the%2520Interactions%2520between%2520the%2520Ribosomal%2520Stalk%2520and%2520EF1A%2520in%2520the%2520GTP-%2520and%2520GDP-Bound%2520Conformations%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D14761%26doi%3D10.1038%2Fs41598-019-51266-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Condeelis, J.</span></span> <span> </span><span class="NLM_article-title">Elongation Factor 1α, Translation and the Cytoskeleton</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/S0968-0004(00)88998-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2FS0968-0004%2800%2988998-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=7610475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK2MXlslGnsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1995&pages=169-170&author=J.+Condeelis&title=Elongation+Factor+1%CE%B1%2C+Translation+and+the+Cytoskeleton&doi=10.1016%2FS0968-0004%2800%2988998-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Elongation factor 1α, translation and the cytoskeleton</span></div><div class="casAuthors">Condeelis, John</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">169-70</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 29 refs.  Topics discussed include: EF1α assocn. with cytoskeleton; compartmentalization of protein formation in cytoplasm; and regulation and assembly of cytoskeletal compartments by EF1α.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOTAblwkTHxLVg90H21EOLACvtfcHk0lhMyz0LZytW_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXlslGnsrg%253D&md5=614af730c13c7fa12a226a22d38a60e6</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2FS0968-0004%2800%2988998-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0004%252800%252988998-7%26sid%3Dliteratum%253Aachs%26aulast%3DCondeelis%26aufirst%3DJ.%26atitle%3DElongation%2520Factor%25201%25CE%25B1%252C%2520Translation%2520and%2520the%2520Cytoskeleton%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1995%26volume%3D20%26spage%3D169%26epage%3D170%26doi%3D10.1016%2FS0968-0004%2800%2988998-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traugh, J. A.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of Elongation Factor 1 (EF-1) by Protein Kinase C Stimulates GDP/GTP-Exchange Activity</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">550</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1995.550_b.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1111%2Fj.1432-1033.1995.550_b.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=8536702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVSktbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=1995&pages=550-556&author=H.+I.+Petersauthor=Y.+E.+Changauthor=J.+A.+Traugh&title=Phosphorylation+of+Elongation+Factor+1+%28EF-1%29+by+Protein+Kinase+C+Stimulates+GDP%2FGTP-Exchange+Activity&doi=10.1111%2Fj.1432-1033.1995.550_b.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of elongation factor 1 (EF-1) by protein kinase C stimulates GDP/GTP-exchange activity</span></div><div class="casAuthors">Peters, Holme I.; Chang, Yu-Wen; Traugh, Jolinda A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">550-6</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Phosphorylation of the α, β, and δ subunits of EF-1 by protein kinase C (PKC) was previously shown to result in stimulation of elongation activity up to 3-fold both in vivo and in vitro.  The α subunit catalyzes the GTP-dependent binding of amino-acyl-tRNA to the ribosome, whereas the βγ and δ subunits of EF-1 catalyze exchange of the residual GDP on EF-1α for GTP.  To det. whether the change in elongation rate following phosphorylation by PKC is due to stimulation of GDP/GTP exchange activity, EF-1 and EF-1·valyl-tRNA-synthetase were purified from rabbit reticulocytes, phosphorylated in vitro by PKC, and the effect of phosphorylation on nucleotide-exchange activity analyzed.  It was found that the α, β, and δ subunits were phosphorylated only on Ser, and phosphopeptide maps showed distinct phosphopeptides for each subunit.  Following quant. phosphorylation of EF-1 by PKC on the α, β, and δ subunits, a 2-fold enhancement of the rate of nucleotide exchange over the nonphosphorylated controls was obsd. with EF-1 and EF-1·valyl-tRNA synthetase.  Stimulation of nucleotide exchange resulted in a 2-fold increase in the formation of EF-1α·GTP·Phe-tRNA, leading to an increased rate of binding of Phe-tRNA to ribosomes.  The magnitude of stimulation of the exchange rate was similar to that reported previously for the rate of elongation following phosphorylation of EF-1 by PKC.  Thus, the enhancement of EF-1 activity in response to 4β-phorbol 12-myristate 13-acetate appears to be due to stimulation of the rate of GDP/GTP exchange following phosphorylation of EF-1 by PKC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjJpx1oLPlu7Vg90H21EOLACvtfcHk0lhD9C7oFBAJ6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVSktbbM&md5=d539311bf073cd9b9ba3133d9c4a65a1</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1995.550_b.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1995.550_b.x%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DH.%2BI.%26aulast%3DChang%26aufirst%3DY.%2BE.%26aulast%3DTraugh%26aufirst%3DJ.%2BA.%26atitle%3DPhosphorylation%2520of%2520Elongation%2520Factor%25201%2520%2528EF-1%2529%2520by%2520Protein%2520Kinase%2520C%2520Stimulates%2520GDP%252FGTP-Exchange%2520Activity%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1995%26volume%3D234%26spage%3D550%26epage%3D556%26doi%3D10.1111%2Fj.1432-1033.1995.550_b.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosutti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalaja, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanconati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dapas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passamonti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaggiante, B.</span></span> <span> </span><span class="NLM_article-title">A Rapid and Specific Method to Simultaneously Quantify Eukaryotic Elongation Factor 1A1 and A2 Protein Levels in Cancer Cells</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">112814</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2019.112814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.jpba.2019.112814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31450069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1yht7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=112814&author=A.+Bosuttiauthor=O.+Kalajaauthor=F.+Zanconatiauthor=B.+Dapasauthor=G.+Grassiauthor=S.+Passamontiauthor=B.+Scaggiante&title=A+Rapid+and+Specific+Method+to+Simultaneously+Quantify+Eukaryotic+Elongation+Factor+1A1+and+A2+Protein+Levels+in+Cancer+Cells&doi=10.1016%2Fj.jpba.2019.112814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid and specific method to simultaneously quantify eukaryotic elongation factor 1A1 and A2 protein levels in cancer cells</span></div><div class="casAuthors">Bosutti, Alessandra; Kalaja, Odeta; Zanconati, Fabrizio; Dapas, Barbara; Grassi, Gabriele; Passamonti, Sabina; Scaggiante, Bruna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112814</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The two isoforms of the eukaryotic Elongation Factor 1A (eEF1A1 and eEF1A2), sustain the progression/aggressiveness of cancer cells.  Thus, they are considered promising therapeutic targets and prognostic markers.  It follows that their precise quantification is of utmost relevance in research and development.  The simultaneous quantification of A1 and A2 proteins in the cells helps the comprehension of cancer biol. mechanisms and response to drug treatments.  However, the high homol. at the amino-acidic level (92%) can cause antibodies cross-reaction.  Moreover, the commonly employed western blotting just gives semi-quant. data and does not allow the detection of both protein targets within the same cell.  Thus, we developed an in cell western (ICW) technique to bypass the above limitations.  Firstly, relevant antibodies cross-reaction was excluded by immunohistochem. on normal pancreatic tissue; then eEF1A1-A2 protein levels were quantitated by ICW in prostate and colorectal cancer cell lines in 96 well plates under different conditions, which include: 1) drug treatment, 2) siRNA silencing, 3) cell seeding d.  We show that: 1) eEF1A1-A2 levels vary depending on the cell type following drug treatment, 2) ICW can accurately detect eEF1A1-A2 protein levels following siRNA silencing, 3) cell seeding d. influences eEF1A1-A2 levels, depending on cell type.  ICW is a valuable tool to specifically det. the intracellular level of eEF1A1-A2 proteins thus contributing to better define their role as potential therapeutic targets and prognostic markers in human tumors as well as for drug effects screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSxqfbA0Jf6rVg90H21EOLACvtfcHk0lhD9C7oFBAJ6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1yht7nM&md5=23b49f89e1d94438173a1223140afb4a</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2019.112814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2019.112814%26sid%3Dliteratum%253Aachs%26aulast%3DBosutti%26aufirst%3DA.%26aulast%3DKalaja%26aufirst%3DO.%26aulast%3DZanconati%26aufirst%3DF.%26aulast%3DDapas%26aufirst%3DB.%26aulast%3DGrassi%26aufirst%3DG.%26aulast%3DPassamonti%26aufirst%3DS.%26aulast%3DScaggiante%26aufirst%3DB.%26atitle%3DA%2520Rapid%2520and%2520Specific%2520Method%2520to%2520Simultaneously%2520Quantify%2520Eukaryotic%2520Elongation%2520Factor%25201A1%2520and%2520A2%2520Protein%2520Levels%2520in%2520Cancer%2520Cells%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2019%26volume%3D176%26spage%3D112814%26doi%3D10.1016%2Fj.jpba.2019.112814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. yi</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J. P.</span></span> <span> </span><span class="NLM_article-title">eEF1A1 Overexpression Enhances Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma</span>. <i>Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2017.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.tranon.2017.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=29248802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzit12ltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=125-131&author=S.+L.+Chenauthor=S.+X.+Luauthor=L.+L.+Liuauthor=C.+H.+Wangauthor=X.+Yangauthor=Z.+yi+Zhangauthor=H.+Z.+Zhangauthor=J.+P.+Yun&title=eEF1A1+Overexpression+Enhances+Tumor+Progression+and+Indicates+Poor+Prognosis+in+Hepatocellular+Carcinoma&doi=10.1016%2Fj.tranon.2017.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">eEF1A1 Overexpression Enhances Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma</span></div><div class="casAuthors">Chen Shi-Lu; Lu Shi-Xun; Liu Li-Li; Wang Chun-Hua; Yang Xia; Zhang Zhi-Yi; Zhang Hui-Zhong; Yun Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-131</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">Liver is a major contributor of protein production physiologically.  The aberrant state of protein synthesis leads to tumor progression.  Eukaryotic elongation factor 1 alpha 1 (eEF1A1) is a major member of the eukaryotic elongation factor family that regulates protein synthesis.  Although eEF1A1 plays an essential role in controlling the cell fate, its clinical significance in tumor development and progression has not been reported.  Here, we aimed to uncover the expression and prognostic significance of eEF1A1 in hepatocellular carcinoma (HCC).  Our data indicated that eEF1A1 expression was elevated in HCC cell lines and clinical samples at both the mRNA and protein levels.  Immunohistochemistry revealed that eEF1A1 expression was upregulated in HCC samples compared with corresponding non-tumorous tissues.  In 50 HCC cases with portal vein embolus, higher eEF1A1 immunoreactivity was detected in tumor metastases compared with the primary lesions.  Kaplan-Meier analysis indicated that increased eEF1A1 expression was closely associated with unfavorable post-surgical overall and disease-free survival in 453 HCC patients.  Moreover, multivariate analysis indicated eEF1A1 as an independent predictor for overall and disease-free survival.  Collectively, our study suggests eEF1A1 as a novel prognostic biomarker and potential therapeutic target for HCC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQao6HF1EqhjTQLBVDQn4bCfW6udTcc2eZzRCpiX5xDbLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzit12ltg%253D%253D&md5=2aba6588f8f9f1b9a0b7518f5cf3d422</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2017.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2017.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%2BL.%26aulast%3DLu%26aufirst%3DS.%2BX.%26aulast%3DLiu%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DC.%2BH.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%2Byi%26aulast%3DZhang%26aufirst%3DH.%2BZ.%26aulast%3DYun%26aufirst%3DJ.%2BP.%26atitle%3DeEF1A1%2520Overexpression%2520Enhances%2520Tumor%2520Progression%2520and%2520Indicates%2520Poor%2520Prognosis%2520in%2520Hepatocellular%2520Carcinoma%26jtitle%3DTransl.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D125%26epage%3D131%26doi%3D10.1016%2Fj.tranon.2017.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricker, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlow, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgopapadakos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huelskamp, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhimolea, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramkissoon, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spunt, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinski, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, C.</span></span> <span> </span><span class="NLM_article-title">Undifferentiated Small Round Cell Sarcoma in a Young Male: A Case Report</span>. <i>Cold Spring Harb. Mol. Case Stud.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">a004812</span>, <span class="refDoi"> DOI: 10.1101/mcs.a004812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1101%2Fmcs.a004812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=32014859" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=a004812&author=C.+A.+Rickerauthor=N.+E.+Berlowauthor=K.+A.+Crawfordauthor=T.+Georgopapadakosauthor=A.+N.+Huelskampauthor=A.+D.+Woodsauthor=E.+Dhimoleaauthor=S.+H.+Ramkissoonauthor=S.+L.+Spuntauthor=E.+R.+Rudzinskiauthor=C.+Keller&title=Undifferentiated+Small+Round+Cell+Sarcoma+in+a+Young+Male%3A+A+Case+Report&doi=10.1101%2Fmcs.a004812"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1101%2Fmcs.a004812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fmcs.a004812%26sid%3Dliteratum%253Aachs%26aulast%3DRicker%26aufirst%3DC.%2BA.%26aulast%3DBerlow%26aufirst%3DN.%2BE.%26aulast%3DCrawford%26aufirst%3DK.%2BA.%26aulast%3DGeorgopapadakos%26aufirst%3DT.%26aulast%3DHuelskamp%26aufirst%3DA.%2BN.%26aulast%3DWoods%26aufirst%3DA.%2BD.%26aulast%3DDhimolea%26aufirst%3DE.%26aulast%3DRamkissoon%26aufirst%3DS.%2BH.%26aulast%3DSpunt%26aufirst%3DS.%2BL.%26aulast%3DRudzinski%26aufirst%3DE.%2BR.%26aulast%3DKeller%26aufirst%3DC.%26atitle%3DUndifferentiated%2520Small%2520Round%2520Cell%2520Sarcoma%2520in%2520a%2520Young%2520Male%253A%2520A%2520Case%2520Report%26jtitle%3DCold%2520Spring%2520Harb.%2520Mol.%2520Case%2520Stud.%26date%3D2020%26volume%3D6%26spage%3Da004812%26doi%3D10.1101%2Fmcs.a004812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span> <span> </span><span class="NLM_article-title">EF1A Interacting with Nucleocapsid Protein of Transmissible Gastroenteritis Coronavirus and Plays a Role in Virus Replication</span>. <i>Vet. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1016/j.vetmic.2014.05.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.vetmic.2014.05.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24974120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSrur7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2014&pages=443-448&author=X.+Zhangauthor=H.+Shiauthor=J.+Chenauthor=D.+Shiauthor=C.+Liauthor=L.+Feng&title=EF1A+Interacting+with+Nucleocapsid+Protein+of+Transmissible+Gastroenteritis+Coronavirus+and+Plays+a+Role+in+Virus+Replication&doi=10.1016%2Fj.vetmic.2014.05.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">EF1A interacting with nucleocapsid protein of transmissible gastroenteritis coronavirus and plays a role in virus replication</span></div><div class="casAuthors">Zhang, Xin; Shi, Hongyan; Chen, Jianfei; Shi, Da; Li, Changlong; Feng, Li</div><div class="citationInfo"><span class="NLM_cas:title">Veterinary Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">443-448</span>CODEN:
                <span class="NLM_cas:coden">VMICDQ</span>;
        ISSN:<span class="NLM_cas:issn">0378-1135</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Transmissible gastroenteritis coronavirus (TGEV) is an enteropathogenic coronavirus that causes diarrhea in pigs, which is correlated with high morbidity and mortality in suckling piglets.  Using the method of GST pull-down with the nucleocapsid (N), N protein was found to interact with swine testes (ST) cells elongation factor 1-alpha (EF1A), an essential component of the translational machinery with an important role in cells.  In vitro and in virus-infected cells interaction was then confirmed by co-pptn.  Knockdown of EF1A impairs N protein proliferation and TGEV replication in host cell.  It was demonstrated that EF1A plays a role in TGEV replication.  The present study thus provides a protein-related information that should be useful for underlying mechanism of coronavirus replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIT0u6ror6V7Vg90H21EOLACvtfcHk0lj0R_TibkkKbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSrur7F&md5=ffa683e84e6636ffb3159869687008ab</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.vetmic.2014.05.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vetmic.2014.05.034%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DL.%26atitle%3DEF1A%2520Interacting%2520with%2520Nucleocapsid%2520Protein%2520of%2520Transmissible%2520Gastroenteritis%2520Coronavirus%2520and%2520Plays%2520a%2520Role%2520in%2520Virus%2520Replication%26jtitle%3DVet.%2520Microbiol.%26date%3D2014%26volume%3D172%26spage%3D443%26epage%3D448%26doi%3D10.1016%2Fj.vetmic.2014.05.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span> <span> </span><span class="NLM_article-title">The Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus Inhibits Cell Cytokinesis and Proliferation by Interacting with Translation Elongation Factor 1α</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">6962</span>– <span class="NLM_lpage">6971</span>, <span class="refDoi"> DOI: 10.1128/JVI.00133-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1128%2FJVI.00133-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18448518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFWmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=6962-6971&author=B.+Zhouauthor=J.+Liuauthor=Q.+Wangauthor=X.+Liuauthor=X.+Liauthor=P.+Liauthor=Q.+Maauthor=C.+Cao&title=The+Nucleocapsid+Protein+of+Severe+Acute+Respiratory+Syndrome+Coronavirus+Inhibits+Cell+Cytokinesis+and+Proliferation+by+Interacting+with+Translation+Elongation+Factor+1%CE%B1&doi=10.1128%2FJVI.00133-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">The nucleocapsid protein of severe acute respiratory syndrome coronavirus inhibits cell cytokinesis and proliferation by interacting with translation elongation factor 1α</span></div><div class="casAuthors">Zhou, Bing; Liu, Junli; Wang, Qiuna; Liu, Xuan; Li, Xiaorong; Li, Ping; Ma, Qingjun; Cao, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6962-6971</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome coronavirus (SARS-CoV) is the etiol. agent of SARS, an emerging disease characterized by atypical pneumonia.  Using a yeast two-hybrid screen with the nucleocapsid (N) protein of SARS-CoV as a bait, the C terminus (amino acids 251 to 422) of the N protein was found to interact with human elongation factor 1-alpha (EF1α), an essential component of the translational machinery with an important role in cytokinesis, promoting the bundling of filamentous actin (F-actin).  In vitro and in vivo interaction was then confirmed by immuno-copptn., far-Western blotting, and surface plasmon resonance.  It was demonstrated that the N protein of SARS-CoV induces aggregation of EF1α, inhibiting protein translation and cytokinesis by blocking F-actin bundling.  Proliferation of human peripheral blood lymphocytes and other human cell lines was significantly inhibited by the infection of recombinant retrovirus expressing SARS-CoV N protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiIRScJzm6N7Vg90H21EOLACvtfcHk0lj0R_TibkkKbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFWmsrw%253D&md5=322cf5b99c4e94f8ee12ad998374809b</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1128%2FJVI.00133-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00133-08%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DCao%26aufirst%3DC.%26atitle%3DThe%2520Nucleocapsid%2520Protein%2520of%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%2520Inhibits%2520Cell%2520Cytokinesis%2520and%2520Proliferation%2520by%2520Interacting%2520with%2520Translation%2520Elongation%2520Factor%25201%25CE%25B1%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D6962%26epage%3D6971%26doi%3D10.1128%2FJVI.00133-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rinehart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renis, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swynenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringfellow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuentzel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Didemnins: Antiviral and Antitumor Depsipeptides from a Caribbean Tunicate</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">933</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1126/science.7233187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1126%2Fscience.7233187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=7233187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaL3MXktlGmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=1981&pages=933-935&author=K.+Rinehartauthor=J.+Gloerauthor=R.+Hughesauthor=H.+Renisauthor=J.+McGovrenauthor=E.+Swynenbergauthor=D.+Stringfellowauthor=S.+Kuentzelauthor=L.+Li&title=Didemnins%3A+Antiviral+and+Antitumor+Depsipeptides+from+a+Caribbean+Tunicate&doi=10.1126%2Fscience.7233187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Didemnins:  antiviral and antitumor depsipeptides from a Caribbean tunicate</span></div><div class="casAuthors">Rinehart, Kenneth L., Jr.; Gloer, James B.; Hughes, Robert G., Jr.; Renis, Harold E.; McGovren, J. Patrick; Swynenberg, Everett B.; Stringfellow, Dale A.; Kuentzel, Sandra L.; Li, Li H.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">4497</span>),
    <span class="NLM_cas:pages">933-5</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Exts. of samples of a Caribbean tunicate (ascidian, sea squirt) of the family Didemnidae inhibit in vitro at low concns. the growth of DNA and RNA viruses as well as L1210 leukemic cells.  The active compds. isolated from the tunicate are didemnin A (I; R = H)  [77327-04-9] didemnin B  [77327-05-0], and didemnin C  [77327-06-1].  Didemnin B (a deriv. of didemnin A) is the component active at the lowest concn. in inhibiting viral replication in vitro and P388 leukemia in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxvIkMzkxqELVg90H21EOLACvtfcHk0lhzJoAtm6AuAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXktlGmsLw%253D&md5=8b8ac5f276e3906db1343344c2b7129c</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1126%2Fscience.7233187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.7233187%26sid%3Dliteratum%253Aachs%26aulast%3DRinehart%26aufirst%3DK.%26aulast%3DGloer%26aufirst%3DJ.%26aulast%3DHughes%26aufirst%3DR.%26aulast%3DRenis%26aufirst%3DH.%26aulast%3DMcGovren%26aufirst%3DJ.%26aulast%3DSwynenberg%26aufirst%3DE.%26aulast%3DStringfellow%26aufirst%3DD.%26aulast%3DKuentzel%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26atitle%3DDidemnins%253A%2520Antiviral%2520and%2520Antitumor%2520Depsipeptides%2520from%2520a%2520Caribbean%2520Tunicate%26jtitle%3DScience%26date%3D1981%26volume%3D212%26spage%3D933%26epage%3D935%26doi%3D10.1126%2Fscience.7233187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urdiales, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morata, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Castro, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Jiménez, F.</span></span> <span> </span><span class="NLM_article-title">Antiproliferative Effect of Dehydrodidemnin B (DDB), a Depsipeptide Isolated from Mediterranean Tunicates</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/0304-3835(96)04151-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2F0304-3835%2896%2904151-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=8603376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK28Xhslejurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1996&pages=31-37&author=J.+L.+Urdialesauthor=P.+Morataauthor=I.+N.+De+Castroauthor=F.+S%C3%A1nchez-Jim%C3%A9nez&title=Antiproliferative+Effect+of+Dehydrodidemnin+B+%28DDB%29%2C+a+Depsipeptide+Isolated+from+Mediterranean+Tunicates&doi=10.1016%2F0304-3835%2896%2904151-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates</span></div><div class="casAuthors">Urdiales, Jose L.; Morata, Pilar; Nunez De Castro, Ignacio; Sanchez-Jimenez, Francisca</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">31-7</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The biol. effects of dehydrodidemnin B (DDB), a novel depsipeptide isolated from Aplidium albicans, were studied on Ehrlich carcinoma growing in vivo and in primary cultures, and compared with those reported for Didemnin B (DB).  Daily administration of DB or DDB (2.5 μg/mouse) almost duplicated the animal life-span and total no. of tumor cells decreased by 70-90%.  Results suggest a major effect of DDB when administered in the lag phase of growth.  DDB behaved as a very potent inhibitor of protein synthesis; consequently, ornithine decarboxylase activity (ODC, EC 4.1.1.17) is drastically reduced by the DDB-treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfkvs5GBkoS7Vg90H21EOLACvtfcHk0lhzJoAtm6AuAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xhslejurc%253D&md5=e8b33a94cc19d5036368d2ead4ff8556</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2F0304-3835%2896%2904151-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3835%252896%252904151-1%26sid%3Dliteratum%253Aachs%26aulast%3DUrdiales%26aufirst%3DJ.%2BL.%26aulast%3DMorata%26aufirst%3DP.%26aulast%3DDe%2BCastro%26aufirst%3DI.%2BN.%26aulast%3DS%25C3%25A1nchez-Jim%25C3%25A9nez%26aufirst%3DF.%26atitle%3DAntiproliferative%2520Effect%2520of%2520Dehydrodidemnin%2520B%2520%2528DDB%2529%252C%2520a%2520Depsipeptide%2520Isolated%2520from%2520Mediterranean%2520Tunicates%26jtitle%3DCancer%2520Lett.%26date%3D1996%26volume%3D102%26spage%3D31%26epage%3D37%26doi%3D10.1016%2F0304-3835%2896%2904151-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmins, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prairie, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, W. B.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Action of Didemnin B, a Depsipeptide from the Sea</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1016/0304-3835(84)90095-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2F0304-3835%2884%2990095-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=6744252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaL2cXlsVeksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1984&pages=279-288&author=L.+H.+Liauthor=L.+G.+Timminsauthor=T.+L.+Wallaceauthor=W.+C.+Kruegerauthor=M.+D.+Prairieauthor=W.+B.+Im&title=Mechanism+of+Action+of+Didemnin+B%2C+a+Depsipeptide+from+the+Sea&doi=10.1016%2F0304-3835%2884%2990095-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of didemnin B, a depsipeptide from the sea</span></div><div class="casAuthors">Li, Li H.; Timmins, Laura G.; Wallace, Tanya L.; Krueger, William C.; Prairie, Mark D.; Im, Wha B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">279-88</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    </div><div class="casAbstract">With the brush border membrane vesicles prepd. from the rat kidney cortex, didemnin B  [77327-05-0] and its parent compd., didemnin A  [77327-04-9] function neither as a K+-specific ionophore nor as an ionophore for Na+ ions while other depsipeptide antibiotics such as valinomycin and gramicidin promote transmembrane movement of K+ and Na+ ions, resp.  Didemnin B inhibits protein synthesis and DNA synthesis much more than RNA synthesis and is in general more potent than didemnin A.  Time course studies reveal that the action of didemnin B is rapid and cannot be reversed after 2 h in contact with the cells.  The inhibition of protein synthesis is almost superimposable to that of L1210 cells growth.  DNA synthesis is also markedly inhibited.  These results collectively suggest that didemnin B acts differently, at least in part, from other depsipeptide antibiotics and its biol. effect is primarily mediated through its inhibition of protein synthesis and to a lesser extent its inhibition of DNA synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0v0XlDSZJHrVg90H21EOLACvtfcHk0lhzJoAtm6AuAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXlsVeksrs%253D&md5=631b48381517473de6adc6cceccf444f</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2F0304-3835%2884%2990095-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3835%252884%252990095-8%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%2BH.%26aulast%3DTimmins%26aufirst%3DL.%2BG.%26aulast%3DWallace%26aufirst%3DT.%2BL.%26aulast%3DKrueger%26aufirst%3DW.%2BC.%26aulast%3DPrairie%26aufirst%3DM.%2BD.%26aulast%3DIm%26aufirst%3DW.%2BB.%26atitle%3DMechanism%2520of%2520Action%2520of%2520Didemnin%2520B%252C%2520a%2520Depsipeptide%2520from%2520the%2520Sea%26jtitle%3DCancer%2520Lett.%26date%3D1984%26volume%3D23%26spage%3D279%26epage%3D288%26doi%3D10.1016%2F0304-3835%2884%2990095-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snapper, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">GTP-Dependent Binding of the Antiproliferative Agent Didemnin to Elongation Factor 1α</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">15411</span>– <span class="NLM_lpage">15414</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(17)40692-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2FS0021-9258%2817%2940692-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=8195179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK2cXkvF2htr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=15411-15414&author=C.+M.+Crewsauthor=J.+L.+Collinsauthor=W.+S.+Laneauthor=M.+L.+Snapperauthor=S.+L.+Schreiber&title=GTP-Dependent+Binding+of+the+Antiproliferative+Agent+Didemnin+to+Elongation+Factor+1%CE%B1&doi=10.1016%2FS0021-9258%2817%2940692-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1α</span></div><div class="casAuthors">Crews, Craig M.; Collins, Jon L.; Lane, William S.; Snapper, Marc L.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">15411-14</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The marine natural product, didemnin B, is a 7-amino acid, cyclic depsipeptide that inhibits G1 cell cycle progression at nanomolar concns. by undefined mechanisms.  It has been reported to exhibit immunosuppressive activities in animals and is undergoing clin. trials as a potential antineoplastic drug.  In addn., at higher concns., didemnin B has been shown to inhibit in vivo and in vitro protein synthesis.  However, the mechanisms by which inhibition is achieved are unknown.  To investigate didemnin's various modes of action, an affinity column was synthesized and used to purify didemnin-binding proteins.  The major retained protein was the 49-kDa guanine nucleotide-binding elongation factor, EF-1α, which was identified by peptide sequence anal.  Moreover, didemnin binds EF-1α only in the presence of GTP but does not inhibit the GTPase activity of EF-1α.  Therefore, EF-1α is likely to be the intracellular target responsible for didemnin B's ability to inhibit protein synthesis.  Furthermore, this specificity of didemnin affinity for the GTP-bound conformation of a guanine nucleotide-binding protein with homol. to the Ras superfamily suggests a possible mode of action for didemnin's antiproliferative activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZGve7U4AtzrVg90H21EOLACvtfcHk0li8i7k7n6DQdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkvF2htr4%253D&md5=cc1202a47982a21397c04ecab1f4e252</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2817%2940692-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252817%252940692-2%26sid%3Dliteratum%253Aachs%26aulast%3DCrews%26aufirst%3DC.%2BM.%26aulast%3DCollins%26aufirst%3DJ.%2BL.%26aulast%3DLane%26aufirst%3DW.%2BS.%26aulast%3DSnapper%26aufirst%3DM.%2BL.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DGTP-Dependent%2520Binding%2520of%2520the%2520Antiproliferative%2520Agent%2520Didemnin%2520to%2520Elongation%2520Factor%25201%25CE%25B1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D15411%26epage%3D15414%26doi%3D10.1016%2FS0021-9258%2817%2940692-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, R. S.</span></span> <span> </span><span class="NLM_article-title">Decoding Mammalian Ribosome-MRNA States by Translational GTPase Complexes</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1229</span>– <span class="NLM_lpage">1240</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.10.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.cell.2016.10.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27863242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWgu7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2016&pages=1229-1240&author=S.+Shaoauthor=J.+Murrayauthor=A.+Brownauthor=J.+Tauntonauthor=V.+Ramakrishnanauthor=R.+S.+Hegde&title=Decoding+Mammalian+Ribosome-MRNA+States+by+Translational+GTPase+Complexes&doi=10.1016%2Fj.cell.2016.10.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Decoding mammalian ribosome-mRNA states by translational GTPase complexes</span></div><div class="casAuthors">Shao, Sichen; Murray, Jason; Brown, Alan; Taunton, Jack; Ramakrishnan, V.; Hegde, Ramanujan S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1229-1240.e15</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">In eukaryotes, accurate protein synthesis relies on a family of translational GTPases that pair with specific decoding factors to decipher the mRNA code on ribosomes.  We present structures of the mammalian ribosome engaged with decoding factor·GTPase complexes representing intermediates of translation elongation (aminoacyl-tRNA·eEF1A), termination (eRF1·eRF3), and ribosome rescue (Pelota·Hbs1l).  Comparative analyses reveal that each decoding factor exploits the plasticity of the ribosomal decoding center to differentially remodel ribosomal proteins and rRNA.  This leads to varying degrees of large-scale ribosome movements and implies distinct mechanisms for communicating information from the decoding center to each GTPase.  Addnl. structural snapshots of the translation termination pathway reveal the conformational changes that choreograph the accommodation of decoding factors into the peptidyl transferase center.  Our results provide a structural framework for how different states of the mammalian ribosome are selectively recognized by the appropriate decoding factor·GTPase complex to ensure translational fidelity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGoP0I-nUEDLVg90H21EOLACvtfcHk0li8i7k7n6DQdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWgu7jF&md5=e1df1f764b28ab554532a0ad6b7228f9</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.10.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.10.046%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DTaunton%26aufirst%3DJ.%26aulast%3DRamakrishnan%26aufirst%3DV.%26aulast%3DHegde%26aufirst%3DR.%2BS.%26atitle%3DDecoding%2520Mammalian%2520Ribosome-MRNA%2520States%2520by%2520Translational%2520GTPase%2520Complexes%26jtitle%3DCell%26date%3D2016%26volume%3D167%26spage%3D1229%26epage%3D1240%26doi%3D10.1016%2Fj.cell.2016.10.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinehart, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faircloth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carney, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namikoshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grávalos, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Quesada, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heid, R. M.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships of the Didemnins</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2819</span>– <span class="NLM_lpage">2834</span>, <span class="refDoi"> DOI: 10.1021/jm960048g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960048g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK28XjsFKmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=2819-2834&author=R.+Sakaiauthor=K.+L.+Rinehartauthor=V.+Kishoreauthor=B.+Kunduauthor=G.+Fairclothauthor=J.+B.+Gloerauthor=J.+R.+Carneyauthor=M.+Namikoshiauthor=F.+Sunauthor=R.+G.+Hughesauthor=D.+G.+Gr%C3%A1valosauthor=T.+G.+De+Quesadaauthor=G.+R.+Wilsonauthor=R.+M.+Heid&title=Structure-Activity+Relationships+of+the+Didemnins&doi=10.1021%2Fjm960048g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships of the Didemnins</span></div><div class="casAuthors">Sakai, Ryuichi; Kishore, Vimal; Kundu, Bijoy; Faircloth, Glynn; Gloer, James B.; Carney, John R.; Namikoshi, Michio; Sun, Furong; Hughes, Robert G., Jr.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2819-2834</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bioactivities of 42 didemnin congeners, either isolated from the marine tunicates Trididemnun solidum and Aplidium albicans or prepd. synthetically and semisynthetically, were compared.  The growth inhibition of various murine and human tumor cells and plaque redn. of HSV-1 and VSV grown on cultured mammalian cells were used to assess cytotoxicity and antiviral activity.  Biochem. assays for macromol. synthesis (protein, DNA, and RNA) and enzyme inhibition (dihydrofolate reductase, thymidylate synthase, DNA polymerase, RNA polymerase, and topoisomerases I and II) were also performed to specify the mechanisms of action of each analog.  Immunosuppressant activity of the didemnins was detd. using a mixed lymphocyte reaction (MLR) assay.  These assays revealed that the native cyclic depsipeptide core is an essential structural requirement for most of the bioactivities of the didemnins, esp. for cytotoxicities and antiviral activities.  The linear side-chain portion of the peptide can be altered with a gain, in some cases, of bioactivities.  In particular, dehydrodidemnin B, tested against several types of tumor cells and in in vivo studies in mice, as well as didemnin M, tested for the mixed lymphocyte reaction and graft vs host reaction in murine systems, showed remarkable gains in their in vitro and in vivo activities compared to didemnin B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6st3hqZo37bVg90H21EOLACvtfcHk0li8i7k7n6DQdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsFKmurg%253D&md5=5585f7731c3c833f690bd3bb5a0fcfa9</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm960048g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960048g%26sid%3Dliteratum%253Aachs%26aulast%3DSakai%26aufirst%3DR.%26aulast%3DRinehart%26aufirst%3DK.%2BL.%26aulast%3DKishore%26aufirst%3DV.%26aulast%3DKundu%26aufirst%3DB.%26aulast%3DFaircloth%26aufirst%3DG.%26aulast%3DGloer%26aufirst%3DJ.%2BB.%26aulast%3DCarney%26aufirst%3DJ.%2BR.%26aulast%3DNamikoshi%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DR.%2BG.%26aulast%3DGr%25C3%25A1valos%26aufirst%3DD.%2BG.%26aulast%3DDe%2BQuesada%26aufirst%3DT.%2BG.%26aulast%3DWilson%26aufirst%3DG.%2BR.%26aulast%3DHeid%26aufirst%3DR.%2BM.%26atitle%3DStructure-Activity%2520Relationships%2520of%2520the%2520Didemnins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D2819%26epage%3D2834%26doi%3D10.1021%2Fjm960048g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crampton, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuentzel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badiner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhuyan, B. K.</span></span> <span> </span><span class="NLM_article-title">Biochemical and Cellular Effects of Didemnins A and B</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1796</span>– <span class="NLM_lpage">1801</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=6713383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaL2cXitVeht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1984&pages=1796-1801&author=S.+L.+Cramptonauthor=E.+G.+Adamsauthor=S.+L.+Kuentzelauthor=L.+H.+Liauthor=G.+Badinerauthor=B.+K.+Bhuyan&title=Biochemical+and+Cellular+Effects+of+Didemnins+A+and+B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and cellular effects of didemnins A and B</span></div><div class="casAuthors">Crampton, Sheri L.; Adams, Earl G.; Kuentzel, Sandra L.; Li, Li H.; Badiner, Gloria; Bhuyan, Bijoy K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1796-801</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Didemnin B  [77327-05-0] inhibited the in vitro growth of B16 > L1210 > V-79 cells = human foreskin fibroblast = 9L > Chinese hamster ovary cells.  Didemnin B was more lethal to exponentially growing B16 cells (50% LD for a 2-h exposure, 17.5 ng/mL) than to plateau-phase cells (50% LD for a 2-h exposure, 100 ng/mL).  After a 24-h exposure, the 50% LD for exponential- and plateau-phase B16 cells was 8.8 and 59.6 ng/mL, resp.  Chinese hamster ovary cells were not killed even at 25,000 ng/mL.  Mitotic cells were the least sensitive to didemnin B, and cells became more sensitive as they progressed into G1 and S phase.  However, since cells in all phases were killed, didemnin B cannot be considered a phase-specific agent.  Didemnin B inhibited the synthesis of protein more than that of DNA, with much less inhibition of RNA synthesis.  Cell progression studies showed that high doses (300 ng/mL for 2 h or 100 ng/mL for 24 h) of didemnin B "froze" the cells in their resp. phases with complete inhibition of cell progression or growth.  At low doses (10 ng/mL for 2 h or 3 ng/mL for 24 h), the cells were blocked at the G1-S border thereby increasing the percentage of G1 cells and decreasing the percentage of S-phase cells.  Cells continued to progress from S phase to G2 + M and from G2 + M to G1.  The cytotoxicity to different cell lines and inhibition of macromol. synthesis by didemnin A  [77327-04-9] is also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxplaEUYV0VbVg90H21EOLACvtfcHk0lhAfDnEdznQVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXitVeht7Y%253D&md5=5d88b14ff96960cca01f35035dc910c1</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCrampton%26aufirst%3DS.%2BL.%26aulast%3DAdams%26aufirst%3DE.%2BG.%26aulast%3DKuentzel%26aufirst%3DS.%2BL.%26aulast%3DLi%26aufirst%3DL.%2BH.%26aulast%3DBadiner%26aufirst%3DG.%26aulast%3DBhuyan%26aufirst%3DB.%2BK.%26atitle%3DBiochemical%2520and%2520Cellular%2520Effects%2520of%2520Didemnins%2520A%2520and%2520B%26jtitle%3DCancer%2520Res.%26date%3D1984%26volume%3D44%26spage%3D1796%26epage%3D1801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanjulu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vera, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SirDeshpande, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfizenmayer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abazeed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krosky, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beidler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joullié, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Protein Synthesis by Didemnins: Cell Potency and SAR</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4212</span>– <span class="NLM_lpage">4218</span>, <span class="refDoi"> DOI: 10.1021/jm000168v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000168v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1Ois7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4212-4218&author=D.+Ahujaauthor=A.+Geigerauthor=J.+M.+Ramanjuluauthor=M.+D.+Veraauthor=B.+SirDeshpandeauthor=A.+Pfizenmayerauthor=M.+Abazeedauthor=D.+J.+Kroskyauthor=D.+Beidlerauthor=M.+M.+Joulli%C3%A9author=P.+L.+Toogood&title=Inhibition+of+Protein+Synthesis+by+Didemnins%3A+Cell+Potency+and+SAR&doi=10.1021%2Fjm000168v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of protein synthesis by didemnins: cell potency and SAR</span></div><div class="casAuthors">Ahuja, Deepika; Geiger, Adam; Ramanjulu, Joshi M.; Vera, Matthew D.; Sir Deshpande, Bhagyashri; Pfizenmayer, Amy; Abazeed, Mohamed; Krosky, Daniel J.; Beidler, David; Joullie, Madeleine M.; Toogood, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4212-4218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthetic and naturally occurring didemnins are potent and specific inhibitors of protein synthesis in vitro.  Structure-activity anal. indicates a requirement for the intact macrocycle; however, the smaller ring size represented by the didemnin analog, tamandarin A, is equipotent to didemnin B.  Replacement of the N,O-dimethyltyrosine by a N-methylphenylalanine or N-methylleucine residue is also well-tolerated.  The rank order for inhibition of protein synthesis in vitro appears to be retained in MCF-7 cells, albeit at much higher potency.  This increase in potency is explained for the first time by data indicating that MCF-7 cells can accumulate didemnin B up to 2-3 orders of magnitude compared to the growth medium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrLN_VBE5ycLVg90H21EOLACvtfcHk0lhAfDnEdznQVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1Ois7c%253D&md5=ab6df5e2873ec2937eaffad9de24ab36</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Fjm000168v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000168v%26sid%3Dliteratum%253Aachs%26aulast%3DAhuja%26aufirst%3DD.%26aulast%3DGeiger%26aufirst%3DA.%26aulast%3DRamanjulu%26aufirst%3DJ.%2BM.%26aulast%3DVera%26aufirst%3DM.%2BD.%26aulast%3DSirDeshpande%26aufirst%3DB.%26aulast%3DPfizenmayer%26aufirst%3DA.%26aulast%3DAbazeed%26aufirst%3DM.%26aulast%3DKrosky%26aufirst%3DD.%2BJ.%26aulast%3DBeidler%26aufirst%3DD.%26aulast%3DJoulli%25C3%25A9%26aufirst%3DM.%2BM.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26atitle%3DInhibition%2520of%2520Protein%2520Synthesis%2520by%2520Didemnins%253A%2520Cell%2520Potency%2520and%2520SAR%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4212%26epage%3D4218%26doi%3D10.1021%2Fjm000168v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Raeve, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepage, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Valckenborgh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Camp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderkerken, K.</span></span> <span> </span><span class="NLM_article-title">Antitumour and Antiangiogenic Effects of Aplidin® in the 5TMM Syngeneic Models of Multiple Myeloma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1966</span>– <span class="NLM_lpage">1974</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6604388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fsj.bjc.6604388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18521088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvV2htLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=1966-1974&author=J.+Caersauthor=E.+Menuauthor=H.+De+Raeveauthor=D.+Lepageauthor=E.+Van+Valckenborghauthor=B.+Van+Campauthor=E.+Alvarezauthor=K.+Vanderkerken&title=Antitumour+and+Antiangiogenic+Effects+of+Aplidin%C2%AE+in+the+5TMM+Syngeneic+Models+of+Multiple+Myeloma&doi=10.1038%2Fsj.bjc.6604388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma</span></div><div class="casAuthors">Caers, J.; Menu, E.; De Raeve, H.; Lepage, D.; Van Valckenborgh, E.; Van Camp, B.; Alvarez, E.; Vanderkerken, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1966-1974</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aplidin is an antitumor drug, currently undergoing phase II evaluation in different haematol. and solid tumors.  In this study, we analyzed the antimyeloma effects of Aplidin in the syngeneic 5T33MM model, which is representable for the human disease.  In vitro, Aplidin inhibited 5T33MMvv DNA synthesis with an IC50 of 3.87 n.  On cell-cycle progression, the drug induced an arrest in transition from G0/G1 to S phase, while Western blot showed a decreased cyclin D1 and CDK4 expression.  Furthermore, Aplidin induced apoptosis by lowering the mitochondrial membrane potential, by inducing cytochrome c release and by activating caspase-9 and caspase-3.  For the in vivo expt., 5T33MM-injected C57Bl/KaLwRij mice were i.p. treated with vehicle or Aplidin (90 μg/kg-1 daily).  Chronic treatment with Aplidin was well tolerated and reduced serum paraprotein concn. by 42% (P<0.001), while BM invasion with myeloma cells was decreased by 35% (P<0.001).  Aplidin also reduced the myeloma-assocd. angiogenesis to basal values.  This antiangiogenic effect was confirmed in vitro and explained by inhibition of endothelial cell proliferation and vessel formation.  These data indicate that Aplidin is well tolerated in vivo and its antitumor and antiangiogenic effects support the use of the drug in multiple myeloma.  British Journal of Cancer (2008) 98, 1966-1974. doi:10.1038/sj.bjc.6604388 www.bjcancer.com Published online 3 June 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXSH4kqhxJC7Vg90H21EOLACvtfcHk0lhAfDnEdznQVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvV2htLw%253D&md5=73d2181640fc9d1e38fe2a8b0f546a3c</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604388%26sid%3Dliteratum%253Aachs%26aulast%3DCaers%26aufirst%3DJ.%26aulast%3DMenu%26aufirst%3DE.%26aulast%3DDe%2BRaeve%26aufirst%3DH.%26aulast%3DLepage%26aufirst%3DD.%26aulast%3DVan%2BValckenborgh%26aufirst%3DE.%26aulast%3DVan%2BCamp%26aufirst%3DB.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DVanderkerken%26aufirst%3DK.%26atitle%3DAntitumour%2520and%2520Antiangiogenic%2520Effects%2520of%2520Aplidin%25C2%25AE%2520in%2520the%25205TMM%2520Syngeneic%2520Models%2520of%2520Multiple%2520Myeloma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D1966%26epage%3D1974%26doi%3D10.1038%2Fsj.bjc.6604388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barboza, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budak-Alpdogan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aracil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertino, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, D.</span></span> <span> </span><span class="NLM_article-title">Plitidepsin (Aplidin) Is a Potent Inhibitor of Diffuse Large Cell and Burkitt Lymphoma and Is Synergistic with Rituximab</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.4161/cbt.13.2.18876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.4161%2Fcbt.13.2.18876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22336911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Oms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=114-122&author=N.+M.+Barbozaauthor=D.+J.+Medinaauthor=T.+Budak-Alpdoganauthor=M.+Aracilauthor=J.+M.+Jimenoauthor=J.+R.+Bertinoauthor=D.+Banerjee&title=Plitidepsin+%28Aplidin%29+Is+a+Potent+Inhibitor+of+Diffuse+Large+Cell+and+Burkitt+Lymphoma+and+Is+Synergistic+with+Rituximab&doi=10.4161%2Fcbt.13.2.18876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab</span></div><div class="casAuthors">Barboza, Nora M.; Medina, Daniel J.; Budak-Alpdogan, Tulin; Aracil, Miguel; Jimeno, Jose M.; Bertino, Joseph R.; Banerjee, Debabrata</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-122</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Plitidepsin (Aplidin), an antitumor agent of marine origin, presently is undergoing phase II/III clin. trials, and has shown promise for the treatment of lymphoma.  Here, we describe the antitumor effects of plitidepsin alone and in combination with rituximab and investigated the effects of each drug and the combination on the cell cycle and mechanism of cell death.  Several Diffuse Large Cell Lymphoma (DLCL) lines and Burkitt cell lines were tested for sensitivity to plitidepsin and rituximab.  All DLCL and Burkitt lymphoma cell lines were inhibited by plitidepsin in nanomolar concns., while rituximab sensitivity varied among different cell lines.  Ramos and the RL cell lines proved sensitive to rituximab and were used to test the effects of each of the two drugs.  The two agents exhibited synergism at all tested concns.  For in vivo studies, irradiated athymic nude mice were engrafted with the Ramos lymphoma.  Treatment was initiated when the tumors were ∼0.5 cm in diam., and toxic and therapeutic effects were monitored.  In the in vivo study, additive effects of the combined two drugs, was demonstrated without an increase in host toxicity.  The in vitro synergy and the in vivo additive antitumor effects without an increase in host toxicity with two relatively non-marrow suppressive agents encourages further development of this combination for treatment of aggressive B-cell lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCZkeiJGxBcbVg90H21EOLACvtfcHk0ljMGHpTVYob7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Oms7k%253D&md5=54d81693e1d711a84c08e4c2be4eff39</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.4161%2Fcbt.13.2.18876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.13.2.18876%26sid%3Dliteratum%253Aachs%26aulast%3DBarboza%26aufirst%3DN.%2BM.%26aulast%3DMedina%26aufirst%3DD.%2BJ.%26aulast%3DBudak-Alpdogan%26aufirst%3DT.%26aulast%3DAracil%26aufirst%3DM.%26aulast%3DJimeno%26aufirst%3DJ.%2BM.%26aulast%3DBertino%26aufirst%3DJ.%2BR.%26aulast%3DBanerjee%26aufirst%3DD.%26atitle%3DPlitidepsin%2520%2528Aplidin%2529%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520Diffuse%2520Large%2520Cell%2520and%2520Burkitt%2520Lymphoma%2520and%2520Is%2520Synergistic%2520with%2520Rituximab%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2012%26volume%3D13%26spage%3D114%26epage%3D122%26doi%3D10.4161%2Fcbt.13.2.18876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Álvarez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Nieto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballero, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateos, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, A.</span></span> <span> </span><span class="NLM_article-title">Plitidepsin: Design, Development, and Potential Place in Therapy</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S94165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.2147%2FDDDT.S94165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28176904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1CltL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=253-264&author=S.+Alonso-%C3%81lvarezauthor=E.+Pardalauthor=D.+S%C3%A1nchez-Nietoauthor=M.+Navarroauthor=M.+D.+Caballeroauthor=M.+V.+Mateosauthor=A.+Mart%C3%ADn&title=Plitidepsin%3A+Design%2C+Development%2C+and+Potential+Place+in+Therapy&doi=10.2147%2FDDDT.S94165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Plitidepsin: design, development, and potential place in therapy</span></div><div class="casAuthors">Alonso-Alvarez, Sara; Pardal, Emilia; Sanchez-Nieto, Diego; Navarro, Miguel; Caballero, Maria Dolores; Mateos, Maria Victoria; Martin, Alejandro</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">253-264</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Plitidepsin is a cyclic depsipeptide that was first isolated from a Mediterranean marine tunicate (Aplidium albicans) and, at present, is manufd. by total synthesis and commercialized as Aplidin.  Its antitumor activity, obsd. in preclin. in vitro and in vivo studies has prompted numerous clin. trials to be conducted over the last 17 years, alone or in combination with other anticancer agents.  Single-agent plitidepsin has shown limited antitumor activity and a tolerable safety profile in several malignancies, such as noncutaneous peripheral T-cell lymphoma, melanoma, and multiple myeloma.  In patients with relapsed or refractory multiple myeloma, plitidepsin activity seems to be enhanced after addn. of dexamethasone while remaining well tolerated, and a Phase III trial comparing plitidepsin plus dexamethasone vs dexamethasone alone is underway.  Addnl. studies are required to better define the role of plitidepsin in combination with other active agents in these indications.  Results of plitidepsin activity in other hematol. malignancies or solid tumors have been disappointing so far.  Further studies analyzing its mechanisms of action and potential biomarkers will help select patients who may benefit most from this drug.  In this review, we critically analyze the published studies on plitidepsin in hematol. malignancies and solid tumors and discuss its current role and future perspectives in treating these malignancies.  We also review its design, pharmaceutical data, and mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLQpZd8DLkQLVg90H21EOLACvtfcHk0ljMGHpTVYob7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1CltL3L&md5=205e3b73fd8e1c2a9cc85a6329d9a0e2</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S94165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S94165%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso-%25C3%2581lvarez%26aufirst%3DS.%26aulast%3DPardal%26aufirst%3DE.%26aulast%3DS%25C3%25A1nchez-Nieto%26aufirst%3DD.%26aulast%3DNavarro%26aufirst%3DM.%26aulast%3DCaballero%26aufirst%3DM.%2BD.%26aulast%3DMateos%26aufirst%3DM.%2BV.%26aulast%3DMart%25C3%25ADn%26aufirst%3DA.%26atitle%3DPlitidepsin%253A%2520Design%252C%2520Development%252C%2520and%2520Potential%2520Place%2520in%2520Therapy%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D253%26epage%3D264%26doi%3D10.2147%2FDDDT.S94165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faivre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chièze, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbaldo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ady-Vago, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Lazaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozahic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pico, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, E.</span></span> <span> </span><span class="NLM_article-title">Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients with Advanced Malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">7871</span>– <span class="NLM_lpage">7880</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.09.357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1200%2FJCO.2005.09.357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16172454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Cqs7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=7871-7880&author=S.+Faivreauthor=S.+Chi%C3%A8zeauthor=C.+Delbaldoauthor=N.+Ady-Vagoauthor=C.+Guzmanauthor=L.+Lopez-Lazaroauthor=S.+Lozahicauthor=J.+Jimenoauthor=F.+Picoauthor=J.+P.+Armandauthor=J.+A.+L.+Martinauthor=E.+Raymond&title=Phase+I+and+Pharmacokinetic+Study+of+Aplidine%2C+a+New+Marine+Cyclodepsipeptide+in+Patients+with+Advanced+Malignancies&doi=10.1200%2FJCO.2005.09.357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies</span></div><div class="casAuthors">Faivre, Sandrine; Chieze, Stephanie; Delbaldo, Catherine; Ady-vago, Nora; Guzman, Cecilia; Lopez-Lazaro, Luis; Lozahic, Stephanie; Jimeno, Jose; Pico, Fernando; Armand, Jean Pierre; Martin, Jose Antonio Lopez; Raymond, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">7871-7880</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To establish the safety, pharmacokinetic parameters, max.-tolerated dose, and recommended dose of aplidine, a novel marine cyclodepsipeptide, in patients with advanced cancer.  Patients and Methods: Using a modified Fibonacci method, we performed a phase I and pharmacokinetic study of aplidine administered as a 24-h i.v. infusion every 2 wk.  Results: Sixty-seven patients received aplidine at a dose ranging from 0.2 to 8 mg/m2.  Dose-limiting myotoxicity corresponding to grade 2 to 3 creatine phosphokinase elevation and grade 1 to 2 myalgia and muscle weakness occurred in two of six patients at 6 mg/m2.  No cardiac toxicity was obsd.  Electron microscopy anal. showed the disappearance of thick filaments of myosin.  Grade 3 muscle toxicity occurred in three of 14 patients at the recommended dose of 5 mg/m2 and seemed to be more readily reversible with oral carnitine (1 g/10 kg).  Therefore, dose escalation was resumed using carnitine prophylactically, allowing an increase in the recommended dose to 7 mg/m2.  Other toxicities were nausea and vomiting, diarrhea, asthenia, and transaminase elevation with mild hematol. toxicity.  Aplidine displayed a long half-life (21 to 44 h), low clearance (45 to 49 L/h), and a high vol. of distribution (1,036 to 1,124 L) with high interpatient variability in plasma, whereas in whole blood, clearance ranged from 3.0 to 6.2 L/h.  Minor responses and prolonged tumor stabilizations were obsd. in patients with medullary thyroid carcinoma.  Conclusion: Muscle toxicity was dose limiting in this study.  Recommended doses of aplidine were 5 and 7 mg/m2 without and with carnitine, resp.  The role of carnitine will be further explored in phase II studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGAxN5YaRqJrVg90H21EOLACvtfcHk0ljMGHpTVYob7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Cqs7fM&md5=e624d758c5f45858616de980d46130b3</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.09.357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.09.357%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DChi%25C3%25A8ze%26aufirst%3DS.%26aulast%3DDelbaldo%26aufirst%3DC.%26aulast%3DAdy-Vago%26aufirst%3DN.%26aulast%3DGuzman%26aufirst%3DC.%26aulast%3DLopez-Lazaro%26aufirst%3DL.%26aulast%3DLozahic%26aufirst%3DS.%26aulast%3DJimeno%26aufirst%3DJ.%26aulast%3DPico%26aufirst%3DF.%26aulast%3DArmand%26aufirst%3DJ.%2BP.%26aulast%3DMartin%26aufirst%3DJ.%2BA.%2BL.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DPhase%2520I%2520and%2520Pharmacokinetic%2520Study%2520of%2520Aplidine%252C%2520a%2520New%2520Marine%2520Cyclodepsipeptide%2520in%2520Patients%2520with%2520Advanced%2520Malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D7871%26epage%3D7880%26doi%3D10.1200%2FJCO.2005.09.357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Izquierdo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jodrell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Martin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germá, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, J. F.</span></span> <span> </span><span class="NLM_article-title">Phase I Clinical and Pharmacokinetic Study of Plitidepsin as a 1-h Weekly Intravenous Infusion in Patients with Advanced Solid Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3105</span>– <span class="NLM_lpage">3112</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-1652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1158%2F1078-0432.CCR-07-1652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18483378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVCmur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=3105-3112&author=M.+A.+Izquierdoauthor=A.+Bowmanauthor=M.+Garc%C3%ADaauthor=D.+Jodrellauthor=M.+Martinezauthor=B.+Pardoauthor=J.+G%C3%B3mezauthor=J.+A.+L%C3%B3pez-Martinauthor=J.+Jimenoauthor=J.+R.+Germ%C3%A1author=J.+F.+Smyth&title=Phase+I+Clinical+and+Pharmacokinetic+Study+of+Plitidepsin+as+a+1-h+Weekly+Intravenous+Infusion+in+Patients+with+Advanced+Solid+Tumors&doi=10.1158%2F1078-0432.CCR-07-1652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Clinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Izquierdo, Miguel A.; Bowman, Angela; Garcia, Margarita; Jodrell, Duncan; Martinez, Marisa; Pardo, Beatriz; Gomez, Javier; Lopez-Martin, Jose A.; Jimeno, Jose; Germa, Jose R.; Smyth, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3105-3112</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Plitidepsin, given as a 1-h weekly i.v. infusion for 3 consecutive weeks during a 4-wk treatment cycle, was investigated in patients with solid tumors to det. the max. tolerated dose and the recommended dose (RD) using this administration schedule.  Consecutive cohorts of patients with metastatic solid tumors or non-Hodgkin's lymphomas were to be treated at escalating doses of plitidepsin in a conventional phase I study including pharmacokinetic analyses of plitidepsin in plasma, whole blood, and blood cell pellets.  Forty-nine patients with solid tumors were enrolled, and 48 were treated with plitidepsin (doses from 0.133 to 3.6 mg/m2/wk).  Dose-limiting toxicities (defining 3.6 mg/m2/wk as the max. tolerated dose) included myalgia, increased creatine phosphokinase levels, and sustained grade 3/4 increases of hepatic enzyme levels.  The RD was established at 3.2 mg/m2/wk.  The most common toxicities were fatigue, vomiting/nausea, anorexia, injection site reaction, and pain, mostly of mild or moderate severity.  Muscular toxicity manifested by mild-moderate myalgia, weakness, and/or creatine phosphokinase elevations occurred in ∼25% of patients and seemed to be dose related.  Transient transaminase elevations were frequent but achieved grade 3 or 4 in only ∼10% of patients.  Plitidepsin lacked significant hematol. toxicity.  No complete or partial tumor responses were obsd.; however, five patients had disease stabilization (including one patient with medullary thyroid carcinoma with an unconfirmed partial response and one patient with renal carcinoma with major tumor shrinkage in lung metastases).  Pharmacokinetic results for the RD indicated a long plasma half-life give value (16.8 ± 7.7 h) and a high vol. of distribution value (525.2 ± 219.3 L).  The recommended dose for plitidepsin given as a weekly 1-h schedule was 3.2 mg/m2/wk.  Muscular and liver toxicity were dose limiting at 3.6 mg/m2/wk.  Addnl. evaluation of this dose dense schedule is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDy48tEz3dmLVg90H21EOLACvtfcHk0lj3apusox79CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVCmur4%253D&md5=83458c84c28f4df267c566b65a6c6d38</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1652%26sid%3Dliteratum%253Aachs%26aulast%3DIzquierdo%26aufirst%3DM.%2BA.%26aulast%3DBowman%26aufirst%3DA.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DM.%26aulast%3DJodrell%26aufirst%3DD.%26aulast%3DMartinez%26aufirst%3DM.%26aulast%3DPardo%26aufirst%3DB.%26aulast%3DG%25C3%25B3mez%26aufirst%3DJ.%26aulast%3DL%25C3%25B3pez-Martin%26aufirst%3DJ.%2BA.%26aulast%3DJimeno%26aufirst%3DJ.%26aulast%3DGerm%25C3%25A1%26aufirst%3DJ.%2BR.%26aulast%3DSmyth%26aufirst%3DJ.%2BF.%26atitle%3DPhase%2520I%2520Clinical%2520and%2520Pharmacokinetic%2520Study%2520of%2520Plitidepsin%2520as%2520a%25201-h%2520Weekly%2520Intravenous%2520Infusion%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D3105%26epage%3D3112%26doi%3D10.1158%2F1078-0432.CCR-07-1652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">The Antiproliferative Agent Didemnin B Uncompetitively Inhibits Palmitoyl Protein Thioesterase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">10488</span>– <span class="NLM_lpage">10492</span>, <span class="refDoi"> DOI: 10.1021/bi9804479</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi9804479" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK1cXktFKqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=10488-10492&author=L.+Mengauthor=N.+Sinauthor=C.+M.+Crews&title=The+Antiproliferative+Agent+Didemnin+B+Uncompetitively+Inhibits+Palmitoyl+Protein+Thioesterase&doi=10.1021%2Fbi9804479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The Antiproliferative Agent Didemnin B Uncompetitively Inhibits Palmitoyl Protein Thioesterase</span></div><div class="casAuthors">Meng, Lihao; Sin, Ny; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">10488-10492</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dynamic protein palmitoylation has been proposed to regulate GTP-binding proteins by controlling their membrane assocn. and thus their access to key signaling proteins.  While the palmitoyl protein thioesterase(s) responsible for depalmitoylation of plasma membrane-assocd. signaling proteins has (have) not been identified, the lysosomal palmitoyl protein thioesterase 1 (PPT1) has proven useful in in vitro studies of membrane localization requirements of GTP-binding proteins.  We have previously reported the binding of the antiproliferative cyclic depsipeptide didemnin B to PPT1.  To investigate the nature of this binding and its possible effects on PPT1 enzymic activity, human PPT1 was expressed in an insect cell baculoviral system, and inhibition assays were performed using both [3H]palmitoyl Ha-Ras and myristoyl-CoA as PPT1 substrates.  Didemnin B was shown to inhibit recombinant human PPT1 with a Ki of 92 nM.  Kinetic anal. of this inhibition revealed that didemnin B inhibits PPT1 uncompetitively.  Providing biochem. support for an uncompetitive mode of inhibition, in vitro binding studies of PPT1 and didemnin indicate that the natural product binds preferentially to the enzyme-substrate complex PPT1-palmitoyl-CoA.  As the first described inhibitor of PPT1, didemnin B may prove to be a useful tool in the investigation of protein palmitoylation regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq81qVLF2dKzLVg90H21EOLACvtfcHk0lj3apusox79CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktFKqsLs%253D&md5=84f48ee72d33cdcced2af6386e1b2db3</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fbi9804479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi9804479%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DThe%2520Antiproliferative%2520Agent%2520Didemnin%2520B%2520Uncompetitively%2520Inhibits%2520Palmitoyl%2520Protein%2520Thioesterase%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D10488%26epage%3D10492%26doi%3D10.1021%2Fbi9804479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">Plitidepsin: A Potential New Treatment for Relapsed/Refractory Multiple Myeloma</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.2217/fon-2018-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.2217%2Ffon-2018-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30111169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFGis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=109-120&author=M.+Leischauthor=A.+Egleauthor=R.+Greil&title=Plitidepsin%3A+A+Potential+New+Treatment+for+Relapsed%2FRefractory+Multiple+Myeloma&doi=10.2217%2Ffon-2018-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma</span></div><div class="casAuthors">Leisch, Michael; Egle, Alexander; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-120</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Plitidepsin is a marine-derived anticancer compd. isolated from the Mediterranean tunicate Applidium albicans.  It exerts pleiotropic effects on cancer cells, most likely by binding to the eukaryotic translation eEF1A2.  This ultimately leads to cell-cycle arrest, growth inhibition and induction of apoptosis via multiple pathway alterations.  Recently, a Phase III randomized trial in patients with relapsed/refractory multiple myeloma reported outcomes for plitidepsin plus dexamethasone compared with dexamethasone.  Median progression-free survival was 3.8 mo in the plitidepsin arm and 1.9 mo in the dexamethasone arm (HR: 0.611; p = 0.0048).  Here, we review preclin. data regarding plitidepsins mechanism of action, give an overview of clin. trial results across different tumor types as well as the latest results in multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreQ2wJUJXILbVg90H21EOLACvtfcHk0lj3apusox79CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFGis7k%253D&md5=011f4da81faa52d1a59279093753f05d</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.2217%2Ffon-2018-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2018-0492%26sid%3Dliteratum%253Aachs%26aulast%3DLeisch%26aufirst%3DM.%26aulast%3DEgle%26aufirst%3DA.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DPlitidepsin%253A%2520A%2520Potential%2520New%2520Treatment%2520for%2520Relapsed%252FRefractory%2520Multiple%2520Myeloma%26jtitle%3DFuture%2520Oncol.%26date%3D2019%26volume%3D15%26spage%3D109%26epage%3D120%26doi%3D10.2217%2Ffon-2018-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mateos, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cibeira, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prosper, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oriol, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De La Rubia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahuerta, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sanz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Extremera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szyldergemajn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrado, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bladé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, J.</span></span> <span> </span><span class="NLM_article-title">Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-h Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3260</span>– <span class="NLM_lpage">3269</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-0469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1158%2F1078-0432.CCR-10-0469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=20530693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3260-3269&author=M.+V.+Mateosauthor=M.+T.+Cibeiraauthor=P.+G.+Richardsonauthor=F.+Prosperauthor=A.+Oriolauthor=J.+De+La+Rubiaauthor=J.+J.+Lahuertaauthor=R.+Garc%C3%ADa-Sanzauthor=S.+Extremeraauthor=S.+Szyldergemajnauthor=C.+Corradoauthor=H.+Singerauthor=C.+S.+Mitsiadesauthor=K.+C.+Andersonauthor=J.+Blad%C3%A9author=J.+San+Miguel&title=Phase+II+Clinical+and+Pharmacokinetic+Study+of+Plitidepsin+3-h+Infusion+Every+Two+Weeks+Alone+or+with+Dexamethasone+in+Relapsed+and+Refractory+Multiple+Myeloma&doi=10.1158%2F1078-0432.CCR-10-0469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma</span></div><div class="casAuthors">Mateos, Maria Victoria; Cibeira, Maria Teresa; Richardson, Paul G.; Prosper, Felipe; Oriol, Albert; de la Rubia, Javier; Lahuerta, Juan Jose; Garcia-Sanz, Ramon; Extremera, Sonia; Szyldergemajn, Sergio; Corrado, Claudia; Singer, Harald; Mitsiades, Constantine S.; Anderson, Kenneth C.; Blade, Joan; San Miguel, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3260-3269</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: This trial evaluated the antitumor activity and safety of the marine-derived cyclodepsipeptide plitidepsin in patients with relapsed/refractory multiple myeloma.  Exptl. Design: This was a prospective, multicenter, open-label, single-arm, phase II trial with plitidepsin at 5 mg/m2 as a 3-h i.v. infusion every two weeks.  The protocol was amended to allow patients with suboptimal response to single-agent plitidepsin to add 20 mg/day on days 1 to 4 of oral dexamethasone every two weeks.  RESULTS: Fifty-one patients started treatment with plitidepsin and 47 were evaluable for efficacy.  The overall response rate (complete response plus partial response plus minimal response) was 13% with plitidepsin alone and 22% in the cohort of patients with the addn. of dexamethasone (n = 19, 18 evaluable).  Both plitidepsin alone and with dexamethasone were feasible and well tolerated.  Anemia (29%) and thrombocytopenia (18%) were the most frequent grade 3/4 hematol. toxicities.  Fatigue (16%), muscular toxicity (6%), and transient alanine aminotransferase/aspartate aminotransferase (27%) and creatine phosphokinase (23%) increases were the most relevant nonhematol. side effects.  A prolonged plasma half-life was obsd. in responding patients as compared with nonresponding patients (P = 0.009).  CONCLUSIONS: Single-agent plitidepsin has limited but reproducible activity in relapsed/refractory multiple myeloma patients.  Activity obsd. after dexamethasone addn. merits further study.  Both regimens were well tolerated in this heavily pretreated population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKP3yz58GO9bVg90H21EOLACvtfcHk0lg6reixF6xAuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKqsrs%253D&md5=3debb134c2651fba943006c99a33837a</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0469%26sid%3Dliteratum%253Aachs%26aulast%3DMateos%26aufirst%3DM.%2BV.%26aulast%3DCibeira%26aufirst%3DM.%2BT.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DProsper%26aufirst%3DF.%26aulast%3DOriol%26aufirst%3DA.%26aulast%3DDe%2BLa%2BRubia%26aufirst%3DJ.%26aulast%3DLahuerta%26aufirst%3DJ.%2BJ.%26aulast%3DGarc%25C3%25ADa-Sanz%26aufirst%3DR.%26aulast%3DExtremera%26aufirst%3DS.%26aulast%3DSzyldergemajn%26aufirst%3DS.%26aulast%3DCorrado%26aufirst%3DC.%26aulast%3DSinger%26aufirst%3DH.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DBlad%25C3%25A9%26aufirst%3DJ.%26aulast%3DSan%2BMiguel%26aufirst%3DJ.%26atitle%3DPhase%2520II%2520Clinical%2520and%2520Pharmacokinetic%2520Study%2520of%2520Plitidepsin%25203-h%2520Infusion%2520Every%2520Two%2520Weeks%2520Alone%2520or%2520with%2520Dexamethasone%2520in%2520Relapsed%2520and%2520Refractory%2520Multiple%2520Myeloma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3260%26epage%3D3269%26doi%3D10.1158%2F1078-0432.CCR-10-0469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geoerger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estlin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearns, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corradini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel, B. De</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prados, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassal, G.</span></span> <span> </span><span class="NLM_article-title">A Phase i and Pharmacokinetic Study of Plitidepsin in Children with Advanced Solid Tumours: An Innovative Therapies for Children with Cancer (ITCC) Study</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2011.10.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.ejca.2011.10.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22119199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=289-296&author=B.+Geoergerauthor=E.+J.+Estlinauthor=I.+Aertsauthor=P.+Kearnsauthor=B.+Gibsonauthor=N.+Corradiniauthor=F.+Dozauthor=P.+Lardelliauthor=B.+De+Miguelauthor=A.+Sotoauthor=R.+Pradosauthor=G.+Vassal&title=A+Phase+i+and+Pharmacokinetic+Study+of+Plitidepsin+in+Children+with+Advanced+Solid+Tumours%3A+An+Innovative+Therapies+for+Children+with+Cancer+%28ITCC%29+Study&doi=10.1016%2Fj.ejca.2011.10.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study</span></div><div class="casAuthors">Geoerger, Birgit; Estlin, Edward J.; Aerts, Isabelle; Kearns, Pamela; Gibson, Brenda; Corradini, Nadege; Doz, Francois; Lardelli, Pilar; De Miguel, Bernardo; Soto, Arturo; Prados, Raquel; Vassal, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-296</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Aims: To det. the max. tolerated dose, the recommended dose (RD) for phase II studies, dose-limiting toxicities and pharmacokinetics (PK) for plitidepsin administered as a 3-h i.v. infusion every 2 wk (one cycle) to children with refractory or relapsed solid tumors.  Methods: Consecutive cohorts of patients were treated according to a std. 3 + 3' design with escalating doses of plitidepsin at 4, 5 and 6 mg/m2.  Addnl. 15 patients were recruited at the RD to further evaluate safety and pharmacokinetic assocns. with respect to age, dose level and toxicity.  Results: Thirty-eight of 41 patients registered received plitidepsin.  Dose-limiting toxicities during the first three treatment cycles related to myalgia, elevated creatine phosphokinase, transaminase increase and nausea/vomiting.  The RD for plitidepsin is 5 mg/m2.  PK analyses revealed high inter-patient variability in plasma, but a similar clearance of plitidepsin in children and adolescents.  One partial response confirmed at 4 wk in a patient with neuroblastoma and one unconfirmed partial response in a pancreatoblastoma were obsd.; four other patients with neuroblastoma, medulloblastoma, glioblastoma and rhabdoid tumor had disease stabilizations lasting ≥3 mo.  Conclusion: Plitidepsin administered to children as a 3-h infusion every 2 wk is received with manageable toxicity for children with cancer, and the RD is 5 mg/m2.  Pharmacokinetic parameters in children and adolescents are comparable to adults.  Future phase II studies of plitidepsin are warranted, and our results suggest that plitidepsin could be appropriately developed in combination with other antitumor where myelosuppression is dose-limiting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8p7iO4pEb8LVg90H21EOLACvtfcHk0lg6reixF6xAuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOlsrs%253D&md5=6331b17a17783608e90048aec2fcae00</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2011.10.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2011.10.036%26sid%3Dliteratum%253Aachs%26aulast%3DGeoerger%26aufirst%3DB.%26aulast%3DEstlin%26aufirst%3DE.%2BJ.%26aulast%3DAerts%26aufirst%3DI.%26aulast%3DKearns%26aufirst%3DP.%26aulast%3DGibson%26aufirst%3DB.%26aulast%3DCorradini%26aufirst%3DN.%26aulast%3DDoz%26aufirst%3DF.%26aulast%3DLardelli%26aufirst%3DP.%26aulast%3DMiguel%26aufirst%3DB.%2BDe%26aulast%3DSoto%26aufirst%3DA.%26aulast%3DPrados%26aufirst%3DR.%26aulast%3DVassal%26aufirst%3DG.%26atitle%3DA%2520Phase%2520i%2520and%2520Pharmacokinetic%2520Study%2520of%2520Plitidepsin%2520in%2520Children%2520with%2520Advanced%2520Solid%2520Tumours%253A%2520An%2520Innovative%2520Therapies%2520for%2520Children%2520with%2520Cancer%2520%2528ITCC%2529%2520Study%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2012%26volume%3D48%26spage%3D289%26epage%3D296%26doi%3D10.1016%2Fj.ejca.2011.10.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spicka, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocio, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakervee, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banh, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Rozario, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimopoulos, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Extremera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahatt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfaro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carella, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuleman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hájek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symeonidis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonneveld, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateos, M. V.</span></span> <span> </span><span class="NLM_article-title">Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">2139</span>– <span class="NLM_lpage">2150</span>, <span class="refDoi"> DOI: 10.1007/s00277-019-03739-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs00277-019-03739-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31240472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1KktrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2019&pages=2139-2150&author=I.+Spickaauthor=E.+M.+Ocioauthor=H.+E.+Oakerveeauthor=R.+Greilauthor=R.+H.+Banhauthor=S.+Y.+Huangauthor=J.+M.+D%E2%80%99Rozarioauthor=M.+A.+Dimopoulosauthor=S.+Mart%C3%ADnezauthor=S.+Extremeraauthor=C.+Kahattauthor=V.+Alfaroauthor=A.+M.+Carellaauthor=N.+Meulemanauthor=R.+H%C3%A1jekauthor=A.+Symeonidisauthor=C.+K.+Minauthor=P.+Cannellauthor=H.+Ludwigauthor=P.+Sonneveldauthor=M.+V.+Mateos&title=Randomized+Phase+III+Study+%28ADMYRE%29+of+Plitidepsin+in+Combination+with+Dexamethasone+vs.+Dexamethasone+Alone+in+Patients+with+Relapsed%2FRefractory+Multiple+Myeloma&doi=10.1007%2Fs00277-019-03739-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma</span></div><div class="casAuthors">Spicka, Ivan; Ocio, Enrique M.; Oakervee, Heather E.; Greil, Richard; Banh, Raymond H.; Huang, Shang-Yi; D'Rozario, James M.; Dimopoulos, Meletios A.; Martinez, Sara; Extremera, Sonia; Kahatt, Carmen; Alfaro, Vicente; Carella, Angelo M.; Meuleman, Nathalie; Hajek, Roman; Symeonidis, Argiris; Min, Chang-Ki; Cannell, Paul; Ludwig, Heinz; Sonneveld, Pieter; Mateos, Maria Victoria</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hematology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2139-2150</span>CODEN:
                <span class="NLM_cas:coden">ANHEE8</span>;
        ISSN:<span class="NLM_cas:issn">0939-5555</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) vs. DXM alone in patients with relapsed/refractory multiple myeloma after at least three but not more than six prior regimens, including at least bortezomib and lenalidomide or thalidomide.  Patients were randomly assigned (2:1) to receive plitidepsin 5 mg/m2 on D1 and D15 plus DXM 40 mg on D1, D8, D15, and D22 (arm A, n = 171) or DXM 40 mg on D1, D8, D15, and D22 (arm B, n = 84) q4wk.  The primary endpoint was progression-free survival (PFS).  Median PFS without disease progression (PD) confirmation (IRC assessment) was 2.6 mo (arm A) and 1.7 mo (arm B) (HR = 0.650; p = 0.0054).  Median PFS with PD confirmation (investigator's assessment) was 3.8 mo (arm A) and 1.9 mo (arm B) (HR = 0.611; p = 0.0040).  Median overall survival (OS, intention-to-treat anal.) was 11.6 mo (arm A) and 8.9 mo (arm B) (HR = 0.797; p = 0.1261).  OS improvement favoring arm A was found when discounting a crossover effect (37 patients crossed over from arm B to arm A) (two-stage method; HR = 0.622; p = 0.0015).  The most common grade 3/4 treatment-related adverse events (% of patients arm A/arm B) were fatigue (10.8%/1.2%), myalgia (5.4%/0%), and nausea (3.6%/1.2%), being usually transient and reversible.  The safety profile does not overlap with the toxicity obsd. with other agents used in multiple myeloma.  In conclusion, efficacy data, the reassuring safety profile, and the novel mechanism of action of plitidepsin suggest that this combination can be an alternative option in patients with relapsed/refractory multiple myeloma after at least three prior therapy lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqESyopQh155bVg90H21EOLACvtfcHk0lg6reixF6xAuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1KktrnE&md5=4ac511b71ece280fd3675f247075a157</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1007%2Fs00277-019-03739-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-019-03739-2%26sid%3Dliteratum%253Aachs%26aulast%3DSpicka%26aufirst%3DI.%26aulast%3DOcio%26aufirst%3DE.%2BM.%26aulast%3DOakervee%26aufirst%3DH.%2BE.%26aulast%3DGreil%26aufirst%3DR.%26aulast%3DBanh%26aufirst%3DR.%2BH.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DD%25E2%2580%2599Rozario%26aufirst%3DJ.%2BM.%26aulast%3DDimopoulos%26aufirst%3DM.%2BA.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DS.%26aulast%3DExtremera%26aufirst%3DS.%26aulast%3DKahatt%26aufirst%3DC.%26aulast%3DAlfaro%26aufirst%3DV.%26aulast%3DCarella%26aufirst%3DA.%2BM.%26aulast%3DMeuleman%26aufirst%3DN.%26aulast%3DH%25C3%25A1jek%26aufirst%3DR.%26aulast%3DSymeonidis%26aufirst%3DA.%26aulast%3DMin%26aufirst%3DC.%2BK.%26aulast%3DCannell%26aufirst%3DP.%26aulast%3DLudwig%26aufirst%3DH.%26aulast%3DSonneveld%26aufirst%3DP.%26aulast%3DMateos%26aufirst%3DM.%2BV.%26atitle%3DRandomized%2520Phase%2520III%2520Study%2520%2528ADMYRE%2529%2520of%2520Plitidepsin%2520in%2520Combination%2520with%2520Dexamethasone%2520vs.%2520Dexamethasone%2520Alone%2520in%2520Patients%2520with%2520Relapsed%252FRefractory%2520Multiple%2520Myeloma%26jtitle%3DAnn.%2520Hematol.%26date%3D2019%26volume%3D98%26spage%3D2139%26epage%3D2150%26doi%3D10.1007%2Fs00277-019-03739-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyse, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schummer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemke-Jahn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penarier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debussche, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brönstrup, M.</span></span> <span> </span><span class="NLM_article-title">Discovery, Structure Elucidation, and Biological Characterization of Nannocystin A, a Macrocyclic Myxobacterial Metabolite with Potent Antiproliferative Properties</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">10145</span>– <span class="NLM_lpage">10148</span>, <span class="refDoi"> DOI: 10.1002/anie.201411377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fanie.201411377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpt1aqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=10145-10148&author=H.+Hoffmannauthor=H.+Koglerauthor=W.+Heyseauthor=H.+Matterauthor=M.+Caspersauthor=D.+Schummerauthor=C.+Klemke-Jahnauthor=A.+Bauerauthor=G.+Penarierauthor=L.+Debusscheauthor=M.+Br%C3%B6nstrup&title=Discovery%2C+Structure+Elucidation%2C+and+Biological+Characterization+of+Nannocystin+A%2C+a+Macrocyclic+Myxobacterial+Metabolite+with+Potent+Antiproliferative+Properties&doi=10.1002%2Fanie.201411377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, structure elucidation, and biological characterization of nannocystin A, a macrocyclic myxobacterial metabolite with potent antiproliferative properties</span></div><div class="casAuthors">Hoffmann, Holger; Kogler, Herbert; Heyse, Winfried; Matter, Hans; Caspers, Michael; Schummer, Dietmar; Klemke-Jahn, Christine; Bauer, Armin; Penarier, Geraldine; Debussche, Laurent; Broenstrup, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">10145-10148</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Microbial natural products are a rich source of bioactive mols. to serve as drug leads and/or biol. tools.  The authors investigated a little-explored myxobacterial genus, Nannocystis sp., and discovered a novel 21-membered macrocyclic scaffold that is composed of a tripeptide and a polyketide part with an epoxyamide moiety.  The relative and abs. configurations of the nine stereocenters was detd. by NMR spectroscopy, mol. dynamics calcns., chem. degrdn., and X-ray crystallog.  The compd., named nannocystin A (I), was found to inhibit cell proliferation at low nanomolar concns. through the early induction of apoptosis.  The mode of action of I could not be matched to that of std. drugs by transcriptional profiling and biochem. expts.  An initial investigation of the structure-activity relationship based on seven analogs demonstrated the importance of the epoxide moiety for high activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqay0zii-YC1LVg90H21EOLACvtfcHk0liNtzqCydIqKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpt1aqtro%253D&md5=d2d35f8ab0531f72c722160781c02c69</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1002%2Fanie.201411377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201411377%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DH.%26aulast%3DKogler%26aufirst%3DH.%26aulast%3DHeyse%26aufirst%3DW.%26aulast%3DMatter%26aufirst%3DH.%26aulast%3DCaspers%26aufirst%3DM.%26aulast%3DSchummer%26aufirst%3DD.%26aulast%3DKlemke-Jahn%26aufirst%3DC.%26aulast%3DBauer%26aufirst%3DA.%26aulast%3DPenarier%26aufirst%3DG.%26aulast%3DDebussche%26aufirst%3DL.%26aulast%3DBr%25C3%25B6nstrup%26aufirst%3DM.%26atitle%3DDiscovery%252C%2520Structure%2520Elucidation%252C%2520and%2520Biological%2520Characterization%2520of%2520Nannocystin%2520A%252C%2520a%2520Macrocyclic%2520Myxobacterial%2520Metabolite%2520with%2520Potent%2520Antiproliferative%2520Properties%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D10145%26epage%3D10148%26doi%3D10.1002%2Fanie.201411377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krastel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roggo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perruccio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspesi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aust, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buntin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estoppey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liechty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mapa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memmert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibaut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoepfner, D.</span></span> <span> </span><span class="NLM_article-title">Nannocystin A: An Elongation Factor 1 Inhibitor from Myxobacteria with Differential Anti-Cancer Properties</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">10149</span>– <span class="NLM_lpage">10154</span>, <span class="refDoi"> DOI: 10.1002/anie.201505069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fanie.201505069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOrtbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=10149-10154&author=P.+Krastelauthor=S.+Roggoauthor=M.+Schirleauthor=N.+T.+Rossauthor=F.+Perruccioauthor=P.+Aspesiauthor=T.+Austauthor=K.+Buntinauthor=D.+Estoppeyauthor=B.+Liechtyauthor=F.+Mapaauthor=K.+Memmertauthor=H.+Millerauthor=X.+Panauthor=R.+Riedlauthor=C.+Thibautauthor=J.+Thomasauthor=T.+Wagnerauthor=E.+Weberauthor=X.+Xieauthor=E.+K.+Schmittauthor=D.+Hoepfner&title=Nannocystin+A%3A+An+Elongation+Factor+1+Inhibitor+from+Myxobacteria+with+Differential+Anti-Cancer+Properties&doi=10.1002%2Fanie.201505069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Nannocystin A: an elongation factor 1 inhibitor from myxobacteria with differential anticancer properties</span></div><div class="casAuthors">Krastel, Philipp; Roggo, Silvio; Schirle, Markus; Ross, Nathan T.; Perruccio, Francesca; Aspesi, Peter, Jr.; Aust, Thomas; Buntin, Kathrin; Estoppey, David; Liechty, Brigitta; Mapa, Felipa; Memmert, Klaus; Miller, Howard; Pan, Xuewen; Riedl, Ralph; Thibaut, Christian; Thomas, Jason; Wagner, Trixie; Weber, Eric; Xie, Xiaobing; Schmitt, Esther K.; Hoepfner, Dominic</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">10149-10154</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cultivation of myxobacteria of the Nannocystis genus led to the isolation and structure elucidation of a class of novel cyclic lactone inhibitors of elongation factor 1.  Whole genome sequence anal. and annotation enabled identification of the putative biosynthetic cluster and synthesis process.  In biol. assays, the compds. displayed antifungal and cytotoxic activity.  Combined genetic and proteomic approaches identified the eukaryotic translation elongation factor 1α (EF-1α) as the primary target for this compd. class.  Nannocystin A (I) displayed differential activity across various cancer cell lines and EEF1A1 expression levels appear to be the main differentiating factor.  Biochem. and genetic evidence support an overlapping binding site of 1 with the anti-cancer compd. didemnin B on EF-1α.  This myxobacterial chemotype thus offers an interesting starting point for further investigations of the potential of therapeutics targeting elongation factor 1.  KT067736 has been submitted to the NCBI/EMBL/DDBJ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5TyLOZkwcUbVg90H21EOLACvtfcHk0liNtzqCydIqKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOrtbvN&md5=bd120071f530c5d2ba7b0d1464b7bbf1</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1002%2Fanie.201505069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201505069%26sid%3Dliteratum%253Aachs%26aulast%3DKrastel%26aufirst%3DP.%26aulast%3DRoggo%26aufirst%3DS.%26aulast%3DSchirle%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DN.%2BT.%26aulast%3DPerruccio%26aufirst%3DF.%26aulast%3DAspesi%26aufirst%3DP.%26aulast%3DAust%26aufirst%3DT.%26aulast%3DBuntin%26aufirst%3DK.%26aulast%3DEstoppey%26aufirst%3DD.%26aulast%3DLiechty%26aufirst%3DB.%26aulast%3DMapa%26aufirst%3DF.%26aulast%3DMemmert%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DRiedl%26aufirst%3DR.%26aulast%3DThibaut%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWeber%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DSchmitt%26aufirst%3DE.%2BK.%26aulast%3DHoepfner%26aufirst%3DD.%26atitle%3DNannocystin%2520A%253A%2520An%2520Elongation%2520Factor%25201%2520Inhibitor%2520from%2520Myxobacteria%2520with%2520Differential%2520Anti-Cancer%2520Properties%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D10149%26epage%3D10154%26doi%3D10.1002%2Fanie.201505069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Murcia, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés-Cabrera, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gago, F.</span></span> <span> </span><span class="NLM_article-title">Structural Rationale for the Cross-Resistance of Tumor Cells Bearing the A399V Variant of Elongation Factor eEF1A1 to the Structurally Unrelated Didemnin B, Ternatin, Nannocystin A and Ansatrienin B</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">915</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1007/s10822-017-0066-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs10822-017-0066-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28900796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVOrtLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=915-928&author=P.+A.+S%C3%A1nchez-Murciaauthor=%C3%81.+Cort%C3%A9s-Cabreraauthor=F.+Gago&title=Structural+Rationale+for+the+Cross-Resistance+of+Tumor+Cells+Bearing+the+A399V+Variant+of+Elongation+Factor+eEF1A1+to+the+Structurally+Unrelated+Didemnin+B%2C+Ternatin%2C+Nannocystin+A+and+Ansatrienin+B&doi=10.1007%2Fs10822-017-0066-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Structural rationale for the cross-resistance of tumor cells bearing the A399V variant of elongation factor eEF1A1 to the structurally unrelated didemnin B, ternatin, nannocystin A and ansatrienin B</span></div><div class="casAuthors">Sanchez-Murcia, Pedro A.; Cortes-Cabrera, Alvaro; Gago, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">915-928</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">At least four classes of structurally distinct natural products with potent antiproliferative activities target the translation elongation factor eEF1A1, which is best known as the G-protein that delivers amino acyl tRNAs (aa-tRNAs) to ribosomes during mRNA translation.  We present mol. models in at. detail that provide a common structural basis for the high-affinity binding of didemnin B, ternatin, ansatrienin B and nannocystin A to eEF1A1, as well as a rationale based on mol. dynamics results that accounts for the deleterious effect of replacing alanine 399 with valine.  The proposed binding site, at the interface between domains I and III, is eminently hydrophobic and exists only in the GTP-bound conformation.  Drug binding at this site is expected to disrupt neither loading of aa-tRNAs nor GTP hydrolysis but would give rise to stabilization of this particular conformational state, in consonance with reported exptl. findings.  The exptl. soln. of the three-dimensional structure of mammalian eEF1A1 has proved elusive so far and the highly homologous eEF1A2 from rabbit muscle has been crystd. and solved only as a homodimer in a GDP-bound conformation.  Interestingly, in this dimeric structure the large interdomain cavity where the drugs studied are proposed to bind is occupied by a mostly hydrophobic α-helix from domain I of the same monomer.  Since binding of this α-helix and any of these drugs to domain III of eEF1A(1/2) is, therefore, mutually exclusive and involves two distinct protein conformations, one intriguing possibility that emerges from our study is that the potent antiproliferative effect of these natural products may arise not only from inhibition of protein synthesis, which is the current dogma, but also from interference with some other non-canonical functions.  From this standpoint, this type of drugs could be considered antagonists of eEF1A1/2 oligomerization, a hypothesis that opens up novel areas of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmNAOwcCMXJ7Vg90H21EOLACvtfcHk0liNtzqCydIqKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVOrtLvO&md5=37285ead63e2005f01a4dce718d68175</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1007%2Fs10822-017-0066-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-017-0066-x%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Murcia%26aufirst%3DP.%2BA.%26aulast%3DCort%25C3%25A9s-Cabrera%26aufirst%3D%25C3%2581.%26aulast%3DGago%26aufirst%3DF.%26atitle%3DStructural%2520Rationale%2520for%2520the%2520Cross-Resistance%2520of%2520Tumor%2520Cells%2520Bearing%2520the%2520A399V%2520Variant%2520of%2520Elongation%2520Factor%2520eEF1A1%2520to%2520the%2520Structurally%2520Unrelated%2520Didemnin%2520B%252C%2520Ternatin%252C%2520Nannocystin%2520A%2520and%2520Ansatrienin%2520B%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2017%26volume%3D31%26spage%3D915%26epage%3D928%26doi%3D10.1007%2Fs10822-017-0066-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Total Synthesis of Nannocystin A</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">9217</span>– <span class="NLM_lpage">9222</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.7b01502</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.7b01502" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSitLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2017&pages=9217-9222&author=Q.+Liuauthor=P.+Huauthor=Y.+He&title=Asymmetric+Total+Synthesis+of+Nannocystin+A&doi=10.1021%2Facs.joc.7b01502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric Total Synthesis of Nannocystin A</span></div><div class="casAuthors">Liu, Qiang; Hu, Ping; He, Yun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9217-9222</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nannocystin A is a novel 21-membered macrolactone isolated from myxobacterium Nanocystis sp.  It is a potent elongation factor 1 inhibitor and inhibits cancer cell line growth at nanomolar concns.  In this work, a concise asym. total synthesis of nannocystin A has been developed, which features Sharpless epoxidn., Stille coupling, and final macrolactamization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzwSW30-JuaLVg90H21EOLACvtfcHk0lgF9tDawpurQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSitLzI&md5=575ebb7508046c5941fdc385cb1fc0a5</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.7b01502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.7b01502%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DHe%26aufirst%3DY.%26atitle%3DAsymmetric%2520Total%2520Synthesis%2520of%2520Nannocystin%2520A%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2017%26volume%3D82%26spage%3D9217%26epage%3D9222%26doi%3D10.1021%2Facs.joc.7b01502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souillart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monks, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwyler, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fürstner, A.</span></span> <span> </span><span class="NLM_article-title">A “Motif-Oriented” Total Synthesis of Nannocystin Ax. Preparation and Biological Assessment of Analogues</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">6977</span>– <span class="NLM_lpage">6994</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.7b02871</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.7b02871" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVant7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=6977-6994&author=Z.+Mengauthor=L.+Souillartauthor=B.+Monksauthor=N.+Huwylerauthor=J.+Herrmannauthor=R.+M%C3%BCllerauthor=A.+F%C3%BCrstner&title=A+%E2%80%9CMotif-Oriented%E2%80%9D+Total+Synthesis+of+Nannocystin+Ax.+Preparation+and+Biological+Assessment+of+Analogues&doi=10.1021%2Facs.joc.7b02871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">A "Motif-Oriented" Total Synthesis of Nannocystin Ax. Preparation and Biological Assessment of Analogues</span></div><div class="casAuthors">Meng, Zhanchao; Souillart, Laetitia; Monks, Brendan; Huwyler, Nikolas; Herrmann, Jennifer; Mueller, Rolf; Fuerstner, Alois</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6977-6994</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The highly cytotoxic cyclodepsipeptides of the nannocystin family are known to bind to the eukaryotic translation elongation factor 1α (EF-1α).  Anal. of the docking pose, as proposed by a previous in silico study, suggested that the trisubstituted alkene moiety and the neighboring Me ether form a domain that might be closely correlated with biol. activity.  This hypothesis sponsored a synthetic campaign which was designed to be "motif-oriented": specifically, a sequence of ring closing alkyne metathesis (RCAM) followed by hydroxy-directed trans-hydrostannation of the resulting cycloalkyne was conceived, which allowed this potentially anchoring substructure to be systematically addressed at a late stage.  This inherently flexible approach opened access to nannocystin Ax itself as well as to ten non-natural analogs.  While the biol. data confirmed the remarkable potency of this class of compds. and showed that the domain in question is indeed an innate part of the pharmacophore, the specific structure/activity relationships can only partly be reconciled with the original in silico docking study; therefore we conclude that this model needs to be carefully revisited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7gaSUvu2SH7Vg90H21EOLACvtfcHk0lgF9tDawpurQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVant7nP&md5=ca254aa5120faddea81e3b37fed4e9ec</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.7b02871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.7b02871%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DSouillart%26aufirst%3DL.%26aulast%3DMonks%26aufirst%3DB.%26aulast%3DHuwyler%26aufirst%3DN.%26aulast%3DHerrmann%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DR.%26aulast%3DF%25C3%25BCrstner%26aufirst%3DA.%26atitle%3DA%2520%25E2%2580%259CMotif-Oriented%25E2%2580%259D%2520Total%2520Synthesis%2520of%2520Nannocystin%2520Ax.%2520Preparation%2520and%2520Biological%2520Assessment%2520of%2520Analogues%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2018%26volume%3D83%26spage%3D6977%26epage%3D6994%26doi%3D10.1021%2Facs.joc.7b02871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">The Chemical Syntheses of Nannocystins</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2252</span>– <span class="NLM_lpage">2260</span>, <span class="refDoi"> DOI: 10.1055/s-0037-1611796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1055%2Fs-0037-1611796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFCrur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=2252-2260&author=Z.+Wang&title=The+Chemical+Syntheses+of+Nannocystins&doi=10.1055%2Fs-0037-1611796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">The chemical syntheses of nannocystins</span></div><div class="casAuthors">Wang, Zhang</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2252-2260</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">1437-210X</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A review.  The broad and potent anticancer activity of the nannocystin family of natural products has attracted significant efforts toward their total syntheses.  Currently, seven total syntheses of different members of the nannocystins have been reported.  In this short review, different synthetic approaches are highlighted.  The reported structure-activity relationship (SAR) studies will also be highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-CyVExyEZ-LVg90H21EOLACvtfcHk0lgF9tDawpurQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFCrur0%253D&md5=6b70c4ba5c6b1f09d8c5771207c9547f</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1055%2Fs-0037-1611796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0037-1611796%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DThe%2520Chemical%2520Syntheses%2520of%2520Nannocystins%26jtitle%3DSynthesis%26date%3D2019%26volume%3D51%26spage%3D2252%26epage%3D2260%26doi%3D10.1055%2Fs-0037-1611796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span> <span> </span><span class="NLM_article-title">Novel Nannocystin A Analogues as Anticancer Therapeutics: Synthesis, Biological Evaluations and Structure–activity Relationship Studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.ejmech.2019.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30878835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFCls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2019&pages=99-111&author=Q.+Liuauthor=X.+Yangauthor=J.+Jiauthor=S.+L.+Zhangauthor=Y.+He&title=Novel+Nannocystin+A+Analogues+as+Anticancer+Therapeutics%3A+Synthesis%2C+Biological+Evaluations+and+Structure%E2%80%93activity+Relationship+Studies&doi=10.1016%2Fj.ejmech.2019.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Novel nannocystin A analogs as anticancer therapeutics: Synthesis, biological evaluations and structure-activity relationship studies</span></div><div class="casAuthors">Liu, Qiang; Yang, Xiaohong; Ji, Jie; Zhang, Shao-Lin; He, Yun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">99-111</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Nannocystin A is a novel 21-membered macrocyclic lactam that targets eukaryotic translation elongation factor 1α (eEF1A) and displays potent antiproliferative activities.  Herein, a series of nannocystin A analogs were synthesized and their structure-activity relationship (SAR) were established based on the MTT assay and western blotting anal.  The SAR enabled us to identify a structurally simplified nannocystin A analog LQ18, which exhibited potent antiproliferative activities with IC50 values ranging from 4.3 to 48 nM against the tested cell lines, and inhibited eEF1A1 expression in A549 cell line.  LQ18 arrested cell cycle at G2 phase and induced A549 cell apoptosis via up-regulation of caspase-3, caspase-9 and bax protein expressions in a dose-dependent manner, while it significantly decreased the bcl-2 expression.  Collectively, these data demonstrated that LQ18 could be a promising lead for the development of structurally novel eEF1A1 inhibitor for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmZIvGRZLOsrVg90H21EOLACvtfcHk0lgzgvALkT_h_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFCls7Y%253D&md5=0e7d15caa20c2f9146d0c61045793b8f</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.%2BL.%26aulast%3DHe%26aufirst%3DY.%26atitle%3DNovel%2520Nannocystin%2520A%2520Analogues%2520as%2520Anticancer%2520Therapeutics%253A%2520Synthesis%252C%2520Biological%2520Evaluations%2520and%2520Structure%25E2%2580%2593activity%2520Relationship%2520Studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D170%26spage%3D99%26epage%3D111%26doi%3D10.1016%2Fj.ejmech.2019.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashima, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, D.</span></span> <span> </span><span class="NLM_article-title">Biological Activity, Structural Features, and Synthetic Studies of (−)-Ternatin, a Potent Fat-Accumulation Inhibitor of 3T3-L1 Adipocytes</span>. <i>Chem. - Asian J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1002/asia.200700243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fasia.200700243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18181124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Wjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=438-446&author=K.+Shimokawaauthor=I.+Mashimaauthor=A.+Asaiauthor=T.+Ohnoauthor=K.+Yamadaauthor=M.+Kitaauthor=D.+Uemura&title=Biological+Activity%2C+Structural+Features%2C+and+Synthetic+Studies+of+%28%E2%88%92%29-Ternatin%2C+a+Potent+Fat-Accumulation+Inhibitor+of+3T3-L1+Adipocytes&doi=10.1002%2Fasia.200700243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Biological activity, structural features, and synthetic studies of (-)-ternatin, a potent fat-accumulation inhibitor of 3T3-L1 adipocytes</span></div><div class="casAuthors">Shimokawa, Kenichiro; Mashima, Itsuka; Asai, Akiko; Ohno, Tomohiro; Yamada, Kaoru; Kita, Masaki; Uemura, Daisuke</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - An Asian Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">438-446</span>CODEN:
                <span class="NLM_cas:coden">CAAJBI</span>;
        ISSN:<span class="NLM_cas:issn">1861-4728</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of studies, including preliminary screening, isolation, structure detn., synthesis, and biol. evaluation, of (-)-ternatin (I) are described.  A highly N-methylated cyclic heptapeptide isolated from the mushroom Coriolus versicolor, 1 shows an inhibitory effect on fat accumulation by 3T3-L1 murine adipocytes (EC50 = 0.02 μg mL-1).  Detailed anal. of 1D and 2D NMR spectra, as well as amino acid anal., suggested four stereoisomers as candidates for 1.  For the complete structural elucidation of I, chem. syntheses were carried out by solid phase peptide synthesis.  By comparing the spectroscopic data for the natural product with the data for the synthetic stereoisomers, the structure of I was confirmed to be cyclo[D-allo-Ile1-L-(NMe)Ala2-L-(NMe)Leu3-L-Leu4-L-(NMe)Ala5-D-(NMe)Ala6-(2R,3R)-3-hydroxy-Leu7].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxOWsG8yJybrVg90H21EOLACvtfcHk0lgzgvALkT_h_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Wjtbk%253D&md5=e011c366fd0ac258f17003747bdf71b0</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1002%2Fasia.200700243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fasia.200700243%26sid%3Dliteratum%253Aachs%26aulast%3DShimokawa%26aufirst%3DK.%26aulast%3DMashima%26aufirst%3DI.%26aulast%3DAsai%26aufirst%3DA.%26aulast%3DOhno%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DKita%26aufirst%3DM.%26aulast%3DUemura%26aufirst%3DD.%26atitle%3DBiological%2520Activity%252C%2520Structural%2520Features%252C%2520and%2520Synthetic%2520Studies%2520of%2520%2528%25E2%2588%2592%2529-Ternatin%252C%2520a%2520Potent%2520Fat-Accumulation%2520Inhibitor%2520of%25203T3-L1%2520Adipocytes%26jtitle%3DChem.%2520-%2520Asian%2520J.%26date%3D2008%26volume%3D3%26spage%3D438%26epage%3D446%26doi%3D10.1002%2Fasia.200700243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Inhibitory Effect on Fat Accumulation of (−)-Ternatin Derivatives Modified in the β-OH-d-Leu7Moiety</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1039/B714710D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1039%2FB714710D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18075648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVanur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=58-60&author=K.+Shimokawaauthor=Y.+Iwaseauthor=K.+Yamadaauthor=D.+Uemura&title=Synthesis+and+Inhibitory+Effect+on+Fat+Accumulation+of+%28%E2%88%92%29-Ternatin+Derivatives+Modified+in+the+%CE%B2-OH-d-Leu7Moiety&doi=10.1039%2FB714710D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and inhibitory effect on fat accumulation of (-)-ternatin derivatives modified in the β-OH-D-Leu7 moiety</span></div><div class="casAuthors">Shimokawa, Kenichiro; Iwase, Yoshiaki; Yamada, Kaoru; Uemura, Daisuke</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-60</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">An efficient synthesis of (-)-ternatin derivs. directed toward their SAR at the β-OH-D-Leu7 moiety and their biol. activities against 3T3-L1 murine adipocytes are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-uiEvw0JJMbVg90H21EOLACvtfcHk0lgzgvALkT_h_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVanur7P&md5=54345d5f52ff75ebc876913fca251712</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1039%2FB714710D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB714710D%26sid%3Dliteratum%253Aachs%26aulast%3DShimokawa%26aufirst%3DK.%26aulast%3DIwase%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DUemura%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520Inhibitory%2520Effect%2520on%2520Fat%2520Accumulation%2520of%2520%2528%25E2%2588%2592%2529-Ternatin%2520Derivatives%2520Modified%2520in%2520the%2520%25CE%25B2-OH-d-Leu7Moiety%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2008%26volume%3D6%26spage%3D58%26epage%3D60%26doi%3D10.1039%2FB714710D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carelli, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethofer, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Ternatin and Improved Synthetic Variants Kill Cancer Cells by Targeting the Elongation Factor-1A Ternary Complex</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e10222</span>, <span class="refDoi"> DOI: 10.7554/eLife.10222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.7554%2FeLife.10222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26651998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVCmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=e10222&author=J.+D.+Carelliauthor=S.+G.+Sethoferauthor=G.+A.+Smithauthor=H.+R.+Millerauthor=J.+L.+Simardauthor=W.+C.+Merrickauthor=R.+K.+Jainauthor=N.+T.+Rossauthor=J.+Taunton&title=Ternatin+and+Improved+Synthetic+Variants+Kill+Cancer+Cells+by+Targeting+the+Elongation+Factor-1A+Ternary+Complex&doi=10.7554%2FeLife.10222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex</span></div><div class="casAuthors">Carelli, Jordan D.; Sethofer, Steven G.; Smith, Geoffrey A.; Miller, Howard R.; Simard, Jillian L.; Merrick, William C.; Jain, Rishi K.; Ross, Nathan T.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e10222/1-e10222/22</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Cyclic peptide natural products have evolved to exploit diverse protein targets, many of which control essential cellular processes.  Inspired by a series of cyclic peptides with partially elucidated structures, we designed synthetic variants of ternatin, a cytotoxic and anti-adipogenic natural product whose mol. mode of action was unknown.  The new ternatin variants are cytotoxic toward cancer cells, with up to 500-fold greater potency than ternatin itself.  Using a ternatin photo-affinity probe, we identify the translation elongation factor-1A ternary complex (eEF1A & amp; #x00B7;GTP & amp; #x00B7;aminoacyl-tRNA) as a specific target and demonstrate competitive binding by the unrelated natural products, didemnin and cytotrienin.  Mutations in domain III of eEF1A prevent ternatin binding and confer resistance to its cytotoxic effects, implicating the adjacent hydrophobic surface as a functional hot spot for eEF1A modulation.  We conclude that the eukaryotic elongation factor-1A and its ternary complex with GTP and aminoacyl-tRNA are common targets for the evolution of cytotoxic natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojDP-U8yDv77Vg90H21EOLACvtfcHk0liWGLgxhVbD-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVCmu7g%253D&md5=72d3537da927c1aaeb08de26669baff3</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.7554%2FeLife.10222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.10222%26sid%3Dliteratum%253Aachs%26aulast%3DCarelli%26aufirst%3DJ.%2BD.%26aulast%3DSethofer%26aufirst%3DS.%2BG.%26aulast%3DSmith%26aufirst%3DG.%2BA.%26aulast%3DMiller%26aufirst%3DH.%2BR.%26aulast%3DSimard%26aufirst%3DJ.%2BL.%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DRoss%26aufirst%3DN.%2BT.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DTernatin%2520and%2520Improved%2520Synthetic%2520Variants%2520Kill%2520Cancer%2520Cells%2520by%2520Targeting%2520the%2520Elongation%2520Factor-1A%2520Ternary%2520Complex%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26spage%3De10222%26doi%3D10.7554%2FeLife.10222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yip, A.</span>; <span class="NLM_string-name">Hann, J.</span>; <span class="NLM_string-name">Bhd, T. S.</span></span> <span> </span><span class="NLM_article-title">Bioactive Compounds</span>. <span class="NLM_patent">WO 2010/062159Al</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=A.+Yip&author=J.+Hann&author=T.+S.+Bhd&title=Bioactive+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYip%26aufirst%3DA.%26atitle%3DBioactive%2520Compounds%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Goietsenoven, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallemand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefranc, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenbussche, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Antwerpen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evidente, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prévost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzy, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornienko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, V.</span></span> <span> </span><span class="NLM_article-title">Targeting of EEF1A with Amaryllidaceae Isocarbostyrils as a Strategy to Combat Melanomas</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4575</span>– <span class="NLM_lpage">4584</span>, <span class="refDoi"> DOI: 10.1096/fj.10-162263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1096%2Ffj.10-162263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=20643906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWqu7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=4575-4584&author=G.+Van%0AGoietsenovenauthor=J.+Huttonauthor=J.+P.+Beckerauthor=B.+Lallemandauthor=F.+Robertauthor=F.+Lefrancauthor=C.+Pirkerauthor=G.+Vandenbusscheauthor=P.+Van+Antwerpenauthor=A.+Evidenteauthor=W.+Bergerauthor=M.+Pr%C3%A9vostauthor=J.+Pelletierauthor=R.+Kissauthor=T.+G.+Kinzyauthor=A.+Kornienkoauthor=V.+Mathieu&title=Targeting+of+EEF1A+with+Amaryllidaceae+Isocarbostyrils+as+a+Strategy+to+Combat+Melanomas&doi=10.1096%2Ffj.10-162263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas</span></div><div class="casAuthors">Van Goietsenoven, Gwendoline; Hutton, Jenna; Becker, Jean-Paul; Lallemand, Benjamin; Robert, Francis; Lefranc, Florence; Pirker, Christine; Vandenbussche, Guy; Van Antwerpen, Pierre; Evidente, Antonio; Berger, Walter; Prevost, Martine; Pelletier, Jerry; Kiss, Robert; Kinzy, Terri Goss; Kornienko, Alexander; Mathieu, Veronique</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4575-4584, 10.1096/fj.10-162263</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Melanomas display poor response rates to adjuvant therapies because of their intrinsic resistance to proapoptotic stimuli.  This study indicates that such resistance can be overcome, at least partly, through the targeting of eEF1A elongation factor with narciclasine, an Amaryllidaceae isocarbostyril controlling plant growth.  Narciclasine displays IC50 growth inhibitory values between 30-100 nM in melanoma cell lines, irresp. of their levels of resistance to proapoptotic stimuli.  Normal noncancerous cell lines are much less affected.  At nontoxic doses, narciclasine also significantly improves (P = 0.004) the survival of mice bearing metastatic apoptosis-resistant melanoma xenografts in their brain.  The eEF1A targeting with narciclasine (50 nM) leads to 1) marked actin cytoskeleton disorganization, resulting in cytokinesis impairment, and 2) protein synthesis impairment (elongation and initiation steps), whereas apoptosis is induced at higher doses only (≥200 nM).  In addn. to mol. docking validation and identification of potential binding sites, we biochem. confirmed that narciclasine directly binds to human recombinant and yeast-purified eEF1A in a nanomolar range, but not to actin or elongation factor 2, and that 5 nM narciclasine is sufficient to impair eEF1A-related actin bundling activity.  EEF1A is thus a potential target to combat melanomas regardless of their apoptosis-sensitivity, and this finding reconciles the pleiotropic cytostatic of narciclasine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowfSWDPcWvSrVg90H21EOLACvtfcHk0liWGLgxhVbD-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWqu7nP&md5=7c10cf11667e956546186a532c83c071</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1096%2Ffj.10-162263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.10-162263%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoietsenoven%26aufirst%3DG.%26aulast%3DHutton%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DJ.%2BP.%26aulast%3DLallemand%26aufirst%3DB.%26aulast%3DRobert%26aufirst%3DF.%26aulast%3DLefranc%26aufirst%3DF.%26aulast%3DPirker%26aufirst%3DC.%26aulast%3DVandenbussche%26aufirst%3DG.%26aulast%3DVan%2BAntwerpen%26aufirst%3DP.%26aulast%3DEvidente%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DPr%25C3%25A9vost%26aufirst%3DM.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DKiss%26aufirst%3DR.%26aulast%3DKinzy%26aufirst%3DT.%2BG.%26aulast%3DKornienko%26aufirst%3DA.%26aulast%3DMathieu%26aufirst%3DV.%26atitle%3DTargeting%2520of%2520EEF1A%2520with%2520Amaryllidaceae%2520Isocarbostyrils%2520as%2520a%2520Strategy%2520to%2520Combat%2520Melanomas%26jtitle%3DFASEB%2520J.%26date%3D2010%26volume%3D24%26spage%3D4575%26epage%3D4584%26doi%3D10.1096%2Ffj.10-162263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doudna, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, V. L.</span></span> <span> </span><span class="NLM_article-title">Structure and Function of the Eukaryotic Ribosome: The next Frontier</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(02)00725-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2FS0092-8674%2802%2900725-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=12007402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1ektLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=153-156&author=J.+A.+Doudnaauthor=V.+L.+Rath&title=Structure+and+Function+of+the+Eukaryotic+Ribosome%3A+The+next+Frontier&doi=10.1016%2FS0092-8674%2802%2900725-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of the eukaryotic ribosome: The next frontier</span></div><div class="casAuthors">Doudna, Jennifer A.; Rath, Virginia L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-156</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 12 refs.  As the catalytic and regulatory centers of protein synthesis in cells, ribosomes are central to many aspects of cell and structural biol.  Recent work highlights the unique properties and complexity of eukaryotic ribosomes and their component rRNAs and proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYViixBvJ0e7Vg90H21EOLACvtfcHk0liWGLgxhVbD-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1ektLg%253D&md5=1fd9c2b6dca0bb75217f7fd3cc0a7b8c</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900725-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900725-0%26sid%3Dliteratum%253Aachs%26aulast%3DDoudna%26aufirst%3DJ.%2BA.%26aulast%3DRath%26aufirst%3DV.%2BL.%26atitle%3DStructure%2520and%2520Function%2520of%2520the%2520Eukaryotic%2520Ribosome%253A%2520The%2520next%2520Frontier%26jtitle%3DCell%26date%3D2002%26volume%3D109%26spage%3D153%26epage%3D156%26doi%3D10.1016%2FS0092-8674%2802%2900725-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klinge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigts-Hoffmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibundgut, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arpagaus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, N.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Eukaryotic 60S Ribosomal Subunit in Complex with Initiation Factor 6</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">948</span>, <span class="refDoi"> DOI: 10.1126/science.1211204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1126%2Fscience.1211204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22052974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGktL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2011&pages=941-948&author=S.+Klingeauthor=F.+Voigts-Hoffmannauthor=M.+Leibundgutauthor=S.+Arpagausauthor=N.+Ban&title=Crystal+Structure+of+the+Eukaryotic+60S+Ribosomal+Subunit+in+Complex+with+Initiation+Factor+6&doi=10.1126%2Fscience.1211204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the eukaryotic 60S ribosomal subunit in complex with initiation factor 6</span></div><div class="casAuthors">Klinge, Sebastian; Voigts-Hoffmann, Felix; Leibundgut, Marc; Arpagaus, Sofia; Ban, Nenad</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">6058</span>),
    <span class="NLM_cas:pages">941-948</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Protein synthesis in all organisms is catalyzed by ribosomes.  In comparison to their prokaryotic counterparts, eukaryotic ribosomes are considerably larger and are subject to more complex regulation.  The ribosome large subunit (60S) catalyzes peptide bond formation and contains the nascent polypeptide exit tunnel.  Here, the authors present the structure of the ribosome 60S subunit of Tetrahymena thermophila in complex with eukaryotic initiation factor 6 (eIF-6), cocrystd. with the antibiotic, cycloheximide (a eukaryotic-specific inhibitor of protein synthesis), at a resoln. of 3.5 Å.  The structure illustrated the complex functional architecture of the eukaryotic 60S subunit, which comprises an intricate network of interactions between eukaryotic-specific ribosomal protein features and RNA expansion segments.  It revealed the roles of eukaryotic ribosomal protein elements in the stabilization of the active site and the extent of eukaryotic-specific differences in other functional regions of the subunit.  Furthermore, it elucidated the mol. basis of the interaction with eIF-6 and provided a structural framework for further studies of ribosome-assocd. diseases and the role of the 60S subunit in the initiation of protein synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8CoHGTFF0wLVg90H21EOLACvtfcHk0liWcGACFXmTMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGktL%252FI&md5=aada14c4da6f4162ce1bc7b26d059d90</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1126%2Fscience.1211204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1211204%26sid%3Dliteratum%253Aachs%26aulast%3DKlinge%26aufirst%3DS.%26aulast%3DVoigts-Hoffmann%26aufirst%3DF.%26aulast%3DLeibundgut%26aufirst%3DM.%26aulast%3DArpagaus%26aufirst%3DS.%26aulast%3DBan%26aufirst%3DN.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Eukaryotic%252060S%2520Ribosomal%2520Subunit%2520in%2520Complex%2520with%2520Initiation%2520Factor%25206%26jtitle%3DScience%26date%3D2011%26volume%3D334%26spage%3D941%26epage%3D948%26doi%3D10.1126%2Fscience.1211204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budkevich, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesebrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loerke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramrath, D. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrand, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nierhaus, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanbonmatsu, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spahn, C. M. T.</span></span> <span> </span><span class="NLM_article-title">Regulation of the Mammalian Elongation Cycle by Subunit Rolling: A Eukaryotic-Specific Ribosome Rearrangement</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2014.04.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.cell.2014.04.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24995983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWgur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2014&pages=121-131&author=T.+V.+Budkevichauthor=J.+Giesebrechtauthor=E.+Behrmannauthor=J.+Loerkeauthor=D.+J.+F.+Ramrathauthor=T.+Mielkeauthor=J.+Ismerauthor=P.+W.+Hildebrandauthor=C.+S.+Tungauthor=K.+H.+Nierhausauthor=K.+Y.+Sanbonmatsuauthor=C.+M.+T.+Spahn&title=Regulation+of+the+Mammalian+Elongation+Cycle+by+Subunit+Rolling%3A+A+Eukaryotic-Specific+Ribosome+Rearrangement&doi=10.1016%2Fj.cell.2014.04.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the Mammalian Elongation Cycle by Subunit Rolling: A Eukaryotic-Specific Ribosome Rearrangement</span></div><div class="casAuthors">Budkevich, Tatyana V.; Giesebrecht, Jan; Behrmann, Elmar; Loerke, Justus; Ramrath, David J. F.; Mielke, Thorsten; Ismer, Jochen; Hildebrand, Peter W.; Tung, Chang-Shung; Nierhaus, Knud H.; Sanbonmatsu, Karissa Y.; Spahn, Christian M. T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-131</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The extent to which bacterial ribosomes and the significantly larger eukaryotic ribosomes share the same mechanisms of ribosomal elongation is unknown.  Here, we present subnanometer resoln. cryoelectron microscopy maps of the mammalian 80S ribosome in the posttranslocational state and in complex with the eukaryotic eEF1A·Val-tRNA·GMPPNP ternary complex, revealing significant differences in the elongation mechanism between bacteria and mammals.  Surprisingly, and in contrast to bacterial ribosomes, a rotation of the small subunit around its long axis and orthogonal to the well-known intersubunit rotation distinguishes the posttranslocational state from the classical pretranslocational state ribosome.  We term this motion "subunit rolling.".  Correspondingly, a mammalian decoding complex visualized in substates before and after codon recognition reveals structural distinctions from the bacterial system.  These findings suggest how codon recognition leads to GTPase activation in the mammalian system and demonstrate that in mammalia subunit rolling occurs during tRNA selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosg2wAF629QrVg90H21EOLACvtfcHk0liWcGACFXmTMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWgur7L&md5=aa8f09b3e758df780e6391d97e7d3444</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.04.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.04.044%26sid%3Dliteratum%253Aachs%26aulast%3DBudkevich%26aufirst%3DT.%2BV.%26aulast%3DGiesebrecht%26aufirst%3DJ.%26aulast%3DBehrmann%26aufirst%3DE.%26aulast%3DLoerke%26aufirst%3DJ.%26aulast%3DRamrath%26aufirst%3DD.%2BJ.%2BF.%26aulast%3DMielke%26aufirst%3DT.%26aulast%3DIsmer%26aufirst%3DJ.%26aulast%3DHildebrand%26aufirst%3DP.%2BW.%26aulast%3DTung%26aufirst%3DC.%2BS.%26aulast%3DNierhaus%26aufirst%3DK.%2BH.%26aulast%3DSanbonmatsu%26aufirst%3DK.%2BY.%26aulast%3DSpahn%26aufirst%3DC.%2BM.%2BT.%26atitle%3DRegulation%2520of%2520the%2520Mammalian%2520Elongation%2520Cycle%2520by%2520Subunit%2520Rolling%253A%2520A%2520Eukaryotic-Specific%2520Ribosome%2520Rearrangement%26jtitle%3DCell%26date%3D2014%26volume%3D158%26spage%3D121%26epage%3D131%26doi%3D10.1016%2Fj.cell.2014.04.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ban, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steitz, T. A.</span></span> <span> </span><span class="NLM_article-title">The Complete Atomic Structure of the Large Ribosomal Subunit at 2.4 A Resolution</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1126/science.289.5481.905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1126%2Fscience.289.5481.905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10937989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BD3cvgslCgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=905-920&author=N.+Banauthor=P.+Nissenauthor=J.+Hansenauthor=P.+B.+Mooreauthor=T.+A.+Steitz&title=The+Complete+Atomic+Structure+of+the+Large+Ribosomal+Subunit+at+2.4+A+Resolution&doi=10.1126%2Fscience.289.5481.905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">The complete atomic structure of the large ribosomal subunit at 2.4 A resolution</span></div><div class="casAuthors">Ban N; Nissen P; Hansen J; Moore P B; Steitz T A</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5481</span>),
    <span class="NLM_cas:pages">905-20</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The large ribosomal subunit catalyzes peptide bond formation and binds initiation, termination, and elongation factors.  We have determined the crystal structure of the large ribosomal subunit from Haloarcula marismortui at 2.4 angstrom resolution, and it includes 2833 of the subunit's 3045 nucleotides and 27 of its 31 proteins.  The domains of its RNAs all have irregular shapes and fit together in the ribosome like the pieces of a three-dimensional jigsaw puzzle to form a large, monolithic structure.  Proteins are abundant everywhere on its surface except in the active site where peptide bond formation occurs and where it contacts the small subunit.  Most of the proteins stabilize the structure by interacting with several RNA domains, often using idiosyncratically folded extensions that reach into the subunit's interior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5gYgXyiJOxLP3FVUi_gf8fW6udTcc2eavA3QgfmBo17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvgslCgsA%253D%253D&md5=8c3401c1958c34bd8b81f98a5081d2b7</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5481.905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5481.905%26sid%3Dliteratum%253Aachs%26aulast%3DBan%26aufirst%3DN.%26aulast%3DNissen%26aufirst%3DP.%26aulast%3DHansen%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DP.%2BB.%26aulast%3DSteitz%26aufirst%3DT.%2BA.%26atitle%3DThe%2520Complete%2520Atomic%2520Structure%2520of%2520the%2520Large%2520Ribosomal%2520Subunit%2520at%25202.4%2520A%2520Resolution%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D905%26epage%3D920%26doi%3D10.1126%2Fscience.289.5481.905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalla Venezia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J.-J.</span></span> <span> </span><span class="NLM_article-title">Emerging Role of Eukaryote Ribosomes in Translational Control</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1226</span>, <span class="refDoi"> DOI: 10.3390/ijms20051226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fijms20051226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFOntrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1226&author=N.+Dalla+Veneziaauthor=A.+Vincentauthor=V.+Marcelauthor=F.+Catezauthor=J.-J.+Diaz&title=Emerging+Role+of+Eukaryote+Ribosomes+in+Translational+Control&doi=10.3390%2Fijms20051226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging role of eukaryote ribosomes in translational control</span></div><div class="casAuthors">Dalla Venezia, Nicole; Vincent, Anne; Marcel, Virginie; Catez, Frederic; Diaz, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1226</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Translation is one of the final steps that regulate gene expression.  The ribosome is the effector of translation through to its role in mRNA decoding and protein synthesis.  Many mechanisms have been extensively described accounting for translational regulation.  However it emerged only recently that ribosomes themselves could contribute to this regulation.  Indeed, though it is well-known that the translational efficiency of the cell is linked to ribosome abundance, studies recently demonstrated that the compn. of the ribosome could alter translation of specific mRNAs.  Evidences suggest that according to the status, environment, development, or pathol. conditions, cells produce different populations of ribosomes which differ in their ribosomal protein and/or RNA compn.  Those observations gave rise to the concept of "specialized ribosomes", which proposes that a unique ribosome compn. dets. the translational activity of this ribosome.  The current review will present how technol. advances have participated in the emergence of this concept, and to which extent the literature sustains this concept today.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwCtKPgHXh07Vg90H21EOLACvtfcHk0lixG7XXM4dHsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFOntrrO&md5=abc8a82eae8a987b480672f552273fb7</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.3390%2Fijms20051226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20051226%26sid%3Dliteratum%253Aachs%26aulast%3DDalla%2BVenezia%26aufirst%3DN.%26aulast%3DVincent%26aufirst%3DA.%26aulast%3DMarcel%26aufirst%3DV.%26aulast%3DCatez%26aufirst%3DF.%26aulast%3DDiaz%26aufirst%3DJ.-J.%26atitle%3DEmerging%2520Role%2520of%2520Eukaryote%2520Ribosomes%2520in%2520Translational%2520Control%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1226%26doi%3D10.3390%2Fijms20051226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in Ribosome Profiling for Deciphering Translational Regulation</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/j.ymeth.2019.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.ymeth.2019.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31103613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSqurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2020&pages=46-54&author=Y.+Wangauthor=H.+Zhangauthor=J.+Lu&title=Recent+Advances+in+Ribosome+Profiling+for+Deciphering+Translational+Regulation&doi=10.1016%2Fj.ymeth.2019.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in ribosome profiling for deciphering translational regulation</span></div><div class="casAuthors">Wang, Yirong; Zhang, Hong; Lu, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Methods (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-54</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  MRNA (mRNA) translation is a central step of gene expression.  Translational regulation plays essential roles in various biol. processes.  Ribosome profiling is a powerful technique to study genome-wide translational regulation at a single-codon resoln.  Based on conventional ribosome profiling procedures, many new exptl. methods have recently been developed to investigate the biol. of mRNA translation from different aspects.  These tech. advances have significantly advanced our understanding of translational regulation at genomic scales from the following perspectives: (1) identification of translational initiation sites; (2) characterization of the dynamics of the complete translation cycle; (3) profiling of active ribosomes; (4) tissue-specific translational regulation; (5) translational regulation in subcellular locations; (6) detection of ribosome traffic jams; (7) plastid translatomes; and (8) ribosome heterogeneity and translational preference.  Here, we summarize the key differences between these new techniques and the conventional ribosome profiling approach.  We also review the computational methods designed to analyze ribosome profiling data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEeAKYSWgiQbVg90H21EOLACvtfcHk0lixG7XXM4dHsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSqurbL&md5=5b88eb8855008017ca71f3a0f6046c47</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2019.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2019.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DJ.%26atitle%3DRecent%2520Advances%2520in%2520Ribosome%2520Profiling%2520for%2520Deciphering%2520Translational%2520Regulation%26jtitle%3DMethods%26date%3D2020%26volume%3D176%26spage%3D46%26epage%3D54%26doi%3D10.1016%2Fj.ymeth.2019.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornstein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mela, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gass, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amendolara, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canoll, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, P. A.</span></span> <span> </span><span class="NLM_article-title">Ribosome Profiling Reveals a Cell-Type-Specific Translational Landscape in Brain Tumors</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">10924</span>– <span class="NLM_lpage">10936</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.0084-14.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1523%2FJNEUROSCI.0084-14.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25122893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1equ7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=10924-10936&author=C.+Gonzalezauthor=J.+S.+Simsauthor=N.+Hornsteinauthor=A.+Melaauthor=F.+Garciaauthor=L.+Leiauthor=D.+A.+Gassauthor=B.+Amendolaraauthor=J.+N.+Bruceauthor=P.+Canollauthor=P.+A.+Sims&title=Ribosome+Profiling+Reveals+a+Cell-Type-Specific+Translational+Landscape+in+Brain+Tumors&doi=10.1523%2FJNEUROSCI.0084-14.2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosome profiling reveals a cell-type-specific translational landscape in brain tumors</span></div><div class="casAuthors">Gonzalez, Christian; Sims, Jennifer S.; Hornstein, Nicholas; Mela, Angeliki; Garcia, Franklin; Lei, Liang; Gass, David A.; Amendolara, Benjamin; Bruce, Jeffrey N.; Canoll, Peter; Sims, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">10924-10936, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Glioma growth is driven by signaling that ultimately regulates protein synthesis.  Gliomas are also complex at the cellular level and involve multiple cell types, including transformed and reactive cells in the brain tumor microenvironment.  The distinct functions of the various cell types likely lead to different requirements and regulatory paradigms for protein synthesis.  Proneural gliomas can arise from transformation of glial progenitors that are driven to proliferate via mitogenic signaling that affects translation.  To investigate translational regulation in this system, we developed a RiboTag glioma mouse model that enables cell-type-specific, genome-wide ribosome profiling of tumor tissue.  Infecting glial progenitors with Cre-recombinant retrovirus simultaneously activates expression of tagged ribosomes and delivers a tumor-initiating mutation.  Remarkably, we find that although genes specific to transformed cells are highly translated, their translation efficiencies are low compared with normal brain.  Ribosome positioning reveals sequence-dependent regulation of ribosomal activity in 5'-leaders upstream of annotated start codons, leading to differential translation in glioma compared with normal brain.  Addnl., although transformed cells express a proneural signature, untransformed tumor-assocd. cells, including reactive astrocytes and microglia, express a mesenchymal signature.  Finally, we observe the same phenomena in human disease by combining ribosome profiling of human proneural tumor and non-neoplastic brain tissue with computational deconvolution to assess cell-type-specific translational regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotHY4TaaVZlLVg90H21EOLACvtfcHk0lixG7XXM4dHsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1equ7vK&md5=5375dd6782e05087460e859df52a173c</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0084-14.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0084-14.2014%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez%26aufirst%3DC.%26aulast%3DSims%26aufirst%3DJ.%2BS.%26aulast%3DHornstein%26aufirst%3DN.%26aulast%3DMela%26aufirst%3DA.%26aulast%3DGarcia%26aufirst%3DF.%26aulast%3DLei%26aufirst%3DL.%26aulast%3DGass%26aufirst%3DD.%2BA.%26aulast%3DAmendolara%26aufirst%3DB.%26aulast%3DBruce%26aufirst%3DJ.%2BN.%26aulast%3DCanoll%26aufirst%3DP.%26aulast%3DSims%26aufirst%3DP.%2BA.%26atitle%3DRibosome%2520Profiling%2520Reveals%2520a%2520Cell-Type-Specific%2520Translational%2520Landscape%2520in%2520Brain%2520Tumors%26jtitle%3DJ.%2520Neurosci.%26date%3D2014%26volume%3D34%26spage%3D10924%26epage%3D10936%26doi%3D10.1523%2FJNEUROSCI.0084-14.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span> <span> </span><span class="NLM_article-title">Survey of the Translation Shifts in Hepatocellular Carcinoma with Ribosome Profiling</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4141</span>– <span class="NLM_lpage">4155</span>, <span class="refDoi"> DOI: 10.7150/thno.35033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.7150%2Fthno.35033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31281537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1ert7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=4141-4155&author=Q.+Zouauthor=Z.+Xiaoauthor=R.+Huangauthor=X.+Wangauthor=X.+Wangauthor=H.+Zhaoauthor=X.+Yang&title=Survey+of+the+Translation+Shifts+in+Hepatocellular+Carcinoma+with+Ribosome+Profiling&doi=10.7150%2Fthno.35033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Survey of the translation shifts in hepatocellular carcinoma with ribosome profiling</span></div><div class="casAuthors">Zou, Qin; Xiao, Zhengtao; Huang, Rongyao; Wang, Xin; Wang, Xun; Zhao, Haitao; Yang, Xuerui</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4141-4155</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Despite the crit. position of translation in the multilevel gene expression regulation program, high-resoln. and genome-wide view of the landscape of RNA translation in solid tumors is still limited.  A set of bioinformatics tools was then applied to these data for the mining of novel insights into the translation shifts in HCC.  Results: This is the first translatome data resource for dissecting dysregulated translation in HCC at the sub-codon resoln.  Based on our data, quant. comparisons of mRNA translation rates yielded the genes and processes that were subjected to patient specific or universal dysregulations of translation efficiencies in tumors.  For example, multiple proteins involved in extracellular matrix organization exhibited significant translational upregulation in tumors.  We then exptl. validated the tumor-promoting functions of two such genes as examples: AGRN and VWA1.  In addn., the data was also used for de novo annotation of the translatomes in tumors and normal tissues, including multiple types of novel non-canonical small ORFs, which would be a resource for further functional studies.  Conclusions: The present study generates the first survey of the HCC translatome with ribosome profiling, which is an insightful data resource for dissecting the translatome shift in liver cancer, at sub-codon resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmowvf1xTblrVg90H21EOLACvtfcHk0lixG7XXM4dHsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1ert7jF&md5=bc79a38554b6ddc5c87c6422126742b0</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.7150%2Fthno.35033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.35033%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DQ.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DX.%26atitle%3DSurvey%2520of%2520the%2520Translation%2520Shifts%2520in%2520Hepatocellular%2520Carcinoma%2520with%2520Ribosome%2520Profiling%26jtitle%3DTheranostics%26date%3D2019%26volume%3D9%26spage%3D4141%26epage%3D4155%26doi%3D10.7150%2Fthno.35033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manfrini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventura, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calamita, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biffo, S.</span></span> <span> </span><span class="NLM_article-title">Ribosome Profiling Unveils Translational Regulation of Metabolic Enzymes in Primary CD4+ Th1 Cells</span>. <i>Dev. Comp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">103697</span>, <span class="refDoi"> DOI: 10.1016/j.dci.2020.103697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.dci.2020.103697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=32330465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXot1Ciurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2020&pages=103697&author=N.+Manfriniauthor=S.+Ricciardiauthor=R.+Alfieriauthor=G.+Venturaauthor=P.+Calamitaauthor=A.+Favalliauthor=S.+Biffo&title=Ribosome+Profiling+Unveils+Translational+Regulation+of+Metabolic+Enzymes+in+Primary+CD4%2B+Th1+Cells&doi=10.1016%2Fj.dci.2020.103697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosome profiling unveils translational regulation of metabolic enzymes in primary CD4+ Th1 cells</span></div><div class="casAuthors">Manfrini, Nicola; Ricciardi, Sara; Alfieri, Roberta; Ventura, Gabriele; Calamita, Piera; Favalli, Andrea; Biffo, Stefano</div><div class="citationInfo"><span class="NLM_cas:title">Developmental & Comparative Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103697</span>CODEN:
                <span class="NLM_cas:coden">DCIMDQ</span>;
        ISSN:<span class="NLM_cas:issn">0145-305X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The transition from a naive to an effector T cell is an essential event that requires metabolic reprogramming.  We have recently demonstrated that the rapid metabolic changes that occur following stimulation of naive T cells require the translation of preexisting mRNAs.  Here, we provide evidence that translation regulates the metabolic asset of effector T cells.  By performing ribosome profiling in human CD4+ Th1 cells, we show that the metab. of glucose, fatty acids and pentose phosphates is regulated at the translational level.  In Th1 cells, each pathway has at least one enzyme regulated at the translational level and selected enzymes have high translational efficiencies. mRNA expression does not predict protein expression.  For instance, PKM2 mRNA is equally present in naive T and Th1 cells, but the protein is abundant only in Th1. 5'-untranslated regions (UTRs) may partly account for this regulation.  Overall we suggest that immunometabolism is controlled by translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLS3bz2OUpBbVg90H21EOLACvtfcHk0liOgjmO9b5WOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXot1Ciurg%253D&md5=4dfe610d40ba2388b05ae997e92fb35a</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.dci.2020.103697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dci.2020.103697%26sid%3Dliteratum%253Aachs%26aulast%3DManfrini%26aufirst%3DN.%26aulast%3DRicciardi%26aufirst%3DS.%26aulast%3DAlfieri%26aufirst%3DR.%26aulast%3DVentura%26aufirst%3DG.%26aulast%3DCalamita%26aufirst%3DP.%26aulast%3DFavalli%26aufirst%3DA.%26aulast%3DBiffo%26aufirst%3DS.%26atitle%3DRibosome%2520Profiling%2520Unveils%2520Translational%2520Regulation%2520of%2520Metabolic%2520Enzymes%2520in%2520Primary%2520CD4%252B%2520Th1%2520Cells%26jtitle%3DDev.%2520Comp.%2520Immunol.%26date%3D2020%26volume%3D109%26spage%3D103697%26doi%3D10.1016%2Fj.dci.2020.103697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mort, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuzhanova, N. A.</span></span> <span> </span><span class="NLM_article-title">A Meta-Analysis of Nonsense Mutations Causing Human Genetic Disease</span>. <i>Hum. Mutat.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1037</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1002/humu.20763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fhumu.20763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18454449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCqu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=1037-1047&author=M.+Mortauthor=D.+Ivanovauthor=D.+N.+Cooperauthor=N.+A.+Chuzhanova&title=A+Meta-Analysis+of+Nonsense+Mutations+Causing+Human+Genetic+Disease&doi=10.1002%2Fhumu.20763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">A meta-analysis of nonsense mutations causing human genetic disease</span></div><div class="casAuthors">Mort, Matthew; Ivanov, Dobril; Cooper, David N.; Chuzhanova, Nadia A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Mutation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1037-1047</span>CODEN:
                <span class="NLM_cas:coden">HUMUE3</span>;
        ISSN:<span class="NLM_cas:issn">1059-7794</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Nonsense mutations account for ∼11% of all described gene lesions causing human inherited disease and ∼20% of disease-assocd. single-basepair substitutions affecting gene coding regions.  Pathol. nonsense mutations resulting in TGA (38.5%), TAG (40.4%), and TAA (21.1%) occur in different proportions to naturally occurring stop codons.  Of the 23 different nucleotide substitutions giving rise to nonsense mutations, the most frequent are CGA→TGA (21%; resulting from methylation-mediated deamination) and CAG→TAG (19%).  The differing nonsense mutation frequencies are largely explicable in terms of variable nucleotide substitution rates such that it is unnecessary to invoke differential translational termination efficiency or differential codon usage.  Some genes are characterized by numerous nonsense mutations but relatively few if any missense mutations (e.g., CHM) whereas other genes exhibit many missense mutations but few if any nonsense mutations (e.g., PSEN1).  Genes in the latter category have a tendency to encode proteins characterized by multimer formation.  Consistent with the operation of a clin. selection bias, genes exhibiting an excess of nonsense mutations are also likely to display an excess of frameshift mutations.  Tumor suppressor (TS) genes exhibit a disproportionate no. of nonsense mutations while most mutations in oncogenes are missense.  A total of 12% of somatic nonsense mutations in TS genes were found to occur recurrently in the hypermutable CpG dinucleotide.  In a comparison of somatic and germline mutational spectra for 17 TS genes, ∼43% of somatic nonsense mutations had counterparts in the germline (rising to 98% for CpG mutations).  Finally, the proportion of disease-causing nonsense mutations predicted to elicit nonsense-mediated mRNA decay (NMD) is significantly higher (P = 1.56 × 10-9) than among nonobserved (potential) nonsense mutations, implying that nonsense mutations that elicit NMD are more likely to come to clin. attention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqclqgu8RD0S7Vg90H21EOLACvtfcHk0liOgjmO9b5WOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCqu7vI&md5=ac21ee29de687326330807cbd0017b4a</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2Fhumu.20763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhumu.20763%26sid%3Dliteratum%253Aachs%26aulast%3DMort%26aufirst%3DM.%26aulast%3DIvanov%26aufirst%3DD.%26aulast%3DCooper%26aufirst%3DD.%2BN.%26aulast%3DChuzhanova%26aufirst%3DN.%2BA.%26atitle%3DA%2520Meta-Analysis%2520of%2520Nonsense%2520Mutations%2520Causing%2520Human%2520Genetic%2520Disease%26jtitle%3DHum.%2520Mutat.%26date%3D2008%26volume%3D29%26spage%3D1037%26epage%3D1047%26doi%3D10.1002%2Fhumu.20763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dabrowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukowy-Bieryllo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zietkiewicz, E.</span></span> <span> </span><span class="NLM_article-title">Advances in Therapeutic Use of a Drug-Stimulated Translational Readthrough of Premature Termination Codons</span>. <i>Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi"> DOI: 10.1186/s10020-018-0024-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1186%2Fs10020-018-0024-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=30134808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BB3c3gvVSjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=25&author=M.+Dabrowskiauthor=Z.+Bukowy-Bierylloauthor=E.+Zietkiewicz&title=Advances+in+Therapeutic+Use+of+a+Drug-Stimulated+Translational+Readthrough+of+Premature+Termination+Codons&doi=10.1186%2Fs10020-018-0024-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons</span></div><div class="casAuthors">Dabrowski Maciej; Bukowy-Bieryllo Zuzanna; Zietkiewicz Ewa</div><div class="citationInfo"><span class="NLM_cas:title">Molecular medicine (Cambridge, Mass.)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Premature termination codons (PTCs) in the coding regions of mRNA lead to the incorrect termination of translation and generation of non-functional, truncated proteins.  Translational readthrough of PTCs induced by pharmaceutical compounds is a promising way of restoring functional protein expression and reducing disease symptoms, without affecting the genome or transcriptome of the patient.  While in some cases proven effective, the clinical use of readthrough-inducing compounds is still associated with many risks and difficulties.  This review focuses on problems directly associated with compounds used to stimulate PTC readthrough, such as their interactions with the cell and organism, their toxicity and bioavailability (cell permeability; tissue deposition etc.).  Various strategies designed to overcome these problems are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTESyJJ7F50JGlSCSgBhwJFfW6udTcc2ebeIpdC5F7YQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3gvVSjtg%253D%253D&md5=a802b3ebc26179642d8941d76281eabb</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1186%2Fs10020-018-0024-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs10020-018-0024-7%26sid%3Dliteratum%253Aachs%26aulast%3DDabrowski%26aufirst%3DM.%26aulast%3DBukowy-Bieryllo%26aufirst%3DZ.%26aulast%3DZietkiewicz%26aufirst%3DE.%26atitle%3DAdvances%2520in%2520Therapeutic%2520Use%2520of%2520a%2520Drug-Stimulated%2520Translational%2520Readthrough%2520of%2520Premature%2520Termination%2520Codons%26jtitle%3DMol.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D25%26doi%3D10.1186%2Fs10020-018-0024-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagel-Wolfrum, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baasov, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfrum, U.</span></span> <span> </span><span class="NLM_article-title">Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs)</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1007/s40259-016-0157-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs40259-016-0157-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26886021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFCit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=49-74&author=K.+Nagel-Wolfrumauthor=F.+M%C3%B6llerauthor=I.+Pennerauthor=T.+Baasovauthor=U.+Wolfrum&title=Targeting+Nonsense+Mutations+in+Diseases+with+Translational+Read-Through-Inducing+Drugs+%28TRIDs%29&doi=10.1007%2Fs40259-016-0157-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs)</span></div><div class="casAuthors">Nagel-Wolfrum, Kerstin; Moeller, Fabian; Penner, Inessa; Baasov, Timor; Wolfrum, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">49-74</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">In recent years, remarkable advances in the ability to diagnose genetic disorders have been made.  The identification of disease-causing genes allows the development of gene-specific therapies with the ultimate goal to develop personalized medicines for each patient according to their own specific genetic defect.  In-depth genotyping of many different genes has revealed that ∼12 % of inherited genetic disorders are caused by in-frame nonsense mutations.  Nonsense (non-coding) mutations are caused by point mutations, which generate premature termination codons (PTCs) that cause premature translational termination of the mRNA, and subsequently inhibit normal full-length protein expression.  Recently, a gene-based therapeutic approach for genetic diseases caused by nonsense mutations has emerged, namely the so-called translational read-through (TR) therapy.  Read-through therapy is based on the discovery that small mols., known as TR-inducing drugs (TRIDs), allow the translation machinery to suppress a nonsense codon, elongate the nascent peptide chain, and consequently result in the synthesis of full-length protein.  Several TRIDs are currently under investigation and research has been performed on several genetic disorders caused by nonsense mutations over the years.  These findings have raised hope for the usage of TR therapy as a gene-based pharmacogenetic therapy for nonsense mutations in various genes responsible for a variety of genetic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMFXoY23VksrVg90H21EOLACvtfcHk0lg043yd14EiYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFCit7k%253D&md5=56a8249101e391d048e1982242099262</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1007%2Fs40259-016-0157-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-016-0157-6%26sid%3Dliteratum%253Aachs%26aulast%3DNagel-Wolfrum%26aufirst%3DK.%26aulast%3DM%25C3%25B6ller%26aufirst%3DF.%26aulast%3DPenner%26aufirst%3DI.%26aulast%3DBaasov%26aufirst%3DT.%26aulast%3DWolfrum%26aufirst%3DU.%26atitle%3DTargeting%2520Nonsense%2520Mutations%2520in%2520Diseases%2520with%2520Translational%2520Read-Through-Inducing%2520Drugs%2520%2528TRIDs%2529%26jtitle%3DBioDrugs%26date%3D2016%26volume%3D30%26spage%3D49%26epage%3D74%26doi%3D10.1007%2Fs40259-016-0157-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kampen, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulima, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vereecke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Keersmaecker, K.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of Ribosomopathies</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1093/nar/gkz637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1093%2Fnar%2Fgkz637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31350888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1OgurfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2020&pages=1013-1028&author=K.+R.+Kampenauthor=S.+O.+Sulimaauthor=S.+Vereeckeauthor=K.+De+Keersmaecker&title=Hallmarks+of+Ribosomopathies&doi=10.1093%2Fnar%2Fgkz637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of ribosomopathies</span></div><div class="casAuthors">Kampen, Kim R.; Sulima, Sergey O.; Vereecke, Stijn; De Keersmaecker, Kim</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1013-1028</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Ribosomopathies are diseases caused by defects in ribosomal constituents or in factors with a role in ribosome assembly.  Intriguingly, congenital ribosomopathies display a paradoxical transition from early symptoms due to cellular hypo-proliferation to an elevated cancer risk later in life.  Another assocn. between ribosome defects and cancer came into view after the recent discovery of somatic mutations in ribosomal proteins and rDNA copy no. changes in a variety of tumor types, giving rise to somatic ribosomopathies.  Despite these clear connections between ribosome defects and cancer, the mol. mechanisms by which defects in this essential cellular machinery are oncogenic only start to emerge.  In this review, the impact of ribosomal defects on the cellular function and their mechanisms of promoting oncogenesis are described.  In particular, we discuss the emerging hallmarks of ribosomopathies such as the appearance of 'onco-ribosomes' that are specialized in translating oncoproteins, dysregulation of translation-independent extra-ribosomal functions of ribosomal proteins, rewired cellular protein and energy metab., and extensive oxidative stress leading to DNA damage.  We end by integrating these findings in a model that can provide an explanation how ribosomopathies could lead to the transition from hypo- to hyper-proliferation in bone marrow failure syndromes with elevated cancer risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgQP1oo3Ap_7Vg90H21EOLACvtfcHk0lg043yd14EiYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1OgurfE&md5=2cd44a5482996d80ca9da5cf5d5bf3b9</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkz637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkz637%26sid%3Dliteratum%253Aachs%26aulast%3DKampen%26aufirst%3DK.%2BR.%26aulast%3DSulima%26aufirst%3DS.%2BO.%26aulast%3DVereecke%26aufirst%3DS.%26aulast%3DDe%2BKeersmaecker%26aufirst%3DK.%26atitle%3DHallmarks%2520of%2520Ribosomopathies%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2020%26volume%3D48%26spage%3D1013%26epage%3D1028%26doi%3D10.1093%2Fnar%2Fgkz637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakhoul, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span> <span> </span><span class="NLM_article-title">Ribosomopathies: Mechanisms of Disease</span>. <i>Clin. Med. Insights Blood Disord.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.4137/CMBD.S16952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.4137%2FCMBD.S16952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25512719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFahsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=7-16&author=H.+Nakhoulauthor=J.+Keauthor=X.+Zhouauthor=W.+Liaoauthor=S.+X.+Zengauthor=H.+Lu&title=Ribosomopathies%3A+Mechanisms+of+Disease&doi=10.4137%2FCMBD.S16952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosomopathies: mechanisms of disease</span></div><div class="casAuthors">Nakhoul, Hani; Ke, Jiangwei; Zhou, Xiang; Liao, Wenjuan; Zeng, Shelya X.; Lu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Medicine Insights: Blood Disorders</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7-16</span>CODEN:
                <span class="NLM_cas:coden">CMIBCH</span>;
        ISSN:<span class="NLM_cas:issn">1179-545X</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica Ltd.</span>)
        </div><div class="casAbstract">A review.  Ribosomopathies are diseases caused by alterations in the structure or function of ribosomal components.  Progress in our understanding of the role of the ribosome in translational and transcriptional regulation has clarified the mechanisms of the ribosomopathies and the relationship between ribosomal dysfunction and other diseases, esp. cancer.  This review aims to discuss these topics with updated information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHrgnGkVB-KbVg90H21EOLACvtfcHk0lg043yd14EiYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFahsbbK&md5=725705ea6ddfd392f8f992d710e21511</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.4137%2FCMBD.S16952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FCMBD.S16952%26sid%3Dliteratum%253Aachs%26aulast%3DNakhoul%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLiao%26aufirst%3DW.%26aulast%3DZeng%26aufirst%3DS.%2BX.%26aulast%3DLu%26aufirst%3DH.%26atitle%3DRibosomopathies%253A%2520Mechanisms%2520of%2520Disease%26jtitle%3DClin.%2520Med.%2520Insights%2520Blood%2520Disord.%26date%3D2014%26volume%3D7%26spage%3D7%26epage%3D16%26doi%3D10.4137%2FCMBD.S16952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frechin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchiar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeffelholz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Holvec, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaval, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winum, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaholz, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyron, J.-F.</span></span> <span> </span><span class="NLM_article-title">Targeting the Human 80S Ribosome in Cancer: From Structure to Function and Drug Design for Innovative Adjuvant Therapeutic Strategies</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">629</span>, <span class="refDoi"> DOI: 10.3390/cells9030629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fcells9030629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVSqt7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=629&author=A.+Gillesauthor=L.+Frechinauthor=K.+Natchiarauthor=G.+Biondaniauthor=O.+Loeffelholzauthor=S.+von+Holvecauthor=J.-L.+Malavalauthor=J.-Y.+Winumauthor=B.+P.+Klaholzauthor=J.-F.+Peyron&title=Targeting+the+Human+80S+Ribosome+in+Cancer%3A+From+Structure+to+Function+and+Drug+Design+for+Innovative+Adjuvant+Therapeutic+Strategies&doi=10.3390%2Fcells9030629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the human 80S ribosome in cancer: from structure to function and drug design for innovative adjuvant therapeutic strategies</span></div><div class="casAuthors">Gilles, Arnaud; Frechin, Leo; Natchiar, Kundhavai; Biondani, Giulia; von Loeffelholz, Ottilie; Holvec, Samuel; Malaval, Julie-Lisa; Winum, Jean-Yves; Klaholz, Bruno P.; Peyron, Jean-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The human 80S ribosome is the cellular nucleoprotein nanomachine in charge of protein synthesis that is profoundly affected during cancer transformation by oncogenic proteins and provides cancerous proliferating cells with proteins and therefore biomass.  Indeed, cancer is assocd. with an increase in ribosome biogenesis and mutations in several ribosomal proteins genes are found in ribosomopathies, which are congenital diseases that display an elevated risk of cancer.  Ribosomes and their biogenesis therefore represent attractive anti-cancer targets and several strategies are being developed to identify efficient and specific drugs.  Homoharringtonine (HHT) is the only direct ribosome inhibitor currently used in clinics for cancer treatments, although many classical chemotherapeutic drugs also appear to impact on protein synthesis.  Here we review the role of the human ribosome as a medical target in cancer, and how functional and structural anal. combined with chem. synthesis of new inhibitors can synergize.  The possible existence of oncoribosomes is also discussed.  The emerging idea is that targeting the human ribosome could not only allow the interference with cancer cell addiction towards protein synthesis and possibly induce their death but may also be highly valuable to decrease the levels of oncogenic proteins that display a high turnover rate (MYC, MCL1).  Cryo-electron microscopy (cryo-EM) is an advanced method that allows the visualization of human ribosome complexes with factors and bound inhibitors to improve our understanding of their functioning mechanisms mode.  Cryo-EM structures could greatly assist the foundation phase of a novel drug-design strategy.  One goal would be to identify new specific and active mols. targeting the ribosome in cancer such as derivs. of cycloheximide, a well-known ribosome inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz64kRp25le7Vg90H21EOLACvtfcHk0lirIxrf5b345g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVSqt7jK&md5=9bf0b6631bcbe83ef4d93d3a7359bcc8</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.3390%2Fcells9030629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells9030629%26sid%3Dliteratum%253Aachs%26aulast%3DGilles%26aufirst%3DA.%26aulast%3DFrechin%26aufirst%3DL.%26aulast%3DNatchiar%26aufirst%3DK.%26aulast%3DBiondani%26aufirst%3DG.%26aulast%3DLoeffelholz%26aufirst%3DO.%26aulast%3Dvon%2BHolvec%26aufirst%3DS.%26aulast%3DMalaval%26aufirst%3DJ.-L.%26aulast%3DWinum%26aufirst%3DJ.-Y.%26aulast%3DKlaholz%26aufirst%3DB.%2BP.%26aulast%3DPeyron%26aufirst%3DJ.-F.%26atitle%3DTargeting%2520the%2520Human%252080S%2520Ribosome%2520in%2520Cancer%253A%2520From%2520Structure%2520to%2520Function%2520and%2520Drug%2520Design%2520for%2520Innovative%2520Adjuvant%2520Therapeutic%2520Strategies%26jtitle%3DCells%26date%3D2020%26volume%3D9%26spage%3D629%26doi%3D10.3390%2Fcells9030629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powell, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisleder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, I. A.</span></span> <span> </span><span class="NLM_article-title">Structure of Cephalotaxine and Related Alkaloids</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4081</span>– <span class="NLM_lpage">4084</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)88620-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2FS0040-4039%2801%2988620-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1969&pages=4081-4084&author=R.+G.+Powellauthor=D.+Weislederauthor=C.+R.+Smithauthor=I.+A.+Wolff&title=Structure+of+Cephalotaxine+and+Related+Alkaloids&doi=10.1016%2FS0040-4039%2801%2988620-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2988620-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252988620-2%26sid%3Dliteratum%253Aachs%26aulast%3DPowell%26aufirst%3DR.%2BG.%26aulast%3DWeisleder%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DWolff%26aufirst%3DI.%2BA.%26atitle%3DStructure%2520of%2520Cephalotaxine%2520and%2520Related%2520Alkaloids%26jtitle%3DTetrahedron%2520Lett.%26date%3D1969%26volume%3D10%26spage%3D4081%26epage%3D4084%26doi%3D10.1016%2FS0040-4039%2801%2988620-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fresno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VÁZQUEZ, D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Translation in Eukaryotic Systems by Harringtonine</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1977.tb11256.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1111%2Fj.1432-1033.1977.tb11256.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=319998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE2sXhtleguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1977&pages=323-330&author=M.+Fresnoauthor=A.+Jim%C3%A9nezauthor=D.+V%C3%81ZQUEZ&title=Inhibition+of+Translation+in+Eukaryotic+Systems+by+Harringtonine&doi=10.1111%2Fj.1432-1033.1977.tb11256.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of translation in eukaryotic systems by harringtonine</span></div><div class="casAuthors">Fresno, Manuel; Jimenez, Antonio; Vazquez, David</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">323-30</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    </div><div class="casAbstract">The Cephalotaxus alkaloids harringtonine [26833-85-2], homoharringtonine [26833-87-4] and isoharringtonine [26833-86-3] inhibited protein synthesis in eukaryotic cells.  The alkaloids did not inhibit, in model systems, any of the steps of the initiation process but blocked poly(U)-directed polyphenylalanine [25191-15-5] synthesis as well as peptide bond formation in the fragment reaction assay, the sparsomycin-induced binding of 3H-labeled (C)U-A-C-C-A-Leu-Ac [54867-59-3], and the enzymic and the non-enzymic binding of Phe-tRNA to ribosomes.  These results suggest that the Cephalotaxus alkaloids inhibit the elongation phase of translation by preventing substrate binding to the acceptor site on the 60-S ribosome subunit and therefore block aminoacyl-tRNA binding and peptide bond formation.  However, the Cephalotaxus alkaloids did not inhibit polypeptide synthesis and peptidyl-3H-labeled puromycin formation in polysomes.  Furthermore, these alkaloids strongly inhibited 14C-labeled trichodermin [4682-50-2] binding to free ribosomes but hardly affect the interaction of the antibiotic with yeast polysomes.  Thus, the Cephalotaxus alkaloids cannot interact with polysomes and therefore only inhibit the initial cycles of elongation.  This explains the polysome run off that has been obsd. by some workers in the presence of harringtonine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSRrYoSRnkVbVg90H21EOLACvtfcHk0lirIxrf5b345g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXhtleguro%253D&md5=36cf4b9cd11f243786429704ea8b06ec</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1977.tb11256.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1977.tb11256.x%26sid%3Dliteratum%253Aachs%26aulast%3DFresno%26aufirst%3DM.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DA.%26aulast%3DV%25C3%2581ZQUEZ%26aufirst%3DD.%26atitle%3DInhibition%2520of%2520Translation%2520in%2520Eukaryotic%2520Systems%2520by%2520Harringtonine%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1977%26volume%3D72%26spage%3D323%26epage%3D330%26doi%3D10.1111%2Fj.1432-1033.1977.tb11256.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ingolia, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lareau, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span> <span> </span><span class="NLM_article-title">Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.cell.2011.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22056041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKgsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2011&pages=789-802&author=N.+T.+Ingoliaauthor=L.+F.+Lareauauthor=J.+S.+Weissman&title=Ribosome+Profiling+of+Mouse+Embryonic+Stem+Cells+Reveals+the+Complexity+and+Dynamics+of+Mammalian+Proteomes&doi=10.1016%2Fj.cell.2011.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes</span></div><div class="casAuthors">Ingolia, Nicholas T.; Lareau, Liana F.; Weissman, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">789-802</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The ability to sequence genomes has far outstripped approaches for deciphering the information they encode.  Here we present a suite of techniques, based on ribosome profiling (the deep sequencing of ribosome-protected mRNA fragments), to provide genome-wide maps of protein synthesis as well as a pulse-chase strategy for detg. rates of translation elongation.  We exploit the propensity of harringtonine to cause ribosomes to accumulate at sites of translation initiation together with a machine learning algorithm to define protein products systematically.  Anal. of translation in mouse embryonic stem cells reveals thousands of strong pause sites and unannotated translation products.  These include amino-terminal extensions and truncations and upstream open reading frames with regulatory potential, initiated at both AUG and non-AUG codons, whose translation changes after differentiation.  We also define a class of short, polycistronic ribosome-assocd. coding RNAs (sprcRNAs) that encode small proteins.  Our studies reveal an unanticipated complexity to mammalian proteomes.  A high-resoln. look at mammalian translation reveals unanticipated diversity in the resulting proteome, including peptide products from putative noncoding RNAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo34Hgu2-Dva7Vg90H21EOLACvtfcHk0lirIxrf5b345g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKgsLnJ&md5=07e899f5084ff6912ea3415c53dbe550</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DIngolia%26aufirst%3DN.%2BT.%26aulast%3DLareau%26aufirst%3DL.%2BF.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26atitle%3DRibosome%2520Profiling%2520of%2520Mouse%2520Embryonic%2520Stem%2520Cells%2520Reveals%2520the%2520Complexity%2520and%2520Dynamics%2520of%2520Mammalian%2520Proteomes%26jtitle%3DCell%26date%3D2011%26volume%3D147%26spage%3D789%26epage%3D802%26doi%3D10.1016%2Fj.cell.2011.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, J. F.</span></span> <span> </span><span class="NLM_article-title">Biologic and Pharmacologic Effects of Harringtonine on Human Leukemia-Lymphoma Cells</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1007/BF00258117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2FBF00258117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=3995683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaL2MXltlCmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1985&pages=206-210&author=Y.+Takemuraauthor=T.+Ohnumaauthor=T.+C.+Chouauthor=T.+Okanoauthor=J.+F.+Holland&title=Biologic+and+Pharmacologic+Effects+of+Harringtonine+on+Human+Leukemia-Lymphoma+Cells&doi=10.1007%2FBF00258117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells</span></div><div class="casAuthors">Takemura, Yuzuru; Ohnuma, Takao; Chou, Tingchao; Okano, Tsuyoshi; Holland, James F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">206-10</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">Ten human leukemia-lymphoma cell lines were tested for the growth-inhibitory effects of harringtonine (HT)  [26833-85-2].  HT was most active against HL-60 acute promyelocytic leukemia cells and least active against DND-41 acute lymphoblastic leukemia cells, with a 70-fold differential activity.  Sensitivity of the cell lines was, in decreasing order: HL-60 > RPMI-8402 > DND-39A ≃ ML-2 ≃ MOLT-3 ≃ KG-1 > Daudi ≃ NALL-1 > BALM-2 > DND-41.  The cell lines with rapid cell growth tended to be more sensitive to HT.  To further elucidate the selectivity of the differential sensitivity, uptake and release of HT were compared in HL-60 and DND-41 cells.  Uptake of [3H]HT into HL-60 and DND-41 cells showed no difference; however, the binding of [3H]HT to cellular components was > 16-fold higher in HL-60 cells than DND-41 cells.  There were also minor, but significant differences in the inhibition of [3H]leucine incorporation into proteins of these 2 cell lines in the presence of 1 μg/mL HT.  To test whether the biol. effects of HT are related to the concn. of, or exposure time to, HT, KG-1 cells were exposed to HT for different periods of time and the growth-inhibitory effects were compared.  Increasing exposure time from 1 h to 3 h resulted in a 100-fold decrease in concn. × exposure time (c × t) at ID50; from 3 h to 6 h, in a 20-fold decrease at ID70; and from 6 h to 24 h, in a 16-fold decrease at ID90.  HT was not inactivated by cells up to 24 h.  Apparently, (a) the sensitivity of different cell lines to HT may be related to the degree of HT binding; and (b) the effects of HT are more dependent on exposure time than concn.  Continuous infusion is thus rational for clin. trials of this drug, and the degree of HT binding to leukemic cells may be predictive of clin. response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ohxQVHpxmrVg90H21EOLACvtfcHk0lgYWin9IStDZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltlCmurY%253D&md5=47515bf3cc60be8b90e850eb0554c864</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1007%2FBF00258117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00258117%26sid%3Dliteratum%253Aachs%26aulast%3DTakemura%26aufirst%3DY.%26aulast%3DOhnuma%26aufirst%3DT.%26aulast%3DChou%26aufirst%3DT.%2BC.%26aulast%3DOkano%26aufirst%3DT.%26aulast%3DHolland%26aufirst%3DJ.%2BF.%26atitle%3DBiologic%2520and%2520Pharmacologic%2520Effects%2520of%2520Harringtonine%2520on%2520Human%2520Leukemia-Lymphoma%2520Cells%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1985%26volume%3D14%26spage%3D206%26epage%3D210%26doi%3D10.1007%2FBF00258117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajczak, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisleder, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Cephalotaxine Esters and Correlation of Their Structures with Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1021/jm00213a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00213a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE2sXotlGjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1977&pages=328-332&author=K.+L.+Mikolajczakauthor=C.+R.+Smithauthor=D.+Weisleder&title=Synthesis+of+Cephalotaxine+Esters+and+Correlation+of+Their+Structures+with+Antitumor+Activity&doi=10.1021%2Fjm00213a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of cephalotaxine esters and correlation of their structures with antitumor activity</span></div><div class="casAuthors">Mikolajczak, Kenneth L.; Smith, Cecil R., Jr.; Weisleder, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">328-32</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Of 22 esters of (-)-cephalotaxine [24316-19-6] prepd. and tested for antitumor activity against P388 lymphocytic leukemia in mice, the Me itaconate (I) [61568-74-9], Me fumarate (II) [61568-73-8], L-mandelate trichloroethyl carbonate (III) [61586-85-4], and trichloroethyl carbonate (IV) [61568-75-0] had consistent and significant activity.  Of these compds., I and IV were most active.  The enantiomer of I, (+)-cephalotaxine Me intaconate [61616-07-7], was inactive.  Structure-activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWkdM3XWn9trVg90H21EOLACvtfcHk0lgYWin9IStDZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXotlGjtQ%253D%253D&md5=70b52ba509ce6d8affff62bfb4bdbede</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1021%2Fjm00213a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00213a002%26sid%3Dliteratum%253Aachs%26aulast%3DMikolajczak%26aufirst%3DK.%2BL.%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DWeisleder%26aufirst%3DD.%26atitle%3DSynthesis%2520of%2520Cephalotaxine%2520Esters%2520and%2520Correlation%2520of%2520Their%2520Structures%2520with%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1977%26volume%3D20%26spage%3D328%26epage%3D332%26doi%3D10.1021%2Fjm00213a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span> <span> </span><span class="NLM_article-title">Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval</span>. <i>Clin. Lymphoma, Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">530</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2013.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.clml.2013.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=23790799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVyltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=530-533&author=H.+M.+Kantarjianauthor=S.+O%E2%80%99Brienauthor=J.+Cortes&title=Homoharringtonine%2FOmacetaxine+Mepesuccinate%3A+The+Long+and+Winding+Road+to+Food+and+Drug+Administration+Approval&doi=10.1016%2Fj.clml.2013.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval</span></div><div class="casAuthors">Kantarjian, Hagop M.; O'Brien, Susan; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lymphoma, Myeloma & Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">530-533</span>CODEN:
                <span class="NLM_cas:coden">CLMLCQ</span>;
        ISSN:<span class="NLM_cas:issn">2152-2669</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Homoharringtonine/omacetaxine is a unique agent with a long history of research development.  It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors.  Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsN71Xouy5eLVg90H21EOLACvtfcHk0lgYWin9IStDZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVyltL8%253D&md5=142d6d379d869bc5ea979b1722c0d41a</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2013.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2013.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DHomoharringtonine%252FOmacetaxine%2520Mepesuccinate%253A%2520The%2520Long%2520and%2520Winding%2520Road%2520to%2520Food%2520and%2520Drug%2520Administration%2520Approval%26jtitle%3DClin.%2520Lymphoma%252C%2520Myeloma%2520Leuk.%26date%3D2013%26volume%3D13%26spage%3D530%26epage%3D533%26doi%3D10.1016%2Fj.clml.2013.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murgo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’ Brien, S. M.</span></span> <span> </span><span class="NLM_article-title">Homoharringtonine: History, Current Research, and Future Directions</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1605</span>, <span class="refDoi"> DOI: 10.1002/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=11745238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvVygsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2001&pages=1591-1605&author=M.+H.+Kantarjianauthor=M.+Talpazauthor=V.+Santiniauthor=A.+Murgoauthor=B.+Chesonauthor=S.+M.+O%E2%80%99+Brien&title=Homoharringtonine%3A+History%2C+Current+Research%2C+and+Future+Directions&doi=10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Homoharringtonine: History, current research, and future directions</span></div><div class="casAuthors">Kantarjian, Hagop M.; Talpaz, Moshe; Santini, Valeria; Murgo, Anthony; Cheson, Bruce; O'Brien, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1591-1605</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Cephalotoxine esters, including homoharringtonine (HHT), have shown encouraging activity in leukemia in initial studies in China and in later studies in the U.S.  The authors conducted a review of the literature to examine the studies pertinent to HHT in relation to preclin. studies and Phase I-II trials in patients with hematol. malignancies and solid tumors.  HHT and analogs appear to induce differentiation and apoptosis.  Studies from China reported high response rates in patients with leukemia.  Trials in the U.S. using short HHT infusions (3-4 mg/m2 daily for 5 days) resulted in a high incidence of cardiovascular complications that were reduced using continuous infusion schedules of 3-7 mg/m2 daily for 5-7 days initially, and later lower dose schedules of 2.5 mg/m2 daily for 7-14 days.  Results in solid tumors were neg.  However encouraging results were reported in patients with acute myeloid leukemia, myelodysplastic syndrome, acute promyelocytic leukemia, and, most important, chronic myeloid leukemia (CML).  In CML patients, HHT has been investigated alone and in combination with interferon-α and low-dose cytarabine in late and early chronic phases, with pos. results.  Addnl. areas of interest include the potential use of HHT for the treatment of central nervous system leukemia, polycythemia vera, and other nonmalignant conditions such as malaria.  New semisynthetic prepns. and HHT derivs. that bypass multidrug resistance may improve the efficacy and toxicity profiles, and broaden the range of antitumor efficacy.  HHT and its derivs. appear to have promising activity in hematol. malignancies, a finding that needs to be pursued.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1dQhgTEUcI7Vg90H21EOLACvtfcHk0lgYWin9IStDZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvVygsrY%253D&md5=ee9e078a86611a4af32064c7b6266bfa</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1097-0142%252820010915%252992%253A6%253C1591%253A%253AAID-CNCR1485%253E3.0.CO%253B2-U%26sid%3Dliteratum%253Aachs%26aulast%3DKantarjian%26aufirst%3DM.%2BH.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DSantini%26aufirst%3DV.%26aulast%3DMurgo%26aufirst%3DA.%26aulast%3DCheson%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599%2BBrien%26aufirst%3DS.%2BM.%26atitle%3DHomoharringtonine%253A%2520History%252C%2520Current%2520Research%252C%2520and%2520Future%2520Directions%26jtitle%3DCancer%26date%3D2001%26volume%3D92%26spage%3D1591%26epage%3D1605%26doi%3D10.1002%2F1097-0142%2820010915%2992%3A6%3C1591%3A%3AAID-CNCR1485%3E3.0.CO%3B2-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vikstrom, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Happo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cluse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kile, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzacasa, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. S.</span></span> <span> </span><span class="NLM_article-title">Translation Inhibitors Induce Cell Death by Multiple Mechanisms and Mcl-1 Reduction Is Only a Minor Contributor</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e409</span>, <span class="refDoi"> DOI: 10.1038/cddis.2012.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fcddis.2012.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=23059828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsV2nuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=e409&author=L.+M.+Lindqvistauthor=I.+Vikstromauthor=J.+M.+Chambersauthor=K.+McArthurauthor=M.+A.+Andersonauthor=K.+J.+Henleyauthor=L.+Happoauthor=L.+Cluseauthor=R.+W.+Johnstoneauthor=A.+W.+Robertsauthor=B.+T.+Kileauthor=B.+A.+Crokerauthor=C.+J.+Burnsauthor=M.+A.+Rizzacasaauthor=A.+Strasserauthor=D.+S.+Huang&title=Translation+Inhibitors+Induce+Cell+Death+by+Multiple+Mechanisms+and+Mcl-1+Reduction+Is+Only+a+Minor+Contributor&doi=10.1038%2Fcddis.2012.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor</span></div><div class="casAuthors">Lindqvist, L. M.; Vikstrom, I.; Chambers, J. M.; McArthur, K.; Ann Anderson, M.; Henley, K. J.; Happo, L.; Cluse, L.; Johnstone, R. W.; Roberts, A. W.; Kile, B. T.; Croker, B. A.; Burns, C. J.; Rizzacasa, M. A.; Strasser, A.; Huang, D. C. S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">Oct.</span>),
    <span class="NLM_cas:pages">e409, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">There is significant interest in treating cancers by blocking protein synthesis, to which hematol. malignancies seem particularly sensitive.  The translation elongation inhibitor homoharringtonine (Omacetaxine mepesuccinate) is undergoing clin. trials for chronic myeloid leukemia, whereas the translation initiation inhibitor silvestrol has shown promise in mouse models of cancer.  Precisely how these compds. induce cell death is unclear, but redn. in Mcl-1, a labile pro-survival Bcl-2 family member, has been proposed to constitute the crit. event.  Moreover, the contribution of translation inhibitors to neutropenia and lymphopenia has not been precisely defined.  Herein, we demonstrate that primary B cells and neutrophils are highly sensitive to translation inhibitors, which trigger the Bax/Bak-mediated apoptotic pathway.  However, contrary to expectations, redn. of Mcl-1 did not significantly enhance cytotoxicity of these compds., suggesting that it does not have a principal role and cautions that strong correlations do not always signify causality.  On the other hand, the killing of T lymphocytes was less dependent on Bax and Bak, indicating that translation inhibitors can also induce cell death via alternative mechanisms.  Indeed, loss of clonogenic survival proved to be independent of the Bax/Bak-mediated apoptosis altogether.  Our findings warn of potential toxicity as these translation inhibitors are cytotoxic to many differentiated non-cycling cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXec6Bnefs-7Vg90H21EOLACvtfcHk0ljxHkAfN9u5iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsV2nuw%253D%253D&md5=c38aced51e737b67d433db2b940578ee</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2012.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2012.149%26sid%3Dliteratum%253Aachs%26aulast%3DLindqvist%26aufirst%3DL.%2BM.%26aulast%3DVikstrom%26aufirst%3DI.%26aulast%3DChambers%26aufirst%3DJ.%2BM.%26aulast%3DMcArthur%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DM.%2BA.%26aulast%3DHenley%26aufirst%3DK.%2BJ.%26aulast%3DHappo%26aufirst%3DL.%26aulast%3DCluse%26aufirst%3DL.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26aulast%3DKile%26aufirst%3DB.%2BT.%26aulast%3DCroker%26aufirst%3DB.%2BA.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DRizzacasa%26aufirst%3DM.%2BA.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DD.%2BS.%26atitle%3DTranslation%2520Inhibitors%2520Induce%2520Cell%2520Death%2520by%2520Multiple%2520Mechanisms%2520and%2520Mcl-1%2520Reduction%2520Is%2520Only%2520a%2520Minor%2520Contributor%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2012%26volume%3D3%26spage%3De409%26doi%3D10.1038%2Fcddis.2012.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. J.</span></span> <span> </span><span class="NLM_article-title">The Natural Compound Homoharringtonine Presents Broad Antiviral Activity in Vitro and in Vivo</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">601</span>, <span class="refDoi"> DOI: 10.3390/v10110601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fv10110601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFehtrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=601&author=H.+J.+Dongauthor=Z.+H.+Wangauthor=W.+Mengauthor=C.+C.+Liauthor=Y.+X.+Huauthor=L.+Zhouauthor=X.+J.+Wang&title=The+Natural+Compound+Homoharringtonine+Presents+Broad+Antiviral+Activity+in+Vitro+and+in+Vivo&doi=10.3390%2Fv10110601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">The natural compound homoharringtonine presents broad antiviral activity in vitro and in vivo</span></div><div class="casAuthors">Dong, Hui-Jun; Wang, Zhao-Hua; Meng, Wen; Li, Cui-Cui; Hu, Yan-Xin; Zhou, Lei; Wang, Xiao-Jia</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">601</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">To complement traditional antivirals, natural compds. that act via host targets and present high barriers to resistance are of increasing interest.  In the work reported here, we detected that homoharringtonine (HHT) presents effective antiviral activity.  HHT completely inhibited infections of vesicular stomatitis virus (VSV), Newcastle disease virus (NDV), and porcine epidemic diarrhea virus (PEDV) at concns. of 50, 100, and 500 nM in cell cultures, resp.  Treatment with HHT at doses of 0.05 or 0.2 mg/kg significantly reduced viral load and relieved severe symptoms in PEDV- or NDV-infected animals.  HHT treatment, however, moderately inhibited avian influenza virus (AIV) infection, suggesting its potent antiviral action is restricted to a no. of classes of RNA viruses.  In this study, we also obsd. that HHT actively inhibited herpes simplex virus type 1 (HSV-1) replication with a 50% inhibitory concn. (IC50) of 139 nM; the treatment with HHT at 1000 nM led to redns. of three orders of magnitude.  Moreover, HHT antagonized the phosphorylation level of endogenous and exogenous eukaryotic initiation factor 4E (p-eIF4E), which might regulate the selective translation of specific mRNA (mRNA).  HHT provides a starting point for further progress toward the clin. development of broad-spectrum antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAx4ZQsCsJibVg90H21EOLACvtfcHk0ljxHkAfN9u5iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFehtrrK&md5=25c44ce9fed168ca4933eabdf489587d</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.3390%2Fv10110601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv10110601%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DZ.%2BH.%26aulast%3DMeng%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DC.%2BC.%26aulast%3DHu%26aufirst%3DY.%2BX.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%2BJ.%26atitle%3DThe%2520Natural%2520Compound%2520Homoharringtonine%2520Presents%2520Broad%2520Antiviral%2520Activity%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DViruses%26date%3D2018%26volume%3D10%26spage%3D601%26doi%3D10.3390%2Fv10110601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ianevski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstad, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zusinaite, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lysvand, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Løseth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landsem, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmring, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksenych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlandsen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aas, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afset, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordbø, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjørås, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kainov, D. E.</span></span> <span> </span><span class="NLM_article-title">Potential Antiviral Options against SARS-CoV-2 Infection</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">642</span>, <span class="refDoi"> DOI: 10.3390/v12060642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fv12060642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGit73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=642&author=A.+Ianevskiauthor=R.+Yaoauthor=M.+H.+Fenstadauthor=S.+Bizaauthor=E.+Zusinaiteauthor=T.+Reisbergauthor=H.+Lysvandauthor=K.+L%C3%B8sethauthor=V.+M.+Landsemauthor=J.+F.+Malmringauthor=V.+Oksenychauthor=S.+E.+Erlandsenauthor=P.+A.+Aasauthor=L.+Hagenauthor=C.+H.+Pettersenauthor=T.+Tensonauthor=J.+E.+Afsetauthor=S.+A.+Nordb%C3%B8author=M.+Bj%C3%B8r%C3%A5sauthor=D.+E.+Kainov&title=Potential+Antiviral+Options+against+SARS-CoV-2+Infection&doi=10.3390%2Fv12060642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Potential antiviral options against SARS-CoV-2 infection</span></div><div class="casAuthors">Ianevski, Aleksandr; Yao, Rouan; Fenstad, Mona Hoeysaeter; Biza, Svetlana; Zusinaite, Eva; Reisberg, Tuuli; Lysvand, Hilde; Loeseth, Kirsti; Landsem, Veslemoey Malm; Malmring, Janne Fossum; Oksenych, Valentyn; Erlandsen, Sten Even; Aas, Per Arne; Hagen, Lars; Pettersen, Caroline H.; Tenson, Tanel; Afset, Jan Egil; Nordboe, Svein Arne; Bjoeraas, Magnar; Kainov, Denis E.</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">642</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">As of June 2020, the no. of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide.  Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections.  However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly.  Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options.  Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells.  We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients.  We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine.  We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy.  Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr4qdtRfWDabVg90H21EOLACvtfcHk0ljxHkAfN9u5iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGit73E&md5=507d1a44014f075da088d01514e9ddd1</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.3390%2Fv12060642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv12060642%26sid%3Dliteratum%253Aachs%26aulast%3DIanevski%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DR.%26aulast%3DFenstad%26aufirst%3DM.%2BH.%26aulast%3DBiza%26aufirst%3DS.%26aulast%3DZusinaite%26aufirst%3DE.%26aulast%3DReisberg%26aufirst%3DT.%26aulast%3DLysvand%26aufirst%3DH.%26aulast%3DL%25C3%25B8seth%26aufirst%3DK.%26aulast%3DLandsem%26aufirst%3DV.%2BM.%26aulast%3DMalmring%26aufirst%3DJ.%2BF.%26aulast%3DOksenych%26aufirst%3DV.%26aulast%3DErlandsen%26aufirst%3DS.%2BE.%26aulast%3DAas%26aufirst%3DP.%2BA.%26aulast%3DHagen%26aufirst%3DL.%26aulast%3DPettersen%26aufirst%3DC.%2BH.%26aulast%3DTenson%26aufirst%3DT.%26aulast%3DAfset%26aufirst%3DJ.%2BE.%26aulast%3DNordb%25C3%25B8%26aufirst%3DS.%2BA.%26aulast%3DBj%25C3%25B8r%25C3%25A5s%26aufirst%3DM.%26aulast%3DKainov%26aufirst%3DD.%2BE.%26atitle%3DPotential%2520Antiviral%2520Options%2520against%2520SARS-CoV-2%2520Infection%26jtitle%3DViruses%26date%3D2020%26volume%3D12%26spage%3D642%26doi%3D10.3390%2Fv12060642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Ambrosio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerriero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debitus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribes, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusset, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietra, F.</span></span> <span> </span><span class="NLM_article-title">Agelastatin A, a New Skeleton Cytotoxic Alkaloid of the Oroidin Family. Isolation from the Axinellid Sponge Agelas Dendromorpha of the Coral Sea</span>. <i>J. Chem. Soc., Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>, (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1306</span>, <span class="refDoi"> DOI: 10.1039/c39930001305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1039%2Fc39930001305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVant7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&pages=1305-1306&issue=16&author=M.+D%E2%80%99Ambrosioauthor=A.+Guerrieroauthor=C.+Debitusauthor=O.+Ribesauthor=J.+Pussetauthor=S.+Leroyauthor=F.+Pietra&title=Agelastatin+A%2C+a+New+Skeleton+Cytotoxic+Alkaloid+of+the+Oroidin+Family.+Isolation+from+the+Axinellid+Sponge+Agelas+Dendromorpha+of+the+Coral+Sea&doi=10.1039%2Fc39930001305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Agelastatin A, a new skeleton cytotoxic alkaloid of the oroidin family. Isolation from the axinellid sponge Agelas dendromorpha of the Coral Sea</span></div><div class="casAuthors">D'Ambrosio, Michele; Guerriero, Antonio; Debitus, Cecile; Ribes, Olivier; Pusset, Jacques; Leroy, Sandrine; Pietra, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Chemical Communications</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1305-6</span>CODEN:
                <span class="NLM_cas:coden">JCCCAT</span>;
        ISSN:<span class="NLM_cas:issn">0022-4936</span>.
    </div><div class="casAbstract">Agelastatin A (I), isolated from the axinellid sponge A. dendromorpha of the Coral Sea, is a new skeleton alkaloid with, unusually for the oroidin family to which it belongs, marked cytotoxicity toward tumor cells in culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH9kgIBHWBbLVg90H21EOLACvtfcHk0liiXYC8cUYbfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVant7c%253D&md5=e121f93fedf1b1b13df356743ef4266a</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1039%2Fc39930001305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39930001305%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Ambrosio%26aufirst%3DM.%26aulast%3DGuerriero%26aufirst%3DA.%26aulast%3DDebitus%26aufirst%3DC.%26aulast%3DRibes%26aufirst%3DO.%26aulast%3DPusset%26aufirst%3DJ.%26aulast%3DLeroy%26aufirst%3DS.%26aulast%3DPietra%26aufirst%3DF.%26atitle%3DAgelastatin%2520A%252C%2520a%2520New%2520Skeleton%2520Cytotoxic%2520Alkaloid%2520of%2520the%2520Oroidin%2520Family.%2520Isolation%2520from%2520the%2520Axinellid%2520Sponge%2520Agelas%2520Dendromorpha%2520of%2520the%2520Coral%2520Sea%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1993%26issue%3D16%26spage%3D1305%26epage%3D1306%26doi%3D10.1039%2Fc39930001305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarlane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erwin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domostoj, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manaviazar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tanani, M.</span></span> <span> </span><span class="NLM_article-title">Agelastatin A: A Novel Inhibitor of Osteopontin-Mediated Adhesion, Invasion, and Colony Formation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1158%2F1535-7163.MCT-07-2251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18347142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtlWhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=548-558&author=C.+K.+Masonauthor=S.+McFarlaneauthor=P.+G.+Johnstonauthor=P.+Croweauthor=P.+J.+Erwinauthor=M.+M.+Domostojauthor=F.+C.+Campbellauthor=S.+Manaviazarauthor=K.+J.+Haleauthor=M.+El-Tanani&title=Agelastatin+A%3A+A+Novel+Inhibitor+of+Osteopontin-Mediated+Adhesion%2C+Invasion%2C+and+Colony+Formation&doi=10.1158%2F1535-7163.MCT-07-2251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation</span></div><div class="casAuthors">Mason, Charlene K.; McFarlane, Suzanne; Johnston, Patrick G.; Crowe, Paul; Erwin, Pauline J.; Domostoj, Mathias M.; Campbell, F. Charles; Manaviazar, Soraya; Hale, Karl J.; El-Tanani, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">548-558</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Effective inhibitors of osteopontin (OPN)-mediated neoplastic transformation and metastasis are still lacking.  (-)-Agelastatin A is a naturally occurring oroidin alkaloid with powerful antitumor effects that, in many cases, are superior to cisplatin in vitro.  In this regard, past comparative assaying of the two agents against a range of human tumor cell lines has revealed that typically (-)-agelastatin A is 1.5 to 16 times more potent than cisplatin at inhibiting cell growth, its effects being most pronounced against human bladder, skin, colon, and breast carcinomas.  In this study, we have investigated the effects of (-)-agelastatin A on OPN-mediated malignant transformation using mammary epithelial cell lines.  Treatment with (-)-agelastatin A inhibited OPN protein expression and enhanced expression of the cellular OPN inhibitor, Tcf-4.  (-)-Agelastatin A treatment also reduced β-catenin protein expression and reduced anchorage-independent growth, adhesion, and invasion in R37 OPN pBK-CMV and C9 cell lines.  Similar effects were obsd. in MDA-MB-231 and MDA-MB-435s human breast cancer cell lines exposed to (-)-agelastatin A.  Suppression of Tcf-4 by RNA interference (short interfering RNA) induced malignant/invasive transformation in parental benign Rama 37 cells; significantly, these events were reversed by treatment with (-)-agelastatin A.  Our study reveals, for the very first time, that (-)-agelastatin A down-regulates β-catenin expression while simultaneously up-regulating Tcf-4 and that these combined effects cause repression of OPN and inhibition of OPN-mediated malignant cell invasion, adhesion, and colony formation in vitro.  We have also shown that (-)-agelastatin A inhibits cancer cell proliferation by causing cells to accumulate in the G2 phase of cell cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlZ8iSW_fmmrVg90H21EOLACvtfcHk0liiXYC8cUYbfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtlWhu7s%253D&md5=dbfeebaa6bc6c48965d5e9b660492668</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2251%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DC.%2BK.%26aulast%3DMcFarlane%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26aulast%3DCrowe%26aufirst%3DP.%26aulast%3DErwin%26aufirst%3DP.%2BJ.%26aulast%3DDomostoj%26aufirst%3DM.%2BM.%26aulast%3DCampbell%26aufirst%3DF.%2BC.%26aulast%3DManaviazar%26aufirst%3DS.%26aulast%3DHale%26aufirst%3DK.%2BJ.%26aulast%3DEl-Tanani%26aufirst%3DM.%26atitle%3DAgelastatin%2520A%253A%2520A%2520Novel%2520Inhibitor%2520of%2520Osteopontin-Mediated%2520Adhesion%252C%2520Invasion%252C%2520and%2520Colony%2520Formation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D548%26epage%3D558%26doi%3D10.1158%2F1535-7163.MCT-07-2251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hale, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domostoj, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tanani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charles Campbell, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, C. K.</span></span> <span> </span><span class="NLM_article-title">Chapter 11 Total Synthesis and Mechanism of Action Studies on the Antitumor Alkaloid, (−)-Agelastatin A</span>. <i>Strateg. Tactics Org. Synth.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1016/S1874-6004(05)80034-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2FS1874-6004%2805%2980034-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=352-394&author=K.+J.+Haleauthor=M.+M.+Domostojauthor=M.+El-Tananiauthor=F.+Charles+Campbellauthor=C.+K.+Mason&title=Chapter+11+Total+Synthesis+and+Mechanism+of+Action+Studies+on+the+Antitumor+Alkaloid%2C+%28%E2%88%92%29-Agelastatin+A&doi=10.1016%2FS1874-6004%2805%2980034-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2FS1874-6004%2805%2980034-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1874-6004%252805%252980034-6%26sid%3Dliteratum%253Aachs%26aulast%3DHale%26aufirst%3DK.%2BJ.%26aulast%3DDomostoj%26aufirst%3DM.%2BM.%26aulast%3DEl-Tanani%26aufirst%3DM.%26aulast%3DCharles%2BCampbell%26aufirst%3DF.%26aulast%3DMason%26aufirst%3DC.%2BK.%26atitle%3DChapter%252011%2520Total%2520Synthesis%2520and%2520Mechanism%2520of%2520Action%2520Studies%2520on%2520the%2520Antitumor%2520Alkaloid%252C%2520%2528%25E2%2588%2592%2529-Agelastatin%2520A%26jtitle%3DStrateg.%2520Tactics%2520Org.%2520Synth.%26date%3D2005%26volume%3D6%26spage%3D352%26epage%3D394%26doi%3D10.1016%2FS1874-6004%2805%2980034-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McClary, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinshteyn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouanneau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusupova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, J. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayinde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusupov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Eukaryotic Translation by the Antitumor Natural Product Agelastatin A</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">613</span>, e5. <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.chembiol.2017.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28457705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFSltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=605-613&author=B.+McClaryauthor=B.+Zinshteynauthor=M.+Meyerauthor=M.+Jouanneauauthor=S.+Pellegrinoauthor=G.+Yusupovaauthor=A.+Schullerauthor=J.+C.+P.+Reyesauthor=J.+Luauthor=Z.+Guoauthor=S.+Ayindeauthor=C.+Luoauthor=Y.+Dangauthor=D.+Romoauthor=M.+Yusupovauthor=R.+Greenauthor=J.+O.+Liu&title=Inhibition+of+Eukaryotic+Translation+by+the+Antitumor+Natural+Product+Agelastatin+A&doi=10.1016%2Fj.chembiol.2017.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Eukaryotic Translation by the Antitumor Natural Product Agelastatin A</span></div><div class="casAuthors">McClary, Brandon; Zinshteyn, Boris; Meyer, Melanie; Jouanneau, Morgan; Pellegrino, Simone; Yusupova, Gulnara; Schuller, Anthony; Reyes, Jeremy Chris P.; Lu, Junyan; Guo, Zufeng; Ayinde, Safiat; Luo, Cheng; Dang, Yongjun; Romo, Daniel; Yusupov, Marat; Green, Rachel; Liu, Jun O.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">605-613.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Protein synthesis plays an essential role in cell proliferation, differentiation, and survival.  Inhibitors of eukaryotic translation have entered the clinic, establishing the translation machinery as a promising target for chemotherapy.  A recently discovered, structurally unique marine sponge-derived brominated alkaloid, (-)-agelastatin A (AglA), possesses potent antitumor activity.  Its underlying mechanism of action, however, has remained unknown.  Using a systematic top-down approach, we show that AglA selectively inhibits protein synthesis.  Using a high-throughput chem. footprinting method, we mapped the AglA-binding site to the ribosomal A site.  A 3.5 Å crystal structure of the 80S eukaryotic ribosome from S. cerevisiae in complex with AglA was obtained, revealing multiple conformational changes of the nucleotide bases in the ribosome accompanying the binding of AglA.  Together, these results have unraveled the mechanism of inhibition of eukaryotic translation by AglA at at. level, paving the way for future structural modifications to develop AglA analogs into novel anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdozB9vaAP57Vg90H21EOLACvtfcHk0liiCO2mM0Hqdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFSltb0%253D&md5=25a42d6159d098efafaf04411840a1bb</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DMcClary%26aufirst%3DB.%26aulast%3DZinshteyn%26aufirst%3DB.%26aulast%3DMeyer%26aufirst%3DM.%26aulast%3DJouanneau%26aufirst%3DM.%26aulast%3DPellegrino%26aufirst%3DS.%26aulast%3DYusupova%26aufirst%3DG.%26aulast%3DSchuller%26aufirst%3DA.%26aulast%3DReyes%26aufirst%3DJ.%2BC.%2BP.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DAyinde%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DDang%26aufirst%3DY.%26aulast%3DRomo%26aufirst%3DD.%26aulast%3DYusupov%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%2BO.%26atitle%3DInhibition%2520of%2520Eukaryotic%2520Translation%2520by%2520the%2520Antitumor%2520Natural%2520Product%2520Agelastatin%2520A%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D605%26epage%3D613%26doi%3D10.1016%2Fj.chembiol.2017.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Total Synthesis of Agelastatins</span>. <i>Pure Appl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">2231</span>– <span class="NLM_lpage">2246</span>, <span class="refDoi"> DOI: 10.1351/PAC-CON-10-08-04</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1351%2FPAC-CON-10-08-04" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFOqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2010&pages=2231-2246&author=G.+Dong&title=Recent+Advances+in+the+Total+Synthesis+of+Agelastatins&doi=10.1351%2FPAC-CON-10-08-04"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the total synthesis of agelastatins</span></div><div class="casAuthors">Dong, Guangbin</div><div class="citationInfo"><span class="NLM_cas:title">Pure and Applied Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2231-2246</span>CODEN:
                <span class="NLM_cas:coden">PACHAS</span>;
        ISSN:<span class="NLM_cas:issn">0033-4545</span>.
    
            (<span class="NLM_cas:orgname">International Union of Pure and Applied Chemistry</span>)
        </div><div class="casAbstract">A review.  Agelastatins represent an important family of marine alkaloids in terms of both exceptional biol. activity and intriguing chem. structure.  In this article, the isolation and biol. activity of agelastatins are reviewed, and proposed biosynthetic pathways are summarized.  The main focus is given to comparative evaluation of recent total syntheses, mainly of agelastatin A.  To date, this has been accomplished by 11 research groups.  Their synthetic routes are analyzed and summarized, with a view to furnishing the reader with insight into different strategic design approaches to assembly of a densely functionalized and compact structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQxVQVSjvP67Vg90H21EOLACvtfcHk0liiCO2mM0Hqdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFOqsbc%253D&md5=7bef89eed87a7abd79c8692f76b2f21d</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1351%2FPAC-CON-10-08-04&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1351%252FPAC-CON-10-08-04%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Total%2520Synthesis%2520of%2520Agelastatins%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D2010%26volume%3D82%26spage%3D2231%26epage%3D2246%26doi%3D10.1351%2FPAC-CON-10-08-04" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hergenrother, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Movassaghi, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Anticancer Activity of All Known (−)-Agelastatin Alkaloids</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">11970</span>– <span class="NLM_lpage">11984</span>, <span class="refDoi"> DOI: 10.1021/jo4020112</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo4020112" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KktbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2013&pages=11970-11984&author=S.+Hanauthor=D.+S.+Siegelauthor=K.+C.+Morrisonauthor=P.+J.+Hergenrotherauthor=M.+Movassaghi&title=Synthesis+and+Anticancer+Activity+of+All+Known+%28%E2%88%92%29-Agelastatin+Alkaloids&doi=10.1021%2Fjo4020112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Anticancer Activity of All Known (-)-Agelastatin Alkaloids</span></div><div class="casAuthors">Han, Sunkyu; Siegel, Dustin S.; Morrison, Karen C.; Hergenrother, Paul J.; Movassaghi, Mohammad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11970-11984</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The full details of our enantioselective total syntheses of (-)-agelastatins A-F, the evolution of a new methodol. for synthesis of substituted azaheterocycles, and the first side-by-side evaluation of all known (-)-agelastatin alkaloids against nine human cancer cell lines are described.  Our concise synthesis of these alkaloids exploits the intrinsic chem. of plausible biosynthetic precursors and capitalizes on a late-stage synthesis of the C-ring.  The crit. copper-mediated cross-coupling reaction was expanded to include guanidine-based systems, offering a versatile prepn. of substituted imidazoles.  The direct comparison of the anticancer activity of all naturally occurring (-)-agelastatins in addn. to eight advanced synthetic intermediates enabled a systematic anal. of the structure-activity relationship within the natural series.  Significantly, (-)-agelastatin A, I (R = Me) is highly potent against six blood cancer cell lines (20-190 nM) without affecting normal red blood cells (>333 μM).  (-)-Agelastatin A and (-)-agelastatin D I (R = H), the two most potent members of this family, induce dose-dependent apoptosis and arrest cells in the G2/M-phase of the cell cycle; however, using confocal microscopy, we have detd. that neither alkaloid affects tubulin dynamics within cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoilGy560IBQbVg90H21EOLACvtfcHk0liiCO2mM0Hqdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KktbzP&md5=cd8e7bc469b46d46e4a6a1963230cd99</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Fjo4020112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo4020112%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%26aulast%3DSiegel%26aufirst%3DD.%2BS.%26aulast%3DMorrison%26aufirst%3DK.%2BC.%26aulast%3DHergenrother%26aufirst%3DP.%2BJ.%26aulast%3DMovassaghi%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520Anticancer%2520Activity%2520of%2520All%2520Known%2520%2528%25E2%2588%2592%2529-Agelastatin%2520Alkaloids%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2013%26volume%3D78%26spage%3D11970%26epage%3D11984%26doi%3D10.1021%2Fjo4020112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stout, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinski, T. F.</span></span> <span> </span><span class="NLM_article-title">Potent Fluorinated Agelastatin Analogues for Chronic Lymphocytic Leukemia: Design, Synthesis, and Pharmacokinetic Studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5085</span>– <span class="NLM_lpage">5093</span>, <span class="refDoi"> DOI: 10.1021/jm4016922</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016922" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5085-5093&author=E.+P.+Stoutauthor=M.+Y.+Choiauthor=J.+E.+Castroauthor=T.+F.+Molinski&title=Potent+Fluorinated+Agelastatin+Analogues+for+Chronic+Lymphocytic+Leukemia%3A+Design%2C+Synthesis%2C+and+Pharmacokinetic+Studies&doi=10.1021%2Fjm4016922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Fluorinated Agelastatin Analogues for Chronic Lymphocytic Leukemia: Design, Synthesis, and Pharmacokinetic Studies</span></div><div class="casAuthors">Stout, E. Paige; Choi, Michael Y.; Castro, Januario E.; Molinski, Tadeusz F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5085-5093</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chronic lymphocytic leukemia (CLL) is the most common lymphoid neoplasia in Western societies and is currently incurable.  Multiple treatment options are practiced, but the available small mol. drugs suffer from dose-limiting toxicity and undesirable side effects.  The need for new, less toxic treatments is a pressing concern.  Here, we demonstrate that (-)-agelastatin A (I, X = Br), a pyrrole-imidazole alkaloid obtained from a marine sponge, exhibits potent in vitro activity against primary cell lines of CLL and disclose the synthesis of several analogs that are equipotent or exceed the potency of the natural product.  The novel synthetic analog, 13-debromo-13-trifluoromethyl agelastatin A I (X = CF3), showed higher activity than the natural product when tested against the same cell lines and is the most potent agelastatin deriv. reported to date.  A detailed in vitro structure-activity relationship of I (X = Br) in CLL compared to that of 22 synthetic analogs is described along with preliminary in vivo pharmacokinetic and metab. studies on the most potent compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD9OSbYEzTfrVg90H21EOLACvtfcHk0lgDQ0nILPkgQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGmtL8%253D&md5=a10cb2a61a81aca656cfc24d14cfa9f2</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Fjm4016922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016922%26sid%3Dliteratum%253Aachs%26aulast%3DStout%26aufirst%3DE.%2BP.%26aulast%3DChoi%26aufirst%3DM.%2BY.%26aulast%3DCastro%26aufirst%3DJ.%2BE.%26aulast%3DMolinski%26aufirst%3DT.%2BF.%26atitle%3DPotent%2520Fluorinated%2520Agelastatin%2520Analogues%2520for%2520Chronic%2520Lymphocytic%2520Leukemia%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Pharmacokinetic%2520Studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5085%26epage%3D5093%26doi%3D10.1021%2Fjm4016922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dyshlovoy, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinovsky, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shubina, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bokemeyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stonik, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honecker, F.</span></span> <span> </span><span class="NLM_article-title">Mycalamide A Shows Cytotoxic Properties and Prevents EGF-Induced Neoplastic Transformation through Inhibition of Nuclear Factors</span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1212</span>– <span class="NLM_lpage">1224</span>, <span class="refDoi"> DOI: 10.3390/md10061212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3390%2Fmd10061212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22822368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38Xotlyjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=1212-1224&author=S.+A.+Dyshlovoyauthor=S.+N.+Fedorovauthor=A.+I.+Kalinovskyauthor=L.+K.+Shubinaauthor=C.+Bokemeyerauthor=V.+A.+Stonikauthor=F.+Honecker&title=Mycalamide+A+Shows+Cytotoxic+Properties+and+Prevents+EGF-Induced+Neoplastic+Transformation+through+Inhibition+of+Nuclear+Factors&doi=10.3390%2Fmd10061212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Mycalamide A shows cytotoxic properties and prevents EGF-induced neoplastic transformation through inhibition of nuclear factors</span></div><div class="casAuthors">Dyshlovoy, Sergey A.; Fedorov, Sergey N.; Kalinovsky, Anatoly I.; Shubina, Larisa K.; Bokemeyer, Carsten; Stonik, Valentin A.; Honecker, Friedemann</div><div class="citationInfo"><span class="NLM_cas:title">Marine Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1212-1224</span>CODEN:
                <span class="NLM_cas:coden">MDARE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-3397</span>.
    
            (<span class="NLM_cas:orgname">MDPI Center</span>)
        </div><div class="casAbstract">We report the isolation of mycalamide A from ascidian Polysyncraton sp. as well as investigation of its cancer preventive properties.  In murine JB6 Cl41 P+ cells, mycalamide A inhibited epidermal growth factor (EGF)-induced neoplastic transformation, and induced apoptosis at subnanomolar or nanomolar concns.  The compd. inhibited transcriptional activity of the oncogenic nuclear factors AP-1 and NF-κB, a potential mechanism of its cancer preventive properties.  Induction of phosphorylation of the kinases MAPK p38, JNK, and ERK was also obsd. at high concns. of mycalamide A.  The drug shows promising potential for both cancer prevention and cytotoxic therapy and should be further developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFrdXle0o-tbVg90H21EOLACvtfcHk0lgDQ0nILPkgQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xotlyjs7g%253D&md5=8ade9a7c7dba8bc28644a183a5c4255c</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.3390%2Fmd10061212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd10061212%26sid%3Dliteratum%253Aachs%26aulast%3DDyshlovoy%26aufirst%3DS.%2BA.%26aulast%3DFedorov%26aufirst%3DS.%2BN.%26aulast%3DKalinovsky%26aufirst%3DA.%2BI.%26aulast%3DShubina%26aufirst%3DL.%2BK.%26aulast%3DBokemeyer%26aufirst%3DC.%26aulast%3DStonik%26aufirst%3DV.%2BA.%26aulast%3DHonecker%26aufirst%3DF.%26atitle%3DMycalamide%2520A%2520Shows%2520Cytotoxic%2520Properties%2520and%2520Prevents%2520EGF-Induced%2520Neoplastic%2520Transformation%2520through%2520Inhibition%2520of%2520Nuclear%2520Factors%26jtitle%3DMar.%2520Drugs%26date%3D2012%26volume%3D10%26spage%3D1212%26epage%3D1224%26doi%3D10.3390%2Fmd10061212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gürel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steitz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. B.</span></span> <span> </span><span class="NLM_article-title">Structures of Triacetyloleandomycin and Mycalamide A Bind to the Large Ribosomal Subunit of Haloarcula Marismortui</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5010</span>– <span class="NLM_lpage">5014</span>, <span class="refDoi"> DOI: 10.1128/AAC.00817-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1128%2FAAC.00817-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19738021" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=5010-5014&author=G.+G%C3%BCrelauthor=G.+Blahaauthor=T.+A.+Steitzauthor=P.+B.+Moore&title=Structures+of+Triacetyloleandomycin+and+Mycalamide+A+Bind+to+the+Large+Ribosomal+Subunit+of+Haloarcula+Marismortui&doi=10.1128%2FAAC.00817-09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1128%2FAAC.00817-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00817-09%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCrel%26aufirst%3DG.%26aulast%3DBlaha%26aufirst%3DG.%26aulast%3DSteitz%26aufirst%3DT.%2BA.%26aulast%3DMoore%26aufirst%3DP.%2BB.%26atitle%3DStructures%2520of%2520Triacetyloleandomycin%2520and%2520Mycalamide%2520A%2520Bind%2520to%2520the%2520Large%2520Ribosomal%2520Subunit%2520of%2520Haloarcula%2520Marismortui%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D5010%26epage%3D5014%26doi%3D10.1128%2FAAC.00817-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruangsiriluk, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocke, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolph, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loria, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpino, P. A.</span></span> <span> </span><span class="NLM_article-title">A Small-Molecule Anti-Secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1362</span>– <span class="NLM_lpage">1371</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.chembiol.2016.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27746128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yqs7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=1362-1371&author=D.+N.+Petersenauthor=J.+Hawkinsauthor=W.+Ruangsirilukauthor=K.+A.+Stevensauthor=B.+A.+Maguireauthor=T.+N.+O%E2%80%99Connellauthor=B.+N.+Rockeauthor=M.+Boehmauthor=R.+B.+Ruggeriauthor=T.+Rolphauthor=D.+Hepworthauthor=P.+M.+Loriaauthor=P.+A.+Carpino&title=A+Small-Molecule+Anti-Secretagogue+of+PCSK9+Targets+the+80S+Ribosome+to+Inhibit+PCSK9+Protein+Translation&doi=10.1016%2Fj.chembiol.2016.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation</span></div><div class="casAuthors">Petersen, Donna N.; Hawkins, Julie; Ruangsiriluk, Wanida; Stevens, Kimberly A.; Maguire, Bruce A.; O'Connell, Thomas N.; Rocke, Benjamin N.; Boehm, Markus; Ruggeri, Roger B.; Rolph, Tim; Hepworth, David; Loria, Paula M.; Carpino, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1362-1371</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that downregulates low-d. lipoprotein (LDL) receptor (LDL-R) levels on the surface of hepatocytes, resulting in decreased clearance of LDL-cholesterol (LDL-C).  Phenotypic screening of a small-mol. compd. collection was used to identify an inhibitor of PCSK9 secretion, (R)-N-(isoquinolin-1-yl)-3-(4-methoxyphenyl)-N-(piperidin-3-yl)propanamide (R-IMPP), which was shown to stimulate uptake of LDL-C in hepatoma cells by increasing LDL-R levels, without altering levels of secreted transferrin.  Systematic investigation of the mode of action revealed that R-IMPP did not decrease PCSK9 transcription or increase PCSK9 degrdn., but instead caused transcript-dependent inhibition of PCSK9 translation.  In support of this surprising mechanism of action, we found that R-IMPP was able to selectively bind to human, but not E. coli, ribosomes.  This study opens a new avenue for the development of drugs that modulate the activity of target proteins by mechanisms involving inhibition of eukaryotic translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbEnbBYD6NKbVg90H21EOLACvtfcHk0lgDQ0nILPkgQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yqs7%252FJ&md5=c375439e6ed7c49daa4625baff8e4e48</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DD.%2BN.%26aulast%3DHawkins%26aufirst%3DJ.%26aulast%3DRuangsiriluk%26aufirst%3DW.%26aulast%3DStevens%26aufirst%3DK.%2BA.%26aulast%3DMaguire%26aufirst%3DB.%2BA.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DT.%2BN.%26aulast%3DRocke%26aufirst%3DB.%2BN.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DRuggeri%26aufirst%3DR.%2BB.%26aulast%3DRolph%26aufirst%3DT.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26atitle%3DA%2520Small-Molecule%2520Anti-Secretagogue%2520of%2520PCSK9%2520Targets%2520the%252080S%2520Ribosome%2520to%2520Inhibit%2520PCSK9%2520Protein%2520Translation%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D1362%26epage%3D1371%26doi%3D10.1016%2Fj.chembiol.2016.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lintner, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Londregan, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowski, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loria, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolph, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doudna, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dullea, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cate, J. H. D. D.</span></span> <span> </span><span class="NLM_article-title">Selective Stalling of Human Translation through Small-Molecule Engagement of the Ribosome Nascent Chain</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">e2001882</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.2001882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pbio.2001882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28323820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1WqurfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=e2001882&author=N.+G.+Lintnerauthor=K.+F.+McClureauthor=D.+Petersenauthor=A.+T.+Londreganauthor=D.+W.+Piotrowskiauthor=L.+Weiauthor=J.+Xiaoauthor=M.+Boltauthor=P.+M.+Loriaauthor=B.+Maguireauthor=K.+F.+Geogheganauthor=A.+Huangauthor=T.+Rolphauthor=S.+Lirasauthor=J.+A.+Doudnaauthor=R.+G.+Dulleaauthor=J.+H.+D.+D.+Cate&title=Selective+Stalling+of+Human+Translation+through+Small-Molecule+Engagement+of+the+Ribosome+Nascent+Chain&doi=10.1371%2Fjournal.pbio.2001882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain</span></div><div class="casAuthors">Lintner, Nathanael G.; McClure, Kim F.; Petersen, Donna; Londregan, Allyn T.; Piotrowski, David W.; Wei, Liuqing; Xiao, Jun; Bolt, Michael; Loria, Paula M.; Maguire, Bruce; Geoghegan, Kieran F.; Huang, Austin; Rolph, Tim; Liras, Spiros; Doudna, Jennifer A.; Dullea, Robert G.; Cate, Jamie H. D.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e2001882/1-e2001882/36</span>CODEN:
                <span class="NLM_cas:coden">PBLIBG</span>;
        ISSN:<span class="NLM_cas:issn">1545-7885</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating the levels of plasma low-d. lipoprotein cholesterol (LDL-C).  Here, we demonstrate that the compd. PF-06446846 inhibits translation of PCSK9 by inducing the ribosome to stall around codon 34, mediated by the sequence of the nascent chain within the exit tunnel.  We further show that PF-06446846 reduces plasma PCSK9 and total cholesterol levels in rats following oral dosing.  Using ribosome profiling, we demonstrate that PF-06446846 is highly selective for the inhibition of PCSK9 translation.  The mechanism of action employed by PF-06446846 reveals a previously unexpected tunability of the human ribosome that allows small mols. to specifically block translation of individual transcripts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqeQbFLtKlX7Vg90H21EOLACvtfcHk0ljmW89zowq6-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1WqurfE&md5=64f33ee234c2425258154ac8368d2518</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.2001882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.2001882%26sid%3Dliteratum%253Aachs%26aulast%3DLintner%26aufirst%3DN.%2BG.%26aulast%3DMcClure%26aufirst%3DK.%2BF.%26aulast%3DPetersen%26aufirst%3DD.%26aulast%3DLondregan%26aufirst%3DA.%2BT.%26aulast%3DPiotrowski%26aufirst%3DD.%2BW.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DBolt%26aufirst%3DM.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DMaguire%26aufirst%3DB.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DRolph%26aufirst%3DT.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DDoudna%26aufirst%3DJ.%2BA.%26aulast%3DDullea%26aufirst%3DR.%2BG.%26aulast%3DCate%26aufirst%3DJ.%2BH.%2BD.%2BD.%26atitle%3DSelective%2520Stalling%2520of%2520Human%2520Translation%2520through%2520Small-Molecule%2520Engagement%2520of%2520the%2520Ribosome%2520Nascent%2520Chain%26jtitle%3DPLoS%2520Biol.%26date%3D2017%26volume%3D15%26spage%3De2001882%26doi%3D10.1371%2Fjournal.pbio.2001882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liaud, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horlbeck, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjoni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cate, J. H. D.</span></span> <span> </span><span class="NLM_article-title">Cellular Response to Small Molecules That Selectively Stall Protein Synthesis by the Ribosome</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1371/journal.pgen.1008057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pgen.1008057" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=1-30&author=N.+Liaudauthor=M.+A.+Horlbeckauthor=L.+A.+Gilbertauthor=K.+Gjoniauthor=J.+S.+Weissmanauthor=J.+H.+D.+Cate&title=Cellular+Response+to+Small+Molecules+That+Selectively+Stall+Protein+Synthesis+by+the+Ribosome&doi=10.1371%2Fjournal.pgen.1008057"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1008057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1008057%26sid%3Dliteratum%253Aachs%26aulast%3DLiaud%26aufirst%3DN.%26aulast%3DHorlbeck%26aufirst%3DM.%2BA.%26aulast%3DGilbert%26aufirst%3DL.%2BA.%26aulast%3DGjoni%26aufirst%3DK.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26aulast%3DCate%26aufirst%3DJ.%2BH.%2BD.%26atitle%3DCellular%2520Response%2520to%2520Small%2520Molecules%2520That%2520Selectively%2520Stall%2520Protein%2520Synthesis%2520by%2520the%2520Ribosome%26jtitle%3DPLoS%2520Genet.%26date%3D2019%26volume%3D15%26spage%3D1%26epage%3D30%26doi%3D10.1371%2Fjournal.pgen.1008057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montabana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dullea, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cate, J. H. D.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Selective Stalling of Human Ribosome Nascent Chain Complexes by a Drug-like Molecule</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1038/s41594-019-0236-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41594-019-0236-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31160784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2it7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=501-509&author=W.+Liauthor=F.+R.+Wardauthor=K.+F.+McClureauthor=S.+T.+L.+Changauthor=E.+Montabanaauthor=S.+Lirasauthor=R.+G.+Dulleaauthor=J.+H.+D.+Cate&title=Structural+Basis+for+Selective+Stalling+of+Human+Ribosome+Nascent+Chain+Complexes+by+a+Drug-like+Molecule&doi=10.1038%2Fs41594-019-0236-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for selective stalling of human ribosome nascent chain complexes by a drug-like molecule</span></div><div class="casAuthors">Li, Wenfei; Ward, Fred R.; McClure, Kim F.; Chang, Stacey Tsai-Lan; Montabana, Elizabeth; Liras, Spiros; Dullea, Robert G.; Cate, Jamie H. D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">501-509</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The drug-like mol. PF-06446846 (PF846) binds the human ribosome and selectively blocks the translation of a small no. of proteins by an unknown mechanism.  In structures of PF846-stalled human ribosome nascent chain complexes, PF846 binds in the ribosome exit tunnel in a eukaryotic-specific pocket formed by 28S rRNA, and alters the path of the nascent polypeptide chain.  PF846 arrests the translating ribosome in the rotated state of translocation, in which the peptidyl-tRNA 3'-CCA end is improperly docked in the peptidyl transferase center.  Selections of mRNAs from mRNA libraries using translation exts. reveal that PF846 can stall translation elongation, arrest termination or even enhance translation, depending on nascent chain sequence context.  These results illuminate how a small mol. selectively targets translation by the human ribosome, and provides a foundation for developing small mols. that modulate the prodn. of proteins of therapeutic interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGgqVCCdqK77Vg90H21EOLACvtfcHk0ljmW89zowq6-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2it7bN&md5=69dde942a5f86ff7942c94a48d0475a9</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1038%2Fs41594-019-0236-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-019-0236-8%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DWard%26aufirst%3DF.%2BR.%26aulast%3DMcClure%26aufirst%3DK.%2BF.%26aulast%3DChang%26aufirst%3DS.%2BT.%2BL.%26aulast%3DMontabana%26aufirst%3DE.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DDullea%26aufirst%3DR.%2BG.%26aulast%3DCate%26aufirst%3DJ.%2BH.%2BD.%26atitle%3DStructural%2520Basis%2520for%2520Selective%2520Stalling%2520of%2520Human%2520Ribosome%2520Nascent%2520Chain%2520Complexes%2520by%2520a%2520Drug-like%2520Molecule%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D501%26epage%3D509%26doi%3D10.1038%2Fs41594-019-0236-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cate, J. H. D.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Human Translation Termination by a Drug-like Compound</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4941</span>, <span class="refDoi"> DOI: 10.1038/s41467-020-18765-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fs41467-020-18765-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=33009412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvF2js77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=4941&author=W.+Liauthor=S.+T.+L.+Changauthor=F.+R.+Wardauthor=J.+H.+D.+Cate&title=Selective+Inhibition+of+Human+Translation+Termination+by+a+Drug-like+Compound&doi=10.1038%2Fs41467-020-18765-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of human translation termination by a drug-like compound</span></div><div class="casAuthors">Li, Wenfei; Chang, Stacey Tsai-Lan; Ward, Fred. R.; Cate, Jamie H. D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4941</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Methods to directly inhibit gene expression using small mols. hold promise for the development of new therapeutics targeting proteins that have evaded previous attempts at drug discovery.  Among these, small mols. including the drug-like compd. PF-06446846 (PF846) selectively inhibit the synthesis of specific proteins, by stalling translation elongation.  These mols. also inhibit translation termination by an unknown mechanism.  Using cryo-electron microscopy (cryo-EM) and biochem. approaches, we show that PF846 inhibits translation termination by arresting the nascent chain (NC) in the ribosome exit tunnel.  The arrested NC adopts a compact α-helical conformation that induces 28 S rRNA nucleotide rearrangements that suppress the peptidyl transferase center (PTC) catalytic activity stimulated by eukaryotic release factor 1 (eRF1).  These data support a mechanism of action for a small mol. targeting translation that suppresses peptidyl-tRNA hydrolysis promoted by eRF1, revealing principles of eukaryotic translation termination and laying the foundation for new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2vlgufrovyLVg90H21EOLACvtfcHk0ljl9Azn0YoKcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvF2js77M&md5=4347d287e0ee4ae2caca282df2267b1d</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-18765-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-18765-2%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DChang%26aufirst%3DS.%2BT.%2BL.%26aulast%3DWard%26aufirst%3DF.%2BR.%26aulast%3DCate%26aufirst%3DJ.%2BH.%2BD.%26atitle%3DSelective%2520Inhibition%2520of%2520Human%2520Translation%2520Termination%2520by%2520a%2520Drug-like%2520Compound%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26spage%3D4941%26doi%3D10.1038%2Fs41467-020-18765-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krause, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serio, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, L. E.</span></span> <span> </span><span class="NLM_article-title">Aminoglycosides: An Overview</span>. <i>Cold Spring Harb. Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">a027029</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a027029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1101%2Fcshperspect.a027029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=27252397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1ylsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=a027029&author=K.+M.+Krauseauthor=A.+W.+Serioauthor=T.+R.+Kaneauthor=L.+E.+Connolly&title=Aminoglycosides%3A+An+Overview&doi=10.1101%2Fcshperspect.a027029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycosides: an overview</span></div><div class="casAuthors">Krause, Kevin M.; Serio, Alisa W.; Kane, Timothy R.; Connolly, Lynn E.</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">a027029/1-a027029/19</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Aminoglycosides are natural or semisynthetic antibiotics derived from actinomycetes.  They were among the first antibiotics to be introduced for routine clin. use and several examples have been approved for use in humans.  They found widespread use as first-line agents in the early days of antimicrobial chemotherapy, but were eventually replaced in the 1980s with cephalosporins, carbapenems, and fluoroquinolones.  Aminoglycosides synergize with a variety of other antibacterial classes, which, in combination with the continued increase in the rise of multidrug-resistant bacteria and the potential to improve the safety and efficacy of the class through optimized dosing regimens, has led to a renewed interest in these broad-spectrum and rapidly bactericidal antibacterials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_dhgL95KDXbVg90H21EOLACvtfcHk0ljl9Azn0YoKcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1ylsbs%253D&md5=675d7f4c769fdcc681171a121e5aa09e</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a027029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a027029%26sid%3Dliteratum%253Aachs%26aulast%3DKrause%26aufirst%3DK.%2BM.%26aulast%3DSerio%26aufirst%3DA.%2BW.%26aulast%3DKane%26aufirst%3DT.%2BR.%26aulast%3DConnolly%26aufirst%3DL.%2BE.%26atitle%3DAminoglycosides%253A%2520An%2520Overview%26jtitle%3DCold%2520Spring%2520Harb.%2520Perspect.%2520Med.%26date%3D2016%26volume%3D6%26spage%3Da027029%26doi%3D10.1101%2Fcshperspect.a027029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, F.</span></span> <span> </span><span class="NLM_article-title">Phenotypic Suppression of Nonsense Mutants in Yeast by Aminoglycoside Antibiotics</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1038/277148a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2F277148a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=366439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaE1MXks12it7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1979&pages=148-150&author=E.+Palmerauthor=J.+M.+Wilhelmauthor=F.+Sherman&title=Phenotypic+Suppression+of+Nonsense+Mutants+in+Yeast+by+Aminoglycoside+Antibiotics&doi=10.1038%2F277148a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics</span></div><div class="casAuthors">Palmer, Edward; Wilhelm, James M.; Sherman, Fred</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5692</span>),
    <span class="NLM_cas:pages">148-50</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Paromomycin (I)  [7542-37-2] (5 mg) phenotypically suppressed the methionine requirement of a yeast (Saccharomyces cerevisiae) strain carrying the amber mutation met8-1.  I suppressed mutations representing lesions in 8 different metabolic paths and in 11 different structural genes.  I could also suppress all 3 nonsense codons, UAG, UAA, and UGA.  I suppressed mutations at concns. as low as 50 μM, the optimal concn. for suppression being ∼100 μM.  In vitro translation expts. studying the incorporation of leucine with a poly(U) template showed that I (0.1-250 μM) stimulated leucine errors but streptomycin  [57-92-1] (0.1-250 μM) had no activity; neomycin  [1404-04-2] (0.1-250 μM) stimulated leucine errors but was less active than I.  I stimulated mistranslation without inhibiting cell-free protein synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRpMEpBxklvLVg90H21EOLACvtfcHk0ljl9Azn0YoKcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXks12it7o%253D&md5=fd09a15094d8ffab9e2040e9f3891cd8</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1038%2F277148a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F277148a0%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DE.%26aulast%3DWilhelm%26aufirst%3DJ.%2BM.%26aulast%3DSherman%26aufirst%3DF.%26atitle%3DPhenotypic%2520Suppression%2520of%2520Nonsense%2520Mutants%2520in%2520Yeast%2520by%2520Aminoglycoside%2520Antibiotics%26jtitle%3DNature%26date%3D1979%26volume%3D277%26spage%3D148%26epage%3D150%26doi%3D10.1038%2F277148a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wangen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span> <span> </span><span class="NLM_article-title">Stop Codon Context Influences Genome-Wide Stimulation of Termination Codon Readthrough by Aminoglycosides</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e52611</span>, <span class="refDoi"> DOI: 10.7554/eLife.52611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.7554%2FeLife.52611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31971508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsF2mtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=e52611&author=J.+R.+Wangenauthor=R.+Green&title=Stop+Codon+Context+Influences+Genome-Wide+Stimulation+of+Termination+Codon+Readthrough+by+Aminoglycosides&doi=10.7554%2FeLife.52611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides</span></div><div class="casAuthors">Wangen, Jamie R.; Green, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e52611</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Stop codon readthrough (SCR) occurs when the ribosome miscodes at a stop codon.  Such readthrough events can be therapeutically desirable when a premature termination codon (PTC) is found in a crit. gene.  To study SCR in vivo in a genome-wide manner, we treated mammalian cells with aminoglycosides and performed ribosome profiling.  We find that in addn. to stimulating readthrough of PTCs, aminoglycosides stimulate readthrough of normal termination codons (NTCs) genome-wide.  Stop codon identity, the nucleotide following the stop codon, and the surrounding mRNA sequence context all influence the likelihood of SCR.  In comparison to NTCs, downstream stop codons in 3'UTRs are recognized less efficiently by ribosomes, suggesting that targeting of crit. stop codons for readthrough may be achievable without general disruption of translation termination.  Finally, we find that G418-induced miscoding alters gene expression with substantial effects on translation of histone genes, selenoprotein genes, and S-adenosylmethionine decarboxylase (AMD1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcLXdaOe4NorVg90H21EOLACvtfcHk0ljl9Azn0YoKcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsF2mtbbM&md5=486793aaedf36805e1784a95dda726ca</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.7554%2FeLife.52611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.52611%26sid%3Dliteratum%253Aachs%26aulast%3DWangen%26aufirst%3DJ.%2BR.%26aulast%3DGreen%26aufirst%3DR.%26atitle%3DStop%2520Codon%2520Context%2520Influences%2520Genome-Wide%2520Stimulation%2520of%2520Termination%2520Codon%2520Readthrough%2520by%2520Aminoglycosides%26jtitle%3DeLife%26date%3D2020%26volume%3D9%26spage%3De52611%26doi%3D10.7554%2FeLife.52611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howard, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fass, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khatri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesteland, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanigan, K. M.</span></span> <span> </span><span class="NLM_article-title">Readthrough of Dystrophin Stop Codon Mutations Induced by Aminoglycosides</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.1002/ana.20052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2Fana.20052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=14991821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFKntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2004&pages=422-426&author=M.+T.+Howardauthor=C.+B.+Andersonauthor=U.+Fassauthor=S.+Khatriauthor=R.+F.+Gestelandauthor=J.+F.+Atkinsauthor=K.+M.+Flanigan&title=Readthrough+of+Dystrophin+Stop+Codon+Mutations+Induced+by+Aminoglycosides&doi=10.1002%2Fana.20052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Readthrough of dystrophin stop codon mutations induced by aminoglycosides</span></div><div class="casAuthors">Howard, Michael T.; Anderson, Christine B.; Fass, Uwe; Khatri, Shikha; Gesteland, Raymond F.; Atkins, John F.; Flanigan, Kevin M.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">422-426</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We report the translational readthrough levels induced by the aminoglycosides gentamicin, amikacin, tobramycin, and paromomycin for eight premature stop codon mutations identified in Duchenne's and Becker's muscular dystrophy patients.  In a transient transfection reporter assay, aminoglycoside treatment results show that one stop codon mutation is suppressed significantly better (up to 10% stop codon readthrough) than the others; five show lower but statistically significant suppression (<2% stop codon readthrough); and two appear refractory to aminoglycoside treatment.  Readthrough levels do not substantially vary between different sources of gentamicin, and, for this set of mutations, the efficiency of termination at the premature stop codon mutation does not appear to correlate with disease severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBC-iaCCOrMrVg90H21EOLACvtfcHk0lg6NcBwqvU9ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFKntbc%253D&md5=84b0ab199baedaf4e338d40e5911b1be</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1002%2Fana.20052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.20052%26sid%3Dliteratum%253Aachs%26aulast%3DHoward%26aufirst%3DM.%2BT.%26aulast%3DAnderson%26aufirst%3DC.%2BB.%26aulast%3DFass%26aufirst%3DU.%26aulast%3DKhatri%26aufirst%3DS.%26aulast%3DGesteland%26aufirst%3DR.%2BF.%26aulast%3DAtkins%26aufirst%3DJ.%2BF.%26aulast%3DFlanigan%26aufirst%3DK.%2BM.%26atitle%3DReadthrough%2520of%2520Dystrophin%2520Stop%2520Codon%2520Mutations%2520Induced%2520by%2520Aminoglycosides%26jtitle%3DAnn.%2520Neurol.%26date%3D2004%26volume%3D55%26spage%3D422%26epage%3D426%26doi%3D10.1002%2Fana.20052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cogan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">South, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodley, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span> <span> </span><span class="NLM_article-title">Aminoglycosides Restore Full-Length Type VII Collagen by Overcoming Premature Termination Codons: Therapeutic Implications for Dystrophic Epidermolysis Bullosa</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1741</span>– <span class="NLM_lpage">1752</span>, <span class="refDoi"> DOI: 10.1038/mt.2014.140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fmt.2014.140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25155989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWktrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=1741-1752&author=J.+Coganauthor=J.+Weinsteinauthor=X.+Wangauthor=Y.+Houauthor=S.+Martinauthor=A.+P.+Southauthor=D.+T.+Woodleyauthor=M.+Chen&title=Aminoglycosides+Restore+Full-Length+Type+VII+Collagen+by+Overcoming+Premature+Termination+Codons%3A+Therapeutic+Implications+for+Dystrophic+Epidermolysis+Bullosa&doi=10.1038%2Fmt.2014.140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycosides Restore Full-length Type VII Collagen by Overcoming Premature Termination Codons: Therapeutic Implications for Dystrophic Epidermolysis Bullosa</span></div><div class="casAuthors">Cogan, Jon; Weinstein, Jacqueline; Wang, Xinyi; Hou, Yingping; Martin, Sabrina; South, Andrew P.; Woodley, David T.; Chen, Mei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1741-1752</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Patients with recessive dystrophic epidermolysis bullosa (RDEB) have severe, incurable skin fragility, blistering, and multiple skin wounds due to mutations in the gene encoding type VII collagen (C7), the major component of anchoring fibrils mediating epidermal-dermal adherence.  Nearly 10-25% of RDEB patients carry nonsense mutations leading to premature stop codons (PTCs) that result in truncated C7.  In this study, we evaluated the feasibility of using aminoglycosides to suppress PTCs and induce C7 expression in two RDEB keratinocyte cell lines (Q251X/Q251X and R578X/R906) and two primary RDEB fibroblasts (R578X/R578X and R163X/R1683X).  Incubation of these cells with aminoglycosides (geneticin, gentamicin, and paromomycin) resulted in the synthesis and secretion of a full-length C7 in a dose-dependent and sustained manner.  Importantly, aminoglycoside-induced C7 reversed the abnormal RDEB cell phenotype and incorporated into the dermal-epidermal junction of skin equiv.  We further demonstrated the general utility of aminoglycoside-mediated readthrough in 293 cells transiently transfected with expression vectors encoding 22 different RDEB nonsense mutations.  This is the first study demonstrating that aminoglycosides can induce PTC readthrough and restore functional C7 in RDEB caused by nonsense mutations.  Therefore, aminoglycosides may have therapeutic potential for RDEB patients and other inherited skin diseases caused by nonsense mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZCDRXfQJBYbVg90H21EOLACvtfcHk0lg6NcBwqvU9ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWktrrN&md5=cfa3fd6b6335c998db44441b33fadbe1</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1038%2Fmt.2014.140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2014.140%26sid%3Dliteratum%253Aachs%26aulast%3DCogan%26aufirst%3DJ.%26aulast%3DWeinstein%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DSouth%26aufirst%3DA.%2BP.%26aulast%3DWoodley%26aufirst%3DD.%2BT.%26aulast%3DChen%26aufirst%3DM.%26atitle%3DAminoglycosides%2520Restore%2520Full-Length%2520Type%2520VII%2520Collagen%2520by%2520Overcoming%2520Premature%2520Termination%2520Codons%253A%2520Therapeutic%2520Implications%2520for%2520Dystrophic%2520Epidermolysis%2520Bullosa%26jtitle%3DMol.%2520Ther.%26date%3D2014%26volume%3D22%26spage%3D1741%26epage%3D1752%26doi%3D10.1038%2Fmt.2014.140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodersen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan-Warren, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wimberly, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, V.</span></span> <span> </span><span class="NLM_article-title">Functional Insights from the Structure of the 30S Ribosomal Subunit and Its Interactions with Antibiotics</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>407</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1038/35030019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2F35030019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=11014183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFyktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2000&pages=340-348&author=A.+P.+Carterauthor=W.+M.+Clemonsauthor=D.+E.+Brodersenauthor=R.+J.+Morgan-Warrenauthor=B.+T.+Wimberlyauthor=V.+Ramakrishnan&title=Functional+Insights+from+the+Structure+of+the+30S+Ribosomal+Subunit+and+Its+Interactions+with+Antibiotics&doi=10.1038%2F35030019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics</span></div><div class="casAuthors">Carter, Andrew P.; Clemons, William M.; Brodersen, Ditlev E.; Morgan-Warren, Robert J.; Wimberly, Brian T.; Ramakrishnan, V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">6802</span>),
    <span class="NLM_cas:pages">340-348</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The 30S ribosomal subunit has two primary functions in protein synthesis.  It discriminates against aminoacyl tRNAs that do not match the codon of mRNA, thereby ensuring accuracy in translation of the genetic message in a process called decoding.  Also, it works with the 50S subunit to move the tRNAs and assocd. mRNA by precisely one codon, in a process called translocation.  Here we describe the functional implications of the high-resoln. 30S crystal structure presented in the accompanying paper, and infer details of the interactions between the 30S subunit and its tRNA and mRNA ligands.  We also describe the crystal structure of the 30S subunit complexed with the antibiotics paromomycin, streptomycin and spectinomycin, which interfere with decoding and translocation.  This work reveals the structural basis for the action of these antibiotics, and leads to a model for the role of the universally conserved 16S RNA residues A1492 and A1493 in the decoding process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwYnLojpZbJbVg90H21EOLACvtfcHk0lg6NcBwqvU9ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFyktbs%253D&md5=f3e5e6211a5e9951a5f878408c73a434</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1038%2F35030019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35030019%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DA.%2BP.%26aulast%3DClemons%26aufirst%3DW.%2BM.%26aulast%3DBrodersen%26aufirst%3DD.%2BE.%26aulast%3DMorgan-Warren%26aufirst%3DR.%2BJ.%26aulast%3DWimberly%26aufirst%3DB.%2BT.%26aulast%3DRamakrishnan%26aufirst%3DV.%26atitle%3DFunctional%2520Insights%2520from%2520the%2520Structure%2520of%2520the%252030S%2520Ribosomal%2520Subunit%2520and%2520Its%2520Interactions%2520with%2520Antibiotics%26jtitle%3DNature%26date%3D2000%26volume%3D407%26spage%3D340%26epage%3D348%26doi%3D10.1038%2F35030019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puglisi, J. D.</span></span> <span> </span><span class="NLM_article-title">Structural Origins of Aminoglycoside Specificity for Prokaryotic Ribosomes</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">1037</span>– <span class="NLM_lpage">1058</span>, <span class="refDoi"> DOI: 10.1006/jmbi.2000.4420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1006%2Fjmbi.2000.4420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=11237617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsFOhu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2001&pages=1037-1058&author=S.+R.+Lynchauthor=J.+D.+Puglisi&title=Structural+Origins+of+Aminoglycoside+Specificity+for+Prokaryotic+Ribosomes&doi=10.1006%2Fjmbi.2000.4420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Origins of Aminoglycoside Specificity for Prokaryotic Ribosomes</span></div><div class="casAuthors">Lynch, Stephen R.; Puglisi, Joseph D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1037-1058</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Aminoglycoside antibiotics, including paromomycin, neomycin and gentamicin, target a region of highly conserved nucleotides in the decoding region aminoacyl-tRNA site of 16 S rRNA on the 30 S subunit.  Change of a single nucleotide, A1408 to G, reduces the affinity of many aminoglycosides for the ribosome; G1408 distinguishes between prokaryotic and eukaryotic ribosomes.  The structures of a prokaryotic decoding region A-site oligonucleotide free in soln. and bound to the aminoglycosides paromomycin and gentamicin C1a were detd. previously.  Here, the structure of a eukaryotic decoding region A-site oligonucleotide bound to paromomycin has been detd. using NMR spectroscopy and compared to the prokaryotic A-site-paromomycin structure.  A conformational change in three adenosine residues of an internal loop, crit. for high-affinity antibiotic binding, was obsd. in the prokaryotic RNA-paromomycin complex in comparison to its free form.  This conformational change is not obsd. in the eukaryotic RNA-paromomycin complex, disrupting the binding pocket for ring I of the antibiotic.  The lack of the conformational change supports footprinting and titrn. calorimetry data that demonstrate approx. 25-50-fold weaker binding of paromomycin to the eukaryotic decoding-site oligonucleotide.  Neomycin, which is much less active against Escherichia coli ribosomes with an A1408G mutation, binds non-specifically to the oligonucleotide.  These results suggest that eukaryotic rRNA has a shallow binding pocket for aminoglycosides, which accommodates only certain antibiotics.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVlkDMuTq_RbVg90H21EOLACvtfcHk0lgCI77v2vi_YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsFOhu7g%253D&md5=907edc24d0cfc864d5235be798357dea</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2000.4420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2000.4420%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DS.%2BR.%26aulast%3DPuglisi%26aufirst%3DJ.%2BD.%26atitle%3DStructural%2520Origins%2520of%2520Aminoglycoside%2520Specificity%2520for%2520Prokaryotic%2520Ribosomes%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D306%26spage%3D1037%26epage%3D1058%26doi%3D10.1006%2Fjmbi.2000.4420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Recht, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douthwaite, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlquist, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puglisi, J. D.</span></span> <span> </span><span class="NLM_article-title">Effect of Mutations in the A Site of 16 S RRNA on Aminoglycoside Antibiotic-Ribosome Interaction</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1998.2446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1006%2Fjmbi.1998.2446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=9931247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK1MXhtV2hurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=33-43&author=M.+I.+Rechtauthor=S.+Douthwaiteauthor=K.+D.+Dahlquistauthor=J.+D.+Puglisi&title=Effect+of+Mutations+in+the+A+Site+of+16+S+RRNA+on+Aminoglycoside+Antibiotic-Ribosome+Interaction&doi=10.1006%2Fjmbi.1998.2446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Mutations in the A Site of 16 S rRNA on Aminoglycoside Antibiotic-Ribosome Interaction</span></div><div class="casAuthors">Recht, Michael I.; Douthwaite, Stephen; Dahlquist, Kam D.; Puglisi, Joseph D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-43</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Decoding of genetic information occurs upon interaction of an mRNA codon-tRNA anticodon complex with the small subunit of the ribosome.  The ribosomal decoding region is assocd. with highly conserved sequences near the 3' end of 16 S rRNA.  The decoding process is perturbed by the aminoglycoside antibiotics, which also interact with this region of rRNA.  Mutations of certain nucleotides in rRNA reduce aminoglycoside binding affinity, as previously demonstrated using a model RNA oligonucleotide system.  Here, predictions from the oligonucleotide system were tested in the ribosome by mutation of universally conserved nucleotides at 1406 to 1408 and 1494 to 1495 in the decoding region of plasmid-encoded bacterial 16 S rRNA.  Phenotypic changes range from the benign effect of U1406→A or A1408→G substitutions, to the highly deleterious 1406G and 1495 mutations that assemble into 30 S subunits but are defective in forming functional ribosomes.  Changes in the local conformation of the decoding region caused by these mutations were identified by chem. probing of isolated 30 S subunits.  Ribosomes contg. 16 S rRNA with mutations at positions 1408, 1407+1494, or 1495 had reduced affinity for the aminoglycoside paromomycin, whereas no discernible redn. in affinity was obsd. with 1406 mutant ribosomes.  These data are consistent with prior NMR structural detn. of aminoglycoside interaction with the decoding region, and further our understanding of how aminoglycoside resistance can be conferred.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogeFJ0bC6ambVg90H21EOLACvtfcHk0lgCI77v2vi_YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtV2hurw%253D&md5=b630e425b105af6a31e75cd6e1e416df</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1998.2446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1998.2446%26sid%3Dliteratum%253Aachs%26aulast%3DRecht%26aufirst%3DM.%2BI.%26aulast%3DDouthwaite%26aufirst%3DS.%26aulast%3DDahlquist%26aufirst%3DK.%2BD.%26aulast%3DPuglisi%26aufirst%3DJ.%2BD.%26atitle%3DEffect%2520of%2520Mutations%2520in%2520the%2520A%2520Site%2520of%252016%2520S%2520RRNA%2520on%2520Aminoglycoside%2520Antibiotic-Ribosome%2520Interaction%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D286%26spage%3D33%26epage%3D43%26doi%3D10.1006%2Fjmbi.1998.2446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinder, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garneau-Tsodikova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doudna Cate, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S. C.</span></span> <span> </span><span class="NLM_article-title">Chemically Related 4,5-Linked Aminoglycoside Antibiotics Drive Subunit Rotation in Opposite Directions</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">7896</span>, <span class="refDoi"> DOI: 10.1038/ncomms8896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fncomms8896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=26224058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWgs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=7896&author=M.+R.+Wassermanauthor=A.+Pulkauthor=Z.+Zhouauthor=R.+B.+Altmanauthor=J.+C.+Zinderauthor=K.+D.+Greenauthor=S.+Garneau-Tsodikovaauthor=J.+H.+Doudna+Cateauthor=S.+C.+Blanchard&title=Chemically+Related+4%2C5-Linked+Aminoglycoside+Antibiotics+Drive+Subunit+Rotation+in+Opposite+Directions&doi=10.1038%2Fncomms8896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically related 4,5-linked aminoglycoside antibiotics drive subunit rotation in opposite directions</span></div><div class="casAuthors">Wasserman, Michael R.; Pulk, Arto; Zhou, Zhou; Altman, Roger B.; Zinder, John C.; Green, Keith D.; Garneau-Tsodikova, Sylvie; Doudna Cate, Jamie H.; Blanchard, Scott C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7896</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Dynamic remodelling of intersubunit bridge B2, a conserved RNA domain of the bacterial ribosome connecting helixes 44 (h44) and 69 (H69) of the small and large subunit, resp., impacts translation by controlling intersubunit rotation.  Here we show that aminoglycosides chem. related to neomycin-paromomycin, ribostamycin and neamine-each bind to sites within h44 and H69 to perturb bridge B2 and affect subunit rotation.  Neomycin and paromomycin, which only differ by their ring-I 6'-polar group, drive subunit rotation in opposite directions.  This suggests that their distinct actions hinge on the 6'-substituent and the drug's net pos. charge.  By solving the crystal structure of the paromomycin-ribosome complex, we observe specific contacts between the apical tip of H69 and the 6'-hydroxyl on paromomycin from within the drug's canonical h44-binding site.  These results indicate that aminoglycoside actions must be framed in the context of bridge B2 and their regulation of subunit rotation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLsIpdhw_dd7Vg90H21EOLACvtfcHk0lgCI77v2vi_YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWgs7rL&md5=592b0846cc6962a8a1303a0b6b938af5</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1038%2Fncomms8896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms8896%26sid%3Dliteratum%253Aachs%26aulast%3DWasserman%26aufirst%3DM.%2BR.%26aulast%3DPulk%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26aulast%3DZinder%26aufirst%3DJ.%2BC.%26aulast%3DGreen%26aufirst%3DK.%2BD.%26aulast%3DGarneau-Tsodikova%26aufirst%3DS.%26aulast%3DDoudna%2BCate%26aufirst%3DJ.%2BH.%26aulast%3DBlanchard%26aufirst%3DS.%2BC.%26atitle%3DChemically%2520Related%25204%252C5-Linked%2520Aminoglycoside%2520Antibiotics%2520Drive%2520Subunit%2520Rotation%2520in%2520Opposite%2520Directions%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D7896%26doi%3D10.1038%2Fncomms8896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattis, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coady, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorson, C. L.</span></span> <span> </span><span class="NLM_article-title">Novel Aminoglycosides Increase SMN Levels in Spinal Muscular Atrophy Fibroblasts</span>. <i>Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">601</span>, <span class="refDoi"> DOI: 10.1007/s00439-006-0245-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs00439-006-0245-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16951947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKmtrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2006&pages=589-601&author=V.+B.+Mattisauthor=R.+Raiauthor=J.+Wangauthor=C.-W.+T.+Changauthor=T.+Coadyauthor=C.+L.+Lorson&title=Novel+Aminoglycosides+Increase+SMN+Levels+in+Spinal+Muscular+Atrophy+Fibroblasts&doi=10.1007%2Fs00439-006-0245-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts</span></div><div class="casAuthors">Mattis, Virginia B.; Rai, Ravi; Wang, Jinhua; Chang, Cheng-Wei T.; Coady, Tristan; Lorson, Christian L.</div><div class="citationInfo"><span class="NLM_cas:title">Human Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-601</span>CODEN:
                <span class="NLM_cas:coden">HUGEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6717</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality.  SMA is caused by the homozygous absence of survival motor neuron-1 (SMN1).  SMN2, a nearly identical copy gene, is retained in all SMA patients and encodes an identical protein as SMN1; however, SMN1 and SMN2 differ by a silent C to T transition which results in the prodn. of an alternatively spliced isoform (SMNΔ7), which encodes a defective protein, demonstrating that the absence of the short peptide encoded by SMN exon 7 is crit. in SMA development.  Previously, we have shown that for some functions heterologous sequences can compensate for the exon 7 peptide, suggesting that the SMN C-terminus functions non-specifically.  Consistent with this hypothesis, we now identify novel aminoglycosides that can induce SMN protein levels in patient fibroblasts.  This hypothesis was supported, in part, by a novel fluorescent SMN read-through assay.  Interestingly, however, through the development of a SMN exon 7-specific antibody, results suggested that levels of normal full-length SMN might also be elevated by aminoglycoside treatment.  These results demonstrate that the compds. that promote read-through may provide an alternative platform for the discovery of compds. that induce SMN protein levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDxozXLlANA7Vg90H21EOLACvtfcHk0lgCI77v2vi_YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKmtrzM&md5=ebc1b03bc34fe42d6a74adacd8593ca8</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1007%2Fs00439-006-0245-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00439-006-0245-7%26sid%3Dliteratum%253Aachs%26aulast%3DMattis%26aufirst%3DV.%2BB.%26aulast%3DRai%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.-W.%2BT.%26aulast%3DCoady%26aufirst%3DT.%26aulast%3DLorson%26aufirst%3DC.%2BL.%26atitle%3DNovel%2520Aminoglycosides%2520Increase%2520SMN%2520Levels%2520in%2520Spinal%2520Muscular%2520Atrophy%2520Fibroblasts%26jtitle%3DHum.%2520Genet.%26date%3D2006%26volume%3D120%26spage%3D589%26epage%3D601%26doi%3D10.1007%2Fs00439-006-0245-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prokhorova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djumagulov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urzhumtsev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusupov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusupova, G.</span></span> <span> </span><span class="NLM_article-title">Aminoglycoside Interactions and Impacts on the Eukaryotic Ribosome</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">E10899</span>– <span class="NLM_lpage">E10908</span>, <span class="refDoi"> DOI: 10.1073/pnas.1715501114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.1715501114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=29208708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWmtLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=E10899-E10908&author=I.+Prokhorovaauthor=R.+B.+Altmanauthor=M.+Djumagulovauthor=J.+P.+Shresthaauthor=A.+Urzhumtsevauthor=A.+Fergusonauthor=C.-W.+T.+Changauthor=M.+Yusupovauthor=S.+C.+Blanchardauthor=G.+Yusupova&title=Aminoglycoside+Interactions+and+Impacts+on+the+Eukaryotic+Ribosome&doi=10.1073%2Fpnas.1715501114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycoside interactions and impacts on the eukaryotic ribosome</span></div><div class="casAuthors">Prokhorova, Irina; Altman, Roger B.; Djumagulov, Muminjon; Shrestha, Jaya P.; Urzhumtsev, Alexandre; Ferguson, Angelica; Chang, Cheng-Wei Tom; Yusupov, Marat; Blanchard, Scott C.; Yusupova, Gulnara</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">E10899-E10908</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Aminoglycosides are chem. diverse, broad-spectrum antibiotics that target functional centers within the bacterial ribosome to impact all 4 principle stages (initiation, elongation, termination, and recycling) of the translation mechanism.  The propensity of aminoglycosides to induce miscoding errors that suppress the termination of protein synthesis supports their potential as therapeutic interventions in human diseases assocd. with premature termination codons (PTCs).  However, the sites of interaction of aminoglycosides with the eukaryotic ribosome and their modes of action in eukaryotic translation remain largely unexplored.  Here, we used the combination of x-ray crystallog. and single-mol. FRET anal. to reveal the interactions of distinct classes of aminoglycosides with the 80S eukaryotic ribosome.  Crystal structures of the 80S ribosome in complex with paromomycin, geneticin (G418), gentamicin, and TC007, solved at 3.3- to 3.7-Å resoln., revealed multiple aminoglycoside-binding sites within the large and small subunits, wherein the 6'-hydroxyl substituent in ring I served as a key determinant of binding to the canonical eukaryotic ribosomal decoding center.  Multivalent binding interactions with the human ribosome were also evidenced through their capacity to affect large-scale conformational dynamics within the pre-translocation complex that contribute to multiple aspects of the translation mechanism.  The distinct impacts of the aminoglycosides examd. suggested that their chem. compn. and distinct modes of interaction with the ribosome influence PTC read-through efficiency.  These findings provide structural and functional insights into aminoglycoside-induced impacts on the eukaryotic ribosome and implicate pleiotropic mechanisms of action beyond decoding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPUCQMKq_QbVg90H21EOLACvtfcHk0lh_5_O2YFQQ1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWmtLrJ&md5=cb086806aff7ff195f63b237a9be682f</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1715501114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1715501114%26sid%3Dliteratum%253Aachs%26aulast%3DProkhorova%26aufirst%3DI.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26aulast%3DDjumagulov%26aufirst%3DM.%26aulast%3DShrestha%26aufirst%3DJ.%2BP.%26aulast%3DUrzhumtsev%26aufirst%3DA.%26aulast%3DFerguson%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DC.-W.%2BT.%26aulast%3DYusupov%26aufirst%3DM.%26aulast%3DBlanchard%26aufirst%3DS.%2BC.%26aulast%3DYusupova%26aufirst%3DG.%26atitle%3DAminoglycoside%2520Interactions%2520and%2520Impacts%2520on%2520the%2520Eukaryotic%2520Ribosome%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3DE10899%26epage%3DE10908%26doi%3D10.1073%2Fpnas.1715501114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kandasamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atia-Glikin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shavit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belakhov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baasov, T.</span></span> <span> </span><span class="NLM_article-title">Increased Selectivity toward Cytoplasmic versus Mitochondrial Ribosome Confers Improved Efficiency of Synthetic Aminoglycosides in Fixing Damaged Genes: A Strategy for Treatment of Genetic Diseases Caused by Nonsense Mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10630</span>– <span class="NLM_lpage">10643</span>, <span class="refDoi"> DOI: 10.1021/jm3012992</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012992" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gru77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10630-10643&author=J.+Kandasamyauthor=D.+Atia-Glikinauthor=E.+Shulmanauthor=K.+Shapiraauthor=M.+Shavitauthor=V.+Belakhovauthor=T.+Baasov&title=Increased+Selectivity+toward+Cytoplasmic+versus+Mitochondrial+Ribosome+Confers+Improved+Efficiency+of+Synthetic+Aminoglycosides+in+Fixing+Damaged+Genes%3A+A+Strategy+for+Treatment+of+Genetic+Diseases+Caused+by+Nonsense+Mutations&doi=10.1021%2Fjm3012992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Increased Selectivity toward Cytoplasmic versus Mitochondrial Ribosome Confers Improved Efficiency of Synthetic Aminoglycosides in Fixing Damaged Genes: A Strategy for Treatment of Genetic Diseases Caused by Nonsense Mutations</span></div><div class="casAuthors">Kandasamy, Jeyakumar; Atia-Glikin, Dana; Shulman, Eli; Shapira, Katya; Shavit, Michal; Belakhov, Valery; Baasov, Timor</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10630-10643</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compelling evidence is now available that gentamicin and Geneticin (G418) can induce the mammalian ribosome to suppress disease-causing nonsense mutations and partially restore the expression of functional proteins.  However, toxicity and relative lack of efficacy at subtoxic doses limit the use of gentamicin for suppression therapy.  Although G418 exhibits the strongest activity, it is very cytotoxic even at low doses.  We describe here the first systematic development of the novel aminoglycoside (S)-11 (I) exhibiting similar in vitro and ex vivo activity to that of G418, while its cell toxicity is significantly lower than those of gentamicin and G418.  Using a series of biochem. assays, we provide proof of principle that antibacterial activity and toxicity of aminoglycosides can be dissected from their suppression activity.  The data further indicate that the increased specificity toward cytoplasmic ribosome correlates with the increased activity and that the decreased specificity toward mitochondrial ribosome confers the lowered cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYhdlMXPmoKrVg90H21EOLACvtfcHk0lh_5_O2YFQQ1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gru77N&md5=e028ed13e63ddb0994692fa088998465</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1021%2Fjm3012992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012992%26sid%3Dliteratum%253Aachs%26aulast%3DKandasamy%26aufirst%3DJ.%26aulast%3DAtia-Glikin%26aufirst%3DD.%26aulast%3DShulman%26aufirst%3DE.%26aulast%3DShapira%26aufirst%3DK.%26aulast%3DShavit%26aufirst%3DM.%26aulast%3DBelakhov%26aufirst%3DV.%26aulast%3DBaasov%26aufirst%3DT.%26atitle%3DIncreased%2520Selectivity%2520toward%2520Cytoplasmic%2520versus%2520Mitochondrial%2520Ribosome%2520Confers%2520Improved%2520Efficiency%2520of%2520Synthetic%2520Aminoglycosides%2520in%2520Fixing%2520Damaged%2520Genes%253A%2520A%2520Strategy%2520for%2520Treatment%2520of%2520Genetic%2520Diseases%2520Caused%2520by%2520Nonsense%2520Mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10630%26epage%3D10643%26doi%3D10.1021%2Fjm3012992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dündar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biberoglu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okur, İ.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tümer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezgü, F. S.</span></span> <span> </span><span class="NLM_article-title">In Vitro Translational Readthrough by Gentamicin and Geneticin Improves GLA Activity in Fabry Disease</span>. <i>Mol. Genet. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">S43</span>, <span class="refDoi"> DOI: 10.1016/j.ymgme.2016.11.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.ymgme.2016.11.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2017&pages=S43&author=H.+D%C3%BCndarauthor=G.+Biberogluauthor=%C4%B0.+Okurauthor=L.+T%C3%BCmerauthor=F.+S.+Ezg%C3%BC&title=In+Vitro+Translational+Readthrough+by+Gentamicin+and+Geneticin+Improves+GLA+Activity+in+Fabry+Disease&doi=10.1016%2Fj.ymgme.2016.11.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1016%2Fj.ymgme.2016.11.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymgme.2016.11.087%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25BCndar%26aufirst%3DH.%26aulast%3DBiberoglu%26aufirst%3DG.%26aulast%3DOkur%26aufirst%3D%25C4%25B0.%26aulast%3DT%25C3%25BCmer%26aufirst%3DL.%26aulast%3DEzg%25C3%25BC%26aufirst%3DF.%2BS.%26atitle%3DIn%2520Vitro%2520Translational%2520Readthrough%2520by%2520Gentamicin%2520and%2520Geneticin%2520Improves%2520GLA%2520Activity%2520in%2520Fabry%2520Disease%26jtitle%3DMol.%2520Genet.%2520Metab.%26date%3D2017%26volume%3D120%26spage%3DS43%26doi%3D10.1016%2Fj.ymgme.2016.11.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebök, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyrene, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorscher, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedwell, D. M.</span></span> <span> </span><span class="NLM_article-title">Evidence That Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic Fibrosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">1683</span>– <span class="NLM_lpage">1692</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.163.7.2004001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1164%2Fajrccm.163.7.2004001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=11401894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BD3MvgsVSquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2001&pages=1683-1692&author=J.+P.+Clancyauthor=Z.+Beb%C3%B6kauthor=F.+Ruizauthor=C.+Kingauthor=J.+Jonesauthor=L.+Walkerauthor=H.+Greerauthor=J.+Hongauthor=L.+Wingauthor=M.+Macalusoauthor=R.+Lyreneauthor=E.+J.+Sorscherauthor=D.+M.+Bedwell&title=Evidence+That+Systemic+Gentamicin+Suppresses+Premature+Stop+Mutations+in+Patients+with+Cystic+Fibrosis&doi=10.1164%2Fajrccm.163.7.2004001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis</span></div><div class="casAuthors">Clancy J P; Bebok Z; Ruiz F; King C; Jones J; Walker L; Greer H; Hong J; Wing L; Macaluso M; Lyrene R; Sorscher E J; Bedwell D M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1683-92</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Here we report the effects of gentamicin treatment on cystic fibrosis transmembrane regulator (CFTR) production and function in CF airway cells and patients with CF with premature stop mutations.  Using immunocytochemical and functional [6-methoxy-N- (3-sulfopropyl) quinolinium (SPQ)-based] techniques, ex vivo exposure of airway cells from stop mutation CF patients led to the identification of surface-localized CFTR in a dose-dependent fashion.  Next, five patients with CF with stop mutations and five CF control subjects were treated with parenteral gentamicin for 1 wk, and underwent repeated in vivo measures of CFTR function (nasal potential difference [PD] measurements and sweat chloride [Cl(-)] testing).  During the treatment period, the number of nasal PD readings in the direction of Cl(-) secretion was increased approximately 3-fold in the stop mutation patient group compared with controls (p < 0.001), and four of five stop mutation patients with CF had at least one reading during gentamicin treatment with a Cl(-) secretory response of more than -5 mV (hyperpolarized).  A response of this magnitude was not seen in any of the CF control subjects (p < 0.05).  In an independent series of experiments designed to test the ability of repeat nasal PDs to detect wild-type CFTR function, evidence of Cl(-) secretion was seen in 88% of control (non-CF) nasal PDs, and 71% were more than -5 mV hyperpolarized.  Together, these results suggest that gentamicin treatment can suppress premature stop mutations in airway cells from patients with CF, and produce small increases in CFTR Cl(-) conductance (as measured by the nasal PD) in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkuB1AyaLPjT69zv1FsJFMfW6udTcc2eaHvkDj6gZLF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvgsVSquw%253D%253D&md5=d773a4fc291c3883ced2a2829f849828</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.163.7.2004001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.163.7.2004001%26sid%3Dliteratum%253Aachs%26aulast%3DClancy%26aufirst%3DJ.%2BP.%26aulast%3DBeb%25C3%25B6k%26aufirst%3DZ.%26aulast%3DRuiz%26aufirst%3DF.%26aulast%3DKing%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DL.%26aulast%3DGreer%26aufirst%3DH.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DWing%26aufirst%3DL.%26aulast%3DMacaluso%26aufirst%3DM.%26aulast%3DLyrene%26aufirst%3DR.%26aulast%3DSorscher%26aufirst%3DE.%2BJ.%26aulast%3DBedwell%26aufirst%3DD.%2BM.%26atitle%3DEvidence%2520That%2520Systemic%2520Gentamicin%2520Suppresses%2520Premature%2520Stop%2520Mutations%2520in%2520Patients%2520with%2520Cystic%2520Fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2001%26volume%3D163%26spage%3D1683%26epage%3D1692%26doi%3D10.1164%2Fajrccm.163.7.2004001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tousson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebök, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitsett, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colledge, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorscher, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedwell, D. M.</span></span> <span> </span><span class="NLM_article-title">Aminoglycoside Suppression of a Premature Stop Mutation in a Cftr–/– Mouse Carrying a Human CFTR-G542X Transgene</span>. <i>J. Mol. Med. (Heidelberg, Ger.)</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1007/s00109-002-0363-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs00109-002-0363-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=12226741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFWktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2002&pages=595-604&author=M.+Duauthor=J.+R.+Jonesauthor=J.+Lanierauthor=K.+M.+Keelingauthor=J.+R.+Lindseyauthor=A.+Toussonauthor=Z.+Beb%C3%B6kauthor=J.+A.+Whitsettauthor=C.+R.+Deyauthor=W.+H.+Colledgeauthor=M.+J.+Evansauthor=E.+J.+Sorscherauthor=D.+M.+Bedwell&title=Aminoglycoside+Suppression+of+a+Premature+Stop+Mutation+in+a+Cftr%E2%80%93%2F%E2%80%93+Mouse+Carrying+a+Human+CFTR-G542X+Transgene&doi=10.1007%2Fs00109-002-0363-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene</span></div><div class="casAuthors">Du, Ming; Jones, Julie R.; Lanier, Jessica; Keeling, Kim M.; Lindsey, J. Russell; Tousson, Albert; Bebok, Zsuzsa; Whitsett, Jeffrey A.; Dey, Chitta R.; Colledge, William H.; Evans, Martin J.; Sorscher, Eric J.; Bedwell, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">595-604</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein.  Since ∼5% of all mutant CF alleles are stop mutations, it can be calcd. that ∼10% of CF patients carry a premature stop mutation in at least one copy of the CFTR gene.  Certain ethnic groups, such as the Ashkenazi Jewish population, carry a much higher percentage of CF stop mutations.  Consequently, a therapeutic strategy aimed at suppressing this class of mutation would be highly desirable for the treatment of this common genetic disease.  We have shown previously that aminoglycoside antibiotics can suppress premature stop mutations in the CFTR gene in a bronchial epithelial cell line [Nat Med (1997) 3:1280].  To address whether aminoglycosides can suppress a CFTR premature stop mutation in an animal model, we constructed a transgenic mouse with a null mutation in the endogenous CFTR locus (Cftr-/-) that also expressed a human CFTR-G542X cDNA under control of the intestinal fatty acid binding protein promoter.  We then investigated whether the daily administration of the aminoglycoside antibiotics gentamicin or tobramycin could restore the expression of a detectable level of CFTR protein.  Immunofluorescence staining of intestinal tissues from Cftr-/- hCFTR-G542X mice revealed that gentamicin treatment resulted in the appearance of hCFTR protein at the apical surface of the glands of treated mice.  Weaker staining was also obsd. in the intestinal glands following tobramycin treatment.  Short-circuit current measurements made on intestinal tissues from these mice demonstrated that a significant no. of pos. cAMP-stimulated transepithelial chloride current measurements could be obsd. following gentamicin treatment (P=0.008) and a near significant no. following tobramycin treatment (P=0.052).  When taken together, these results indicate that gentamicin, and to a lesser extent tobramycin, can restore the synthesis of functional hCFTR protein by suppressing the hCFTR-G542X premature stop mutation in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSLJYvlzwj6rVg90H21EOLACvtfcHk0lhW_bksR_WL6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFWktbc%253D&md5=17729b95ae1d83d560eacef495968c37</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1007%2Fs00109-002-0363-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-002-0363-1%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DJ.%2BR.%26aulast%3DLanier%26aufirst%3DJ.%26aulast%3DKeeling%26aufirst%3DK.%2BM.%26aulast%3DLindsey%26aufirst%3DJ.%2BR.%26aulast%3DTousson%26aufirst%3DA.%26aulast%3DBeb%25C3%25B6k%26aufirst%3DZ.%26aulast%3DWhitsett%26aufirst%3DJ.%2BA.%26aulast%3DDey%26aufirst%3DC.%2BR.%26aulast%3DColledge%26aufirst%3DW.%2BH.%26aulast%3DEvans%26aufirst%3DM.%2BJ.%26aulast%3DSorscher%26aufirst%3DE.%2BJ.%26aulast%3DBedwell%26aufirst%3DD.%2BM.%26atitle%3DAminoglycoside%2520Suppression%2520of%2520a%2520Premature%2520Stop%2520Mutation%2520in%2520a%2520Cftr%25E2%2580%2593%252F%25E2%2580%2593%2520Mouse%2520Carrying%2520a%2520Human%2520CFTR-G542X%2520Transgene%26jtitle%3DJ.%2520Mol.%2520Med.%2520%2528Heidelberg%252C%2520Ger.%2529%26date%3D2002%26volume%3D80%26spage%3D595%26epage%3D604%26doi%3D10.1007%2Fs00109-002-0363-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barton-Davis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoturma, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leland, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, H. L.</span></span> <span> </span><span class="NLM_article-title">Aminoglycoside Antibiotics Restore Dystrophin Function to Skeletal Muscles of Mdx Mice</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1172/JCI7866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1172%2FJCI7866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10449429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADyaK1MXltlektbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=375-381&author=E.+R.+Barton-Davisauthor=L.+Cordierauthor=D.+I.+Shoturmaauthor=S.+E.+Lelandauthor=H.+L.+Sweeney&title=Aminoglycoside+Antibiotics+Restore+Dystrophin+Function+to+Skeletal+Muscles+of+Mdx+Mice&doi=10.1172%2FJCI7866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice</span></div><div class="casAuthors">Barton-Davis, Elisabeth R.; Cordier, Laurence; Shoturma, Daria I.; Leland, Stuart E.; Sweeney, H. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">375-381</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, leading to the absence of the dystrophin protein in striated muscle.  A significant no. of these mutations are premature stop codons.  On the basis of the observation that aminoglycoside treatment can suppress stop codons in cultured cells, we tested the effect of gentamicin on cultured muscle cells from the mdx mouse - an animal model for DMD that possesses a premature stop codon in the dystrophin gene.  Exposure of mdx myotubes to gentamicin led to the expression and localization of dystrophin to the cell membrane.  We then evaluated the effects of differing dosages of gentamicin on expression and functional protection of the muscles of mdx mice.  We identified a treatment regimen that resulted in the presence of dystrophin in the cell membrane in all striated muscles examd. and that provided functional protection against muscular injury.  To our knowledge, our results are the first to demonstrate that aminoglycosides can suppress stop codons not only in vitro but also in vivo.  Furthermore, these results raise the possibility of a novel treatment regimen for muscular dystrophy and other diseases caused by premature stop codon mutations.  This treatment could prove effective in up to 15% of patients with DMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraj2EpBjywyrVg90H21EOLACvtfcHk0lhW_bksR_WL6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltlektbo%253D&md5=1df883f4c95a9381df3a7801ec5bd08c</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1172%2FJCI7866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI7866%26sid%3Dliteratum%253Aachs%26aulast%3DBarton-Davis%26aufirst%3DE.%2BR.%26aulast%3DCordier%26aufirst%3DL.%26aulast%3DShoturma%26aufirst%3DD.%2BI.%26aulast%3DLeland%26aufirst%3DS.%2BE.%26aulast%3DSweeney%26aufirst%3DH.%2BL.%26atitle%3DAminoglycoside%2520Antibiotics%2520Restore%2520Dystrophin%2520Function%2520to%2520Skeletal%2520Muscles%2520of%2520Mdx%2520Mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1999%26volume%3D104%26spage%3D375%26epage%3D381%26doi%3D10.1172%2FJCI7866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brendel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belakhov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gärtner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nudelman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baasov, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huppke, P.</span></span> <span> </span><span class="NLM_article-title">Readthrough of Nonsense Mutations in Rett Syndrome: Evaluation of Novel Aminoglycosides and Generation of a New Mouse Model</span>. <i>J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1007/s00109-010-0704-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1007%2Fs00109-010-0704-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=21120444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFSntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=389-398&author=C.+Brendelauthor=V.+Belakhovauthor=H.+Wernerauthor=E.+Wegenerauthor=J.+G%C3%A4rtnerauthor=I.+Nudelmanauthor=T.+Baasovauthor=P.+Huppke&title=Readthrough+of+Nonsense+Mutations+in+Rett+Syndrome%3A+Evaluation+of+Novel+Aminoglycosides+and+Generation+of+a+New+Mouse+Model&doi=10.1007%2Fs00109-010-0704-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model</span></div><div class="casAuthors">Brendel, Cornelia; Belakhov, Valery; Werner, Hauke; Wegener, Eike; Gaertner, Jutta; Nudelman, Igor; Baasov, Timor; Huppke, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">389-398</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">35% Of patients with Rett syndrome carry nonsense mutations in the MECP2 gene.  We have recently shown in transfected HeLa cells that readthrough of nonsense mutations in the MECP2 gene can be achieved by treatment with gentamicin and geneticin.  This study was performed to test if readthrough can also be achieved in cells endogenously expressing mutant MeCP2 and to evaluate potentially more effective readthrough compds.  A mouse model was generated carrying the R168X mutation in the MECP2 gene.  Transfected HeLa cells expressing mutated MeCP2 fusion proteins and mouse ear fibroblasts isolated from the new mouse model were treated with gentamicin and the novel aminoglycosides NB30, NB54, and NB84.  The localization of the readthrough product was tested by immunofluorescence.  Readthrough of the R168X mutation in mouse ear fibroblasts using gentamicin was detected but at lower level than in HeLa cells.  As expected, the readthrough product, full-length Mecp2 protein, was located in the nucleus.  NB54 and NB84 induced readthrough more effectively than gentamicin, while NB30 was less effective.  Readthrough of nonsense mutations can be achieved not only in transfected HeLa cells but also in fibroblasts of the newly generated Mecp2R168X mouse model.  NB54 and NB84 were more effective than gentamicin and are therefore promising candidates for readthrough therapy in Rett syndrome patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU2XsdLCdFSrVg90H21EOLACvtfcHk0lj4Rnmnu8ZjEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFSntbg%253D&md5=f22d74f345c5c322ecf8c2c94035ccf4</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1007%2Fs00109-010-0704-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-010-0704-4%26sid%3Dliteratum%253Aachs%26aulast%3DBrendel%26aufirst%3DC.%26aulast%3DBelakhov%26aufirst%3DV.%26aulast%3DWerner%26aufirst%3DH.%26aulast%3DWegener%26aufirst%3DE.%26aulast%3DG%25C3%25A4rtner%26aufirst%3DJ.%26aulast%3DNudelman%26aufirst%3DI.%26aulast%3DBaasov%26aufirst%3DT.%26aulast%3DHuppke%26aufirst%3DP.%26atitle%3DReadthrough%2520of%2520Nonsense%2520Mutations%2520in%2520Rett%2520Syndrome%253A%2520Evaluation%2520of%2520Novel%2520Aminoglycosides%2520and%2520Generation%2520of%2520a%2520New%2520Mouse%2520Model%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2011%26volume%3D89%26spage%3D389%26epage%3D398%26doi%3D10.1007%2Fs00109-010-0704-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodley, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinkovich, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keene, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span> <span> </span><span class="NLM_article-title">Gentamicin Induces Functional Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa Patients</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">3028</span>– <span class="NLM_lpage">3038</span>, <span class="refDoi"> DOI: 10.1172/JCI92707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1172%2FJCI92707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28691931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlvF2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=3028-3038&author=D.+T.+Woodleyauthor=J.+Coganauthor=Y.+Houauthor=C.+Lyuauthor=M.+P.+Marinkovichauthor=D.+Keeneauthor=M.+Chen&title=Gentamicin+Induces+Functional+Type+VII+Collagen+in+Recessive+Dystrophic+Epidermolysis+Bullosa+Patients&doi=10.1172%2FJCI92707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients</span></div><div class="casAuthors">Woodley David T; Cogan Jon; Hou Yingping; Lyu Chao; Chen Mei; Marinkovich M Peter; Marinkovich M Peter; Keene Douglas</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3028-3038</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable disease caused by mutations in the gene encoding type VII collagen, the major component of anchoring fibrils (AF).  We previously demonstrated that gentamicin produced functional type VII collagen in RDEB cells harboring nonsense mutations.  Herein, we determined whether topical or intradermal gentamicin administration induces type VII collagen and AFs in RDEB patients.  METHODS:  A double-blind, placebo-controlled pilot trial assessed safety and efficacy of topical and intradermal gentamicin in 5 RDEB patients with nonsense mutations.  The topical arm tested 0.1% gentamicin ointment or placebo application 3 times daily at 2 open erosion sites for 2 weeks.  The intradermal arm tested daily intradermal injection of gentamicin solution (8 mg) or placebo into 2 intact skin sites for 2 days in 4 of 5 patients.  Primary outcomes were induction of type VII collagen and AFs at the test sites and safety assessment.  A secondary outcome assessed wound closure of topically treated erosions.  RESULTS:  Both topical and intradermal gentamicin administration induced type VII collagen and AFs at the dermal-epidermal junction of treatment sites.  Newly created type VII collagen varied from 20% to 165% of that expressed in normal human skin and persisted for 3 months.  Topical gentamicin corrected dermal-epidermal separation, improved wound closure, and reduced blister formation.  There were no untoward side effects from gentamicin treatments.  Type VII collagen induction did not generate anti-type VII collagen autoantibodies in patients' blood or skin.  CONCLUSION:  Topical and intradermal gentamicin suppresses nonsense mutations and induces type VII collagen and AFs in RDEB patients.  Gentamicin therapy may provide a readily available treatment for RDEB patients with nonsense mutations.  TRIAL REGISTRATION:  ClinicalTrials.gov NCT02698735.  FUNDING:  Epidermolysis Bullosa Research Partnership, Epidermolysis Bullosa Medical Research Foundation, NIH, and VA Merit Award.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXoJ0sTrmDnD0O18WR3iAofW6udTcc2eY6WEqhyFzGXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlvF2gtA%253D%253D&md5=aea7ab7324f450b0ce8c92ac4552a799</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1172%2FJCI92707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI92707%26sid%3Dliteratum%253Aachs%26aulast%3DWoodley%26aufirst%3DD.%2BT.%26aulast%3DCogan%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DLyu%26aufirst%3DC.%26aulast%3DMarinkovich%26aufirst%3DM.%2BP.%26aulast%3DKeene%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DM.%26atitle%3DGentamicin%2520Induces%2520Functional%2520Type%2520VII%2520Collagen%2520in%2520Recessive%2520Dystrophic%2520Epidermolysis%2520Bullosa%2520Patients%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D3028%26epage%3D3038%26doi%3D10.1172%2FJCI92707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">James, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillicrap, D.</span></span> <span> </span><span class="NLM_article-title">Aminoglycoside Suppression of Nonsense Mutations in Severe Hemophilia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">3043</span>– <span class="NLM_lpage">3048</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-03-1307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1182%2Fblood-2005-03-1307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=16051741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Wntr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=3043-3048&author=P.+D.+Jamesauthor=S.+Rautauthor=G.+E.+Rivardauthor=M.+C.+Poonauthor=M.+Warnerauthor=S.+McKennaauthor=J.+Leggoauthor=D.+Lillicrap&title=Aminoglycoside+Suppression+of+Nonsense+Mutations+in+Severe+Hemophilia&doi=10.1182%2Fblood-2005-03-1307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycoside suppression of nonsense mutations in severe hemophilia</span></div><div class="casAuthors">James, Paula D.; Raut, Sanj; Rivard, Georges E.; Poon, Man-Chiu; Warner, Margaret; McKenna, Susan; Leggo, Jayne; Lillicrap, David</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3043-3048</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Aminoglycoside antibiotics exhibit their bactericidal effect by interfering with normal ribosomal activity.  In this pilot study, we have evaluated the effect of the aminoglycoside antibiotic gentamicin on the factor VIII (FVIII) and IX levels of severe hemophiliacs with known nonsense mutations.  Five patients were enrolled and each patients was given 3 consecutive days of gentamicin at a dose of 7 mg/kg i.v. every 24 h.  Two patients (patient no. 1: hemophilia A, Ser1395Stop; and patient no. 5: hemophilia B, Arg333Stop) showed a decrease in their activated partial thromboplastin time (aPTT), an increase in their FVIII (0.016 IU/mL, 1.6%) or FIX (0.02 IU/mL, 2%) levels, and an increase in thrombin generation.  The remaining 3 patients (patient no. 2: hemophilia B, Arg252Stop; patient no. 3: hemophilia A, Arg2116Stop; and patient no. 4: hemophilia A, Arg427Stop) showed no response in the aPTTs or factor levels, but one (patient no. 2: hemophilia B, Arg252Stop) showed an increase in the factor IX antigen level (2% - 5.5%) that persisted throughout the period of the study and was concordant with an increase in thrombin generation.  Gentamicin is unlikely to be an effective treatment for severe hemophilia due to its potential toxicities and the minimal response documented in this report.  This study, however, does provide a proof of principle, suggesting that ribosomal interference with a less toxic agent may be a potential therapeutic mechanism for severe hemophilia patients with nonsense mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9gNUVX1ORO7Vg90H21EOLACvtfcHk0lj4Rnmnu8ZjEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Wntr%252FF&md5=b5ff28adaaab7e0286bd3832d73b7159</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-03-1307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-03-1307%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DP.%2BD.%26aulast%3DRaut%26aufirst%3DS.%26aulast%3DRivard%26aufirst%3DG.%2BE.%26aulast%3DPoon%26aufirst%3DM.%2BC.%26aulast%3DWarner%26aufirst%3DM.%26aulast%3DMcKenna%26aufirst%3DS.%26aulast%3DLeggo%26aufirst%3DJ.%26aulast%3DLillicrap%26aufirst%3DD.%26atitle%3DAminoglycoside%2520Suppression%2520of%2520Nonsense%2520Mutations%2520in%2520Severe%2520Hemophilia%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D3043%26epage%3D3048%26doi%3D10.1182%2Fblood-2005-03-1307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martorell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barquinero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, F.</span></span> <span> </span><span class="NLM_article-title">Variable Readthrough Responsiveness of Nonsense Mutations in Hemophilia A</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.3324/haematol.2018.212118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.3324%2Fhaematol.2018.212118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=31197069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVartL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2020&pages=508-518&author=L.+Martorellauthor=V.+Cortinaauthor=R.+Parraauthor=J.+Barquineroauthor=F.+Vidal&title=Variable+Readthrough+Responsiveness+of+Nonsense+Mutations+in+Hemophilia+A&doi=10.3324%2Fhaematol.2018.212118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Variable readthrough responsiveness of nonsense mutations in hemophilia A</span></div><div class="casAuthors">Martorell, Lluis; Cortina, Vicente; Parra, Rafael; Barquinero, Jordi; Vidal, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">508-518</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Readthrough therapy relies on the use of small mols. that enable premature termination codons in mRNA open reading frames to be misinterpreted by the translation machinery, thus allowing the generation of full-length, potentially functional proteins from mRNA carrying nonsense mutations.  In patients with hemophilia A, nonsense mutations potentially sensitive to readthrough agents represent approx. 16% of the point mutations.  The aim of this study was to measure the readthrough effect of different compds. and to analyze the influence of premature termination codon context in selected nonsense mutations causing hemophilia A.  To this end, primary fibroblasts from three patients with hemophilia A caused by nonsense mutations (p.W1586X, p.Q1636X and p.R1960X) and Chinese hamster ovary (CHO) cells transfected with 12 different plasmids encoding mutated F8 (p.Q462X, p.Q1705X, p.Q1764X, p.W274X, p.W1726X, p.W2015X, p.W2131X, p.R1715X, p.R1822X, p.R1960X, p.R2071X and p.R2228X) were treated with gentamicin, geneticin, PTC124, RTC13 or RTC14.  Responses were assessed by analyzing not only F8 mRNA expression and FVIII biosynthesis (FVIII antigen by ELISA, western blot and immunofluorescence) but also the FVIII activity (by chromogenic assay).  In the patients' fibroblasts, readthrough agents neither stabilized F8 mRNA nor increased FVIII protein or activity to detectable levels.  In CHO cells, only in five of the 12 F8 variants, readthrough treatment increased both FVIII antigen and activity levels, which was assocd. with a redn. in intracellular accumulation of truncated forms and an increase in full-length proteins.  These results provide exptl. evidence of genetic context dependence of nonsense suppression by readthrough agents and of factors predicting responsiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1avzpFJ00r7Vg90H21EOLACvtfcHk0likrKlyUaxe2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVartL7L&md5=187226504e5758ec335ec769fafaa5d4</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2018.212118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2018.212118%26sid%3Dliteratum%253Aachs%26aulast%3DMartorell%26aufirst%3DL.%26aulast%3DCortina%26aufirst%3DV.%26aulast%3DParra%26aufirst%3DR.%26aulast%3DBarquinero%26aufirst%3DJ.%26aulast%3DVidal%26aufirst%3DF.%26atitle%3DVariable%2520Readthrough%2520Responsiveness%2520of%2520Nonsense%2520Mutations%2520in%2520Hemophilia%2520A%26jtitle%3DHaematologica%26date%3D2020%26volume%3D105%26spage%3D508%26epage%3D518%26doi%3D10.3324%2Fhaematol.2018.212118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sermet-Gaudelus, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renouil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fajac, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parbaille, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierrot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bismuth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesure, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousset, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, A.</span></span> <span> </span><span class="NLM_article-title">In Vitro Prediction of Stop-Codon Suppression by Intravenous Gentamicin in Patients with Cystic Fibrosis: A Pilot Study</span>. <i>BMC Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5</span>, <span class="refDoi"> DOI: 10.1186/1741-7015-5-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1186%2F1741-7015-5-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17394637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BD2s3isVaqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=5&author=I.+Sermet-Gaudelusauthor=M.+Renouilauthor=A.+Fajacauthor=L.+Bidouauthor=B.+Parbailleauthor=S.+Pierrotauthor=N.+Davyauthor=E.+Bismuthauthor=P.+Reinertauthor=G.+Lenoirauthor=J.+F.+Lesureauthor=J.+P.+Roussetauthor=A.+Edelman&title=In+Vitro+Prediction+of+Stop-Codon+Suppression+by+Intravenous+Gentamicin+in+Patients+with+Cystic+Fibrosis%3A+A+Pilot+Study&doi=10.1186%2F1741-7015-5-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study</span></div><div class="casAuthors">Sermet-Gaudelus Isabelle; Renouil Michel; Fajac Anne; Bidou Laure; Parbaille Bastien; Pierrot Sebastien; Davy Nolwen; Bismuth Elise; Reinert Philippe; Lenoir Gerard; Lesure Jean Francois; Rousset Jean Pierre; Edelman Aleksander</div><div class="citationInfo"><span class="NLM_cas:title">BMC medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which acts as a chloride channel activated by cyclic AMP (cAMP).  The most frequent mutation found in 70% of CF patients is F508del, while premature stop mutations are found in about 10% of patients.  In vitro aminoglycoside antibiotics (e.g. gentamicin) suppress nonsense mutations located in CFTR permitting translation to continue to the natural termination codon.  Pharmacologic suppression of stop mutations within the CFTR may be of benefit to a significant number of patients.  Our pilot study was conducted to determine whether intravenous gentamicin suppresses stop codons in CF patients and whether it has clinical benefits.  METHODS:  A dual gene reporter system was used to determine the gentamicin-induced readthrough level of the most frequent stop mutations within the CFTR in the French population.  We investigated readthrough efficiency in response to 10 mg/kg once-daily intravenous gentamicin perfusions in patients with and without stop mutations.  Respiratory function, sweat chloride concentration, nasal potential difference (NPD) and CFTR expression in nasal epithelial cells were measured at baseline and after 15 days of treatment.  RESULTS:  After in vitro gentamicin incubation, the readthrough efficiency for the Y122X mutation was at least five times higher than that for G542X, R1162X, and W1282X.  In six of the nine patients with the Y122X mutation, CFTR immunodetection showed protein at the membrane of the nasal epithelial cells and the CFTR-dependent Cl- secretion in NPD measurements increased significantly.  Respiratory status also improved in these patients, irrespective of the gentamicin sensitivity of the bacteria present in the sputum.  Mean sweat chloride concentration decreased significantly and normalised in two patients.  Clinical status, NPD and sweat Cl- values did not change in the Y122X patients with no protein expression, in patients with the other stop mutations investigated in vitro and those without stop mutations.  CONCLUSION:  Suppression of stop mutations in the CFTR gene with parenteral gentamicin can be predicted in vitro and is associated with clinical benefit and significant modification of the CFTR-mediated Cl- transport in nasal and sweat gland epithelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVYdCWSD9Hn5Pq5LRczm8ffW6udTcc2eaUK9_vI5qoSrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3isVaqsw%253D%253D&md5=ebab098cbb11bbc01cc129f4a33a4f98</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1186%2F1741-7015-5-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7015-5-5%26sid%3Dliteratum%253Aachs%26aulast%3DSermet-Gaudelus%26aufirst%3DI.%26aulast%3DRenouil%26aufirst%3DM.%26aulast%3DFajac%26aufirst%3DA.%26aulast%3DBidou%26aufirst%3DL.%26aulast%3DParbaille%26aufirst%3DB.%26aulast%3DPierrot%26aufirst%3DS.%26aulast%3DDavy%26aufirst%3DN.%26aulast%3DBismuth%26aufirst%3DE.%26aulast%3DReinert%26aufirst%3DP.%26aulast%3DLenoir%26aufirst%3DG.%26aulast%3DLesure%26aufirst%3DJ.%2BF.%26aulast%3DRousset%26aufirst%3DJ.%2BP.%26aulast%3DEdelman%26aufirst%3DA.%26atitle%3DIn%2520Vitro%2520Prediction%2520of%2520Stop-Codon%2520Suppression%2520by%2520Intravenous%2520Gentamicin%2520in%2520Patients%2520with%2520Cystic%2520Fibrosis%253A%2520A%2520Pilot%2520Study%26jtitle%3DBMC%2520Med.%26date%3D2007%26volume%3D5%26spage%3D5%26doi%3D10.1186%2F1741-7015-5-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selimoglu, E.</span></span> <span> </span><span class="NLM_article-title">Aminoglycoside-Induced Ototoxicity</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.2174/138161207779313731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.2174%2F138161207779313731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17266591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Wjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=119-126&author=E.+Selimoglu&title=Aminoglycoside-Induced+Ototoxicity&doi=10.2174%2F138161207779313731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycoside-induced ototoxicity</span></div><div class="casAuthors">Selimoglu, Erol</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-126</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has long been known that the major irreversible toxicity of aminoglycosides is ototoxicity.  Among them, streptomycin and gentamicin are primarily vestibulotoxic, whereas amikacin, neomycin, dihydrosterptomycin, and kanamycin are primarily cochleotoxic.  Cochlear damage can produce permanent hearing loss, and damage to the vestibular app. results in dizziness, ataxia, and(or) nystagmus.  Aminoglycosides appear to generate free radicals within the inner car, with subsequent permanent damage to sensory cells and neurons, resulting in permanent hearing loss.  Two mutations in the mitochondrial 12 S rRNA gene have been previously reported to predispose carriers to aminoglycoside-induced ototoxicity.  As aminoglycosides are indispensable agents both in the treatment of infections and Meniere's disease, a great effort has been made to develop strategies to prevent aminoglycoside ototoxicity.  Anti-free radical agents, such as salicylate, have been shown to attenuate the ototoxic effects of aminoglycosides.  In this paper, incidence, predisposition, mechanism, and prevention of aminoglycoside-induced ototoxicity is discussed in the light of literature data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN-qswAWEgqLVg90H21EOLACvtfcHk0likrKlyUaxe2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Wjs78%253D&md5=8196d5701e29edf5e259bad9a284596c</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.2174%2F138161207779313731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161207779313731%26sid%3Dliteratum%253Aachs%26aulast%3DSelimoglu%26aufirst%3DE.%26atitle%3DAminoglycoside-Induced%2520Ototoxicity%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2007%26volume%3D13%26spage%3D119%26epage%3D126%26doi%3D10.2174%2F138161207779313731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molloy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Land, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longcroft-Neal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. D. C.</span></span> <span> </span><span class="NLM_article-title">Adverse Effects of a Single Dose of Gentamicin in Adults: A Systematic Review</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1111/bcp.13439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1111%2Fbcp.13439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28940715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Ois7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=223-238&author=R.+S.+Haywardauthor=J.+Hardingauthor=R.+Molloyauthor=L.+Landauthor=K.+Longcroft-Nealauthor=D.+Mooreauthor=J.+D.+C.+Ross&title=Adverse+Effects+of+a+Single+Dose+of+Gentamicin+in+Adults%3A+A+Systematic+Review&doi=10.1111%2Fbcp.13439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effects of a single dose of gentamicin in adults: a systematic review</span></div><div class="casAuthors">Hayward, Rachel S.; Harding, Jan; Molloy, Rob; Land, Lucy; Longcroft-Neal, Kate; Moore, David; Ross, Jonathan D. C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-238</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : To systematically review the frequency and type of adverse events assocd. with a single dose of i.v. or i.m. gentamicin in adults, for any indication, in studies where a comparator was available.  Methods : A review protocol was developed and registered (PROSPERO: CRD42013003229).  Studies were eligible for review if they: recruited participants aged ≥16 years; used gentamicin i.m. or i.v. as a single one-off dose; compared gentamicin to another medication or placebo; and monitored adverse events.  MEDLINE, EMBASE, Cochrane Library, trial registries, conference proceedings and other relevant databases were searched up to Nov. 2016.  Risk of bias was assessed on all included studies.  Results : In total, 15 522 records were identified.  After removal of duplicates, screening of title/abstrs. for relevance and independent selection of full texts by two reviewers, 36 studies were included.  Across all the included studies, 24 107 participants received a single one-off dose of gentamicin (doses ranged from 1 mg kg-1 to 480 mg per dose).  Acute kidney injury was described in 2520 participants receiving gentamicin.  The large majority of cases were reversible.  There were no cases of ototoxicity reported in patients receiving gentamicin.  A meta-anal. was not performed due to study heterogeneity.  Conclusions : A significant no. of patients saw a transient rise in creatinine after a single dose of gentamicin at doses up to 480 mg.  Persistent renal impairment and other adverse events were relatively rare.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3-N_DuC0C6bVg90H21EOLACvtfcHk0likrKlyUaxe2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Ois7w%253D&md5=97139451036ca458debaf8de94874fa0</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13439%26sid%3Dliteratum%253Aachs%26aulast%3DHayward%26aufirst%3DR.%2BS.%26aulast%3DHarding%26aufirst%3DJ.%26aulast%3DMolloy%26aufirst%3DR.%26aulast%3DLand%26aufirst%3DL.%26aulast%3DLongcroft-Neal%26aufirst%3DK.%26aulast%3DMoore%26aufirst%3DD.%26aulast%3DRoss%26aufirst%3DJ.%2BD.%2BC.%26atitle%3DAdverse%2520Effects%2520of%2520a%2520Single%2520Dose%2520of%2520Gentamicin%2520in%2520Adults%253A%2520A%2520Systematic%2520Review%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D84%26spage%3D223%26epage%3D238%26doi%3D10.1111%2Fbcp.13439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, M.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial DNA Mutations Associated with Aminoglycoside Induced Ototoxicity</span>. <i>J. Otol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.joto.2017.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2Fj.joto.2017.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=29937831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fhtleqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1-8&author=Z.+Gaoauthor=Y.+Chenauthor=M.+Guan&title=Mitochondrial+DNA+Mutations+Associated+with+Aminoglycoside+Induced+Ototoxicity&doi=10.1016%2Fj.joto.2017.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial DNA mutations associated with aminoglycoside induced ototoxicity</span></div><div class="casAuthors">Gao Zewen; Chen Ye; Guan Min-Xin; Gao Zewen; Chen Ye; Guan Min-Xin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of otology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aminoglycosides (AmAn) are widely used for their great efficiency against gram-negative bacterial infections.  However, they can also induce ototoxic hearing loss, which has affected millions of people around the world.  As previously reported, individuals bearing mitochondrial DNA mutations in the 12S rRNA gene, such as m.1555A>G and m.1494C>T, are more prone to AmAn-induced ototoxicity.  These mutations cause human mitochondrial ribosomes to more closely resemble bacterial ribosomes and enable a stronger aminoglycoside interaction.  Consequently, exposure to AmAn can induce or worsen hearing loss in these individuals.  Furthermore, a wide range of severity and penetrance of hearing loss was observed among families carrying these mutations.  Studies have revealed that these mitochondria mutations are the primary molecular mechanism of genetic susceptibility to AmAn ototoxicity, though nuclear modifier genes and mitochondrial haplotypes are known to modulate the phenotypic manifestation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTusxX5zh2Y9tXdcedVHT5tfW6udTcc2eYWb-bXKng4x7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fhtleqtg%253D%253D&md5=85bf2742534289c23e34cb6c83156bb9</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1016%2Fj.joto.2017.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.joto.2017.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGuan%26aufirst%3DM.%26atitle%3DMitochondrial%2520DNA%2520Mutations%2520Associated%2520with%2520Aminoglycoside%2520Induced%2520Ototoxicity%26jtitle%3DJ.%2520Otol.%26date%3D2017%26volume%3D12%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.joto.2017.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Welch, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomizawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifillis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paushkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotta, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilde, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasugi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turpoff, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almstead, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weetall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branstrom, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colacino, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babiak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northcutt, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spatrick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, H. L.</span></span> <span> </span><span class="NLM_article-title">PTC124 Targets Genetic Disorders Caused by Nonsense Mutations</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>447</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1038/nature05756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fnature05756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=17450125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvVaju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2007&pages=87-91&author=E.+M.+Welchauthor=E.+R.+Bartonauthor=J.+Zhuoauthor=Y.+Tomizawaauthor=W.+J.+Friesenauthor=P.+Trifillisauthor=S.+Paushkinauthor=M.+Patelauthor=C.+R.+Trottaauthor=S.+Hwangauthor=R.+G.+Wildeauthor=G.+Karpauthor=J.+Takasugiauthor=G.+Chenauthor=S.+Jonesauthor=H.+Renauthor=Y.+C.+Moonauthor=D.+Corsonauthor=A.+A.+Turpoffauthor=J.+A.+Campbellauthor=M.+M.+Connauthor=A.+Khanauthor=N.+G.+Almsteadauthor=J.+Hedrickauthor=A.+Mollinauthor=N.+Risherauthor=M.+Weetallauthor=S.+Yehauthor=A.+A.+Branstromauthor=J.+M.+Colacinoauthor=J.+Babiakauthor=W.+D.+Juauthor=S.+Hirawatauthor=V.+J.+Northcuttauthor=L.+L.+Millerauthor=P.+Spatrickauthor=F.+Heauthor=M.+Kawanaauthor=H.+Fengauthor=A.+Jacobsonauthor=S.+W.+Peltzauthor=H.+L.+Sweeney&title=PTC124+Targets+Genetic+Disorders+Caused+by+Nonsense+Mutations&doi=10.1038%2Fnature05756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">PTC124 targets genetic disorders caused by nonsense mutations</span></div><div class="casAuthors">Welch, Ellen M.; Barton, Elisabeth R.; Zhuo, Jin; Tomizawa, Yuki; Friesen, Westley J.; Trifillis, Panayiota; Paushkin, Sergey; Patel, Meenal; Trotta, Christopher R.; Hwang, Seongwoo; Wilde, Richard G.; Karp, Gary; Takasugi, James; Chen, Guangming; Jones, Stephen; Ren, Hongyu; Moon, Young-Choon; Corson, Donald; Turpoff, Anthony A.; Campbell, Jeffrey A.; Conn, M. Morgan; Khan, Atiyya; Almstead, Neil G.; Hedrick, Jean; Mollin, Anna; Risher, Nicole; Weetall, Marla; Yeh, Shirley; Branstrom, Arthur A.; Colacino, Joseph M.; Babiak, John; Ju, William D.; Hirawat, Samit; Northcutt, Valerie J.; Miller, Langdon L.; Spatrick, Phyllis; He, Feng; Kawana, Masataka; Feng, Huisheng; Jacobson, Allan; Peltz, Stuart W.; Sweeney, H. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">7140</span>),
    <span class="NLM_cas:pages">87-91</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nonsense mutations promote premature translational termination and cause anywhere from 5-70% of the individual cases of most inherited diseases.  Studies on nonsense-mediated cystic fibrosis have indicated that boosting specific protein synthesis from <1% to as little as 5% of normal levels may greatly reduce the severity or eliminate the principal manifestations of disease.  To address the need for a drug capable of suppressing premature termination, we identified PTC124-a new chem. entity that selectively induces ribosomal readthrough of premature but not normal termination codons.  PTC124 activity, optimized using nonsense-contg. reporters, promoted dystrophin prodn. in primary muscle cells from humans and mdx mice expressing dystrophin nonsense alleles, and rescued striated muscle function in mdx mice within 2-8 wk of drug exposure.  PTC124 was well tolerated in animals at plasma exposures substantially in excess of those required for nonsense suppression.  The selectivity of PTC124 for premature termination codons, its well characterized activity profile, oral bioavailability and pharmacol. properties indicate that this drug may have broad clin. potential for the treatment of a large group of genetic disorders with limited or no therapeutic options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-j-BIHWRRyLVg90H21EOLACvtfcHk0lh13dCayrflpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvVaju7o%253D&md5=c4eecae6e36e8d128a1dc8af8d472e7c</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1038%2Fnature05756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05756%26sid%3Dliteratum%253Aachs%26aulast%3DWelch%26aufirst%3DE.%2BM.%26aulast%3DBarton%26aufirst%3DE.%2BR.%26aulast%3DZhuo%26aufirst%3DJ.%26aulast%3DTomizawa%26aufirst%3DY.%26aulast%3DFriesen%26aufirst%3DW.%2BJ.%26aulast%3DTrifillis%26aufirst%3DP.%26aulast%3DPaushkin%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DTrotta%26aufirst%3DC.%2BR.%26aulast%3DHwang%26aufirst%3DS.%26aulast%3DWilde%26aufirst%3DR.%2BG.%26aulast%3DKarp%26aufirst%3DG.%26aulast%3DTakasugi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DMoon%26aufirst%3DY.%2BC.%26aulast%3DCorson%26aufirst%3DD.%26aulast%3DTurpoff%26aufirst%3DA.%2BA.%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26aulast%3DConn%26aufirst%3DM.%2BM.%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DAlmstead%26aufirst%3DN.%2BG.%26aulast%3DHedrick%26aufirst%3DJ.%26aulast%3DMollin%26aufirst%3DA.%26aulast%3DRisher%26aufirst%3DN.%26aulast%3DWeetall%26aufirst%3DM.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DBranstrom%26aufirst%3DA.%2BA.%26aulast%3DColacino%26aufirst%3DJ.%2BM.%26aulast%3DBabiak%26aufirst%3DJ.%26aulast%3DJu%26aufirst%3DW.%2BD.%26aulast%3DHirawat%26aufirst%3DS.%26aulast%3DNorthcutt%26aufirst%3DV.%2BJ.%26aulast%3DMiller%26aufirst%3DL.%2BL.%26aulast%3DSpatrick%26aufirst%3DP.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DKawana%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DJacobson%26aufirst%3DA.%26aulast%3DPeltz%26aufirst%3DS.%2BW.%26aulast%3DSweeney%26aufirst%3DH.%2BL.%26atitle%3DPTC124%2520Targets%2520Genetic%2520Disorders%2520Caused%2520by%2520Nonsense%2520Mutations%26jtitle%3DNature%26date%3D2007%26volume%3D447%26spage%3D87%26epage%3D91%26doi%3D10.1038%2Fnature05756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedwell, D. M.</span></span> <span> </span><span class="NLM_article-title">PTC124 Is an Orally Bioavailable Compound That Promotes Suppression of the Human CFTR-G542X Nonsense Allele in a CF Mouse Model</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2064</span>– <span class="NLM_lpage">2069</span>, <span class="refDoi"> DOI: 10.1073/pnas.0711795105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.0711795105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=18272502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2064-2069&author=M.+Duauthor=X.+Liuauthor=E.+M.+Welchauthor=S.+Hirawatauthor=S.+W.+Peltzauthor=D.+M.+Bedwell&title=PTC124+Is+an+Orally+Bioavailable+Compound+That+Promotes+Suppression+of+the+Human+CFTR-G542X+Nonsense+Allele+in+a+CF+Mouse+Model&doi=10.1073%2Fpnas.0711795105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model</span></div><div class="casAuthors">Du, Ming; Liu, Xiaoli; Welch, Ellen M.; Hirawat, Samit; Peltz, Stuart W.; Bedwwell, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2064-2069</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonsense mutations inactivate gene function and are the underlying cause of a large percentage of the individual cases of many genetic disorders.  PTC124 is an orally bioavailable compd. that promotes readthrough of premature translation termination codons, suggesting that it may have the potential to treat genetic diseases caused by nonsense mutations.  Using a mouse model for cystic fibrosis (CF), we show that s.c. injection or oral administration of PTC124 to Cftr-/- mice expressing a human CFTR-G542X transgene suppressed the G542X nonsense mutation and restored a significant amt. of human (h)CFTR protein and function.  Translational readthrough of the premature stop codon was demonstrated in this mouse model in two ways.  First, immunofluorescence staining showed that PTC124 treatment resulted in the appearance of hCFTR protein at the apical surface of intestinal glands in Cftr-/- hCFTR-GS42X mice.  In addn., functional assays demonstrated that PTC124 treatment restored 24-29% of the av. cAMP-stimulated transepithelial chloride currents obsd. in wild-type mice.  These results indicate that PTC124 can effectively suppress the hCFTR-G542X nonsense mutation in vivo.  In light of its oral bioavailability, safety toxicol. profile in animal studies, and efficacy with other nonsense alleles, PTC124 has the potential to be an important therapeutic agent for the treatment of inherited diseases caused by nonsense mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogGIOgesV_abVg90H21EOLACvtfcHk0ljHxl3CLso4ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7g%253D&md5=61692496750638a95a3b688e486a4653</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711795105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711795105%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWelch%26aufirst%3DE.%2BM.%26aulast%3DHirawat%26aufirst%3DS.%26aulast%3DPeltz%26aufirst%3DS.%2BW.%26aulast%3DBedwell%26aufirst%3DD.%2BM.%26atitle%3DPTC124%2520Is%2520an%2520Orally%2520Bioavailable%2520Compound%2520That%2520Promotes%2520Suppression%2520of%2520the%2520Human%2520CFTR-G542X%2520Nonsense%2520Allele%2520in%2520a%2520CF%2520Mouse%2520Model%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2064%26epage%3D2069%26doi%3D10.1073%2Fpnas.0711795105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregory-evans, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory-Evans, K.</span></span> <span> </span><span class="NLM_article-title">Postnatal Manipulation of Pax6 Dosage Reverses Congenital Tissue Malformation Defects</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1172/JCI70462</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1172%2FJCI70462" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24355924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFeiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=111-116&author=C.+Y.+Gregory-evansauthor=X.+Wangauthor=K.+M.+Wasanauthor=J.+Zhaoauthor=A.+L.+Metcalfeauthor=K.+Gregory-Evans&title=Postnatal+Manipulation+of+Pax6+Dosage+Reverses+Congenital+Tissue+Malformation+Defects&doi=10.1172%2FJCI70462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects</span></div><div class="casAuthors">Gregory-Evans, Cheryl Y.; Wang, Xia; Wasan, Kishor M.; Zhao, Jinying; Metcalfe, Andrew L.; Gregory-Evans, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-116</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Aniridia is a congenital and progressive panocular condition with poor visual prognosis that is assocd. with brain, olfactory, and pancreatic abnormalities.  Development of aniridia is linked with nonsense mutations that result in paired box 6 (PAX6) haploinsufficiency.  Here, we used a mouse model of aniridia to test the hypothesis that manipulation of Pax6 dosage through a mutation-independent nonsense mutation suppression strategy would limit progressive, postnatal damage in the eye.  We focused on the nonsense suppression drugs 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid (ataluren) and gentamicin.  Remarkably, we demonstrated that nonsense suppression not only inhibited disease progression but also stably reversed corneal, lens, and retinal malformation defects and restored elec. and behavioral responses of the retina.  The most successful results were achieved through topical application of the drug formulation START (0.9% sodium chloride, 1% Tween 80, 1% powd. ataluren, 1% CM-cellulose), which was designed to enhance particle dispersion and to increase suspension viscosity.  These observations suggest that the eye retains marked developmental plasticity into the postnatal period and remains sensitive to mol. remodeling.  Furthermore, these data indicate that other neurol. developmental anomalies assocd. with dosage-sensitive genetic mutations may be reversible through nonsense suppression therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMqjOU_Vfk67Vg90H21EOLACvtfcHk0ljHxl3CLso4ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFeiug%253D%253D&md5=8bd96b6898e5f0c2a466db6253714f59</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1172%2FJCI70462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI70462%26sid%3Dliteratum%253Aachs%26aulast%3DGregory-evans%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWasan%26aufirst%3DK.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMetcalfe%26aufirst%3DA.%2BL.%26aulast%3DGregory-Evans%26aufirst%3DK.%26atitle%3DPostnatal%2520Manipulation%2520of%2520Pax6%2520Dosage%2520Reverses%2520Congenital%2520Tissue%2520Malformation%2520Defects%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D111%26epage%3D116%26doi%3D10.1172%2FJCI70462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovács, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, D. A.</span></span> <span> </span><span class="NLM_article-title">The Novel Cln1R151X Mouse Model of Infantile Neuronal Ceroid Lipofuscinosis (INCL) for Testing Nonsense Suppression Therapy</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddu428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1093%2Fhmg%2Fddu428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=25205113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitl2gt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=185-196&author=J.+N.+Millerauthor=A.+D.+Kov%C3%A1csauthor=D.+A.+Pearce&title=The+Novel+Cln1R151X+Mouse+Model+of+Infantile+Neuronal+Ceroid+Lipofuscinosis+%28INCL%29+for+Testing+Nonsense+Suppression+Therapy&doi=10.1093%2Fhmg%2Fddu428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">The novel Cln1R151X mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy</span></div><div class="casAuthors">Miller, Jake N.; Kovacs, Attila D.; Pearce, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-196</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease, are a group of autosomal recessive neurodegenerative disorders in children characterized by the progressive onset of seizures, blindness, motor and cognitive decline and premature death.  Patients with mutations in CLN1 primarily manifest with infantile NCL (INCL or Haltia-Santavuori disease), which is second only to congenital NCL for its age of onset and devastating progression.  CLN1 encodes a lysosomal enzyme, palmitoyl-protein thioesterase 1 (PPT1).  Nonsense mutations in CLN1 account for 52.3% of all disease causing alleles in infantile NCL, the most common of which worldwide is the p.R151X mutation.  Previously, we have shown how nonsense-mediated decay is involved in the degrdn. of CLN1 mRNA transcripts contg. the p.R151X mutation in human lymphoblast cell lines.  We have also shown how the read-through drugs gentamicin and ataluren (PTC124) increase CLN1 (PPT1) enzyme activity.  Here, we provide the initial characterization of the novel Cln1R151X mouse model of infantile neuronal ceroid lipofuscinosis that we have generated.  This nonsense mutation model recapitulates the mol., histol. and behavioral phenotypes of the human disease.  Cln1R151X mice showed a significant decrease in Cln1 mRNA level and PPT1 enzyme activity, accumulation of autofluorescent storage material, astrocytosis and microglial activation in the brain.  Behavioral characterization of Cln1R151X mice at 3 and 5 mo of age revealed significant motor deficits as measured by the vertical pole and rotarod tests.  We also show how the read-through compd. ataluren (PTC124) increases PPT1 enzyme activity and protein level in Cln1R151X mice in a proof-of-principle study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-UfjtGsCSCLVg90H21EOLACvtfcHk0ljHxl3CLso4ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitl2gt7s%253D&md5=ab3153c6871564b86be93ccb87fb0f2a</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddu428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddu428%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DJ.%2BN.%26aulast%3DKov%25C3%25A1cs%26aufirst%3DA.%2BD.%26aulast%3DPearce%26aufirst%3DD.%2BA.%26atitle%3DThe%2520Novel%2520Cln1R151X%2520Mouse%2520Model%2520of%2520Infantile%2520Neuronal%2520Ceroid%2520Lipofuscinosis%2520%2528INCL%2529%2520for%2520Testing%2520Nonsense%2520Suppression%2520Therapy%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2015%26volume%3D24%26spage%3D185%26epage%3D196%26doi%3D10.1093%2Fhmg%2Fddu428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finkel, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanigan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnemann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northcutt, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elfring, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, S. W.</span></span> <span> </span><span class="NLM_article-title">Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e81302</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0081302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pone.0081302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=24349052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsVOmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e81302&author=R.+S.+Finkelauthor=K.+M.+Flaniganauthor=B.+Wongauthor=C.+Bonnemannauthor=J.+Sampsonauthor=H.+L.+Sweeneyauthor=A.+Rehaauthor=V.+J.+Northcuttauthor=G.+Elfringauthor=J.+Barthauthor=S.+W.+Peltz&title=Phase+2a+Study+of+Ataluren-Mediated+Dystrophin+Production+in+Patients+with+Nonsense+Mutation+Duchenne+Muscular+Dystrophy&doi=10.1371%2Fjournal.pone.0081302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy</span></div><div class="casAuthors">Finkel, Richard S.; Flanigan, Kevin M.; Wong, Brenda; Bonnemann, Carsten; Sampson, Jacinda; Sweeney, H. Lee; Reha, Allen; Northcutt, Valerie J.; Elfring, Gary; Barth, Jay; Peltz, Stuart W.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e81302/1-e81302/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Approx. 13% of boys with Duchenne muscular dystrophy (DMD) have a nonsense mutation in the dystrophin gene, resulting in a premature stop codon in the corresponding mRNA and failure to generate a functional protein.  Ataluren (PTC124) enables ribosomal readthrough of premature stop codons, leading to prodn. of full-length, functional proteins.  Methods: This Phase 2a open-label, sequential dose-ranging trial recruited 38 boys with nonsense mutation DMD.  The first cohort (n = 6) received ataluren three times per day at morning, midday, and evening doses of 4, 4, and 8 mg/kg; the second cohort (n = 20) was dosed at 10, 10, 20 mg/kg; and the third cohort (n = 12) was dosed at 20, 20, 40 mg/kg.  Treatment duration was 28 days.  Change in full-length dystrophin expression, as assessed by immunostaining in pre- and post-treatment muscle biopsy specimens, was the primary endpoint.  Findings: Twenty three of 38 (61%) subjects demonstrated increases in post-treatment dystrophin expression in a quant. anal. assessing the ratio of dystrophin/spectrin.  A qual. anal. also showed pos. changes in dystrophin expression.  Expression was not assocd. with nonsense mutation type or exon location.  Ataluren trough plasma concns. active in the mdx mouse model were consistently achieved at the mid- and high-dose levels in participants.  Ataluren was generally well tolerated.  Interpretation: Ataluren showed activity and safety in this short-term study, supporting evaluation of ataluren 10, 10, 20 mg/kg and 20, 20, 40 mg/kg in a Phase 2b, double-blind, long-term study in nonsense mutation DMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquxNJecOocsbVg90H21EOLACvtfcHk0lh3sp2qI9CqQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsVOmtrw%253D&md5=c7198497eed795894e094ae044d35624</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0081302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0081302%26sid%3Dliteratum%253Aachs%26aulast%3DFinkel%26aufirst%3DR.%2BS.%26aulast%3DFlanigan%26aufirst%3DK.%2BM.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DBonnemann%26aufirst%3DC.%26aulast%3DSampson%26aufirst%3DJ.%26aulast%3DSweeney%26aufirst%3DH.%2BL.%26aulast%3DReha%26aufirst%3DA.%26aulast%3DNorthcutt%26aufirst%3DV.%2BJ.%26aulast%3DElfring%26aufirst%3DG.%26aulast%3DBarth%26aufirst%3DJ.%26aulast%3DPeltz%26aufirst%3DS.%2BW.%26atitle%3DPhase%25202a%2520Study%2520of%2520Ataluren-Mediated%2520Dystrophin%2520Production%2520in%2520Patients%2520with%2520Nonsense%2520Mutation%2520Duchenne%2520Muscular%2520Dystrophy%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De81302%26doi%3D10.1371%2Fjournal.pone.0081302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, C. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torricelli, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkel, R. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanigan, K. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goemans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydemann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muntoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osorio, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schara, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sejersen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, P. B</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, H L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topaloglu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulinius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilchez, J. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elfring, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riebling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, R. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, S. W</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercuri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfano, L. N</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eagle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayhew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzone, E. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Hamid, H. Z</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apkon, S. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barohn, R. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloetzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vaud, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, R. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabrol, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jongno-gu, D.-r.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comi, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darras, B. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastgir, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desguerre, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, R. G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finanger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannaccone, S. T</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karachunski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotze, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, J. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Queiroz
Campos Araujo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renfroe, J B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Resende, M. B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tennekoon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vita, G.</span></span> <span> </span><span class="NLM_article-title">Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">1489</span>– <span class="NLM_lpage">1498</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)31611-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1016%2FS0140-6736%2817%2931611-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=28728956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtF2hsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=1489-1498&author=C.+M+McDonaldauthor=C.+Campbellauthor=R.+E.+Torricelliauthor=R.+S+Finkelauthor=K.+M+Flaniganauthor=N.+Goemansauthor=P.+Heydemannauthor=A.+Kaminskaauthor=J.+Kirschnerauthor=F.+Muntoniauthor=A.+N.+Osorioauthor=U.+Scharaauthor=T.+Sejersenauthor=P.+B+Shiehauthor=H+L.+Sweeneyauthor=H.+Topalogluauthor=M.+Tuliniusauthor=J.+J+Vilchezauthor=T.+Voitauthor=B.+Wongauthor=G.+Elfringauthor=H.+Krogerauthor=X.+Luoauthor=J.+McIntoshauthor=T.+Ongauthor=P.+Rieblingauthor=M.+Souzaauthor=R.+J+Spiegelauthor=S.+W+Peltzauthor=E.+Mercuriauthor=L.+N+Alfanoauthor=M.+Eagleauthor=M.+K+Jamesauthor=L.+Lowesauthor=A.+Mayhewauthor=E.+S+Mazzoneauthor=L.+Nelsonauthor=K.+J+Roseauthor=H.+Z+Abdel-Hamidauthor=S.+D+Apkonauthor=R.+J+Barohnauthor=E.+Bertiniauthor=C.+Bloetzerauthor=L.+C.+de+Vaudauthor=R.+J+Butterfieldauthor=B.+Chabrolauthor=J.-H.+Chaeauthor=D.-r.+Jongno-guauthor=G.+P.+Comiauthor=B.+T+Darrasauthor=J.+Dastgirauthor=I.+Desguerreauthor=R.+G+Escobarauthor=E.+Finangerauthor=M.+Guglieriauthor=I.+Hughesauthor=S.+T+Iannacconeauthor=K.+J+Jonesauthor=P.+Karachunskiauthor=M.+Kudrauthor=T.+Lotzeauthor=J.+K+Mahauthor=K.+Mathewsauthor=Y.+Nevoauthor=J.+Parsonsauthor=Y.+Pereonauthor=A.+P.+de+Queiroz%0ACampos+Araujoauthor=J+B.+Renfroeauthor=M.+B.+D.+de+Resendeauthor=M.+Ryanauthor=K.+Selbyauthor=G.+Tennekoonauthor=G.+Vita&title=Ataluren+in+Patients+with+Nonsense+Mutation+Duchenne+Muscular+Dystrophy+%28ACT+DMD%29%3A+A+Multicentre%2C+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C+Phase+3+Trial&doi=10.1016%2FS0140-6736%2817%2931611-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial</span></div><div class="casAuthors">McDonald, Craig M.; Campbell, Craig; Torricelli, Ricardo Erazo; Finkel, Richard S.; Flanigan, Kevin M.; Goemans, Nathalie; Heydemann, Peter; Kaminska, Anna; Kirschner, Janbernd; Muntoni, Francesco; Osorio, Andres Nascimento; Schara, Ulrike; Sejersen, Thomas; Shieh, Perry B.; Sweeney, H. Lee; Topaloglu, Haluk; Tulinius, Mar; Vilchez, Juan J.; Voit, Thomas; Wong, Brenda; Elfring, Gary; Kroger, Hans; Luo, Xiaohui; McIntosh, Joseph; Ong, Tuyen; Riebling, Peter; Souza, Marcio; Spiegel, Robert J.; Peltz, Stuart W.; Mercuri, Eugenio</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">10101</span>),
    <span class="NLM_cas:pages">1489-1498</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Duchenne muscular dystrophy (DMD) is a severe, progressive, and rare neuromuscular, X-linked recessive disease.  Dystrophin deficiency is the underlying cause of disease; therefore, mutation-specific therapies aimed at restoring dystrophin protein prodn. are being explored.  We aimed to assess the efficacy and safety of ataluren in ambulatory boys with nonsense mutation DMD.  We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 54 sites in 18 countries located in North America, Europe, the Asia-Pacific region, and Latin America.  Boys aged 7-16 years with nonsense mutation DMD and a baseline 6-min walk distance (6MWD) of 150 m or more and 80% or less of the predicted normal value for age and height were randomly assigned (1:1), via permuted block randomisation (block size of four) using an interactive voice-response or web-response system, to receive ataluren orally three times daily (40 mg/kg per day) or matching placebo.  Randomisation was stratified by age (<9 years vs ≥9 years), duration of previous corticosteroid use (6 mo to <12 mo vs ≥12 mo), and baseline 6MWD (<350 m vs ≥350 m).  Patients, parents and caregivers, investigational site personnel, PTC Therapeutics employees, and all other study personnel were masked to group allocation until after database lock.  The primary endpoint was change in 6MWD from baseline to week 48.  We addnl. did a prespecified subgroup anal. of the primary endpoint, based on baseline 6MWD, which is reflective of anticipated rates of disease progression over 1 yr.  The primary anal. was by intention to treat.  This study is registered with ClinicalTrials.gov, no. NCT01826487.  Between March 26, 2013, and Aug 26, 2014, we randomly assigned 230 patients to receive ataluren (n=115) or placebo (n=115); 228 patients comprised the intention-to-treat population.  The least-squares mean change in 6MWD from baseline to week 48 was -47·7 m (SE 9·3) for ataluren-treated patients and -60·7 m (9·3) for placebo-treated patients (difference 13·0 m [SE 10·4], 95% CI -7·4 to 33·4; p=0·213).  The least-squares mean change for ataluren vs. placebo in the prespecified subgroups was -7·7 m (SE 24·1, 95% CI -54·9 to 39·5; p=0·749) in the group with a 6MWD of less than 300 m, 42·9 m (15·9, 11·8-74·0; p=0·007) in the group with a 6MWD of 300 m or more to less than 400 m, and -9·5 m (17·2, -43·2 to 24·2; p=0·580) in the group with a 6MWD of 400 m or more.  Ataluren was generally well tolerated and most treatment-emergent adverse events were mild to moderate in severity.  Eight (3%) patients (n=4 per group) reported serious adverse events; all except one event in the placebo group (abnormal hepatic function deemed possibly related to treatment) were deemed unrelated to treatment.  Change in 6MWD did not differ significantly between patients in the ataluren group and those in the placebo group, neither in the intention-to-treat population nor in the prespecified subgroups with a baseline 6MWD of less than 300 m or 400 m or more.  However, we recorded a significant effect of ataluren in the prespecified subgroup of patients with a baseline 6MWD of 300 m or more to less than 400 m.  Baseline 6MWD values within this range were assocd. with a more predictable rate of decline over 1 yr; this finding has implications for the design of future DMD trials with the 6-min walk test as the endpoint.PTC Therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrdEeegEaHJLVg90H21EOLACvtfcHk0lh3sp2qI9CqQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtF2hsL3N&md5=25ae69e359455aca9d716e964aa09015</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2931611-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252931611-2%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonald%26aufirst%3DC.%2BM%26aulast%3DCampbell%26aufirst%3DC.%26aulast%3DTorricelli%26aufirst%3DR.%2BE.%26aulast%3DFinkel%26aufirst%3DR.%2BS%26aulast%3DFlanigan%26aufirst%3DK.%2BM%26aulast%3DGoemans%26aufirst%3DN.%26aulast%3DHeydemann%26aufirst%3DP.%26aulast%3DKaminska%26aufirst%3DA.%26aulast%3DKirschner%26aufirst%3DJ.%26aulast%3DMuntoni%26aufirst%3DF.%26aulast%3DOsorio%26aufirst%3DA.%2BN.%26aulast%3DSchara%26aufirst%3DU.%26aulast%3DSejersen%26aufirst%3DT.%26aulast%3DShieh%26aufirst%3DP.%2BB%26aulast%3DSweeney%26aufirst%3DH%2BL.%26aulast%3DTopaloglu%26aufirst%3DH.%26aulast%3DTulinius%26aufirst%3DM.%26aulast%3DVilchez%26aufirst%3DJ.%2BJ%26aulast%3DVoit%26aufirst%3DT.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DElfring%26aufirst%3DG.%26aulast%3DKroger%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DOng%26aufirst%3DT.%26aulast%3DRiebling%26aufirst%3DP.%26aulast%3DSouza%26aufirst%3DM.%26aulast%3DSpiegel%26aufirst%3DR.%2BJ%26aulast%3DPeltz%26aufirst%3DS.%2BW%26aulast%3DMercuri%26aufirst%3DE.%26aulast%3DAlfano%26aufirst%3DL.%2BN%26aulast%3DEagle%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DM.%2BK%26aulast%3DLowes%26aufirst%3DL.%26aulast%3DMayhew%26aufirst%3DA.%26aulast%3DMazzone%26aufirst%3DE.%2BS%26aulast%3DNelson%26aufirst%3DL.%26aulast%3DRose%26aufirst%3DK.%2BJ%26aulast%3DAbdel-Hamid%26aufirst%3DH.%2BZ%26aulast%3DApkon%26aufirst%3DS.%2BD%26aulast%3DBarohn%26aufirst%3DR.%2BJ%26aulast%3DBertini%26aufirst%3DE.%26aulast%3DBloetzer%26aufirst%3DC.%26aulast%3Dde%2BVaud%26aufirst%3DL.%2BC.%26aulast%3DButterfield%26aufirst%3DR.%2BJ%26aulast%3DChabrol%26aufirst%3DB.%26aulast%3DChae%26aufirst%3DJ.-H.%26aulast%3DJongno-gu%26aufirst%3DD.-r.%26aulast%3DComi%26aufirst%3DG.%2BP.%26aulast%3DDarras%26aufirst%3DB.%2BT%26aulast%3DDastgir%26aufirst%3DJ.%26aulast%3DDesguerre%26aufirst%3DI.%26aulast%3DEscobar%26aufirst%3DR.%2BG%26aulast%3DFinanger%26aufirst%3DE.%26aulast%3DGuglieri%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DI.%26aulast%3DIannaccone%26aufirst%3DS.%2BT%26aulast%3DJones%26aufirst%3DK.%2BJ%26aulast%3DKarachunski%26aufirst%3DP.%26aulast%3DKudr%26aufirst%3DM.%26aulast%3DLotze%26aufirst%3DT.%26aulast%3DMah%26aufirst%3DJ.%2BK%26aulast%3DMathews%26aufirst%3DK.%26aulast%3DNevo%26aufirst%3DY.%26aulast%3DParsons%26aufirst%3DJ.%26aulast%3DPereon%26aufirst%3DY.%26aulast%3Dde%2BQueiroz%2BCampos%2BAraujo%26aufirst%3DA.%2BP.%26aulast%3DRenfroe%26aufirst%3DJ%2BB.%26aulast%3Dde%2BResende%26aufirst%3DM.%2BB.%2BD.%26aulast%3DRyan%26aufirst%3DM.%26aulast%3DSelby%26aufirst%3DK.%26aulast%3DTennekoon%26aufirst%3DG.%26aulast%3DVita%26aufirst%3DG.%26atitle%3DAtaluren%2520in%2520Patients%2520with%2520Nonsense%2520Mutation%2520Duchenne%2520Muscular%2520Dystrophy%2520%2528ACT%2520DMD%2529%253A%2520A%2520Multicentre%252C%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26spage%3D1489%26epage%3D1498%26doi%3D10.1016%2FS0140-6736%2817%2931611-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sermet-Gaudelus, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeck, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimir, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeulen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogenet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanssens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajayi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elfring, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. L.</span></span> <span> </span><span class="NLM_article-title">Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">1262</span>– <span class="NLM_lpage">1272</span>, <span class="refDoi"> DOI: 10.1164/rccm.201001-0137OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1164%2Frccm.201001-0137OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=20622033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1eqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=1262-1272&author=I.+Sermet-Gaudelusauthor=K.+D.+Boeckauthor=G.+J.+Casimirauthor=F.+Vermeulenauthor=T.+Lealauthor=A.+Mogenetauthor=D.+Rousselauthor=J.+Fritschauthor=L.+Hanssensauthor=S.+Hirawatauthor=N.+L.+Millerauthor=S.+Constantineauthor=A.+Rehaauthor=T.+Ajayiauthor=G.+L.+Elfringauthor=L.+L.+Miller&title=Ataluren+%28PTC124%29+Induces+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Protein+Expression+and+Activity+in+Children+with+Nonsense+Mutation+Cystic+Fibrosis&doi=10.1164%2Frccm.201001-0137OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis</span></div><div class="casAuthors">Sermet-Gaudelus, Isabelle; de Boeck, Kris; Casimir, Georges J.; Vermeulen, Francois; Leal, Teresinha; Mogenet, Agnes; Roussel, Delphine; Fritsch, Janine; Hanssens, Laurence; Hirawat, Samit; Miller, Nilsen L.; Constantine, Scott; Reha, Allen; Ajayi, Temitayo; Elfring, Gary L.; Miller, Langdon L.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1262-1272</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Nonsense (premature stop codon) mutations in mRNA for the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis (CF) in approx. 10% of patients.  Ataluren (PTC124) is an oral drug that permits ribosomes to readthrough premature stop codons in mRNA to produce functional protein.  Objectives: To evaluate ataluren activity, safety, and pharmacokinetics in children with nonsense mutation CF.  Methods: Patients were assessed in two 28-day cycles, comprising 14 days on and 14 days off ataluren.  Patients took ataluren three times per day (morning, midday, and evening) with randomization to the order of receiving a lower dose (4, 4, and 8 mg/kg) and a higher dose (10, 10, and 20 mg/kg) in the two cycles.  Measurements and Main Results: The study enrolled 30 patients (16 male and 14 female, ages 6 through 18 yr) with a nonsense mutation in at least one allele of the CFTR gene, a classical CF phenotype, and abnormal baseline nasal epithelial chloride transport.  Ataluren induced a nasal chloride transport response (at least a -5-mV improvement) or hyperpolarization (value more elec. neg. than -5 mV) in 50% and 47% of patients, resp., with more hyperpolarizations at the higher dose.  Improvements were seen in seven of nine nonsense mutation genotypes represented.  Ataluren significantly increased the proportion of nasal epithelial cells expressing apical full-length CFTR protein.  Adverse events and lab. abnormalities were infrequent and usually mild.  Ataluren pharmacokinetics were similar to those in adults.  Conclusions: In children with nonsense mutation CF, ataluren can induce functional CFTR prodn. and is well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYmpNckBQweLVg90H21EOLACvtfcHk0lhEKc0EdOhwFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1eqsg%253D%253D&md5=bc4306006e48f8ae7a96e1c8227feebb</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1164%2Frccm.201001-0137OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201001-0137OC%26sid%3Dliteratum%253Aachs%26aulast%3DSermet-Gaudelus%26aufirst%3DI.%26aulast%3DBoeck%26aufirst%3DK.%2BD.%26aulast%3DCasimir%26aufirst%3DG.%2BJ.%26aulast%3DVermeulen%26aufirst%3DF.%26aulast%3DLeal%26aufirst%3DT.%26aulast%3DMogenet%26aufirst%3DA.%26aulast%3DRoussel%26aufirst%3DD.%26aulast%3DFritsch%26aufirst%3DJ.%26aulast%3DHanssens%26aufirst%3DL.%26aulast%3DHirawat%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DN.%2BL.%26aulast%3DConstantine%26aufirst%3DS.%26aulast%3DReha%26aufirst%3DA.%26aulast%3DAjayi%26aufirst%3DT.%26aulast%3DElfring%26aufirst%3DG.%2BL.%26aulast%3DMiller%26aufirst%3DL.%2BL.%26atitle%3DAtaluren%2520%2528PTC124%2529%2520Induces%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Protein%2520Expression%2520and%2520Activity%2520in%2520Children%2520with%2520Nonsense%2520Mutation%2520Cystic%2520Fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26spage%3D1262%26epage%3D1272%26doi%3D10.1164%2Frccm.201001-0137OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aslam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, I. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southern, K. W</span></span> <span> </span><span class="NLM_article-title">Ataluren and Similar Compounds (Specific Therapies for Premature Termination Codon Class I Mutations) for Cystic Fibrosis</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_fpage">CD012040</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD012040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1002%2F14651858.CD012040" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=CD012040&author=A.+Aslamauthor=I.+P+Sinhaauthor=K.+W+Southern&title=Ataluren+and+Similar+Compounds+%28Specific+Therapies+for+Premature+Termination+Codon+Class+I+Mutations%29+for+Cystic+Fibrosis&doi=10.1002%2F14651858.CD012040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD012040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD012040%26sid%3Dliteratum%253Aachs%26aulast%3DAslam%26aufirst%3DA.%26aulast%3DSinha%26aufirst%3DI.%2BP%26aulast%3DSouthern%26aufirst%3DK.%2BW%26atitle%3DAtaluren%2520and%2520Similar%2520Compounds%2520%2528Specific%2520Therapies%2520for%2520Premature%2520Termination%2520Codon%2520Class%2520I%2520Mutations%2529%2520for%2520Cystic%2520Fibrosis%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2016%26spage%3DCD012040%26doi%3D10.1002%2F14651858.CD012040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mcelroy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrie, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warbrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, W. H. I.</span></span> <span> </span><span class="NLM_article-title">A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e1001593</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.1001593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1371%2Fjournal.pbio.1001593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=23824517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFGjsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=e1001593&author=S.+P.+Mcelroyauthor=T.+Nomuraauthor=L.+S.+Torrieauthor=E.+Warbrickauthor=U.+Gartnerauthor=G.+Woodauthor=W.+H.+I.+McLean&title=A+Lack+of+Premature+Termination+Codon+Read-Through+Efficacy+of+PTC124+%28Ataluren%29+in+a+Diverse+Array+of+Reporter+Assays&doi=10.1371%2Fjournal.pbio.1001593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays</span></div><div class="casAuthors">McElroy, Stuart P.; Nomura, Toshifumi; Torrie, Leah S.; Warbrick, Emma; Gartner, Ulrike; Wood, Gavin; McLean, W. H. Irwin</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1001593</span>CODEN:
                <span class="NLM_cas:coden">PBLIBG</span>;
        ISSN:<span class="NLM_cas:issn">1545-7885</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The drug mol. PTC124 (Ataluren) has been described as a read-through agent, capable of suppressing premature termination codons (PTCs) and restoring functional protein prodn. from genes disrupted by nonsense mutations.  Following the discovery of PTC124 there was some controversy regarding its mechanism of action with two reports attributing its activity to an off-target effect on the Firefly luciferase (FLuc) reporter used in the development of the mol.  Despite questions remaining as to its mechanism of action, development of PTC124 continued into the clinic and it is being actively pursued as a potential nonsense mutation therapy.  To thoroughly test the ability of PTC124 to read through nonsense mutations, we conducted a detailed assessment comparing the efficacy of PTC124 with the classical aminoglycoside antibiotic read-through agent geneticin (G418) across a diverse range of in vitro reporter assays.  We can confirm the off-target FLuc activity of PTC124 but found that, while G418 exhibits varying activity in every read-through assay, there is no evidence of activity for PTC124.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLzPdUkQVuG7Vg90H21EOLACvtfcHk0lhEKc0EdOhwFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFGjsLzK&md5=f611a69f45a185ea002f4073da436a7e</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1001593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1001593%26sid%3Dliteratum%253Aachs%26aulast%3DMcelroy%26aufirst%3DS.%2BP.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DTorrie%26aufirst%3DL.%2BS.%26aulast%3DWarbrick%26aufirst%3DE.%26aulast%3DGartner%26aufirst%3DU.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DMcLean%26aufirst%3DW.%2BH.%2BI.%26atitle%3DA%2520Lack%2520of%2520Premature%2520Termination%2520Codon%2520Read-Through%2520Efficacy%2520of%2520PTC124%2520%2528Ataluren%2529%2520in%2520a%2520Diverse%2520Array%2520of%2520Reporter%2520Assays%26jtitle%3DPLoS%2520Biol.%26date%3D2013%26volume%3D11%26spage%3De1001593%26doi%3D10.1371%2Fjournal.pbio.1001593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Auld, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorne, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lea, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaile, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanzlik, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglese, J.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis for the High-Affinity Binding and Stabilization of Firefly Luciferase by PTC124</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">4878</span>– <span class="NLM_lpage">4883</span>, <span class="refDoi"> DOI: 10.1073/pnas.0909141107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1073%2Fpnas.0909141107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=20194791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFaqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=4878-4883&author=D.+S.+Auldauthor=S.+Lovellauthor=N.+Thorneauthor=W.+A.+Leaauthor=D.+J.+Maloneyauthor=M.+Shenauthor=G.+Raiauthor=K.+P.+Battaileauthor=C.+J.+Thomasauthor=A.+Simeonovauthor=R.+P.+Hanzlikauthor=J.+Inglese&title=Molecular+Basis+for+the+High-Affinity+Binding+and+Stabilization+of+Firefly+Luciferase+by+PTC124&doi=10.1073%2Fpnas.0909141107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124</span></div><div class="casAuthors">Auld, Douglas S.; Lovell, Scott; Thorne, Natasha; Lea, Wendy A.; Maloney, David J.; Shen, Min; Rai, Ganesha; Battaile, Kevin P.; Thomas, Craig J.; Simeonov, Anton; Hanzlik, Robert P.; Inglese, James</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4878-4883, S4878/1-S4878/14</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Firefly luciferase (FLuc), an ATP-dependent bioluminescent reporter enzyme, is broadly used in chem. biol. and drug discovery assays.  PTC124 (Ataluren; (3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid)) discovered in an FLuc-based assay targeting nonsense codon suppression, is an unusually potent FLuc-inhibitor.  Paradoxically, PTC124 and related analogs increase cellular FLuc activity levels by posttranslational stabilization.  In this study, we show that FLuc inhibition and stabilization is the result of an inhibitory product formed during the FLuc-catalyzed reaction between its natural substrate, ATP, and PTC124.  A 2.0 Å cocrystal structure revealed the inhibitor to be the acyl-AMP mixed-anhydride adduct PTC124-AMP, which was subsequently synthesized and shown to be a high-affinity multisubstrate adduct inhibitor (MAI; KD = 120 pM) of FLuc.  Biochem. assays, liq. chromatog./mass spectrometry, and near-attack conformer modeling demonstrate that formation of this novel MAI is absolutely dependent upon the precise positioning and reactivity of a key meta-carboxylate of PTC124 within the FLuc active site.  We also demonstrate that the inhibitory activity of PTC124-AMP is relieved by free CoA, a component present at high concns. in luciferase detection reagents used for cell-based assays.  This explains why PTC124 can appear to increase, instead of inhibit, FLuc activity in cell-based reporter gene assays.  To our knowledge, this is an unusual example in which the "off-target" effect of a small mol. is mediated by an MAI mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIPfC1eBndl7Vg90H21EOLACvtfcHk0ljP87Cu4PpxFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFaqsbo%253D&md5=e22180fb96672f3fa7cdc907b7ada4fe</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0909141107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0909141107%26sid%3Dliteratum%253Aachs%26aulast%3DAuld%26aufirst%3DD.%2BS.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DThorne%26aufirst%3DN.%26aulast%3DLea%26aufirst%3DW.%2BA.%26aulast%3DMaloney%26aufirst%3DD.%2BJ.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DRai%26aufirst%3DG.%26aulast%3DBattaile%26aufirst%3DK.%2BP.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DHanzlik%26aufirst%3DR.%2BP.%26aulast%3DInglese%26aufirst%3DJ.%26atitle%3DMolecular%2520Basis%2520for%2520the%2520High-Affinity%2520Binding%2520and%2520Stabilization%2520of%2520Firefly%2520Luciferase%2520by%2520PTC124%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D4878%26epage%3D4883%26doi%3D10.1073%2Fpnas.0909141107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melfi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leonardo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo
Piccionello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pibiri, I.</span></span> <span> </span><span class="NLM_article-title">Toward a Rationale for the PTC124 (Ataluren) Promoted Readthrough of Premature Stop Codons: A Computational Approach and GFP-Reporter Cell-Based Assay</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1021/mp400230s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400230s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsF2mtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=653-664&author=L.+Lentiniauthor=R.+Melfiauthor=A.+Di+Leonardoauthor=A.+Spinelloauthor=G.+Baroneauthor=A.+Paceauthor=A.+Palumbo%0APiccionelloauthor=I.+Pibiri&title=Toward+a+Rationale+for+the+PTC124+%28Ataluren%29+Promoted+Readthrough+of+Premature+Stop+Codons%3A+A+Computational+Approach+and+GFP-Reporter+Cell-Based+Assay&doi=10.1021%2Fmp400230s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay</span></div><div class="casAuthors">Lentini, Laura; Melfi, Raffaella; Di Leonardo, Aldo; Spinello, Angelo; Barone, Giampaolo; Pace, Andrea; Palumbo Piccionello, Antonio; Pibiri, Ivana</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">653-664</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The presence in the mRNA of premature stop codons (PTCs) results in protein truncation responsible for several inherited (genetic) diseases.  A well-known example of these diseases is cystic fibrosis (CF), where approx. 10% (worldwide) of patients have nonsense mutations in the CF transmembrane regulator (CFTR) gene.  PTC124 (3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-benzoic acid), also known as Ataluren, is a small mol. that has been suggested to allow PTC readthrough even though its target has yet to be identified.  In the lack of a general consensus about its mechanism of action, we exptl. tested the ability of PTC124 to promote the readthrough of premature termination codons by using a new reporter.  The reporter vector was based on a plasmid harboring the H2B histone coding sequence fused in frame with the green fluorescent protein (GFP) cDNA, and a TGA stop codon was introduced in the H2B-GFP gene by site-directed mutagenesis.  Addnl., an unprecedented computational study on the putative supramol. interaction between PTC124 and an 11-codon (33-nucleotides) sequence corresponding to a CFTR mRNA fragment contg. a central UGA nonsense mutation showed a specific interaction between PTC124 and the UGA codon.  Altogether, the H2B-GFP-opal based assay and the mol. dynamics (MD) simulation support the hypothesis that PTC124 is able to promote the specific readthrough of internal TGA premature stop codons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoMyq0NCLi-rVg90H21EOLACvtfcHk0ljP87Cu4PpxFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsF2mtrg%253D&md5=9db7ec531aa57c1e0c376d05612bfd2f</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1021%2Fmp400230s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400230s%26sid%3Dliteratum%253Aachs%26aulast%3DLentini%26aufirst%3DL.%26aulast%3DMelfi%26aufirst%3DR.%26aulast%3DDi%2BLeonardo%26aufirst%3DA.%26aulast%3DSpinello%26aufirst%3DA.%26aulast%3DBarone%26aufirst%3DG.%26aulast%3DPace%26aufirst%3DA.%26aulast%3DPalumbo%2BPiccionello%26aufirst%3DA.%26aulast%3DPibiri%26aufirst%3DI.%26atitle%3DToward%2520a%2520Rationale%2520for%2520the%2520PTC124%2520%2528Ataluren%2529%2520Promoted%2520Readthrough%2520of%2520Premature%2520Stop%2520Codons%253A%2520A%2520Computational%2520Approach%2520and%2520GFP-Reporter%2520Cell-Based%2520Assay%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D653%26epage%3D664%26doi%3D10.1021%2Fmp400230s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damoiseaux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henning, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, R. A.</span></span> <span> </span><span class="NLM_article-title">Nonaminoglycoside Compounds Induce Readthrough of Nonsense Mutations</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>206</i></span>,  <span class="NLM_fpage">2285</span>– <span class="NLM_lpage">2297</span>, <span class="refDoi"> DOI: 10.1084/jem.20081940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1084%2Fjem.20081940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=19770270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1SrtbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=2009&pages=2285-2297&author=L.+Duauthor=R.+Damoiseauxauthor=S.+Nahasauthor=K.+Gaoauthor=H.+Huauthor=J.+M.+Pollardauthor=J.+Goldstineauthor=M.+E.+Jungauthor=S.+M.+Henningauthor=C.+Bertoniauthor=R.+A.+Gatti&title=Nonaminoglycoside+Compounds+Induce+Readthrough+of+Nonsense+Mutations&doi=10.1084%2Fjem.20081940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Nonaminoglycoside compounds induce readthrough of nonsense mutations</span></div><div class="casAuthors">Du, Liutao; Damoiseaux, Robert; Nahas, Shareef; Gao, Kun; Hu, Hailiang; Pollard, Julianne M.; Goldstine, Jimena; Jung, Michael E.; Henning, Susanne M.; Bertoni, Carmen; Gatti, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2285-2297</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Large nos. of genetic disorders are caused by nonsense mutations for which compd.-induced readthrough of premature termination codons (PTCs) might be exploited as a potential treatment strategy.  We have successfully developed a sensitive and quant. high-throughput screening (HTS) assay, protein transcription/translation (PTT)-ELISA, for identifying novel PTC-readthrough compds. using ataxia-telangiectasia (A-T) as a genetic disease model.  This HTS PTT-ELISA assay is based on a coupled PTT that uses plasmid templates contg. prototypic A-T mutated (ATM) mutations for HTS.  The assay is luciferase independent.  We screened ∼34,000 compds. and identified 12 low-mol.-mass nonaminoglycosides with potential PTC-readthrough activity.  From these, two leading compds. consistently induced functional ATM protein in ATM-deficient cells contg. disease-causing nonsense mutations, as demonstrated by direct measurement of ATM protein, restored ATM kinase activity, and colony survival assays for cellular radiosensitivity.  The two compds. also demonstrated readthrough activity in mdx mouse myotube cells carrying a nonsense mutation and induced significant amts. of dystrophin protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpsc57CownCbVg90H21EOLACvtfcHk0ljP87Cu4PpxFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1SrtbnI&md5=4bc19a6fde2c6fa1e66130ff622bd894</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1084%2Fjem.20081940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20081940%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DL.%26aulast%3DDamoiseaux%26aufirst%3DR.%26aulast%3DNahas%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DPollard%26aufirst%3DJ.%2BM.%26aulast%3DGoldstine%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DHenning%26aufirst%3DS.%2BM.%26aulast%3DBertoni%26aufirst%3DC.%26aulast%3DGatti%26aufirst%3DR.%2BA.%26atitle%3DNonaminoglycoside%2520Compounds%2520Induce%2520Readthrough%2520of%2520Nonsense%2520Mutations%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2009%26volume%3D206%26spage%3D2285%26epage%3D2297%26doi%3D10.1084%2Fjem.20081940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kayali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khitrov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prikhodko, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, C.</span></span> <span> </span><span class="NLM_article-title">Read-through Compound 13 Restores Dystrophin Expression and Improves Muscle Function in the Mdx Mouse Model for Duchenne Muscular Dystrophy</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4007</span>– <span class="NLM_lpage">4020</span>, <span class="refDoi"> DOI: 10.1093/hmg/dds223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1093%2Fhmg%2Fdds223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22692682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yntr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=4007-4020&author=R.+Kayaliauthor=J.-M.+Kuauthor=G.+Khitrovauthor=M.+E.+Jungauthor=O.+Prikhodkoauthor=C.+Bertoni&title=Read-through+Compound+13+Restores+Dystrophin+Expression+and+Improves+Muscle+Function+in+the+Mdx+Mouse+Model+for+Duchenne+Muscular+Dystrophy&doi=10.1093%2Fhmg%2Fdds223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy</span></div><div class="casAuthors">Kayali, Refik; Ku, Jin-Mo; Khitrov, Gregory; Jung, Michael E.; Prikhodko, Olga; Bertoni, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4007-4020</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Mols. that induce ribosomal read-through of nonsense mutations in mRNA and allow prodn. of a full-length functional protein hold great therapeutic potential for the treatment of many genetic disorders.  Two such read-through compds., RTC13 and RTC14, were recently identified by a luciferase-independent high-throughput screening assay and were shown to have potential therapeutic functions in the treatment of nonsense mutations in the ATM and the dystrophin genes.  We have now tested the ability of RTC13 and RTC14 to restore dystrophin expression into skeletal muscles of the mdx mouse model for Duchenne muscular dystrophy (DMD).  Direct i.m. injection of compd. RTC14 did not result in significant read-through activity in vivo and demonstrated the levels of dystrophin protein similar to those detected using gentamicin.  In contrast, significant higher amts. of dystrophin were detected after i.m. injection of RTC13.  When administered systemically, RTC13 was shown to partially restore dystrophin protein in different muscle groups, including diaphragm and heart, and improved muscle function.  An increase in muscle strength was detected in all treated animals and was accompanied by a significant decrease in creatine kinase levels.  These studies establish the therapeutic potential of RTC13 in vivo and advance this newly identified compd. into preclin. application for DMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa4PAhMiCO-bVg90H21EOLACvtfcHk0liLq89CX3BvYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yntr3L&md5=75c2b41df1bb6d0465e75b518143578f</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fdds223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fdds223%26sid%3Dliteratum%253Aachs%26aulast%3DKayali%26aufirst%3DR.%26aulast%3DKu%26aufirst%3DJ.-M.%26aulast%3DKhitrov%26aufirst%3DG.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DPrikhodko%26aufirst%3DO.%26aulast%3DBertoni%26aufirst%3DC.%26atitle%3DRead-through%2520Compound%252013%2520Restores%2520Dystrophin%2520Expression%2520and%2520Improves%2520Muscle%2520Function%2520in%2520the%2520Mdx%2520Mouse%2520Model%2520for%2520Duchenne%2520Muscular%2520Dystrophy%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2012%26volume%3D21%26spage%3D4007%26epage%3D4020%26doi%3D10.1093%2Fhmg%2Fdds223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damoiseaux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Completo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fike, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, R. A.</span></span> <span> </span><span class="NLM_article-title">A New Series of Small Molecular Weight Compounds Induce Read through of All Three Types of Nonsense Mutations in the ATM Gene</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1653</span>– <span class="NLM_lpage">1660</span>, <span class="refDoi"> DOI: 10.1038/mt.2013.150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1038%2Fmt.2013.150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=23774824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12is7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=1653-1660&author=L.+Duauthor=M.+E.+Jungauthor=R.+Damoiseauxauthor=G.+Completoauthor=F.+Fikeauthor=J.+M.+Kuauthor=S.+Nahasauthor=C.+Piaoauthor=H.+Huauthor=R.+A.+Gatti&title=A+New+Series+of+Small+Molecular+Weight+Compounds+Induce+Read+through+of+All+Three+Types+of+Nonsense+Mutations+in+the+ATM+Gene&doi=10.1038%2Fmt.2013.150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">A New Series of Small Molecular Weight Compounds Induce Read Through of All Three Types of Nonsense Mutations in the ATM Gene</span></div><div class="casAuthors">Du, Liutao; Jung, Michael E.; Damoiseaux, Robert; Completo, Gladys; Fike, Francesca; Ku, Jin-Mo; Nahas, Shareef; Piao, Cijing; Hu, Hailiang; Gatti, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1653-1660</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chem.-induced read through of premature stop codons might be exploited as a potential treatment strategy for genetic disorders caused by nonsense mutations.  Despite the promise of this approach, only a few read-through compds. (RTCs) have been discovered to date.  These include aminoglycosides (e.g., gentamicin and G418) and nonaminoglycosides (e.g., PTC124 and RTC13).  The therapeutic benefits of these RTCs remain to be detd.  In an effort to find new RTCs, we screened an addnl. ∼36,000 small mol. wt. compds. using a high-throughput screening (HTS) assay that we had previously developed and identified two novel RTCs, GJ071, and GJ072.  The activity of these two compds. was confirmed in cells derived from ataxia telangiectasia (A-T) patients with three different types of nonsense mutation in the ATM gene.  Both compds. showed activity comparable to stop codons (TGA, TAG, and TAA) PTC124 and RTC13.  Early structure-activity relationship studies generated eight active analogs of GJ072.  Most of those analogs were effective on all three stop codons.  GJ071 and GJ072, and some of the GJ072 analogs, appeared to be well tolerated by A-T cells.  We also identified another two active RTCs in the primary screen, RTC204 and RTC219, which share a key structural feature with GJ072 and its analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7y6ey8JUWZ7Vg90H21EOLACvtfcHk0liLq89CX3BvYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12is7%252FK&md5=f012fa596ae8f63c503a255d7e1ba046</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1038%2Fmt.2013.150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2013.150%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DL.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DDamoiseaux%26aufirst%3DR.%26aulast%3DCompleto%26aufirst%3DG.%26aulast%3DFike%26aufirst%3DF.%26aulast%3DKu%26aufirst%3DJ.%2BM.%26aulast%3DNahas%26aufirst%3DS.%26aulast%3DPiao%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DGatti%26aufirst%3DR.%2BA.%26atitle%3DA%2520New%2520Series%2520of%2520Small%2520Molecular%2520Weight%2520Compounds%2520Induce%2520Read%2520through%2520of%2520All%2520Three%2520Types%2520of%2520Nonsense%2520Mutations%2520in%2520the%2520ATM%2520Gene%26jtitle%3DMol.%2520Ther.%26date%3D2013%26volume%3D21%26spage%3D1653%26epage%3D1660%26doi%3D10.1038%2Fmt.2013.150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomašić, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterlin Mašič, L.</span></span> <span> </span><span class="NLM_article-title">Rhodanine as a Scaffold in Drug Discovery: A Critical Review of Its Biological Activities and Mechanisms of Target Modulation</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">549</span>– <span class="NLM_lpage">560</span>, <span class="refDoi"> DOI: 10.1517/17460441.2012.688743</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=10.1517%2F17460441.2012.688743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=22607309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC38XptFWmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=549-560&author=T.+Toma%C5%A1i%C4%87author=L.+Peterlin+Ma%C5%A1i%C4%8D&title=Rhodanine+as+a+Scaffold+in+Drug+Discovery%3A+A+Critical+Review+of+Its+Biological+Activities+and+Mechanisms+of+Target+Modulation&doi=10.1517%2F17460441.2012.688743"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation</span></div><div class="casAuthors">Tomasic, Tihomir; Peterlin Masic, Lucija</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">549-560</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Rhodanine-based compds. have been assocd. with numerous biol. activities.  After many years of research in drug discovery, they have gained a reputation as being pan assay interference compds. (PAINS) and frequent hitters in screening campaigns.  Rhodanine-based compds. are also aggregators that can non-specifically interact with target proteins as well as Michael acceptors and interfere photometrically in biol. assays due to their color.Areas covered: The authors review the recently reported biol. activities of rhodanine-based compds.  Furthermore, the article provides details of their synthesis and occurrence in compd. libraries through high-throughput screening (HTS) and virtual high-throughput screening (VHTS).  Addnl., the authors provide the reader with possible mechanisms of non-specific target modulation, anal. of the crystal structures of enzyme-rhodanine complexes and a comparison of rhodanine and thiazolidine-2,4-dione moieties.Expert opinion: The biol. activity of compds. possessing a rhodanine moiety should be considered very critically despite the convincing data obtained in biol. assays.  In addn. to the lack of selectivity, unusual structure-activity relationship profiles and safety and specificity problems mean that rhodanines are generally not optimizable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorolVH32PdC7Vg90H21EOLACvtfcHk0liLq89CX3BvYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptFWmtLw%253D&md5=a02e78c0c7788aaeb044f3753c901117</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1517%2F17460441.2012.688743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2012.688743%26sid%3Dliteratum%253Aachs%26aulast%3DToma%25C5%25A1i%25C4%2587%26aufirst%3DT.%26aulast%3DPeterlin%2BMa%25C5%25A1i%25C4%258D%26aufirst%3DL.%26atitle%3DRhodanine%2520as%2520a%2520Scaffold%2520in%2520Drug%2520Discovery%253A%2520A%2520Critical%2520Review%2520of%2520Its%2520Biological%2520Activities%2520and%2520Mechanisms%2520of%2520Target%2520Modulation%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D549%26epage%3D560%26doi%3D10.1517%2F17460441.2012.688743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+Screening+Libraries+and+for+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0liH8sAaOyu2Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZC9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZC9','PDB','5ZC9'); return false;">PDB: 5ZC9</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V8X" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V8X','PDB','2V8X'); return false;">PDB: 2V8X</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UO9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UO9','PDB','6UO9'); return false;">PDB: 6UO9</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4TPW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4TPW','PDB','4TPW'); return false;">PDB: 4TPW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LZS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LZS','PDB','5LZS'); return false;">PDB: 5LZS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4UJE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4UJE','PDB','4UJE'); return false;">PDB: 4UJE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MEI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MEI','PDB','5MEI'); return false;">PDB: 5MEI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OM0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OM0','PDB','6OM0'); return false;">PDB: 6OM0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OLE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OLE','PDB','6OLE'); return false;">PDB: 6OLE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NDV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NDV','PDB','5NDV'); return false;">PDB: 5NDV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4V51" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4V51','PDB','4V51'); return false;">PDB: 4V51</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OBM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OBM','PDB','5OBM'); return false;">PDB: 5OBM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IES" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IES','PDB','3IES'); return false;">PDB: 3IES</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01746&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01746%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01746" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                14MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ab0ddab0d1234","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
